<SEC-DOCUMENT>0001213900-18-012209.txt : 20180906
<SEC-HEADER>0001213900-18-012209.hdr.sgml : 20180906
<ACCEPTANCE-DATETIME>20180906163046
ACCESSION NUMBER:		0001213900-18-012209
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20180630
FILED AS OF DATE:		20180906
DATE AS OF CHANGE:		20180906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		181057882

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2018_aytubioscience.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>UNITED
STATES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Mark
One)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#9746;
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the fiscal year ended June 30, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#9744;
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number 333-146542</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 16.5pt"><B>AYTU
BIOSCIENCE, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
Name of Registrant as Specified in Its Charter)</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 49%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 49%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>47-0883144</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction of</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>incorporation or organization)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S. Employer</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Identification Number)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center; width: 49%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>373 Inverness Parkway</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Suite 206</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Englewood, Colorado</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center; width: 49%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>80112</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(720)
437-6580</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Registrant&rsquo;s
telephone number, including area code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Act: None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section&nbsp;12(g) of the Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock, par value $.0001 per share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 216pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the Registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by a check mark whether the Registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the Registrant was required
to file such reports) and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation&nbsp;S-K is not contained herein, and
will not be contained, to the best of the Registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated
by reference in Part&nbsp;III of this Form 10-K or any amendment to this Form&nbsp;10-K&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definition of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act. (check one):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&nbsp;filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;(Do
    not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of common stock held by non-affiliates of the Registrant as of December&nbsp;31, 2017 was $7.9 million
based on the closing price of $44.60 as of that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of shares outstanding of each of the Registrant&rsquo;s classes of common stock, as of the latest practicable date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">As of August 31, 2018,
there were 1,801,411 shares of common stock outstanding and 0 shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom"><B>PAGE</B></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 84%"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
    I</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;1B</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPERTIES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL PROCEEDINGS</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET
    FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELECTED FINANCIAL DATA</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S DISCUSSION
    AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;7A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE
    DISCLOSURES ABOUT MARKET RISK</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS
    AND SUPPLEMENTARY DATA</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGES IN AND DISAGREEMENTS
    WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;9A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;9B</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER INFORMATION</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART III</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, EXECUTIVE
    OFFICERS, AND CORPORATE GOVERNANCE</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITY OWNERSHIP OF
    CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS
    AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT
    FEES AND SERVICES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART IV</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item&nbsp;15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS AND FINANCIAL
    STATEMENT SCHEDULES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</FONT></A></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">86</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2018ex23-1_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;23.1</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10k2018ex31-1_aytubio.htm">Exhibit&nbsp;31.1</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2018ex31-2_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 31.2</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2018ex32-1_aytubio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 32.1</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K refers to trademarks, such as Aytu, Natesto, ZolpiMist, ProstaScint, Primsol, MiOXSYS, RedoxSYS, and
Fiera which are protected under applicable intellectual property laws and are our property or the property of our subsidiaries.
This Form 10-K also contains trademarks, service marks, copyrights and trade names of other companies which are the property of
their respective owners. Solely for convenience, our trademarks and tradenames referred to in this Form 10-K may appear without
the <SUP>&reg;</SUP> or &trade; symbols, but such references are not intended to indicate in any way that we will not assert,
to the fullest extent under applicable law, our rights to these trademarks and tradenames.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unless
otherwise indicated or unless the context otherwise requires, references in this Form 10-K to the &ldquo;Company,&rdquo; &ldquo;Aytu,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo; are to Aytu BioScience, Inc. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We obtained statistical data, market and product data,
and forecasts used throughout this Form 10-K from market research, publicly available information and industry publications. While
we believe that the statistical data, industry data and forecasts and market research are reliable, we have not independently verified
the data, and we do not make any representation as to the accuracy of the information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking Statements </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This Annual Report on Form 10-K, or Annual
Report, includes forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and
Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical
facts contained in this Annual Report, including statements regarding our anticipated future clinical and regulatory events, future
financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements.
Forward-looking statements are generally written in the future tense and/or are preceded by words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;suggest,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; or similar
words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements
include, without limitation, statements regarding the markets for our approved products and our plans for our approved products,
the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future
clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, the
potential future commercialization of our product candidates, our anticipated future cash position and future events under our
current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties and
assumptions, including without limitation the risks described in &ldquo;Risk Factors&rdquo; in Part&nbsp;I, Item&nbsp;1A of this
Annual Report. These risks are not exhaustive. Other sections of this Annual Report include additional factors that could adversely
impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New
risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess
the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results
to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements
as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. We
assume no obligation to update or supplement forward-looking statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained statistical data, market and product data, and forecasts used throughout this Form 10-K from market research, publicly
available information and industry publications. While we believe that the statistical data, industry data and forecasts and market
research are reliable, we have not independently verified the data, and we do not make any representation as to the accuracy of
the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AYTU
BIOSCIENCE, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART&nbsp;I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>Item&nbsp;1.
Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant
medical needs. We have multiple approved products on the market, and we seek to build a portfolio of novel therapeutics that serve
large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists
of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries.
We are currently concentrating on hypogonadism, male infertility and, recently, insomnia and plan to expand into other indications
for which we believe there are significant medical needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
acquired exclusive U.S. rights to Natesto<SUP>&reg;</SUP> (testosterone) nasal gel, a novel formulation of testosterone delivered
via a discreet, easy-to-use nasal gel, and we launched Natesto in the U.S. with our direct sales force in late summer 2016. Natesto
is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and
is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently
available TRTs and competes in a $1.8 billion market accounting for over 6.8 million prescriptions annually. Importantly, as Natesto
is delivered via the nasal mucosa and not the skin, there is no risk of testosterone transference to others, a known potential
side effect and black box warning associated with all other topically applied TRTs, including the market leader AndroGel<SUP>&reg;</SUP>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S. we market MiOXSYS<SUP>&reg;</SUP>, a novel in vitro diagnostic system that is currently CE marked (which generally enables
it to be sold within the European Economic Area), Health Canada cleared, and Australian TGA and Mexican COFEPRAS-approved, and
for which we intend to initiate a clinical study to enable FDA clearance in the U.S. &nbsp;Our MiOXSYS system is a novel, point-of-care
semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility. Male
infertility is a prevalent and underserved condition and oxidative stress (the core biological component measured by the MiOXSYS
system) is widely implicated in its pathophysiology. MiOXSYS was developed from our previously developed oxidation-reduction potential
research platform known as RedoxSYS<SUP>&reg;</SUP>. We are advancing MiOXSYS toward FDA clearance as an aid in the assessment
of male infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018 we acquired an exclusive U.S. license to ZolpiMist&trade;. ZolpiMist is an FDA-approved prescription product that is
indicated for the short-term treatment of insomnia, and is the only oral spray formulation of zolpidem tartrate - the most widely
prescribed prescription sleep aid in the U.S. ZolpiMist is commercially available and competes in the non-benzodiazepine prescription
sleep aid category, a $1.8 billion prescription drug category with over 43 million prescriptions written annually. Thirty million
prescriptions of zolpidem tartrate (Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;, Edluar&reg;, ZolpiMist&trade;, and generic forms
of immediate-release, controlled release, and orally dissolving tablet formulations) are written each year in the U.S., representing
almost 70% of the non-benzodiazepine sleep aid category. Approximately 2.5 million prescriptions are written for novel formulations
of zolpidem tartrate products (controlled release and sublingual tablets). We intend to integrate ZolpiMist into our sales force&rsquo;s
promotional efforts as an adjunct product to Natesto as there is substantial overlap of physician prescribers of both testosterone
and prescription sleep aids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future we will look to acquire additional commercial-stage or near-market products, including existing products we believe
can offer distinct commercial advantages. Our management team&rsquo;s prior experience has involved identifying both clinical-stage
and commercial-stage assets that can be launched or re-launched to increase value, with a focused commercial infrastructure specializing
in novel, niche products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Natesto&reg;
(testosterone) nasal gel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 22, 2016, we entered into an agreement to acquire the exclusive U.S. rights, which rights we acquired on July 1, 2016, to
Natesto (testosterone) nasal gel, from Acerus Pharmaceuticals Corporation, or Acerus. Natesto is a patented, FDA-approved testosterone
replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the U.S. Natesto is
a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable,
Transportation Security Administration, or TSA-compliant, and easy to use. Importantly, Natesto is not applied directly to the
patient&rsquo;s skin as other topically applied TRTs. Rather, Natesto is delivered directly into the nasal mucosa via a proprietary
nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&rsquo;s female
partner or children &mdash; as other topically (primarily gels and solutions) administered TRTs do by virtue of their delivery
directly onto the skin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
launched Natesto in the U.S. in late summer 2016 with our direct sales force, and we are positioning Natesto as the ideal treatment
solution for men with active, busy lifestyles who suffer from hypogonadism. Natesto is also positioned for men who have previously
been prescribed a TRT, including Androgel, and want a product with a different clinical profile available in a convenient, easy-to-use,
effective therapeutic option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MiOXSYS&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.2pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MiOXSYS
is a rapid <I>in vitro</I> diagnostic system that performs a semen analysis test used to measure static oxidation-reduction potential,
or sORP, in human semen. MiOXSYS is a CE marked system (that is also Health Canada, Australian TGA and Mexican COFEPRAS approved)
and is an accurate, easy to use, and fast infertility assessment tool that directly measures oxidative stress in semen though
the direct measurement of oxidation-reduction potential. It is estimated that 72.4 million couples worldwide experience infertility
problems. In the U.S., approximately 10% of couples are defined as infertile. Male infertility is responsible for between 40 &ndash;
50% of all infertility cases and affects approximately 7% of all men. Male infertility is often unexplained (idiopathic), and
this idiopathic infertility is frequently associated with increased levels of oxidative stress in the semen. As such, having a
rapid, easy-to-use diagnostic platform to measure oxidative stress may provide a practical way for male infertility specialists
to improve semen analysis and infertility assessments without having to refer patients to outside clinical laboratories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male
infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. The global male infertility
market is expected to grow to over $300 million by 2020 with a compound annual growth rate, or CAGR, of nearly 5% from 2014 to
2020. Oxidative stress is broadly implicated in the pathophysiology of idiopathic male infertility, yet very few diagnostic tools
exist to effectively measure oxidative stress levels in men. However, antioxidants are widely available and recommended to infertile
men without easy, accurate assessment methods available for initial evaluation and subsequent response to antioxidant intervention.
With the introduction of the MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool
to assess the degree of oxidative stress and potentially enable the monitoring of patients&rsquo; responses to antioxidant therapy
as a treatment regimen for infertility. The MiOXSYS System received CE marking in Europe in January 2016 and obtained Health Canada
Class II Medical Device approval in March 2016. The product subsequently received Australian TGA approval in November of 2017
and clearance in Mexico in March of 2018. We expect to advance MiOXSYS into clinical trials in the U.S. in order to enable 510k
de novo clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZolpiMist&trade;
(zolpidem tartrate oral spray)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2018, the Company acquired an exclusive license for ZolpiMist from Magna Pharmaceuticals, Inc. This agreement allows
for Aytu&rsquo;s exclusive commercialization of ZolpiMist in the U.S. and Canada, and the ability to sublicense the product for
commercialization in Canada. The ZolpiMist license adds another unique, commercial-stage product to the Company&rsquo;s product
portfolio and provides our U.S. sales force with another novel product to sell to their already-called-on primary care (family
medicine, internal medicine, general practice) physician targets. More than half of our sales force&rsquo;s Natesto physician
targets are primary care physicians, so there is a significant overlap in targets and opportunity to enable them to efficiently
sell both Natesto and ZolpiMist to these prevalent, high-prescribing clinicians. The Company expects to formally launch ZolpiMist
through its U.S. sales force in late 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZolpiMist
is an FDA-approved prescription product that is indicated for the short-term treatment of insomnia, and is the only oral spray
formulation of zolpidem tartrate - the most widely prescribed prescription sleep aid in the U.S. ZolpiMist is commercially available
and competes in the non-benzodiazepine prescription sleep aid category, a $1.8 billion prescription drug category with over 43
million prescriptions written annually. Thirty million prescriptions of zolpidem tartrate (Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;,
Edluar&reg;, ZolpiMist&trade;, and generic forms of immediate-release, controlled release, and orally dissolving tablet formulations)
are written each year in the U.S., representing almost 70% of the non-benzodiazepine sleep aid category. Approximately 2.5 million
prescriptions are written for novel formulations of zolpidem tartrate products (controlled release and sublingual tablets).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.5pt 0pt 0">ZolpiMist (5 mg per dose and available in both a
30-dose and 60-dose canister) was approved for marketing by the FDA in December of 2008 and was shown to be bioequivalent to Ambien&reg;
5 mg and 10 mg tablets. ZolpiMist is indicated for the short-term treatment of insomnia characterized by difficulties with sleep
initiation and is contraindicated in patients with a known hypersensitivity to zolpidem tartrate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
elements of our business strategy include:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanding
the commercialization of Natesto in the U.S. for the treatment of hypogonadism with our direct sales force.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relaunching
ZolpiMist, a prescription sleep aid that will be a complementary product to Natesto, in primary care physician offices sold through
our U.S. sales force<B>. </B>Establishing MiOXSYS as a leading in vitro diagnostic system around the world in the assessment of
male infertility through ex-US partnering; and progressing MiOXSYS through the FDA&rsquo;s 510k de novo clearance pathway.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquiring
additional marketed products and late-stage development assets that can be efficiently marketed through our growing commercial
organization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to augment our core in-development and commercial assets through efficient identification of complementary products. We intend
to seek assets that are near commercial stage or already generating revenues. Further, we intend to seek to acquire products through
asset purchases, licensing, co-development, or collaborative commercial arrangements (including co-promotions and co-marketing
arrangements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has extensive experience across a wide range of business development activities and have in-licensed or acquired
products from large, mid-sized, and small enterprises in the U.S. and abroad. Through an assertive product and business development
approach, we expect that we will build a substantial portfolio of complementary commercial and near-commercial-stage products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
History </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vyrix
Pharmaceuticals, Inc., or Vyrix, was incorporated under the laws of the State of Delaware on November 18, 2013 and was wholly-owned
by Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), or Ampio, immediately prior to the completion of the Merger (defined below).
Vyrix was previously a carve-out of the sexual dysfunction therapeutics business, including the late-stage men&rsquo;s health
product candidates, Zertane and Zertane-ED, from Ampio, that carve out was announced in December 2013. Luoxis Diagnostics, Inc.,
or Luoxis, was incorporated under the laws of the State of Delaware on January 24, 2013 and was majority-owned by Ampio immediately
prior to the completion of the Merger. Luoxis was initially focused on developing and advancing the RedoxSYS System. The MiOXSYS
System was developed following the completed development of the RedoxSYS System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 20, 2015, Rosewind formed Rosewind Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed
for the purpose of the Merger. On April 16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub
L, Inc. merged with and into Luoxis, and Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis
merged with and into Rosewind with Rosewind as the surviving corporation (herein referred to as the Merger). Concurrent with the
closing of the Merger, Rosewind abandoned its pre-merger business plans, solely to pursue the specialty pharmaceuticals, devices,
and diagnostics markets, focusing on large areas of medical need, including the business of Vyrix and Luoxis. When we discuss
our business in this Report, we include the pre-Merger business of Luoxis and Vyrix.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2015, we (i) reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name
from Rosewind Corporation to Aytu BioScience, Inc., and (ii) effected a reverse stock split in which each common stock holder
received one share of common stock for each 12.174 shares outstanding. At our annual meeting of shareholders held on May 24, 2016,
our shareholders approved (1) an amendment to our Certificate of Incorporation to reduce the number of authorized shares of common
stock from 300.0 million to 100.0 million, which amendment was effective on June 1, 2016, and (2) an amendment to our Certificate
of Incorporation to affect a reverse stock split at a ratio of 1-for-12 which became effective on June 30, 2016. At our special
meeting of shareholders held on July 26, 2017, our shareholders approved an amendment to our Certificate of Incorporation to affect
a reverse stock split at a ratio of 1-for-20 which became effective on August 25, 2017. At our annual meeting of shareholders
held on June 27, 2018, our shareholders approved another reverse stock split at a ratio of 1-for-20 which became effective on
August 10, 2018. All share and per share amounts in this report have been adjusted to reflect the effect of these reverse stock
splits (hereafter referred to collectively as the &ldquo;Reverse Stock Splits&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the near-term, we expect to create value for shareholders by implementing a focused, four-pronged strategy. Our primary focus
is on growing sales of Natesto in the U.S. and relaunching ZolpiMist through our sales force, expanding the MiOXSYS business both
inside and outside the U.S., advancing MiOXSYS toward FDA clearance, and continuing to build a product pipeline through efficient
business development. Upon achieving growth of our current, revenue-generating products, we intend to build a complementary portfolio
of aligned assets that can be efficiently commercialized through our specialty sales force and, when appropriate, aligned distribution
partners outside the U.S. In just over three years since our formation through the merger, we have acquired or in-licensed four
FDA-approved, marketed assets (and have since divested one asset &ndash; Primsol&reg; Solution and have discontinued another,
ProstaScint&reg;), launched a U.S.-based specialty sales force, advanced our lead diagnostic asset MiOXSYS to CE marking, Health
Canada clearance, Australian TGA approval, and Mexican COFEPRAS clearance, engaged in asset purchase and licensing discussions
for products aligned to our strategy, launched Natesto in the U.S. through our own sales force, licensed ZolpiMist in the U.S.
and Canada, and are now preparing for ZolpiMist&rsquo;s re-launch through our sales force.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aytu
BioScience&rsquo;s Strategic Value Drivers&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary elements of our strategy are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effectively
commercializing Natesto and ZolpiMist, our FDA-approved products through our U.S. sales force</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Natesto</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
testosterone is a condition affecting approximately 13 million U.S. men, with U.S. revenues reaching $1.8 billion for the twelve
months ending December of 2017. The market is expected to grow, and we believe multiple factors are in place to position Natesto
favorably in gaining market share in this large, growing market. By gaining less than a 5% share of the current U.S. market (assuming
similar pricing and reimbursement), a novel TRT product could achieve annual gross revenues in excess of $90.0 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
is a novel, FDA-approved testosterone replacement therapy, or TRT, indicated for the treatment of hypogonadism in men. Natesto
is the only nasal formulation of testosterone and is delivered via a proprietary nasal gel to enable simple, discreet application
of testosterone into the nostrils. By virtue of applying Natesto to the nasal mucosa, and not to the man&rsquo;s skin, there is
no risk of transference to others. As such, Natesto is the only TRT that does not have a black box warning associated with this
potential for transference. Additionally, Natesto is a convenient form of testosterone that does not require application to large
areas of the man&rsquo;s body (arms, shoulders, upper torso) as required with the market-leading product AndroGel and other topically-applied
gels. A convenient form of TRT, applied two-to-three times a day in the nostrils, may be an appropriate option for men with hypogonadism
who have active lifestyles, travel frequently, and value having a discreet way to treat their hypogonadism. Additionally, with
Natesto&rsquo;s unique pharmacokinetic profile including rapid time to C<SUB>max</SUB> and clearance in 6-8 hours, we believe
Natesto may present an improved safety profile over the currently marketed TRT formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZolpiMist</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZolpiMist
is commercially available and competes in the non-benzodiazepine prescription sleep aid category, a $1.8 billion prescription
drug category with over 43 million prescriptions written annually. Thirty million prescriptions of zolpidem tartrate (Ambien&reg;,
Ambien&reg; CR, Intermezzo&reg;, Edluar&reg;, ZolpiMist&trade;, and generic forms of immediate-release, controlled release, and
orally dissolving tablet formulations) are written each year in the U.S., representing almost 70% of the non-benzodiazepine sleep
aid category. Approximately 2.5 million prescriptions are written for novel formulations of zolpidem tartrate products (controlled
release and sublingual tablets).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZolpiMist
is a novel, FDA-approved prescription product that is indicated for the short-term treatment of insomnia, and is the only oral
spray formulation of zolpidem tartrate - the most widely prescribed prescription sleep aid in the U.S. Because of ZolpiMist&rsquo;s
oral spray delivery, patients achieve rapid increases in zolpidem tartrate blood levels with a low 5 mg dose per spray. Due to
the rapid absorption through the mucosa and increase in blood levels, patients may achieve quicker sleep onset while avoiding
first-pass liver metabolism.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have launched a commercial infrastructure in the U.S. in order to support increased sales and distribution of Natesto, and now
ZolpiMist. We have a highly experienced sales force including over thirty full-time sales representatives, and this team is distinctly
focused on impacting the prescribing of physicians throughout the U.S. Through this efficient, dedicated sales channel we believe
we will be able to increase prescribing of our unique commercial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expanding
rest-of-world commercialization of MiOXSYS for male infertility</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS System is our proprietary <I>in vitro</I> diagnostic system that measures oxidation-reduction potential (ORP) in semen
as an aid in the diagnosis of male infertility. MiOXSYS is CE Marked, Health Canada, Australian TGA and Mexico COFEPRIS approved.
Through the measurement of oxidation-reduction potential, oxidative stress is directly assessed in that ORP incorporates all known
and unknown oxidants and antioxidants in semen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male
infertility is prevalent and underserved, and oxidative stress is widely implicated in its pathophysiology. As such, we have bolstered
our research focus in this area with the MiOXSYS System to complement our focus on urologic conditions. The ex-US global male
infertility market is estimated at over $800 million in diagnostics, therapeutics, and procedure costs. Oxidative stress is broadly
implicated in the pathophysiology of idiopathic male infertility, yet very few diagnostic tools exist to effectively measure oxidative
stress levels in men. However, antioxidants are widely available and recommended to infertile men. With the introduction of the
MiOXSYS System, we believe for the first time there will be an easy and effective diagnostic tool to assess degree of oxidative
stress, monitor patients&rsquo; responses to antioxidant therapy and improve diagnosis of male infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oxidative stress is recognized as a cause of DNA damage, which
results in higher rates of sperm dysfunction and infertility. The MiOXSYS System is the only system that directly measures oxidation-reduction
potential to provide a comprehensive measurement of oxidative stress, and multiple studies have demonstrated the predictive value
of ORP as it relates to both predicting semen quality (sperm motility, sperm concentration, sperm morphology) and correlates to
infertility rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MiOXSYS
has now been sold into 29 countries around the world through a distribution network comprised of companies who are active in the
infertility market. We support the commercialization of MiOXSYS through active development of clinical and scientific data, promotion
to key opinion leaders in the field of infertility, and active work with our distributor partners to promote the benefits of MiOXSYS
and its key diagnostic output, static oxidation-reduction potential (sORP). Prominent centers around the world have utilized MiOXSYS
in both clinical and research environments, and these include Cleveland Clinic in Cleveland, Ohio, Tulane University in New Orleans,
Louisiana, Hamad Medical Corporation in Doha, Qatar, Dokkyo University Hospital in Tokyo, Japan, Singapore General Hospital in
Singapore, Invicta Clinic in Poland, Zech Clinic in Austria, and many others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2017, the European Society for Human Reproduction and Embryology (ESHRE) published clinical
guidelines surrounding Recurrent Pregnancy Loss. This notable organization specifically recommended testing for DNA damage in sperm
for men whose female partners have suffered recurrent pregnancy loss. The MiOXSYS System is capable of performing this test. Additionally,
oxidative stress is implicated as a cause of DNA damage and testing and potential treatment to improve seminal oxidative stress
levels is recommended. This publication highlights the growing base of support for advanced semen testing in the context of oxidative
stress testing to further assess sperm damage and help further identify potential underlying causes of damage. We expect this guideline,
along with the increasing body of evidence supporting oxidation-reduction potential as a strongly correlated marker in male infertility,
to further drive awareness of the clinical utility of MiOXSYS and accelerate adoption for the MiOXSYS System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advance
MiOXSYS through clinical studies to enable FDA clearance.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
MiOXSYS now CE marked, Health Canada, Australian TGA and Mexican COFEPRAS approved, and available for sale in many markets outside
the U.S., we believe we are positioned to initiate our clinical studies in the U.S. to enable 510k de novo clearance in the near
future. We expect to receive guidance from the FDA on clinical study design and patient criteria and implement the required clinical
program as soon as possible. If cleared in the U.S., MiOXSYS would be the first and only semen analysis diagnostic test cleared
by the FDA for the detection of oxidative stress in infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged with the FDA initially and submitted a pre-submission around the concept of oxidation-reduction potential measurement
as an aid in the assessment of male infertility and believe that, with further development of a specific male infertility intended
use, we can re-approach the FDA with a clinical study plan and specific protocol developed that would enable us to progress with
a pivotal clinical trial, thus enabling 510k de novo clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identifying
                                         and acquiring complementary commercial-stage or near commercial-stage assets</B>&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to diversify our product portfolio and create more
value, we intend to seek to acquire complementary products or product candidates to develop and/or commercialize, including marketed
assets. Initially, the focus will be on acquiring commercial stage products or near-commercial stage product candidates for large,
underserved conditions. We will opportunistically consider products or product candidates based on their ability to create value
and complement our infrastructure&rsquo;s focus and expertise. We plan to pursue product acquisitions, inclusive of therapeutics,
diagnostics, and devices, which we will evaluate for their strategic fit and potential for near-term and/or accretive value to
us. In a little over two months from the Company&rsquo;s merger in April 2015, we began generating revenue from the acquisition
of ProstaScint, we later launched Natesto in July 2016, and will launch ZolpiMist through its U.S. sales force in late 2018. We
expect to continue to identify and acquire additional, complementary assets in the future as part of our expansion plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
FDA &ndash; Approved Products&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
two primary therapeutic products have received FDA approval for marketing in the U.S.: Natesto and ZolpiMist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Natesto
for Testosterone Replacement&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 22, 2016, we entered into a license and supply agreement
to acquire the exclusive U.S. rights, which rights we acquired on July 1, 2016, to Natesto<SUP>&reg;</SUP> (testosterone) nasal
gel from Acerus Pharmaceuticals Corporation, or Acerus. Natesto is a patented, FDA-approved testosterone replacement therapy,
or TRT, and is the only nasally-administered formulation of testosterone available in the U.S. Natesto is a discreet, easy-to-administer
nasal gel that may be appropriate for men with active lifestyles as Natesto is small, portable, TSA-compliant, and easy to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importantly,
Natesto is not applied directly to the patient&rsquo;s skin as other topically applied TRTs are. Rather, it is delivered directly
into the nasal mucosa via a patented nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone
transference to a man&rsquo;s female partner or children &mdash; as other topically (primarily gels) administered TRTs do by virtue
of their delivery directly onto the skin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Image
of Natesto (testosterone) nasal gel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unique delivery of Natesto also enables simple, discreet use by a single application into each nostril three times daily and may
improve compliance over topical forms that are applied to large sections of the arms, shoulders, and other large areas of the
man&rsquo;s upper torso. It also offers a more discreet method of TRT administration compared to films and patches (such as Androderm&reg;)
and doesn&rsquo;t involve the pain, potential for site injection infections, and the administration inconvenience of the implantable
and/or injectable TRTs such as Testopel&reg; (pellets), Aveed&reg; (injectable testosterone undecanoate) or testosterone cypionate
injections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
concern associated with the use of the currently marketed testosterone gels is the unintentional transfer of testosterone to women
(or children) by skin contact with the man&rsquo;s application site. In the event of a female partner receiving inadvertent testosterone
exposure due to intimate contact with her male partner, she may develop hyperandrogenism, a condition characterized by excess
levels of androgens. This condition may result in women developing acne, scalp hair loss, excessive facial or body hair, breast
atrophy, and other symptoms. Natesto, as it is nasally administered, does not present this potential complication of &lsquo;transference&rsquo;
and thus does not have a black box warning as is associated with the topically applied testosterone supplements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
is a nasally-administered androgen indicated for replacement therapy in adult males for conditions associated with a deficiency
or absence of endogenous testosterone including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis,
vanishing testis syndrome, orchiectomy, Klinefelter&rsquo;s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH] and luteinizing
hormone [LH]) above the normal range.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypogonadotropic
hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic
injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal
or low range.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
U.S. Testosterone Replacement Therapy (TRT) Market</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have an opportunity to significantly increase revenue with Natesto in the U.S. as Natesto competes in a large, growing
market. The U.S. TRT market is large, with annual revenues in the U.S. of $1.8 billion for the 12-month period ending December
2017. At the current market size of $1.8 billion, a product with 5% market penetration could achieve sales in excess of $90 million
annually, assuming comparatively similar product pricing and reimbursement levels as seen with other TRTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, injections,
and patches. Testopel, an implantable pellet implanted directly under the skin by a physician, is also FDA-approved and marketed
by Endo International plc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA-approved TRTs include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brand
    Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 26%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
    of Delivery</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 22%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
    Approved</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Black
    Box Warning</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Androderm&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Film/Patch</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actavis</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1995</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AndroGel&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AbbVie</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2000</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aveed&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injection</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Axiron&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solution</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eli Lilly &amp;
    Company</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2010</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fortesta&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2010</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Striant&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extended Release
    Tablet</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2003</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testim&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo Pharmaceuticals</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2002</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testoderm&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Film/Patch</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Johnson &amp; Johnson</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1993</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Testopel&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Injection</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endo International</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1972</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vogelxo&reg;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gel</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upsher-Smith</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AndroGel&reg;,
marketed by AbbVie, is the leading TRT and had 2017 revenues of over $1.0 billion and over 1.3 million prescriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importantly,
however, AndroGel is now facing generic competition with the expiration of key patents for its 1.0% formulation, and it is expected
that generic equivalents to its 1.62% formulation will soon be introduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>About
Hypogonadism</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male
hypogonadism is a condition in which the body does not produce enough testosterone &mdash; the hormone that plays a key role in
masculine growth and development during puberty &mdash; or has an impaired ability to produce sperm, or both. Men can be born
with male hypogonadism, or it can develop later in life from injury or infection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypogonadism
is formally defined as deficient or absent male gonadal function that results in insufficient testosterone secretion. Hypogonadism
may be caused primarily by testicular failure, or secondarily by hypothalamic-pituitary axis dysfunction, resulting in the production
or release of insufficient testosterone to maintain testosterone-dependent functions and systems. It can also result from a combination
of testicular failure and hypothalamic-pituitary axis dysfunction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hypogonadism
affects an estimated 13 million men in the U.S., and although it may occur in men at any age, low testosterone levels are especially
common in older males. More than 60% of men over age 65 have free testosterone levels below the normal values of men aged 30 to
35. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
testosterone, as male hypogonadism is also known, is associated with a number of signs and symptoms, most notably loss of libido
and erectile dysfunction (ED). Other signs of low testosterone include depressive symptoms, a decrease in cognitive abilities,
irritability and lethargy or loss of energy. Deficient endogenous testosterone also has negative effects on bone mass and is a
significant risk factor for osteoporosis in men. Progressive decrease in muscle mass and muscle strength, and testicular dysfunction,
often resulting in impaired sperm production, are also associated with low testosterone levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
younger patient may have pure hypogonadism as a primary event, whereas an older man may have an age-related decline in testosterone
production that is a part of his ED profile. However, because both ED and loss of libido are hallmarks of hypogonadism, for a
patient who presents with ED it is recommended that he have a basic hormone profile to determine if he has low testosterone. Treatments
to normalize testosterone can not only improve libido, energy level and the potential to have normal erections, but can also improve
the response to sildenafil, if that is deemed appropriate treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Natesto
Clinical Studies Demonstrating Safety and Efficacy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
has been shown to be safe and effective in men with hypogonadism and was approved by the FDA in May 2014.The details of the U.S.-based
pivotal trial are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its pivotal clinical trial, Natesto was evaluated for efficacy in a 90-day, open-label, multicenter study of 306 hypogonadal men.
Eligible patients were 18 years of age and older (mean age 54 years) and had morning serum total testosterone concentrations less
than 300 ng/dL. Patients were Caucasian (89%), African-American (6%), Asian (5%), or of other ethnicities (less than 1%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
were instructed to self-administer Natesto (11 mg of testosterone) intranasally either two or three times daily.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary endpoint was the percentage of patients with an average serum total testosterone concentration (C<SUB>avg</SUB>) within
the normal range (300 to 1050 ng/dL) on Day 90.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secondary endpoint was the percentage of patients with a maximum total testosterone concentration (C<SUB>max</SUB>) above three
predetermined limits: greater than 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 78 hypogonadal men received Natesto (11 mg of testosterone) three times daily (33 mg of testosterone daily). Of these,
a total of 73 hypogonadal men were included in the statistical evaluation of efficacy (total testosterone pharmacokinetics) on
Day 90 based on the intent-to-treat (ITT) population with last observation carried forward (LOCF). Ninety percent of these 73
patients had a C<SUB>avg</SUB> within the normal range (300 to 1050 ng/dL) on Day 90. The percentages of patients with C<SUB>avg
</SUB>below the normal range (less than 300 ng/dL) and above the normal range (greater than 1050 ng/dL) on Day 90 were 10% and
0%, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below (Table 3 from the Natesto Prescribing Information) summarizes the mean (SD) serum total testosterone concentrations
on Day 90 in 69 patients who had a full pharmacokinetic sampling profile and were treated with Natesto (11 mg of testosterone)
three times daily for 90 days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: #000000"><B>Table 3:
Mean (SD) Serum Total Testosterone Concentrations on Day 90 Following</B></FONT><BR>
<FONT STYLE="color: #000000"><B>Administration of Natesto (11 mg of testosterone) Three Times Daily</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; border-top: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #000000"><B>Natesto
    </B></FONT><FONT STYLE="color: #000000"><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(11 mg of testosterone) Three Times Daily (N=69)</B></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">C<SUB>avg</SUB>(ng/dL)</FONT></TD>
    <TD STYLE="text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">421 (116)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">C<SUB>max</SUB>(ng/dL)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">1044 (378)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">C<SUB>min</SUB>(ng/dL)</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #000000">215
    (74)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: #000000">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the same clinical trial studying, the safety and efficacy of Natesto, which was conducted at 39 U.S. outpatient sites, it was
shown that 70% of the per protocol patients in the twice-daily &lsquo;titration arm&rsquo; (n=141) achieved normal testosterone
levels. Ninety-one percent of the per protocol patients in the thrice-daily group (n=77) achieved normal testosterone levels,
demonstrating that the majority of men in both treatment groups achieved normalization of testosterone levels while taking Natesto.
The efficacy of both B.I.D. (twice daily) and T.I.D. (three times daily) dosing of Natesto is demonstrated in the graphs below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recently
Presented Natesto Safety and Efficacy Data</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary
endpoints that were measured in the above-referenced pivotal trial included the impact on Natesto &ndash; over 90 days &ndash;
on erectile function, as well as on mood. The 90-day clinical trial demonstrated that &ndash; within 30 days of initiating treatment
with Natesto &ndash; subjects exhibited a statistically significant and clinically meaningful improvement in all five domains
of erectile function. Specifically, at the end of the 90-day treatment period, improvement from baseline for each domain were
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42%
                                         improvement in intercourse satisfaction</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38%
                                         improvement in overall satisfaction</FONT></TD></TR>                                                                                                                                 <TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">36% improvement in erectile function</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35%
                                         improvement in orgasmic function</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31%
                                         improvement in sexual desire</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-indent: -18pt">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to demonstrating a significant improvement in erectile function, Natesto also exhibits a substantial impact on mood as
measured by the Positive Affect and Negative Affect Schedule (PANAS). As early as 30 days &ndash; and continuing up to day 90
&ndash; Natesto demonstrates a substantial increase in Positive Affect and a substantial decrease in Negative Affect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to efficacy parameters, safety parameters have also been examined and recently reported. Safety issues frequently associated
with prolonged use of testosterone replacement therapies, most notably injectable agents, include the fact that gonadotropin levels
(specifically luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels) frequently decrease and result in diminished
endogenous testosterone production (primarily through the reduction of LH) and reduced sperm production (primarily through the
reduction of FSH), both of which have negative implications on reproductive health and overall male hormonal balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
restores serum testosterone to normal levels while follicle stimulating hormone (FSH) and luteinizing hormone (LH) remained well
within the reference range over 90 days of Natesto administration. Also, hematocrit (responsible for maintaining blood thickness)
was not significantly impacted by Natesto over 360 days of treatment. It has been established that other testosterone replacement
therapies alter levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) and increase hematocrit, so we believe
Natesto&rsquo;s clinical profile may offer distinct safety advantages for patients over the other currently available therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
treated with Natesto for 90 days, restored serum testosterone levels while FSH and LH levels remained within the reference range
as depicted in the figure below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
these same patients maintained normal hematocrit levels over a 360-day extension period in the pivotal trial &ndash; as depicted
in the figure below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Natesto
Product Features and Patient Benefits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Natesto has a unique opportunity to gain market share in the more than $1.8 billion U.S. market given Natesto&rsquo;s
novel features and patient benefits, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ease
                                         of administration; appropriate for men with busy, active lives;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
                                         efficacy in pivotal FDA trials with a unique, low dose of testosterone; Effective in
                                         improving serum testosterone levels while using a proven, lower dose of testosterone;
                                         significant symptom improvement, notably:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
caused statistically significant improvements in each of the 5 domains of erectile function (<I>P</I> &lt; 0.0001); The majority
of the effect on erectile dysfunction was evident by Day&nbsp;30.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantial
Increase in Positive Affect <I>and</I> Substantial Decrease in Negative Affect (PANAS) as early as day 30 (<I>P</I> &lt; 0.0001).</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discreet
                                         product presentation and ease of transport (TSA compliant); Important for men who travel
                                         frequently and desire a simple, portable solution that travels easily with them;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                         risk of secondary exposure to testosterone due to dermal transference, an important consideration
                                         when thinking about a hypogonadal man&rsquo;s partner&rsquo;s or child&rsquo;s safety;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
                                         has a favorable safety profile as demonstrated by the following:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
incidence of rising Prostate specific antigen (&ldquo;PSA&rdquo;) levels than the market leading product AndroGel; Natesto demonstrates
a 5.5% rate of rising PSA levels in clinical trials, while AndroGel demonstrated a rising PSA rate of over 11% in clinical trials.
This is an important consideration as physicians concerned with understanding and tracking prostate cancer risk frequently monitor
PSA levels in men over 50 years of age.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
restored serum testosterone to normal levels while Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) remained well
within the reference range over 90 days.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hematocrit
(increased blood thickness) was not significantly impacted by Natesto over 360 days of treatment.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-indent: -18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
has proven efficacy and a product profile well suited for men suffering from hypogonadism who have active, busy lifestyles who
want a simple, discreet TRT option. We believe Natesto can play an important role in the treatment of hypogonadism, a condition
affecting approximately 13 million U.S. men.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Natesto Market Events</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recent market events involving prospective Natesto competitors
may lead to an improved competitive position for Natesto in the U.S. as we continue to build awareness and expand market share
in the TRT category. On January 10th, 2018 Lipocine Inc. (NASDAQ: LPCN) announced that the Bone, Reproductive and Urologic Drugs
Advisory Committee (&ldquo;BRUDAC&rdquo; also known as &ldquo;AdCom&rdquo;) of the U.S. FDA voted six in favor and thirteen against
the benefit/risk profile of Tlando, Lipocine&rsquo;s oral testosterone product candidate for testosterone replacement therapy
(&ldquo;TRT&rdquo;) in adult males with hypogonadism. Additionally, on January 9<SUP>th</SUP>, 2018 the FDA held a separate Advisory
Committee meeting to review privately-held Clarus Therapeutics&rsquo; oral testosterone candidate Jatenzo. The committee also
voted against approving Clarus&rsquo; candidate primarily over safety concerns. Thus, it is highly unlikely that either product
will be approved by FDA at this time, and the prospect of an FDA approval at any point in the future remains doubtful. In fact,
Lipocine issued a press release in May 2018 confirming that Lipocine had received a Complete Response Letter (CRL) from the FDA
informing the company that Tlando was not approvable in its current form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the recommendations to not approve Tlando and Jatenzo and the subsequent Complete Response Letter on Tlando specifically,
could yield important commercial benefits for Natesto and further bolsters Natesto&rsquo;s unique market position as the only
topical TRT without a BLACK BOX warning explicitly warning users of these agents against the risk of testosterone transference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One of the issues cited as a reason for the negative AdCom
sentiment, and subsequent CRL, on these oral testosterone therapies is related to the products&rsquo; cardiovascular risk profiles
as presented in their New Drug Applications. Also, and more generally, an increase in hematocrit levels is broadly cited as a
safety concern in the TRT category and has been noted to be an issue of potential focus for future TRT product candidates. Importantly
(and in direct contrast to many agents in the TRT category), Natesto (over 360 days on treatment demonstrated) no significant
increase in hematocrit levels and may, therefore, offer an improved safety profile over the established products in the TRT category.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
in October 2017, Antares Pharmaceuticals received a CRL from the FDA for its product candidate Xyosted&reg;, an injectable testosterone
replacement therapy. In its response, the FDA cited multiple safety concerns related and, we believe, the launch of this product
may be substantially delayed &ndash; or may not occur at all. Antares has recently resubmitted the application for approval for
Xyosted, and the FDA has issued a PDUFA date of September 29, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
CRLs point to the high burden of proof placed on developers of TRT product candidates and, we believe, further validates the value
of Natesto as an-already-FDA-approved product in this $1.8 billion product category. With the prospects of future prospective
competitive products in doubt, Natesto&rsquo;s competitive position may be improved and even more sustainable for the foreseeable
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZolpiMist
for the Short-Term Treatment of Insomnia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2018 the Company signed an exclusive license for ZolpiMist&trade; (Zolpidem Tartrate Oral Spray) with Magna Pharmaceuticals,
Inc. This agreement allows for Aytu&rsquo;s exclusive commercialization of ZolpiMist in the U.S. and the ability to sublicense
the product for commercialization in Canada. The ZolpiMist license adds another unique, commercial-stage product to the Company&rsquo;s
product portfolio and provides our U.S. commercial team with another novel product to sell to their already-called-on physician
targets. More than half of our sales force&rsquo;s Natesto physician targets are primary care physicians (family medicine, internal
medicine, general practice), so there is a significant overlap in targets and opportunity to enable them to efficiently sell both
Natesto and ZolpiMist to these prevalent, high-prescribing clinicians. The Company expects to formally launch ZolpiMist through
its U.S. sales force in late 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZolpiMist
is an FDA-approved prescription product that is indicated for the short-term treatment of insomnia and is the only oral spray
formulation of zolpidem tartrate - the most widely prescribed prescription sleep aid in the U.S. ZolpiMist is commercially available
and competes in the non-benzodiazepine prescription sleep aid category, a $1.8 billion prescription drug category with over 43
million prescriptions written annually. Thirty million prescriptions of zolpidem tartrate (Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;,
Edluar&reg;, ZolpiMist&trade;, and generic forms of immediate-release, controlled release, and orally dissolving tablet formulations)
are written each year in the U.S., representing almost 70% of the non-benzodiazepine sleep aid category. Approximately 2.5 million
prescriptions are written for novel formulations of zolpidem tartrate products (controlled release and sublingual tablets).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ZolpiMist (5 mg per dose and available in both a 30-dose and
60-dose canister) was approved for marketing by the FDA in December of 2008 and was shown to be bioequivalent to Ambien&reg; 5
mg and 10 mg tablets. ZolpiMist is indicated for the short-term treatment of insomnia characterized by difficulties with sleep
initiation and is contraindicated in patients with a known hypersensitivity to zolpidem tartrate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Image
of ZolpiMist in its Child-Resistant Container</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_008.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to ZolpiMist&rsquo;s unique oral spray delivery and the resulting rapid absorption through the oral mucosa, ZolpiMist has several
clinical advantages over oral tablet formulations, most notably a rapid onset of action that quickly induces sleep. Additionally,
and also due to the product&rsquo;s oral spray formulation, ZolpiMist does not require swallowing and may therefore be easier
and more convenient to take than tablets for patients who have difficulty swallowing or have an aversion to taking tablets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmacokinetic
data as published in the ZolpiMist Clinical Study Report demonstrate multiple distinctions between ZolpiMist and oral zolpidem
tartrate tablets in the study that led to the product&rsquo;s approval. Specifically, more patients achieve high blood levels
of zolpidem faster with oral spray delivery than with tablets &ndash; and this is expected to derive faster onset of sleep.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a study of 46 insomnia patients, a significantly higher proportion of patients receiving 5 mg of zolpidem tartrate achieved plasma
levels associated with sedation with the oral spray formulation than with the oral tablet formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
figure below depicts the difference in plasma levels between patients taking ZolpiMist and patients taking Ambien oral tablets.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, 23% of patients demonstrated sedation-associated
blood levels 10 minutes post taking ZolpiMist, while zero zolpidem tartrate tablet patients achieved those levels (20 ng/mL).
Similarly, almost twice as many ZolpiMist patients (77%) achieved sedation-associated blood levels than zolpidem tartrate tablet
patients (40%) at 20 minutes, a statistically significant difference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Time
to various sedation-associated blood levels are shown in the figure below.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
ZolpiMist offers patients the convenience and speed of onset available through an oral spray, this method of administration may
also present a desirable option for patients who have difficulty swallowing. Estimates suggest that 15% of the elderly population
is affected by dysphagia, with potentially higher incidence among stroke and dementia patients, as well as patients with neurological
diseases, cancers of the head and neck, and esophagus. For these patients, many of whom are challenged with sleep difficulties,
ZolpiMist may be an appropriate first option. For patients not affected by dysphagia, they may simply want a faster, more convenient
way to take zolpidem tartrate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. prescription sleep aid (non-benzodiazepine) category is large, and many primary care physicians prescribe these products
routinely. Achieving even a modest 1% share of this 30 million prescription-a-year zolpidem tartrate category could achieve approximately
$75 million in net revenues. While the Company has not made revenue projections for ZolpiMist, we do believe this product represents
a substantial revenue opportunity for the Company given the product&rsquo;s market potential and the unique product features and
patient benefits of ZolpiMist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MiOXSYS
<I>In Vitro</I> Diagnostic System for Male Infertility&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male
infertility is a significant medical condition that urologists and infertility specialists treat frequently in the office setting
or specialized fertility centers around the world. Of all sexually active couples, 8% to 12% are infertile and male infertility
is the sole cause or contributing factor up to 50% of the time. The global male infertility market is large and growing. The market
for male infertility diagnosis and treatments is expected to grow to more than $300 million globally by 2020, with a CAGR of nearly
5% from 2014 to 2020. Despite the prevalence of male infertility, difficulties remain in effectively diagnosing root causes. Oxidative
stress assessment is considered a standard practice in complex andrology laboratories around the world, but due to various factors
oxidative stress testing is not routinely employed in clinicians&rsquo; offices or standard laboratory settings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seminal
oxidative stress has been well established throughout the peer-reviewed literature to play a substantial role in unexplained male
infertility, and researchers and clinicians actively consider oxidative stress when conducting laboratory infertility assessment.
While oxidative stress is well established as a leading contributing factor to male infertility, a significant proportion of male
infertility remains unexplained in part because of the lack of standardized tests available to clinicians and researchers to assess
oxidative stress in semen and plasma. This lack of standardization has resulted in poor implementation of semen and plasma analysis
around the world. Further, current testing platforms are cost-prohibitive for small office settings or local medical laboratories
and require extensive training and on-site expertise. Additionally, antioxidant supplementation is frequently recommended to patients
by clinicians without an effective method of measuring treatment success. As such, we believe introducing the MiOXSYS System to
assess oxidative stress levels in semen and seminal fluid represents a significant commercial opportunity and novel way for clinicians
to assess male factor infertility and assess therapeutic responses of patients in a simple, reliable, and cost-effective way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS System was CE marked in January 2016, and we have started early commercialization efforts outside the U.S. Since CE marking,
MiOXSYS has received Health Canada approval, approval by Australia&rsquo;s TGA, and was most recently approved by Mexico&rsquo;s
COFEPRIS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
attractive aspect of the reproductive health market relates to reimbursement as infertility treatments and the associated diagnostic
tests are generally paid directly by patients. The current infertility treatments could cost in excess of $10,000 per treatment
cycle, so the addition of a moderately priced oxidative stress test would consume nominal relative costs while providing specific,
actionable information needed to improve the oxidative status of infertile patients. The current infertility treatments include
antioxidant supplements and lifestyle modifications that lower oxidative stress (e.g., smoking cessation, exercise, dietary changes,
etc.), so the measurements reported by the MiOXSYS System could effectively guide treatment in the infertile patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global male infertility market is expected to grow to more than $300 million by 2020. With a substantial base of conditions for
which the MiOXSYS System may present utility, we believe there is significant revenue potential from this first-in-class system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our strategy to develop future clinical applications of the RedoxSYS System (the MiOXSYS System&rsquo;s predecessor product
for plasma and whole blood detection), we have conducted initial studies in male reproductive health. Male infertility is a significant
medical condition in which oxidative stress is well known to play a substantial role. As such, we believe developing a clinical
application to assess oxidative stress levels with the uniquely designed and programmed MiOXSYS System for semen analysis represents
a significant commercial opportunity. Oxidative stress is well established as a leading contributing factor to male infertility.
Further, a significant proportion of male infertility remains unexplained in part because of the lack of standardized tests available
to clinicians and researchers to assess oxidative stress in semen and seminal plasma. This lack of standardization has resulted
in poor implementation of semen and plasma analysis around the world. Further, currently available tests are cumbersome, time
consuming to perform, and costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted initial proof-of-concept clinical studies in male infertility with a leading research center in the U.S., which demonstrated
that oxidation-reduction potential effectively measures oxidative stress levels in semen and seminal plasma &mdash; and that these
levels strongly correlate with established markers of infertility. Semen analysis studies are routinely conducted to assess causes
of infertility, so we expect clinicians and oxidative stress researchers to readily integrate the MiOXSYS System into routine
use upon the completion of more extensive studies and regulatory clearance for this use. Additional studies are now in the late
planning stages that will evaluate the MiOXSYS System&rsquo;s performance in the detection of oxidative stress levels and correlations
with key semen parameters in both healthy and infertile males. The MiOXSYS System must receive 510k de novo clearance from the
FDA before we can market it for clinical use in the U.S. Of the $300 million male infertility market projected for 2020, the North
American, Middle Eastern, and Asia Pacific markets dominate due to prevalence, awareness of treatment, and availability of treatment
resources. Thus, it is important that we have already established distribution relationships and direct access to major oxidative
stress researchers in many of these important markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our initial proof of concept studies with a leading center in the U.S. with the MiOXSYS system, we conducted our CE mark-enabling
study with over 300 infertile patients. The two key studies conducted with these leading centers are presented below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.-Based
Proof-of-Concept Clinical Study&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifty-one
(51) male patients were seen at the Cleveland Clinic&rsquo;s andrology laboratory for suspected infertility. In addition to standard
semen analyses (WHO 5<SUP>th</SUP> Edition, 2010), samples were measured for oxidative stress using the MiOXSYS System. Raw sORP
values were normalized to sperm concentration (mv/10<SUP>6</SUP> sperm/mL) and compared across six semen parameters that are associated
with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive motility, and normal morphology.
Higher sORP values are associated with a higher state of oxidative stress given that sORP is a direct measure of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
with abnormally low ejaculate volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm
concentration or overall total number, have significantly higher sORP values than those in the normal range. Abnormally few motile
sperm or few sperm with a progressive motility were also associated with significantly higher sORP values than those in the normal
range. Lastly, semen samples that had fewer normal sperm had slightly, but not significantly, higher sORP values. Thus, most abnormal
semen parameters appear to be associated with higher measures of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
samples that achieve all six parameters associated with fertile semen are compared to samples that fail one or more of the parameters,
the samples that meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of
1.635 mv/10<SUP>6</SUP> sperm/mL separated those that met fertility standards from those that did not. In the current study, 85.7%
of samples that met standards fell below this cutoff value, whereas 71.8% of those that failed one or more parameters had sORP
values above this cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff is abnormal in
at least one of the semen parameters, is 96.5%. Lastly, the more parameters that a semen sample falls within the abnormal range,
the higher the sORP values, thus those that are abnormal on five or six parameters have higher sORP values than those that are
abnormal on one or two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
derived from patients confirms the results obtained in an international fertility clinic. Overall, semen that falls into the abnormal
range for concentration, total number, motility, and morphology have higher levels of oxidative stress as indicated by higher
sORP values. These values are uniquely obtained using the MiOXSYS System for semen analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2016, we observed encouraging data from two additional prospective studies of the MiOXSYS System that demonstrated its clinical
utility as a tool for measuring ORP to assess the degree of oxidative stress levels in human semen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first study measured sORP in the semen samples of infertile men that correlated well with the sperm concentration, motility, and
morphology. The second study further suggests that sORP is an easy to determine one-step indicator of increased oxidative stress
in semen samples of infertile men especially with leukocytospermia. The results are currently being validated in a larger cohort
of infertile men.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>International
Pivotal Clinical Study&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three-hundred
sixty-six (366) male partners from couples seeking fertility advisement in Hamad Medical Corporation in Doha, Qatar were recruited.
In addition to standard semen analyses (WHO 5<SUP>th</SUP> Edition, 2010), samples were measured for oxidative stress using the
MiOXSYS System. Raw sORP values were normalized to sperm concentration (mv/10<SUP>6</SUP> sperm/mL) and compared across six semen
parameters that are associated with fertility: ejaculate volume, concentration, total sperm number, total motility, progressive
motility, and normal morphology. Higher sORP values are associated with a higher state of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
with abnormally low ejaculate volume had similar sORP values as those with a normal volume. Those with an abnormally low sperm
concentration or overall total number, have significantly higher sORP values than those in the normal range. Abnormally few motile
sperm or few sperm with a progressive motility were also associated with significantly higher sORP values than those in the normal
range. Lastly, semen samples that had fewer normal sperm had significantly higher sORP values than those that fell into the range
of normal morphology. Thus, most abnormal semen parameters appear to be associated with higher measures of oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
samples that achieve all six parameters associated with fertile semen are compared to samples that fail one or more of the parameters,
the samples that meet the parameters have significantly lower sORP values than those that fail one or more. A cutoff value of
1.635 mv/10<SUP>6</SUP> sperm/mL separated those that met fertility standards from those that did not. In the current study, 91.43%
of samples that met fertility standards fell below this cutoff value whereas 59.5% of those that failed one or more had sORP values
above this cutoff. The probability that a semen sample with a measured sORP value higher than the cutoff is abnormal in at least
one of the semen parameters, is 98.6%. Lastly, the more parameters that a semen samples falls within the abnormal range, the higher
the sORP values, thus those that are abnormal on five or six parameters have higher sORP values than those that are abnormal on
one or two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
derived from patients at the Hamad urology department clinic confirms the results obtained in the U.S. fertility clinic. Overall,
semen that falls into the abnormal range for concentration, total number, motility, and morphology have higher levels of oxidative
stress as indicated by higher sORP values. These values are obtained uniquely using the MiOXSYS System for semen analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
clinical and scientific studies have been conducted at leading urology and andrology centers around the world, including seven
recently presented studies at the 34<SUP>th</SUP> annual meeting of European Society for Reproduction and Human Embryology (ESHRE),
which was hosted in Barcelona, Spain July 1-4, 2018. The original abstracts from those presentations are included below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigating
the reproducibility and reliability of the ORP measurement as a marker of sperm quality across different fertility centers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Agarwal<SUP>1</SUP>, R. Chandrakumar<SUP>1</SUP>, M. Arafa<SUP>2</SUP>,
H. Elbardisi<SUP>2</SUP>, H. Okada<SUP>3</SUP>, K. Suzuki<SUP>3</SUP>, S. Homa<SUP>4</SUP>, A. Killeen<SUP>5</SUP>, B.</P>

<P STYLE="margin: 0pt 0">Balaban<SUP>6</SUP>, A. Ayaz<SUP>7</SUP> R. Saleh<SUP>8</SUP>, A. Armagan<SUP>9</SUP>, S. Roychoudhury<SUP>1</SUP>,
S. Sikka<SUP>7</SUP></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
The Cleveland Clinic Foundation, American Center for Reproductive Medicine- Department of Urology- Cleveland Clinic, Cleveland-
Ohio, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Hamad Medical Corporation, Urology, Doha, Qatar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Dokkyo Medical University, Urology, Koshigaya, Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
University of Kent, Andrology, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Doctor&rsquo;s Laboratory, Andrology, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Tulane University, Urology, New Orleans, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
Sohag University, Urology, Sohag, Egypt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Bezmialem Vakif University, Urology, Istanbul, Turkey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
Assam University, Life Science and Bioinformatics, Silchar, India.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investigate
the reproducibility and reliability of the ORP measurement as a marker of sperm quality across different fertility centers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORP
provided equal or less variability than the current semen analysis measures across 9 different fertility centers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discrete
measures of free radicals, antioxidant activity, and oxidative damage suggest an ambiguous relationship between the redox system
and male fertility. Static oxidation-reduction potential (sORP) measures the balance between all oxidants and antioxidants providing
a comprehensive status of the redox system. In a previous study, ORP and semen analysis data were compared between two andrology
laboratories, in which ORP remained consistent in both datasets individually or in combined data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospective study was carried out jointly by nine participating fertility centers on 1,644 subjects. The study was approved by
the institutional ethics committee and subjects were consented prior to participation. Subjects were grouped into those that had
all normal semen parameters (concentration, total cell, total motility, progressive motility, and morphology) according to WHO
2010 guidelines and those who failed to meet one or more criteria. ANOVA/t-test measures were used to determine significant differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusion
criteria included azoospermia, presence of sexually transmitted disease or chronic disease, use of prescription, OTC medications
or antioxidants. Samples were collected, and semen parameters assessed using the WHO 2010 guidelines. ORP was measured (mV) using
the MiOXSYS system and normalized to sperm concentration (mV/10 <SUP>6</SUP> sperm/ml). For group comparisons, only those samples
with a concentration &gt; 0.999x 106 sperm/ml were included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of ORP reflects the oxidative relationship between the sperm cell and its environment - the expulsion of oxidants, a by-product
of cellular metabolism, into the seminal environment and the deactivation of them by extracellular antioxidants. The resulting
ORP measurement reflects the average of the final ten (10) seconds (or twenty readings) of the sample. Of the 1,644 samples, 138
were found to have normal semen parameters and 1,506 were found to have abnormal semen parameters. The mean ORP value (mV/10 6
sperm/ml) in the semen of the abnormal group was 5.07mV/10 6 sperm/ml whereas that of the normal group was 0.88 mV/106 sperm/ml
(p = 0.001) . The SD for ORP was equal to or better than most measures, with exception to morphology. However, it should be noted
that morphology is the parameter with the highest variability typically found between laboratories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations,
reasons for caution:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
enrollment of an even number of healthy controls with proven fertility was limited in comparison to the male infertility group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wider
implications of the findings:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORP
remains stable even with measurable differences in sperm parameters, and it therefore can be used as a supplementary test to semen
analysis to confirm oxidative stress and poor semen quality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigating
if ORP can reliably predict semen samples that meet normal reference range of WHO criteria from those that fail to meet across
fertility centers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;Agarwal<SUP>1</SUP>,
H.&nbsp;El bardisi<SUP>2</SUP>, M.&nbsp;Arafa<SUP>2</SUP>, H.&nbsp;Okada<SUP>3</SUP>, K.&nbsp;Suzuki<SUP>3</SUP>, S.&nbsp;Homa<SUP>4</SUP>,
A.&nbsp;Kileen<SUP>5</SUP>, B.&nbsp;Balaban<SUP>6</SUP>, A.&nbsp;Ayaz<SUP>7</SUP>, R.&nbsp;Saleh<SUP>8</SUP>, A.&nbsp;Armagan<SUP>9</SUP>,
C.&nbsp;Dorsey<SUP>10</SUP>, S.&nbsp;Roychoudhury<SUP>11</SUP>, S.&nbsp;Sikka<SUP>7</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
American Center for Reproductive Medicine- Cleveland Clinic, Urology, Cleveland, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Hamad Medical Corporation, Urology, Doha, Qatar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Dokkyo Medical University, Urology, Koshigaya, Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
University of Kent, Andrology, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The Doctors Laboratory, Andrology, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
American Hospital of Istanbul, Assisted Reproductive Medicine Unit, Istanbul, Turkey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Tulane University, Urology, New Orleans, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
Sohag University, Urology, Sohag, Egypt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Bezmialem Vakif University, Urology, Istanbul, Turkey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
Aytu BioScience, Englewood, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
Assam University, Life Science and Bioinformatics, Silchar, India.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify
if ORP measure could reliably predict semen samples that meet normal reference range of WHO criteria from those that fail to meet
across fertility centers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the 1,644 samples analyzed, the ORP measure provided the greatest predictability when distinguishing abnormal from normal semen
quality among patients undergoing infertility evaluation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discrete
measures of free radicals, antioxidant activity, and oxidative damage suggest an ambiguous relationship between the redox system
and male fertility. Oxidation-reduction potential (ORP) measures the balance between all oxidants and antioxidants providing a
comprehensive status of the redox system. In previous studies, ORP has been tested in semen samples using the MiOXSYS System as
an alternative method for measuring oxidative stress and distinguishing normal controls from male factor infertility patients;
thus, ORP levels may be used to clarify the relationship between the redox system and semen parameters associated with male infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospective study was carried out jointly by nine participating fertility centers on 1,644 subjects. The study was approved by
the institutional ethics committee and subjects were consented prior to participation. Subjects were grouped into those that had
all normal semen parameters (concentration, total concentration, total motility, progressive motility, and morphology) according
to WHO 2010 guidelines and those who failed to meet one or more criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusion
criteria included azoospermia, presence of sexually transmitted disease or chronic diseases, use of prescription, OTC medications
or antioxidants. Samples were collected and semen parameters assessed using the WHO 2010 guidelines. ORP was measured (mV) using
the MiOXSYS system and normalized to concentration (mV/10<SUP>6</SUP> sperm/ml). For group comparisons, only those samples with
a concentration &gt; 0.999xl 0<SUP>6</SUP> sperm/ml were included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the current study, using an ORP test in conjunction with the semen analysis measures resulted in the detection of abnormal semen
quality with a 98.1% sensitivity, 40.6% specificity, 94.7% positive predictive value, and 66.6% negative predictive value. ORP
provides a unique and statistically significant contribution in classifying semen quality into abnormal and normal status. A logistic
regression performed on all measures (six semen analysis parameters and ORP measure) revealed the predictability of identifying
abnormal/ normal semen quality within the samples. Measures were categorized according to overall contribution and significance.
ORP ranked the highest (beta 2.88, p = 0.01) in terms of predicting abnormal/ normal semen quality, followed by progressive motility
(beta 2.29, p= 0.001), and total motility (beta .494, p= 0.005). Utilizing ORP and semen analysis combined, the overall performance
characteristics were 98.1 sensitivity, 40.6 specificity, 93.3% positive predictive value, and 66.7% negative predictive value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations,
reasons for caution:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of healthy controls with proven fertility was limited in comparison to the male infertility group. While semen parameters
are an important part of the assessment of the infertile male, the gold standard is the reproductive outcome. Pregnancy outcomes
were not prospectively measured in the infertile group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wider
implications of the findings:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abnormal
ORP levels will be especially useful in pinpointing the altered functional status of the sperm in patients with idiopathic male
infertility and thereby directing those men toward accurate therapeutic management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Does
an electrochemical assay using the MiOXSYS CE-marked analyzer, consistently meet the requirements and specifications to reliably
measure static oxidation reduction potential (sORP) in human semen?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S.&nbsp;Homa<SUP>1</SUP>, A.&nbsp;Vassiliou<SUP>2</SUP>, C.&nbsp;Martin<SUP>3</SUP>, A.&nbsp;Killeen<SUP>3</SUP>, A.&nbsp;Dawkins<SUP>3</SUP>, T.&nbsp;Yap<SUP>4</SUP></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Andrology Solutions, Andrology, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
University of Kent, Department of Biosciences, Canterbury, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
The Doctors Laboratory, Department of Andrology, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Guy&rsquo;s Hospital, The Urology Centre, London, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
an electrochemical assay using the MiOXSYS CE-marked analyzer, consistently meet the requirements and specifications to reliably
measure static oxidation reduction potential (sORP) in human semen?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS assay is robust, performing according to expectations and has been standardized and validated to reliably and accurately
measure sORP in human semen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low
levels of reactive oxygen species (ROS) are prerequisite for sperm function. Physiological levels of ROS are maintained by antioxidants
(reductants) in the local environment. A disturbance in the balance between oxidants and antioxidants leads to oxidative stress
(OS), impairing sperm function and genetic integrity. A novel method for assessing OS in semen involves measuring sORP using the
MiOXSYS galvanostat-based technology analyzer. ORP measures levels of oxidants and reductants, providing a more comprehensive
measure of OS than measurement of ROS alone. Although the MiOXSYS assay effectively measures sORP in semen, it has yet to be fully
validated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
study was a technical validation of an assay for measuring sORP using the MiOXSYS CE-marked analyzer. It included 40 replicate
measurements of control samples on different days and on two separate analyzers. Intra- and inter-technician variability was determined
from 40 replicates. The characteristics of sORP in semen and the effects of independent variables were measured in 6 replicate
samples from 19 men. Variables included time from ejaculation, temperature, mechanical agitation and freeze-thaw action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assay requires applying 30&micro;1 sample onto a disposable sensor which is inserted into the MiOXSYS analyzer and a current is
applied. sORP is displayed in mV after 2-4 min. Values were recorded for different operators, days and analyzers using multipurpose
handling medium (Irvine Scientific, CA, USA) as a control. Semen samples were obtained from consenting men attending for routine
semen analysis to determine the stability of seminal ORP under different conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Measurement
of sORP (mV) using the CE-marked MiOXSYS platform (Aytu BioScience, CO, USA) demonstrated repeatability between 40 replicates
of the same control sample with no significant difference between measurements (mean sORP (mV) &plusmn; SEM= 281.5 &plusmn; 4.8;
CV= 0.1). Readings remained consistent across multiple operators (p= 0.67), separate analyzers (p= 0.95) and on different days
(p= 0.09).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
there was no significant difference between sORP values for 40 replicates of a single semen sample (mean sORP (mV) &plusmn; SEM=
45.1 &plusmn; 1.0; CV= 0.1). Although readings remain relatively stable in semen up to 45 min post ejaculation (p=0.06), there
are significant variations in seminal sORP values across all samples by 60 min post ejaculation (p &lt; 0.005). sORP in semen
remains stable after freezing and thawing as values do not change significantly (p= 0.47). This was demonstrated across biological
replicates (n= 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was a significant difference between sORP in semen after mechanical agitation using a bench-top vortex (p=0.005) and between samples
incubated at different temperatures (2 -6&deg;C, 20-24&deg; (and 36 + 1 &deg;C; p=0.003).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations,
reasons for caution:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validation of the MiOXSYS platform was carried out in one laboratory only. A multicenter validation would assist in confirming
the reproducibility and reliability of the test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wider
implications of the findings:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
simple to use, cost effective assay could be implemented in conjunction with semen analysis providing a welcomed addition to routine
diagnostic testing for male infertility. It may be particularly relevant to men with unexplained infertility, whose partners experience
a delay in conception, multiple assisted conception failures or miscarriages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Can
sperm oxidative stress, measured as static oxidation-reduction potential (sORP), predict high levels of sperm DNA damage?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;Lee<SUP>1</SUP>, B.&nbsp;Yeel<SUP>2</SUP>, A.&nbsp;Qu1<SUP>3</SUP>, S.&nbsp;Shahani<SUP>1</SUP>, S.&nbsp;Moskovtsevl<SUP>4</SUP>, C.&nbsp;Librach<SUP>4,5,6</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
cReATe Fertility Center, Andrology, Toronto, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
University of Toronto, Physiology, Toronto, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
University of Toronto, Medicine, Toronto, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
University of Toronto, Obstetrics and Gynaecology, Toronto, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
CReATe Fertility Center, Reproductive Endrocrinology, Toronto, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
Women&rsquo;s College Hospital, Gynaecology, Toronto, Canada.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Can
sperm oxidative stress, measured as static oxidation-reduction potential (sORP), predict high levels of sperm DNA damage?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sORP
was positively correlated (p= 0.002) to DNA damage and a sORP cut-off of 2.37 mV/10<SUP>6</SUP> sperm/ml was predictive of high
levels of DNA damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
levels of sperm DNA damage have been associated with decreased pregnancy rates and an increased risk of miscarriage. While the
causes are multifactorial, sperm oxidative stress has been shown to play a key role in the etiology of DNA damage. The MiOXSYS
system uses sORP, a global measure of the balance between oxidants and reductants, to determine oxidative stress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospective, institutional REB approved cross-sectional study was performed on 52 male, infertile patients presenting to the Andrology
laboratory for routine semen analysis after 2-5 days of abstinence at the CReATe Fertility Center between July 2017 and January
2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male
infertility patients with leukocytospermia or sperm concentration &lt;1 million/ml were excluded. Semen analysis was conducted
as per WHO 2010 guidelines. sORP was measured using the MiOXSYS system. DNA damage was evaluated by standard flow cytometric acridine
orange-based assay as DNA Fragmentation Index (DFI). sORP was compared between a high DFI (30%) and low DFI (&lt;30%) group and
correlated to semen parameters. Receiver Operator Curve (ROC) analysis determined the sORP cut-off predictive of high DFI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mean paternal age was 39.2&plusmn;6.1 years (age range: 28 - 54 years). The mean sperm concentration was 43.0&plusmn;37.2 M/ml,
total motility was 55.2&plusmn;14.5 %, morphology was 6.5&plusmn;4.2 %, and DFI was 21.7&plusmn;10.1 %. A significant positive
correlation was found between sORP and DFI (r=0.43, p= 0.002). A significant negative correlation was found between sORP and concentration
(r=-0.46, p= 0.0006) and between sORP and morphology (r=-0.33, p=0.02). Mean sORP was significantly higher (p=0.03) in the high
DFI group (4.29&plusmn;2.52mV/10<SUP>6</SUP> sperm/ml) compared to the low DFI group (1.87&plusmn;2.17 mV/106 sperm/ml). ROC analysis
indicated that a sORP cut-off of 2.37 mV/10<SUP>6</SUP> sperm/ml had a sensitivity of 75.0%, a specificity of 77.2%, a positive
predictive value (PPV) of 37.5% and a negative predictive value (NPV) 94.5%. The area under the ROC (AUROC) was 0.84 (95% Cl:
0.72 - 0.96, p=0.003) and the diagnostic accuracy was 76.9%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #363636"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations,
reasons for caution:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
additional confirmatory DNA damage methodologies were assessed. The DNA damage assay used in this study is generally considered
the gold standard, however several alternatives are also routinely used. Larger standardized studies are needed to confirm the
performance characteristics of sORP in predicting high DFI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wider
implications of the findings:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Requiring
as little as 5 minutes to complete and a drop (30 ul) of semen, the MiOXSYS system provides a rapid, cost-effective measure of
global oxidative stress easily integrated into clinical workflows. It can be used to specifically identify patients with oxidative
stress induced DNA damage for anti-oxidant therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Does
evaluation of static oxidation-reduction potential (sORP) with MiOXSYS System relate with WHO 2010 (World Health Organization)
sperm parameters and DNA fragmentation in infertile patients? </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.&nbsp;Scarselli<SUP>1</SUP>, S.&nbsp;Gatti<SUP>1</SUP>, E.&nbsp;Cursio<SUP>1</SUP>, A.&nbsp;Pristera<SUP>1</SUP>, V.&nbsp;Zazzaro<SUP>1</SUP>, M.&nbsp;Minasi<SUP>1</SUP>,
A.&nbsp;Ruberti<SUP>1</SUP>, S.&nbsp;Muzzi<SUP>1</SUP>, M.&nbsp;Varricchio<SUP>1</SUP>, A.&nbsp;Caragia<SUP>1</SUP>, P.&nbsp;Greco<SUP>1</SUP>, E.&nbsp;lovine<SUP>1</SUP>,
V.&nbsp;Casciani<SUP>1</SUP>, E.&nbsp;Greco<SUP>1</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
European Hospital, Reproductive Medicine, Rome, Italy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
evaluation of static oxidation-reduction potential (sORP) with MiOXSYS System relate with WHO 2010 (World Health Organization)
sperm parameters and DNA fragmentation in infertile patients?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is association between sORP and sperm parameters: sORP levels are higher in patients with lower concentration, motility and morphology
and with higher DNA fragmentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spermatozoa
have a physiological equilibrium between ROS (Reactive Oxygen Species) and anti - oxidants. This equilibrium assures ordinary
functions such as chromatin compaction, lipid membrane modification and sperm-oocyte fusion. When ROS are overproduced this
equilibrium is lost, generating oxidative stress (OS), possible cause of lipid peroxidation, apoptosis and DNA damages or
fragmentation. Seminal plasma contains anti-oxidant factors (enzymatic and non-enzymatic) to prevent post-ejaculation OS,
however many studies demonstrate that in infertile men anti-oxidant levels are low and ROS are high; these concentrations may
be influenced by both exogenous and endogenous factors: smoking, alcohol assumption, infection and inflammation of male
um-genital tract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semen
from 84 infertile men were evaluated, according to WHO 2010, during June and July 2017. On their first visit at Reproductive Medicine
Unit, patients underwent semen analysis and sORP evaluation and divided in two groups according to semen morphology. Group A (N=45)
included patients with morphology 3 or 4 and group B (N=39) patients with morphology &lt;4. Men with ejaculatory dysfunction,
varicocele, sexually transmitted diseases and exposed to radiation or chemotherapeutic agents were excluded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Semen
samples were produced after 72 -120 hours of sexual abstinence and analyzed after complete liquefaction, evaluating semen parameters
and DNA fragmentation with TUNEL (Terminal deoxynucleotidyl transferase UTP-driven Nick End Labeling) test. MiOXSYS was used to
evaluate sORP (expressed in millivolt/sperm concentration 10<SUP>6</SUP>/ml), a &rsquo;snapshot&rsquo; of the current balance of the redox
system. A higher sORP level indicates an imbalance in the activity of all available oxidants relative to all available antioxidants
in ejaculates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mean
male age was 42.1&plusmn;6.3 in group A and 38.2&plusmn;6.5 in group B (p&lt;0.05). Semen volume was 3.2&plusmn;2.3 ml in group
A and 3.0&plusmn;2.0 in group B (NS). Sperm concentration was 47.2&plusmn;18.0 mil/ml in group A and 24.7&plusmn;19.0 mil/ml in
group B (p&lt; 0.05). Sperm motility (progressive plus not progressive) was 66.7&plusmn; 7.4 and 44.3&plusmn; 20.0 in group A
and B respectively (p&lt; 0.05). Morphology was 4.2&plusmn; 0.5 in group A and 2.1&plusmn; 0.7 in group B (NS). Round cells concentration
was 2.3&plusmn;2.0 and 2.7&plusmn;2.0 mil/ml in group A and B respectively (NS). DNA fragmentation measure with TUNEL test resulted
to be 7.5&plusmn;6.4 in group A and 11.0&plusmn;8.1 in group B (p&lt;0.05).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Does
varicocelectomy improve Oxidation Reduction Potential (ORP) as an independent measure of oxidative stress (OS) in infertile men?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.&nbsp;Elbardisi<SUP>1</SUP>, A.&nbsp;Majzoub<SUP>1</SUP>, S.&nbsp;AISaid<SUP>1</SUP>, A.&nbsp;Agarwal<SUP>2</SUP>, R.&nbsp;Henkel<SUP>3</SUP>, H.&nbsp;Shehadeh<SUP>1</SUP>,
K.&nbsp;Alrumaihi<SUP>1</SUP>, M.&nbsp;Arafa<SUP>1</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Hamad Medical Corporation, Urology, Doha, Qatar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Cleveland clinic, Urology, Ohio, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
University of the Western Cape, Medical Bioscience, Bellville, South Africa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
varicocelectomy improve Oxidation Reduction Potential (ORP) as an independent measure of oxidative stress (OS) in infertile men?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elevated
oxidative stress is related with poor semen quality in men with varicocele. Varicocele surgery reduces the ORP levels and improves
sperm count.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
with varicocele tend to have poor sperm quality and are at higher risk of being infertile. Although the pathophysiology of infertility
in males with varicocele has been extensively studied, the underlying mechanism remains unclear. Many reports have shown that
oxidative stress is one of the underlying mechanisms of poor semen quality in infertile men with varicocele. ORP has been validated
as a diagnostic marker of poor semen quality and oxidative stress in men with infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospective,
case control study of 43 infertile patients with clinical grade 2-3 varicocele attending a male infertility clinic during January
to November 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
patients underwent microsurgical subinguinal varicocelectomy. Full medical history and clinical examination was collected. Semen
samples were done using WHO Fifth edition criteria and ORP levels were measured by MiOXSYS analyzer before surgery and 3 months
post-varicocelectomy. The results were compared by Wilcoxon rank sum test and Spearman&rsquo;s correlation test and a P value &lt; 0.05
was considered significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
semen parameters (concentration, total motility and normal sperm form) showed an improvement post- surgery but it was not statistically
significant. However, the ORP level was significantly reduced after the surgery (10.4 &plusmn; 3.3 vs. 4.6 &plusmn; 1.1, p value
&lt;0.001). All semen parameters (concentration, total motility and normal form) were negatively correlated with ORP pre-operatively.
However, only sperm count maintained this significant negative correlation post operatively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations,
reasons for caution:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
small sample size of this study may be a limitation. However, we report on a pilot study describing the effect of varicocelectomy
on oxidative stress measures using the ORP system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wider
implications of the findings:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORP
can be used as a prognostic factor for counselling patients before varicocelectomy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Is
oxidative stress a clinical indicator for testicular function in infertile men?</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.&nbsp;Arafa<SUP>1</SUP>,
A.&nbsp;Majzoub<SUP>2</SUP>, A.&nbsp;Agarwal<SUP>3</SUP>, R.&nbsp;Henkel<SUP>4</SUP>, J.&nbsp;Eliwa<SUP>5</SUP>, S.&nbsp;AISaid<SUP>2</SUP>,
A.&nbsp;AIAnsari<SUP>1</SUP>, H.&nbsp;Elbardisi<SUP>1</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Hamad Medical Corporation, Urology/Surgery, Doha, Qatar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Hamad General Corporation, Urology, Doha, Qatar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Cleveland Clinic, American Center for Reproductive Medicine, Cleveland, U.S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
University of the Western Cape, Department of Medical Bioscience, Bellville, South Africa</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
University of Kuwait, Faculty of Medicine, Kuwait, Kuwait</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
question:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Is
oxidative stress a clinical indicator for testicular function in infertile men?</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
answer:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxidative
stress measured by oxidation reduction potential (ORP) can be considered a clinical indicator of spermatogenic and not endocrine
function of the testis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is known already:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxidative
stress plays a major role in the pathogenesis of male infertility. ORP is a new marker of oxidative stress that has been shown
to correlate inversely with important semen parameters in infertile men. ORP levels can be used to discriminate normal fertile
men from infertile males. Besides semen parameters, testicular size and FSH are considered as prognostic markers of spermatogenesis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
design, size, duration:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross
sectional, retrospective study on 660 patients attending a male infertility clinic during January to March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants/materials,
setting, methods:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
records of recruited patients were reviewed. The data extracted included medical history, clinical examination, semen analysis
(WHO 5<SUP>th</SUP> edition), ORP (using the MiOXSYS system), hormonal assay including FSH, LH, prolactin, testosterone and estradiol
as well as testicular size assessment by scrotal ultrasound. After checking for normal distribution of the data by the Chi-squared
test, Spearman rank test was used to detect correlations between different parameters. Statistical significance was defined as
p&lt;0.05.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Main
results and the role of chance:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORP
showed negative correlation with sperm count (r= -0.793, P&lt; 0.0001), motile sperm count (r= -0.579; P&lt; 0.0001), progressive
motility (r= -0.431; P&lt;0.0001) and normal sperm morphology (r= -0.458; P&lt; 0.0001). ORP also correlated with sperm DNA fragmentation
(r= 0.264, P&lt; 0.0001). ORP levels showed significant correlation with the testicular size (r= -0.386; P&lt; 0.0001), serum
FSH (r= 0.273; P&lt;0.0001) and serum LH concentrations (r= 0.182; P=0.0002), but not with testosterone, estradiol and prolactin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations,
reasons for caution:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main limitation is the lack of fertile controls in this study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wider
implications of the findings:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORP
can be used as a marker of spermatogenesis in infertile men. Further studies should be carried out to demonstrate the effect of
treating OS on spermatogenesis. Since varicocele patients show seminal oxidative stress, smaller testes and higher FSH values,
ORP could possibly be used as adjunct indicator of varicocele.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RedoxSYS
System for Research Use&nbsp;&amp; Background of the Development of MiOXSYS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
completed the development of the RedoxSYS System (MiOXSYS&rsquo; predecessor product) during the two years preceding the April
2015 Merger. In 2014, we received ISO 13485 certification, demonstrating our compliance with global quality standards in medical
device manufacturing. This enabled the launch of the RedoxSYS System into the research market around the world. We also received
a CE marking in Europe in January 2016 and Health Canada clearance in March 2016 to begin the market development of the RedoxSYS
System as a clinical diagnostic in Europe, Canada, and elsewhere around the world where CE marking is recognized. We launched
sales efforts into the research market in late 2014 and since that time have placed the RedoxSYS System at a number of prominent
research centers around the world. We expect to leverage these research relationships and build numerous applications in areas
where researchers are studying oxidative stress. Currently, there are no available research or clinical platforms that measure
oxidation-reduction potential in biologic fluids (i.e., blood, plasma, serum, semen, seminal fluid, cerebrospinal fluid, tissue,
and cells). While oxidative stress is commonly studied in research settings around the world (both academia and industry), the
current assessment methods are incomplete, time consuming, and often impractical for assessing oxidative stress completely. To
position the RedoxSYS System effectively in the research market, we have placed key personnel in the U.S., Europe, and Asia to
develop direct relationships with researchers and distributors of research products. Through these relationships we have conducted
various proof of concept studies and clinical exploratory studies. Most notably through these collaborations utilizing the RedoxSYS
System, we identified the application of oxidation-reduction potential in male infertility assessment while measuring oxidation-reduction
potential in semen and seminal plasma. As such, the MiOXSYS System was developed specifically for assessing semen and seminal
plasma ORP levels in a clinical setting for a rapid, reliable oxidative stress assessment. While we expect additional clinical
applications to be developed through our research and distributor relationships, our near-term focus is on continuing the development
of MiOXSYS for use in semen analysis for male infertility assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Background
on the MiOXSYS System&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MiOXSYS
is a novel, portable device that measures oxidation-reduction potential, or ORP, a global measure of oxidative stress. MiOXSYS
is the first and only system that measures ORP in biologic specimens to provide a complete measure of redox balance, which is
broadly implicated across a wide range of both acute and chronic conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Oxidation-Reduction
Potential&rsquo;s Role in Assessing Male Infertility&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oxidation-reduction
potential is defined in the published literature as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 43.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 43.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ORP
in a biological system is an integrated measure of the balance between total oxidants and reductants. In plasma, many constituents
contribute to the ORP. Reactive oxygen species (ROS), such as the superoxide ion, hydroxyl radical, hydrogen peroxide, nitric
oxide, peroxynitrite, transition metal ions, and hypochlorous acid, contribute to the oxidative potential. Plasma reductants include
thiols, vitamin C, tocopherol, &beta;-carotene, lycopene, uric acid, bilirubin, and flavonoids. Enzymes such as superoxide dismutase,
or SOD, catalase, and glutathione peroxidase, are involved in the conversion of ROS into less reactive species. ORP monitoring
of plasma represents a single measurement that integrates the overall quantitative balance among the oxidants and reductants of
the system.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
that ORP represents a single, global measure of oxidative stress in a biological system, we believe the potential for ORP to serve
as a standardized marker in semen analysis and other aspects of infertility assessment is significant. A major limitation of oxidative
stress assays relates to the fact that there is poor standardization in testing. As many factors contribute to oxidative stress
(e.g., free radical proliferation, antioxidant depletion, DNA damage, etc.), it is important to have an integrated measure that
combines all known and unknown oxidants and reductants in the respective system into one measurement. We believe ORP is an integrated
measure of oxidative stress that can be easily and quickly measured with the MiOXSYS System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the context of infertility, having an integrated value representing all relevant biologic constituents contributing to oxidative
stress will enable simple, robust analysis in a three-minute test. There are various techniques in use to assess semen in cases
of male infertility. The most commonly implemented techniques involve DNA fragmentation, oxidative stress analysis, microscopic
examination, sperm penetration assays, sperm agglutination, computer assisted semen analysis, and others. The currently available
oxidative stress analysis tools are widely considered expensive and cumbersome to use in routine clinical practice. In both developed
countries as well as in the developing world, expensive analysis tools and recurring reagent expenses make routine testing nearly
impossible to implement with regularity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
MiOXSYS System Overview&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS System is comprised of two distinct, patented components that enable a system capable of measuring the ORP and antioxidant
capacity of a biological fluid: an analyzer and sensor strips. In mechanical terms, ORP is defined as the potential between a
working electrode, and a reference electrode at equilibrium. The RedoxSYS System has been specifically studied in human whole
blood, serum, semen, seminal plasma, blood plasma, and other biological fluids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS System measures a distinct element to determine a patient&rsquo;s oxidation reduction potential, which we call Static
ORP. Static ORP is defined as the standard potential between a working electrode and a reference electrode with no driving current
(or extremely small current). This is proportional to the balance of redox agents and is what is classically defined as ORP. Low
ORP values mean that the biological sample is in the normal range of oxidative stress. Higher than normal ORP values means that
the biological sample is in a higher oxidation state. Higher levels of seminal oxidative stress (and sORP levels correspondingly)
correlate closely with infertility rates in men.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
MiOXSYS Analyzer&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS analyzer is a portable, lightweight desktop platform that may be used in a clinical or research laboratory or near a patient
care area. The analyzer is a small device that accepts an inserted sensor that has collected a small specimen as obtained by traditional
specimen collection procedures. The analyzer is battery powered and equipped with a custom 5 lead strip connector. The reader
consists of a Galvanostat analog circuit with greater than 1012 MHz input impedance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
analyzer contains a 10 MHz external crystal (internal 4X PLL for 40 MHz operation), and a programming/serial header is externally
accessible. The device has internal power/heart-beat indicator LED, primary storage of 128Mbit (16Mbyte) SPI Flash (3.3V) (Bulk
data storage), and secondary storage of 2Mbit (256Kbyte) SPI FRAM (3.3V) (Hi-Speed Storage).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS analyzer contains a user-friendly interface that is flexibly designed to accommodate multiple endpoints depending upon
the specific clinical condition being considered. The interface is LCD, 16x2, with a white backlight, variable delay auto-off
time-out. Two status LED indicators are visible through front panel mounted lenses. Further, the reader contains three DPDT push-button
switches (Left, Center, Right), power on button(s) for battery mode operation, switch usage switch, audible alerts, strip detection,
and test completion signals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the MiOXSYS analyzer enables data transfer, has USB serial communication, and is configured for data download to a connected PC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS analyzer&rsquo;s power management consists of an external 5VDC power jack with input capacitance and filtering, a boost
converter supplied by external 5VDC power or internal Li-Ion battery, and provides main 5VDC digital board supply. The reader
functions with or without the battery connected. The battery lasts in excess of 24 hours with continuous operation to enable prolonged
use outside of a laboratory setting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Image
of the MiOXSYS Analyzer&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_011.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
MiOXSYS Disposable Sensors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MiOXSYS disposable sensors, via standard biological specimen collection techniques, receive 20 &ndash; 40 microliters of a specimen
from which the ORP clinical analysis is performed. The ORP sensor strips are small, disposable, and biocompatible and consist
of a ceramic substrate and a five-lead configuration. Significant intellectual property surrounds the design, construct, and electrochemical
algorithms associated with the sensors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Image
of the MiOXSYS Disposable Sensors&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_012.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulatory
Pathway&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
achieved ISO 13485: 2003 in late 2013 following the successful development of an ISO-compliant medical device quality system.
Following the issuance of our ISO certification, we obtained CE marking for the RedoxSYS System, which has enabled initial market
development in Europe and markets that accept a CE marking. In December 2015, we obtained CE marking for MiOXSYS following technical
validation and clinical study completion in male infertility assessment. In March 2016, we obtained Health Canada Class II Medical
approvals for MiOXSYS and have subsequently received Australian TGA approval and Mexican COFEPRIS approval in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., we intend to pursue 510k de novo clearance with the FDA for the MiOXSYS System. We have engaged with the FDA and have
received confirmation that MiOXSYS is likely appropriate for the 510k de novo pathway, and we are pursuing regulatory clearance
accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Commercial Strategy&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cleared for the infertility intended use, we intend to seek to commercialize the MiOXSYS System as a new tool for the assessment
of oxidative stress in infertility in men. We envision pursuing allocating our direct sales effort to high priority urology/andrology
laboratories, infertility clinics and reference centers across the U.S. We have identified the primary, influential centers in
the U.S. and believe our commercial deployment will be efficient through a focused sales and marketing effort. We intend to seek
to sell the MiOXSYS System into individual centers and laboratories but will focus our revenue model on the repeat ordering of
the disposable, single use MiOXSYS sensors. We expect to realize a favorable gross margin on the basis of estimated low cost of
goods sold on both components of the system. We envision an average selling price for the disposable sensors of approximately
$25, but we have not finalized pricing at this point. We envision selling the MiOXSYS analyzers for approximately $2,500 (pricing
not final) but may also pursue an instrument rental agreement model with minimum disposable sensor purchase requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to leverage our current Natesto commercialization efforts in urology target offices, with a distinct focus on urologists
and andrologists who treat and manage male infertility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ROW
Commercial Strategy&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., we have commenced commercialization of the RedoxSYS and MiOXSYS Systems. To efficiently execute our strategy of
introducing MiOXSYS to urologists and andrologists around the world, we utilize a network of established distributors in the
target markets in Europe and Asia. We have established distribution arrangements with multiple distributors in multiple
countries, and through these distributors, we have sold MiOXSYS in over  29 countries around the world. We employ a
razor-razorblade revenue model outside the U.S., relying on the initial sale of the MiOXSYS System and repeat purchases of
the disposable MiOXSYS sensors by distributors for sale to their direct customers. We also have direct selling relationships
with end users and service these accounts directly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Business Development Strategy &mdash; Identifying &amp; Acquiring Complementary Assets&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key growth and value driver for our Company is the ongoing identification and acquisition of novel products for commercialization
through our commercial infrastructure. We seek to identify unique products serving large areas of unmet needs that may be non-strategic,
undervalued or under-resourced by the company that currently markets the product. We believe that we can continue to acquire strategically
aligned products at an appropriate valuation and grow those products via our focused sales and marketing efforts. We will also
consider acquiring novel, late-stage development products that represent unique commercial opportunities and can be efficiently
developed and subsequently commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will continue to look to identify unique product assets to acquire based on specific attributes including but not limited to:
therapeutic area/indication; growth potential; intellectual property position (patents, regulatory, manufacturing or development
technicalities, etc.); valuation; strategic fit; commercial orientation and other factors. However, during fiscal 2019, our primary
focus will be on growing our current core assets, advancing the commercialization and U.S. regulatory development of MiOXSYS,
and working towards cash-flow breakeven.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we do not have any pharmaceutical product candidates that we are actively developing as of the date of this Report, we may in
the future acquire such products. Currently, we are developing one medical device candidate, the MiOXSYS System, for which regulatory
approval must be received before we can market this within the U.S. Regulatory approval processes for our current and any future
product candidates are discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Approval
Process for Pharmaceutical Products&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or
the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting,
sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications, NDAs,
warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
civil penalties, and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
product development in the U.S. typically involves the performance of satisfactory nonclinical, also referred to as pre-clinical,
laboratory and animal studies under the FDA&rsquo;s Good Laboratory Practice, or GLP, regulation, the development and demonstration
of manufacturing processes, which conform to FDA mandated current good manufacturing requirements, or cGMP, including a quality
system regulating manufacturing, the submission and acceptance of an Investigational New Drug Application (&ldquo;IND&rdquo;),
which must become effective before human clinical trials may begin in the U.S., obtaining the approval of Institutional Review
Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in
clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication
for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements
typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of
the product or disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
tests generally include laboratory evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well
as certain animal studies to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry,
manufacturing controls and analytical data and the clinical trial protocol, which details the objectives of the trial, the parameters
to be used in monitoring safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted
to the FDA as part of an IND, which must become effective before human clinical trials can begin. The entire clinical trial and
its protocol must be in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is
used to refer to various FDA laws and regulations, as well as international scientific standards intended to protect the rights,
health and safety of patients, define the roles of clinical trial sponsors and assure the integrity of clinical trial data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns
or questions about the intended conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies
generally take several years to complete, and there is no guarantee that an IND based on those studies will become effective,
allowing clinical testing to begin. In addition to FDA review of an IND, each medical site that desires to participate in a proposed
clinical trial must have the protocol reviewed and approved by an independent IRB or Ethics Committee, or EC. The IRB considers,
among other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance
with the FDA&rsquo;s GCP requirements. The FDA and/or IRB may order the temporary, or permanent, discontinuation of a clinical
trial or that a specific clinical trial site be halted at any time or impose other sanctions for failure to comply with requirements
under the appropriate entity jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap.
In Phase 1 clinical trials, a product candidate is typically introduced either into healthy human subjects or patients with the
medical condition for which the new drug is intended to be used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main purpose of the trial is to assess a product candidate&rsquo;s safety and the ability of the human body to tolerate the product
candidate. Phase 1 clinical trials generally include less than 50 subjects or patients. During Phase 2 trials, a product candidate
is studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it
is intended to be used in order to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary
or potential efficacy of the product candidate for specific target diseases or medical conditions, and (iii) assess dosage tolerance
and determine the optimal dose for Phase 3 trials. Phase 3 trials are generally undertaken to demonstrate clinical efficacy and
to further test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship
of the product candidate. Phase 3 trials are generally designed to reach a specific goal or endpoint, the achievement of which
is intended to demonstrate the candidate product&rsquo;s clinical efficacy and adequate information for labeling of the approved
drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are three main types of NDAs, which are covered by Section 505 of the FDC Act: (1) an application that contains full reports of
investigations of safety and efficacy (Section 505(b)(1)); (2) an application that contains full reports of investigations of
safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by
or for the applicant and for which the application has not obtained a right of reference (Section 505(b)(2)); and (3) an application
that contains information to show that the proposed product is identical in active ingredient, dosage form, strength, route of
administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved
product (Section 505(j)). Section 505(b)(2) expressly permits the FDA to rely, for approval of an NDA, on data not developed by
the applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required
before marketing of the product may begin in the U.S. The NDA must include the results of all pre-clinical, clinical, and other
testing and a compilation of data relating to the product&rsquo;s pharmacology, chemistry, manufacture, and controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the FDA&rsquo;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing,
the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications
for standard review drug products are reviewed within ten months; most applications for priority review drugs are reviewed in
six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment
where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three
additional months to consider certain late-submitted information, or information intended to clarify information already provided
in the submission. The FDA may also refer applications for novel drug products, or drug products which present difficult questions
of safety or efficacy, to an advisory committee &mdash; typically a panel that includes clinicians and other experts &mdash; for
review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation
of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect
one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at
which the drug is manufactured. The FDA will not approve the product unless compliance with cGMP is satisfactory and the NDA contains
data that provide substantial evidence that the drug is safe and effective in the indication studied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter.
A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing
or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&rsquo;s
satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions
in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the
drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk
evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REMS
can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU
can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain
circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential
market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance
to monitor the drug&rsquo;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory
standards is not maintained or problems are identified following initial marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Hatch-Waxman Act&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&rsquo;s
product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&rsquo;s
Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange
Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA. An
ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the
listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than
the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, pre-clinical or
clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to
as &ldquo;generic equivalents&rdquo; to the listed drug and can often be substituted by pharmacists under prescriptions written
for the original listed drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&rsquo;s Orange
Book that: 1) the required patent information has not been filed; 2) the listed patent has expired; 3) the listed patent has not
expired, but will expire on a particular date and approval is sought after patent expiration; or 4) the listed patent is invalid
or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&rsquo;s
listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the applicant does not challenge
the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have
expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph
IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders
may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent
infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving
the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement
case that is favorable to the ANDA applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ANDA application also will not be approved until any non-patent exclusivity listed in the Orange Book for the referenced product
has expired. Federal law provides a period of five years following approval of a drug containing no previously approved active
ingredients during which ANDAs for generic versions of those drugs cannot be submitted, unless the submission contains a Paragraph
IV challenge to a listed patent &mdash; in which case the submission may be made four years following the original product approval.
Federal law provides for a period of three years of exclusivity during which FDA cannot grant effective approval of an ANDA based
on the approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route
of administration or combination, or for a new use; the approval of which was required to be supported by new clinical trials
conducted by, or for, the applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Post-Approval
Regulation&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product candidate receives regulatory approval, the approval is typically limited to specific clinical indications. Further,
even after regulatory approval is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions
on its use or even complete withdrawal of the product from the market. Any FDA-approved products manufactured or distributed by
us are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences.
Further, drug manufacturers, and their subcontractors, are required to register their establishments with the FDA and state agencies.
They are subject to periodic inspections by the FDA and state agencies for compliance with cGMP, which impose rigorous procedural
and documentation requirements upon us and our contract manufacturers. We cannot be certain that we or our present or future contract
manufacturers or suppliers will be able to comply with cGMP regulations and other FDA regulatory requirements. Failure to comply
with these requirements may result in, among other things, total or partial suspension of production activities, failure of the
FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA approves one or more of our product candidates, we and the contract manufacturers we use for manufacture of clinical supplies
and commercial supplies must provide certain updated safety and efficacy information. Product changes, as well as certain changes
in the manufacturing process or facilities where the manufacturing occurs, or other post-approval changes may necessitate additional
FDA review and approval. The labeling, advertising, promotion, marketing and distribution of a drug or biologic product or medical
devices, also must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which include, among others, standards
and regulations for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities,
and promotional activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide
by these regulations can result in penalties, including the issuance of a warning letter directing us to correct deviations from
regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Approval
Process for Medical Devices&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., the FDCA, FDA regulations and other federal and state statutes and regulations govern, among other things, medical device
design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing,
labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. The FDA
regulates the design, manufacturing, servicing, sale and distribution of medical devices, including molecular diagnostic test
kits and instrumentation systems. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as FDA refusal to approve pending applications, warning letters, product recalls, product seizures,
total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, each medical device we wish to distribute commercially in the U.S. will require marketing authorization
from the FDA prior to distribution. The two primary types of FDA marketing authorization applicable to a device are premarket
notification, also called 510k de novo clearance, and premarket approval, also called PMA approval. The type of marketing authorization
is generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I,
II or III) based on the degree of risk the FDA determines to be associated with a device and the level of regulatory control deemed
necessary to ensure the device&rsquo;s safety and effectiveness. Devices requiring fewer controls because they are deemed to pose
lower risk are placed in Class I or II. Class I devices are deemed to pose the least risk and are subject only to general controls
applicable to all devices, such as requirements for device labeling, premarket notification and adherence to the FDA&rsquo;s current
Good Manufacturing Practices, or cGMP, known as the Quality System Regulations, or QSR. Class II devices are intermediate risk
devices that are subject to general controls and may also be subject to special controls such as performance standards, product-specific
guidance documents, special labeling requirements, patient registries or post-market surveillance. Class III devices are those
for which insufficient information exists to assure safety and effectiveness solely through general or special controls and include
life sustaining, life-supporting or implantable devices, devices of substantial importance in preventing impairment of human health,
or which present a potential, unreasonable risk of illness or injury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
Class I devices and some Class II devices are exempted by regulation from the 510k de novo clearance requirement and can be marketed
without prior authorization from the FDA. Some Class I devices that have not been so exempted and Class II devices are eligible
for marketing through the 510k de novo clearance pathway. By contrast, devices placed in Class III require PMA approval prior
to commercial marketing. The PMA approval process is more stringent, time-consuming and expensive than the 510k de novo clearance
process, however, the 510k de novo clearance process has also become increasingly stringent and expensive. The FDA has provided
initial guidance to us that the MiOXSYS System is likely appropriate for the 510k de novo clearance process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">510k
de novo Clearance. To obtain 510k de novo clearance for a medical device, an applicant must submit a premarket notification to
the FDA demonstrating that the device is &ldquo;substantially equivalent&rdquo; to a device legally marketed in the U.S. that
is not subject to PMA approval, commonly known as the &ldquo;predicate device.&rdquo; A device is substantially equivalent if,
with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics or
(ii) different technological characteristics and the information submitted demonstrates that the device is as safe and effective
as a legally marketed device and does not raise different questions of safety or effectiveness. A showing of substantial equivalence
sometimes, but not always, requires clinical data. Generally, the 510k de novo clearance process can exceed 90 days and may extend
to a year or more.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device has received 510k de novo clearance for a specific intended use, any change or modification that significantly affects
its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may
require a new 510k de novo clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a
modification could significantly affect the device&rsquo;s safety or effectiveness is initially left to the manufacturer using
available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product
at any time and may require the manufacturer to cease marketing and recall the modified device until 510k de novo clearance or
PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we can submit a medical device for 510k de novo clearance, we may have to perform a series of generally short studies over a period
of months, including method comparison, reproducibility, interference and stability studies to ensure that users can perform the
test successfully. Some of these studies may take place in clinical environments but are not usually considered clinical trials.
For PMA submissions, we would generally be required to conduct a longer clinical trial over a period of years that supports the
clinical utility of the device and how the device will be used.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
clinical investigations of most devices are subject to the investigational device exemption, or IDE, requirements, clinical investigations
of diagnostic tests, including our products and products under development, are generally exempt from the IDE requirements. Thus,
clinical investigations by intended users for intended uses of our products generally do not require the FDA&rsquo;s prior approval
but may require approval of an Institutional Review Board, or IRB, and written informed consent by the patient, provided the clinical
evaluation testing is non-invasive, does not require an invasive sampling procedure that presents a significant risk, does not
intentionally introduce energy into the subject and is not used as a diagnostic procedure without confirmation by another medically
established test or procedure. In addition, our products must be labeled per FDA regulations &ldquo;for research use only-RUO&rdquo;
or &ldquo;for investigational use only-IUO,&rdquo; and distribution controls must be established to assure that our products distributed
for research, method comparisons or clinical evaluation studies are used only for those purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulation
after FDA Clearance or Approval&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
devices we manufacture or distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation
by the FDA and certain state agencies. We are required to adhere to applicable regulations setting forth detailed cGMP requirements,
as set forth in the QSR, which include, among other things, testing, control and documentation requirements. Noncompliance with
these standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total
or partial suspension of production, refusal of the government to grant 510k de novo clearance or PMA approval of devices, withdrawal
of marketing approvals and criminal prosecutions, fines and imprisonment. Our contract manufacturers&rsquo; facilities operate
under the FDA&rsquo;s cGMP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
Regulatory Approval&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
of the U.S., our ability to market our product candidates will be contingent also upon our receiving marketing authorizations
from the appropriate foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory approval
process in most industrialized countries generally encompasses risks similar to those we will encounter in the FDA approval process.
The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite
approvals, may vary widely from country to country and differ from those required for FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, we are required under the European Medical Device Directive (Council Directive 93/42/EEC) to affix the CE
mark to certain of our products in order to sell the products in member countries of the European Union. The CE mark is an international
symbol that represents adherence to certain essential principles of safety and effectiveness mandated in the European Medical
Device Directive, which are referred to as the &ldquo;essential requirements&rdquo;. Once affixed, the CE mark enables a product
to be sold within the European Economic Area, or EEA, which is composed of the 28-member states of the EU plus Norway, Iceland
and Liechtenstein as well as other countries that accept the CE mark.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
demonstrate compliance with the essential requirements, we must undergo a conformity assessment procedure which varies according
to the type of medical device and its classification. Except for low risk medical devices (Class I with no measuring function
and which are not sterile) where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the
conformity of its products with the essential requirements of the Medical Devices Directive, a conformity assessment procedure
requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a notified
body. Depending on the relevant conformity assessment procedure, the notified body would typically audit and examine the technical
file and the quality system for the manufacture, design and final inspection of our devices. The notified body issues a CE certificate
of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device
and its manufacturer and their conformity with the essential requirements. This certificate entitles the manufacturer to affix
the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we modify our devices, we may need to apply for permission to affix the CE mark to the modified product. Additionally, we may
need to apply for a CE mark for any new products that we may develop in the future. Certain products regulated as medical devices
according to EC-Directives are subject to vigilance requirements for reporting of adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be subject to additional regulations in other countries in which we market, sell and import our products, including Canada.
We or our distributors must receive all necessary approvals or clearance prior to marketing and/or importing our products in those
markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
International Standards Organization, or ISO, promulgates internationally recognized standards, including those for the requirements
of quality systems. To support ISO certifications, surveillance audits are conducted by a notified body yearly and recertification
audits every three years that assess continued compliance with the relevant ISO standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Regulatory Matters&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities
in addition to the FDA, including, in the U.S., the Centers for Medicare &amp; Medicaid Services, other divisions of the Department
of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission,
the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments. In the
U.S., sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing
and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and
more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation
Act, or ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration,
additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances
Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under
the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to
federal and state consumer protection and unfair competition laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping,
licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances,
failure to meet applicable regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties,
injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals,
or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies
with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify
or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially
affect our business in an adverse way.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for
example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall
or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they
could adversely affect the operation of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Patent Term Restoration and Marketing Exclusivity&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and other specific aspects of the FDA approval of our drug candidates, some of our U.S. patents may
be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly
referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration
cannot extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term
restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus
the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved
drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent.
The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension
or restoration. In the future, if any of our NDA&rsquo;s are approved, we intend to apply for restoration of patent term for one
of our currently owned or licensed patents to add patent life beyond the current expiration date, depending on the expected length
of the clinical trials and other factors involved in the filing of the relevant NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA
provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to obtain approval of an
NDA for a new chemical entity, or NCE. A drug is a new chemical entity if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. Recently, the
FDA stated that it may change its interpretation of 5-year NCE exclusivity determinations to apply to each drug substance in a
fixed-combination drug product, not for the drug product as a whole. If this change is implemented, for example, a fixed-combination
drug product that contains a drug substance with a single, new active moiety would be eligible for 5-year NCE exclusivity, even
if the fixed-combination also contains a drug substance with a previously approved active moiety. During the exclusivity period,
the FDA may not accept for review an abbreviated new drug application, or ANDA, or a Section 505(b)(2) NDA submitted by another
company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as
the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to
all the data required for approval. However, an application may be submitted after four years if it contains a certification of
patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides
three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,
for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification
for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving
ANDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct
or obtain a right of reference to all of the pre-clinical studies and adequate and well-controlled clinical trials necessary to
demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer a seven-year period of marketing
exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the U.S..
Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity,
which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a
pediatric trial in accordance with an FDA-issued &ldquo;Written Request&rdquo; for such a trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reimbursement
for our Products in the U.S.&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
and ZolpiMist are covered by many commercial insurance providers and pharmacy benefit management companies and are largely dependent
upon reimbursement for continued use in the U.S. market. Natesto and ZolpiMist are also covered under a Rebate Agreement between
us and Centers for Medicare and Medicaid Services. This, in turn, enables states to offer public payer coverage of Natesto and
ZolpiMist through their separate Medicare and public assistance programs. Additionally, privately managed Medicare Part D plans
may choose to cover Natesto and ZolpiMist prescriptions through their plans&rsquo; pharmacy benefits. We do not anticipate that
the sales of the MiOXSYS System, if approved for sale in the U.S., will be heavily dependent upon reimbursement by third-party
payors in the U.S. given that infertility testing and treatment is infrequently covered by commercial insurers or public payors.
Traditionally, sales of pharmaceuticals, diagnostics, ad devices that are not &ldquo;lifestyle&rdquo; indications depend, in part,
on the extent to which products will be covered by third-party payors, such as government health programs, commercial insurance
and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and
services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
of third-party reimbursement for our product candidate or a decision by a third-party payor to not cover our product candidates
could reduce physician usage of the product candidate and have a material adverse effect on our sales, results of operations and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for
its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product
or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched
in the European Union do not follow price structures of the U.S. and generally tend to be significantly lower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>DEA
Regulation&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natesto
and ZolpiMist, already approved by the FDA, are both a &ldquo;controlled substance&rdquo; as defined in the Controlled Substances
Act of 1970, or CSA, because Natesto contains testosterone and ZolpiMist contains zolpidem tartrate. As a result, the U.S. Drug
Enforcement Agencies, or DEA, have Natesto listed and regulated as a Schedule III substance and have ZolpiMist listed and regulated
as a Schedule IV substance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance.
The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations
are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.
Similarly, separate registrations are also required for separate facilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA typically inspects a facility to review its security measures prior to issuing a registration and on a periodic basis. Reports
must also be made for thefts or losses of any controlled substance, and to obtain authorization to destroy any controlled substance.
In addition, special permits and notification requirements apply to imports and exports of narcotic drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA establishes annually an aggregate quota for how much of a controlled substance may be produced in total in the U.S. based
on the DEA&rsquo;s estimate of the quantity needed to meet legitimate scientific and medicinal needs. The DEA may adjust aggregate
production quotas and individual production and procurement quotas from time to time during the year, although the DEA has substantial
discretion in whether or not to make such adjustments. Our or our manufacturers&rsquo; quotas of an active ingredient may not
be sufficient to meet commercial demand or complete clinical trials. Any delay, limitation or refusal by the DEA in establishing
our or our manufacturers&rsquo; quota for controlled substances could delay or stop our clinical trials or product launches, which
could have a material adverse effect on our business, financial position and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enforce these requirements, the DEA conducts periodic inspections of registered establishments that handle controlled substances.
Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in administrative,
civil or criminal enforcement action that could have a material adverse effect on our business, results of operations and financial
condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate administrative proceedings to
revoke those registrations. In some circumstances, violations could result in criminal proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states also independently regulate controlled substances. We and our manufacturers will be subject to state regulation on distribution
of these products, including, for example, state requirements for licensures or registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aytu
has an exclusive license from Acerus Pharmaceuticals Corporation for the U.S. rights to intellectual property related to a nasal
gel drug product containing testosterone to treat hypogonadism in males, including the FDA approved product Natesto&reg;, as well
as an authorized generic version and OTC versions thereof. The license includes sublicense rights to intellectual property owned
by Mattern Pharmaceuticals and exclusively licensed to Acerus by Mattern Pharmaceuticals. The sublicensed intellectual property
includes four Orange Book listed patents directed at nasal gel formulations containing testosterone or methods of testosterone
replacement therapy by nasal administration of the same. It further includes three patents that are not listed in the Orange Book
directed at a testosterone formulation, a method of making a testosterone formulation and a method for reducing physical or chemical
interactions between a nasal testosterone formulation and a plastic container.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Acerus license also grants rights to intellectual property owned by Acerus which includes nine nonprovisional patent applications,
some of which may be abandoned. These patent applications include at least four pending applications directed to testosterone
titration methods, intranasal testosterone bio-adhesive gel formulations, and controlled release testosterone formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an extensive range of intellectual property for MiOXSYS and RedoxSYS. We have patent protection in the U.S. and several other
large markets worldwide for MiOXSYS and the oxidation-reduction potential platform. Specifically, we have numerous patents issued
and pending for the RedoxSYS/MiOXSYS systems, the sensors, and their clinical and scientific use in the U.S., Europe, Canada,
Israel, Japan, and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent portfolio related to RedoxSYS/MiOXSYS is focused on the U.S. and core foreign jurisdictions which include Europe, Canada,
Israel, Japan and China. The portfolio is supported in the U.S. and core foreign jurisdictions and consists of 43 issued patents
and 23 pending applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
portfolio primarily consists of eight families filed in the U.S. and in core foreign jurisdictions. The first family includes
seventeen issued patents and one pending application with claims directed to the measurement of the ORP of a patient sample to
evaluate various conditions. The standard 20-year expiration for patents in this family is in 2028. The second family includes
two pending U.S. applications, two issued U.S. patents, two pending applications in core foreign jurisdictions and four issued
patents in core foreign jurisdictions with claims directed to the measurement of the ORP capacity of a patient sample to evaluate
various conditions. The standard 20-year expiration for patents in this family is in 2033. The third family includes sixteen issued
patents and two pending applications with claims directed to devices and methods for the measurement of ORP and ORP capacity.
The standard 20-year expiration for patents in this family is in 2032. The fourth family includes one pending U.S. application,
one issued U.S. patent, two issued patents in core foreign jurisdictions and four pending applications in core foreign jurisdictions
with claims directed to multiple layer gel test strip measurement devices and methods of making for use in measuring ORP and ORP
capacity. The standard 20-year expiration for patents in this family is in 2033. The fifth family includes one pending U.S. application
and seven pending applications in core foreign jurisdictions with claims directed to methods for determining fertility characteristics
from the ORP of a biological sample. The standard 20-year expiration for patents in this family is in 2035. The sixth family includes
one pending U.S. application with claims directed to methods for evaluating stroke patients from the ORP characteristics of a
biological sample. The standard 20-year expiration for patents in this family is in 2036. The seventh family includes one pending
application filed under the Patent Cooperation Treaty with claims directed to methods for embryo selection from the ORP characteristics
of a biological sample. The standard 20-year expiration for patents in this family is in 2038. The eighth family includes one
pending U.S. provisional application with disclosure directed to methods for determining fertility characteristics from the ORP
of a biological sample.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain trade secrets and proprietary know-how that we seek to protect through confidentiality and nondisclosure agreements.
These agreements may not provide meaningful protection or adequate remedies in the event of unauthorized use or disclosure of
confidential and proprietary information. If we do not adequately protect our trade secrets and proprietary know-how, our competitive
position and business prospects could be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to seek U.S. and foreign patent protection for drug and device products we discover, as well as therapeutic and device
products and processes. We expect also to seek patent protection or rely upon trade secret rights to protect certain other technologies
which may be used to discover and characterize drugs and device products and processes, and which may be used to develop novel
therapeutic and diagnostic products and processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of companies such as ours involve complex legal and factual questions and, therefore, their enforceability cannot
be predicted with any certainty. Our issued and licensed patents, and those that may be issued to us in the future, may be challenged,
invalidated or circumvented, and the rights granted under the patents or licenses may not provide us with meaningful protection
or competitive advantages. Our competitors may independently develop similar technologies or duplicate any technology developed
by us, which could offset any advantages we might otherwise realize from our intellectual property. Furthermore, even if our product
candidates receive regulatory approval, the time required for development, testing, and regulatory review could mean that protection
afforded us by our patents may only remain in effect for a short period after commercialization. The expiration of patents or
license rights we hold could adversely affect our ability to successfully commercialize our pharmaceutical drugs or diagnostics,
thus harming our operating results and financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be able to protect our proprietary intellectual property rights from unauthorized use by third parties primarily to the extent
that such rights are covered by valid and enforceable patents or are effectively maintained as trade secrets. If we must litigate
to protect our intellectual property from infringement, we may incur substantial costs and our officers may be forced to devote
significant time to litigation-related matters. The laws of certain foreign countries do not protect intellectual property rights
to the same extent as do the laws of the U.S. Our pending patent applications, or those we may file or license from third parties
in the future, may not result in patents being issued. Until a patent is issued, the claims covered by an application for patent
may be narrowed or removed entirely, thus depriving us of adequate protection. As a result, we may face unanticipated competition,
or conclude that without patent rights the risk of bringing product candidates to market exceeds the returns we are likely to
obtain. We are generally aware of the scientific research being conducted in the areas in which we focus our research and development
efforts, but patent applications filed by others are maintained in secrecy for at least 18 months and, in some cases in the U.S.,
until the patent is issued. The publication of discoveries in scientific literature often occurs substantially later than the
date on which the underlying discoveries were made. As a result, it is possible that patent applications for products similar
to our drug or diagnostic products and product candidates may have already been filed by others without our knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual
property rights, and it is possible that our development of products and product candidates could be challenged by other pharmaceutical
or biotechnology companies. If we become involved in litigation concerning the enforceability, scope and validity of the proprietary
rights of others, we may incur significant litigation or licensing expenses, be prevented from further developing or commercializing
a product or product candidate, be required to seek licenses that may not be available from third parties on commercially acceptable
terms, if at all, or subject us to compensatory or punitive damage awards. Any of these consequences could materially harm our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is highly competitive and subject to significant and rapid technological change as researchers learn more
about diseases and develop new technologies and treatments. Significant competitive factors in our industry include product efficacy
and safety; quality and breadth of an organization&rsquo;s technology; skill of an organization&rsquo;s employees and its ability
to recruit and retain key employees; timing and scope of regulatory approvals; government reimbursement rates for, and the average
selling price of, products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual
property and patent rights and their protection; and sales and marketing capabilities. Market acceptance of our current products
and product candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative therapies
or tests, (ii) the actual or perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing, and
distribution capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a very small specialty pharmaceuticals company compared to other companies that we are competing against. Our current and
potential competitors include large pharmaceutical, biotechnology, diagnostic, and medical device companies, as well as specialty
pharmaceutical and generic drug companies. Many of our current and potential competitors have substantially greater financial,
technical and human resources than we do and significantly more experience in the marketing, commercialization, discovery, development
and regulatory approvals of products, which could place us at a significant competitive disadvantage or deny us marketing exclusivity
rights. Specifically, our competitors will most likely have larger sales teams and have more capital resources to support their
products then we do.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accordingly,
our competitors may be more successful than we may be in achieving widespread market acceptance and obtaining FDA approval for
product candidates. We anticipate that we will face intense and increasing competition as new products enter the market, as advanced
technologies become available and as generic forms of currently branded products become available. Finally, the development of
new treatment methods for the diseases we are targeting could render our products non-competitive or obsolete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
cannot assure you that any of our products that we acquire or successfully develop will be clinically superior or scientifically
preferable to products developed or introduced by our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
current approved products compete in highly competitive fields whereby there are numerous options available to clinicians including
generics. These generic treatment options are frequently less expensive and more widely available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Natesto</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Natesto
competes in a growing market. The U.S. TRT market is large, with annual revenues in the U.S. in 2017 of approximately $1.8 billion.
At the current market size of approximately $1.8 billion, a product with 5% market penetration could achieve sales of approximately
$90 million annually, assuming comparatively similar product pricing and reimbursement levels as seen with other TRTs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions, and
patches. Testopel&reg;, an injectable pellet typically implanted directly under the skin by a physician, is also FDA-approved.
AndroGel is the market-leading TRT and is marketed by AbbVie.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>ZolpiMist</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ZolpiMist
competes in a large prescription category with over 43 million prescriptions written annually and generating $1.8 billion in wholesale
sales. The non-benzodiazepine prescription sleep aid market is dominated by zolpidem tartrate (brand name Ambien), which accounts
for approximately 30 million prescriptions annually. Various forms of zolpidem tartrate are commercially available, including
both immediate release and controlled release tablets as well as orally dissolving tablets. ZolpiMist is the only oral spray formulation
of zolpidem tartrate and, if only achieving 1% of the &lsquo;zolpidem market&rsquo; this product could generate 300,000 prescriptions
annually in the U.S. No zolpidem tartrate products are actively marketed in the U.S., so we believe our sales force will have
the ability to effectively influence physician prescribing and grow ZolpiMist prescriptions.</FONT></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MiOXSYS&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With
respect to MiOXSYS competitive offerings, there are other oxidative stress diagnostic tests available throughout the world, although
none are approved in the U.S. for clinical use, and none are used specifically in semen analysis. &lsquo;General use&rsquo; oxidative
stress diagnostic systems that are marketed for clinical use outside the U.S. include the FRAS 4 system (H&amp;D srl), FREE Carpe
Diem (Diacron International), and the FORM and FORMPlus systems (Callegari srl). These systems are used in both research and clinical
settings but do not generate significant sales in the clinical setting and, again, are not used specifically in semen analysis
for infertility testing. These potentially competitive oxidative stress systems&rsquo; testing parameters differ significantly
from MiOXSYS and would need to demonstrate clinical superiority to MiOXSYS in order to substantially detract from MiOXSYS prescribing
and sales. Additionally, to our knowledge, these systems have not demonstrated clinical feasibility in human semen or seminal
plasma. These tests are used for research use, but they do not measure oxidation-reduction potential and, we believe, are not
directly competitive to the MiOXSYS System in the context of research use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
strategy is to minimize our research and development activities. When we do conduct research and development, we intend to utilize
consultants with domain experience for research, development and regulatory guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
MiOXSYS System has been developed in conjunction with numerous medical device and diagnostic development consultants. Further,
we have relationships with regulatory consultants who are actively assisting in the development of our regulatory strategy with
the FDA as MiOXSYS advances to this stage. To complement our internal clinical research efforts with the MiOXSYS System, we have
engaged with numerous academic and private researchers around the world to identify and develop research and clinical applications
for the MiOXSYS System. Through these engagements we have access to data and analyses that, we believe, will enable us to develop
new uses for the MiOXSYS and RedoxSYS systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Manufacturing&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
business strategy is to use cGMP compliant contract manufacturers for the manufacture of clinical supplies as well as for commercial
supplies if required by our commercialization plans, and to transfer manufacturing responsibility to our collaboration partners
when possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Natesto</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 22, 2016, we entered into a license and supply agreement with Acerus pursuant to which we will pay Acerus a supply price
per unit of the greater of (i) a fixed percentage of Acerus&rsquo; cost of goods sold for Natesto, not to exceed a fixed ceiling
price and (ii) a moderate double digit percentage of net sales for the first year of the agreement, that increased in each of
the second and third years and remains constant after that.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MiOXSYS/RedoxSYS&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
secured supply and quality agreements with manufacturers for both the RedoxSYS and MiOXSYS instruments as well as the RedoxSYS
and MiOXSYS sensor strips. Both manufacturers hold long-standing ISO 13485:2003 certifications and are established medical device
manufacturers. Both manufacturers have high volume manufacturing capacity such that production volumes can be easily scaled. Both
manufacturers have been audited by our quality engineers and are fully compliant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>ZolpiMist</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
June 11, 2018 we entered into a licensing agreement with Magna Pharmaceuticals, Inc. pursuant to which we assumed a manufacturing
agreement with a cGMP compliant contract manufacturer. We expect to continue manufacturing through that third-party and have made
an initial purchase of product the we expect to supply us for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Employees&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of August 31, 2018, we had 57 full-time employees and utilized
the services of a number of consultants on a temporary basis. Overall, we have not experienced any work stoppage and do not anticipate
any work stoppage in the foreseeable future. None of our employees is subject to a collective bargaining agreement. Management
believes that relations with our employees are good.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Available
Information </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
principal executive offices are located at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112 USA, and our phone number
is (720)&nbsp;437-6580.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
maintain a website on the internet at <I>http://www.aytubio.com</I>. We make available, free of charge, through our website, by
way of a hyperlink to a third-party site that includes filings we make with the SEC website (<I>www.sec.gov)</I>, our annual reports
on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K and amendments to those reports electronically
filed or furnished pursuant to Section&nbsp;15(d) of the Exchange Act. The information on our website is not, and shall not be
deemed to be, a part of this Annual Report on Form&nbsp;10-K or incorporated into any other filings we make with the SEC. In addition,
the public may read and copy any materials we file with the SEC at the SEC&rsquo;s Public Reference Room at 100&nbsp;F&nbsp;Street,
N.E., Washington D.C., 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at
1-800-SEC-0330.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Code
of Ethics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have adopted a written code of ethics that applies to our officers, directors and employees, including our principal executive
officer and principal accounting officer. We intend to disclose any amendments to, or waivers from, our code of ethics that are
required to be publicly disclosed pursuant to rules of the SEC by filing such amendment or waiver with the SEC. This code of ethics
and business conduct can be found in the corporate governance section of our website, <I>http://www.aytubio.com</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_003"></A>Item&nbsp;1A.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risk
                                         Factors </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Investing
in our securities includes a high degree of risk. You should consider carefully the specific factors discussed below, together
with all of the other information contained in this Annual Report. If any of the following risks actually occurs, our business,
financial condition, results of operations and future prospects would likely be materially and adversely affected. This could
cause the market price of our securities to decline and could cause you to lose all or part of your investment. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risks
Related to Our Financial Condition and Capital Requirements</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have a limited operating history, have incurred losses, and can give no assurance of profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a commercial-stage healthcare company with a limited operating history. Prior to implementing our commercial strategy in the
fourth calendar quarter of 2015, we did not have a focus on profitability. As a result, we have not generated substantial revenue
to date and are not profitable and have incurred losses in each year since our inception. Our net loss for the years ended June
30, 2018 and 2017 was $10.2 million and $22.5million, respectively. We have not demonstrated the ability to be a profit-generating
enterprise to date. Even though we expect to have revenue growth in the next several fiscal years, it is uncertain that the revenue
growth will be significant enough to offset our expenses and generate a profit in the future. Our ability to generate significant
revenue is uncertain, and we may never achieve profitability. We have a very limited operating history on which investors can
evaluate our potential for future success. Potential investors should evaluate us in light of the expenses, delays, uncertainties,
and complications typically encountered by early-stage healthcare businesses, many of which will be beyond our control. These
risks include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">uncertain
                                         market acceptance of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">lack
                                         of sufficient capital;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">U.S.
                                         regulatory approval of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">foreign
                                         regulatory approval of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">unanticipated
                                         problems, delays, and expense relating to product development and implementation;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">lack
                                         of sufficient intellectual property;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         ability to attract and retain qualified employees;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">competition;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">technological
                                         changes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result of our limited operating history, and the increasingly competitive nature of the markets in which we compete, our historical
financial data, is of limited value in anticipating future operating expenses. Our planned expense levels will be based in part
on our expectations concerning future operations, which is difficult to forecast accurately based on our limited operating history
and the recentness of the acquisition of our products Natesto, ZolpiMist, and MiOXSYS. We may be unable to adjust spending in
a timely manner to compensate for any unexpected budgetary shortfall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have not received any substantial revenues from the commercialization of our current products to date and might not receive significant
revenues from the commercialization of our current products or our product candidates in the near term. Even though Natesto and
ZolpiMist are each an approved drug that we are marketing, we only acquired Natesto in April 2016 and ZolpiMist in June 2018.
In addition, we only launched our MiOXSYS device in early fiscal 2017. As a result, we have limited experience on which to base
the revenue we could expect to receive from sales of these products. To obtain revenues from our products and product candidates,
we must succeed, either alone or with others, in a range of challenging activities, including expanding markets for our existing
products and completing clinical trials of our product candidates, obtaining positive results from those clinical trials, achieving
marketing approval for those product candidates, manufacturing, marketing and selling our existing products and those products
for which we, or our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement
for our products from private insurance or government payors. We, and our collaborators, if any, may never succeed in these activities
and, even if we do, or one of our collaborators does, we may never generate revenues that are sufficient enough for us to achieve
profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain necessary capital
when needed may force us to delay, limit or terminate our product expansion and development efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are expending resources to expand the market for Natesto, ZolpiMist, and MiOXSYS, none of which might be as successful as we anticipate
or at all and all of which might take longer and be more expensive to market than we anticipate. We also are currently advancing
our MiOXSYS device through clinical development. Developing product candidates is expensive, lengthy and risky, and we expect
to incur research and development expenses in connection with our ongoing clinical development activities with the MiOXSYS System.
As of June 30, 2018, our cash, cash equivalents and restricted cash totaling $7.1 million, available to fund our operations offset
by an aggregate $2.3 million in accounts payable and other and accrued liabilities. In November 2016, we conducted a public offering
of our common stock and warrants from which we received gross proceeds of approximately $8.6 million. We closed on a private placement
of common stock, Series A preferred stock and warrants in August 2017 from which we received gross proceeds of approximately $11.8
million. We also closed on an underwritten public offering of our common stock, warrants, and Series B preferred stock in March
2018 from which we received gross proceeds of approximately $12.9 million. Our operating plan may change as a result of many factors
currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt
financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic
alliances and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to
continue the expansion of marketing efforts for Natesto and ZolpiMist and to obtain regulatory approval for, and to commercialize,
our current product candidate, the MiOXSYS System. Raising funds in the current economic environment, as well our lack of operating
history, may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans,
we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability
to expand any existing product or develop and commercialize our product candidates. In addition, we cannot guarantee that future
financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing
may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity
or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional
equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased
fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability
to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through
arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required
to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which
may have a material adverse effect on our business, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we are unable to obtain funding on a timely basis, we may be unable to expand the market for Natesto, ZolpiMist, or MiOXSYS and/or
be required to significantly curtail, delay or discontinue one or more of our research or development programs for the MiOXSYS
system, or any future product candidate or expand our operations generally or otherwise capitalize on our business opportunities,
as desired, which could materially affect our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we do not obtain the capital necessary to fund our operations, we will be unable to successfully expand the commercialization
of Natesto and ZolpiMist and to develop, obtain regulatory approval of, and commercialize, our current product candidate, the
MiOXSYS System.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
expansion of marketing and commercialization activities for our existing products and the development of pharmaceutical products,
medical diagnostics and medical devices is capital-intensive. We anticipate we may require additional financing to continue to
fund our operations. Our future capital requirements will depend on, and could increase significantly as a result of, many factors
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         costs, progress and timing of our efforts to expand the marketing of Natesto and ZolpiMist;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">progress
                                         in, and the costs of, our pre-clinical studies and clinical trials and other research
                                         and development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         costs of securing manufacturing arrangements for commercial production;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         scope, prioritization and number of our research and development programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         achievement of milestones or occurrence of other developments that trigger payments under
                                         any collaboration agreements we obtain;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         costs of establishing, expanding or contracting for sales and marketing capabilities
                                         for any existing products and if we obtain regulatory clearances to market our current
                                         product candidate, the MiOXSYS system;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical
                                         trial costs under future collaboration agreements, if any; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         costs involved in filing, prosecuting, enforcing and defending patent claims and other
                                         intellectual property rights. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our commercialization efforts
or our technologies, research or development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
will incur increased costs associated with, and our management will need to devote substantial time and effort to, compliance
with public company reporting and other requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a public company, we incur significant legal, accounting and other expenses. In addition, the rules and regulations of the SEC
and any national securities exchange to which we may be subject in the future impose numerous requirements on public companies,
including requirements relating to our corporate governance practices, with which we will need to comply. Further, we will continue
to be required to, among other things, file annual, quarterly and current reports with respect to our business and operating results.
Based on currently available information and assumptions, we estimate that we will incur up to approximately $500,000 in expenses
on an annual basis as a direct result of the requirements of being a publicly traded company. Our management and other personnel
will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable
laws and regulations, and our efforts and initiatives to comply with those requirements could be expensive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with
applicable regulations could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Pursuant to Section
404 of the Sarbanes-Oxley Act, our management conducted an assessment of the effectiveness of our internal controls over financial
reporting for the year ended June 30, 2018 and concluded that such control was effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">However,
if in the future we were to conclude that our internal control over financial reporting were not effective, we cannot be certain
as to the timing of completion of our evaluation, testing and remediation actions or their effect on our operations because there
is presently no precedent available by which to measure compliance adequacy. As a consequence, we may not be able to complete
any necessary remediation process in time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also,
there can be no assurance that we will not identify one or more material weaknesses in our internal controls in connection with
evaluating our compliance with Section 404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial
statement errors which, in turn, could require us to restate our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we are unable to conclude that we have effective internal control over financial reporting or if our independent auditors are
unwilling or unable to provide us, when required, with an attestation report on the effectiveness of internal control over financial
reporting as required by Section 404 of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock
price could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet
the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to maintain listing on the NASDAQ Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risks
Related to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Natesto,
ZolpiMist, and MiOXSYS may prove to be difficult to effectively commercialize as planned.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Various
commercial, regulatory, and manufacturing factors may impact our ability to maintain or grow revenues from sales of Natesto, MiOXSYS,
ProstaScint and Fiera. Specifically, we may encounter difficulty by virtue of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability to adequately market and increase sales of any of these products;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability to secure continuing prescribing of any of these products by current or previous
                                         users of the product;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability to effectively transfer and scale manufacturing as needed to maintain an adequate
                                         commercial supply of these products;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reimbursement
                                         and medical policy changes that may adversely affect the pricing, profitability or commercial
                                         appeal of Natesto, ZolpiMist, or MiOXSYS; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability to effectively identify and align with commercial partners outside the U.S.,
                                         or the inability of those selected partners to gain the required regulatory, reimbursement,
                                         and other approvals needed to enable commercial success of MiOXSYS.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have limited experience selling our current products as they were acquired from other companies or were recently approved for
sale. As a result, we may be unable to successfully commercialize our products and product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Despite
our management&rsquo;s extensive experience in launching and managing commercial-stage healthcare companies, we have limited marketing,
sales and distribution experience with our current products. Our ability to achieve profitability depends on attracting and retaining
customers for our current products, and building brand loyalty for Natesto, ZolpiMist, and MiOXSYS. To successfully perform sales,
marketing, distribution and customer support functions, we will face a number of risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to attract and retain skilled support team, marketing staff and sales force necessary
                                         to increase the market for our approved products and to maintain market acceptance for
                                         our product candidates;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         ability of our sales and marketing team to identify and penetrate the potential customer
                                         base; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         difficulty of establishing brand recognition and loyalty for our products.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, we may seek to enlist one or more third parties to assist with sales, distribution and customer support globally or
in certain regions of the world. If we do seek to enter into these arrangements, we may not be successful in attracting desirable
sales and distribution partners, or we may not be able to enter into these arrangements on favorable terms, or at all. If our
sales and marketing efforts, or those of any third-party sales and distribution partners, are not successful, our currently approved
products may not achieve increased market acceptance and our product candidates may not gain market acceptance, which would materially
impact our business and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, any of our current or
future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may not be able to develop our current or any future product candidates. Our product candidates will require substantial additional
clinical development, testing, and regulatory approval before we are permitted to commence commercialization. The clinical trials
of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and
rigorous review and regulation by numerous government authorities in the U.S. and in other countries where we intend to test and,
if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate,
we must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use
in each target indication. This process can take many years and may include post-marketing studies and surveillance, which will
require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage
successfully completes the FDA regulatory approval process and is commercialized. Accordingly, even if we are able to obtain the
requisite financing to continue to fund our development and clinical programs, we cannot assure you that any of our product candidates
will be successfully developed or commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are not permitted to market a product in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product
from the FDA, or in any foreign countries until we receive the requisite approval from such countries. Obtaining approval of an
NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate
for many reasons, including, among others:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         may not be able to demonstrate that a product candidate is safe and effective to the
                                         satisfaction of the FDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         results of our clinical trials may not meet the level of statistical or clinical significance
                                         required by the FDA for marketing approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may disagree with the number, design, size, conduct or implementation of our clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may require that we conduct additional clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may not approve the formulation, labeling or specifications of any product candidate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         clinical research organizations, or CROs, that we retain to conduct our clinical trials
                                         may take actions outside of our control that materially adversely impact our clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate
                                         that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks,
                                         such as the risk of drug abuse by patients or the public in general;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may disagree with our interpretation of data from our pre-clinical studies and clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may not accept data generated at our clinical trial sites;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
                                         an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have
                                         difficulties scheduling an advisory committee meeting in a timely manner or the advisory
                                         committee may recommend against approval of our application or may recommend that the
                                         FDA require, as a condition of approval, additional pre-clinical studies or clinical
                                         trials, limitations on approved labeling or distribution and use restrictions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as
                                         a condition of approval or post-approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may not approve the manufacturing processes or facilities of third-party manufacturers
                                         with which we contract; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA may change its approval policies or adopt new regulations. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
same risks apply to applicable foreign regulatory agencies from which we may seek approval for any of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully
market any product candidate. Moreover, because a substantial portion of our business is or may be dependent upon our product
candidates, any such setback in our pursuit of initial or additional regulatory approval would have a material adverse effect
on our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we fail to successfully acquire new products, we may lose market position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Acquiring
new products is an important factor in our planned sales growth, including products that already have been developed and found
market acceptance. If we fail to identify existing or emerging consumer markets and trends and to acquire new products, we will
not develop a strong revenue source to help pay for our development activities as well as possible acquisitions. This failure
would delay implementation of our business plan, which could have a negative adverse effect on our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we do not secure collaborations with strategic partners to test, commercialize and manufacture product candidates, we may not
be able to successfully develop products and generate meaningful revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may enter into collaborations with third parties to conduct clinical testing, as well as to commercialize and manufacture our
products and product candidates. If we are able to identify and reach an agreement with one or more collaborators, our ability
to generate revenues from these arrangements will depend on our collaborators&rsquo; abilities to successfully perform the functions
assigned to them in these arrangements. Collaboration agreements typically call for milestone payments that depend on successful
demonstration of efficacy and safety, obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not
guaranteed, even when efficacy and safety are demonstrated. Further, the economic environment at any given time may result in
potential collaborators electing to reduce their external spending, which may prevent us from developing our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if we succeed in securing collaborators, the collaborators may fail to develop or effectively commercialize our products or product
candidates. Collaborations involving our product candidates pose a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may not have sufficient resources or may decide not to devote the necessary resources
                                         due to internal constraints such as budget limitations, lack of human resources, or a
                                         change in strategic focus;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may believe our intellectual property is not valid or is unenforceable or the product
                                         candidate infringes on the intellectual property rights of others;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may dispute their responsibility to conduct development and commercialization activities
                                         pursuant to the applicable collaboration, including the payment of related costs or the
                                         division of any revenues;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may decide to pursue a competitive product developed outside of the collaboration arrangement;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may not be able to obtain, or believe they cannot obtain, the necessary regulatory approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may delay the development or commercialization of our product candidates in favor of
                                         developing or commercializing their own or another party&rsquo;s product candidate; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">collaborators
                                         may decide to terminate or not to renew the collaboration for these or other reasons.
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result, collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient
manner or at all. For example, our former collaborator that licensed our former product candidate, Zertane conducted clinical
trials which we believe demonstrated efficacy in treating PE, but the collaborator undertook a merger that we believe altered
its strategic focus and thereafter terminated the collaboration agreement. The Merger also created a potential conflict with a
principal customer of the acquired company, which sells a product to treat premature ejaculation in certain European markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaboration
agreements are generally terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to
commercialization of a product candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations
that achieve the collaborator&rsquo;s objectives and meet our expectations, we may be unable to advance our products or product
candidates and may not generate meaningful revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
or our strategic partners may choose not to continue an existing product or choose not to develop a product candidate at any time
during development, which would reduce or eliminate our potential return on investment for that product.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
any time and for any reason, we or our strategic partners may decide to discontinue the development or commercialization of a
product or product candidate. If we terminate a program in which we have invested significant resources, we will reduce the return,
or not receive any return, on our investment and we will have missed the opportunity to have allocated those resources to potentially
more productive uses. If one of our strategic partners terminates a program, we will not receive any future milestone payments
or royalties relating to that program under our agreement with that party. As an example, we discontinued the development of Zertane
in June 2016, sold Primsol in March 2017, and abandoned Fiera and ProstaScint in June 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
pre-commercial product candidates are expected to undergo clinical trials that are time-consuming and expensive, the outcomes
of which are unpredictable, and for which there is a high risk of failure. If clinical trials of our product candidates fail to
satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we or our collaborators may incur additional costs
or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product
candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-clinical
testing and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot
guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. It may take several years
to complete the pre-clinical testing and clinical development necessary to commercialize a drug, and delays or failure can occur
at any stage. Interim results of clinical trials do not necessarily predict final results, and success in pre-clinical testing
and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical
and biotechnology industries have suffered significant setbacks in advanced clinical trials even after promising results in earlier
trials and we cannot be certain that we will not face similar setbacks. The design of a clinical trial can determine whether its
results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical
trial is well advanced. An unfavorable outcome in one or more trials would be a major set-back for that product candidate and
for us. Due to our limited financial resources, an unfavorable outcome in one or more trials may require us to delay, reduce the
scope of, or eliminate one or more product development programs, which could have a material adverse effect on our business, prospects
and financial condition and on the value of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with clinical testing and trials, we face a number of risks, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                         product candidate is ineffective, inferior to existing approved medicines, unacceptably
                                         toxic, or has unacceptable side effects;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">patients
                                         may die or suffer other adverse effects for reasons that may or may not be related to
                                         the product candidate being tested;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         results may not confirm the positive results of earlier testing or trials; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         results may not meet the level of statistical significance required by the FDA or other
                                         regulatory agencies to establish the safety and efficacy of the product candidate. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we do not successfully complete pre-clinical and clinical development, we will be unable to market and sell products derived from
our product candidates and generate revenues. Even if we do successfully complete clinical trials, those results are not necessarily
predictive of results of additional trials that may be needed before an NDA may be submitted to the FDA. Although there are a
large number of drugs in development in the U.S. and other countries, only a small percentage result in the submission of an NDA
to the FDA, even fewer are approved for commercialization, and only a small number achieve widespread physician and consumer acceptance
following regulatory approval. If our clinical trials are substantially delayed or fail to prove the safety and effectiveness
of our product candidates in development, we may not receive regulatory approval of any of these product candidates and our business,
prospects and financial condition will be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Delays,
suspensions and terminations in any clinical trial we undertake could result in increased costs to us and delay or prevent our
ability to generate revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Human
clinical trials are very expensive, time-consuming, and difficult to design, implement and complete. Should we undertake the development
of a pharmaceutical product candidate, we would expect the necessary clinical trials to take up to 24 months to complete, but
the completion of trials for any product candidates may be delayed for a variety of reasons, including delays in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">demonstrating
                                         sufficient safety and efficacy to obtain regulatory approval to commence a clinical trial;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reaching
                                         agreement on acceptable terms with prospective CROs and clinical trial sites;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">validating
                                         test methods to support quality testing of the drug substance and drug product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtaining
                                         sufficient quantities of the drug substance or device parts;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">manufacturing
                                         sufficient quantities of a product candidate;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtaining
                                         approval of an IND from the FDA;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtaining
                                         institutional review board approval to conduct a clinical trial at a prospective clinical
                                         trial site;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">determining
                                         dosing and clinical design and making related adjustments; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">patient
                                         enrollment, which is a function of many factors, including the size of the patient population,
                                         the nature of the protocol, the proximity of patients to clinical trial sites, the availability
                                         of effective treatments for the relevant disease and the eligibility criteria for the
                                         clinical trial. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
commencement and completion of clinical trials for our product candidates may be delayed, suspended or terminated due to a number
of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">lack
                                         of effectiveness of product candidates during clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse
                                         events, safety issues or side effects relating to the product candidates or their formulation
                                         or design;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">inability
                                         to raise additional capital in sufficient amounts to continue clinical trials or development
                                         programs, which are very expensive;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         need to sequence clinical trials as opposed to conducting them concomitantly in order
                                         to conserve resources;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability to enter into collaborations relating to the development and commercialization
                                         of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
                                         by us or our collaborators to conduct clinical trials in accordance with regulatory requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability or the inability of our collaborators to manufacture or obtain from third parties
                                         materials sufficient for use in pre-clinical studies and clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">governmental
                                         or regulatory delays and changes in regulatory requirements, policy and guidelines, including
                                         mandated changes in the scope or design of clinical trials or requests for supplemental
                                         information with respect to clinical trial results;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
                                         of our collaborators to advance our product candidates through clinical development;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays
                                         in patient enrollment, variability in the number and types of patients available for
                                         clinical trials, and lower-than anticipated retention rates for patients in clinical
                                         trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">difficulty
                                         in patient monitoring and data collection due to failure of patients to maintain contact
                                         after treatment;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                         regional disturbance where we or our collaborative partners are enrolling patients in
                                         our clinical trials, such as a pandemic, terrorist activities or war, or a natural disaster;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">varying
                                         interpretations of our data, and regulatory commitments and requirements by the FDA and
                                         similar foreign regulatory agencies. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Many
of these factors may also ultimately lead to denial of an NDA for a product candidate. If we experience delay, suspensions or
terminations in a clinical trial, the commercial prospects for the related product candidate will be harmed, and our ability to
generate product revenues will be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, we may encounter delays or product candidate rejections based on new governmental regulations, future legislative or
administrative actions, or changes in FDA policy or interpretation during the period of product development. If we obtain required
regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">varying
                                         interpretations of data and commitments by the FDA and similar foreign regulatory agencies;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">diminishment
                                         of any competitive advantages that such product candidates may have or attain. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furthermore,
if we fail to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, we may
encounter or be subject to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">diminishment
                                         of any competitive advantages that such product candidates may have or attain;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays
                                         or termination in clinical trials or commercialization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refusal
                                         by the FDA or similar foreign regulatory agencies to review pending applications or supplements
                                         to approved applications;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">product
                                         recalls or seizures;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">suspension
                                         of manufacturing;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">withdrawals
                                         of previously approved marketing applications; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">fines,
                                         civil penalties, and criminal prosecutions. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>The
medical device regulatory clearance or approval process is expensive, time consuming and uncertain, and the failure to obtain
and maintain required clearances or approvals could prevent us from broadly commercializing the MiOXSYS System for clinical use.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
MiOXSYS System is subject to 510k de novo clearance by the FDA prior to its marketing for commercial use in the U.S., and to regulatory
approvals beyond CE marking required by certain foreign governmental entities prior to its marketing outside the U.S. In addition,
any changes or modifications to a device that has received regulatory clearance or approval that could significantly affect its
safety or effectiveness, or would constitute a major change in its intended use, may require the submission of a new application
for 510k de novo clearance, pre-market approval, or foreign regulatory approvals. The 510k de novo clearance and pre-market approval
processes, as well as the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally
takes from four to twelve months from submission to obtain 510k de novo clearance, and from one to three years from submission
to obtain pre-market approval; however, it may take longer, and 510k de novo clearance or pre-market approval may never be obtained.
We have limited experience in filing FDA applications for 510k de novo clearance and pre-market approval. In addition, we are
required to continue to comply with applicable FDA and other regulatory requirements even after obtaining clearance or approval.
There can be no assurance that we will obtain or maintain any required clearance or approval on a timely basis, or at all. Any
failure to obtain or any material delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements
could harm our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>The
approval process for pharmaceutical and medical device products outside the U.S. varies among countries and may limit our ability
to develop, manufacture and sell our products internationally. Failure to obtain marketing approval in international jurisdictions
would prevent our product candidates from being marketed abroad.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
order to market and sell our products in the European Union and many other jurisdictions, we, and our collaborators, must obtain
separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among
countries and may involve additional testing. We may conduct clinical trials for, and seek regulatory approval to market, our
product candidates in countries other than the U.S. Depending on the results of clinical trials and the process for obtaining
regulatory approvals in other countries, we may decide to first seek regulatory approvals of a product candidate in countries
other than the U.S., or we may simultaneously seek regulatory approvals in the U.S. and other countries. If we or our collaborators
seek marketing approval for a product candidate outside the U.S., we will be subject to the regulatory requirements of health
authorities in each country in which we seek approval. With respect to marketing authorizations in Europe, we will be required
to submit a European Marketing Authorisation Application, or MAA, to the European Medicines Agency, or EMA, which conducts a validation
and scientific approval process in evaluating a product for safety and efficacy. The approval procedure varies among regions and
countries and may involve additional testing, and the time required to obtain approval may differ from that required to obtain
FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Obtaining
regulatory approvals from health authorities in countries outside the U.S. is likely to subject us to all of the risks associated
with obtaining FDA approval described above. In addition, marketing approval by the FDA does not ensure approval by the health
authorities of any other country, and approval by foreign health authorities does not ensure marketing approval by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Even
if we, or our collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation
of our products may limit how we or they market our products, which could materially impair our ability to generate revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if we receive regulatory approval for a product candidate, this approval may carry conditions that limit the market for the product
or put the product at a competitive disadvantage relative to alternative therapies. For instance, a regulatory approval may limit
the indicated uses for which we can market a product or the patient population that may utilize the product, or may be required
to carry a warning in its labeling and on its packaging. Products with black box warnings are subject to more restrictive advertising
regulations than products without such warnings. These restrictions could make it more difficult to market any product candidate
effectively. Accordingly, assuming we, or our collaborators, receive marketing approval for one or more of our product candidates,
we, and our collaborators expect to continue to expend time, money and effort in all areas of regulatory compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Any
of our products and product candidates for which we, or our collaborators, obtain marketing approval in the future could be subject
to post-marketing restrictions or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties
if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products
following approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
of our approved products and product candidates for which we, or our collaborators, obtain marketing approval, as well as the
manufacturing processes, post approval studies and measures, labeling, advertising and promotional activities for such products,
among other things, are or will be subject to continual requirements of and review by the FDA and other regulatory authorities.
These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements,
requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents,
requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate
is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions
of approval, including the FDA requirement to implement a REMS to ensure that the benefits of a drug outweigh its risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or
efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval
marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications
and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&rsquo;
communications regarding off-label use and if we, or our collaborators, do not market any of our product candidates for which
we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement
action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion
and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care
fraud and abuse laws and state consumer protection laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization
of our product candidates may be delayed, and our business will be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other
product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific
studies and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may
publicly announce the expected timing of some of these milestones, such as the initiation or completion of an ongoing clinical
trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product. The achievement
of many of these milestones may be outside of our control. All of such milestones are based on a variety of assumptions which
may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         available capital resources or capital constraints we experience;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         rate of progress, costs and results of our clinical trials and research and development
                                         activities, including the extent of scheduling conflicts with participating clinicians
                                         and collaborators, and our ability to identify and enroll patients who meet clinical
                                         trial eligibility criteria;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         receipt of approvals from the FDA and other regulatory agencies and the timing thereof;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">other
                                         actions, decisions or rules issued by regulators;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to access sufficient, reliable and affordable supplies of compounds used in the
                                         manufacture of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         efforts of our collaborators with respect to the commercialization of our products; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         securing of, costs related to, and timing issues associated with, product manufacturing
                                         as well as sales and marketing activities. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we fail to achieve announced milestones in the timeframes we announce and expect, the commercialization of our product candidates
may be delayed and our business, prospects and results of operations may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays
that prevent us from successfully commercializing product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
rely, and will rely in the future, on medical institutions, clinical investigators, contract research organizations, contract
laboratories, and collaborators to perform data collection and analysis and others to carry out our clinical trials. Our development
activities or clinical trials conducted in reliance on third parties may be delayed, suspended, or terminated if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         third parties do not successfully carry out their contractual duties or fail to meet
                                         regulatory obligations or expected deadlines;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         replace a third party; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         quality or accuracy of the data obtained by third parties is compromised due to their
                                         failure to adhere to clinical protocols, regulatory requirements, or for other reasons.
                                         </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third
party performance failures may increase our development costs, delay our ability to obtain regulatory approval, and delay or prevent
the commercialization of our product candidates. While we believe that there are numerous alternative sources to provide these
services, in the event that we seek such alternative sources, we may not be able to enter into replacement arrangements without
incurring delays or additional costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Even
if collaborators with which we contract in the future successfully complete clinical trials of our product candidates, those product
candidates may not be commercialized successfully for other reasons.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if we contract with collaborators that successfully complete clinical trials for one or more of our product candidates, those
candidates may not be commercialized for other reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
                                         to receive regulatory clearances required to market them as drugs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">being
                                         subject to proprietary rights held by others;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">being
                                         difficult or expensive to manufacture on a commercial scale;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">having
                                         adverse side effects that make their use less desirable; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failing
                                         to compete effectively with products or treatments commercialized by competitors. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Any
third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to
comply with, and experience delays in, our product commercialization as a result of these regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
manufacturing processes and facilities of third-party manufacturers we have engaged for our current approved products are, and
any future third-party manufacturer will be, required to comply with the federal Quality System Regulation, or QSR, which covers
procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization,
storage and shipping of devices. The FDA enforces the QSR through periodic unannounced inspections of manufacturing facilities.
Any inspection by the FDA could lead to additional compliance requests that could cause delays in our product commercialization.
Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with the manufacturing processes
and facilities of third-party manufacturers we engage, including the failure to take satisfactory corrective actions in response
to an adverse QSR inspection, can result in, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">administrative
                                         or judicially imposed sanctions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">injunctions
                                         or the imposition of civil penalties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">recall
                                         or seizure of the product in question;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">total
                                         or partial suspension of production or distribution;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">withdrawal
                                         or suspension of marketing clearances or approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">clinical
                                         holds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">warning
                                         letters;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refusal
                                         to permit the export of the product in question; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">criminal
                                         prosecution. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely
harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the
FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception.
Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects
in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources,
expose us to product liability or other claims, and harm our reputation with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
face substantial competition from companies with considerably more resources and experience than we have, which may result in
others discovering, developing, receiving approval for, or commercializing products before or more successfully than us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
compete with companies that design, manufacture and market already-existing and new urology and sexual wellbeing products. We
anticipate that we will face increased competition in the future as new companies enter the market with new technologies and/or
our competitors improve their current products. One or more of our competitors may offer technology superior to ours and render
our technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater
name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources
to invest in new technologies, more substantial experience in product marketing and new product development, greater regulatory
expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If we are
not able to compete successfully, we may not generate sufficient revenue to become profitable. Our ability to compete successfully
will depend largely on our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">expand
                                         the market for our approved products, especially Natesto, MiOXSYS and Fiera;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">successfully
                                         commercialize our product candidates alone or with commercial partners;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">discover
                                         and develop product candidates that are superior to other products in the market;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain
                                         required regulatory approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">attract
                                         and retain qualified personnel; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain
                                         patent and/or other proprietary protection for our product candidates. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Established
pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could
make our products and product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize
medicines before us. Other companies are or may become engaged in the discovery of compounds that may compete with the product
candidates we are developing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Natesto
competes in a large, growing market. The U.S. prescription testosterone market is comprised primarily of topically applied treatments
in the form of gels, solutions, and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under
the skin by a physician, are also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
ZolpiMist, we compete with companies that design, manufacture and market treatments for insomnia, some of which have a large market
share.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the MiOXSYS System, we compete with companies that design, manufacture and market already existing and new in-vitro diagnostics
and diagnostic imaging systems and radio-imaging agents for cancer detection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
anticipate that we will face increased competition in the future as new companies enter the market with new technologies and our
competitors improve their current products. One or more of our competitors may offer technology superior to ours and render our
technology obsolete or uneconomical. Most of our current competitors, as well as many of our potential competitors, have greater
name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources
to invest in new technologies, more substantial experience in new product development, greater regulatory expertise, more extensive
manufacturing capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully,
we may not generate sufficient revenue to become profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
new product we develop or commercialize that competes with a currently-approved product must demonstrate compelling advantages
in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful. If
we are not able to compete effectively against our current and future competitors, our business will not grow and our financial
condition and operations will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Government
restrictions on pricing and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact
our ability to generate revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
continuing efforts of the government, insurance companies, managed care organizations and other payors of health care costs to
contain or reduce costs of health care may adversely affect one or more of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         or our collaborators&rsquo; ability to set a price we believe is fair for our approved
                                         products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to generate revenue from our approved products and achieve profitability; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         availability of capital. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
2010 enactments of the Patient Protection and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation
Act, or the Health Care Reconciliation Act, significantly impacted the provision of, and payment for, health care in the U.S.
Various provisions of these laws are designed to expand Medicaid eligibility, subsidize insurance premiums, provide incentives
for businesses to provide health care benefits, prohibit denials of coverage due to pre-existing conditions, establish health
insurance exchanges, and provide additional support for medical research. Amendments to the PPACA and/or the Health Care Reconciliation
Act, as well as new legislative proposals to reform healthcare and government insurance programs, along with the trend toward
managed healthcare in the U.S., could influence the purchase of medicines and medical devices and reduce demand and prices for
our products and product candidates, if approved. This could harm our or our collaborators&rsquo; ability to market any approved
products and generate revenues. As we expect to receive significant revenues from reimbursement of our Natesto and ProstaScint
products by commercial third-party payors and government payors, cost containment measures that health care payors and providers
are instituting and the effect of further health care reform could significantly reduce potential revenues from the sale of any
of our products and product candidates approved in the future, and could cause an increase in our compliance, manufacturing, or
other operating expenses. In addition, in certain foreign markets, the pricing of prescription drugs and devices is subject to
government control and reimbursement may in some cases be unavailable. We believe that pricing pressures at the federal and state
level, as well as internationally, will continue and may increase, which may make it difficult for us to sell any approved product
at a price acceptable to us or any of our future collaborators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, in some foreign countries, the proposed pricing for a drug or medical device must be approved before it may be lawfully
marketed. The requirements governing pricing vary widely from country to country. For example, the European Union provides options
for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product
or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. A member state may require that physicians prescribe the generic version of a drug instead of our approved branded
product. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products
will allow favorable reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical
products launched in the European Union do not follow price structures of the U.S. and generally tend to have significantly lower
prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
financial results will depend on the acceptance among hospitals, third-party payors and the medical community of our products
and product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
future success depends on the acceptance by our target customers, third-party payors and the medical community that our products
and product candidates are reliable, safe and cost-effective. Many factors may affect the market acceptance and commercial success
of our products and product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to convince our potential customers of the advantages and economic value our
                                         products and product candidates over existing technologies and products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         relative convenience and ease of our products and product candidates over existing technologies
                                         and products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         introduction of new technologies and competing products that may make our products and
                                         product candidates less attractive for our target customers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         success in training medical personnel on the proper use of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         willingness of third-party payors to reimburse our target customers that adopt our products
                                         and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         acceptance in the medical community of our products and product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         extent and success of our marketing and sales efforts; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">general
                                         economic conditions. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>



<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
third-party payors do not reimburse our customers for the products we sell or if reimbursement levels are set too low for us to
sell one or more of our products at a profit, our ability to sell those products and our results of operations will be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">While
Natesto and ZolpiMist are already FDA-approved and generating revenues in the U.S., they may not receive, or continue to receive,
physician or hospital acceptance, or they may not maintain adequate reimbursement from third party payors. Additionally, even
if one of our product candidates is approved and reaches the market, the product may not achieve physician or hospital acceptance,
or it may not obtain adequate reimbursement from third party payors. In the future, we might possibly sell other product candidates
to target customers substantially all of whom receive reimbursement for the health care services they provide to their patients
from third-party payors, such as Medicare, Medicaid, other domestic and foreign government programs, private insurance plans and
managed care programs. Reimbursement decisions by particular third-party payors depend upon a number of factors, including each
third-party payor&rsquo;s determination that use of a product is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                         covered benefit under its health plan;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">appropriate
                                         and medically necessary for the specific indication;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">cost
                                         effective; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">neither
                                         experimental nor investigational. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third-party
payors may deny reimbursement for covered products if they determine that a medical product was not used in accordance with cost-effective
diagnosis methods, as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may
refuse to reimburse for procedures and devices deemed to be experimental.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Obtaining
coverage and reimbursement approval for a product from each government or third-party payor is a time consuming and costly process
that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our potential product
to each government or third-party payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage
and reimbursement. In addition, eligibility for coverage does not imply that any product will be covered and reimbursed in all
cases or reimbursed at a rate that allows our potential customers to make a profit or even cover their costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third-party
payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement for medical
products and services. Levels of reimbursement may decrease in the future, and future legislation, regulation or reimbursement
policies of third-party payors may adversely affect the demand for and reimbursement available for any product or product candidate,
which in turn, could negatively impact pricing. If our customers are not adequately reimbursed for our products, they may reduce
or discontinue purchases of our products, which would result in a significant shortfall in achieving revenue expectations and
negatively impact our business, prospects and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Manufacturing
risks and inefficiencies may adversely affect our ability to produce our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expect to engage third parties to manufacture components of the MiOXSYS and RedoxSYS systems. We have an agreement for supplies
of Natesto with Acerus, from whom we license Natesto. We have an agreement with a third-party manufacturer for our ZolpiMist product
as well. For any future product, we expect to use third-party manufacturers because we do not have our own manufacturing capabilities.
In determining the required quantities of any product and the manufacturing schedule, we must make significant judgments and estimates
based on inventory levels, current market trends and other related factors. Because of the inherent nature of estimates and our
limited experience in marketing our current products, there could be significant differences between our estimates and the actual
amounts of product we require. If we do not effectively maintain our supply agreements for Natesto and Fiera, we will face difficulty
finding replacement suppliers, which could harm sales of those products. If we do not secure collaborations with manufacturing
and development partners to enable production to scale of the MiOXSYS System, we may not be successful in selling or in commercializing
the MiOXSYS System in the event we receive regulatory approval of the MiOXSYS System. If we fail in similar endeavors for future
products, we may not be successful in establishing or continuing the commercialization of our products and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reliance
on third-party manufacturers entails risks to which we would not be subject if we manufactured these components ourselves, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reliance
                                         on third parties for regulatory compliance and quality assurance;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">possible
                                         breaches of manufacturing agreements by the third parties because of factors beyond our
                                         control;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">possible
                                         regulatory violations or manufacturing problems experienced by our suppliers; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">possible
                                         termination or non-renewal of agreements by third parties, based on their own business
                                         priorities, at times that are costly or inconvenient for us. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Further,
if we are unable to secure the needed financing to fund our internal operations, we may not have adequate resources required to
effectively and rapidly transition our third party manufacturing. We may not be able to meet the demand for our products if one
or more of any third-party manufacturers is unable to supply us with the necessary components that meet our specifications. It
may be difficult to find alternate suppliers for any of our products or product candidates in a timely manner and on terms acceptable
to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Any
third-party manufacturers we engage are subject to various governmental regulations, and we may incur significant expenses to
comply with, and experience delays in, our product commercialization as a result of these regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
manufacturing processes and facilities of third-party manufacturers we engage for our current and any future FDA-approved products
are required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design,
testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA
enforces the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to
additional compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA
requirements, or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party
manufacturers we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection,
can result in, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">administrative
                                         or judicially imposed sanctions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">injunctions
                                         or the imposition of civil penalties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">recall
                                         or seizure of the product in question;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">total
                                         or partial suspension of production or distribution;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">withdrawal
                                         or suspension of marketing clearances or approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">clinical
                                         holds;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">warning
                                         letters;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">refusal
                                         to permit the export of the product in question; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">criminal
                                         prosecution. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
of these actions, in combination or alone, could prevent us from marketing, distributing or selling our products, and would likely
harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. We believe the
FDA would request that we initiate a voluntary recall if a product was defective or presented a risk of injury or gross deception.
Regulatory agencies in other countries have similar authority to recall drugs or devices because of material deficiencies or defects
in design or manufacture that could endanger health. Any recall would divert our management attention and financial resources,
expose us to product liability or other claims, and harm our reputation with customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory
burdens and other risks and uncertainties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
future profitability will depend, in part, on our ability to commercialize our products and product candidates in foreign markets
for which we intend to primarily rely on collaboration with third parties. If we commercialize our products or product candidates
in foreign markets, we would be subject to additional risks and uncertainties, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         inability to directly control commercial activities because we are relying on third parties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         burden of complying with complex and changing foreign regulatory, tax, accounting and
                                         legal requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">different
                                         medical practices and customs in foreign countries affecting acceptance in the marketplace;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">import
                                         or export licensing requirements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">longer
                                         accounts receivable collection times;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">longer
                                         lead times for shipping;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">language
                                         barriers for technical training;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">reduced
                                         protection of intellectual property rights in some foreign countries, and related prevalence
                                         of generic alternatives to our products;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">foreign
                                         currency exchange rate fluctuations;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         customers&rsquo; ability to obtain reimbursement for our products in foreign markets;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         interpretation of contractual provisions governed by foreign laws in the event of a contract
                                         dispute. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Foreign
sales of our products or product candidates could also be adversely affected by the imposition of governmental controls, political
and economic instability, trade restrictions and changes in tariffs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are subject to various regulations pertaining to the marketing of our approved products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are subject to various federal and state laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of
payment or acceptance of kickbacks or other remuneration for the purchase of our products, including inducements to potential
patients to request our products and services. Additionally, any product promotion educational activities, support of continuing
medical education programs, and other interactions with health-care professionals must be conducted in a manner consistent with
the FDA regulations and the Anti-Kickback Statute. The Anti-Kickback Statute prohibits persons or entities from knowingly and
willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of
an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal
healthcare program such as the Medicare and Medicaid programs. Violations of the Anti-Kickback Statute can also carry potential
federal False Claims Act liability. Additionally, many states have adopted laws similar to the Anti-Kickback Statute. Some of
these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third party payer, not
only the Medicare and Medicaid programs, and do not contain identical safe harbors. These and any new regulations or requirements
may be difficult and expensive for us to comply with, may adversely impact the marketing of our existing products or delay introduction
of our product candidates, which may have a material adverse effect on our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
products and product candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit
the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials
and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Further,
if a product candidate receives marketing approval and we or others identify undesirable side effects caused by the product after
the approval, or if drug abuse is determined to be a significant problem with an approved product, a number of potentially significant
negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulatory
                                         authorities may withdraw or limit their approval of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">regulatory
                                         authorities may require the addition of labeling statements, such as a &ldquo;Black Box
                                         warning&rdquo; or a contraindication;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         may be required to change the way the product is distributed or administered, conduct
                                         additional clinical trials or change the labeling of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         may decide to remove the product from the marketplace;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         could be sued and held liable for injury caused to individuals exposed to or taking the
                                         product; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         reputation may suffer. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially
increase the costs of commercializing an affected product or product candidates and significantly impact our ability to successfully
commercialize or maintain sales of our product or product candidates and generate revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Natesto
and ZolpiMist contain, and future other product candidates may contain, controlled substances, the manufacture, use, sale, importation,
exportation, prescribing and distribution of which are subject to regulation by the DEA.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Natesto
and ZolpiMist, which are both approved by the FDA, are regulated by the DEA as Schedule III controlled substances. Before any
commercialization of any product candidate that contains a controlled substance, the DEA will need to determine the controlled
substance schedule, taking into account the recommendation of the FDA. This may be a lengthy process that could delay our marketing
of a product candidate and could potentially diminish any regulatory exclusivity periods for which we may be eligible. Natesto
and ZolpiMist are, and our other product candidates may, if approved, be regulated as &ldquo;controlled substances&rdquo; as defined
in the Controlled Substances Act of 1970, or CSA, and the implementing regulations of the DEA, which establish registration, security,
recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements administered
by the DEA. These requirements are applicable to us, to our third-party manufacturers and to distributors, prescribers and dispensers
of our product candidates. The DEA regulates the handling of controlled substances through a closed chain of distribution. This
control extends to the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion
into illicit channels of commerce. A number of states and foreign countries also independently regulate these drugs as controlled
substances.</FONT></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established
medicinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V,
with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk
of abuse among such substances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Natesto
is regulated by the DEA as a Schedule III controlled substance, and ZolpiMist as a Schedule IV controlled substance. Consequently,
the manufacturing, shipping, storing, selling and using of the products are subject to a high degree of regulation. Also, distribution,
prescribing and dispensing of these drugs are highly regulated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual
registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance.
The registration is specific to the particular location, activity and controlled substance schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because
of their restrictive nature, these laws and regulations could limit commercialization of our product candidates containing controlled
substances. Failure to comply with these laws and regulations could also result in withdrawal of our DEA registrations, disruption
in manufacturing and distribution activities, consent decrees, criminal and civil penalties and state actions, among other consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
testosterone replacement therapies are found, or are perceived, to create health risks, our ability to sell Natesto could be materially
adversely affected and our business could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Recent
publications have suggested potential health risks associated with testosterone replacement therapy, such as increased cardiovascular
disease risk, including increased risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement,
increased red blood cells, development of clinical prostate disease, including prostate cancer, and the suppression of sperm production.
Prompted by these events, the FDA held a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further.
The FDA has also asked health care professionals and patients to report side effects involving prescription testosterone products
to the agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
the T-class Advisory Committee meeting held on September 17, 2014, the Advisory Committee discussed (i) the identification of
the appropriate patient population for whom testosterone replacement therapy should be indicated and (ii) the potential risk of
major adverse cardiovascular events, defined as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated
with testosterone replacement therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
the meeting, the Advisory Committee voted that the FDA should require sponsors of testosterone products to conduct a post marketing
study (e.g. observational study or controlled clinical trial) to further assess the potential cardiovascular risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">It
is possible that the FDA&rsquo;s evaluation of this topic and further studies on the effects of testosterone replacement therapies
could demonstrate the risk of major adverse cardiovascular events or other health risks or could impose requirements that impact
the marketing and sale of Natesto, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">mandate
                                         that certain warnings or precautions be included in our product labeling;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">require
                                         that our product carry a &ldquo;black box warning&rdquo;; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">limit
                                         use of Natesto to certain populations, such as men without specified conditions. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Demonstrated
testosterone replacement therapy safety risks, as well as negative publicity about the risks of hormone replacement therapy, including
testosterone replacement, could hurt sales of and impair our ability to successfully relaunch Natesto, which could have a materially
adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>FDA
action regarding testosterone replacement therapies could add to the cost of producing and marketing Natesto.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
FDA is requiring post-marketing safety studies for all testosterone replacement therapies approved in the U.S. to assess long-term
cardiovascular events related to testosterone use. Depending on the total cost and structure of the FDA&rsquo;s proposed safety
studies there may be a substantial cost associated with conducting these studies. Pursuant to our license agreement with Acerus
Pharmaceuticals, Acerus is obligated to reimburse us for the entire cost of any studies required for Natesto by the FDA. However,
in the event that Acerus is not able to reimburse us for the cost of any required safety studies, we may be forced to incur this
cost, which could have a material adverse impact on our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
approved products may not be accepted by physicians, patients, or the medical community in general.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if the medical community accepts a product as safe and efficacious for its indicated use, physicians may choose to restrict the
use of the product if we or any collaborator is unable to demonstrate that, based on experience, clinical data, side-effect profiles
and other factors, our product is preferable to any existing medicines or treatments. We cannot predict the degree of market acceptance
of any of our approved products, which will depend on a number of factors, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         efficacy and safety of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         approved labeling for the product and any required warnings;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         advantages and disadvantages of the product compared to alternative treatments;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         and any collaborator&rsquo;s ability to educate the medical community about the safety
                                         and effectiveness of the product;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         reimbursement policies of government and third-party payors pertaining to the product;
                                         and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         market price of our product relative to competing treatments. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>



<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal
of these materials could be time consuming and costly.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
research and development processes may involve the controlled use of hazardous materials, including chemicals and biological materials.
We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be
sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability
may exceed any insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture,
storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants
into the environment and human health and safety matters. Compliance with environmental laws and regulations may be expensive
and may impair our research and development efforts. If we fail to comply with these requirements, we could incur substantial
costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational
changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended
environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intellectual
Property Risks Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are dependent on our relationships and license agreements, and we rely on the patent rights granted to us pursuant to the license
agreements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
number of our patent rights for are derived from our license agreements with third parties. Pursuant to these license agreements,
we have licensed rights to various patents and patent applications within and outside of the United States. We may lose our rights
to these patents and patent applications if we breach our obligations under such license agreements, including, without limitation,
our financial obligations to the licensors. If we violate or fail to perform any term or covenant of the license agreements, the
licensors may terminate the license agreements upon satisfaction of applicable notice requirements and expiration of any applicable
cure periods. Additionally, any termination of license agreements, whether by us or the licensors will not relieve us of our obligation
to pay any license fees owing at the time of such termination. If we fail to retain our rights under these license agreements,
we will not be able to commercialize certain products subject to patent or patent application, and our business, results of operations,
financial condition and prospects would be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
commercial success of our products depends, in large part, on our ability to use patents licensed to us by third parties in order
to exclude others from competing with our products. The patent position of emerging pharmaceutical companies like us can be highly
uncertain and involve complex legal and technical issues. Until our licensed patents are interpreted by a court, either because
we have sought to enforce them against a competitor or because a competitor has preemptively challenged them, we will not know
the breadth of protection that they will afford us. Our patents may not contain claims sufficiently broad to prevent others from
practicing our technologies or marketing competing products. Third parties may intentionally attempt to design around our patents
or design around our patents so as to compete with us without infringing our patents. Moreover, the issuance of a patent is not
conclusive as to its validity or enforceability, and so our patents may be invalidated or rendered unenforceable if challenged
by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
ability to compete may decline if we do not adequately protect our proprietary rights or if we are barred by the patent rights
of others.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
commercial success depends on obtaining and maintaining proprietary rights to our products and product candidates as well as successfully
defending these rights against third-party challenges. We will only be able to protect our products and product candidates from
unauthorized use by third parties to the extent that valid and enforceable patents, or effectively protected trade secrets, cover
them. Our ability to obtain patent protection for our products and product candidates is uncertain due to a number of factors,
including that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         may not have been the first to make the inventions covered by pending patent applications
                                         or issued patents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         may not have been the first to file patent applications for our products and product
                                         candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">others
                                         may independently develop identical, similar or alternative products, compositions or
                                         devices and uses thereof;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         disclosures in patent applications may not be sufficient to meet the statutory requirements
                                         for patentability;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
                                         or all of our pending patent applications may not result in issued patents;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         may not seek or obtain patent protection in countries that may eventually provide us
                                         a significant business opportunity;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
                                         patents issued to us may not provide a basis for commercially viable products, may not
                                         provide any competitive advantages, or may be successfully challenged by third parties;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         compositions, devices and methods may not be patentable;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">others
                                         may design around our patent claims to produce competitive products which fall outside
                                         of the scope of our patents; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">others
                                         may identify prior art or other bases which could invalidate our patents. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if we have or obtain patents covering our products and product candidates, we may still be barred from making, using and selling
them because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products
that are similar or identical to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic
products, diagnostic devices, personal care products and devices and some of these relate to our products and product candidates.
These could materially affect our ability to sell our products and develop our product candidates. Because patent applications
can take many years to issue, there may be currently pending applications unknown to us that may later result in issued patents
that our products and product candidates may infringe. These patent applications may have priority over patent applications filed
by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Obtaining
and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance
fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the
lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during
the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition,
there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process
can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in
the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully
or inadvertently, our competitive position could suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal
actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition,
these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are
unenforceable. We may or may not choose to pursue litigation or other actions against those that have infringed on our patents,
or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail
to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could harm
our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Pharmaceutical
and medical device patents and patent applications involve highly complex legal and factual questions, which, if determined adversely
to us, could negatively impact our patent position.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
patent positions of pharmaceutical and medical device companies can be highly uncertain and involve complex legal and factual
questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain
and difficult to determine and are often affected materially by the facts and circumstances that pertain to the patented compositions
and the related patent claims. The standards of the U.S. Patent and Trademark Office, or USPTO, are sometimes uncertain and could
change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued,
may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings,
and U.S. patents may be subject to re-examination proceedings, post-grant review and/or inter partes review in the USPTO. Foreign
patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result
in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims
of the patent or patent application. In addition, such interference, re-examination, post-grant review, inter partes review and
opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection
against competitive products or processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, changes in or different interpretations of patent laws in the U.S. and foreign countries may permit others to use our
discoveries or to develop and commercialize our technology and products and product candidates without providing any compensation
to us or may limit the number of patents or claims we can obtain. The laws of some countries do not protect intellectual property
rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending our intellectual
property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we fail to obtain and maintain patent protection and trade secret protection of our products and product candidates, we could
lose our competitive advantage and competition we face would increase, reducing any potential revenues and adversely affecting
our ability to attain or maintain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Developments
in patent law could have a negative impact on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability
and any such changes could have a negative impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number
of significant changes to U.S. patent law. These changes include a transition from a &ldquo;first-to-invent&rdquo; system to a
&ldquo;first-to-file&rdquo; system, changes the way issued patents are challenged, and changes the way patent applications are
disputed during the examination process. These changes may favor larger and more established companies that have greater resources
to devote to patent application filing and prosecution. The USPTO has developed regulations and procedures to govern the full
implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents
Act, and, in particular, the first-to-file provisions, became effective on March 16, 2013. Substantive changes to patent law associated
with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly,
it is not clear what, if any, impact the America Invents Act will ultimately have on the cost of prosecuting our patent applications,
our ability to obtain patents based on our discoveries and our ability to enforce or defend any patents that may issue from our
patent applications, all of which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to patent protection, because we operate in the highly technical field of discovery and development of therapies and
medical devices, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However,
trade secrets are difficult to protect. We expect to enter into confidentiality and intellectual property assignment agreements
with our employees, consultants, outside scientific and commercial collaborators, sponsored researchers, and other advisors. These
agreements generally require that the other party keep confidential and not disclose to third parties all confidential information
developed by the party or made known to the party by us during the course of the party&rsquo;s relationship with us. These agreements
also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive
property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and
technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee
or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may
not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse
we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable.
In addition, courts outside the U.S. may be less willing to protect trade secrets. Trade secrets may be independently developed
by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as
our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor,
our competitive position could be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may not be able to enforce our intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies
have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual
property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for us to
stop the infringement of some of our patents, if obtained, or the misappropriation of our other intellectual property rights.
For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
In addition, many countries limit the enforceability of patents against third parties, including government agencies or government
contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country
basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent
protection in certain countries, and we will not have the benefit of patent protection in such countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from
other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.
In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain
adequate protection for our technology and the enforcement of intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Third
parties may assert ownership or commercial rights to inventions we develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third
parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We have or expect
to have written agreements with collaborators that provide for the ownership of intellectual property arising from our collaborations.
These agreements provide that we must negotiate certain commercial rights with collaborators with respect to joint inventions
or inventions made by our collaborators that arise from the results of the collaboration. In some instances, there may not be
adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration.
If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a
third-party collaborator&rsquo;s materials where required, or if disputes otherwise arise with respect to the intellectual property
developed with the use of a collaborator&rsquo;s samples, we may be limited in our ability to capitalize on the market potential
of these inventions. In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants
obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations
of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and
interfere with our ability to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership
dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive
rights in that intellectual property. Either outcome could have an adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Third
parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated
trade secrets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
might employ individuals who were previously employed at universities or other biopharmaceutical or medical device companies,
including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the
proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or
other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these
claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>A
dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be
time consuming and costly, and an unfavorable outcome could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
is significant litigation in the pharmaceutical and medical device industries regarding patent and other intellectual property
rights. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened
litigation, we may be exposed to future litigation by third parties based on claims that our products or product candidates infringe
the intellectual property rights of others. If our development and commercialization activities are found to infringe any such
patents, we may have to pay significant damages or seek licenses to such patents. A patentee could prevent us from using the patented
drugs, compositions or devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets,
or to determine the scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel
or consultants formerly employed by other companies involved in one or more areas similar to the activities conducted by us. Either
we or these individuals may be subject to allegations of trade secret misappropriation or other similar claims as a result of
prior affiliations. If we become involved in litigation, it could consume a substantial portion of our managerial and financial
resources, regardless of whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception
of an adverse ruling in defending ourselves against these claims could have a material adverse impact on our cash position and
stock price. Any legal action against us or our collaborators could lead to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">payment
                                         of damages, potentially treble damages, if we are found to have willfully infringed a
                                         party&rsquo;s patent rights;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">injunctive
                                         or other equitable relief that may effectively block our ability to further develop,
                                         commercialize, and sell products; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we
                                         or our collaborators having to enter into license arrangements that may not be available
                                         on commercially acceptable terms, if at all, all of which could have a material adverse
                                         impact on our cash position and business, prospects and financial condition. As a result,
                                         we could be prevented from commercializing our products and product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risks
Related to Our Organization, Structure and Operation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
intend to acquire, through asset purchases or in-licensing, businesses or products, or form strategic alliances, in the future,
and we may not realize the intended benefits of such acquisitions or alliances.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
intend to acquire, through asset purchases or in-licensing, additional businesses or products, form strategic alliances and/or
create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses
or assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses or assets
if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties
in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent
us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition
or alliance, we will achieve the expected synergies to justify the transaction. These risks apply to our acquisition of Natesto
in April 2016 and ZolpiMist in June 2018. As an example, we acquired Primsol in October 2015, but sold it in March 2017. Depending
on the success or lack thereof of any of our existing or future acquired products and product candidates, we might seek to out-license,
sell or otherwise dispose of any of those products or product candidates, which could adversely impact our operations if the dispositions
triggers a loss, accounting charge or other negative impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>In
fiscal 2018, the great majority of our gross revenue and gross accounts receivable were due to three significant customers, the
loss of which could materially and adversely affect our results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following customers contributed greater than&nbsp;10%&nbsp;of the Company&rsquo;s gross revenue during the year ended June 30, 2018
and 2017, respectively. As of June 30, 2018, three customers accounted for 86% of gross revenue. The revenue from these customers
as a percentage of gross revenue was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    A</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    C</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">30</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    B</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
loss of one or more of the Company&rsquo;s significant partners or collaborators could have a material adverse effect on its business,
operating results or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are also subject to credit risk from our accounts receivable related to our product sales. As of June 30, 2018, three customers
accounted for 81% of gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Year
    Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    C</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    B</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which
could disrupt our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2018, we had 52 full-time employees, and in connection with being a public company, we expect to continue to increase
our number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue
to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and
train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away
from its day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our limited
resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities,
loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant
costs and may divert financial resources from other projects, such as the planned expanded commercialization of our approved products
and the development of our product candidates. If our management is unable to effectively manage our expected development and
expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and
we may not be able to implement our business strategy. Our future financial performance and our ability to expand the market for
our approved products and develop our product candidates, if approved, and compete effectively will depend, in part, on our ability
to effectively manage the future development and expansion of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
depend on key personnel and attracting qualified management personnel and our business could be harmed if we lose personnel and
cannot attract new personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
success depends to a significant degree upon the technical and management skills of our directors, officers and key personnel.
Any of our directors could resign from our board at any time and for any reason. Although our executive officers Joshua Disbrow,
Jarrett Disbrow and David Green have employment agreements, the existence of an employment agreement does not guarantee the retention
of the executive officer for any period of time, and each agreement obligates us to pay the officer lump sum severance of two
years of salary if we terminate him without cause, as defined in the agreement, which could hurt our liquidity. The loss of the
services of any of these individuals would likely have a material adverse effect on us. Our success also will depend upon our
ability to attract and retain additional qualified management, marketing, technical, and sales executives and personnel. We do
not maintain key person life insurance for any of our officers or key personnel. The loss of any of our directors or key executives,
or the failure to attract, integrate, motivate, and retain additional key personnel could have a material adverse effect on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
compete for such personnel, including directors, against numerous companies, including larger, more established companies with
significantly greater financial resources than we possess. There can be no assurance that we will be successful in attracting
or retaining such personnel, and the failure to do so could have a material adverse effect on our business, prospects, financial
condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Product
liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential
of our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
risk that we may be sued on product liability claims is inherent in the development and commercialization of pharmaceutical, medical
device and personal care products and devices. Side effects of, or manufacturing defects in, products that we develop and commercialized
could result in the deterioration of a patient&rsquo;s condition, injury or even death. Once a product is approved for sale and
commercialized, the likelihood of product liability lawsuits increases. Claims may be brought by individuals seeking relief for
themselves or by individuals or groups seeking to represent a class. These lawsuits may divert our management from pursuing our
business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial
liabilities and may be forced to limit or forgo further commercialization of the affected products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may be subject to legal or administrative proceedings and litigation other than product liability lawsuits which may be costly
to defend and could materially harm our business, financial condition and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
we maintain general liability, clinical trial liability and product liability insurance, this insurance may not fully cover potential
liabilities. In addition, inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise
protect against potential product or other legal or administrative liability claims could prevent or inhibit the commercial production
and sale of any of our products and product candidates that receive regulatory approval, which could adversely affect our business.
Product liability claims could also harm our reputation, which may adversely affect our collaborators&rsquo; ability to commercialize
our products successfully.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which
could result in a material disruption of our product development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Despite
the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and
electrical failures. While we do not believe that we have experienced any such system failure, accident, or security breach to
date, if such an event were to occur and cause interruptions in our operations, it could result in a loss of clinical trial data
for our product candidates which could result in delays in our regulatory approval efforts and significantly increase our costs
to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data
or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of
confidential or proprietary information, we could incur liabilities and the further development of our product candidates could
be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2018, we had federal net operating loss carryforwards of approximately $59.3 million. The available net operating
losses, if not utilized to offset taxable income in future periods, will begin to expire in 2031 and will completely expire in
2037. Under the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;) and the regulations promulgated thereunder,
including, without limitation, the consolidated income tax return regulations, various corporate changes could limit our ability
to use our net operating loss carryforwards and other tax attributes (such as research tax credits) to offset our income. Because
Ampio&rsquo;s equity ownership interest in our company fell to below 80% in January 2016, we were deconsolidated from Ampio&rsquo;s
consolidated federal income tax group. As a result, certain of our net operating loss carryforwards may not be available to us
and we may not be able to use them to offset our U.S. federal taxable income. As a consequence of the deconsolidation, it is possible
that certain other tax attributes and benefits resulting from U.S. federal income tax consolidation may no longer be available
to us. Our company and Ampio do not have a tax sharing agreement that could mitigate the loss of net operating losses and other
tax attributes resulting from the deconsolidation or our incurrence of liability for the taxes of other members of the consolidated
group by reason of the joint and several liability of group members. In addition to the deconsolidation risk, an &ldquo;ownership
change&rdquo; (generally a 50% change (by value) in equity ownership over a three-year period) under Section 382 of the Code could
limit our ability to offset, post-change, our U.S. federal taxable income. Section 382 of the Code imposes an annual limitation
on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards
and certain recognized built-in losses. We believe that the August 2017 financing created over a 50% change in our equity ownership
so our current tax loss carryforward will be limited in the future. Either the deconsolidation or the ownership change scenario
could result in increased future tax liability to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Several
stockholders potentially own a significant percentage of our stock and could be able to exert significant control over matters
subject to stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our August 2017 and March 2018 offerings, some entities who
invested in our common and preferred stock and warrant financing owned common and/or preferred stock and warrants that potentially
would enable them to beneficially own in excess of 4.99% or 9.99% of our common stock. The preferred stock and warrants held by
these investors contain a provision that prohibits the conversion or exercise of the preferred stock or warrants should the holder
beneficially own in excess of 4.99% or 9.99%, as elected by the investor, after giving effect to such conversion or exercise. However,
the significant ownership potential of these investors, and the significant investment that they have made in our company, could
give these stockholders the ability to influence us through their ownership positions, even if they are prohibited from converting
or exercising their preferred stock or warrants to acquire more than 4.99% or 9.99% of our common stock at any time. Further, this
significant ownership potential may prevent or discourage unsolicited acquisition proposals or offers for our common stock that
you may feel are in your best interest as one of our stockholders.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Restrictions
under our August 2017 Securities Purchase Agreement may limit our ability to raise funds and operate our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
August 2017 Securities Purchase Agreement contains covenants described below that may restrict our ability to finance future operations
or capital needs or to engage in other business activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the 24 months following the Effective Date, as defined in the Securities Purchase Agreement, upon any issuance by us of any common
stock or common stock equivalents for cash consideration or indebtedness or a combination thereof (a &ldquo;Subsequent Financing&rdquo;),
each investor in the offering will have the right to participate in up to an amount of the Subsequent Financing equal to 35% of
the Subsequent Financing on the same terms, conditions and price provided for in the Subsequent Financing.&nbsp;The &ldquo;Effective
Date&rdquo; is the earliest of the date that (a) the initial registration statement registering all of the shares of common stock
and the shares of common stock into which the Series A Preferred Stock is convertible and the warrants (collectively, the &ldquo;Securities&rdquo;)
are exercisable has been declared effective by the SEC, (b) all of the Securities have been sold pursuant to Rule 144 or may be
sold pursuant to Rule 144 without the requirement for our company to be in compliance with the current public information required
under Rule 144 and without volume or manner-of-sale restrictions or (c) following the one year anniversary of August 15, 2017,
all of the Securities may be sold pursuant to an exemption from registration under Section 4(1) of the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), without volume or manner-of-sale restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Until
the later of (i) 270 days after the Effective Date and (ii) 365 days from August 15, 2017, without the consent of investors that
purchased at least 51% of the shares of common stock in the offering, we may not issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any shares of common stock or common stock equivalents, or file any registration statement
covering the issuance or resale of any shares of common stock or common stock equivalents. If the value weighted average price
of our common stock exceeds $1.00 (as adjusted for stock splits, stock dividends and similar corporate events) for five or more
consecutive trading days, this right will terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Until
such time as no investor in the August 2017 offering holds any of the warrants, we are prohibited from effecting or entering into
an agreement to affect any issuance by us of our common stock or common stock equivalents involving a Variable Rate Transaction,
as defined in the Securities Purchase Agreement. &ldquo;Variable Rate Transaction&rdquo; means a transaction in which we (i) issue
any debt or equity securities that are convertible into common stock either (A) at a conversion price, exercise price or exchange
rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of our common stock
at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price
that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence
of specified or contingent events directly or indirectly related to our business or the market for our common stock or (ii) enter
into any transaction under, any agreement, including, but not limited to, an equity line of credit, an &ldquo;at-the-market&rdquo;
offering or similar agreement, whereby we may issue securities at a future determined price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
restrictions and covenants in the August 2017 Securities Purchase Agreement, as well as any future financing agreements that we
may enter into, may restrict our ability to finance our operations, engage in business activities or expand or fully pursue our
business strategies. Our ability to comply with these covenants may be affected by events beyond our control and we may not be
able to meet those covenants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Risks
Related to Securities Markets and Investment in our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
failure to meet the continued listing requirements of the NASDAQ Capital Market could result in a delisting of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we fail to satisfy the continued listing requirements of the NASDAQ Capital Market, such as the corporate governance requirements
or the minimum closing bid price requirement, the exchange may take steps to delist our common stock. Such a delisting would likely
have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when
you wish to do so. In the event of a delisting, we anticipate that we would take actions to restore our compliance with applicable
exchange requirements, such as stabilize our market price, improve the liquidity of our common stock, prevent our common stock
from dropping below such exchange&rsquo;s minimum bid price requirement, or prevent future non-compliance with such exchange&rsquo;s
listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 9, 2018, we received a letter from NASDAQ indicating that the Company has failed to comply with the minimum bid price requirement
of NASDAQ Listing Rule 5550(a)(2). NASDAQ Listing Rule 5550(a)(2) requires that companies listed on the Nasdaq Capital Market
maintain a minimum closing bid price of at least $1.00 per share. However, on August 10, 2018, we effected a 1-for-20 reverse
stock split, which has brought us back into compliance with NASDAQ Listing Rule 5550(a)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Future
sales and issuances of our equity securities or rights to purchase our equity securities, including pursuant to equity incentive
plans, would result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to
fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We
may, as we have in the past, sell common stock, convertible securities or other equity securities in one or more transactions
at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities
in more than one transaction, investors may be further diluted by subsequent sales. Such sales may also result in material dilution
to our existing stockholders, and new investors could gain rights superior to existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to our 2015 Stock Plan, our Board of Directors is currently
authorized to award up to a total of 3.0 million shares of common stock or options to purchase shares of common stock to our officers,
directors, employees and non-employee consultants. As of June 30, 2018, options to purchase 1,798 shares of common stock issued
under our 2015 Stock Plan at a weighted average exercise price of $325.97 per share were outstanding. In addition, at June 30,
2018, there were outstanding warrants to purchase an aggregate of 1,882,661 shares of our common stock at a weighted average exercise
price of $25.94. Stockholders will experience dilution in the event that additional shares of common stock are issued under our
2015 Stock Plan, or options issued under our 2015 Stock Plan are exercised, or any warrants are exercised for shares of our common
stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
share price is volatile and may be influenced by numerous factors, some of which are beyond our control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control. In addition to the factors discussed in this &ldquo;Risk Factors&rdquo; section
and elsewhere in this prospectus, these factors include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         products or product candidates we acquire for commercialization;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         products and product candidates we seek to pursue, and our ability to obtain rights to
                                         develop, commercialize and market those product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         decision to initiate a clinical trial, not to initiate a clinical trial or to terminate
                                         an existing clinical trial;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">actual
                                         or anticipated adverse results or delays in our clinical trials;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         failure to expand the market for our currently approved products or commercialize our
                                         product candidates, if approved;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">unanticipated
                                         serious safety concerns related to the use of any of our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">overall
                                         performance of the equity markets and other factors that may be unrelated to our operating
                                         performance or the operating performance of our competitors, including changes in market
                                         valuations of similar companies;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">conditions
                                         or trends in the healthcare, biotechnology and pharmaceutical industries;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">introduction
                                         of new products offered by us or our competitors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">announcements
                                         of significant acquisitions, strategic partnerships, joint ventures or capital commitments
                                         by us or our competitors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to maintain an adequate rate of growth and manage such growth;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">issuances
                                         of debt or equity securities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">sales
                                         of our common stock by us or our stockholders in the future, or the perception that such
                                         sales could occur;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">trading
                                         volume of our common stock;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ineffectiveness
                                         of our internal control over financial reporting or disclosure controls and procedures;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">general
                                         political and economic conditions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">effects
                                         of natural or man-made catastrophic events; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">other
                                         events or factors, many of which are beyond our control;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse
                                         regulatory decisions;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
                                         or departures of key scientific or management personnel;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes
                                         in laws or regulations applicable to our product candidates, including without limitation
                                         clinical trial requirements for approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disputes
                                         or other developments relating to patents and other proprietary rights and our ability
                                         to obtain patent protection for our product candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         dependence on third parties, including CROs and scientific and medical advisors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to uplist our common stock to a national securities exchange;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
                                         to meet or exceed any financial guidance or expectations regarding development milestones
                                         that we may provide to the public;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">actual
                                         or anticipated variations in quarterly operating results; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
                                         to meet or exceed the estimates and projections of the investment community.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of
our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including
those described in these &ldquo;Risk Factors,&rdquo; could have a dramatic and material adverse impact on the market price of
our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our
stock price and any trading volume could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
trading market for our common stock that may develop will depend in part on the research and reports that securities or industry
analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research
on us or our business. If no securities or industry analysts commence coverage of our company, the trading price for our stock
could be negatively affected. If securities or industry analysts initiate coverage, and one or more of those analysts downgrade
our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more
of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease,
which might cause our stock price and any trading volume to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
effected a reverse stock split at a ratio of 1-for-20 on August 10, 2018, which may not achieve one or more of our objectives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have effected four reverse stock splits since June 8, 2015, each of which has impacted the trading liquidity of the shares of
our common stock. There can be no assurance that the market price per share of our common stock after a reverse stock split will
remain unchanged or increase in proportion to the reduction in the number of shares of our common stock outstanding before the
reverse stock split. The market price of our shares may fluctuate and potentially decline after a reverse stock split. Accordingly,
the total market capitalization of our common stock after a reverse stock split may be lower than the total market capitalization
before the reverse stock split. Moreover, the market price of our common stock following a reverse stock split may not exceed
or remain higher than the market price prior to the reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Additionally,
there can be no assurance that a reverse stock split will result in a per-share market price that will attract institutional investors
or investment funds or that such share price will satisfy investing guidelines of institutional investors or investment funds.
As a result, the trading liquidity of our common stock may not necessarily improve. Further, if a reverse stock split is effected
and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a
reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Future
sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan or
otherwise, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
could need significant additional capital in the future to continue our planned operations. To raise capital, we may sell common
stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors
in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material dilution
to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our
common stock. Further, any future sales of our common stock by us or resales of our common stock by our existing stockholders
could cause the market price of our common stock to decline. Any future grants of options, warrants or other securities exercisable
or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market,
could have an adverse effect on the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Some
provisions of our charter documents and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition
may be beneficial to some of our stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Provisions
in our Certificate of Incorporation and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make
it more difficult for a third-party to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         authorization of 50.0 million shares of &ldquo;blank check&rdquo; preferred stock, the
                                         rights, preferences and privileges of which may be established and shares of which may
                                         be issued by our Board of Directors at its discretion from time to time and without stockholder
                                         approval;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">limiting
                                         the removal of directors by the stockholders;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">allowing
                                         for the creation of a staggered board of directors;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">eliminating
                                         the ability of stockholders to call a special meeting of stockholders; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">establishing
                                         advance notice requirements for nominations for election to the board of directors or
                                         for proposing matters that can be acted upon at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it
more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members
of our management. In addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits
a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period
of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved
by the board of directors. This provision could have the effect of discouraging, delaying or preventing someone from acquiring
us or merging with us, whether or not it is desired by or beneficial to our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
provision of our Certificate of Incorporation or Bylaws or of Delaware law that is applicable to us that has the effect of delaying
or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our
common stock in the event that a potentially beneficial acquisition is discouraged, and could also affect the price that some
investors are willing to pay for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>The
elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights
held by our directors, officers and employees may result in substantial expenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Certificate of Incorporation and our Bylaws eliminate the personal liability of our directors and officers to us and our stockholders
for damages for breach of fiduciary duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate
of Incorporation and our Bylaws and individual indemnification agreements we intend to enter with each of our directors and executive
officers provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by the
Delaware law and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action,
suit or proceeding prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures
to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further,
those provisions and resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current
or former directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
do not intend to pay cash dividends on our capital stock in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have never declared or paid any dividends on our common stock and do not anticipate paying any dividends in the foreseeable future.
Any future payment of cash dividends in the future would depend on our financial condition, contractual restrictions, solvency
tests imposed by applicable corporate laws, results of operations, anticipated cash requirements and other factors and will be
at the discretion of our Board of Directors. Our stockholders should not expect that we will ever pay cash or other dividends
on our outstanding capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_004"></A>Item
                          1B.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Unresolved
                                         Staff Comments </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_005"></A>Item&nbsp;2.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Properties
                                         </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2015, Aytu entered into a 37-month operating lease for office space in Raleigh, North Carolina. This lease has initial base
rent of $3,000 a month, with total base rent over the term of the lease of approximately $112,000. In June 2018, the Company entered
into a 12-month operating lease, beginning on August 1, 2018, for a new office space in Raleigh. This lease has base rent of $1,100
a month, with total rent over the term of the lease of approximately $13,200. In August 2015, the Company entered into a 37-month
operating lease in Englewood, Colorado. This lease has an initial base rent of $9,000 a month with a total base rent over the
term of the lease of approximately $318,000. In October 2017, the Company signed an amendment to the 37-month operating lease
in Englewood, Colorado. The amendment extended the lease for an additional 24 months beginning October 1, 2018. The base rent
will remain at $9,000 a month. The Company recognizes rent expense on a straight-line basis over the term of each lease. Differences
between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term
deferred rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_006"></A>Item&nbsp;3.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Legal
                                         Proceedings </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are currently not party to any material legal or administrative proceedings and are not aware of any material pending or threatened
legal or administrative proceedings in which we will become involved.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"><A NAME="a_007"></A></TD><TD STYLE="width: 48.95pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;4.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Mine
                                         Safety Disclosures </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_008"></A>PART&nbsp;II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_009"></A>Item&nbsp;5.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Market
                                         for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases
                                         of Equity Securities </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Market
Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
common stock has been listed on the NASDAQ Capital Market under the symbol &ldquo;AYTU&rdquo; since October 20, 2017. Prior to
October 20, 2017, our common stock was quoted on the OTCQX and prior to that, on the OTCQB. The following table sets forth the
range of high and low bid prices for our common stock on the OTCQX or OTCQB, or high and low sales prices on the NASDAQ Capital
Market, as applicable, for the periods shown. The quotations for the OTCQX or OTCQB represent inter-dealer prices without retail
markup, markdown or commission, and may not necessarily represent actual transactions. All share prices give effect to our 1-for-20
reverse stock split completed in August 2017, and 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Fiscal Year ended June 30, 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif">First Quarter (ended September 30, 2016)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,000.00</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,204.00</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Second Quarter (ended December 31, 2016)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,556.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">408.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Third Quarter (ended March 31, 2017)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">504.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">296.44</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Quarter (ended June 30, 2017)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">364.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">204.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><B>Fiscal Year ended June 30, 2018</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><B>High</B></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><B>Low</B></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif">First Quarter (ended September 30, 2017)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">240.00</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">66.80</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Second Quarter (ended December 31, 2017)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">136.40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Third Quarter (ended March 31, 2018)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">85.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Fourth Quarter (ended June 30, 2018)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.66</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 31, 2018, the closing price as reported on the NASDAQ
of our common stock was $4.31. As of August 31, 2018, there were 497 holders of record of our common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Equity
Compensation Plan Information </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with our private placement of approximately $5.2 million of convertible notes in July and August 2015, we were obligated
to issue to the placement agents warrants for a number of shares equal to 8% of the number of shares of our common stock issued
upon conversion of the notes and any accrued interest. The placement agents&rsquo; warrants have a term of five years from the
date of issuance of the related notes in July and August 2015, an exercise price equal to 100% of the price per share at which
equity securities were sold in our next equity financing and provide for cashless exercise. Those warrants were not approved by
our stockholders. In connection with the conversions of the notes in February 2016 and May 2016, which were triggered by an equity
financing in January 2016 and our public offering of common stock and warrants in May 2016, respectively, we issued warrants to
one placement agent to purchase an aggregate of 57 shares of our common stock at a weighted average exercise price of $2,031.58
per share and warrants to the other placement agent to purchase an aggregate of 58 shares of our common stock at a weighted average
exercise price of $1,920 per share. In connection with our May 2016 public offering, we issued warrants to purchase an aggregate
of 279 shares of common stock at an exercise price of $300 to the underwriters of the public offering. In July 2016, we issued
warrants to purchase an aggregate of 221 shares of common stock at an exercise price of $1,600 to initial investors. In connection
with our November 2016 public offering, we issued warrants to purchase an aggregate of 1,009 shares of common stock with an exercise
price of $300.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2015, our shareholders approved the adoption of a stock and option award plan (the &ldquo;2015 Plan&rdquo;). At the Special
meeting of stockholders on July 26, 2017, the Aytu Stockholders voted to increase the plan to 3.0 million shares. The 2015 Plan
permits grants of equity awards to employees, directors and consultants. The following table displays equity compensation plan
information as of June 30, 2018.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">Plan Category</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0">Number
    of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights (a)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0">Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights (b)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0">Number
    of Securities Remaining Available for Issuance under Equity Compensation Plans (Excluding Securities Reflected in
    Column (a)) (c)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,798</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;325.97</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,961,002</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-align: left; text-indent: 0">Equity compensation plans not approved by security holders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: right; text-indent: 0">1,624</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: left; text-indent: 0">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: right; text-indent: 0">594.63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 1.5pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding-top: 0; padding-right: 0; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">3,422</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">453.47</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,961,002</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have not paid any cash dividends on our common stock and our Board of Directors presently intends to continue a policy of retaining
earnings, if any, for use in our operations. The declaration and payment of dividends in the future, of which there can be no
assurance, will be determined by the Board of Directors in light of conditions then existing, including earnings, financial condition,
capital requirements and other factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the
distribution of the dividend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">we would
    not be able to pay our debts as they become due in the usual course of business; or</FONT></TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our total assets would be
    less than the sum of our total liabilities plus the amount that would be needed to satisfy the rights of stockholders who
    have preferential rights superior to those receiving the distribution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Except
as set forth above, there are no restrictions that currently materially limit our ability to pay dividends or which we reasonably
believe are likely to limit materially the future payment of dividends on common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Board of Directors has the right to authorize the issuance of preferred stock, without further stockholder approval, the holders
of which may have preferences over the holders of our common stock as to payment of dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 55.45pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_010"></A>Item&nbsp;6.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Selected
                                         Financial Data </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 55.45pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_011"></A>Item&nbsp;7.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Management&rsquo;s
                                         Discussion and Analysis of Financial Condition and Results of Operations </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>You
should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and the related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion
and analysis, including information with respect to our plans and strategy for our business and related financing, includes forward-looking
statements that involve risks and uncertainties. You should read the &ldquo;Risk Factors&rdquo; section of this Form 10-K for
a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview, Liquidity and Capital Resources </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu is an emerging specialty pharmaceutical company focused
on commercializing novel products that address significant medical needs. Aytu is focused on commercializing products that address
hypogonadism (low testosterone), insomnia, and male infertility and plans to expand into other therapeutic areas as the company
continues to execute on its growth plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the date of this Report, we have financed
operations through a combination of private and public debt and equity financings, funds from the sale of our products, and
occasionally through divestures of non-strategic assets. Our financing transactions have included private placements of stock
and convertible notes, and public offerings of the Company&rsquo;s equity securities. Since the formation of Aytu in June
2015, the Company has raised approximately $49.9 million from the sale of its securities to investors and the exercise of
warrants by investors.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: white 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our operations have historically consumed
cash and are expected to continue to require cash, but at a declining rate. The Company&rsquo;s revenue has increased 14% and 26%
for each of the past two fiscal years and is expected to continue to increase, allowing the Company to rely less on its existing
cash balance and proceeds from financing transactions. Despite increased revenue, cash used in operations during fiscal year 2018
was $16 million compared to $13.8 million in 2017, due to the Company completing the build-out of its&rsquo;s commercial infrastructure
in 2018. As of the date of this Report, we expect our commercial costs to remain approximately flat or to increase modesty as we
continue to focus on revenue growth. Our current asset position of $9.5 million plus the proceeds expected from ongoing product
sales will be used to fund operations. We will access the capital markets to fund operations if and when needed, and to the extent
it becomes probable that existing cash and other current assets may become exhausted. The timing and amount of capital that may
be raised is dependent on market conditions and the terms and conditions upon which investors would require to provide such capital.
There is no guarantee that capital will be available on terms that we consider to be in the best interests of the Company and our
stockholders, or at all. However, we have been successful is accessing the capital markets in the past and are confident in our
ability to access the capital markets again, if needed. Since the Company does not have a cash balance as of June 30, 2018, sufficient
to cover potential operating losses for the twelve months following the expected filing date of this Annual Report, ASU 2014-15,
Presentation of Financial Statements&mdash;Going Concern (Subtopic 205-40) requires us to report that there is an indication that
substantial doubt about the Company&rsquo;s ability to continue as a going concern exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to raise adequate capital in the future when
it is required, we can adjust our operating plans to reduce the magnitude of the capital need under our existing operating plan.
Some of the adjustments that could be made include delays of and reductions to product support programs, reductions in headcount,
narrowing the scope of one or more of our commercialization programs, or reductions to our research and development programs. Without
sufficient operating capital, we could be required to relinquish rights to product candidates on less favorable terms than we would
otherwise choose. This may lead to impairment or other charges, which could materially affect our balance sheet and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have incurred accumulated net losses since inception, and
at June 30, 2018, we had an accumulated deficit of $79.3 million. Our net loss declined to $10.2 million from $22.5 million for
fiscal 2018 and 2017, respectively. We used $16.0 million and $13.8 million in cash from operations during fiscal 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations&mdash;June 30, 2018 Compared to June&nbsp;30,
2017 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Results of operations for the year ended June 30, 2018 (&ldquo;fiscal
2018&rdquo;) and the year ended June&nbsp;30, 2017 (&ldquo;fiscal 2017&rdquo;) reflected losses of approximately $10.2 million
and $22.5 million, respectively. The decline in losses was driven by increasing revenue, and by non-operating gains resulting from
the revaluation of derivative liability related to outstanding warrants and to the reduction of expected milestone payments due
to the revaluation of contingent consideration due to GAAP, primarily related to Natesto and the abandonment of the Fiera product
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><I>Product revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We continue to generate material revenues from the commercialization
of our products and have recently launched a new product, ZolpiMist, that competes in the $1.8 billion prescription sleep aid market.
We recognized approximately $3.7 million and $3.2 million of net revenue from Natesto, ProstaScint, Primsol, MiOXSYS and Fiera
sales during fiscal 2018 and 2017, respectively. The addition of ZolpiMist is expected to be additive to the growing base of revenue
from Natesto and MiOXSYS. Since we have discontinued the non-strategic assets Primsol, ProstaScint and Fiera, we do not expect
to recognize revenue from those products in fiscal year 2019. The majority of our fiscal year 2018 revenue came from Natesto sales.
Revenue from Natesto sales increased 155% in fiscal 2018 compared to fiscal 2017.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As is customary in the pharmaceutical industry, our gross product
sales are subject to a variety of deductions in arriving at reported net product sales. Provisions for these deductions are estimated
and recorded concurrently with the recognition of gross revenue from product sales and include coupons, discounts, chargebacks,
distributor fees, processing fees, allowances for returns and Medicaid rebates. Provision balances relating to estimated amounts
payable to direct customers are netted against accounts receivable and balances relating to indirect customers are included in
accounts payable and accrued liabilities. The provisions recorded to reduce gross product sales and net product sales are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0">Gross product and service revenue</TD><TD STYLE="width: 1%; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0">7,861,000</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0">4,694,000</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0">Provisions to reduce gross product sales to net product and service sales</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0">(4,201,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0">(1,472,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0">Net product and service revenue</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0">3,660,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0">3,222,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0">Percentage to net sales</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0">46.6</TD><TD STYLE="text-align: left; padding-left: 0">%</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0">68.6</TD><TD STYLE="text-align: left; padding-left: 0">%</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Expenses </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cost of Sales </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The cost of sales of $2.1 million and $1.4 million recognized
for fiscal 2018 and fiscal 2017, respectively, are related to the Natesto, ZolpiMist, ProstaScint, Primsol, Fiera, and the MiOXSYS
and RedoxSYS Systems. The increase in cost of sales for fiscal 2018 was due to an increase in product sales and the impairment
of the AWH inventory, which represented $0.8 million or 38% of the cost of sales for fiscal 2018. We expect cost of sales to increase
in the future due to and in line with growth in revenue from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs consist of clinical trials and
sponsored research, sponsored research &ndash; related party and consultants and other. These costs relate solely to research and
development without an allocation of general and administrative expenses and are summarized as follows:</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0">Clinical trials and sponsored research</TD><TD STYLE="width: 1%; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0">102,000</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0">956,000</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">Sponsored research - related party</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0">-</TD><TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0">388,000</TD><TD STYLE="text-align: left; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0">Consultants and other</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0">66,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0">4,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0">168,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0">1,348,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"><I>Comparison of Years Ended June 30, 2018 and 2017 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses decreased $1.2 million, or
87.5%, in fiscal 2018 compared to fiscal 2017. The decrease was due primarily to focusing our resource commitment on our commercial
products and our decision to abandon sales and development support of ProstaScint in fiscal 2018, for which we reversed a previously
accrued liability in the amount of $398,000 which reduced fiscal year 2018 research and development expenses. We anticipate research
and development expense to increase in fiscal 2019 as we anticipate funding a study to further support the clinical application
of our MiOXSYS System, and to fund further clinical studies for Natesto to potentially support new claims and to comply with FDA
post-marketing study requirements.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales, General and Administrative </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales, general and administrative expenses consist of labor
costs, including personnel costs for employees in executive, commercial, business development and operational functions; stock-based
compensation; patents and intellectual property; professional fees including legal, auditing, accounting, investor relations, shareholder
expense and printing and filing of SEC reports; occupancy, travel and other expenses including rent, governmental and regulatory
compliance, insurance, and professional subscriptions; and directors fees. These costs are summarized as follows:</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Labor</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,620,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,488,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">597,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,227,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,437,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,133,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Occupancy, travel and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,523,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,267,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Patent costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">395,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Director fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Management fee - related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">165,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,732,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,608,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Comparison of Years Ended June 30, 2018 and 2017 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales, general and administrative costs remained approximately
level in fiscal 2018 compared to fiscal 2017. The most significant expense was due to labor costs, patent costs, and occupancy,
travel and other, which were related to increased labor rates, FDA fees, and increased spend on marketing efforts. This increase
was offset by stock-based compensation, compared to fiscal 2017, due to a reduction in the fair value of the stock options and
restricted stock that was issued to directors, executives and employees. We expect future selling, general and administrative expenses
to remain consistent with historical spending rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Impairment of Intangible Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The expense related to impairment of intangible assets was $1.9
million for fiscal 2018. The impairment was related to the discontinuation of the Fiera product line due to lower than expected
sales performance of the Fiera products and the contract manufacturer no longer supporting the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Impairment of intangible assets was $1.3 million for fiscal
2017, which was related to the impairment of the ProstaScint product which was discontinued in fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Amortization of Intangible Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense for the remaining intangible assets was
$1.6 million and $1.7 million for fiscal 2018 and fiscal 2017, respectively. This expense is related to corresponding amortization
of its finite-lived intangible assets. We expect this expense to remain flat for fiscal 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Operating Activities </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2018, our operating activities consumed $16.0
million of cash. Our cash use was $5.8 million greater than our net loss, primarily due to non-cash gains such as derivative income
and other gains which reduced our fiscal 2018 losses, offset by depreciation, amortization and accretion, and the expense related
to the impairment of intangible assets which increased losses in fiscal 2018. Increases in our prepaid expense and decreases in
accounts payable and accrued liabilities balance increased cash use in 2018 while an increase in accrued compensation decreased
cash use in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2017, our operating activities used $13.8 million
in cash. The use of cash was approximately $8.7 million lower than the net loss due primarily to non-cash charges for asset impairment,
stock-based compensation, issuance of restricted stock, depreciation, amortization and accretion, amortization of prepaid research
and development - related party, common stock issued to executives, warrants issued to initial investors, and an increase in accounts
payable. These charges were offset by a decrease in accrued compensation, accrued liabilities, and accounts receivable, a gain
on the sale of an asset, and derivative income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash Used in Investing Activities </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2018, cash of $484,000 was used to acquire fixed
and operating assets in addition to a deposit for office space and a royalty payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2017, cash was received through the sale of Primsol,
the sale of our common stock investment in Acerus and the merger with Nuelle, Inc. Cash was also used to make contractual payments
for acquired products, and to purchase fixed assets.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Net Cash from Financing Activities </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash of $22.7 million was provided by financing activities
during fiscal 2018. The private placement completed in August 2017 contributed gross proceeds of $11.8 million, which was reduced
by offering costs of $1.4 million. The March 2018 Offering provided gross proceeds of $12.9 million, which was reduced by offering
costs of $1.3 million. Finally, we received aggregate proceeds of $0.7 million from the exercise of warrants by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash of $10.2 million provided by financing activities during
fiscal 2017 was primarily related to our warrant tender offer of $2.2 million offset by issuance costs of $312,000, our registered
public offering of $8.6 million of common stock and warrants offset by cash issuance costs of $998,000, and the issuance of common
stock to Lincoln Park Capital of $740,000 offset by issuance costs of $91,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Introduction of Natesto Patient Reimbursement Support Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the Company&rsquo;s fourth quarter, several factors contributed
to accelerate Natesto revenue growth and to position Natesto for further growth. In the third quarter of 2018, the Company piloted
an initiative aimed at improving patient access, increasing prescription fill rates, and improving net revenue per prescription.
This initiative, called the Natesto Support Program, introduced a third-party resource that assists patients and physician offices
with the insurance approval process for Natesto. The program was rolled out across all sales territories in the fourth quarter
of 2018. In conjunction with the roll-out of this initiative, the Company eliminated Company funded $0 prescription vouchers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of management&rsquo;s implementation of the Natesto
Support Program and despite the discontinuation of $0 vouchers, the Company realized Natesto net revenue growth of 178% with only
a 12% decline in unit volume during the fourth quarter of 2018 compared to the third quarter of 2018. Natesto revenue grew from
$292,598 in Q3 to $805,212 in Q4. Historically, the use of $0 vouchers represented the largest deduction from gross revenue in
the determination of net revenue, so the elimination of these vouchers while essentially maintaining demand were key elements of
the significantly increased revenue. The table below represents the rate of coupon usage, which was the most significant factor
in driving revenue growth since the implementation of the Natesto Support Program and elimination of Company funded $0 vouchers
in the fourth quarter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coupons as a percentage of gross revenue decreased each month
over the most recent two quarter period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">January 2018: 83%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">February 2018: 59%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2018: 62%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2018: 32%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">May 2018: 31%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">June 2018: 23%</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Natesto Support Program has since been enhanced by the addition
of other services including, among other items, mail order delivery services. This enhancement, called <I>Natesto Direct</I>, was
launched in August 2018. Management intends to manage the services under <I>Natesto Direct</I> with changes from time-to-time to
provide other features that encourage Natesto initial usage and refill rates. As a result, Natesto is well positioned for both
volume and revenue growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Natesto Spermatogenesis Study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A significant clinical study of Natesto is underway that may
substantially improve the product&rsquo;s clinical profile and enable access to a broader subset of hypogonadal patients. In the
second half of fiscal 2018 the University of Miami&rsquo;s Department of Urology began an investigator-initiated trial led by Dr.
Ranjith Ramasamy, MD, the Director of Reproductive Urology at Miami. The study is entitled <I>Natesto Effects on Testosterone,
Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters,</I> and is designed to test the hypothesis that treatment
of hypogonadal men with Natesto maintains normal or near normal semen parameters, while also assessing Natesto&rsquo;s impact on
gonadotropin levels and endogenous testosterone production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this study proves the hypothesis and demonstrates maintenance
of semen parameters, gonadotropins, or endogenous testosterone levels, to our knowledge it would be the first such study to demonstrate
any of these effects, which could lead to unique clinical claims in Natesto&rsquo;s product label. The implications of these potential
clinical findings are significant as stated by Dr. Ramasamy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 76.5pt 0pt 0.75in"><I>&ldquo;Currently, there are no FDA-approved
therapies to treat men with low testosterone who wish to preserve their fertility. About 20% of men with Low T deal with these
decisions, and Natesto could be an alternative for simultaneously increasing testosterone while preserving sperm production.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The study will assess 40 patients with confirmed hypogonadism
(testosterone (T) &lt; 350 on two consecutive samples collected more than 1.5 hours apart in the morning, and each man will complete
2 complete sperm cycles (~ 24 weeks; 6 study visits) while taking Natesto three times daily. More than twenty patients have been
enrolled to date, and we anticipate that the study&rsquo;s final readout will occur around June 2019. An interim data readout is
expected in October or November of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>TRT Market Dynamics</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Several recent developments in the U.S. testosterone replacement
therapy market may favorably impact Natesto&rsquo;s near and longer-term market position as an FDA-approved treated with an established
efficacy and safety profile and being actively marketed by a focused sales infrastructure. First, the market leading product Androgel,
has experienced diminished promotion over the last several quarters due to the product&rsquo;s relative age and importance in the
AbbVie product portfolio. As such, there is limited field-based promotion and sampling to high prescribing physicians. Also, Eli
Lilly formally discontinued Axiron in July 2017 primarily due to patents expiry resulting in further reduction in promotional voice
in the U.S. in the TRT category. With the two market-leading products&rsquo; promotional voice reduced or eliminated, this may
present a unique opportunity for the Company and Natesto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Along with the de-prioritization of the two market leading gels,
the TRT pipeline assets experienced significant regulatory setbacks recently. Antares Pharma&rsquo;s injectable candidate Xyosted&trade;
received a Complete Response Letter from the FDA in October 2017 stating that the drug&rsquo;s New Drug Application was not approvable
based on safety data presented in the application. Antares has since resubmitted a New Drug Application, but it remains to be seen
whether or not the safety concerns have been sufficiently addressed. In May 2018, Lipocine and Clarus Therapeutics&rsquo; oral
testosterone candidates were rejected at the FDA following negative FDA advisory committee sentiment expressed in January of 2018
as to the approvability of both compounds. Both products applications contained data demonstrating significant safety concerns,
and both applications received a Complete Response Letter. As such, we understand Lipocine is conducting additional safety studies
to potentially overcome the safety concerns, but it should be noted that this was the company&rsquo;s second Complete Response
Letter for their candidate, Tlando&trade;. The likelihood of approval in the near term appears in doubt at this time for both oral
candidates, and Antares&rsquo; PDUFA date for the resubmitted application is in late September with no assurance of approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations and Commitments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information regarding our Contractual Obligations and Commitments
is contained in Note 6 to the Financial Statements. We have no off-balance sheet arrangements, financings, or other relationships
with unconsolidated entities or other persons, also known as &ldquo;variable interest entities.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_012"></A>Item&nbsp;7A.</B></FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Quantitative and Qualitative Disclosures about Market
Risks </B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_013"></A>Item&nbsp;8.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Financial
                                         Statements and Supplementary Data </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements required by this item are identified in Item&nbsp;(a)(1) of Part IV and begin at page&nbsp;F-1 of this Annual
Report on Form 10-K and are incorporated herein by reference.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_014"></A>Item&nbsp;9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Changes
                                         in and Disagreements with Accountants on Accounting and Financial Disclosure</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_015"></A>Item&nbsp;9A.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Controls
                                         and Procedures </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Evaluation
of Disclosure Controls and Procedures </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate &ldquo;disclosure controls and procedures,&rdquo; as such
term is defined in Rules&nbsp;13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;),
that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange
Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information
is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate,
to allow timely decisions regarding required disclosure. Our management has concluded that our disclosure controls and procedures
were effective as of the end of the period covered by this Report to provide the reasonable assurance discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Management&rsquo;s
Annual Report on Internal Control over Financial Reporting </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is
defined in Rules 13a-15(f) under the Exchange Act). Our management assessed the effectiveness of our internal control over financial
reporting as of June 30, 2018. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission in <I>Internal Control-Integrated Framework (2013)</I>. Our management has concluded
that, as of June 30, 2018, our internal control over financial reporting is effective based on these criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EKS&amp;H
LLLP, the independent registered public accounting firm that audited our financial statements included in this Annual Report on
Form 10-K, was not required to issue an attestation report on our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Changes
in Internal Control over Financial Reporting </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
were no changes in our internal controls over financial reporting, known to the chief executive officer or the chief financial
officer that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_016"></A>Item&nbsp;9B.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other
                                         Information </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously disclosed on our Current Report on Form 8-K filed
with the Securities and Exchange Commission on June 13, 2018, on June 11, 2018, Aytu entered into a license agreement with Magna
Pharmaceuticals, Inc. On September 5, 2018, Aytu and Magna Pharmaceuticals, Inc. agreed to amend and restate the license
agreement effective as of June 11, 2018. The amended and restated license agreement supersedes and replaces the license agreement.
Pursuant to the amended and restated license agreement, Magna Pharmaceuticals, Inc. granted to the company an exclusive, sub-licensable,
royalty-bearing license in the United States and Canada related to ZolpiMist. The amended and restated license agreement may be
terminated by either Aytu or Magna Pharmaceuticals, Inc. on the occurrence of a material breach of the amended and restated license
agreement and by Aytu in its discretion upon a sixty (60) day prior written notice and the payment of a termination fee of $50,000.
As consideration for the license granted, Aytu made an initial cash payment to Magna Pharmaceuticals, Inc. in the amount of $400,000
on June 11, 2018 and a payment of $300,000 on July 31, 2018. Additionally, the company will pay Magna Pharmaceuticals, Inc. certain
royalty fees between 10% and 20% of Net Sales (as defined in the amended and restated license agreement) until 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the material terms of the amended
and restated license agreement is qualified in its entirety by reference to the text of the amended and restated license agreement
which is attached hereto as Exhibit 10.31 and is incorporated herein in its entirety by reference.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_017"></A>PART
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0%; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_018"></A>Item&nbsp;10.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Directors
                                         and Executive Officers, and Corporate Governance </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the names and ages of all of
our directors and executive officers as of August 31, 2018. Our Board of Directors is currently comprised of five members, who
are elected annually to serve for one year or until their successor is duly elected and qualified, or until their earlier resignation
or removal. Executive officers serve at the discretion of the Board of Directors and are appointed by the Board of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Age</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Position</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Joshua R. Disbrow</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center">43</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Chairman and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Jarrett T. Disbrow</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Chief Operating Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">David A. Green</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">56</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Chief Financial Officer, Secretary, and Treasurer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Michael Macaluso</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">66</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Carl C. Dockery</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">55</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">John A. Donofrio, Jr.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">50</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Gary V. Cantrell</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Director</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following is a biographical summary of the experience of our executive officers and directors during the past five years, and
an indication of directorships held by the director in other companies subject to the reporting requirements under the federal
securities law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Joshua
R. Disbrow &ndash; Chairman and Chief Executive Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Joshua
R. Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive
Officer of Luoxis since January 2013. Mr. Disbrow was also the Chief Operating Officer of Ampio since December 2012. Prior to
joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company,
from May 2007 through October 2012. He joined Arbor as that company&rsquo;s second full-time employee. Mr. Disbrow led the company&rsquo;s
commercial efforts from inception to the company&rsquo;s acquisition in 2010 and growth to over $127 million in net sales in 2011.
By the time Mr. Disbrow departed Arbor in late 2012, he had led the growth of the commercial organization to comprise over 150
people in sales, marketing sales training, managed care, national accounts, and other commercial functions. Mr. Disbrow has spent
over 17 years in the pharmaceutical, diagnostic and medical device industries and has held positions of increasing responsibility
in sales, marketing, sales management, commercial operations and commercial strategy. Prior to joining Arbor, Mr. Disbrow served
as Regional Sales Manager with Cyberonics, Inc., a medical device company focused on neuromodulation therapies from June 2005
through April 2007. Prior to joining Cyberonics he was the Director of Marketing at LipoScience, an in vitro diagnostics company.
Mr. Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University. Mr. Disbrow&rsquo;s
experience in executive management and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate
finance led to the conclusion that he should serve as a director of our Company in light of our business and structure.</FONT></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Gary
V. Cantrell &ndash; Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gary Cantrell joined our Board in July 2016. He has 30 years
of experience in the life sciences industry ranging from clinical experience as a respiratory therapist to his current position
as Principle of Averaden, LLC. Since July 2015, Mr. Cantrell consulted for pharmaceutical and bio technology companies. Most notably,
he served as an exclusive business development consultant with Mayne Pharma (ASX: MYX) for 2.5 years. Mr. Cantrell served as CEO
of Yasoo Health Inc., a global specialty nutritional company from 2007 through June 2016, highlighted by the sale of its majority
asset AquADEKs to Actavis in March 2016. Previously, he was President of The Catevo Group, a U.S.-based healthcare consulting firm.
Prior to that, he was Executive Vice President, Sales and Marketing for TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company,
where he led all commercial activities for a public specialty pharmaceutical business. His previous 22 years were at GlaxoSmithKline
plc where he held progressively senior management positions in sales, marketing and business development. Mr. Cantrell is a graduate
of Wichita State University and serves as an advisor to several emerging life science companies. He served as a director for Yasoo
Health Inc., Yasoo Health Limited and Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial,
venous, neurovascular and biliary stents, which was sold to Cordis, while a Division of Johnson &amp; Johnson in March 2013. Mr.
Cantrell served as a director of Vyrix Pharmaceuticals from February 2014 to April 2015. Mr. Cantrell&rsquo;s experience in consulting
and executive management within the pharmaceutical industry led to the conclusion that he should serve as a director of our company
in light of our business and structure.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Carl
C. Dockery &ndash; Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Carl
Dockery joined our Board in April 2016. Mr. Dockery is a financial executive with 30 years of experience as an executive in the
insurance and reinsurance industry and more recently in 2006 as the founder and president of a registered investment advisory
firm, Alpha Advisors, LLC. Mr. Dockery&rsquo;s career as an insurance executive began in 1988 as an officer and director of two
related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as
vice president of Gulf Insurance Co. Ltd. of Grand Cayman. Familiar with the London reinsurance market, in the 1990s, Mr. Dockery
worked at Lloyd&rsquo;s and the London Underwriting Centre brokering various types of reinsurance placements. Mr. Dockery serves
as a director of CytoDyn Inc. (OTCQB: &ldquo;CYDY&rdquo;), a biotechnology company. Mr. Dockery graduated from Southeastern University
with a Bachelor of Arts in Humanities. Mr. Dockery&rsquo;s financial expertise and experience, as well as his experience as a
director of a publicly traded biopharmaceutical company, led to the conclusion that he should serve as a director of our company
in light of our business and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>John
A. Donofrio, Jr. &ndash; Director</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">John
Donofrio joined our Board in July 2016. He is a Senior Finance Executive with over 25 years of experience in the pharmaceutical
industry. Mr. Donofrio is trusted finance leader with a proven track record of building strategy, financial management, business
partnering, leading teams and strong collaboration among all levels of an organization. In March of 2018, Mr. Donofrio was appointed
Chief Financial Officer of TrialCard. TrialCard is a technology-enabled pharmaceutical solutions company that provides patient-centric
solutions to the pharmaceutical industry improving access, affordability and adherence to medicines. Mr. Donofrio is responsible
for overall finance strategy, accounting, tax, treasury management, reporting and internal controls. Prior to joining TrialCard,
he served as the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz. Merz
is a specialty healthcare company dedicated to the development and marketing of innovative quality Aesthetics and Neurosciences
products for physicians and patients in the U.S. and Canada. Prior to joining Merz, Mr. Donofrio served as Vice President, Stiefel
Global Finance, U.S. Specialty Business and Puerto Rico for Stiefel, a GlaxoSmithKline plc company from July 2009 to July 2013.
In that role, Mr. Donofrio was responsible for the financial strategy, management reporting, and overall control framework for
the Global Dermatology Business Unit. He was also the Senior Finance Partner accountable for the U.S. Specialty Business Units
of GlaxoSmithKline plc. Mr. Donofrio served as a director of Vyrix Pharmaceuticals from February 2014 to April 2015. Mr. Donofrio
holds a degree in Accounting from North Carolina State University. Mr. Donofrio&rsquo;s financial expertise and diverse experience
in the pharmaceutical industry, led to the conclusion that he should serve as a director of our company in light of our business
and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Michael
E. Macaluso &ndash; Director</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Michael
Macaluso has been a member of our Board of Directors since April 2015. Mr. Macaluso is also the Chairman and Chief Executive Officer
of Ampio. Mr. Macaluso has been a member of Ampio Pharmaceuticals&rsquo; Board of Directors since March 2010 and Ampio&rsquo;s
Chief Executive Officer since January 2012. Mr. Macaluso served in the roles of president and Chief Executive Officer of Isolagen,
Inc. (AMEX: ILE) from June 2001 until September 2004. Mr. Macaluso also served on the board of directors of Isolagen from June
2001 until April 2005. From October 1998 until June 2001, Mr. Macaluso was the owner of Page International Communications, a manufacturing
business. Mr. Macaluso was a founder and principal of International Printing and Publishing, a position Mr. Macaluso held from
1989 until 1997, when he sold that business to a private equity firm. Mr. Macaluso&rsquo;s experience in executive management
and marketing within the pharmaceutical industry, monetizing company opportunities, and corporate finance led to the conclusion
that he should serve as a director of our company in light of our business and structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Jarrett
T. Disbrow &ndash; Chief Operating Officer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jarrett
Disbrow has been employed by us since April 16, 2015. Prior to the closing of the Merger, Mr. Disbrow was the Chief Executive
Officer of Vyrix from November 2013. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, or Eurus Pharma, where he held the position
of general manager from 2011 to 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive
officer of Arbor Pharmaceuticals, Inc., or Arbor Pharmaceuticals from 2006 to 2010. Following Arbor Pharmaceuticals&rsquo; acquisition
in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Prior to founding Arbor Pharmaceuticals
in 2006, he was head of marketing for Accentia Biopharmaceuticals, Inc. from 2002 to 2006. Mr. Disbrow began his career with GlaxoWellcome,
Inc. (now GlaxoSmithKline plc) from 1997 to 2001, where he held positions of increasing responsibility in sales and later marketing.
Mr. Disbrow received a BS in business management from North Carolina State University in Raleigh, NC. Mr. Disbrow served on our
Board of Directors from April 2015 to July 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>David
A. Green &ndash; Chief Financial Officer, Secretary, and Treasurer</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David A. Green has been our Chief Financial Officer since December
18, 2017. Prior to joining Aytu BioScience, Mr. Green was the Chief Accounting Officer from 2016 to 2017 of Intarcia Therapeutics,
a biopharmaceutical company engaged in late stage clinical development, where he was involved in IPO readiness and some of the
largest private financing transactions in history for a pre-commercial, venture funded, life science company. Mr. Green was a consultant
with DAG Associates from 2014 to 2017 working in various senior operating and advisory roles for clients such as Q Therapeutics,
Perseon Corporation and Lineagen, Inc.&nbsp; Mr. Green served as Chief Financial Officer of Catheter Connections, a venture financed
medical device company that was acquired by Merit Medical [NASDAQ: MMSI] from 2012 to 2014; and CFO of Specialized Health Products
International, a publicly traded medical device company that was acquired by C.R. Bard [NYSE: BCR] from 2006 to 2008. Prior to
his operating&nbsp;roles, Mr. Green advised a broad range of life science companies on issues of&nbsp;corporate finance and the&nbsp;use
of strategic transactions to accelerate growth as&nbsp;a Managing Director of Duff &amp; Phelps and as a member of Ernst &amp;&nbsp;Young&rsquo;s&nbsp;Palo
Alto&nbsp;Center for Strategic Transactions<SUP>&reg;</SUP>.&nbsp;&nbsp;Mr. Green began his career performing medical&nbsp;research
after he&nbsp;received a Bachelor of Science in chemistry from the State&nbsp;University of New York.&nbsp;Mr. Green holds a Masters
of Business Administration in finance from the University of Rochester and is a Certified Public Accountant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Family
Relationships&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jarrett
T. Disbrow, our Chief Operating Officer, is the brother of Joshua R. Disbrow, our Chief Executive Officer and a director. There
are no other family relationships among or between any of our other current or former executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Involvement
in Certain Legal Proceedings&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None
of our directors or executive officers has been involved in any legal proceeding in the past 10 years that would require disclosure
under Item 401(f) of Regulation S-K promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Section
16(a) Beneficial Ownership Reporting Compliance </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section&nbsp;16(a)
of the Securities Exchange Act requires our officers and directors and persons who own more than 10% of our outstanding common
stock to file reports of ownership and changes in ownership with the Securities and Exchange</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Commission.&nbsp;These officers,
directors and stockholders are required by regulations under the Securities Exchange Act to furnish us with copies of all forms
they file under Section&nbsp;16(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
solely on our review of the copies of forms we have received, we believe that all such required reports have been timely filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Code
of Ethics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this Item regarding our Code of Ethics is found in Part I, Item 1, under the caption &ldquo;Code of Ethics.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Board
Committees </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board has established an Audit Committee, Compensation Committee
and Nominating and Governance Committee.&nbsp;Our Audit Committee consists of Mr. Donofrio (Chair), Mr. Cantrell and Mr. Dockery.&nbsp;Our
Compensation Committee consists of Mr. Cantrell (Chair), Mr. Dockery and Mr. Donofrio.&nbsp;Our Nominating and Governance Committee
consists of Mr. Dockery (Chair), Mr. Cantrell and Mr. Donofrio. The independence of our directors is discussed in Part III, Item
13 under the caption &ldquo;Director Independence.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each of the above-referenced committees operates pursuant to
a formal written charter. The charters for these committees, which have been adopted by our Board, contain a detailed description
of the respective committee&rsquo;s duties and responsibilities and are available on our website at <U>http://www.aytubio.com</U>
under the &ldquo;Investor Relations&mdash;Corporate Governance&rdquo; tab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board has determined Mr. Donofrio qualifies as an audit
committee financial expert, as defined in Item&nbsp;407(d)(5) of Regulation S-K promulgated by the SEC.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholder
Proposals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
bylaws establish procedures for stockholder nominations for elections of directors and bringing business before any annual meeting
or special meeting of stockholders. A stockholder entitled to vote in the election of directors may nominate one or more persons
for election as directors at a meeting only if written notice of such stockholder&rsquo;s intent to make such nomination or nominations
has been delivered to our Corporate Secretary at our principal executive offices not less than 90 days nor more than 120 days
prior to the first anniversary of the prior year&rsquo;s annual meeting. In the event that the date of the annual meeting is more
than 30 days before or more than 60 days after the anniversary date of the prior year&rsquo;s annual meeting, the stockholder
notice must be given not more than 120 days nor less than the later of 90 days prior to the date of the annual meeting or, if
it is later, the 10<SUP>th</SUP> day following the date on which the date of the annual meeting is first publicly announced or
disclosed by us. These notice deadlines are the same as those required by the SEC&rsquo;s Rule 14a-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the bylaws, a stockholder&rsquo;s notice must set forth among other things: (a) as to each person whom the stockholder proposes
to nominate for election or reelection as a director all information relating to such person that is required to be disclosed
in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant
to Regulation 14A under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder;
and (b) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business
desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in
such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
have been no changes to these nominating procedures since the adoption of the bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_019"></A>Item&nbsp;11.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Executive
                                         Compensation </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Executive
Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
accordance with Item 402 of Regulation S-K promulgated by the SEC, we are required to disclose certain information regarding the
makeup of and compensation for our company&rsquo;s directors and named executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
establishing executive compensation, our Board is guided by the following goals:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
should consist of a combination of cash and equity awards that are designed to fairly pay the executive officers and directors
for work required for a company of our size and scope;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
should align the executive officers&rsquo; and directors&rsquo; interests with the long-term interests of stockholders; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
should assist with attracting and retaining qualified executive officers and directors.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Compensation
of Directors&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
current compensation package for non-employee directors, effective July 1, 2017, consists of: an annual cash retainer of $40,000
for the board chair, $25,000 for each other director, $10,000 for each committee chair and $5,000 for each other committee member;
a grant of 65,000 restricted shares of stock upon appointment to the board; and an annual stock option grant of 15,000 shares
thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table provides information regarding all compensation paid to non-employee directors of Aytu during the fiscal year
ended June 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees Earned or Paid in Cash</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">All Other Compensation</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(1)</P></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Gary V. Cantrell (2)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">45,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">101,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">146,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Carl C. Dockery (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">45,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">101,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">146,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">John A. Donofrio Jr. (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">45,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">101,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">146,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Michael E. Macaluso (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">101,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">126,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
column reflects the aggregate grant date fair value of restricted stock.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
                                         of June 30, 2018, the number of restricted shares held by each non-employee director
                                         was as follows: 2,663 restricted shares for Mr. Cantrell; 2,663 restricted shares for
                                         Mr. Dockery; 2,663 restricted shares for Mr. Donofrio; 2,663 restricted shares for Mr.
                                         Macaluso.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>



<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Executive
Officer Compensation&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth all cash compensation earned, as well as certain other compensation paid or accrued for the years ended
June 30, 2018 and 2017 to each of the following named executive officers.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Name and Principal Position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Salary ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Bonus ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Award ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Option Award ($)(1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Non-Equity Incentive Plan Compensation ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Change in Pension Value and Nonqualified Deferred Compensation Earnings ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">All Other Compensation ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total ($)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">(a)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(b)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(c)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(d)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(e)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(f)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(g)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(h)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(i)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(j)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-left: 5pt; text-indent: -5pt">Named Executive Officers</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: -0.125in">Joshua R. Disbrow</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; width: 11%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief Executive Officer</I></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2018</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">303,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">303,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">606,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>since
December 2012</I></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">614,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">189,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">1,053,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: -0.125in">Jarrett T. Disbrow</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief
Operating Officer, Secretary&nbsp;</I></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">202,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">452,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>and
Treasurer</I></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">533,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">189,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">972,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: -0.125in">David A. Green (2)</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief
Financial Officer</I></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">135,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">152,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">287,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>since
December 2017</I></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: -0.125in">Gregory A. Gould (3)</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief
Financial Officer</I></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">96,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">96,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0">2017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">10,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">533,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">79,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: right; text-indent: 0">622,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Option
                                         awards are reported at fair value at the date of grant. See Item 15 of Part IV, &ldquo;Notes
                                         to the Financial Statements &mdash; Note 8 &mdash; Equity Instruments.&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mr.
                                         Green was appointed to Chief Financial Officer, Secretary and Treasurer full time effective
                                         December 18, 2017.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mr.
                                         Gould was appointed to Chief Financial Officer, Secretary and Treasurer full time effective
                                         June 16, 2017 and he resigned in November 2017.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
executive officers are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our
behalf. Executives are reimbursed for business expenses directly related to Aytu business activities, such as travel, primarily
for business development as we grow and expand our product lines. On average, each executive incurs between $1,000 to $3,000 of
out-of-pocket business expenses each month. The executive management team meets weekly and determines which activities they will
work on based upon what we determine will be the most beneficial to our company and our shareholders. No interest is paid on amounts
reimbursed to the executives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grants
of Plan-Based Awards&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding grants of plan-based awards to the Named Executive Officers during the
year ended June 30, 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Name</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Grant
    Date</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">All
    Other Stock Awards: Number of Shares of Stock or<BR>
 Units&nbsp;(#)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Base
    Price of Stock Awards ($/Share)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Grant
    Date Fair Value of Stock Awards<BR> ($)(1)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left"><FONT STYLE="font-size: 10pt">Named Executive Officers</FONT></TD><TD STYLE="font-size: 10pt; font-style: italic"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Joshua R Disbrow</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">11/7/2017</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7,500</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">40.40</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">303,000</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Jarrett T Disborw</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">11/7/2017</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">5,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">40.40</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">202,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">David A. Green</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1/2/2018</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">3,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">40.40</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">151,500</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-size: 10pt">
<TD STYLE="width: 0; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         amounts reported in this column represent the aggregate grant date fair value computed
                                         in accordance with FASB ASC 718, excluding the effect of any estimated forfeitures and
                                         may not correspond to the actual value that will be realized by the named executive officer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End 2018 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table contains certain information concerning unexercised options for the Named Executive Officers as of June 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding: 0 0 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="17" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Option
    Awards</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Stock
    Awards</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0"><FONT STYLE="font-size: 10pt">Name</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Number
    of Securities Underlying Unexercised Options Exercisable (#)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Number
    of Securities Underlying Unexercised Options Unexercisable (#)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Equity
    Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Option
    Exercise Price ($)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Option
    Expiration Date</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Number
    of Shares or Units of Stock That Have Not Vested (#)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Market
    Value of Shares or Units of Stock That Have Not Vested ($) (1)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Equity
    Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Equity
    Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0 0 0 5pt; font-size: 10pt; font-style: italic; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Named
    Executive Officers</FONT></TD>
    <TD STYLE="padding: 0 0 0 5pt; font-size: 10pt; font-style: italic; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-style: italic"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-style: italic"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-style: italic"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-style: italic"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; font-style: italic"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 11%; font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Joshua
    R. Disbrow</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">84</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">42</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">328.00</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">11/11/2025</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">7,975</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">2,074</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Joshua
    R. Disbrow</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">328.00</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">7/7/2026</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Jarrett
    T. Disbrow</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">83</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">42</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">328.00</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">11/11/2025</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">5,413</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">1,407</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Jarrett
    T. Disbrow</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">328.00</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">7/7/2026</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">David A.
    Green</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">3,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">975</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Gregory
    A. Gould</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">328.00</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">11/15/2019</FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 5pt; text-indent: -5pt"><FONT STYLE="font-size: 10pt">Gregory
    A. Gould</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">328.00</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">11/15/2019</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                         on $0.26 per share which was the closing price of our common stock on NASDAQ on June
                                         29, 2018, the last trading day of that fiscal year.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Joshua Disbrow in connection with his employment as our Chief Executive Officer. The
agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or as a result
of officer&rsquo;s disability, or by the officer with or without Good Reason (as defined below). Mr. Disbrow is entitled to receive
$250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary. Mr. Disbrow is also
eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans.
On April 16, 2017, we extended this agreement for another 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Jarrett Disbrow, our Chief Operating Officer, in connection with his employment with
us. The agreement is for a term of 24 months beginning on April 16, 2015, subject to termination by us with or without Cause or
as a result of the officer&rsquo;s disability, or by the officer with or without Good Reason (as defined below). Mr. Disbrow is
entitled to receive $250,000 in annual salary, plus a discretionary performance bonus with a target of 125% of his base salary.
Mr. Disbrow is also eligible to participate in the benefit plans maintained by us from time to time, subject to the terms and
conditions of such plans. On April 16, 2017, we extended this agreement for another 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 15, 2017, we entered into an employment agreement with Gregory A. Gould, effective June 16, 2017, to serve as our Chief Financial
Officer. Mr. Gould had been serving as our Chief Financial Officer on a part-time basis since April 2015. The agreement is identical
to the two-year employment agreement entered into effective April 16, 2017, with Jarrett Disbrow, our Chief Operating Officer,
except for the position that Mr. Gould is to occupy. The agreement is for a term of 24 months beginning on June 16, 2017, subject
to termination by us with or without Cause (as defined below) or as a result of Mr. Gould&rsquo;s disability, or by Mr. Gould
with or without Good Reason (as defined below). Mr. Gould is entitled to receive $250,000 in annual salary, plus a discretionary
performance bonus with a target of 125% of his base salary, based on his individual achievements and company performance objectives
established by the board or the compensation committee in consultation with Mr. Gould. Mr. Gould is also eligible to participate
in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans. On October 26, 2017,
Gregory A. Gould resigned as the Chief Financial Officer of Aytu BioScience, Inc. Mr. Gould&rsquo;s resignation became effective
on November 15, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
entered into an employment agreement with David A. Green, effective December 18, 2017, to serve as our Chief Financial Officer.
The agreement is subject to termination by us with or without Cause (as defined below) or as a result of Mr. Green&rsquo;s disability,
or by Mr. Green with or without Good Reason (as defined below). Mr. Green is entitled to receive $250,000 in annual salary, plus
a discretionary performance bonus with a target of 50% of his base salary, based on his individual achievements and company performance
objectives established by the board or the compensation committee in consultation with Mr. Green. Mr. Green is also eligible to
participate in the benefit plans maintained by us from time to time, subject to the terms and conditions of such plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Payments
Provided Upon Termination for Good Reason or Without Cause&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the employment agreements, in the event employment is terminated without Cause by us or the officer terminates his employment
with Good Reason, we will be obligated to pay him any accrued compensation and a lump sum payment equal to two times his base
salary in effect at the date of termination, as well as continued participation in the health and welfare plans for up to two
years. All vested stock options shall remain exercisable from the date of termination until the expiration date of the applicable
award. So long as a Change in Control is not in effect, then all options which are unvested at the date of termination Without
Cause or for Good Reason shall be accelerated as of the date of termination such that the number of option shares equal to 1/24<SUP>th
</SUP>the number of option shares multiplied by the number of full months of such officer&rsquo;s employment shall be deemed vested
and immediately exercisable by the officer. Any unvested options over and above the foregoing shall be cancelled and of no further
force or effect and shall not be exercisable by such officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;Good
Reason&rdquo; means, without the officer&rsquo;s written consent, there is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    material reduction in the officer&rsquo;s overall responsibilities or authority, or scope of duties (it being understood that
    the occurrence of a Change in Control shall not, by itself, necessarily constitute a reduction in the officer&rsquo;s responsibilities
    or authority);</FONT></TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    material reduction of the level of the officer&rsquo;s compensation (excluding any bonuses) (except where there is a general
    reduction applicable to the management team generally, provided, however, that in no case may the base salary be reduced below
    certain specified amounts); or</FONT></TD></TR>
</TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    material change in the principal geographic location at which the officer must perform his services. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;Cause&rdquo;,
means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">conviction
    of, or entry of a plea of guilty to, or entry of a plea of nolo contendere with respect to, any crime, other than a traffic
    violation or a misdemeanor;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">willful
    malfeasance or willful misconduct by the officer in connection with his employment;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">gross
    negligence in performing any of his duties;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 21px; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; width: 24px; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">willful
    and deliberate violation of any of our policies;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">unintended
    but material breach of any written policy applicable to all employees adopted by us which is not cured to the reasonable satisfaction
    of the board;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">unauthorized
    use or disclosure of any proprietary information or trade secrets of us or any other party as to which the officer owes an
    obligation of nondisclosure as a result of the officer&rsquo;s relationship with us;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">willful
    and deliberate breach of his obligations under the employment agreement; or</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 21px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    other material breach by officer of any of his obligations which is not cured to the reasonable satisfaction of the board.
    </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Payments
Provided Upon a Change in Control&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the event of a Change in Control of us, all stock options, restricted stock and other stock-based grants granted or may be granted
in the future by us to the officers will immediately vest and become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;Change
in Control&rdquo; means: the occurrence of any of the following events:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
acquisition by any individual, entity, or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (the
&ldquo;Acquiring Person&rdquo;), other than us, or any of our Subsidiaries, of beneficial ownership (within the meaning of Rule
13d-3- promulgated under the Exchange Act) of 50% or more of the combined voting power or economic interests of the then outstanding
voting securities of us entitled to vote generally in the election of directors (excluding any issuance of securities by us in
a transaction or series of transactions made principally for bona fide equity financing purposes); or</FONT></TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
acquisition of us by another entity by means of any transaction or series of related transactions to which we are party (including,
without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any issuance of securities by
us in a transaction or series of transactions made principally for bona fide equity financing purposes) other than a transaction
or series of related transactions in which the holders of the voting securities of us outstanding immediately prior to such transaction
or series of related transactions retain, immediately after such transaction or series of related transactions, as a result of
shares in us held by such holders prior to such transaction or series of related transactions, at least a majority of the total
voting power represented by the outstanding voting securities of us or such other surviving or resulting entity (or if we or such
other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or</FONT></TD>
</TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
sale or other disposition of all or substantially all of the assets of us in one transaction or series of related transactions.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
only obligation to Joshua Disbrow and Jarrett Disbrow had a Change in Control occurred as of June 30, 2018, would be the acceleration
of the vesting of all options held by them at that date. On June 30, 2018, the closing price of our common stock was below the
exercise price for all of the options held by Joshua Disbrow and Jarrett Disbrow and therefore there would have been no economic
benefit to them upon the acceleration of vesting of those options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.65in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_020"></A>Item&nbsp;12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Security
                                         Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
                                         </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information with respect to
the beneficial ownership of our common stock as of August&nbsp;31, 2018 for:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">each
beneficial owner of more than 5% of our outstanding common stock;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">each
of our director and named executive officers; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">all
of our directors and executive officers as a group.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beneficial ownership is determined in accordance with the rules
of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power
or investment power with respect to those securities and include common stock that can be acquired within 60 days of August&nbsp;31,
2018. The percentage ownership information shown in the table is based upon 1,801,411 shares of common stock outstanding as of
August&nbsp;31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Except
as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have
sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property
laws. The information is not necessarily indicative of beneficial ownership for any other purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In computing the number of shares of common stock beneficially
owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to options
and warrants held by that person that are immediately exercisable or exercisable within 60 days of August&nbsp;31, 2018. We did
not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial
ownership representing less than 1% is denoted with an asterisk (*). The information in the tables below are based on information
known to us or ascertained by us from public filings made by the stockholders. Except as otherwise indicated in the table below,
addresses of the director, executive officers and named beneficial owners are in care of Aytu BioScience, Inc., 373 Inverness Parkway,
Suite 206, Englewood, Colorado 80112.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR>
 Shares<BR>
 Beneficially <BR> Owned</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage&nbsp;of<BR> Shares <BR> Beneficially<BR> Owned</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">5% Stockholders:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Directors and Named Executive Officers:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Joshua R. Disbrow <SUP>(1)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">42,360</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.33</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jarrett T. Disbrow <SUP>(2)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.18</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">David A. Green <SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Michael Macaluso <SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Carl C. Dockery <SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">John Donofrio <SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,701</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gary Cantrell <SUP>(7)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,878</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All directors and executive officers as a group (seven persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,702</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.74</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Represents
beneficial ownership of less than 1%.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i) 16,573 shares, (ii) 7,975 restricted shares, (iii) 184 vested options to purchase shares of stock, and (iv) 17,628 shares
issuable upon the exercise of warrants. Does not include 116 shares held by an irrevocable trust for estate planning in which
Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by the trust, Mr. Disbrow
is not the trustee of the trust (nor is any member of Mr. Disbrow&rsquo;s immediate family) and Mr. Disbrow does not have or share
the power to revoke the trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have beneficial ownership
over the shares purchased and held by the trust.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i) 16,562 shares, (ii) 5,413 restricted shares, (iii) shares underlying 184 vested options to purchase shares of common stock
and (iv) 17,556 shares issuable upon the exercise of warrants. Does not include 116 shares held by an irrevocable trust for estate
planning in which Mr. Disbrow is a beneficiary. Mr. Disbrow does not have or share investment control over the shares held by
the trust, Mr. Disbrow is not the trustee of the trust (nor is any member of Mr. Disbrow&rsquo;s immediate family) and Mr. Disbrow
does not have or share the power to revoke the trust. As such, under Rule 16a-8(b) and related rules, Mr. Disbrow does not have
beneficial ownership over the shares purchased and held by the trust.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of restricted shares</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i) 75 shares, (ii)&nbsp;2,663 restricted shares, and (iii)&nbsp;vested options to purchase 105 shares of common stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i) 2,663 restricted shares, (ii) shares underlying vested options to purchase 38 shares of common stock, and (iii) 2,094 shares
held by Alpha Venture Capital Partners, L.P Mr. Dockery is the President of the general partner of Alpha Venture Capital Partners,
L.P. and therefore may be deemed to beneficially own the shares beneficially owned by Alpha Venture Capital Partners, L.P.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i)&nbsp;2,663 restricted shares, and (ii)&nbsp;vested options to purchase 38 shares of common stock.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)</SUP></FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
of (i)&nbsp;2,663 restricted shares, (ii)&nbsp;177 shares, and (iii)&nbsp;vested options to purchase 38 shares of common stock.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Information
regarding our equity compensation plans is contained in Part II, Item 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 10%; font-size: 10pt; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><A NAME="a_021"></A>Item&nbsp;13.
</B></P>

</TD>
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Certain Relationships, Related Transactions, and Director Independence</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related Party Transactions&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We describe below all transactions and series of similar transactions,
other than compensation arrangements, during the last three fiscal years, to which we were a party or will be a party, in which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the amounts involved
exceeded or will exceed $120,000; and</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">any of our directors,
executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons,
had or will have a direct or indirect material interest.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Executive Stock Purchases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two Aytu executive officers, Joshua Disbrow and Jarrett Disbrow,
participated in the August 2017 offering. Each officer purchased 4,167 units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Three Aytu executive officers, Joshua Disbrow, Jarrett Disbrow
and David Green, participated in the March 2018 offering. Joshua Disbrow and Jarrett Disbrow each purchased 11,306 units. Mr. Green
purchased 3,330 units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Services Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2015, Aytu entered into an agreement with Ampio, whereby
Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff
and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016, July 2016, and again in January
2017 resulting in an amount of $12,000 per month. This agreement was terminated in June 2017. Ampio was the Company&rsquo;s largest
stockholder during part of this period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sponsored Research Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, Luoxis entered into a sponsored research agreement
with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or. The agreement, which
was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related
to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000
which was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance
sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Co-Pay Support</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, the Company entered into a master services agreement
with TrialCard Incorporated (&ldquo;TCI&rdquo;), a vendor selected to support the Company sponsored co-pay program. In supporting
the program, TCI will make disbursements to qualified patients presenting valid prescriptions for Natesto and ZolpiMist on behalf
of Aytu. Disbursements will be based upon business rules determined by Aytu. The Company agreed to pay fees monthly to TCI for
account management, data analytics, implementation, and technology and to reimburse TCI for certain direct costs incurred by TCI
to support the Company&rsquo;s program. Expenses are expected to be approximately $19,000 per month based on volumes and performance
of our program. One of the Aytu directors, Mr. Donofrio, is an executive officer of TCI and has no direct interest in the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Review, Approval or Ratification of Transactions with Related
Persons&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Effective upon its adoption
in July 2016, pursuant to the Audit Committee Charter, the Audit Committee is responsible for reviewing and approving all related
party transactions as defined under Item 404 of Regulation S-K, after reviewing each such transaction for potential conflicts
of interests and other improprieties. Our policies and procedures for review and approval of transactions with related persons
are in writing in our Code of Conduct and Ethics available on our website at <U>http://www.aytubio.com</U> under the &ldquo;Investor
Relations&mdash;Corporate Governance&rdquo; tab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to the adoption of the Audit Committee Charter, and due
to the small size of our company, we did not have a formal written policy regarding the review of related party transactions, and
relied on our Board of Directors to review, approve or ratify such transactions and identify and prevent conflicts of interest.
Our Board of Directors reviewed any such transaction in light of the particular affiliation and interest of any involved director,
officer or other employee or stockholder and, if applicable, any such person&rsquo;s affiliates or immediate family members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Independence&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the NASDAQ Capital Market. Therefore,
we must comply with the exchange rules regarding director independence. Audit Committee members must satisfy the independence criteria
set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, for listed companies. In order to be considered
to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or
her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly,
any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated
person of the listed company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Three of our five directors are independent under the definition
of NASDAQ. The other two directors are not independent under either definition due to (i) being an executive officer of our Company,
in the case of Josh Disbrow, and (ii) the payments we make to Ampio under the services agreement with Aytu, in the case of Mr.
Macaluso.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 10%; font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><A NAME="a_022"></A>Item&nbsp;
14.</B></P>

</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Principal Accountant Fees and Services</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EKS&amp;H LLLP has served as our independent auditor since April
2015 and has been appointed by our Board of Directors to continue as our independent auditor for the fiscal year ending June 30,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents aggregate fees for professional
services rendered by our independent registered public accounting firm, EKS&amp;H LLLP, for the audit of our annual financial statements
for the respective periods, all of which were approved by our full Board of Directors for fiscal 2017 and by the Audit Committee
for fiscal 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; font-size: 10pt">Audit fees <FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">223,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">132,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Audit-related fees <FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">52,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">90,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Tax fees <FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; font-size: 10pt">Total Fees</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">275,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">222,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><SUP>&nbsp;</SUP></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"><SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt">Audit fees are comprised of annual audit fees and quarterly review fees. In 2018 we also completed a full audit of Nuelle upon
the acquisition.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"><SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt">Audit-related fees for both fiscal year 2017 and 2018 were comprised of fees related to registration statements, including
for our November 2016 public offering, our August 2017 private offering, S-3 filing and our March 2018 public offering, respectively.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"><SUP>(3)</SUP></TD><TD STYLE="font-size: 10pt">Tax fees are comprised of tax compliance, preparation and consultation fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_023"></A>PART&nbsp;IV </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.05pt; text-indent: -55.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B><A NAME="a_024"></A>Item&nbsp;15.
Exhibits and Consolidated Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 36.7pt; font-size: 10pt"><B>(a)(1)</B></TD><TD STYLE="font-size: 10pt"><B>Financial Statements </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">The following documents are filed as part of this
Form 10-K, as set forth on the Index to Financial Statements found on</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 30.6pt; font-size: 10pt"></TD><TD STYLE="width: 18.35pt; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt">Report of Independent Registered Public Accounting Firm</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 30.6pt; font-size: 10pt"></TD><TD STYLE="width: 18.35pt; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt">Consolidated Balance Sheets as of June 30, 2018 and 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 30.6pt; font-size: 10pt"></TD><TD STYLE="width: 18.35pt; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt">Consolidated Statements of Operations for the years ended June 30, 2018 and 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 30.6pt; font-size: 10pt"></TD><TD STYLE="width: 18.35pt; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt">Consolidated Statements of Stockholders&rsquo; Equity (Deficit) for the years ended June 30, 2018 and 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 30.6pt; font-size: 10pt"></TD><TD STYLE="width: 18.35pt; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt">Consolidated Statements of Cash Flows for the years ended June 30, 2018 and 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -18.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 30.6pt; font-size: 10pt"></TD><TD STYLE="width: 18.35pt; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt">Consolidated Notes to the Financial Statements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><B></B></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.7pt; text-indent: -36.7pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 36.7pt; font-size: 10pt"><B>(a)(2)</B></TD><TD STYLE="font-size: 10pt"><B>Financial Statement Schedules </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">Not Applicable.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0; font-size: 10pt"></TD><TD STYLE="width: 36.7pt; font-size: 10pt"><B>(a)(3)</B></TD><TD STYLE="font-size: 10pt"><B>Exhibits</B>&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; width: 9%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 46%; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Description</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 10%; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Registrant&rsquo;s</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Form</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 10%; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Filed</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 10%; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 10%; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Filed</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Herewith</B>&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex31.htm">Certificate of Incorporation</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/09/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416106487/v441568_ex3-1.htm">Certificate of Amendment of Certificate of Incorporation effective June 1, 2016</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/02/16&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416111027/v443180_ex3-1.htm">Certificate of Amendment of Certificate of Incorporation, effective June 30, 2016</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">7/01/16</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed on August 11, 2017.</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8/16/17</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417045636/v474281_ex3-1.htm">Certificate of Amendment of Certificate of Incorporation, effective August 25, 2017</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8/29/17</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018010718/f8k081018ex3-1_aytubio.htm">Certificate of Amendment of Certificate of Incorporation, effective August 10, 2018</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8/10/18</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex32.htm">Bylaws</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/09/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515262003/d50939dex42.htm">Form of Placement Agent Warrant issued in 2015 Convertible Note Financing</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">7/24/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416099585/v439153_ex4-1.htm">Warrant Agent Agreement, dated May 6, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">5/6/16</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416124782/v449009_ex4-5.htm">First Amendment to May 6, 2016 Warrant Agent Agreement between Aytu BioScience, Inc. and VStock Transfer LLC.</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">S-1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">9/21/16</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416131142/v450891_ex4-1.htm">Warrant Agent Agreement, dated November 2, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">11/2/16</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417011968/v460775_ex4-1.htm">Form of Amended and Restated Underwriters&rsquo; Warrant (May 2016 Financing)</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3/1/17</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417011968/v460775_ex4-2.htm">Form of Amended and Restated Underwriters&rsquo; Warrant (October 2016 Financing)</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">3/1/17</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex4-1.htm">Form of Common Stock Purchase Warrant issued on August 15, 2017.</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8/16/17</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.2#</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex104.htm">Asset Purchase Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Valeant International (Barbados) SRL, effective as of December 2, 2011</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/08/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.3#</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex105.htm">Manufacturing and Supply Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Ethypharm S.A., dated September&nbsp;10,&nbsp;2012</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/08/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 46%"><FONT STYLE="font-size: 10pt"><B>Description</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt"><B>Registrant&rsquo;s</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Form</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Filed</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt"><B>Filed</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Herewith</B>&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="f10k2018ex10-4_aytubio.htm"><FONT STYLE="font-size: 10pt">License, Development and Commercialization Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011</FONT></A></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center">X</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.5#</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex107.htm"><FONT STYLE="font-size: 10pt">Distribution
Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and FBM Industria Farmaceutica, Ltda., dated as of March&nbsp;1,
2012</FONT></A></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/08/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.6#</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex108.htm">Distribution and License Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9, 2014</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/08/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.7#</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex109.htm">Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated September 1, 2009</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/08/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.8#</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515201036/d932809dex1014.htm">Addendum No. 4 to Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated March 17, 2014</A></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">5/27/15</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>

<TR STYLE="font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515142145/d912919dex1011.htm">Promissory Note issued by Ampio to the Registrant on April 16, 2015</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">4/22/15</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515142145/d912919dex1012.htm">Subscription Agreement between the Registrant and Ampio, dated April 16, 2015</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">4/22/15</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="f10k2018ex10-11_aytubio.htm"><FONT STYLE="font-size: 10pt">Voting Agreement between the Registrant and Ampio, dated April 21, 2015</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; font-size: 10pt">X</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515201036/d932809dex1014.htm">Asset Purchase Agreement between Jazz Pharmaceuticals, Inc. and Rosewind Corporation, dated May&nbsp;20, 2015</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">5/27/15</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515262003/d50939dex101.htm"><FONT STYLE="font-size: 10pt">Form of Note Purchase Agreement for 2015 Convertible Note Financing</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">7/24/15</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515338925/d90730dex1018.htm">Asset Purchase Agreement, dated October 5, 2015, between Aytu BioScience, Inc. and FSC Laboratories, Inc.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">10/07/15 &nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515342680/d58016dex1019.htm">Master Services Agreement between Biovest International, Inc. and Aytu BioScience, Inc., entered into on October 8, 2015, and effective October 5, 2015</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10/13/15</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416076273/v429234_ex10-1.htm">Form of Subscription Agreement for January 2016 common stock purchases</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">1/20/16</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416095924/v437781_ex10-1.htm">License and Supply Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">4/25/16</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416095924/v437781_ex10-2.htm">Subscription Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">4/25/16</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416102582/v440068_ex10-1.htm">First Amendment, dated May 15, 2016, to Employment Agreement dated September 16, 2015 between Aytu BioScience, Inc. and Jonathan McGrael</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">5/16/16</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-1.htm">Purchase Agreement, dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">7/28/16&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Description</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Registrant&rsquo;s</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Form</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Filed</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B>&nbsp;</FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Filed</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Herewith</B>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt; width: 9%"><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt; width: 46%"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-2.htm">Registration Rights Agreement dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt">7/28/16&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt; width: 10%"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt; width: 10%">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.22&dagger;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417020925/v464415_ex10-1.htm">Employment Agreement, effective as of April 16, 2017, between Aytu BioScience, Inc. and Joshua R. Disbrow.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">4/18/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.23&dagger;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417020925/v464415_ex10-2.htm">Employment Agreement, effective as of April 16, 2017, between Aytu BioScience, Inc. and Jarrett T. Disbrow.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">4/18/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417026452/v465720_ex10-1.htm">Asset Purchase Agreement, dated March 31, 2017, between Allegis Holdings, LLC and Aytu BioScience, Inc.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">10-Q</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">5/11/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.25#</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417046061/v473641_ex10-25.htm"><FONT STYLE="font-size: 10pt">Merger Agreement, dated May 3, 2017, between Nuelle, Inc. and Aytu BioScience, Inc.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding: 0; text-align: center; font-size: 10pt">10-K</TD>
    <TD STYLE="padding: 0; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding: 0; text-align: center; font-size: 10pt">8/31/17</TD>
    <TD STYLE="padding: 0; text-align: center; font-size: 10pt"></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; padding: 0; text-align: center; font-size: 10pt">10.25</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0; font-size: 10pt"></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.26&dagger;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417032942/v469126_ex10-1.htm">Employment Agreement, effective as of June, 2017, between Aytu BioScience, Inc. and Gregory A. Gould.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">6/19/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.27&dagger;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417038709/v471569_ex10-1.htm">2015 Stock Option and Incentive Plan, as amended on July 26, 2017.</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">7/27/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-1.htm"><FONT STYLE="font-size: 10pt">Securities Purchase Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8/16/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-2.htm"><FONT STYLE="font-size: 10pt">Registration Rights Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">8/16/17</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.30</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018003557/f8k032318ex10-1_aytubio.htm">Warrant Exercise Agreement dated March 23, 2018</A></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">8-K</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">3/28/18</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">10.1</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">10.31</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="f10k2018ex10-31_aytubio.htm">Amended and Restated Exclusive License Agreement, dated June 11, 2018, between Aytu BioScience, Inc. and Magna Pharmaceuticals, Inc.</A>

</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; font-size: 10pt">X</TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="f10k2018ex23-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Consent of EKS&amp;H LLLP, Independent Registered Public Accounting Firm.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="f10k2018ex31-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate of the Chief Executive Officer of Aytu BioScience, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="f10k2018ex31-2_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate of the Chief Financial Officer of Aytu BioScience, Inc. pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">X</FONT></TD></TR>

<TR STYLE="font-size: 10pt; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="f10k2018ex32-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate of the Chief Executive Officer and the Chief Financial Officer of Aytu BioScience, Inc. pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">101*</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">XBRL (extensible Business Reporting Language). The following materials from Aytu BioScience, Inc.&rsquo;s
Annual Report on Form 10-K for the year ended June 30, 2018 formatted in XBRL: (i) the Balance Sheets, (ii) the Statements of Operations,
(iii) the Statements of Stockholders&rsquo; Equity (Deficit), (iv) the Statements of Cash Flows, and (v) the Notes to the Financial
Statements.</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">X</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Indicates is a management contract or compensatory plan or arrangement. </FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; text-align: left; padding-right: 0; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">#</FONT></TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">The company has received confidential treatment of certain portions of this agreement. These portions have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_025"></A>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section&nbsp;13 or 15(d) of
the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; padding: 0; text-indent: 0; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>AYTU BIOSCIENCE, INC.</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; font-size: 10pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; font-size: 10pt; width: 36%">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: September 6, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-align: left; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; text-align: left; border-bottom: Black 1.5pt solid; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">/s/ Joshua R. Disbrow</P>
</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0; text-align: left; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Joshua R. Disbrow</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Chairman and Chief Executive Officer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Principal Executive Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below
by the following persons on behalf of the Registrant in the capacities indicated, on September 6, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="width: 49%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; width: 49%; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Joshua R. Disbrow&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chairman and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(Principal Executive Officer)</I></P></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ David A. Green&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(Principal Financial and Accounting Officer)</I></P></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">David A. Green</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Michael Macaluso&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Director</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Michael Macaluso</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Carl Dockery&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Carl Dockery</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ John Donofrio Jr.&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">John Donofrio Jr.</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Gary Cantrell</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; font-size: 10pt">Director</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">Gary Cantrell</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="padding: 0 0 1.5pt; width: 90%; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; width: 10%; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding: 0; text-align: center; text-indent: 0; vertical-align: bottom; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="#f_001"><FONT STYLE="font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="#f_002"><FONT STYLE="font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="#f_003"><FONT STYLE="font-size: 10pt">Consolidated Statements of Operations</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="#f_004"><FONT STYLE="font-size: 10pt">Consolidated Statements of Stockholders&rsquo; Equity (Deficit)</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="#f_005"><FONT STYLE="font-size: 10pt">Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="background-color: White; font-size: 10pt">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0; font-size: 10pt"><A HREF="#f_006"><FONT STYLE="font-size: 10pt">Consolidated Notes to the Financial Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center; padding: 0; text-indent: 0; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">To the Shareholders
and Board of Directors of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Aytu BioScience, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Englewood,
Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.6in 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OPINION ON THE FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.4pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited
the accompanying consolidated balance sheets of Aytu BioScience, Inc. (the &ldquo;Company&rdquo;) as of June 30, 2018 and 2017, and
the related consolidated statements of operations, stockholders&rsquo; (deficit) equity, and cash flows for each year in the two-year
period ended June 30, 2018, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2018 and
2017, and the results of its operations and its cash flows for each year in the two- year period ended June 30, 2018, in conformity
with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SUBSTANTIAL DOUBT ABOUT
THE COMPANY&rsquo;S ABILITY TO CONTINUE AS A GOING CONCERN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the
financial statements, the Company has suffered recurring losses from operations and has an accumulated deficit that raises substantial
doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note
3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BASIS FOR OPINION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial
statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the
Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted
our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose
of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express
no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits
included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 50%; font-size: 10pt"></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ EKS&amp;H
    LLLP</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver,
    Colorado </FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">September 6, 2018</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                         have served as the Company&rsquo;s auditor since <FONT STYLE="font-size: 10pt">2015.</FONT></FONT></P>

</TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_002"></A>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-weight: bold; text-align: center; font-size: 10pt">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">7,012,527</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">802,328</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Restricted cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">100,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">75,214</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Accounts receivable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">578,782</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">528,039</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Inventory, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,338,973</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,312,221</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Prepaid expenses and other</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">440,009</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">310,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">9,470,291</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,028,562</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Fixed assets, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">218,684</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">647,254</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Developed technology, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,337,333</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Customer contracts, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">77,667</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Trade names, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">164,037</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Licensed assets, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">11,120,086</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">9,231,072</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-indent: 10pt; font-size: 10pt">Goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">238,426</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Patents, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">245,944</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">271,278</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Deposits</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">5,088</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">2,888</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Total long-term assets</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">11,589,802</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">11,969,955</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">Total assets</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">21,060,093</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,998,517</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-weight: bold; text-align: center; font-size: 10pt">Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Accounts payable and other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">2,119,672</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">2,220,400</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">185,882</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">782,536</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Accrued compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">540,674</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">339,704</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Current deferred rent</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,450</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,673</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Current contingent consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">547,100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">261,155</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,394,778</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,610,468</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Long-term contingent consideration</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,146,829</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">7,386,782</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Long-term deferred rent</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,451</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Warrant derivative liability</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">93,981</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">7,635,588</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">10,998,701</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Commitments and contingencies (Note 6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 1,794,762 and 41,244, respectively as of June 30, 2018 and 2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">179</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">92,681,918</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">73,069,541</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(79,257,592</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(69,069,729</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">13,424,505</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,999,816</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">21,060,093</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,998,517</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_003"></A>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Product revenue, net</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,660,120</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,221,590</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Total product revenue</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,660,120</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,221,590</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">Cost of sales</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,050,544</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,417,355</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">167,595</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">959,857</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Research and development - related party (Note 9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">387,960</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Sales, general and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">17,732,490</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">17,442,627</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Sales, general and administrative - related party (Note 9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">165,131</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Impairment of intangible assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,856,020</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,265,125</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Amortization of intangible assets</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">1,553,705</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">1,708,771</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">23,360,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">23,346,826</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(19,700,234</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(20,125,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Other (expense) income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Interest (expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(749,423</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(2,534,358</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">(Loss) on investment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(61,519</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt">Other gain</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,277,873</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Derivative income</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,983,921</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">212,809</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt">Total other (expense)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">9,512,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(2,383,068</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">Net loss</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(10,187,863</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(22,508,304</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Weighted average number of common shares outstanding</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">665,605</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">466,024</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt">Basic and diluted net loss per common share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">(15.31</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">(48.30</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_004"></A>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Stockholders&rsquo;
Equity (Deficit)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; padding-right: 0; padding-left: 0; border-bottom: Black 1.5pt solid; font-size: 10pt">Preferred Stock</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; padding-right: 0; padding-left: 0; border-bottom: Black 1.5pt solid; font-size: 10pt">Common Stock</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">Additional<BR>
paid-in</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">Accumulated</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">Total<BR>
 Stockholders&rsquo;</TD><TD STYLE="text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="padding-left: 0; text-align: center; padding-right: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">Shares</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">Amount</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">Shares</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">Amount</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">capital</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; padding-right: 0; padding-left: 0; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; font-size: 10pt">Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 23%; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Balance - June 30, 2016</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;9,355</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">56,646,677</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">(46,561,425</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">10,085,253</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Lincoln&nbsp;&nbsp;Park stock issuance, net of issuance costs $90,924</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">966</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">648,933</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">648,933</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,502,092</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,502,092</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issuance of restricted stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,500</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">724,613</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">724,613</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Common stock issued to executives</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">357</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">509,996</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">509,996</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issurance of warrants to initial investors</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">596,434</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">596,434</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issuance of common stock, net of $997,865 in issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">14,338</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,671,580</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,671,581</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrants issued in connection with registered offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,470,646</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,470,646</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrants issued in connection with registered offering to the placement agents for the over-allotment option</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">172,629</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">172,629</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">292,630</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">292,630</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrant tender offer, net of $312,159 in issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">7,478</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,931,122</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,931,123</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrant amendments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">64,690</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">64,690</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Investment in Subsidiary</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,250</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,837,499</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,837,500</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(22,508,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(22,508,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Balance - June 30, 2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">41,244</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">73,069,541</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(69,069,729</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,999,816</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">348,515</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">348,515</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issuance of restricted stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">38,350</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">248,415</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">248,419</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Earn-out payment to Nuelle shareholders</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,208</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">250,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">250,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issuance of preferred and common stock, net of $1,402,831 in cash issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">113</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">159,834</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">16</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,319,150</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,319,167</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issuance of preferred and common stock, net of $1,294,235 in cash issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">161</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,076,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">108</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">9,166,316</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">9,166,425</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrants issued in connection with registered offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,439,360</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,439,360</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Preferred stock converted in common stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(274</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(2</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">394,839</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">39</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(37</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">S-3 registered offering cost</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(60,450</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(60,450</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrant exercises</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">80,750</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">8</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">677,092</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">677,100</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Issuance of warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">179,287</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">179,287</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrant amendments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,633</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,633</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Warrant exercise of derivative warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">40,096</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">40,096</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Adjustment for rounding of shares due to stock split</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">537</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(10,187,863</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(10,187,863</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in; font-size: 10pt">Balance - June 30, 2018</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,794,762</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">179</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">92,681,918</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(79,257,592</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">13,424,505</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_005"></A>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 9pt">Year Ended June
    30,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 9pt">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 9pt">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">Cash flows from operating activities:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Net loss</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(10,187,863</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(22,508,304</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Adjustments to reconcile net loss to cash used
    in operating activities:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Depreciation, amortization and accretion</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">2,591,270</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">4,364,680</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Impairment of intangible assets</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">1,856,020</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">1,265,125</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Stock-based compensation expense</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">348,515</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">2,502,092</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance of restricted stock</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">248,419</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">724,613</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Other gain</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(6,277,873</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrants issuance and amendments</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">183,920</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">1,507</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Derivative income</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(3,983,921</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(212,809</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Amortization of prepaid research and development
    - related party (Note 9)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">335,454</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Loss on investment</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">61,519</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Common stock issued to executives</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">509,996</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance of warrants to initial investors</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">596,434</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 10pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Gain on sale of asset</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(428,374</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets
    and liabilities:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">(Increase) in accounts receivable</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(50,743</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(355,031</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">(Increase) decrease in inventory</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(26,752</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">195,427</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">(Increase) in prepaid expenses and other</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(129,249</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(95,202</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">(Decrease) increase in accounts payable and other</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(109,707</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">493,217</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">(Decrease) in accrued liabilities</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(596,654</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(414,570</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Increase (decrease) in accrued compensation</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">200,970</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(861,226</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 30pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">(Decrease) in deferred
    rent</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(6,674</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(4,200</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Net cash used in operating activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(15,940,322</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(13,829,652</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Cash flows used in investing activities:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Deposit</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(2,200</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Purchases of fixed assets</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(74,707</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(111,608</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Contingent consideration payment</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(7,385</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Purchase of assets</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(400,000</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(6,000,000</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Investment in Acerus</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">1,071,707</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Sale of investment in Acerus cost</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(91,864</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Sales of Primsol assets</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">1,750,000</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Purchase of Primsol asset</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(750,000</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Cash proceed from Nuelle</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">613,309</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Cost related to Nuelle
    acquisition</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(16,082</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Net cash used in investing activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(484,292</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(3,534,538</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Cash flows from financing activities:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance of preferred, common stock and warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">11,839,995</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance costs related to preferred, common stock
    and warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(1,402,831</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance of preferred, common stock and warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">12,900,020</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance costs related to preferred, common stock
    and warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(1,294,235</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrant exercises</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">677,100</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">S-3 registered offering cost</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(60,450</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance of common stock to Lincoln Park</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">739,857</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Costs related to the sale of common stock</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(90,924</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrant tender offer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">2,243,282</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrant tender offer cost</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(312,159</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Registered offering</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">8,602,499</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Registered offering costs</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(997,865</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 20pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Over-allotment warrants
    purchased by placement agents</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">2,852</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Net cash provided by financing activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">22,659,599</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">10,187,542</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Net change in cash and cash equivalents</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">6,234,985</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">(7,176,648</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Cash and cash equivalents at beginning of
    period</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">877,542</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">8,054,190</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">Cash and cash equivalents at end of period</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">7,112,527</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">877,542</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrants issued to investors and underwriters (see Note 4)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">4,117,997</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrant exercise of derivative warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">40,096</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Contingent consideration included in accounts payable</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">8,980</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Earn-out payment to Nuelle Shareholders</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">250,000</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Purchase of asset included in contingent consideration</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">293,216</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Contingent consideration</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">2,553,169</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Issuance of common stock to Nuelle share holders</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">1,837,500</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Fixed assets included in accounts payable</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">10,789</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrants issued in connection with the equity financing to the placement
    agents</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">292,630</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">Warrants amended in connection with warrant tender offer</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-size: 9pt">63,182</FONT></TD><TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these financial statements.</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="f_006"></A>AYTU BIOSCIENCE, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 &ndash; Business, Basis of Presentation, Business
Combinations, Divestitures, License/Supply Agreement and Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience, Inc. (&ldquo;Aytu&rdquo;, the &ldquo;Company&rdquo;
or &ldquo;we&rdquo;) was incorporated as Rosewind Corporation on August&nbsp;9, 2002 in the State of Colorado. Aytu was re-incorporated
in the state of Delaware on June&nbsp;8, 2015. <FONT STYLE="background-color: white">Aytu is an emerging specialty pharmaceutical
company focused on commercializing novel products that address significant medical needs. Aytu is focused on commercializing products
that address hypogonadism (low testosterone), insomnia, and male infertility and plans to expand into other therapeutic areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of Presentation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The audited consolidated financial statements include the operations
of Aytu and its wholly-owned subsidiary, Aytu Women&rsquo;s Health, LLC. All significant inter-company balances and transactions
have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements of the Company
have been prepared in accordance with U.S. generally accepted accounting principles (&ldquo;U.S. GAAP&rdquo;). On August 10, 2018,
Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding
(herein referred to collectively as the &ldquo;Reverse Stock Splits&rdquo;). All share and per share amounts in this report have
been adjusted to reflect the effect of these Reverse Stock Splits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination&mdash;ProstaScint</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2015, Aytu completed an asset purchase agreement with
Jazz Pharmaceuticals, Inc. (&ldquo;Jazz Pharmaceuticals&rdquo;). Pursuant to the agreement, Aytu purchased assets related to the
Jazz Pharmaceuticals&rsquo; product known as ProstaScint<SUP>&reg;</SUP> (capromab pendetide), a late life cycle imaging agent,
including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the
&ldquo;ProstaScint Business&rdquo;), and assumed certain of Jazz Pharmaceuticals&rsquo; liabilities, including those
related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront payment of $1.0
million. We will pay a revenue share of 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment
of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017
at $54,000 using a discounted cash flow. As of June 30, 2018, the value for the contingent consideration was adjusted to $0 based
upon the abandonment of ProstaScint in the quarter ended June 30, 2018, thus resulting in no future revenues around this product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the asset purchase agreement, we were required to
make our first revenue share payment to Jazz Pharmaceuticals during the March 31, 2018 quarter which was approximately $7,400.
We will make our final revenue share payment to Jazz Pharmaceuticals in the first quarter of fiscal 2019, which is approximately
$9,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2017, the ProstaScint asset was determined to be
impaired based upon sales projections at that time and because we were planning to discontinue sales of ProstaScint in fiscal 2019,
consistent with product expiry dating. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000
for trade names and $0 for customer contracts. At June 30, 2018, we reevaluated the ProstaScint asset and abandoned sales of ProstaScint
in the current fiscal year, and we recognized the remainder of the amortization expense in the quarter ended June 30, 2018. The
amortization expense was $61,000 and $159,000 for fiscal 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination&mdash;Primsol</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, Aytu entered into and closed on an Asset Purchase
Agreement with FSC Laboratories, Inc. (&ldquo;FSC&rdquo;). Pursuant to the agreement, Aytu purchased assets related to FSC&rsquo;s
product known as Primsol&reg; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in
progress and all marketing and sales assets and materials related solely to Primsol (together, the &ldquo;Primsol Business&rdquo;),
and assumed certain of FSC&rsquo;s liabilities, including those related to the sale and marketing of Primsol arising after the
closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense of $0 and $184,000 was recognized in fiscal
2018 and fiscal 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Divestiture &ndash; Primsol</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2017, we entered into and closed on an Asset Purchase
Agreement with Allegis Holdings, LLC (the &ldquo;Purchaser&rdquo;). Pursuant to the agreement, we sold to the Purchaser all of
our assets related to our Primsol product, including certain intellectual property and contracts, inventory, work in process and
all marketing assets and materials related solely to Primsol (together, the &ldquo;Primsol Asset&rdquo;). We retain any liability
associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol
Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense
on our statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>License and Supply Agreement&mdash;Natesto</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, Aytu entered into and closed a license and supply
agreement to acquire the exclusive U.S. rights to Natesto&reg; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation
(&ldquo;Acerus&rdquo;). We acquired the right effective upon the expiration of the former licensee&rsquo;s rights, which occurred
on June 30, 2016. The licensee&rsquo;s term runs for the greater of eight years or until the expiry of the latest to expire patent
including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu made an upfront payment of $2.0 million to Acerus upon
execution of the agreement. In October 2016, we paid an additional $2.0 million. In January 2017, Aytu paid the final upfront payment
of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5
million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share.
These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares
until after August 29, 2016. During fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1
million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $0 and $62,000 during fiscal 2018 and
2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the upfront payments, we must make the following
one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum
aggregate amount payable under such milestone payments will be $37.5 million):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &ldquo;First Milestone&rdquo;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the net identifiable asset acquired totaled
$10.5 million which is being amortized over eight years. The amortization expense for fiscal 2018 and fiscal 2017 was $1.3 million,
respectively. The estimated future amortization of Natesto after June 30, 2018 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; text-align: left; font-size: 10pt">2019</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">1,319,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,319,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,319,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,319,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,319,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">1,317,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">7,912,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was initially valued at $3.2 million
using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2018, the contingent consideration was revalued at $1.8 million
using the same Monte Carlo simulation methodology, and based on current interest rates, expected sales potential, and Aytu stock
trading variables. The contingent consideration accretion expense for fiscal 2018 and 2017 was $694,000, and $228,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>License and Supply Agreement&mdash;ZolpiMist </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, Aytu signed an exclusive license agreement for
ZolpiMist&trade; (Zolpidem Tartrate Oral Spray) from Magna Pharmaceuticals, Inc., (&ldquo;Magna&rdquo;). This agreement allows
for Aytu&rsquo;s exclusive commercialization of ZolpiMist in the U.S. and Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu made an upfront payment of $400,000 to Magna upon execution of the agreement. In July 2018, we paid
an additional $300,000, of which, $297,000 was included in current contingent consideration at June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The intangible asset was valued at $3.2 million and will be
amortized over the life of the license agreement up to seven years. The Company&rsquo;s allocation on consideration transferred
for ZolpiMist as of the purchase date of June 11, 2018 was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; text-align: left; font-size: 10pt">&nbsp;Intangible assets</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">3,200,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">&nbsp;Total assets acquired</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,200,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amortization expense for fiscal 2018 was $39,000. The estimated
future amortization of ZolpiMist after June 30, 2018 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; text-align: left; font-size: 10pt">2019</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">464,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">464,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">464,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">464,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">464,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">888,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,208,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also agreed to make certain royalty payments to Magna which
will be calculated as a percentage of our ZolpiMist net sales which will be payable within 45 days of the end of the quarter during
which the applicable net sales occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Twenty percent (20%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Fifteen percent (15%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2022</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Ten percent (10%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2025</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration, related to these royalty payments, was valued at $2.6 million using a Monte
Carlo simulation, as of June 11, 2018. The contingent consideration accretion expense for fiscal 2018 and 2017 was $23,000, and
$0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Merger/Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, Aytu Women&rsquo;s Health, LLC., (&ldquo;AWH&rdquo;)
a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc. (&ldquo;Nuelle&rdquo;), a women&rsquo;s sexual health company. This transaction
expanded our product portfolio with the addition of the Fiera<SUP>&reg;</SUP> personal care device for women.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the Merger, (i) each share of Nuelle common stock and each
option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the
right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 6,250 shares of our
common stock and agreed to make future revenue earn-out and milestone payments subject to certain performance criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nuelle preferred stockholders were entitled to revenue earn-out
payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all
tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The first $1.0 million of revenue earn-out payments was paid
in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.
The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&rsquo;s portion of the revenue earn-out
by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to
the Nuelle stockholders of the revenue earn-out or any public disclosure by us of the earn-out being due and payable.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense of $110,000 and $22,000 was recognized
in fiscal 2018 and 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was valued at $1.9 million using
a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for fiscal 2018 and 2017 was $64,000,
and 12,000 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the quarter ended September 30, 2017, we paid the first
revenue earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which represented the revenue earn-out
payment for fiscal 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the quarter ended December 31, 2017, we made a $238,000
prepayment, issued in Aytu common stock, which represented the revenue earn-out payment for the remaining balance due on the first
$1.0 million in net revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2018, the AWH assets were determined to be impaired
based upon sales performance and the manufacturer no longer supporting the product. The value for all AWH intangible assets were
adjusted to zero. The contingent consideration was revalued to zero as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Contingent Consideration</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; font-size: 10pt">Balance as of June 30, 2017</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">1,940,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">64,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Decrease due to contractual payment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(250,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to remeasurement</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(1,754,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Principals of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">These consolidated financial statements
include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&rsquo;s Health. All material intercompany transactions
and balances have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu considers all highly liquid instruments purchased with
an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a certificate of deposit
investment account. Aytu&rsquo;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors
its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year,
and as of June 30, 2018, Aytu has maintained balances in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue Recognition </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Product&nbsp;&amp; Service Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company recognizes revenue only when
all of the following criteria have been met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -0.2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="color: windowtext">Persuasive evidence
of an arrangement exists,</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="color: windowtext">Delivery has occurred,</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="color: windowtext">The fee for the arrangement
is fixed or determinable, and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; font-size: 10pt"></TD><TD STYLE="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</TD><TD STYLE="font-size: 10pt"><FONT STYLE="color: windowtext">Collectability is
reasonably assured.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Persuasive evidence of an arrangement exists
- The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue. Certain
contracts allow for revenue recognition at the time of shipment and others at the time of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Delivery has occurred - The Company recognizes
revenue when delivery of certain products occurs at the customers&rsquo; designated location.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Device sales are typically recorded when
products are shipped to customers. Drug sales are typically recorded when the product arrives at the customer&rsquo;s dock. Provisions
for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period
the related sales are recorded and are estimated at the time of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fee for the arrangement is fixed or
determinable - Prior to recognizing revenue, a customer&rsquo;s fee is either fixed or determinable under the terms of the written contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collectability is reasonably assured -
The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a
customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which
evaluates the customer&rsquo;s financial position and ultimately its ability to pay. The Company does not enter into arrangements unless
collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment
history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is
recognized on a cash basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Estimated Sales Returns and Allowances </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu records estimated reductions in revenue for potential returns
of products by customers. As a result, management must make estimates of potential future product returns and other allowances
related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends
and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different
estimates, material differences in the amount of the Company&rsquo;s reported revenue could result. As of June 30, 2018, and 2017,
we accrued $17,000 and $58,000, respectively, in our estimated returns allowance. Estimates of potential returns and allowances
are trued up each quarter for the difference between estimates made in the prior quarter and actual results that become available
after the end of each reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Shipping and Handling</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&rsquo;s shipping and handling costs
are included in cost of goods sold for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accounts Receivable </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Accounts receivable are recorded at
their estimated net realizable value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation
allowance accordingly. As of June 30, 2018, we had an allowance for doubtful accounts of $0, and as of June 30, 2017, there had
been an allowance for doubtful accounts of $44,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Concentration of Business Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following counterparties contributed
greater than&nbsp;10%&nbsp;of the Company&rsquo;s gross revenue during the year ended June 30, 2018 and 2017, respectively. The counterparties,
sometimes referred to as partners or customers, are large wholesale distributors that resell our products to retailers. As of June
30, 2018, three customers accounted for 84% of gross revenue. The revenue from these counterparties as a percentage of gross revenue
was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; font-size: 10pt">Customer A</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">32</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">34</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Customer C</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">30</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">18</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Customer B</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">24</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">22</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The loss of one or more of the Company&rsquo;s significant partners
or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company
is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit
risk exists as of&nbsp;June&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We are also subject to credit risk
from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our
accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse
effect on our financial position, liquidity or results of operations. As of June 30, 2018, three customers accounted for 81% of
gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; font-size: 10pt">Customer C</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">35</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">18</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Customer A</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">27</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">25</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Customer B</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">19</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">17</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">Other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">12</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">0</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Inventories </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories consist of raw materials, work in process and finished
goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu
periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items.
If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable
value in the period that the impairment is first recognized. Inventory for our abandoned products was written down during fiscal
2018. Therefore, we currently have a reserve of $0 for slow moving inventory as of June 30, 2018 and $310,000 at June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory balances consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; font-size: 10pt">Raw materials</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">239,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">442,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Work in process</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">442,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Finished goods</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,100,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">738,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">Reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(310,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,339,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,312,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fixed Assets </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are recorded at cost. After being placed in service,
the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font-size: 10pt">Estimated Useful Lives</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">in years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 64%; text-align: left; font-size: 10pt">Manufacturing equipment</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center; font-size: 10pt">2 - 5</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">213,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">405,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Leasehold improvements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">3</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">112,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">111,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Office equipment, furniture and other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">2 - 5</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">344,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">287,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Lab equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">3 - 5</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">90,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">90,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Less accumulated depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(540,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(246,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Fixed assets, net</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">219,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">647,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu recorded the following depreciation and amortization expense
in the respective periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="width: 76%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Depreciation and amortization expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">294,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">134,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patents </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costs of establishing patents, consisting of legal and filing
fees paid to third parties, are expensed as incurred. The cost of the Luoxis patents were $380,000 when they were acquired in connection
with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which
expires in March 2028. Patents consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; font-size: 10pt">Patents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">380,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">380,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Less accumulated amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(134,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(109,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Patents, net</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">271,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu recorded the following amortization expense in the respective
periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="width: 76%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Amortization expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">25,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">26,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future amortization from the year ended June 30, 2018 is as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; text-align: left; font-size: 10pt">2019</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">25,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">25,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">25,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">25,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">25,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">121,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Business Combinations </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for its business acquisitions under the
acquisition method of accounting as indicated in the Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;) Accounting
Standards Codification (&ldquo;ASC&rdquo;) 805, &ldquo;Business Combinations&rdquo;, which requires the acquiring entity in a business
combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired
business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets
acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest
in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes
and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value
of the identified net assets acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Goodwill </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Nuelle, ProstaScint and Primsol&nbsp;purchase price allocations
were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted
up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities
acquired required the use of estimates by management, and were based upon currently available data, as noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company allocated the excess of purchase price over the
identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the
value placed on entering new markets and expanding market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company tests its goodwill for impairment annually, or whenever
events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair
value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market
conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that
an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating
expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company
must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets.
Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to
the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&nbsp;20, 2015,
Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $74,000 related to
the ProstaScint goodwill for the year ended June 30, 2017. There was an impairment of $238,000 related to the Fiera goodwill during
the year ended June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in accordance with Generally
Accepted Accounting Principles in the United States of America (&ldquo;GAAP&rdquo;) requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of
the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject
to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation,
valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable,
and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu has been included in the consolidated tax returns of Ampio
for tax years ending on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&rsquo;s ownership percentage of
Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu&rsquo;s taxes were
computed and reported on a &ldquo;separate return&rdquo; basis for these financial statements. Deferred taxes are provided on an
asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and
tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are
the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation
allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will
not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date
of enactment. &#9;&#9;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount of income taxes and related income tax positions
taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax
positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining
the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized
upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&rsquo;s
policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB
ASC 740-10. &ldquo;Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109&rdquo; (ASC 740-10) and tax
position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes,
the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and
penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant
tax position requires recognition under ASC 740-10. &#9;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu accounts for share-based payments by recognizing compensation
expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair
value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the
graded method. Forfeitures are adjusted for as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is recognizing compensation cost equal to the fair
value of the stock at the grant dates prorated over the vesting period of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred with
expenses recorded in the respective period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income (Loss) Per Common Share </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic income (loss) per common share is calculated by dividing
the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during
that period. <FONT STYLE="background-color: white">Diluted net loss per share reflects the potential of securities that could
share in the net loss of Aytu. Basic and diluted loss per share was the same in 2018 and 2017. Although there were common stock
equivalents of 1,923,199 and 18,366 shares outstanding at June 30, 2018 and 2017, respectively, consisting of stock options, unvested
restricted stock and warrants; they were not included in the calculation of the diluted net loss per share because they would
have been anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Fair Value of Financial Instruments and Derivative Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of financial instruments, including cash
and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate
their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated
discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable
securities was based on quoted market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu accounts for liability warrants by recording the fair value
of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial
instruments and related warrants were calculated using a lattice valuation model. We recorded a derivative expense at the inception
of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods
was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income
or expense for the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The fair value of the
warrants issued to the placement agents in connection with the registered offering were valued using the lattice valuation methodology.
Changes in the fair value in subsequent periods were recorded to derivative income or expense.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Adoption of Newly Issued Accounting Pronouncements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, the FASB issued ASU No. 2017-09,
&ldquo;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&nbsp;(ASU 2017-09).&rdquo; ASU 2017-09
clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification
accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15,
2017, with early adoption permitted. In the quarter ended March 31, 2018, the Company adopted this pronouncement, the impact
of which was immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-01, &ldquo;Business
Combinations (Topic 805) Clarifying the Definition of a Business.&rdquo; The amendment clarifies the definition of a business,
which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets
or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance
is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively
for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods.
Early adoption is permitted. As of the quarter ended June 30, 2018, the pronouncement does not apply to the Company, however, if
Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business
combination or an asset purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-04, &ldquo;Intangibles
- Goodwill and Other (Topic 350).&rdquo; The amendment simplifies the subsequent measurement of goodwill by removing the second
step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test
by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount
by which the carrying amount exceeds the reporting unit&rsquo;s fair value; however, the loss recognized should not exceed the
total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment
for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective
basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal
years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1,
2017. The Company early adopted this standard in fiscal 2018. There was no impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements, Not Adopted as
of June 30, 2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">From March 2016 through
December 2016, the Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) issued ASU 2016-20, ASU 2016-12, ASU 2016-11,
ASU 2016-10 and ASU 2016-08. These updates all clarify aspects of the guidance in ASU 2014-09, Revenue from Contracts with Customers
(Topic 606), which represents comprehensive reform to revenue recognition principals related to customer contracts. The effective
date of these updates for the Company is July 1, 2018. Adoption of this ASU is either full retrospective to each prior period presented
or modified retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We finalized our assessment
of the new standard and will be adopting using the modified retrospective method as we have concluded that the impact of adopting
the new standard is not significant as it relates to historical revenues, future revenues, or accounting for incremental costs
of obtaining a contract with a customer. Going forward we will need to have disclosures de-segregating revenue to comply with this
standard. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We have analyzed the five-steps
for each type of contract with our customers and concluded that: (1) The new guidance will not change our existing policy and practice
for identifying contracts with customers, nor give rise to changes to our existing policy and practice or create new concern surrounding
the collectability of our receivables from customers, (2) none of our contracts with customers contain multiple performance obligations
that are not fulfilled at the same time, and (3) the new guidance will not change our existing policy and practice regarding the
recording of variable consideration. Our financial reporting process will remain essentially unchanged. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Additionally, Subtopic
340-40 requires the capitalization of all incremental costs that we incur to obtain a contract with a customer that would not have
been incurred if the contract had not been obtained, provided we expect to recover those costs. We performed an analysis and noted
that there are no material customer acquisition costs that are incremental and that are expected to be recovered at a future time.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; background-color: white">The aforementioned
modified retrospective method of transition will not result in a cumulative adjustment as of July 1, 2018. Additionally, no other
line items in the statement of operations or the balance sheet will reflect any changes due to the adoption of the new standard.
Adoption of the standards related to revenue recognition had no material impact to cash from or used in operating, financing, or
investing on our consolidated cash flows statements. </FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">In June 2016, the FASB
issued ASU 2016-13, &ldquo;Financial Instruments &ndash; Credit Losses&rdquo; to require the measurement of expected credit losses
for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts.
The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected
credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.
The standard is effective for interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted
for interim and annual reporting periods beginning after December 15, 2018. The Company is currently assessing the impact that
ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued ASU 2016-02, &ldquo;Leases
(Topic 842).&rdquo; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a
lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance
or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective
for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective
transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of
the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018,
the FASB issued ASU 2018-10, &ldquo;Codification Improvements to Topic 842, Leases.&rdquo; The improvements in this amendment will
be effective at the same time as ASU 2016-02. Also, in July 2018, the FASB issued ASU 2018-11, &ldquo;Leases (Topic 842): Targeted
Improvements.&rdquo; The Board decided to provide another transition method, in addition to the existing transition method, by
allowing entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment
to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of its adoption
of these standards on its consolidated financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 &ndash; Going Concern </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As reflected in the accompanying
financial statements, for the year ended June 30, 2018, the Company had a net loss of $10.2 million and net cash used in
operations of $16.0 million. At June 30, 2018, Aytu had $7.1 million of cash, cash equivalents and restricted cash,
stockholders&rsquo; equity of $13.5 million and an accumulated deficit of $79.3 million. In addition, the Company is in the
early stage of commercialization and has not yet generated profits for the most recent four quarters ended June 30, 2018. We
used an average of $4.0 million of cash per quarter for operating activities. These factors raised substantial doubt about
the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Looking forward, we expect cash used in
operating activities to be in the range of historical amounts, and we expect our revenue to increase. We also expect to raise new
capital if and when needed. Therefore, it is uncertain as to whether the Company is sufficiently capitalized. Since the Company
does not have a cash balance as of June 30, 2018, sufficient to cover potential operating losses for the twelve months following
the expected filing date of this Annual Report, ASU 2014-15, Presentation of Financial Statements&mdash;Going Concern (Subtopic
205-40) requires us to report that there is an indication that substantial doubt about the Company&rsquo;s ability to continue
as a going concern exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ability of the Company to continue its operations is dependent
on management&rsquo;s plans, which include continuing to build on the historical growth trajectory of Natesto, launching the recently
licensed ZolpiMist product, seeking to acquire cash generating assets and if needed, accessing the capital markets through the
sale of our securities. Based on our ability to raise capital in the past as well as our continued growth, the Company believes
additional financing will be available and will continue to be available to support the current level of operations for at least
the next 12 months from the date of this report. There can be no assurance, however, that such financing will be available on terms
which are favorable to the Company, or at all.&nbsp;While Company management believes that its plan to fund ongoing operations
will be successful, there is uncertainty due to the Company&rsquo;s limited operating history and therefore no assurance that its
plan will be successfully realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared on
a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification
of the liabilities that might be necessary should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &ndash; Fair Value Considerations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of financial instruments, including cash
and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate
their fair value due to their short maturities. The fair value of the warrant derivative liability was valued using the lattice
valuation methodology. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash
flows and assessment of the probability of occurrence of potential future events. The valuation policies are determined by the
Chief Financial Officer and approved by the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authoritative guidance defines fair value as the price that
would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants
at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of
observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data
obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&rsquo;s assumptions of what market
participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
The hierarchy is broken down into three levels based on reliability of the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; width: 8%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Level&nbsp;1:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Level&nbsp;2:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</FONT></TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Level&nbsp;3:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">Unobservable inputs that are supported by little or no market activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu&rsquo;s assets and liabilities which are measured at fair
value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.
Aytu&rsquo;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change
in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents Aytu&rsquo;s financial liabilities
that were accounted for at fair value on a recurring basis as of June 30, 2018 and 2017, by level within the fair value hierarchy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Fair Value Measurements Using</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 1</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 2</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 3</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-decoration: underline; font-size: 10pt">June 30, 2018</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">LIABILITIES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 52%; text-align: left; font-size: 10pt">Warrant derivative liability</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">94,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">94,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Contingent consideration</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">4,694,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">4,694,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-decoration: underline; font-size: 10pt">June 30, 2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">LIABILITIES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Warrant derivative liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Contingent consideration</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">7,648,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">7,648,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrant derivative liability was valued using the lattice valuation methodology because that model
embodies the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative
liability are not actively traded and are, therefore, classified as Level 3 liabilities. Significant assumptions in valuing the
warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants,
were as follows as of issuance and as of June 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30, <BR>
2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">At Issuance</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-decoration: underline; font-size: 10pt">Warrants:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-indent: 20pt; font-size: 10pt">Volatility</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">173.4</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">188.0</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt">Equivalent term (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4.13</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">5.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt">Risk-free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2.69</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1.83</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: 20pt; font-size: 10pt">Dividend yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">0.00</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">0.00</TD><TD STYLE="text-align: left; font-size: 10pt">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth a reconciliation of changes in
the warrant derivative liability for the period ended June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Derivative Instruments</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; font-size: 10pt">Balance as of June 30, 2016</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">276,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant issuances</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Change in fair value included in earnings (February 28, 2017)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(213,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Reclassification of warrant from liability to equity upon amendment</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(63,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">Balance as of June 30, 2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant issuances</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,118,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant exercises</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(40,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Change in fair value included in earnings</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(3,984,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">94,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We classify our contingent consideration liability in connection with the acquisition of ProstaScint,
Natesto, ZolpiMist and the merger with Nuelle within Level 3 as factors used to develop the estimated fair value are unobservable
inputs that are not supported by market activity. We estimate the fair value of our contingent consideration liability based on
contractual payment obligations, discount rates, probabilities of payment, and expected future performance. Contingent payment
amounts are discounted back to the current period using a discounted cash flow methodology. The contingent consideration related
to the AWH assets was prepaid up to the first $1.0 million in net revenue. Since we will not be able to manufacture more product
(see Note 1), we will not generate any additional revenue. Therefore, we will not exceed $1.0 million and thus, we have adjusted
the remaining contingent consideration balance to zero. This adjustment is reflected in Other Gain on the Consolidated Statement
of Operations. We also reduced the contingent consideration for ProstaScint by $57,000 to reflect that product&rsquo;s abandonment.
As of June 30, 2018, the value for the contingent consideration was adjusted to $0 based upon the abandonment of ProstaScint in
June 2018. Also, as of June 30, 2018, the contingent consideration related to Natesto was revalued at $1.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth a summary of changes in the contingent
consideration for the period ended June 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Contingent Consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 88%; font-size: 10pt">Balance as of June 30, 2016</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">3,869,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to purchase of assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,927,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">306,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to remeasurement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,256,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to impairment</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(710,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">Balance as of June 30, 2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">7,648,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to purchase of assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,846,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">801,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Decrease due to contractual payment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(266,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to remeasurement</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(6,335,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">4,694,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was valued using the Monte-Carlo
valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments.
Contingent consideration is not actively traded and therefore classified as Level 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &ndash; Income Taxes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously discussed in Note 2 - Summary of Significant Accounting
Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ending on or before December 31,
2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company&rsquo;s
taxes have been computed and reported on a &ldquo;separate return&rdquo; basis. Ampio and Aytu did not have a tax sharing agreement
for the consolidated return periods. Accordingly, certain tax attributes, e.g. net operating loss carryforwards, reflected in these
financial statements, may or may not be available to Aytu. In January 2016, Ampio&rsquo;s ownership interest in Aytu fell below 80% so
that Aytu will no longer be included in the Ampio consolidated tax return. The deconsolidation resulted in approximately $4.5 million
of net operating loss carryforwards originating prior to the incorporation of Vyrix and Luoxis no longer being available to Aytu.
Upon deconsolidation, the deferred tax asset and related valuation allowance for these pre-incorporation net operating losses have
been removed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 6.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 10pt">Income tax benefit resulting from applying statutory rates in jurisdictions
in which Aytu is taxed (Federal and various states) differs from the income tax provision (benefit) in the Aytu financial statements.
The following table reflects the reconciliation for the respective periods.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Benefit at statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(2,807,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-27.55</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(7,653,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-34.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(585,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-5.74</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(681,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-3.03</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.22</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.52</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.90</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(465,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-4.56</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.02</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in taxrate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0.30</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0.05</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Remeasurement of deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,648,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65.25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of phased-in taxrate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">891,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.75</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,745,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-26.94</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,922,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35.20</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Derivative income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,029,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-10.10</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">101,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.97</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.44</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net income tax provision (benefit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Deferred income taxes arise from temporary differences in the recognition of certain items for income
tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred
tax assets &#9;and liabilities are as follows for the respective periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets (liabilities):</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in">Deferred rent</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Net operating loss carry forward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,458,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,435,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Intangibles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">651,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,559,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,044,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,362,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Unrealized loss on investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Capital loss carry forward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">385,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Contribution carry forward</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Allowance for doubtful accounts</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total deferred income tax assets (liabilities)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,718,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,369,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,718,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19,369,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total deferred income tax assets (liabilities)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In assessing the realizability of deferred tax assets, management
considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate
realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary
differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable
income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than
not it will realize the benefits of these deductible differences, net of the valuation allowance provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has federal net operating losses of approximately
$59.3 million and $42.3 million as of June 30, 2018 and June 30, 2017, respectively that, subject to limitation, may be available
in future tax years to offset taxable income. The available federal net operating losses, if not utilized to offset taxable income
in future periods, will begin to expire in 2031 through 2037. The Company has state net operating losses of approximately $50.3
million and $32.8 million as of June 30, 2018 and June 30, 2017, respectively that, subject to limitation, may be available in
future tax years to offset taxable income. The available state net operating losses, if not utilized to offset taxable income in
future periods, will begin to expire in 2025 through 2037. Under the provisions of the Internal Revenue Code, substantial changes
in the Company&rsquo;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. Net
operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which
they are generated has been closed by statute. The amount &#9;subject to disallowance is limited to the NOL utilized. Accordingly,
the Company may be subject to examination for prior NOLs generated as such NOLs are utilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2018, and 2017, the Company has no
liability for gross unrecognized tax benefits or related interest and penalties. Aytu has made its best estimates of certain
income tax amounts included in the financial statements. Application of the Company&rsquo;s accounting policies and estimates,
however, involves the exercise of judgement and use of assumptions as to future uncertainties and, as a result, could differ
from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or
assumptions have been in the past, how much the estimates or assumptions have changed and how likely such changes may have a
material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of
limitations, the Company would not be subject to federal or Colorado income tax examinations for tax years prior to 2014 and
2013, respectively. However, given the net operating losses generated since inception, all tax years since inception are
subject to examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 10pt">On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the &ldquo;Tax Reform
Act&rdquo;) was signed into law by the President of the United States. The Tax Reform Act significantly revised the U.S. corporate
income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. GAAP
requires that the impact of tax legislation be recognized in the period in which the law was enacted. As a result of the Tax Reform
Act, the Company recorded a tax expense of $6.6 million due to a re-measurement of deferred tax assets and liabilities at a blended
rate in the three months ended December 31, 2017, which is fully offset by a reduction in valuation allowance. The Company recorded
additional tax expense of $0.1 million related to re- measurement of deferred tax assets and liabilities in the three months ended
March 31, 2018. The tax expense is a provisional amount and the Company&rsquo;s current best estimate. Any adjustments recorded to the
provisional amounts will be included in income from operations as an adjustment to tax expense, net of any related valuation allowance.
The provisional amount incorporates assumptions made based upon the Company&rsquo;s current interpretation of the Tax Reform Act and
may change as the Company receives additional clarification and implementation guidance.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 &ndash; Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commitments and contingencies are described below and summarized
by the following table as of June&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 23%; text-align: left; font-size: 10pt">Prescription database</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">774,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">774,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 8%; text-align: right; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">Natesto</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,500,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">2,500,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Supply order</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">167,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">167,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Office lease</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">258,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">122,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">109,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">27,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,699,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,063,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">109,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">27,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">2,500,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Prescription Database</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2016, Aytu entered into an agreement with a vendor that
will provide Aytu with prescription database information. Aytu agreed to pay approximately $1.9 million over three years for access
to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Natesto</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, the Company entered into an agreement with Acerus,
whereby Aytu is required to make milestone payments to Acerus. The first milestone payment of $2.5 million must be paid even if
the milestone is not reached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Supply Order</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, Aytu submitted a purchase order for 45,000 units
of ZolpiMist, which are expected to arrive in fiscal 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Office Lease </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2015, Aytu entered into a 37-month operating lease for
office space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term
of the lease of approximately $112,000. In June 2018, the Company entered into a 12-month operating lease, beginning on August
1, 2018, for a new office space in Raleigh. This lease has base rent of $1,100 a month, with total rent over the term of the lease
of approximately $13,200. In September 2015, the Company entered into a 37-month operating lease in Englewood, Colorado. This lease
has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000. In October
2017, the Company signed an amendment to the 37-month operating lease in Englewood, Colorado. The amendment extended the lease
for an additional 24 months beginning October 1, 2018. The base rent will remain at $9,000 a month. The Company recognizes rent
expense on a straight-line basis over the term of each lease. Differences between the straight-line net expenses on rent payments
are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods
was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="width: 76%; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Rent expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">142,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">139,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &ndash; Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Capital Stock </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2018 and June 30, 2017, Aytu had 1,794,762 and 41,244
common shares outstanding, respectively, and no preferred shares outstanding. The Company has 100&nbsp;million shares of common
stock authorized with a par value of $0.0001&nbsp;per share and 50&nbsp;million shares of preferred stock authorized with a par
value of $0.0001 per share, of which 500 were designated Series A Convertible Preferred Stock and 161 were designated as Series
B Convertible Preferred Stock. Included in the common stock outstanding are 38,738 shares of restricted stock granted to executives,
directors, employees and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we entered into a purchase agreement (the &ldquo;Purchase
Agreement&rdquo;), together with a registration rights agreement (the &ldquo;Registration Rights Agreement&rdquo;),
with Lincoln Park Capital Fund, LLC (&ldquo;Lincoln Park&rdquo;). Upon signing the Purchase Agreement, Lincoln Park
agreed to purchase 335 shares of our common stock for $500,000 as an initial purchase under the agreement. We also issued as a
commitment fee to Lincoln Park of 131 shares of common stock. Between September 2016 and June 2017, Lincoln Park purchased an additional
500 shares for $240,000, the issuance costs related to these purchases totaled $91,000, resulting in net proceeds of $649,000.
We terminated the Purchase Agreement effective August 16, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we issued 2,500 shares of restricted stock as
compensation to certain executive officers and directors, which vest in July 2026. This expense is included in sales, general and
administrative. For the year ended June 30, 2017, the expense was $725,000. The original fair value of the restricted stock was
$3.2 million. As of June 30, 2017, the remaining unrecognized expense is $2.5 million. During fiscal 2017, one of the Company&rsquo;s
executive officers resigned and his restricted stock vested in full upon this event. This resulted in the Company recognizing the
remainder of the expense related to this executive&rsquo;s restricted stock grant of $430,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2016, we issued an aggregate of 357 shares of common
stock as bonuses for performance in 2016 to three executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November 2016, we raised gross proceeds of approximately
$8.6 million through a public offering of 14,338 Units. Offering costs totaled $1.0 million resulting in net cash proceeds of $7.6
million. We also issued underwriter warrants in connection with the offering with a fair value of $293,000, resulting in net proceeds
of $7.3 million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock.
The common stock issued had a relative fair value of $3.7 million and a fair value of $4.4 million. The investor warrants have
an exercise price of $744.00 per share and will expire five years from the date of issuance. These investor warrants have a relative
fair value of $3.5 million and a fair value of $4.2 million. We also granted the underwriters a 45-day option (the Over-Allotment
Option) to purchase up to an additional 2,151 shares of common stock and/or warrants. The underwriters purchased 714 of this Over-Allotment
Option for the warrants and paid $4.00 per over-allotment warrant. These warrants have the same terms as the warrants sold in the
registered offering. These warrants have a relative fair value of $173,000, a fair value of $208,000, and proceeds of $3,000, which
was the purchase price per the underwriting agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2017, the Company consummated its warrant tender
offer to exercise, at a temporarily reduced exercise price of $300.00 per share, (i) outstanding warrants to purchase 4,334 shares
of common stock with an exercise price of $2,400.00 per share, which were originally issued to investors in the Company&rsquo;s
May 2016 financing (the &ldquo;May 2016 Warrants&rdquo;), and (ii) outstanding warrants to purchase 15,051 shares of common stock
with an exercise price of $744.00 per share, which were originally issued to investors in the Company&rsquo;s October 2016 financing
(the &ldquo;October 2016 Warrants&rdquo; and together with the May 2016 Warrants, the &ldquo;Original Warrants&rdquo;). Original
warrants to purchase an aggregate of 7,477 shares of common stock were tendered and exercised in the warrant tender offer, for
aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not tendered and exercised remain
in effect at the pre-tender offer exercise prices of $2,400.00 per share and $744.00 per share, respectively (see Note 11).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, we entered into a Merger Agreement with Nuelle,
Inc. and its stockholders, pursuant to which Nuelle would become our wholly owned subsidiary (the &ldquo;Merger&rdquo;). The Merger
closed on May 5, 2017. As part of the Merger, we issued to the Nuelle preferred stockholders an aggregate of 6,250 shares of our
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2017, we entered into a Securities Purchase Agreement
with various accredited investors pursuant to which, upon closing on August 15, 2017, we sold Class A and Class B equity units
for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase
one and one-half (1.5) shares of common stock and were sold at a price of $60.00 per unit. Class B units consist of one (1) share
of our newly created Series A Preferred Stock and warrants to purchase one and one-half (1.5) shares of common stock for each share
of common stock into which the Series A Preferred Stock is convertible and were sold at a price of $20,000.00 per unit to those
purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding
common stock following the offering. These Series A Preferred stock were convertible into common shares at $60.00 per common share,
or an aggregate of 37,500 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the offering, we issued an aggregate of 159,834 shares of
our common stock, 113 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 315,755 shares of our common
stock, which included 19,749 warrants issued to the placement agents as compensation for the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incurred certain expenses related to this transaction to
attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in
the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the closing of the financing, we terminated
the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective
on August 16, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2017, Aytu issued 151 shares of common stock in
connection with the Nuelle earn-out (see Note 1). In October 2017, we made a $238,000 prepayment in Aytu common stock, which represented
the revenue earn-out payment for the remaining balance due on the first $1.0 million in net revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2017, investors holding Aytu Series A Preferred shares
exercised their right to convert 18 Aytu Series A Preferred shares into 5,834 shares of Aytu common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2018, investors holding Aytu Series A Preferred
shares exercised their right to convert 95 Aytu Series A Preferred shares into 31,667 shares of Aytu common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 6, 2018, Aytu completed an underwritten public offering
for total gross proceeds of $12 million, before deducting cash offering costs inclusive of underwriting discounts, commissions
and other offering expenses totaling $1.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities sold by the Company consist of (i) Class A Units
consisting of an aggregate of 976,000 shares of our common stock and warrants to purchase an aggregate of 976,000 shares of common
stock, at a public offering price of $9.00 per Class A Unit, and (ii) Class B Units consisting of 161 shares of our Series B Preferred
Stock, with a stated value of $20,000 per share, and convertible into an aggregate of 357,356 shares of common stock, and warrants
to purchase an aggregate of 357,356 shares of common stock, at a public offering price of $20,000 per Class B Unit. The warrants
have an exercise price of $10.80, are exercisable upon issuance and will expire five years from the date of issuance. The Company
granted the underwriters a 45-day option to purchase an additional 200,000 shares of common stock and/or warrants to purchase an
additional 200,000 shares of common stock. In connection with the closing of this offering, the underwriters partially exercised
their over-allotment option and purchased an additional 200,000 warrants. On March 26, 2018, the underwriters exercised their over-allotment
option to purchase an additional 100,000 shares of common stock, resulting in gross proceeds of approximately $900,000, before
deducting costs of $63,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2018, investors holding Aytu Series B Preferred shares
exercised their right to convert 161 Aytu Series B Preferred shares into 357,356 shares of Aytu common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In fiscal 2018, warrants issued from the registered offerings
to purchase an aggregate of 80,750 shares of common stock were exercised for aggregate gross proceeds to our Company of approximately
$677,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Equity Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June&nbsp;1, 2015, Aytu&rsquo;s stockholders approved the
2015 Stock Option and Incentive Plan (the &ldquo;2015 Plan&rdquo;), which, as amended in July 2017, provides for the award of stock
options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common
stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied
without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back
to the shares of common stock available for issuance under the 2015 Plan. As of June 30, 2018, we have 2,961,055 shares that are
available for grant under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the 2015 Stock Plan, 3.0 million shares of its common
stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model.
In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including
the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected
option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based
on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity. There&rsquo;s no issuances during the year
ended June 30, 2018, therefore, no assumptions are used for fiscal 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used for the year ended June 30, 2017, as none were issued in fiscal 2018, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Year Ended</P>
                                                                           <P STYLE="margin-top: 0; margin-bottom: 0">June&nbsp;30,</P></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 84%; text-align: left; font-size: 10pt">Expected volatility</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; font-size: 10pt">178% - 185%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Risk free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">0.97% - 1.88%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Expected term (years)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">5.0 - 6.5</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Dividend yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">0%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock option activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of<BR>
 Options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR>
 Average<BR>
 Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Weighted</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Average<BR> Remaining&nbsp;Contractual<BR> Life in Years</P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Outstanding June 30, 2016</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">829</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,204.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">364.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(75</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,664.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,292.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Outstanding June 30, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">326.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(129</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">328.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">328.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,798</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">325.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercisable at June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">325.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.69</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Available for grant at June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,961,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table details the options outstanding at June
30, 2018 by range of exercise prices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Range of Exercise Prices</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of<BR>
 Options<BR>
 Outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR>
 Average<BR>
 Exercise<BR>
 Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR>
 Average<BR>
 Remaining<BR>
 Contractual<BR>
 Life of<BR>
 Options<BR>
 Outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of<BR>
 Options<BR>
 Exercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR>
 Average<BR>
 Exercise<BR>
 Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">280.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">76</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">280.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">8.85</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">76</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">280.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">328.00</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,722</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">328.00</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">6.86</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,299</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">328.00</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,798</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">325.97</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">6.95</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,375</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">325.35</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2017, Aytu issued 10,000 shares of restricted stock
to employees pursuant to the 2015 Plan, which vest in September 2027. In November 2017, 150 of these restricted shares were cancelled.
Also, in November 2017, Aytu issued 24,750 shares of restricted stock to executives, directors and consultants pursuant to the
2015 Plan, which vest in November 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2018, Aytu issued 3,750 shares of restricted stock
to an officer pursuant to the 2015 Plan, which vest in January 2028. In March 2018, Aytu issued 650 shares of restricted stock
to employees pursuant to the 2015 Plan, which vest in March 2028. During the three months ended March 31, 2018, 650 shares of restricted
stock were cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2018, we modified 2,000 shares of restricted stock
for accelerated vesting and recognized an increase in aggregate stock compensation expense of $14,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted stock activity is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Number of <BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted <BR> Average Grant <BR> Date Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average <BR> Remaining <BR> Contractual Life in <BR> Years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">Unvested at June 30, 2017</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="width: 64%; font-size: 10pt">Granted</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">39,150</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">39.80</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">Vested</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(1,150</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">40.40</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">40.40</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; font-size: 10pt">Unvested at June 30, 2018</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">37,200</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right; font-size: 10pt">39.80</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: center; font-size: 10pt">9.4</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu previously issued 1,538 shares of restricted stock outside the Aytu BioScience 2015 Stock Option
and Inventive Plan, which vest in July 2026. The unrecognized expense related to these shares was $1,593,000 as of June 30, 2018
and will be recognized over the 10-year vesting period. During fiscal 2018, the expense related to these awards was $139,000. During
the quarter ended December 31, 2017, we modified 413 shares of restricted stock for accelerated vesting and recognized a reduction
in aggregate stock compensation expense of $36,000. During the quarter ended March 31, 2018, we modified 200 shares of restricted
stock for accelerated vesting and recognized a reduction in aggregate stock compensation expense of $37,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense related to the fair value of
stock options and restricted stock was included in the statements of operations as selling, general and administrative expenses
as set forth in the table below. Aytu determined the fair value of stock compensation as of the date of grant using the Black-Scholes
option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation
expense for the stock option and restricted stock issuances for fiscal 2018 and 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Sales, general and administrative:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt">Stock options</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">349,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">2,502,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Restricted stock</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">248,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">725,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">Total share-based compensation expense</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">597,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,227,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of&nbsp;June 30, 2018, there was&nbsp;$161,000 of total unrecognized option-based compensation expense
related to non-vested stock options. The Company expects to recognize this expense over a weighted-average period of 6.95 years.
As of June 30, 2018, there was $2,945,000 of total unrecognized share-based compensation expense related to the non-vested restricted
stock. The Company expects to recognize this expense over a weighted-average period of 8.63 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of all warrants is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Number of <BR> Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average Remaining Contractual Life in Years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 64%; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2016</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">5,538</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">2,480.40</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: center; font-size: 10pt">4.71</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Issuance of settlement warrants to initial investors</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">221</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">1,600.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants issued to investors in connection with the registered offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">15,051</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">744.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants issued to placement agents for the registered offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,009</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">300.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(7,477</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">300.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2017</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,342</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right; font-size: 10pt">1,005.80</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: center; font-size: 10pt">4.23</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued in connection with the August 2017 private offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">296,006</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">72.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued to underwriters in connection with the August 2017 private offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">19,749</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">72.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued in connection with the March 2018 public offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,533,356</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">10.80</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued to investor</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">100,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">10.80</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants expired</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(42</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">21,744.00</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(80,750</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">8.20</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2018</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,882,661</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right; font-size: 10pt">25.94</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: center; font-size: 10pt">4.61</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2017, Aytu issued warrants to purchase 221 shares
of common stock to initial investors of the Company at an exercise price of $1,600.00 and a term of five years from July 2016.
These warrants generated a non-cash expense of $596,000 for the year ended June 30, 2017, which is included in sales, general and
administrative expense. These warrants are accounted for under equity treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our November 2016 public offering, we issued
to the underwriters of the public offering warrants to purchase an aggregate of 1,009 shares of common stock at an exercise price
of $744.00 and a term of five years. These warrants are accounted for under equity treatment. In February 2017, we reduced the
exercise price of these warrants to $300.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Also, in connection with our November 2016 public offering,
we issued to investors warrants to purchase an aggregate of 15,051 shares of common stock, which includes the over-allotment warrants,
at an exercise price of $744.00 with a term of five years. These warrants are accounted for under equity treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2017, the Company consummated its warrant tender
offer to exercise, at a temporarily reduced exercise price of $300.00 per share, (i) outstanding warrants to purchase 4,334 shares
of common stock with an exercise price of $2,400.00 per share, which were originally issued to investors in the Company&rsquo;s
May 2016 financing (the &ldquo;May 2016 Warrants&rdquo;), and (ii) outstanding warrants to purchase 15,051 shares of common stock
with an exercise price of $744.00 per share, which were originally issued to investors in the Company&rsquo;s October 2016 financing
(the &ldquo;October 2016 Warrants&rdquo; and together with the May 2016 Warrants, the &ldquo;Original Warrants&rdquo;). Original
Warrants to purchase an aggregate of 7,477 shares of common stock were tendered and exercised in the warrant tender offer, for
aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not exercised remain in effect
at the pre-tender offer exercise prices of $2,400.00 per share and $744.00 per share, respectively. The incremental fair value,
which had no book impact, was $178,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company also reduced the exercise prices of an aggregate
of 1,288 warrants to purchase shares of common stock, which were originally issued as underwriters&rsquo; compensation in the May
2016 and October 2016 financings, from $2,400.00 per share and $744.00 per share, respectively, to $300.00 per share. The amended
warrants related to the May 2016 financing adjusted the accounting for these warrants from liability classification to equity.
The incremental fair value of these warrant modifications, which had no book impact, was $23,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our August 2017 private offering, we issued
warrants to purchase an aggregate of 315,755 shares of common stock at an exercise price of $72.00 and a term of five years to
investors and underwriters. The remaining outstanding warrants from that offering are accounted for using derivative liability
treatment (see Note 5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our March 2018 public offering,&nbsp;we issued
to investors and underwriters warrants to purchase an aggregate of 1,533,356 shares of common stock&nbsp;at an exercise price of
$10.80 with a term of five years from March 6, 2018. These warrants are accounted for under equity treatment. Of the 1,533,356
warrants issued in the March 2018 public offering, 5,750 were exercised in fiscal 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2018, Aytu BioScience, Inc. entered into a warrant
exercise agreement with an investor of the Company&rsquo;s outstanding warrants. Pursuant to the exercise agreement, the Company
agreed to reduce the exercise price of the investor&rsquo;s warrant to purchase 75,000 shares of the Company&rsquo;s common stock
from $72.00 to one cent less than the closing price on the last trading day prior to the exercise date; provided that the investor
exercised the warrant for cash by March 23, 2018, and the Company also agreed to issue the investor a new warrant to purchase 100,000
shares of the Company&rsquo;s common stock at an exercise price of $10.80 per share. In accordance with the exercise agreement,
the investor exercised the warrant and the Company received net proceeds of $615,000. The new warrant to purchase 100,000 shares
of the Company&rsquo;s common stock are accounted for under equity treatment and have a fair value of $179,000. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2018, the warrants we issued to the placement agent,
in connection with our private placement in 2013, expired. &nbsp;The 42 placement agent warrants have a term of five years from
the date of issuance and an exercise price of $21,744.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants related to the August Financing issued in fiscal
2018 were valued using the lattice option pricing model. These warrants were accounted for as liability warrants (see Note 5).
The warrants related to the March Financing in fiscal 2018 were valued using the Black Scholes pricing model and were accounted
for as equity warrants. In order to calculate the fair value of the warrants, certain assumptions were made, including the selling
price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and contractual
life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing
a weighted average of comparable published betas of peer companies. The risk-free interest rate is based on the U.S. Treasury yield
in effect at the time of the grant for treasury securities of similar maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant assumptions in valuing the warrants issued and modified
during the year ended June 30, 2018 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">Year Ended June 30,</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt">Expected volatility</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt">173.40% - 188.00%</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt">156.64% - 169.22%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt">Risk free interest rate</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt">1.83% - 2.69%</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt">1.63% - 1.87%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="text-align: left; white-space: nowrap; font-size: 10pt">Contractual term (years)</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt">4.13 - 5</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; font-size: 10pt">3.46 - 4.67</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="width: 76%; text-align: left; white-space: nowrap; font-size: 10pt">Dividend yield</TD><TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt">0%</TD><TD STYLE="width: 1%; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt">0%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Related Party Transactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Executive Stock Purchases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two Aytu executive officers, Joshua Disbrow and Jarrett Disbrow,
participated in the August 2017 offering. Each officer purchased 4,167 units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Three Aytu executive officers, Joshua Disbrow, Jarrett Disbrow
and David Green, participated in the March 2018 offering. Joshua Disbrow and Jarrett Disbrow each purchased 11,306 units. Mr. Green
purchased 3,330 units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Services Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2015, Aytu entered into an agreement with Ampio, whereby
Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff
and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016, July 2016, and again in January
2017 resulting in an amount of $12,000 per month. This agreement was terminated in June 2017. Ampio was the Company&rsquo;s largest
stockholder during part of this period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sponsored Research Agreement </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, Luoxis entered into a sponsored research agreement
with TRLLC, an entity controlled by Ampio&rsquo;s director and Chief Scientific Officer, Dr.&nbsp;Bar-Or. The agreement, which
was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related
to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000
which was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance
sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Co-Pay Support</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, the Company entered into a master services agreement
with TrialCard Incorporated (&ldquo;TCI&rdquo;), a vendor selected to support the Company sponsored co-pay program. In supporting
the program, TCI will make disbursements to qualified patients presenting valid prescriptions for Natesto and ZolpiMist on behalf
of Aytu. Disbursements will be based upon business rules determined by Aytu. The Company agreed to pay fees monthly to TCI for
account management, data analytics, implementation, and technology and to reimburse TCI for certain direct costs incurred by TCI
to support the Company&rsquo;s program. Expenses are expected to be approximately $19,000 per month based on volumes and performance
of our program. One of the Aytu directors, Mr. Donofrio, is an executive officer of TCI and has no direct interest in the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Segment Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Aytu manages our Company
and aggregated our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&rsquo;s
Health. The Aytu segment consists of our core male urology products. The Aytu Women&rsquo;s Health segment contains our women&rsquo;s
health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Consolidated revenue:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="width: 76%; padding-left: 9pt; font-size: 10pt">Aytu</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">3,417,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 9%; text-align: right; font-size: 10pt">3,175,000</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&rsquo;s Health</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">243,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">47,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">Consolidated revenue</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,660,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,222,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">Consolidated net loss:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-left: 9pt; font-size: 10pt">Aytu</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">(7,783,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">(22,349,000</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&rsquo;s Health</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(2,405,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(159,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font-size: 10pt">Consolidated net loss</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(10,188,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(22,508,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-left: 9pt; font-size: 10pt">Total assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="padding-left: 9pt; font-size: 10pt">Aytu</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">21,053,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">11,779,000</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&rsquo;s Health</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">7,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,220,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Total assets</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">21,060,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,999,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 11 &ndash; Employee Benefit Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu has a 401(k) plan that allows participants to contribute
a portion of their salary, subject to eligibility requirements and annual IRS limits. The Company matches 50% of the first 6% contributed
to the plan by employees. In fiscal 2018, the Company&rsquo;s match was $119,000.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 12 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 31, we made the second payment towards an asset purchase totaling $300,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors approved a reverse stock split in which
each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 10, 2018.
This adjustment is reflected in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August, the Aytu sales force began promotions of ZolpiMist
to U.S. clinicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 5, 2018, Aytu and Magna Pharmaceuticals, Inc. agreed to amend and restate the license agreement
effective as of June 11, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>f10k2018ex10-4_aytubio.htm
<DESCRIPTION>LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN THE REGISTRANT (AS ASSIGNED TO IT BY AMPIO/VYRIX) AND DAEWOONG PHARMACEUTICALS CO., LTD., EFFECTIVE AS OF AUGUST 23, 2011
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSE,
DEVELOPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND
COMMERCIALIZATION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><BR>
 BETWEEN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMPIO
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DAEWOONG
PHARMACEUTICALS CO., LTD</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 167.8pt 0pt 176.6pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LICENSE,
DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 167.8pt 0pt 176.6pt; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFINITIONS</FONT></TD>
    <TD STYLE="width: 5%; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LICENSES</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE OF KNOW-HOW</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MILESTONE PAYMENTS</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT; JOINT STEERING COMMITTEE</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEVELOPMENT</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGULATORY MATTERS</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMERCIALIZATION</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANUFACTURE AND SUPPLY; PAYMENT FOR PRODUCTS</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS, WARRANTIES AND COVENANTS; DISCLAIMER</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTELLECTUAL PROPERTY</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONFIDENTIALITY/PUBLICATIONS</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TERM AND TERMINATION</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EFFECTS OF TERMINATION OR EXPIRATION</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNOUNCEMENT</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOVERNING LAW</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISPUTE RESOLUTION</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICES</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORCE MAJEURE</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEMNIFICATION AND INSURANCE</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-ASSIGNABILITY</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LANGUAGE</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENTIRE AGREEMENT</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEPARABILITY</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEPENDENT CONTRACTORS; NO PARTNERSHIP</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMENDMENT AND WAIVER</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTERPARTS</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">THIS LICENSE, DEVELOPMENT
AND COMMERCIALIZATION AGREEMENT (this &ldquo;Agreement&rdquo;) is made and entered into on August 23, 2011 (the &ldquo;Effective
Date&rdquo;) by and between Ampio Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 5445
DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (&ldquo;Ampio&rdquo;), and Daewoong Pharmaceuticals Co., Ltd, having
its principal place of business at 163-3 Samsungdong, Kangnam-gu, Seoul, Republic of Korea (&ldquo;Daewoong&rdquo;). Each of Ampio
and Daewoong is sometimes referred to herein as a &ldquo;Party&rdquo; and collectively, as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">WHEREAS, Ampio has developed certain intellectual
property relating to the use of Tramadol for the treatment of premature ejaculation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">WHEREAS, Daewoong has substantial
expertise in the research, development, distribution, sales and marketing of pharmaceutical products in the Republic of Korea;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">WHEREAS, Ampio desires
to grant to Daewoong, and Daewoong desires to obtain from Ampio, the right to develop, market and sell products containing Tramadol
for certain indications in the Republic of Korea, all on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties hereto agree
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1 Definitions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.1 &ldquo;Affiliate&rdquo; means any corporation,
firm, partnership, limited liability company or other entity that controls, is controlled by or is under common control with a
Party to this Agreement. For purposes of this definition, any entity will be regarded as in &ldquo;control&rdquo; of another entity
if (a) it directly or indirectly owns more than fifty percent (50%) of the voting stock of the other entity or such lesser maximum
percentage permitted in those jurisdictions where majority ownership by foreign entities is prohibited, (b) it owns or has a right
to own more than fifty percent (50%) of the net assets of an entity without voting securities, or (c) it possesses, directly or
indirectly, the power to direct or cause the direction of the management and policies of the entity, whether through contract or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.2 &ldquo;Ampio&rdquo; means
Ampio Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.3 &ldquo;Ampio Know-How&rdquo; means
all Information that is Controlled by Ampio or its Affiliates as of the Effective Date or during the Term and is necessary or
useful for the Development, Manufacture or Commercialization of the Product in the Field in accordance with the terms of this
Agreement. For clarity, Ampio Know-How excludes Information claimed in any Ampio Patent. For avoidance of doubt, Ampio
Know-How shall exclude the Information of any Third Party that becomes an Acquiror of Ampio, except for any Information
included within the definition of &ldquo;Ampio Know-How&rdquo; that is developed by such Acquiror after the closing of such
acquisition in the course of conducting activities on behalf of Ampio under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.4 &ldquo;Ampio Licensee&rdquo; means licensees
of Tramadol and/or Products outside the Territory during the Term of this Agreement, under any Ampio Patents (both inside and outside
the Territory), Ampio Know-How or Ampio Regulatory Documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.5 &ldquo;Ampio Patents&rdquo;
means any Patent that (a) is Controlled by Ampio or its Affiliates as of the Effective Date or at any time during the Term, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(b) claims the composition of matter, use or Manufacture
of a Product in the Field. A list of Ampio Patents in existence as of the Effective Date is attached hereto as Exhibit 1.5, and
Ampio shall update such list from time to time to include additional Ampio Patents, including patents issuing from any listed application
or claiming priority thereto or otherwise continuing therefrom. For the avoidance of doubt, Ampio Patents shall include Product
Patents (as defined in Section 11.1), and shall exclude the Daewoong Patents and the Patents of any Third Party that becomes an
Acquiror of Ampio, except for (i) any Patents claiming inventions that are included within the definition of an &ldquo;Ampio Patent&rdquo;
that are developed by such Acquiror in the course of conducting activities on behalf of Ampio under this Agreement, or (ii) any
Patents Controlled by such Acquiror at the closing of the acquisition of Ampio that claim the composition, use or manufacture of
the Product as in existence as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.6 &ldquo;Ampio Technology&rdquo;
means the Ampio Patents and Ampio Know-How.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.7 &ldquo;CMC&rdquo; means
chemistry, manufacturing and controls as specified by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.8 &ldquo;Combination Product&rdquo;
means a Product that includes Tramadol and a PDE5 inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.9 &ldquo;Commercially Reasonable Efforts&rdquo;
means those efforts consistent with the exercise of prudent scientific and business judgment in an active and ongoing program as
applied by a Party to the development and commercialization of its own pharmaceutical products at a similar stage of development
and with similar market potential. Commercially Reasonable Efforts requires that a Party, at a minimum, assigns responsibility
for such obligations to qualified employees, sets annual goals and objectives for carrying out such obligations, and allocates
resources designed to meet such goals and objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.10 &ldquo;Commercialization&rdquo; with a correlative
meaning for &ldquo;Commercialize&rdquo; and &ldquo;Commercializing&rdquo;, means all activities undertaken before and after obtaining
Regulatory Approvals relating specifically to the pre-launch, launch, promotion, detailing, medical education and medical liaison
activities, marketing, pricing, reimbursement, sale, and distribution of the Products, including: (a) strategic marketing, sales
force detailing, advertising, medical education and liaison, and market and Product support; (b) any postmarketing clinical studies
for use in generating data to be submitted to Regulatory Authorities (and all associated reporting requirements); and (c) all customer
support, Product distribution, invoicing and sales activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.11 &ldquo;Confidential Information&rdquo; means,
with respect to a Party, all reports and other Information of such Party that is disclosed to the other Party under this Agreement,
whether in oral, written, graphic, electronic or other form. All Information disclosed by either Party pursuant to the Mutual Confidentiality
Agreement between the Parties dated December 8, 2010 (the &ldquo;Mutual CDA&rdquo;), shall be deemed to be such Party&rsquo;s Confidential
Information disclosed hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.12 &ldquo;Control&rdquo; means, with respect
to any material, Information, or intellectual property right, that a Party owns or has a license to such material, Information,
or intellectual property right and, in each case, has the ability to grant to the other Party access, a license, or a sublicense
(as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing
agreement or other arrangement with any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">1.13 &ldquo;Develop&rdquo;
or &ldquo;Development&rdquo; means all activities relating to preparing and conducting preclinical testing, toxicology testing,
human clinical studies, and regulatory activities (e.g., regulatory applications) with respect to the Product, together with the
manufacturing of the Product for the purpose of conducting the foregoing activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.14 &ldquo;Development Costs&rdquo; means the
internal costs and out-of-pocket costs incurred as an expense by or on behalf of a Party or its Affiliates in carrying out the
Development of the Product in accordance with the approved Development Plan, including, without limitation, (i) the costs of clinical
trials (including costs of procuring the Product(s), placebos and comparator drugs used in such clinical trials), (ii) filing fees
and other costs associated with any Regulatory Filings; (iii) costs related to manufacturing development; and (iv) all other costs
that are directly attributable and reasonably allocable to the Development activities for the Products. For purposes of this definition:
(a) out-of-pocket costs mean the actual expense incurred with respect to a Third Party for specific Development activities relating
to the Products; and (b) internal costs means the applicable FTE rate multiplied by the number of FTE hours expended in carrying
out the Development activities in accordance with the Development Plan. For clarity, the costs associated with attending or participating
in meetings of the JSC are expressly excluded from this definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.15 &ldquo;Dollar&rdquo; means
a U.S. dollar, and &ldquo;$&rdquo; shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.16 &ldquo;Daewoong&rdquo;
means Daewoong Pharmaceuticals Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.17 &ldquo;Daewoong Know-How&rdquo; means
all Information that (a) is Controlled by Daewoong or its Affiliates as of the Effective Date and applied or used in connection
with the Development, Manufacture or Commercialization by Daewoong of the Product, or (b) arises from Daewoong&rsquo;s activities
under this Agreement, but excluding any and all Product Inventions (as defined in Section 11.1). For clarity, Daewoong Know-How
excludes Information claimed in any Daewoong Patent. For the avoidance of doubt, Daewoong Know-How shall exclude the Information
of any Third Party that becomes an Acquiror of Daewoong, except for any Information included within the definition of &ldquo;Daewoong
Know-How&rdquo; that is developed by such Acquiror after the closing of such acquisition in the course of conducting activities
on behalf of Daewoong under this Agreement.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.18 &ldquo;Daewoong Patent&rdquo; means any
Patent that (a) is Controlled by Daewoong or its Affiliates as of the Effective Date and applied or used in connection with the
Development, Manufacture or Commercialization by Daewoong of the Product hereunder, or (b) claims any inventions made by Daewoong,
other than the Product Inventions (as defined in Section 11.1), in the course of conducting its activities under this Agreement.
A list of the Daewoong Patents in existence as of the Effective Date, if any, is as attached hereto as Exhibit 1.18, and Daewoong
shall update such list from time to time to include additional Daewoong Patents, including patents issuing from any listed application
or claiming priority thereto or otherwise continuing therefrom. For the avoidance of doubt, Daewoong Patents shall exclude the
Patents of any Third Party that becomes an Acquiror of Daewoong, except for (i) any Patents claiming inventions that are included
within the definition of a &ldquo;Daewoong Patent&rdquo; that are developed by such Acquiror in the course of conducting activities
on behalf of Daewoong under this Agreement, or (ii) any Patents Controlled by such Acquiror at the closing of the acquisition of
Daewoong that claim the composition, use or manufacture of the Product as in existence as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.19 &ldquo;Daewoong Technology&rdquo;
means the Daewoong Patents and Daewoong Know-How.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.20 &ldquo;FDA&rdquo; means
the United States Food and Drug Administration and any successors thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.21 &ldquo;Field&rdquo; means
the treatment of premature ejaculation and/or erectile dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.22 &ldquo;Finish&rdquo; means
to label and package vials or other containers of a Product suitable for distribution to final users.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.23 &ldquo;First Commercial Sale&rdquo; means
the first sale to a Third Party of a Product in a given regulatory jurisdiction after Regulatory Approval has been obtained in
such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.24 &ldquo;Governmental Authority&rdquo; means
any multi-national, federal, state, local, municipal, provincial or other government authority of any nature (including any governmental
division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.25 &ldquo;Information&rdquo; means any
data, results, technology, business information and information of any type whatsoever, in any tangible or intangible form, including,
without limitation, know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications,
formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), software, algorithms,
marketing reports, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, toxicological,
preclinical and clinical test data), analytical and quality control data, stability data, other study data and procedures.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.26 &ldquo;Laws&rdquo; means all laws, statutes,
rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state,
provincial, county, city or other political subdivision, domestic or foreign, including any regulatory agency policy or informal
regulatory agency guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.27 &ldquo;Manufacture&rdquo; with a correlative
meaning for &ldquo;Manufacturing,&rdquo; means all activities related to the manufacturing of a pharmaceutical product, or any
ingredient thereof, including manufacturing Product in finished form for Development, manufacturing finished Product for Commercialization,
packaging, in-process and finished Product testing, release of Product or any component or ingredient thereof, quality assurance
activities related to manufacturing and release of Product, ongoing stability tests and regulatory activities related to any of
the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.28 &ldquo;Net Sales&rdquo; means the gross sales
price for the Product invoiced by Daewoong or any of its Affiliates or Sublicensees to Third Party customers for sales or other
transfers or dispositions for consideration of a Product, less (i) documented discounts (including customary trade, quantity, cash
and patient discount programs discounts), retroactive price reductions, charge-back payments and rebates granted to managed health
care organizations or to federal, state and local governments, their agencies, and purchasers and reimbursers or to trade customers;
(ii) credits for returns, such as unrecoverable damaged goods or rejections and including Product returned in connection with recalls
or withdrawals; (iii) transportation charges including insurance; and (iv) any value added taxes or governmental charges, including
custom duties, levied on the sale of the Product. Net Sales shall not include any payments among Daewoong, its Affiliates and Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.29 &ldquo;Patent&rdquo; means (a) pending patent
applications (and patents issuing therefrom), issued patents, utility models and designs; and (b) reissues, substitutions, confirmations,
registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations- in-part,
or divisions of or to any patents, patent applications, utility models or designs, in each case being enforceable within the applicable
territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.30 &ldquo;Product&rdquo; means any formulation
that includes Tramadol that is suitable for use in the Field. Product includes, without limitation, Combination Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.31 &ldquo;Regulatory Approval&rdquo; means,
with respect to a Product in any country or jurisdiction, all approvals (including, where required, pricing and reimbursement
approvals), registrations, licenses or authorizations from the relevant Regulatory Authority in a country or jurisdiction that
is specific to Product and necessary to market and sell such Product in such country or jurisdiction.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.32 &ldquo;Regulatory Authority&rdquo;
means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting
Regulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement
approval of a Product in such country or regulatory jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.33 &ldquo;Regulatory Documentation&rdquo; means
all Regulatory Filings, registrations, filings, applications, licenses, authorizations and approvals (including Regulatory Approvals),
all correspondence submitted to or received from Regulatory Authorities (including minutes and official contact reports relating
to any communications with any Regulatory Authorities), and all clinical studies, data and supporting documents contained therein,
in each case relating to Tramadol or the Products, and all data contained in any of the foregoing (including advertising and promotional
and marketing documents, adverse event files, PSURs, medical event reports, compliant files and the like).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.34 &ldquo;Regulatory Filings&rdquo; means, with
respect to the Products, any submission to a Regulatory Authority of any appropriate regulatory application specific to Products,
and shall include, without limitation, any submission to a regulatory advisory board and any supplement or amendment thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.35 &ldquo;Retained Territory&rdquo;
means all countries and territories in the world other than the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.36 &ldquo;Territory&rdquo;
means the Republic of Korea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.37 &ldquo;Third Party&rdquo;
means any party other than a Party to this Agreement and such Party&rsquo;s Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.38 &ldquo;Tramadol&rdquo; means 2-[(dimethylamino)methyl]-
1-(3-methoxyphenyl)-cyclohexanol and all pharmaceutically-acceptable forms (e.g., solvates, polymorphs and salts) thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.39 &ldquo;Tramadol Only Product&rdquo;
means a Product that includes Tramadol only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.40 &ldquo;Transfer Price&rdquo;
means US$0.97 per tablet, subject to annual adjustment as set forth in the Supply Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.41 &ldquo;Valid Claim&rdquo; means any claim
contained in any Ampio Patent in the Territory which has not been revoked or held unenforceable, unpatentable or invalid by a decision
of a court or other governmental agency or competent jurisdiction, unappealable or unappealed within the time allowed for appeal,
and which has not been admitted to be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">1.42 &ldquo;Zertane&rdquo; means Ampio&rsquo;s
trademark and/or trade dress for Tramadol.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2 Licenses</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.1 <U>License to Daewoong</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Subject to the terms and conditions of this
Agreement, Ampio hereby grants Daewoong an exclusive (even as to Ampio except as provided in this Section 2.1 below), royalty-bearing
license, with the right to sublicense directly or through multiple tiers as provided in Section 2.3, under the Ampio Technology,
to research, Develop, Finish, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed,
import, have imported, and otherwise Commercialize the Products in the Field in the Territory. For clarity, the foregoing licenses
exclude the right to Manufacture or have Manufactured the Product, except for the right to Finish the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Notwithstanding the rights granted to Daewoong
in Section 2.1 and without limiting the generality of Section 2.4, Ampio retains the following: (i) the right to conduct or have
conducted clinical trials and other studies in the Territory for the generation of data in support of any regulatory submissions
to any Regulatory Authority in the Retained Territory; and (ii) the right to Manufacture or have Manufactured Product anywhere
in the Territory, in each case together with the right to import and export the Product in such territories for such purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.2 <U>License to Ampio</U>.
Subject to the terms and conditions of this Agreement, Daewoong hereby grants to Ampio (a) a non-exclusive, royalty-free license
(with the right to sublicense as provided below) in the Field under the Daewoong Technology to Develop, use, make, and have made
the Products in the Territory pursuant to the terms of this Agreement and the Supply Agreement, and (b) a non-exclusive, royalty-free,
perpetual, irrevocable license, with the right to grant sublicenses through multiple tiers, under the Daewoong Technology to research,
develop, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported,
export, have exported and otherwise commercialize the Products in the Retained Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.3 <U>Sublicenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Daewoong may grant
sublicenses to one or more Third Parties (any such Third Parties, together with all their direct and indirect Sublicensees, collectively,
&rdquo;Sublicensees&rdquo;) of the licenses granted to Daewoong hereunder, subject to Ampio&rsquo;s prior written consent with
respect to the identity of the potential Sublicensee, such consent shall not be unreasonably withheld. Daewoong shall remain responsible
for the performance of its obligations set forth herein by each of its Sublicensees.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Daewoong
shall, within thirty (30) days after granting any sublicense under Section 2.1(a) above, notify Ampio of the grant of such
sublicense and provide Ampio with a true and complete copy of such sublicense agreement. Each sublicense agreement shall not
conflict with the terms and conditions under this Agreement. Daewoong shall, in each agreement under which it grants a
sublicense under the license set forth in Section 2.1 (each, a &ldquo;Sublicense Agreement&rdquo;), include the following
terms and conditions: (i) the Sublicensee is required to carry out such tasks to ensure that Daewoong will comply with its
obligations to Ampio hereunder; (ii) the Sublicensee is required to provide the following to Daewoong if such Sublicense
Agreement terminates during the term of this Agreement: (A) the assignment and transfer of ownership and possession of all
Regulatory Filings and Regulatory Approvals held or possessed by such Sublicensee, and (B) the assignment of all intellectual
property Controlled by such Sublicensee that covers or embodies a Product or its respective use, manufacture, sale, or
importation and was created by or on behalf of such Sublicensee during the exercise of its rights or fulfillment of its
obligations pursuant to such Sublicense Agreement; and (iii) if this Agreement terminates pursuant to Section 13.2 prior to
the expiration of the Term, then Ampio may, at its sole discretion: (X) assume Daewoong&rsquo;s rights and obligations under
such Sublicense Agreement; or (Y) terminate such Sublicense Agreement. Each Sublicense Agreement shall include the
Sublicensee&rsquo;s obligations set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.4 <U>Negative Covenant; No Implied License</U>.
Each Party covenants that it will not use or practice any of the other Party&rsquo;s intellectual property rights licensed to it
under this Article 2 except for the purposes expressly permitted in the applicable license grant. Except as explicitly set forth
in this Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.5 <U>Diversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Daewoong hereby covenants
and agrees that it will not, and will ensure that its Affiliates, Sublicensees and subcontractors will not, either directly or
indirectly, promote, market, distribute, import, sell or have sold Products, including via the Internet or mail order, to any
Third Party, address or Internet Protocol (&ldquo;IP&rdquo;) address in the Retained Territory. As to such countries in the Retained
Territory: (i) Daewoong shall refrain from establishing or maintaining any branch, warehouse or distribution facility for the
Product in such countries; (ii) Daewoong shall not engage in any advertising or promotional activities relating to the Products
directed primarily to customers or other buyers or users of the Products located in such countries; and (iii) Daewoong shall not
solicit orders from any prospective purchaser located in such countries. If Daewoong receives any order from a prospective purchaser
located in a country in the Retained Territory, Daewoong shall immediately refer that order to Ampio. Daewoong shall not accept
any such orders. Daewoong may not deliver or tender (or cause to be delivered or tendered) any Products outside of the Territory.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) If any of Daewoong&rsquo;s Products is diverted
for use in the Retained Territory, the following shall apply: (i) if such Product were diverted by an identifiable customer, distributor,
employee, consultant or agent of Daewoong then, upon the request of Ampio, Daewoong shall not sell such category of Product to,
or allow the sale of such category of Product by, any such customer, distributor, employee, consultant or agent for the remaining
Term and shall use commercially reasonable efforts to buy back all such Product from such customer, distributor, employee, consultant
or agent within seven (7) business days of receiving such request from Ampio; or (ii) Daewoong shall use commercially reasonable
efforts to investigate the location of such diverted Product and buy it back; but, if and to the extent that, Daewoong elects not
to, or is unable to, buy back the applicable diverted Product, then Ampio may, in its sole discretion, buy back the applicable
diverted Product and Daewoong shall reimburse Ampio for all reasonable costs incurred by Ampio in connection with the buy-back
of any such diverted Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.6 <U>Exclusivity</U>.
During the Term: (a) neither Daewoong nor its Affiliates will, either by itself or through the grant of licenses or sublicenses,
without Ampio&rsquo;s written consent, commercialize any formulation that includes Tramadol in the Field in the Territory or in
the Retained Territory except under this Agreement; and (b) Daewoong will not, and will ensure that its Affiliates will not, either
by itself or through the grant of licenses or sublicenses: commercialize another product for the treatment of premature ejaculation
and/or erectile dysfunction in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2.7 <U>Registration of
License</U>. Daewoong shall have the right to record or register the licenses granted hereunder, and allow its Sublicensees to
record or register the sublicenses granted under the Sublicense Agreement, at any patent office or other relevant authority in
the Territory. Ampio shall execute all documents and give all declarations regarding the licenses or sublicenses and reasonably
cooperate with Daewoong or its Sublicensees at the costs of Daewoong or its Sublicensees to the extent such documents, declarations
and/or cooperation are required for such record or registration of the licenses or sublicenses for the benefit of Daewoong or its
Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">3 Disclosure of Know-How</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">3.1 <U>Disclosure of Ampio Know-How and Ampio
Regulatory Documentation</U>. Within sixty (60) days after the Effective Date of this Agreement, Ampio shall disclose or make available
to Daewoong copies of all of the Ampio Know-How and Ampio Regulatory Documentation, including such Ampio Know-How and Ampio Regulatory
Documentation identified on Exhibit 3.1. Thereafter during the term of this Agreement, Ampio shall disclose and make available
to Daewoong all future Ampio Know-How and Ampio Regulatory Documentation on a regular basis, provided that all material new Ampio
Know-How and Ampio Regulatory Documentation shall be provided without delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">3.2 <U>Disclosure of Daewoong Know-How and
Daewoong Regulatory Documentation</U>. Daewoong shall disclose or make available to Ampio, during the term of this Agreement,
any and all Daewoong Know-How and Daewoong Regulatory Documentation on a regular basis, provided that all material Daewoong Know-How
and Daewoong Regulatory Documentation shall be provided without delay.&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">4 Milestone Payments</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">4.1 <U>Milestone Payments</U>. In consideration
of the rights and licenses granted to Daewoong by Ampio hereunder, Daewoong shall pay to Ampio the following milestone amounts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom">Event</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payment (U.S.&nbsp;Dollars)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.2in; text-align: left; vertical-align: top">1.</TD>
    <TD STYLE="text-align: left; vertical-align: top">Upon signing of this Agreement by both Parties</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">2.</TD>
    <TD STYLE="text-align: left; vertical-align: top">Within five (5) business days following the approval of Tramadol for sale in the Territory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">3.</TD>
    <TD STYLE="text-align: left; vertical-align: top">Within five (5) business days following the approval of the Combination Product for sale in the Territory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">700,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">4.</TD>
    <TD STYLE="text-align: left; vertical-align: top"> Within twenty (20) business days following the end of the first calendar quarter where cumulative Net Sales in the Territory
exceed US$10 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 1 million</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">5.</TD>
    <TD STYLE="text-align: left; vertical-align: top">Within twenty (20) business days following the end of the first calendar quarter whether cumulative Net Sales in the Territory
exceed US$20 million</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 1 million</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left; vertical-align: top; padding-left: 0.375in">TOTAL PAYMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">For clarity, milestone events 4 and 5 may occur
during the same calendar year, in which event each of the accompanying milestone payments shall become due. In addition, the milestones
will apply to sales of Products by Daewoong, its Affiliates and Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">4.2 <U>Non-Refundable</U>.
Any payments made by Daewoong in accordance with Section 4.1 shall, once they are paid, not be refundable nor creditable for any
reason whatsoever, unless otherwise expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">4.3 <U>Single Payments</U>. The payments
specified in Section 4.1 shall be made only one time upon the first occurrence of the event described in Section 4.1, regardless
of how many times such event may be achieved with regard to the Products covered by this Agreement.&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">5 Management; Joint Steering
Committee</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">5.1 <U>Alliance Managers</U>. Within
thirty (30) days following the Effective Date, each Party will appoint (and notify the other Party of the identity of) a
representative having the appropriate qualifications including a general understanding of pharmaceutical Development and
Commercialization issues to act as its alliance manager under this Agreement (&ldquo;Alliance Manager&rdquo;). The Alliance
Managers will serve as the primary contact points between the Parties for the purpose of providing each Party with
information on the progress of the other Party&rsquo;s Development and Commercialization of the Products. The Alliance
Managers will also be primarily responsible for facilitating the flow of information and otherwise promoting communication,
coordination and collaboration between the Parties, providing single point communication for seeking consensus both
internally within each Party&rsquo;s respective organization, including facilitating review of external corporate
communications, and raising cross-Party and/or cross-functional disputes in a timely manner. Each Party may replace its
Alliance Manager on written notice to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">5.2 <U>Joint Steering Committee</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Within thirty (30) days after the Effective
Date, the Parties will establish a joint steering committee (the &ldquo;Joint Steering Committee&rdquo; or &ldquo;JSC&rdquo;) to
plan, administer, evaluate and carry out all aspects of the Development, manufacture, regulatory and Commercialization activities
by Daewoong hereunder with respect to the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) The JSC will consist of representatives
of Ampio and Daewoong. The representatives may be from various functional groups (e.g., clinical development, regulatory, medical
affairs, pharmacovigilance, commercial and manufacturing). Daewoong will appoint a chair of the JSC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) The Parties shall schedule the
half-yearly JSC meetings and agree to such schedule at least quarterly in advance. Either Party may call additional ad hoc
meetings of the JSC as the needs arise with reasonable advance notice to the other Party, and such ad hoc meetings shall be
conducted at times that are mutually agreed upon by the Parties. All meetings and other communications of the JSC shall be
conducted in English. No later than five (5) business days prior to any regularly scheduled meeting of the JSC, the
chairperson of the JSC shall prepare and circulate an agenda for such meeting and, as soon as practicable, all materials,
documents and information for the meeting for distribution to both Parties; provided, however, that either Party may propose
additional topics to be included on such agenda, either prior to or in the course of such meeting. The JSC may meet in
person, by videoconference or by teleconference. The chairperson of the JSC will be responsible for preparing reasonably
detailed written minutes of all JSC meetings that reflect, without limitation, material decisions made at such meetings. The
JSC chairperson shall send draft meeting minutes to the Daewoong members and the Ampio members of the JSC for review and
approval within ten (10) business days after each JSC meeting. Such minutes will be deemed approved unless one or more
members of the JSC objects to the accuracy of such minutes within ten (10) business days of receipt. Further, upon
Daewoong&rsquo;s request, Ampio will use commercially reasonable efforts to coordinate any meeting among Ampio, Daewoong and
any other Ampio Licensees for the exchange of information helpful for the Development of the Products. In addition to
the regularly scheduled meetings, Daewoong shall call additional ad hoc meetings of the JSC prior to making any major
decisions in the Development of the Products in the Territory. The Parties shall also maintain regular, frequent and informal
communications for Ampio to obtain updates from Daewoong and for the Parties to discuss the progress of the Development of
the Products in the Territory.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) The JSC shall strive to seek consensus in
its actions and decision making process. In the event of a disagreement between the Ampio members and Daewoong members of the JSC,
either Party may refer the matter to one senior executive of each Party (i.e., the Chief Executive Officer or Managing Director
of such Party or an executive of such Party who reports directly to the Chief Executive Officer or Managing Director) for resolution.
If such senior executives cannot resolve the matter within ten (10) business days, then such senior executive of Daewoong shall
have the final decision making authority on such matter, provided that any final determination made by such senior executive of
Daewoong shall be consistent with the terms of this Agreement, further provided that Daewoong shall not make any decision with
respect to the following critical issues without the consent of Ampio, such consent not to be unreasonably withheld or delayed:
(A) discontinue the Development of any Product; (B) initiate or discontinue any clinical trial; (C) unreasonably delay the process
of or cease to seek Regulatory Approval for any Product; (D) unreasonably delay or cancel the commercial launch of any Product;
and (E) remove any Product from the market, other than for safety reasons. For clarity, Ampio shall take the lead with respect
to all determinations relating to any clinical trials relating to any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">5.3 <U>Costs of Governance</U>. The Parties
agree that the costs incurred by each Party in connection with its participation at any meetings under this Article 5 shall be
borne solely by such Party, except that the costs of necessary translations and translators shall be divided equally between the
Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">6 Development</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">6.1 <U>Development Plan</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Within sixty (60) days after the Effective
Date (or such longer period of time as recommended by the JSC), the Parties will agree upon a development plan for the Development
of the Products in the Territory (the &ldquo;Development Plan&rdquo;). The Development Plan includes all clinical studies to be
performed for the Products, including those that are required for Regulatory Approval for the Products in the Territory. The Development
Plan shall also each specify the plans, timeline and budget for preparing the necessary Regulatory Filings and for obtaining Regulatory
Approvals for the Products in the Territory, which will provide for filing for Regulatory Approvals of the Products in the Territory
as soon as practicable following the Effective Date. Daewoong shall conduct the Development activities in accordance with the
then-current Development Plan (including the timelines set forth therein) and under the direction of the JSC.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) From time to time during the Term, Daewoong
shall update and amend, as appropriate, the then-current Development Plan and submit such updated or amended Development Plan for
the JSC&rsquo;s approval, such approval not to be unreasonably withheld or delayed. Once approved by the JSC, each updated or amended
Development Plan shall become effective and supersede the previous Development Plan as of the date of such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">6.2 <U>Daewoong Development
Activities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(a) Daewoong shall Develop the Products and
seek Regulatory Approval by timely and diligently conducting all Development activities under the Development Plan (the &ldquo;Daewoong
Development Activities&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(b) The status, progress and results of the
Development activities in the Territory shall be discussed at meetings of the JSC, and Daewoong shall provide the JSC with a written
report on the status and progress of such Development activities on a half-yearly basis at least five</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(5) business days prior to each scheduled
JSC meeting. In addition, Daewoong shall make available to Ampio such information about such Development activities as may be reasonably
requested by Ampio from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">6.3 <U>Compliance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Daewoong agrees that in performing its obligations
under this Agreement: (i) it shall comply with all applicable Laws; and (ii) it will not employ or engage any person who has been
debarred by any Regulatory Authority, or, to such Party&rsquo;s knowledge, is the subject of debarment proceedings by a Regulatory
Authority. Daewoong shall have the right to engage subcontractors for the performance of its obligations under the Development
Plan. Daewoong remains responsible for the performance of such subcontractor(s) and the engagement of such subcontractors shall
not relieve Daewoong from its obligations to comply with the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Daewoong shall
maintain complete, current and accurate records of all work conducted by it under the Development Plan, and all data and
other Information resulting from such work. Daewoong shall cause the Sublicensees to maintain complete, current and accurate
records of all work conducted by such Sublicensees under the Development Plan, and all data and other Information resulting
from such work. Such records shall fully and properly reflect all work done and results achieved in the performance of the
Development activities in good scientific manner appropriate for regulatory purposes. Ampio shall have the right to review
all records maintained by Daewoong or such Sublicensees at reasonable times, upon Ampio&rsquo;s written request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) Daewoong shall document all preclinical
studies and clinical trials conducted by or for it in written study reports and shall provide Ampio with a summary of each such
report in English promptly after its completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">6.4 <U>Development Costs</U>.
As between the Parties, Daewoong shall bear all Development Costs for the Development: (a) conducted by or for Daewoong and incurred
by Daewoong; or (b) conducted by Ampio for Daewoong at the written request of or with the written consent of Daewoong and incurred
by Ampio, in each case after the Effective Date in connection with the research, manufacture and Development (including development
of manufacturing processes for the Products and other matters relating to the chemistry, manufacture and controls of the Products)
of the Products in accordance with the Development Plan or the other provisions of this Agreement, as well as any other research,
manufacture and development of the Products by Daewoong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7 Regulatory Matters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.1 <U>Daewoong Regulatory
Responsibilities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Subject to the termination of this Agreement,
Daewoong shall own all Regulatory Filings and Regulatory Approvals for the Products in the Territory, and shall be solely responsible
for preparing any and all Regulatory Filings for the Products in the Territory at its sole expense in accordance with the Daewoong
Development Plan, with the direction of the JSC and subject to the terms of this Article 7. Ampio shall assist Daewoong or its
Sublicensees as they may reasonably request in connection with the preparation and filing of such Regulatory Filings, at Daewoong&rsquo;s
or its Sublicensees&rsquo; reasonable request and expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Daewoong shall keep Ampio informed of regulatory
developments specific to Products throughout the Territory, and Ampio shall have the right to contribute to the regulatory plans
and strategies for the Products in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) Daewoong shall, and shall ensure
that its Sublicensees will, lead discussions with any Regulatory Authority related to any Development of any Products.
Daewoong will, and will cause its Sublicensees to, inform Ampio of any such discussions in advance to the extent practicable,
and Daewoong will, and will ensure that its Sublicensees will, reasonably consider any input from Ampio in preparation for
such discussions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) Daewoong shall, and
shall ensure that its Sublicensees will, be responsible to ensure, at its sole expense, that the Development, manufacture and
Commercialization of the Products in the Territory are in compliance with all applicable Laws, including without limitation all
rules and regulations promulgated by any of the Regulatory Authorities in the Territory. Specifically and without limiting the
foregoing, Daewoong shall, and shall ensure that its Sublicensees will, file all compliance filings, certificates and safety reporting
(subject to Section 7.2(a)) in the Territory at its sole expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) to the extent permitted by the applicable
Regulatory Authority and as requested by Ampio, Daewoong shall, and shall ensure that its Sublicensees will, allow representatives
of Ampio to participate in any scheduled conference calls and meetings between Daewoong or its Sublicensees and the Regulatory
Authority at Ampio&rsquo;s expense. If Ampio elects not to participate in such calls or meetings, Daewoong shall, and shall ensure
that its Sublicensees will, provide Ampio with written summaries of such calls and meetings in English as soon as practicable after
the conclusion thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(f) with respect to all Regulatory Filings,
Daewoong shall, and shall ensure that its Affiliates and Sublicensees will: (i) submit only data and information that are free
from fraud or material falsity; (ii) not use bribery or the payment of illegal gratuities in connection with its Regulatory Filings
for the Products; and (iii) submit only data and information that are accurate and reliable in all material respects for purposes
of supporting Regulatory Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.2 <U>Adverse Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Within one (1) year prior to the planned
first Regulatory Approval of the Products in the Territory, the Parties shall discuss in good faith and enter into a pharmacovigilance
and adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to
the Products, such as safety data sharing, adverse events reporting and prescription events monitoring (the &ldquo;Pharmacovigilance
Agreement&rdquo;). Such Pharmacovigilance Agreement shall govern the global pharmacovigilance procedures to be agreed upon by Daewoong,
Ampio, Ampio Licensees and the commercial partners of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Prior to the execution of such Pharmacovigilance
Agreement, the Parties agree to coordinate the pharmacovigilance procedures in connection with the Development of the Products,
and Daewoong shall submit to Ampio all safety information and reporting in a manner that meets the reporting requirements in the
Retained Territory. Each Party shall notify the other Party within twenty-four (24) hours of such Party&rsquo;s learning of any
Serious Adverse Events (as defined below) that is attributed to or potentially attributable to the use of the Products. Each Party
shall also provide the other Party, on an annual basis and more frequently as reasonably requested by the other Party, a summary
report of Adverse Events (as defined below), as well as those Serious Adverse Events that are not attributable to the use of the
Products. As used herein, unless defined differently by the FDA, &ldquo;Adverse Events&rdquo; means any side effect, injury, toxicity
or sensitivity reaction, or any unexpected incident, and the severity thereof, whether or not determined to be attributable to
any Product, and &ldquo;Serious Adverse Events&rdquo; means an Adverse Event which results in death, is immediately life-threatening,
results in persistent and significant disability/incapacity or requires in-patient hospitalization or prolongation of existing
hospitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) After the execution of the Pharmacovigilance
Agreement, the Parties shall comply with such Pharmacovigilance Agreement with respect to all aspects of pharmacovigilance activities
with respect to the Products, and Section 7.2(b) above shall be of no further effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.3 <U>No Harmful Actions</U>. If either Party
believes that the other Party, as the case may be, is taking or intends to take any action with respect to the Product that could
reasonably be expected to have a material adverse impact upon the regulatory status of the Product in the Retained Territory or
the Territory, such Party shall have the right to bring the matter to the attention of the JSC. Without limiting the foregoing,
unless the Parties otherwise agree: (a) Daewoong shall not communicate with any Regulatory Authority having jurisdiction in the
Retained Territory, unless so ordered by such Regulatory Authority, in which case Daewoong shall provide immediately to Ampio notice
of such order; and (b) Daewoong shall not submit any Regulatory Filings or seek Regulatory Approvals for the Products in the Retained
Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.4 <U>Notification of Threatened Action</U>.
Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action,
inspection or communication by or from any party, including, without limitation, a Regulatory Authority, which may affect the safety
or efficacy claims of a Product or the continued marketing of a Product. Upon receipt of such information, the Parties shall consult
with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.5 <U>Data Exchange and Use</U>. This
Section 7.5 shall not apply to any pharmacovigilance data (which is addressed in Section 7.2). Daewoong shall, and shall
ensure that its Sublicensees will, provide Ampio with copies of all final submissions and correspondence to and from all
Regulatory Authorities relating to the Products in the Field within seven (7) days of submission or receipt, as applicable,
and shall, and shall ensure that its Sublicensees will, provide Ampio a summary of each significant submission (such as
application for approval for clinical trials, Regulatory Approval and fast track or orphan drug designation, the protocol for
clinical trials and any modifications thereof) in English as soon as practicable but in any event within ten (10) business
days after such submission. Each Party shall permit the other Party to access, and shall provide the other Party with rights
to reference and use in association with the Products in the Field, all of its, its Affiliates&rsquo;, and its or their
licensees&rsquo; and Sublicensees&rsquo; regulatory, preclinical and clinical data documentation, Regulatory Filings, and
Regulatory Approvals with respect to the Products in the Field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.6 <U>Remedial Actions</U>.
Each Party will, and will ensure that its Affiliates and Sublicensees will, notify the other Party immediately, and promptly confirm
such notice in writing, if it obtains information indicating that a Product may be subject to any recall, corrective action or
other regulatory action with respect to a Product taken by virtue of applicable Law in the Territory (a &ldquo;Remedial Action&rdquo;).
The Parties (or Daewoong&rsquo;s Sublicensees and Ampio), as the case may be, will assist each other in gathering and evaluating
such information as is necessary to determine the necessity of conducting a Remedial Action. Daewoong shall, and shall ensure that
its Affiliates and Sublicensees will, maintain or have maintained adequate records to permit the Parties to trace the manufacture
of the Product and the distribution and, to the extent feasible, the use of the Product. In the event Daewoong or its any Sublicensee
determines that any Remedial Action with respect to a Product in the Field in the Territory should be commenced or Remedial Action
is required by any Regulatory Authority having jurisdiction over the matter, Daewoong will, and will ensure that its Sublicensees
will, as the case may be, control and coordinate all efforts necessary to conduct such Remedial Action. In the event Ampio determines
that any Remedial Action with respect to a Product outside the Field in the Territory should be commenced or Remedial Action is
required by any Regulatory Authority having jurisdiction over the matter, Ampio will control and coordinate all efforts necessary
to conduct such Remedial Action. For clarity, as between the Parties, Ampio shall have sole discretion with respect to any matters
relating to any Remedial Action in the Retained Territory. The cost and expense of a Remedial Action arising from the development,
manufacture or commercialization of the Product in the Field in the Territory shall be borne solely by Daewoong or its Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">7.7 <U>Rights of Reference to
Regulatory Documentation</U>. Each Party hereby grants to the other Party a right of reference to all Regulatory
Documentation filed by such Party for the Products subject to the scope of the licenses granted hereunder, including, for the
avoidance of doubt, all such Regulatory Documentation filed by Ampio for Regulatory Approval of the Products in the Retained
Territory and all supplemental filings related thereto, and all &ldquo;Certificate(s) of Pharmaceutical Product&rdquo; and/or
&ldquo;Certificate(s) of Free Sales&rdquo; resulting from Regulatory Approval of such Products, solely for the purpose of
seeking, obtaining and maintaining Regulatory Approvals for, and the Commercialization of, the Product in the Territory and
the Field, consistent with the roles of the Parties set forth in this Agreement. In addition, Daewoong hereby grants to Ampio
a right of reference to all Regulatory Documentation filed by Daewoong in the Territory for the purpose of Ampio, its
Affiliates or any Ampio Licensees developing and obtaining and/or maintaining Regulatory Approvals anywhere in the world for
the Products in the Field in the Retained Territory.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">8 Commercialization</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">8.1 <U>Overview of Commercialization
in the Territory</U>. Daewoong, its Affiliates and its Sublicensees will have responsibility for all decisions related to and implementation
of Commercialization activities, including but not limited to price, reimbursement and distribution, for the Products in the Territory,
at its sole expense. Daewoong will prepare and submit to the JSC a commercialization plan no later than six (6) months prior to
the anticipated date of Regulatory Approval for the first Product in the Territory (the &ldquo;Commercialization Plan&rdquo;).
Such Commercialization Plan shall incorporate the commercialization diligence requirements set forth below. Daewoong will update
such Commercialization Plan on a yearly basis and will provide quarterly reports to Ampio describing Daewoong&rsquo;s progress
against such Commercialization Plan. Daewoong shall use Commercially Reasonable Efforts to maximize sales of the Products throughout
the Territory in accordance with the Commercialization Plan. Furthermore, Ampio and Daewoong agree that the initial commercial
price for a Tramadol Only Product shall be US$5.00 per tablet, and if the parties decide the Net Sales needs to be adjusted, the
parties shall discuss in good faith with the JSC. For clarification, the commercial price means the cost of medicine that the patient
pays the pharmacy for a Tramadol Only Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">8.2 <U>Trademark</U>. Daewoong
shall have the right to brand the Products using Daewoong related trademarks and any other trademarks and trade names it determines
appropriate for the Products in consultation with Ampio (&ldquo;Product Marks&rdquo;). Daewoong shall own all rights in the Product
Marks and register and maintain the Product Marks in the countries and regions it determines reasonably necessary. Notwithstanding
any provisions in this Agreement, Daewoong shall be the exclusive sole owner for the Product Marks even after the termination of
this Agreement for whatever reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9 Manufacture and Supply;
Payment for Products</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.1 <U>General Supply Terms</U>. Ampio shall,
itself or through one or more Third Party contract manufacturers, manufacture the Products in finished form in unlabeled containers
in accordance with the terms of Section 9, including the performance of all manufacturing process development and scale-up for
the Products (and associated regulatory activities), and shall supply to Daewoong, and Daewoong shall purchase from Ampio, all
of Daewoong and its Affiliates&rsquo; and its/their Sublicensees&rsquo; requirements of the Products for Development and Commercial
activities as and to the extent set forth in this Agreement and the Supply Agreement. Daewoong shall be responsible for labelling
and packaging all Products supplied by Ampio to Daewoong under this Agreement and the Supply Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.2 <U>Supply Agreement</U>. Within sixty (60)
days after the Effective, the Parties shall enter into a supply agreement and quality agreement governing the supply of Products
to Daewoong for clinical and commercial use, as well as the quality control and quality assurance procedures thereon (collectively
the &ldquo;Supply Agreement&rdquo;) and any other operational agreements and procedures as deemed necessary by the Parties for
such supply of the Products. The terms of such Supply Agreement shall be negotiated in good faith by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.3 <U>Payment and Pricing</U>. The Supply Agreement
shall provide for payment by Daewoong for Product supplied by Ampio in the manner prescribed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Tramadol-Only Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: 0.5in">(i) Within thirty (30)
days after supply by Ampio to Daewoong, its Affiliates or its Sublicensees of any Tramadol-Only Product, Daewoong shall pay to
Ampio an amount equal to Transfer Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: 0.5in">(ii) Within thirty (30)
days after the end of each calendar quarter, Daewoong shall pay to Ampio an amount equal to the difference between (x) 25% of the
Net Sales of such Tramadol-Only Product minus (y) the Transfer Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Combination Product. The
transfer price for the Combination Product will be determined at a later date via the Supply Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.4 <U>Reports; Records</U>.
During the term of this Agreement after First Commercial Sale of the first Product, Daewoong shall furnish or cause to be furnished
to Ampio within thirty (30) days after the end of each calendar quarter (each a &ldquo;Reporting Period&rdquo;) a written report
or reports (the &ldquo;Sales Report&rdquo;) covering the applicable Reporting Period and containing the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) the Net Sales of Products
in the Territory during the Reporting Period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) the royalties, payable
in U.S. Dollars, which shall have accrued hereunder in respect to such Net Sales;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) withholding taxes, if
any, required by Law to be deducted in respect of such royalties; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) the exchange rates used
in determining the amount of U.S. Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.5 <U>Exchange Rates; Reports</U>.
With respect to sales of Product invoiced in U.S. Dollars, the Net Sales and royalty payable shall be expressed in such
currency as it is. With respect to sales of Product invoiced in a currency other than U.S. Dollars, the Net Sales and royalty
payable shall be expressed in the domestic currency of the Republic of Korea together with the U.S. Dollars equivalent of the
royalty payable, calculated using the average exchange rates posted in <I>The Financial Times</I> published on the first and
last days of each month within each calendar quarter (each a &ldquo;Reporting Period&rdquo;). Sales Reports shall be due
thirty (30) days following the close of each respective Reporting Period. Daewoong and its Affiliates and Sublicensees shall
keep legible, verifiable and accurate records in sufficient detail to enable the royalties payable hereunder to be determined
and substantiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.6 <U>Withholding Tax</U>.
Daewoong shall deduct any withholding taxes and other statutory duties from all payments set forth herein and pay them to the proper
tax authorities if required by applicable Law. Daewoong shall maintain official receipts related to any withholding taxes and forward
copies of such receipts to Ampio. The Parties will exercise their commercially reasonable efforts to ensure that any withholding
taxes imposed are reduced as far as possible under the provisions of the current or any future double taxation agreement between
the Republic of Korea and the United States of America. If, according to Laws applied to the Parties, this reduction requires a
certificate of tax exemption, and in order to achieve such reduction, each Party shall cooperate with the other Party with applicable
legal procedure and shall provide the other Party with the claim for a certificate of tax exemption in respect of royalties paid
on the official form containing a certification of residence of the competent tax authority and other appropriate documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.7 <U>Audit Rights</U>. Ampio shall have the
right to have an independent public accounting firm of its own selection, except one to whom Daewoong, its Affiliates or Sublicensees
may have reasonable objection, and at Ampio&rsquo;s own expense (except if the result of such audit results in an underpayment
exceeding five percent (5%) of the payments that were paid to Ampio), examine the relevant books and records of account of Daewoong
and any of its Affiliates and Sublicensees during reasonable business hours upon reasonable prior written notice to Daewoong and
not more often than once each calendar year, for not more than two (2) previous years, to determine whether appropriate payment
have been made to Ampio hereunder. Ampio may exercise such right until the end of one (1) year after the termination or expiration
of this Agreement. Daewoong shall promptly pay to Ampio the full amount of any undisputed underpayment. If the amount of the underpayment
is greater than five percent (5%) on an annualized basis, Daewoong shall pay interest on that amount that is in excess of five
percent (5%) at the rate of LIBOR plus two percent (2%) per year, compounding annually from the date payment was due. Ampio shall
promptly pay to Daewoong the full amount of any overpayment. Such public accounting firm shall treat as confidential, and shall
not disclose to Ampio, any information other than information which could otherwise be given to Ampio pursuant to any provision
of this Agreement, all of which shall be treated as Confidential Information of Daewoong hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">9.8 <U>Recalls and Voluntary
Withdrawals</U>. The Parties shall exchange their internal standard operating procedures (&ldquo;SOPs&rdquo;) for conducting
product recalls reasonably in advance of the First Commercial Sale of Product in the Territory, and shall discuss and resolve
any conflicts between such SOPs and issues relating thereto promptly after such exchange. If either Party becomes aware of
information relating to any released Product that indicates that a unit or batch of Product may not conform to the
specifications thereof, or that potential adulteration, misbranding, and/or other issues have arisen that relate to the
safety or efficacy of such released Product, it shall promptly so notify the other Party. To the extent Daewoong requires
such information to comply with applicable Laws or to determine whether to conduct a recall, Ampio shall promptly disclose to
Daewoong any CMC Information related to such nonconformance, adulteration, misbranding or other related issue. Daewoong shall
have the right, at its expense (except as provided herein), to control any Product recall, field correction, or withdrawal of
any released Product in the applicable jurisdiction in the Territory. Ampio shall have the right, at its expense, to control
any Product recall, field correction, or withdrawal of any released Product in the Retained Territory. Ampio shall be
responsible for all costs incurred for any recall, field correction, or withdrawal of any released Product for the Territory
to the extent such event of recall, field correction, or withdrawal is due to the material breach by Ampio of this Agreement
or the Supply Agreement. Daewoong shall be responsible for all other costs incurred for any recall, field correction, or
withdrawal of any released Product for the Territory. The procedures and consequences of such recalls shall be defined in the
Supply Agreement. The Party having the right to control such recall pursuant to this Section 9.8 may, at its sole discretion,
take appropriate courses of action, which shall be consistent with the internal SOPs of such Party; provided, however, that
such controlling Party shall promptly notify the other Party of any recall action being considered and where
practicable, consider the views of the non-controlling Party prior to taking any recall action. Daewoong shall maintain
complete and accurate records of any recall according to its then current SOPs in the Territory for such periods as may be
required by applicable Laws, but in no event for less than three (3) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">9.9
<U>Payment</U>. Any invoice will be issued by Ampio together with the delivery of the Products to Daewoong and shall be paid by
Daewoong within thirty (30) days upon receipt by Daewoong of such invoice and acceptance by Daewoong of the applicable Product
shipment by wire transfer on a bank account designated by Ampio. All payments to Ampio shall be in US Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10 Representations, Warranties
and Covenants; Disclaimer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10.1 <U>No Representation of Success</U>. Ampio
does not warrant that Daewoong can successfully develop, obtain Regulatory Approvals for, or market the Products in the Territory
by using and relying upon the Ampio Patents, the Ampio Know-How and the Ampio Regulatory Documentation supplied by Ampio hereunder
and further that, except as expressly provided in Section 10.2, the Ampio Patents, the Ampio Know-How and the Ampio Regulatory
Documentation has not any defect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10.2 <U>Ampio Representations,
Warranties and Covenants</U>. Ampio covenants, and represents and warrants to Daewoong as of the Effective Date, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Ampio is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Ampio has full right and authority
to use the Ampio Patents, the Ampio Know-How and the Ampio Regulatory Documentation and to enter into this Agreement and to
grant the licenses to Daewoong as herein described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) This Agreement has been duly authorized
by all requisite corporate action, and when executed and delivered will become a valid and binding contract of Ampio enforceable
against Ampio in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other
Laws affecting creditors&rsquo; rights generally from time to time if effect, and to general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) The execution, delivery and performance
of this Agreement does not and will not conflict with any other agreement, contract, instrument or understanding, oral or written,
to which Ampio is a party, or by which it is bound, nor will it violate any Law applicable to Ampio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) All necessary consents, approvals and authorizations
of all regulatory and governmental authorities and other persons or entities required to be obtained by Ampio in connection with
the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(f) Ampio has not granted as of the Effective
Date, and will not grant during the term of this Agreement, any licenses to any Affiliate or Third Party under the Ampio Patents,
Ampio Know-How or Ampio Regulatory Documentation which would conflict with the licenses granted to Daewoong hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10.3 <U>Daewoong Representations
and Warranties</U>. Daewoong covenants, and represents and warrants to Ampio as of the Effective Date, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Daewoong is a corporation duly organized,
validly existing and in good standing under the laws of jurisdiction in which it is incorporated and it has full right and authority
to enter into this Agreement and to accept the rights and licenses granted as herein described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) This Agreement has been duly authorized
by all requisite corporate action, and when executed and delivered will become a valid and binding contract of Daewoong enforceable
against Daewoong in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium and other
Laws affecting creditors&rsquo; rights generally from time to time if effect, and to general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) The execution,
delivery and performance of this Agreement does not and will not conflict with any other agreement, contract, instrument or
understanding, oral or written, to which Daewoong is a party, or by which it is bound, nor will it violate any Law applicable
to Daewoong.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) All necessary consents, approvals and authorizations
of all regulatory and governmental authorities and other persons or entities required to be obtained by Daewoong in connection
with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) Daewoong has not as of the Effective Date
knowingly performed any acts that are inconsistent with the terms and purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(f) Daewoong warrants that any sublicense granted
hereunder by Daewoong or any Sublicensee shall be subject to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(g) Daewoong has undertaken the investigation
and has evaluated documents and information as practically it has deemed necessary to enable it to make an informed and intelligent
decision with respect to the execution, delivery and performance of this Agreement. Daewoong agrees to enter into this Agreement
in the terms and conditions herein on the Effective Date based upon its own inspection, examination and determination with respect
thereto as to all matters, and without reliance upon any express or implied representations or warranties of any nature made by
or on behalf of or imputed to Ampio or their Affiliates, except as expressly set forth in this Agreement. Without limiting the
generality of the foregoing, and except as expressly set forth in this Agreement, Daewoong acknowledges that Ampio is making no
representation or warranty with respect to any Ampio Know-How, Ampio Patent or Ampio Regulatory Documentation licensed to Daewoong
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10.4 <U>Limitation of Warranty</U>.
EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTY, AND EACH PARTY HEREBY DISCLAIMS
ALL IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO ANY OF THE MATERIALS,
INFORMATION, SERVICES OR LICENSES PROVIDED PURSUANT TO THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">10.5 <U>Performance by
Affiliates</U>. The Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates
and Third Party contractors provided, however, that each Party shall remain responsible and liable for the performance by its Affiliates
and Third Party contractors and shall cause its Affiliates and Third Party contractors to comply with the provisions of this Agreement
in connection with such performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11 Intellectual Property</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.1 <U>Ownership of Inventions;
Assignment</U>. Each Party shall own all right, title, and interest in and to any inventions made solely by such Party&rsquo;s
employees, agents, independent contractors and sublicensees in the course of conducting its activities under this Agreement during
the Term, together with all intellectual property rights therein, including any rights to applications or other protections for
any of the foregoing. The Parties shall jointly own all inventions made jointly by the employees, agents, independent contractors
or sublicensees of each Party, in accordance with joint ownership interests of co-inventors under U.S. patent laws (that is, each
Party shall have full rights to license, assign and exploit such joint inventions (and any patents arising therefrom) anywhere
in the world, without any requirement of gaining the consent of, or accounting to, the other Party), subject to the licenses granted
herein and subject to any other intellectual property held by such other Party; provided, however, that Daewoong shall not have
the right to practice any jointly owned invention in any activities related to a product that competes with the Product. The Parties
shall determine which Party will file, prosecute and maintain the Patents claiming or covering such jointly owned inventions. Inventorship
shall be determined in accordance with U.S. patent laws. Notwithstanding the foregoing, Daewoong agrees to assign and hereby assigns
and transfers to Ampio all of its right, title and interest in and to any such solely owned or jointly owned inventions that relate
to the composition of matter, manufacture or use of the Product (&ldquo;Product Inventions&rdquo;), and agrees to take, and to
cause its employees, agents, consultants and sublicensees to take, all further acts reasonably required to evidence such assignment
and transfer to Ampio, at Ampio&rsquo;s reasonable expense. Daewoong hereby appoints Ampio as its attorney-in-fact to sign such
documents as Ampio deems necessary for Ampio to obtain ownership and to apply for, secure, and maintain patent or other proprietary
protection of such Product Inventions if Ampio is unable, after reasonable inquiry, to obtain Daewoong&rsquo;s (or its employee&rsquo;s
or agent&rsquo;s) signature on such a document. Daewoong hereby waives, on behalf of itself, its parent, subsidiaries, Affiliates
and partners as well as all of its employees and independent contractors, any rights of first refusal it, he, or she may have with
respect to any contemplated technology transfer, in whole or in part, of the Product Inventions or any related patent, patent application,
copyright or copyright application related thereto as well as any right accorded to it, him, or her, by statute or otherwise, to
use any Product Invention or any Patent or copyright related thereto. All Patents claiming or covering any Product Invention shall
be referred to herein as &ldquo;Product Patents.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.2 <U>Disclosure of Inventions</U>. Daewoong
shall, and shall cause its Third Party Subcontractors, Affiliates and Sublicensees to, promptly disclose to Ampio any invention
disclosures, or other similar documents, submitted to it by its employees, agents, consultants or independent contractors describing
inventions that may be Product Inventions, and all Information relating to such inventions to the extent necessary for the preparation,
filing and maintenance of any Patent with respect to such invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.3 <U>Prosecution of Patents</U>.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Ampio shall have the sole right to prepare,
file, prosecute and maintain the Ampio Patents at Ampio&rsquo;s own costs and expenses. If Ampio determines in its sole discretion
to abandon all claims in any Ampio Patent in the Territory, then Ampio shall provide Daewoong with written notice of such determination
within a period of time reasonably necessary to allow Daewoong to determine its interest in such Ampio Patent(s). In the event
Daewoong provides written notice expressing its interest in obtaining such Ampio Patent(s), Ampio shall assign and transfer to
Daewoong the ownership of, and interest in, such Ampio Patent(s) in the Territory, such transfer to be at Daewoong&rsquo;s reasonable
expense (but without payment to Ampio). Thereafter, Daewoong shall bear all of the costs of preparation, filing, prosecution and
maintenance of such assigned and transferred Patents, which shall not be treated as Ampio Patents and shall be treated as Daewoong
Patents, and Daewoong may prosecute such Daewoong Patents at its sole discretion; provided, however, in the event that Daewoong
decides to abandon or not maintain any such Patent(s), Daewoong shall promptly provide Ampio with written notice of such decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Daewoong shall be solely responsible to file,
prosecute and maintain Daewoong Patents. With respect to Daewoong Patents under which Ampio receives a license pursuant to Section
2.2 hereof, Daewoong shall provide Ampio reasonable opportunity to review and comment on such prosecution efforts regarding such
Daewoong Patents, including by providing Ampio with a copy of material communications from any patent authority in the Territory
regarding such Daewoong Patent(s), and by providing drafts of any material filings or responses to be made to such patent authorities
in advance of submitting such filings or responses. Daewoong shall reasonably consider such comments by Ampio in connection with
the prosecution of Daewoong Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.4 <U>Patent Term Extensions in the
Territory</U>. The JSC will discuss and recommend for which, if any, of the Patents within the Ampio Patents and Daewoong
Patents in the Territory the Parties should seek Patent Term Extensions in the Territory. Ampio, in the case of the Ampio
Patents, and Daewoong in the case of the Daewoong Patents, shall have the final decision-making authority with respect to
applying for any such Patent Term Extensions in the Territory, and will act with reasonable promptness in light of the
development stage of the Product to apply for any such Patent Term Extensions, where it so elects; provided, however, that if
only one such Patent can obtain a Patent Term Extension, then the Parties will consult in good faith to determine which such
Patent should be the subject of efforts to obtain a Patent Term Extension, and in any event Ampio&rsquo;s decision on such
matter will control in the case of a disagreement. The Party that does not apply for an extension hereunder will cooperate
fully with the other Party in making such filings or actions, for example and without limitation, by making available all
required regulatory data and information and executing any required authorizations to apply for such Patent Term Extension.
All expenses incurred in connection with activities of each Party with respect to the Patent(s) for which such Party seeks
Patent Term Extensions pursuant to this Section 11.4 shall be entirely borne by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.5 <U>Infringement of Patents
by Third Parties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Each Party shall promptly notify the other
Party in writing of any existing or threatened infringement in the Territory of the Ampio Patents or Daewoong Patents of which
it becomes aware, and shall provide all evidence in such Party&rsquo;s possession demonstrating such infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) If a Third Party infringes any Ampio Patent
in the Territory by making, using, importing, offering for sale or selling the Product or a competitive product in the Field (a
&ldquo;Product Infringement&rdquo;), each Party shall share with the other Party all Information available to it regarding such
alleged infringement. Ampio shall have the sole and exclusive right, but not the obligation, to bring an appropriate suit or other
action against any person or entity engaged in such Product Infringement in the Territory. Daewoong shall provide to Ampio reasonable
assistance in such enforcement, at Ampio&rsquo;s request and expense, including joining such action as a party plaintiff if required
by applicable Laws to pursue such action. Ampio shall keep Daewoong regularly informed of the status and progress of such enforcement
efforts, shall reasonably consider Daewoong&rsquo;s comments on any such efforts, and shall seek consent of Daewoong in any important
aspects of such enforcement, including determination of litigation strategy and filing of important papers to the competent court,
which shall not be unreasonably withheld or delayed. Each Party shall bear all of its own internal costs incurred in connection
with its activities under this Section 11.5(b). Daewoong shall be entitled to separate representation in such matter by counsel
of its own choice and at its own expense, but Daewoong shall at all times cooperate fully with Ampio bringing such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) If Ampio, in its sole discretion,
determines not to exercise its right to bring an action against Product Infringement in the Territory, Daewoong shall be
entitled to do so. Ampio shall provide to Daewoong reasonable assistance in such enforcement, at Daewoong&rsquo;s request and
expense, including joining such action as a party plaintiff if required by applicable Laws to pursue such action. Daewoong
shall keep Ampio regularly informed of the status and progress of such enforcement efforts, shall reasonably consider
Ampio&rsquo;s comments on any such efforts, and shall seek consent of Ampio in any important aspects of such enforcement,
including determination of litigation strategy and filing of important papers to the competent court, which shall not be
unreasonably withheld or delayed. Each Party shall bear all of its own internal costs incurred in connection with its
activities under this Section 11.5(c). Ampio shall be entitled to separate representation in such matter by counsel of its
own choice and at its own expense, but Ampio shall at all times cooperate fully with Daewoong bringing such action.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; margin-left: 0.5in">(d) For any and all infringement
of any Daewoong Patent anywhere in the Territory, Daewoong shall have the sole and exclusive right, but not the obligation, to
bring, at Daewoong&rsquo;s expense and in its sole control, an appropriate suit or other action against any person or entity engaged
in such infringement of the Daewoong Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) Daewoong shall not settle any claim, suit
or action that it brought under this Section 11.5 involving Ampio Patents without the prior written consent of Ampio, which consent
shall not be unreasonably withheld or delayed; provided that Ampio shall have the sole discretion to withhold consent in the event
it determines that such settlement would restrict in any material respect the scope of the Ampio Patents or its rights or interests
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(f) If either Party recovers monetary damages
from any Third Party in a suit or action brought hereunder with respect to Ampio Patents or Daewoong Patents, including in a settlement,
such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation (including,
for this purpose, a reasonable allocation of expenses of internal counsel), and any remaining amounts shall be split as follows:
(i) the portion of such amounts that represents recovery for lost sales in the Territory shall be retained by Daewoong and treated
as Net Sales, on which Daewoong shall make a transfer price payment, and (ii) any remaining amounts shall be retained by the Party
bring such suit or action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.6 <U>Infringement of Third
Party Rights in the Territory</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">(a) If any Product used or sold by either
Party, its Affiliates, licensees or sublicensees becomes the subject of a Third Party&rsquo;s claim or assertion of infringement
of a Patent granted by a jurisdiction within the Territory, the Party first having notice of the claim or assertion shall promptly
notify the other Party, the Parties shall agree on and enter into an &ldquo;identity of interest agreement&rdquo; wherein such
Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly
meet to consider the claim or assertion and the appropriate course of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) Daewoong shall have the first
right, but not the obligation, to defend any such Third Party threatened or asserted claim of infringement of a Patent as
described in Section 11.6(a) above, at Daewoong&rsquo;s expense. If Daewoong does not commence actions to defend such claim
within thirty (30) days after it receives notice thereof (or within thirty (30) days after it should have given notice
thereof to Ampio as required by Section 11.6(a)), then to the extent allowed by applicable Laws, Ampio shall have the right,
but not the obligation, to control the defense of such claim by counsel of its choice, at Ampio&rsquo;s expense. The
non-defending Party shall reasonably cooperate with the Party conducting the defense of the claim or assertion, including, if
required to conduct such defense, furnishing a power of attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) Each Party shall have the right to participate
or otherwise be involved in any such action controlled by the other Party, in each case at the participating Party&rsquo;s sole
cost and expense. If a Party elects to so participate or be involved, the controlling Party shall provide the participating Party
and its counsel with an opportunity to consult with the controlling Party and its counsel regarding the prosecution of such action
(including reviewing the contents of any correspondence, legal papers or other documents related thereto), and the controlling
Party shall take into account reasonable requests of the participating Party regarding such enforcement or defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) Neither Party shall enter into any settlement
of any claim described in this Section 11.6 that affects the other Party&rsquo;s rights or interests or the scope of any Ampio
Patent and/or Daewoong Patent in any material respect without such other Party&rsquo;s written consent. Each Party shall have the
right to decline to defend or to tender defense of any such claim to the other Party upon reasonable notice, including if the other
Party fails to agree to a settlement that such Party proposes. If a Party desires to take a license under any applicable Third
Party intellectual property rights for the purpose of Developing or Commercializing the Product in the Field, then such Party shall
submit the terms of such license to the JSC for review and approval. Any such license agreement will require the applicable Third
Party to grant licenses to both Daewoong and Ampio for performing their respective obligations and exercising their respective
rights in the Territory under this Agreement, will contain a release of any liabilities accrued prior to the effective date of
such license agreement, and will be subject to the mutual agreement of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.7 <U>Patent Marking</U>.
Daewoong (or its Affiliate or Sublicensees) shall mark Product marketed and sold by Daewoong (or its Affiliate or Sublicensees)
hereunder with appropriate patent numbers or indicia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.8 <U>Patent Oppositions
and Other Proceedings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Daewoong shall be prohibited from initiating
or requesting any interference or opposition proceeding with respect to, or making, filing or maintaining any claim to challenge
the validity, infringement or enforceability of, any Ampio Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) If either Party
desires to bring an opposition, action for declaratory judgment, nullity action, interference, declaration for
non-infringement, reexamination or other attack upon the validity, title or enforceability of a Patent owned or controlled by
a Third Party and having one or more claims that covers the Product, or the use, sale, offer for sale or importation of the
Product (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party&rsquo;s
claim or assertion of infringement under Section 11.6, in which case the provisions of Section 11.6 shall govern), such Party
shall so notify the other Party and the Parties shall promptly confer to determine whether to bring such action or the manner
in which to settle such action. Daewoong shall have the exclusive right, but not the obligation, to bring at its own expense
and in its sole control any such action in the Territory. If Daewoong does not bring such an action in the Territory, within
ninety (90) days of notification thereof pursuant to this Section 11.8(b) (or earlier, if required by the nature of the
proceeding), then Ampio shall have the right, but not the obligation, to bring, at Ampio&rsquo;s sole expense, such action.
The Party not bringing an action under this Section 11.8(b) shall be entitled to separate representation in such proceeding
by counsel of its own choice and at its own expense, and shall cooperate fully with the Party bringing such action. Any
awards or amounts received in bringing any such action shall be retained by the Party initiating such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) If any Ampio Patent
or Daewoong Patent or Patent Term Extension related thereto becomes the subject of any proceeding commenced by a Third Party within
the Territory in connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference
or other attack upon the validity, title or enforceability thereof (except insofar as such action is a counterclaim to or defense
of, or accompanies a defense of, an action for infringement against a Third Party under Section 11.5, in which case the provisions
of Section 11.5 shall govern), then the Party responsible for filing, preparing, prosecuting and maintaining such Patent or Patent
Term Extension as set forth in Sections 11.3 or 11.4 hereof shall control such defense at its own cost and expense. The controlling
Party shall permit the non-controlling Party to participate in the proceeding to the extent permissible under applicable Laws,
and to be represented by its own counsel in such proceeding, at the non-controlling Party&rsquo;s expense. If either Party decides
that it does not wish to defend against such action, then the other Party shall have the right to assume defense of such Third-Party
action at its own expense. Any awards or amounts received in defending any such Third-Party action shall be allocated between
the Parties as provided in Section 11.5(f).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">11.9 <U>Compendial Listing and Register of
Exclusive License</U>. Upon request of Daewoong, Ampio shall cooperate with Daewoong to (i) file appropriate information with the
applicable Regulatory Authority listing any Ampio Patents in the patent listing source in the Territory that is equivalent or similar
to the Orange Book in the U.S., if any, and (ii) register Daewoong&rsquo;s license granted hereunder to the applicable Regulatory
Authority, a patent and trademark office or other relevant governmental agency or offices in the Territory, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12 Confidentiality/Publications</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.1 <U>Confidentiality</U>.
Subject to any other provisions of this Agreement, each Party (the &rdquo;Receiving Party&rdquo;), for itself and its Affiliates
and their (direct and indirect) licensees and Sublicensees, agrees that it shall, during the term of this Agreement and for a period
of five (5) years thereafter or ten (10) years from the Effective Date, whichever is longer, (i) hold in confidence using not less
than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value
the Confidential Information received before or after the Effective Date from the other Party (the &ldquo;Disclosing Party&rdquo;),
(ii) not disclose such Confidential Information to any Third Party, except for those disclosures expressly permitted in this Section
12 below, and (iii) not use such Confidential Information for any purpose other than the purposes expressly permitted by this Agreement,
without first obtaining the prior written consent of the Disclosing Party, except as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) such Confidential Information is a part
of the public domain, or is known to the Receiving Party or any of its Affiliates without any obligation to keep it confidential,
prior to its disclosure by the Disclosing Party to the Receiving Party hereunder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) such Confidential Information becomes a
part of the public domain after its disclosure by the Disclosing Party to the Receiving Party hereunder without any breach by the
Receiving Party of this Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) such Confidential Information which the
Receiving Party can demonstrate that it has been independently developed either prior to its disclosure by the Disclosing Party
to the Receiving Party hereunder or without the use of Confidential Information of the Disclosing Party; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) such Confidential Information
is disclosed to the Receiving Party by a Third Party who has the right to make such disclosure; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) such Confidential Information
is required to be disclosed by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.2 <U>Authorized Disclosure</U>. The Receiving
Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure
is for a permitted purpose and is reasonably necessary in the following instances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) filing or prosecuting Patents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) as part of or in support of Regulatory
Filings (provided that such Party has the right to use the Confidential Information for such purpose under Section 2.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) in prosecuting or defending
litigation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) in order to comply with applicable non-patent
Laws (including the rules and regulations of the Securities and Exchange Commission (the &rdquo;SEC&rdquo;) or any other national
securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party&rsquo;s counsel, such disclosure
is necessary for such compliance; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) disclosure, solely on a &ldquo;need to
know basis&rdquo;, to Affiliates, potential and existing collaborators (including Sublicensees), permitted acquirers or assignees
under Section 21, subcontractors, investment bankers, investors and lenders, and their and each of the Parties&rsquo; respective
directors, employees, contractors and agents, each of whom prior to disclosure must be bound by written obligations of confidentiality
and non-use no less restrictive than the obligations set forth in this Section 12 (other than potential and existing investors
and lenders of Daewoong, with respect to which Daewoong shall use commercially reasonable efforts to be so bound); provided, however,
that the Receiving Party shall remain responsible for any failure by any Third Party who receives Confidential Information pursuant
to this Section 12.2(e) to treat such Confidential Information as required under this Section 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">If and whenever any Confidential Information is
disclosed in accordance with this Section 12.2, such disclosure shall not cause any such information to cease to be Confidential
Information except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach
of this Agreement). Where reasonably possible and other than with respect to Section 12.2(e), the Receiving Party shall notify
the Disclosing Party of the Receiving Party&rsquo;s intent to make such disclosure pursuant to this Section 12.2 sufficiently prior
to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate in
keeping with the terms of this Agreement to protect the confidentiality of the subject Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.3 <U>Terms of this
Agreement</U>. The Parties shall treat the terms of this Agreement as Confidential Information of both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.4 <U>Relationship to Confidentiality Agreement</U>.
This Agreement supersedes the Mutual CDA, provided that all &ldquo;Information&rdquo; disclosed or received by the Parties thereunder
shall be deemed &ldquo;Confidential Information&rdquo; hereunder and shall be subject to the terms and conditions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">12.5 <U>Publications</U>. If either Party wishes
to publish any information, data or results regarding Tramadol or Products in written, oral or other form in any scientific journals
or scientific conferences, a manuscript of the proposed publication shall first be sent to the other Party at least thirty (30)
days in advance of such publication for review. Unless the reviewing Party informs the other in writing during this thirty (30)
day period that the proposed publication must be delayed in order to protect a patentable invention or changed to avoid disclosure
of Confidential Information of the Reviewing Party, the other Party shall be free to publish such results without restriction.
In the event that a delay of the proposed publication is required, the other Party shall withhold such submission for publication
for one additional period, up to sixty (60) days, or such other period as the Parties may mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">13 Term and Termination</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">13.1 <U>Term</U>. This
Agreement shall become effective on the Effective Date. Unless sooner terminated in accordance with any other provision of this
Agreement, the term of this Agreement shall expire on the tenth anniversary of the date of the First Commercial Sale by Daewoong
of the first Product in the Territory (the &ldquo;Initial Term&rdquo;). Thereafter, this Agreement shall be automatically renewed
for successive periods of two (2) years. Either Party shall have the right to terminate this Agreement at the end of the Initial
Term or at the end of any two (2) year renewal term by sending to the other Party a written notice of such termination at least
ninety (90) days prior to the expiration of such Initial Term or renewal term as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">13.2 <U>Termination by Either
Party</U>. Notwithstanding the stipulation in Section 13.1, either Party may terminate this Agreement upon the occurrence of any
of the following itemized events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Such Party notifies the other Party of the
fact of material default or breach of any material provision in this Agreement by the notified Party, and the notified Party fails
to take corrective measures to mitigate or cure such default or breach within sixty (60) days from the date of notification; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) The other Party files in any court
or agency pursuant to any statute or regulation pertaining to bankruptcy, solvency, or payment of debts, of any state or
country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of such other Party or of its assets, or if such other Party shall be served with an involuntary petition
against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the
filing thereof, or if such other Party shall be a party to its dissolution or liquidation, or if such other Party shall make
an assignment for the benefit of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">14 Effects of Termination
or Expiration</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">14.1 <U>Survival</U>. Expiration
or termination of this Agreement for any reason shall be without prejudice to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) the obligations of confidentiality provided for
in Section 12 shall survive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) the Parties&rsquo; right
to receive all payments accrued under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) Ampio&rsquo;s right of
inspecting books and account of Daewoong and its Affiliates and Sublicensees pursuant to Article 9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) the rights and ownership in any Patents,
Know-How and Regulatory Documentation the respective Party has obtained prior to expiration or termination of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) Ampio&rsquo;s rights
provided for in Section 2.2 shall survive and be co-exclusive, perpetual, irrevocable, royalty-free and fully paid-up; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(f) any other rights or remedies
which either Party may then or thereafter have hereunder or at law or in equity or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">In addition to the foregoing, the following
provisions shall survive expiration or termination of this Agreement for any reason and shall continue in full force and effect:
Sections 1, 2.4, 4, 6.4, 7, 10, 11, 12, 14 and 15-27. Unless otherwise provided in this Section 14 and elsewhere herein, the license
grants contained in Sections 2.1 (except as otherwise provided in Section 2.3(b)), and all other licenses and other rights and
obligations hereunder, shall terminate upon termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">14.2 <U>Adverse Termination
Consequences for Daewoong</U>. Upon termination of this Agreement for any reason, Daewoong, its Affiliates and Terminated
Sublicensees shall cease use of the Ampio Patents, Ampio Know-How and the Ampio Regulatory Documentation. In addition,
Daewoong shall destroy or return (with confirmation letter to Ampio upon request) to Ampio any and all Ampio Know-How and
Ampio Regulatory Documentation in the possession of Daewoong, its Affiliates and Terminated Sublicensees, without delay, with
the exception that each of Daewoong and its Affiliates and Terminated Sublicensees may keep one copy for its legal files.
Furthermore, upon termination of this Agreement by Ampio under Section 13.2, Daewoong hereby grants to Ampio, effective only
upon such termination, a fully paid-up (except as provided below) worldwide non-exclusive license, with the right to
sublicense, under the Daewoong Patents, Daewoong Know How and Daewoong Regulatory Documentation, to develop, have developed,
make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Tramadol
and/or Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">14.3 <U>Inventory Sell-Off</U>.
Upon termination of this Agreement for any reason, Daewoong shall notify Ampio of the amount of Tramadol and Products Daewoong
and its Affiliates and Sublicensees then have on hand, and, if they so wish, Daewoong and its Affiliates and Sublicensees shall
thereupon be permitted to sell that amount of Tramadol and Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">14.4 <U>Transfer of Regulatory
Approvals</U>. Upon termination of this Agreement by Ampio under Section 13.2, Daewoong shall, and shall cause its Affiliates and
any Terminated Sublicensees to, upon Ampio&rsquo;s request, transfer to Ampio and/or its Affiliates and/or any Third Party appointed
by Ampio (hereinafter referred to as &ldquo;Transferee&rdquo;) with reasonable assistance, excluding financial assistance, to the
extent permissible under the Laws of the Territory, the Regulatory Approvals which Daewoong or its Affiliates or Terminated Sublicensees
have with respect to the Products in the Territory, in each case subject to all licenses granted by any of them (whether or not
in effect) to any Surviving Sublicensees and further subject to the royalty obligations (if any) set forth in Section 14.2. Such
assistance shall include, among others, an authorization by Daewoong or its Affiliates or Terminated Sublicensees given to the
Transferee to access to the Regulatory Approvals filed by Daewoong or its Affiliates or Terminated Sublicensees with the Regulatory
Authorities with respect to the Products in the Territory (<I>e.g.</I>, Regulatory Filings), the provision by Daewoong, if necessary,
to the Transferee of the Daewoong Know-How and such other acts which the Transferee may reasonably request Daewoong in order to
transfer such Regulatory Approvals with respect to the Products in the Territory, subject in all cases to such licenses held by
the Surviving Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">15 Announcement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">No public announcement concerning the existence
of or terms of this Agreement shall be made, either directly or indirectly, by any Party to this Agreement, except as may be required
by Law or as may be required for recording purposes or as permitted by Section 12.2, without first obtaining the written approval
of the other Party and agreement upon the nature and text of such announcement or disclosure. Other than with respect to Section
12.2(e), the Party desiring to make any such public announcement shall inform the other Party of the proposed announcement in reasonably
sufficient time prior to public release, and shall provide the other Party with a written copy thereof, in order to allow such
other Party to review, comment upon and approve such announcement, which such approval shall not be unreasonably withheld or delayed.
It is the intention of the Parties to issue a press release upon signing this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">16 Governing Law</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The formation, validity and performance of this
Agreement shall be governed by and interpreted in accordance with the internal substantive laws of the State of Delaware, without
giving effect to any choice of law rules in the State of Delaware or elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">17 Dispute Resolution</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">17.1 <U>Organization Resolution</U>. The
Parties will try to settle their differences amicably between themselves. In the event of any controversy or claim arising out
of or relating to any provision of this Agreement or the performance or alleged non-performance of a Party of its obligations
under this Agreement (&ldquo;Dispute&rdquo;), a Party may notify the other Party in writing of such Dispute. If the Parties are
unable to resolve the Dispute within sixty (60) days of receipt of the written notice by the other Party, such Dispute shall be
referred to a senior executive of Daewoong and Ampio, who will use their good faith efforts to resolve the Dispute within thirty
(30) days after it was referred to them. If the senior executives are unable to resolve the Dispute, the Parties shall refer the
Dispute to arbitration as provided for in Section 17.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">17.2 <U>Jurisdiction by Agreement</U>. Any Dispute
that is not resolved as provided in Section 17.1, whether before or after termination of this Agreement, shall be submitted exclusively
for resolution to arbitration administrated by the International Chamber of Commerce (&ldquo;ICC&rdquo;) and be finally settled
in accordance with the Rules of International Conciliation and Arbitration of ICC. The arbitration shall be subject to the governing
law set forth in Section 16, shall be held in New York, New York, in front of a panel of three (3) arbitrators, shall be conducted
in the English language, shall be final and binding determination of the Dispute and not subject to judicial review, and shall
not include any award of damages expressly prohibited by Section 17.3, and judgment upon any award rendered by the arbitrators
may be entered in any court having jurisdiction over the liable Party. Except for Disputes the resolution of which require the
arbitration of material rights of any Third Party, this Section 17.2 shall be the exclusive remedy with respect to any Dispute
for either Party or their Affiliates, provided that this Section 17 shall not restrict the Parties&rsquo; rights to seek preliminary
injunctive relief before a court of any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">17.3 <U>Consequential Damages</U>.
Neither Party hereto will be liable for special, incidental, indirect, punitive, exemplary or consequential damages arising out
of this Agreement or performance of its obligations hereunder or the exercise of its rights hereunder, including lost profits,
anticipated profit, lost goodwill, lost revenue, lost contracts, and lost opportunity arising from or relating to any breach of
this Agreement, regardless of the causes of action or theories of liability alleged any notice of such damages. Nothing in this
Section 17.3 is intended to limit or restrict the indemnification rights or obligations of either Party under Section 20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">18 Notices</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">18.1 Any notice required to be given under this
Agreement shall be given in the English language by sending such notices by postage-prepaid registered airmail or an internationally
recognized overnight courier service addressed to the other Party at the address listed below:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">For Ampio:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Ampio Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">5445 DTC Parkway, Suite 925</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Greenwood Village, Colorado 80111</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Attention:
Bruce G. Miller and Don Wingerter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">With a required copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Goodwin Procter LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Exchange Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">53 State Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Boston, Massachusetts 02109</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Attn: Lawrence Wittenberg,
Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">For Daewoong:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Daewoong Pharmaceuticals Co., Ltd</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">163-3 Samsungdong,
Kangnam-gu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Seoul, Republic of Korea</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Attention:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">Either Party may notify the other Party of a different
address to receive the other Party&rsquo;s notices in accordance with the manner described in this Section 18.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">18.2 In the case where any notice is sent by airmail,
such notice shall be sent return receipt requested and is deemed to be received by the other Party upon endorsement, by an employee
or agent of the other Party of such receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">19 Force Majeure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">19.1 Neither Party shall be liable for any failure
to perform as required by this Agreement if such failure is due to circumstances reasonably beyond the control of such Party, including
requisition or interference by any government, state or local authorities, war, riots, civil disturbances, terrorism, strikes or
other labour disputes, accidents, failure to secure required governmental approval, civil disorders or acts of aggression, acts
of God, energy or other conservation shortages, plague or other such occurrences (&ldquo;Force Majeure&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">19.2 If and when any Party is hindered in its
performance of its obligations under this Agreement by reason of Force Majeure, the performance shall be suspended during, but
not longer than, the continuance of such circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">19.3 Either Party hereto whose performance of
obligations has been hindered by reason of Force Majeure shall, to the extent possible, inform the other Party immediately, and
shall use reasonable efforts to overcome the effect of the Force Majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">20 Indemnification and
Insurance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">20.1 Ampio shall defend, indemnify and hold harmless
Daewoong and its Affiliates and Sublicensees, and their officers, directors, employees, agents, distributors and suppliers, and
their respective successors, assigns, heirs and representatives (collectively, &rdquo;Daewoong Indemnitees&rdquo;) from and against
all liabilities, damages, losses, suits, proceedings, actions, claims, judgments and costs and expenses (including legal fees and
expenses) resulting from any Third Party claim made or suit brought (collectively, &rdquo;Losses&rdquo;) to the extent the same
is arising from or related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Ampio&rsquo;s material breach of any term of
this Agreement (including any express representation or warranty made herein),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) the negligence, recklessness or willful misconduct
or fraud on the part of Ampio or any of its Affiliates, or Ampio Licensees or any of their respective officers, directors, employees,
agents, distributors and suppliers, or any of their respective successors, assigns, heirs or representatives with respect to Tramadol
or Products supplied by Ampio or in the performance of Ampio&rsquo;s obligations or exercise of Ampio&rsquo;s rights under this
Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) any actual or alleged violation of Law
(other than any patent or other intellectual property Laws) in the performance of Ampio&rsquo;s obligations or exercise of Ampio&rsquo;s
rights under this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) any product liability claim related to Tramadol
or Products manufactured, used or sold by any of Ampio or its Affiliates or Ampio Licensees or any of their respective successors,
assigns, heirs or representatives. prior to the Effective Date or during the term of this Agreement or after termination or expiration
of this Agreement, and any product liability claim related to Tramadol or Products arising from manufacturing Tramadol or Products
supplied to Daewoong hereunder, including (i) non conformance of Tramadol or Products to Tramadol specifications and (ii) non manufacture
of Tramadol or Products according to cGMP, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) any claim of infringement or misappropriation
of a Third Party&rsquo;s patent, copyright, trade secret or trademark right, or any other intellectual property right arising from
the development, registration, manufacture, marketing, promotion, distribution, importation, offer for sale or sale or other commercialization
of Tramadol or Products, or chemical agents for making or using the same, by any of Ampio or its Affiliates or Ampio Licensees
or any of their respective successors, assigns, heirs or representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">However, Ampio shall not be required to indemnify
any Daewoong Indemnitee to the extent that any such claims or suits arose out of or resulted from the negligence, recklessness
or willful misconduct or fraud of any Daewoong Indemnitees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">20.2 Daewoong shall defend, indemnify and hold
harmless Ampio or any of its Affiliates, or Ampio Licensees or any of their respective officers, directors, employees, agents,
distributors and suppliers, or any of their respective successors, assigns, heirs or representatives (collectively, &ldquo;Ampio
Indemnitees&rdquo;) from and against all Losses to the extent the same is arising from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(a) Daewoong&rsquo;s material breach of any term
of this Agreement (including any express representation or warranty made herein),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(b) the negligence, recklessness or willful
misconduct or fraud on the part of any Daewoong Indemnitee with respect to the Product produced by Daewoong or in the performance
of Daewoong&rsquo;s obligations or exercise of Daewoong&rsquo;s rights under this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(c) any actual or alleged violation of Law
(other than any patent or other intellectual property Laws) in the performance of Daewoong&rsquo;s obligations or exercise of Daewoong&rsquo;s
rights under this Agreement,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(d) any product liability claim related to Tramadol
or Product manufactured, used or sold by any Daewoong or its Affiliates or Sublicensees or any of their respective successors,
assigns, heirs or representatives during the term of this Agreement or after termination or expiration of this Agreement, unless
and to the extent such claim arose out of or resulted from (i) non conformance of Tramadol or Products supplied by Ampio to Tramadol
specifications or (ii) non manufacture of Tramadol or Products supplied by Ampio or any of its Affiliates according to cGMP, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(e) use of any data from
any clinical studies conducted by or on behalf of Ampio or Ampio Licensees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">(f) any claim of infringement or misappropriation
of a Third Party&rsquo;s patent, copyright, trade secret or trademark right, or any other intellectual property right arising from
the development, registration, manufacture, marketing, promotion, distribution, importation, offer for sale or sale or other commercialization
of Tramadol or Product, or chemical agents for making or using the same, by any of Daewoong or its Affiliates or Sublicensees or
any of their respective successors, assigns, heirs or representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">However, Daewoong shall not be required to indemnify
any Ampio Indemnitee to the extent that any such claims or suits arose out of or resulted from the negligence, recklessness or
willful misconduct or fraud of any Ampio Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">20.3 <U>Indemnification Procedures</U>.
A Party which intends to claim indemnification under Section 20.1 or 20.2 (the &rdquo;Indemnitee&rdquo;) will promptly notify
the other Party (the &ldquo;Indemnitor&rdquo;) in writing of any claim, suit, proceeding or action in respect of which the
Indemnitee or any of the other Ampio Indemnitees or Daewoong Indemnitees, as applicable, intend to claim such indemnification
within a reasonable period of time after the assertion of such claim; provided, however, that the failure to provide written
notice of such claim within a reasonable period of time will not relieve the Indemnitor of any of its obligations hereunder,
except to the extent that the Indemnitor is prejudiced by such failure to provide prompt notice. The Indemnitor will have the
right to assume the complete control of the defence, compromise or settlement of any such claim (provided that no settlement
of any claim will include any admission of wrongdoing on the part of an Indemnitee or the other Ampio Indemnitees or Daewoong
Indemnitees, as applicable, or materially and adversely effect the rights of the Indemnitee or the other Ampio Indemnitees or
Daewoong Indemnitees, as applicable, in each case without the prior written consent of such Indemnitee, which such consent
will not be unreasonably withheld or delayed). The Indemnitor may, at its own expense, employ legal counsel to defend the
claim at issue. The Indemnitee may, in its sole discretion and at its own expense, employ legal counsel to represent it and
the other Ampio Indemnitees or Daewoong Indemnitees, as applicable (in addition to the legal counsel employed by the
Indemnitor) in any such matter, and in such event legal counsel selected by the Indemnitee will be required to confer and
cooperate with such counsel of the Indemnitor in such defence, compromise or settlement for the purpose of informing and
sharing information with the Indemnitor. The Indemnitee will, at its own expense, make available to Indemnitor those Ampio
Indemnitees or Daewoong Indemnitees, as applicable, whose assistance, testimony or presence is necessary, useful or
appropriate to assist the Indemnitor in evaluating, defending or settling any such claim; provided, however, that any such
access will be conducted in such a manner as not to interfere unreasonably with the operations of the businesses of
Indemnitee or the other Ampio Indemnitees or Daewoong Indemnitees, as applicable; and will otherwise fully cooperate with the
Indemnitor and its legal counsel in the investigation and defence of such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">20.4 <U>Insurance</U>. Both
Parties will procure and maintain adequate insurance in order to be able to cover claims under this Agreement. Upon request, each
Party shall provide proof of adequate coverage to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">21 Non-assignability</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">This Agreement is personal to the Parties hereto
and shall not be assignable to any Third Party by either Party without the prior written consent of the other Party, which shall
not be unreasonably withheld or delayed; <U>provided</U>, <U>however</U>, that any Party may assign this Agreement in full to an
Affiliate of such Party without prior written consent, but with prior written notice, and <U>provided</U>, <U>further</U>, that
any Party may assign this Agreement to any entity with which such Party may merge or consolidate (or engage in some other form
of corporate combination), or to which it may transfer all or substantially all of its assets to which this Agreement relates.
All successors and permitted assignees of a Party shall be subject to, and will be bound by, all the terms and conditions of this
Agreement. Any attempted assignment made contrary to the provisions hereof will be void. This Agreement shall inure to the benefit
of and be binding on the Parties&rsquo; successors, permitted assigns and legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">22 Language</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">22.1 This text of this Agreement in the English
language shall be the original text, and any text in another language, even if such a text is made by translation of the text in
English language or prepared by any of the Parties hereto for the purpose of its own convenience, shall have no meaning for any
purpose between the Parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">22.2 Any information to be provided under this
Agreement, including any Know-How, shall be provided in the English language. The words &ldquo;include&rdquo;, &ldquo;includes&rdquo;
and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo;. The words &rdquo;herein&rdquo;,
&ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo;, and words of similar import, shall be construed to refer to this Agreement in
its entirety and not to any particular provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">23 Entire Agreement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">This Agreement
(together with the Exhibits attached hereto and the Development Plan) shall constitute the entire agreement between the Parties
hereto concerning the subject matter hereof and shall supersede any other agreements, whether oral or written, express or implied,
with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">24 Separability</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">24.1 In the event any portion of this Agreement
shall be held illegal, void or ineffective, the remaining portions hereof shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">24.2 If any of the terms or provisions of this
Agreement are in conflict with any applicable Law, then such terms or provisions shall be deemed inoperative to the extent that
they may conflict therewith and shall be deemed to be modified to conform with such Law. The Parties shall make a good faith effort
to replace any invalid or unenforceable term or provision with a valid and enforceable one such that the objectives contemplated
by the Parties when entering this Agreement may be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">25 Independent Contractors;
No Partnership</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The Parties hereto are independent contractors.
In making and performing this Agreement, the Parties are acting, and intend to be treated, as independent entities performing a
contract, and nothing contained in this Agreement is to be construed or implied or deemed to create an agency, partnership, joint
venture or an employee/employer relationship between Daewoong and Ampio. This Agreement is not, and will not be deemed to be, a
partnership agreement or joint venture agreement, expressly or by implication. Employees of each Party remain employees of said
Party and will be considered at no time agents of or owing a fiduciary duty to the other Party. Neither Party will have any implied
right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party
to any other contract, agreement or undertaking with any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">26 Amendment and Waiver</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">The Parties hereto may amend, modify or alter
any of the provisions of this Agreement, but such amendment, modification or alteration will be valid and binding on either Party
only if memorized by a written instrument that explicitly refers to this Agreement and is duly executed by both Parties hereto.
The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of such obligation.
Waiver of any nonaction of any provision hereof shall not be deemed to be a waiver of any other rights or remedies of such provision
or any other provision on such occasion or any succeeding occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">27 Counterparts</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">This Agreement may be executed by the Parties
in one or more identical counterparts, all of which together will constitute this Agreement. If this Agreement is executed in counterparts,
no signatory hereto will be bound until both Parties have duly executed a counterpart of this Agreement. Facsimile execution and
delivery of this Agreement by the Parties shall be legal, valid and binding execution and delivery of this Agreement for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[<I>remainder of this
page intentionally left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">IN WITNESS WHEREOF, the
Parties hereto have caused this Agreement to be executed in duplicate counterparts by their duly authorized representatives, each
fully executed copy hereof to be deemed as original, as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampio Pharmaceuticals, Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ DB Wingerter</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daewoong Pharmaceuticals Co., Ltd</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jong Wook Lee</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Jong Wook Lee</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President &amp; CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">License, Development and Commercialization Agreement between Ampio and Daewoong</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>EXHIBIT 1.5</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>AMPIO
PATENTS</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">To be provided within 15 days after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">License, Development and Commercialization Agreement between Ampio and Daewoong</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>EXHIBIT 1.18</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>DAEWOONG
PATENTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">To be provided within 15 days after the Effective
Date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">License, Development and Commercialization Agreement between Ampio and Daewoong</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>EXHIBIT
3.1</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>AMPIO KNOW-HOW
AND AMPIO REGULATORY DOCUMENTATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">Within sixty (60) days
after the Effective Date of this Agreement, Ampio shall disclose or make available to Daewoong copies of all of the Ampio Know-How
and Ampio Regulatory Documentation, including the following Ampio Know-How and Ampio Regulatory Documentation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">1. Trial Master File
(&ldquo;TMF&rdquo;) for &ldquo;A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and
Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets In Male Subjects with Premature Ejaculation&rdquo;
(&ldquo;Study&rdquo;), Sponsors Protocol codes: BVF-324.301 and BVF-324.302, as received by Ampio from Kendle International, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">Protocol Summaries and Synopses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Protocol Amendments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">ICF/SIS - Study Templates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Q-A Logs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">QC Documentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Case Report Forms and Amendments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">eCRF Completion
Guidelines</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Recruitment Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Source Document Templates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Investigator Brochure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Certificates of Analysis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Correspondence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Clinical Study Reports</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Audit Certificates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Regulatory Authority Documents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Translations, translation certificates &amp;
checklists</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Country Documentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Central Ethics Committee Documentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Final
Statistical Analysis Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Investigational Medicinal Product Dossier</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1in">Bioequivalence Study</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0.5in">Alcohol Interference Study</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-indent: 0.5in">2. SAS datasets with
safety and efficacy data for &ldquo;A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy
and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets In Male Subjects with Premature Ejaculation&rdquo;
(&ldquo;Study&rdquo;), Sponsors Protocol Codes: BVF-324.301 and BVF-324.302, as received by Ampio from Kendle International.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">License, Development and Commercialization Agreement between Ampio and Daewoong</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>f10k2018ex10-11_aytubio.htm
<DESCRIPTION>VOTING AGREEMENT BETWEEN THE REGISTRANT AND AMPIO, DATED APRIL 21, 2015
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: center"><B><U>VOTING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS VOTING AGREEMENT
(this &ldquo;<B><I>Agreement</I></B>&rdquo;), dated as of April 21, 2015, is made between Rosewind Corporation, a Colorado corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), and Ampio Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;<B><I>Shareholder</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Recitals</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the
Shareholder is the beneficial owner (as defined in Rule l3d-3 under the Securities Exchange Act of 1934, as amended) of 141,535,750
outstanding shares of common stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), of the Company,
which shares entitle the beneficial owner to vote at a meeting of the shareholders of the Company or by written consent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, each
of the Shareholder and the Company will derive significant value from the consummation of the Proposed Transactions (as defined
below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, in
consideration of the foregoing, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Shareholder
agrees to vote all of the shares of the Common Stock beneficially owned by the Shareholder at one or more Company shareholder meetings
or by written consent in favor of proposals approved by the Board of Directors of the Company (the &ldquo;Board&rdquo;) and authorizing
the Company to (1) re-incorporate into the State of Delaware through a plan of conversion; (2) effectuate a reverse stock split
of the Company&rsquo;s common stock, at a ratio of one new share for every approximately 12.174 shares currently outstanding; (3)
change the name of the Company from &ldquo;Rosewind Corporation&rdquo; to &ldquo;Aytu Bioscience, Inc.&rdquo;; and (4)&nbsp;approve
a new stock option and incentive plan (collectively, the &ldquo;<B><I>Proposed Transactions</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the foregoing and the mutual promises, representations, warranties, covenants and agreements contained herein,
the parties hereto, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">1.</FONT></TD><TD><B><U>Voting Provisions</U></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(a) </FONT><U>Agreement
to Vote Shares of the Company&rsquo;s Stock</U>. The Shareholder hereby agrees during the Term (as defined in <U>Section 3</U>
below) of this Agreement to vote or cause to be voted all shares of Company&rsquo;s Common Stock owned of record and/or beneficially
(as defined in Rule 13d-3 of the Exchange Act of 1934, as amended) by the Shareholder (the &ldquo;<B><I>Shares</I></B>&rdquo;),
in each case, as of the applicable record date for any annual or special meeting of shareholders or in connection with any solicitation
of shareholder action by written consent (each, a &ldquo;<B><I>Shareholders Meeting</I></B>&rdquo;), in favor of each of the Proposed
Transactions and to be present for quorum purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(b) </FONT>
<U>No Other Voting Agreement</U>. The Shareholder hereby agrees that the Shareholder shall not enter into any agreement or understanding
with any other person the effect of which would be to violate the provisions and agreements contained in this <U>Section 1</U>,
provided that the foregoing shall not restrict the Shareholder from selling or otherwise disposing of the Shareholder&rsquo;s Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">2.</FONT></TD><TD STYLE="text-align: justify"><B><U>Other Proxies Revoked</U></B>. The Shareholder represents and warrants that any proxies heretofore
given in respect of the Shareholder&rsquo;s Shares are not irrevocable, and that all such proxies have been or are hereby revoked.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">3.</FONT></TD><TD STYLE="text-align: justify"><B><U>Term of Agreement</U></B>. The term of this Agreement shall commence on the date of this
Agreement and shall remain in full force and effect until the approval by the Company&rsquo;s stockholders of the Proposed Transactions
(the &ldquo;<B><I>Term</I></B>&rdquo;). For avoidance of doubt, upon the termination of this Agreement, the parties will have no
continuing obligations pursuant to this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">4.</FONT></TD><TD STYLE="text-align: justify"><B><U>Representations and Warranties of the Shareholder</U></B>. The Shareholder hereby represents
and warrants to the Company as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(a) </FONT><U>Authority,
etc</U>. The Shareholder has all necessary power and authority to execute and deliver this Agreement and to consummate the transactions
contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby
by the Shareholder have been duly authorized by all necessary action on the part of the Shareholder and constitutes a legal, valid
and binding obligation of the Shareholder, enforceable against the Shareholder in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(b) </FONT><U>Ownership
of Shares</U>. The Shareholder is, as of the date hereof, the beneficial owner of 141,535,750 shares of Common Stock. The Shareholder
has sole voting power and sole power to issue instructions with respect to the matters set forth in <U>Section 1</U> hereof, sole
power of disposition, sole power of conversion, sole power to agree to all of the matters set forth in this Agreement, in each
case with respect to all of the Shares, with no limitations, qualifications or restrictions on such rights, subject only to applicable
securities laws and the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(c) </FONT><U>No
Conflicts</U>. No filing with, and no permit, authorization, consent or approval of, any governmental entity is necessary for the
execution of this Agreement by the Shareholder and the consummation by the Shareholder of the transactions contemplated hereby.
None of the execution and delivery of this Agreement by the Shareholder, the consummation by the Shareholder of the transactions
contemplated hereby or compliance by the Shareholder with any of the provisions hereof shall (A) conflict with or result in any
breach of any applicable documents to which the Shareholder is a party, or (B)&nbsp;violate any order, writ, injunction, decree,
judgment, order, statute, rule or regulation applicable to the Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(d) </FONT><U>No
Encumbrances</U>. The Shares and the certificates representing such Shares are now held by the Shareholder, or by a nominee or
custodian for the benefit of the Shareholder, free and clear of all liens, claims, security interests, proxies, voting trusts or
agreements, understandings or arrangements or any other encumbrances whatsoever, except for any such encumbrances or proxies arising
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="color: #010000">5.</FONT></TD><TD STYLE="text-align: justify"><B><U>Covenants of The Shareholder</U></B>. The Shareholder covenants and agrees that, during the
Term, the Shareholder shall not (i) grant any proxies or powers of attorney, deposit any of the Shares into a voting trust or enter
into a voting agreement with respect to any of the Shares or (ii) take any action that would make any representation or warranty
of the Shareholder contained herein untrue or incorrect or have the effect of preventing, disabling or delaying the Shareholder
from performing the Shareholder&rsquo;s obligations under this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">Covenants of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company covenants and
agrees that it shall hold a Shareholders Meeting as soon as is reasonably practicable for the purpose of voting upon the Proposed
Transactions, unless the Board determines after the date of this Agreement that it is no longer advisable for the Company to do
so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify"><FONT STYLE="color: #010000">(a) </FONT><B><U>Miscellaneous</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">(a) <U>Further
Assurances</U>. From time to time, at any other party&rsquo;s written request and without further consideration, each party
hereto shall execute and deliver such additional documents and take all such further lawful action as may be necessary or
desirable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(b) </FONT><U>Entire
Agreement</U>. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and
supersedes all other prior agreements and understandings, both written and oral, between the parties with respect to the subject
matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(c) </FONT><U>Assignment</U>.
This Agreement shall not be assigned by operation of law or otherwise without the prior written consent of the other party, provided
that the Buyers may assign and transfer, at its sole discretion, its rights and obligations hereunder to any of their affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(d) </FONT><U>Amendments,
Waivers, Etc</U>. This Agreement may not be amended, changed, supplemented, waived or otherwise modified or terminated, except
upon the execution and delivery of a written agreement executed by all of the relevant parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(e) </FONT><U>Notices</U>.
All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be
deemed to have been duly received if so given) by hand delivery, fax, or by mail (registered or certified mail, postage prepaid,
return receipt requested) or by any courier service, such as FedEx, providing proof of delivery. All communications hereunder shall
be delivered to the respective parties at the following addresses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Shareholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Ampio Pharmaceuticals, Inc.<BR>
373 Inverness Parkway, Suite 200<BR>
Englewood, Colorado 80112<BR>
Attention: Gregory A. Gould<BR>
Facsimile: (720) 437-6501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Rosewind Corporation<BR>
373 Inverness Parkway, Suite 200<BR>
Englewood, Colorado 80112<BR>
Attention: Joshua R. Disbrow<BR>
Facsimile: (720) 437-6501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Goodwin Procter LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">620 Eighth Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">New York, New York 10018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Attention: Andrew H. Goodman, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Facsimile: (212) 355-3333</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or to such other address as the person
to whom notice is given may have previously furnished to the others in writing in the manner set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(f) </FONT><U>Severability</U>.
Whenever possible, each provision or portion of any provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law but if any provision or portion of any provision of this Agreement is held to be invalid, illegal
or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will not affect any other provision or portion of any provision in such jurisdiction, and this Agreement will be reformed, construed
and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never
been contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(g) </FONT><U>Specific
Performance</U>. Each of the parties hereto recognizes and acknowledges that a breach by it of any covenants or agreements contained
in this Agreement will cause the other party to sustain damages for which it would not have an adequate remedy at law for money
damages, and therefore each of the parties hereto agrees that in the event of any such breach the aggrieved party shall be entitled
to the remedy of specific performance of such covenants and agreements and injunctive and other equitable relief in addition to
any other remedy to which it may be entitled, at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(h) </FONT><U>Remedies
Cumulative</U>. All rights, powers and remedies provided under this Agreement or otherwise available in respect hereof at law or
in equity shall be cumulative and not alternative, and the exercise of any thereof by any party shall not preclude the simultaneous
or later exercise of any other such right, power or remedy by such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(i) </FONT><U>No
Waiver</U>. The failure of any party hereto to exercise any right, power or remedy provided under this Agreement or otherwise available
in respect hereof at law or in equity, or to insist upon compliance by any other party hereto with its obligations hereunder, and
any custom or practice of the parties at variance with the terms hereof shall not constitute a waiver by such party of its right
to exercise any such or other right, power or remedy or to demand such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(j) </FONT><U>No
Third Party Beneficiaries</U>. This Agreement is not intended to be for the benefit of, and shall not be enforceable by, any person
who or which is not a party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(k) </FONT><U>Governing
Law</U>. This Agreement, and the legal relations between the parties hereto, shall be governed and construed in accordance with
the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(l) </FONT><U>Waiver
of Jury Trial</U>. EACH OF THE PARTIES HEREBY KNOWINGLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ANY RIGHTS THEY MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS AGREEMENT OR ANY OTHER
DOCUMENTS ENTERED INTO IN CONNECTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL OR WRITTEN),
OF ANY PARTY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(m) </FONT><U>Descriptive
Headings</U>. The descriptive headings used herein are inserted for convenience of reference only and are not intended to be part
of or to affect the meaning or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: #010000">(n) </FONT><U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, and by the different parties hereto in separate counterparts, each
of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.
Delivery of an executed counterpart of a signature page to this Agreement by facsimile shall be effective as delivery of a manually
executed counterpart of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
each of the Company and the Shareholder has caused this Voting Agreement to be duly executed as of the day and year first above
written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>ROSEWIND CORPORATION</B></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0; width: 35%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Joshua R. Disbrow</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; text-indent: 0">President and Chief Executive Officer</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>AMPIO PHARMACEUTICALS, INC.</B></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Gregory A. Gould</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; text-indent: 0">Chief Financial Officer</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<FONT STYLE="font-variant: small-caps">Signature
Page to Voting Agreement</FONT>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>4
<FILENAME>f10k2018ex10-31_aytubio.htm
<DESCRIPTION>AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT, DATED JUNE 11, 2018, BETWEEN AYTU BIOSCIENCE, INC. AND MAGNA PHARMACEUTICALS, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.31</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amended and Restated Exclusive
License Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-variant: small-caps">This
<B>Exclusive License Agreement</B></FONT> (the &ldquo;<U>Agreement</U>&rdquo;) is entered into as of June 11, 2018 (the &ldquo;<U>Effective
Date</U>&rdquo;) by and between Aytu BioScience, Inc., a Delaware corporation (&ldquo;<U>Licensee</U>&rdquo;), and Magna Pharmaceuticals,
Inc. a Kentucky corporation (&ldquo;<U>Licensor</U>&rdquo;). Licensor and Licensee may be referred to herein individually as a
&ldquo;<U>Party</U>&rdquo; or collectively, as the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Recitals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>Whereas,</B></FONT>
Licensor owns or controls certain intellectual property, regulatory approvals documentation, data, and other materials with respect
to the Product (as defined below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>Whereas,</B></FONT>
Licensee wishes to license such rights in order to further develop and Commercialize the Products (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>Now,
Therefore,</B></FONT> in consideration of the foregoing and the covenants and promises contained in this Agreement, the Parties
agree as follows:</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Definitions.
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-variant: normal">The following capitalized terms
shall have the subsequent meanings when used in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>2018
Maintenance Fee</U>&rdquo; has the meaning assigned to it in the Reimbursement Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>
&ldquo;<U>Abandoned Patent</U>&rdquo; has the meaning assigned to it in Section 5.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Abandoned
Trademark</U>&rdquo; has the meaning assigned to it in Section 5.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>AE</U>&rdquo;
and &ldquo;<U>SAE</U>&rdquo; have the meanings assigned to them in Section 4.6.c.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to either Party, any person, corporation or other business entity which, directly or indirectly through one
or more intermediaries, actually controls, is actually controlled by, or is under common control with such Party. As used in this
Section 1.1, &ldquo;control&rdquo; means to possess, directly or indirectly, the power to affirmatively direct the management and
policies of such person, corporation or other business entity, whether through ownership of at least fifty percent (50%) of the
voting securities or by contract relating to voting rights or corporate governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Agreement</U>&rdquo;
has the meaning assigned to it in the Preamble of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Applicable
Law</U>&rdquo; means all applicable laws, rules, regulations and guidelines that may apply to the development, marketing, manufacturing
or sale of Products or the performance of either Party&rsquo;s obligations, or the exercise of either Party&rsquo;s rights, under
this Agreement, including but not limited to all laws, regulations and guidelines governing the import, export, development, marketing,
distribution and sale of the Product in the Territory and, to the extent relevant, all GCP, GLP or GMP standards or guidelines
promulgated by any Regulatory Authorities or the ICH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>Intentionally
omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday, or a day that is a federal legal holiday in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Buyout
Payment</U>&rdquo; has the meaning assigned to it in Section 3.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Calendar
Day</U>&rdquo; means each of those seven (7) days in the week.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Calendar
Quarter</U>&rdquo; means each of those three (3) calendar month periods of each Calendar Year ending March 31, June 30, September
30 and December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Calendar
Year</U>&rdquo; means (a) for the first Calendar Year, the period commencing on the Effective Date and ending on December 31 of
the same year, (b) for the Calendar Year in which this Agreement expires or is terminated, the period beginning on January 1 of
such Calendar Year and ending on the effective date of such expiration or termination, and (c) for all other years, each successive
twelve (12) consecutive month period beginning on January 1 and ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Claims</U>&rdquo;
has the meaning assigned to it in Section 11.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Code</U>&rdquo;
has the meaning assigned to it in Section 2.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Commercialize</U>&rdquo;
or &ldquo;<U>Commercialization</U>&rdquo; means all activities that are undertaken after Regulatory Approval of a Product in a
particular jurisdiction and that relate to the commercial marketing, sale, and/or distribution of such Product, including but not
limited to advertising and/or promotional activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Commercially
Reasonable Efforts</U>&rdquo; means the carrying out of obligations or tasks in a manner consistent with the efforts that are consistent
with the general standards used by comparable companies in the pharmaceutical industry for commercializing similar pharmaceutical
products of similar market potential, profit potential or strategic value resulting from its own research efforts or for its own
benefit, taking into account technical, regulatory, commercial and intellectual property factors, target product profiles, product
labeling, past performance, costs, economic return, the regulatory environment and competitive market conditions in the therapeutic
or market niche, all based on conditions then prevailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Competing
Product</U>&rdquo; means any product or combination(s) of products containing the active pharmaceutical ingredient zolpidem tartrate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Confidential
Information</U>&rdquo; means all information and know-how and any tangible embodiments thereof provided by or on behalf of one
Party to the other Party either in connection with the discussions and negotiations pertaining to this Agreement or in the course
of performing under this Agreement, which may include data, knowledge, practices, processes, ideas, research plans, formulation
or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel
matters relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors
or business; provided, that, information or know-how of a Party will not be deemed Confidential Information of such Party for purposes
of this Agreement if such information or know-how: (a) was already known to the receiving Party, other than under an obligation
of confidentiality or non-use, at the time of disclosure to such receiving Party, as can be shown by written records; (b) was generally
available or known to parties reasonably skilled in the field to which such information or know-how pertains, or was otherwise
part of the public domain, at the time of its disclosure to such receiving Party; (c) became generally available or known to parties
reasonably skilled in the field to which such information or know-how pertains, or otherwise became part of the public domain,
after its disclosure to such receiving Party through no fault of the receiving Party; (d) was disclosed to such receiving Party,
other than under an obligation of confidentiality or non-use, by a Third Party who had no obligation to the disclosing Party not
to disclose such information or know-how to others, as can be shown by written records; or (e) was independently discovered or
developed by such receiving Party, as can be shown by its written records, without the use or benefit of, or reliance on, Confidential
Information belonging to the disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Controlled</U>&rdquo;
means, with respect to any Patent, Know-How, Regulatory Filing or Regulatory Approval, the possession by a Party of the ability
to grant a license or sublicense, or make an assignment or transfer thereof, as provided for herein without violating the terms
of any arrangement or agreements between such Party and any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Controlling
Party</U>&rdquo; has the meaning assigned to it in Section 6.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Cover</U>&rdquo;
&ldquo;<U>Covered</U>&rdquo; or &ldquo;<U>Covering</U>&rdquo; means that the use, manufacture, sale, offer for sale, development,
commercialization or importation of the subject matter in question by an unlicensed entity would infringe a Valid Claim of a Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Delivered
Inventory</U>&rdquo; has the meaning assigned to it in Section 4.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Develop</U>&rdquo;
&ldquo;<U>Development</U>&rdquo; or &ldquo;<U>Developing</U>&rdquo; means, with respect to a Product, engaging in preclinical,
clinical, and other research or development activities, which may include but is not limited to research, pre-clinical, clinical
and regulatory activities directed towards obtaining the initial Regulatory Approval of a Product in a particular jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>DMF</U>&rdquo;
means a drug master file, as provided for in the United States Code of Federal Regulations (&ldquo;<U>CFR</U>&rdquo;) at 21 CFR
&sect;&nbsp;314.420 or similar submission to or file maintained with the FDA or other Governmental Authority or Regulatory Authority
that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing,
processing, packaging, and storing of one or more human drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Effective
Date</U>&rdquo; has the meaning assigned to it in the Preamble of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Executive
Officers</U>&rdquo; has the meaning assigned to it in Section 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>FDA</U>&rdquo;
means the United States Food and Drug Administration, or any successor federal agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Field</U>&rdquo;
means any use, application, or purpose, including, without limitation, the treatment, palliation, diagnosis, or prevention of any
human or animal disease, disorder or condition related to the treatment of insomnia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>GCP</U>&rdquo;
means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses
and reporting of clinical trials, including, as applicable, (a) Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional
Review Boards), and 312 (Investigational New Drug Application) of the CFR, as may be amended from time to time, (b) as set forth
in European Commission Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical
trials on medicinal products for human use, and brought into law by European Commission Directive 2005/28/EC laying down the principles
and detailed guidelines for good clinical practice for investigational medicinal products, (c) as set forth in the ICH Harmonised
Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials
on medicinal products in the Territory, and (d) the equivalent Applicable Laws in any relevant country, each as may be amended
and applicable from time to time and in each case, that provide for, among other things, assurance that the clinical data and reported
results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>GLP</U>&rdquo;
means all applicable Good Laboratory Practice standards, including, as applicable, (a) as set forth in the then-current good laboratory
practice standards promulgated or endorsed by the FDA as defined in Title 21, Part 58 of the CFR, (b) as set forth in European
Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices, as may be amended from
time to time as well as any Rules Governing Medicinal Products in the European Community Vol. III, ISBN 92.825 9619-2 (ex&mdash;OECD
principles of GLP), and (c) the Applicable Laws in any relevant country, each as may be amended and applicable from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>GMP</U>&rdquo;
means all applicable Good Manufacturing Practices including, as applicable, (a) the principles detailed in the U.S. Current Good
Manufacturing Practices, Title 21, Parts 210, 211, 601 and 610 of the CFR, (b) the applicable part of quality assurance to ensure
that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended
use, as defined in European Commission Directive 2003/94/EC laying down the principals and guidelines of good manufacturing practice,
(c) the principles detailed in the ICH Q7A guidelines, (d) the Rules Governing Medicinal Products in the European Community, Volume
IV Good Manufacturing Practice for Medicinal Products, and (e) the equivalent Applicable Laws in any relevant country, each as
may be amended and applicable from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Governmental
Authority</U>&rdquo; means any court, agency, department or other instrumentality of any foreign, federal, state, county, city
or other political subdivision (including any supra-national agency such as in the European Union).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Hatch-Waxman
Act</U>&rdquo; has the meaning assigned to it in Section 6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>H-W
Suit Notice</U>&rdquo; has the meaning assigned to it in Section 6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>ICH</U>&rdquo;
means the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>IND</U>&rdquo;
means an Investigational New Drug Application filed with the FDA or the equivalent application or filing filed with any Regulatory
Authority outside of the United States (including any supra-national agency such as in the European Union) necessary to commence
human clinical trials in such jurisdiction, and including all regulations at 21 CFR &sect;&nbsp;312 <I>et. seq.</I>, and equivalent
foreign regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Infringement</U>&rdquo;
has the meaning assigned to it in Section 6.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Initiation
Notice</U>&rdquo; has the meaning assigned to it in Section 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>July
Payment</U>&rdquo; has the meaning assigned to it in Section 3.1.b.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Know-How</U>&rdquo;
means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, inventions, means, methods,
processes, practices, formulas, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs,
drawings, assembly procedures, computer programs, apparatuses, specifications, data, records, results and other material, and other
drug discovery and development technology, pre-clinical and clinical trial results, manufacturing procedures, test procedures and
purification and isolation techniques, (whether or not confidential, proprietary, patented or patentable) in written, electronic
or any other form now known or hereafter developed, and all improvements, whether to the foregoing or otherwise, and other discoveries,
developments inventions and other intellectual property (whether or not confidential, proprietary, patented or patentable), provided
that Know-How shall not include Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensee</U>&rdquo;
has the meaning assigned to it in the Preamble of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensee
Indemnitee</U>&rdquo; has the meaning assigned to it in Section 11.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensee
Know-How</U>&rdquo; means all Know-How coming under the Control of Licensee during the term of this Agreement with respect to its
Commercialization of Products in the Territory that is necessary to Develop or Commercialize Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor</U>&rdquo;
shall have the meaning as set forth in the Preamble of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor
Approvals</U>&rdquo; means the Regulatory Approval(s) identified on <U>Schedule&nbsp;2.2</U> and all associated Regulatory Approvals
and Regulatory Filings in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor
Indemnitees</U>&rdquo; has the meaning assigned to it in Section 11.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor
Know-How</U>&rdquo; means all Know-How owned or Controlled by Licensor or its Affiliates as of the Effective Date or during the
term of the Agreement relating to the discovery, research, Development, testing, manufacture, or Commercialization of Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor
Patents</U>&rdquo; means (a) those Patents and Patent applications previously provided to Licensee by Licensor (the &ldquo;<U>Initial
Licensor Patents</U>&rdquo;); (b) any other Patents owned, controlled, or licensed by Licensor or any Affiliate thereof Covering
any of the subject matter described in or Covered by the Initial Licensor Patents; (c) any divisionals, continuations, continuations-in-part,
conversion, extensions, term restorations, registrations, re-instatements, amendments, reissuances, corrections, substitutions,
re-examinations, registrations, revalidations, supplementary protection certificates, renewals, and foreign counterparts of the
Initial Licensor Patents, and any other Patents owned, controlled, or licensed by Licensor claiming priority to any of the foregoing
or any of the Patents referenced in clause (a) or (b) above; and (d) all patents issuing from any of the Patents mentioned in clause
(a), (b), or (c) above and any foreign counterparts of any such Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor
Technology</U>&rdquo; means the Licensor Know-How and the Licensor Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Licensor
Trademarks</U>&rdquo; means the trademarks set forth on <U>Schedule 1.32</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Losses</U>&rdquo;
has the meaning assigned to it in Section 11.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Louisville
Product Supply</U>&rdquo; has the meaning assigned to it in Section 4.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>NDA</U>&rdquo;
means a new drug application (as defined in Title 21 of the CFR, as amended from time to time) submitted to the FDA seeking regulatory
approval to market and sell the Product for human therapeutic use in the United States (including a new drug application submitted
under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Net
Sales</U>&rdquo; means gross amounts invoiced or otherwise received for Licensee&rsquo;s, its Affiliates&rsquo;, and Sublicensees&rsquo;
sales of Products<I>, </I>less the sum of the following, to the extent related to the sale of such Products: (1) discounts in amounts
reasonable or customary in the trade, including but not limited to trade, cash, consumer, and quantity discounts, and credits,
price adjustments or allowances for damaged Products, returns, defects, recalls or rejections of Products or retroactive price
reductions; (2) reasonable rebates, coupons, vouchers, credits, and chargeback payments granted to patients, federal, state/provincial,
local and other governments or managed health care organizations, including their agencies, purchasers, and/or reimbursers, under
programs available under or required by Applicable Law, or reasonably entered into to sustain and/or increase market share for
Products; (3) sales, value added, use, excise, and similar taxes; (4)&nbsp;amounts allowed or credited on returns for defective,
damaged, expired, or otherwise unuseable or unsaleable Products; (5) freight, shipping, handling, and insurance charges; (6) import
or export duties, tariffs, or similar charges incurred with respect to the import or export of Products into or out of any country;
(7) distribution commissions/fees (including fees related to services provided pursuant to distribution service agreements with
wholesalers) payable to any Third Party providing distribution services with respect to Products; and (8) amounts repaid or credited
or provisions made for uncollectible amounts. Such amounts shall be determined from the books and records of Licensee, its Affiliates,
and Sublicensees maintained in accordance with such reasonable accounting principles as may be consistently applied by Licensee,
its Affiliates, and Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">Products are considered
&ldquo;sold&rdquo; when billed out or invoiced or, in the event such Products are not billed out or invoiced, when the consideration
for sale of the Products is received. Notwithstanding the foregoing, Net Sales shall not include, and shall be deemed zero with
respect to, (i) Products used by Licensee, its Affiliates, or Sublicensees for their internal use, (ii) the distribution of reasonable
quantities of promotional samples of Products, (iii) Products provided for clinical trials or research, development, or evaluation
purposes, or (iv) Products provided by or on behalf of Licensee, an Affiliate or a Sublicensee to Licensee, an Affiliate or a Sublicensee
for purposes of resale, provided such resale is subject to or triggers payments due Licensor under Section 3.2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Party</U>&rdquo;
or &ldquo;<U>Parties</U>&rdquo; shall have the meaning as set forth in the Preamble of this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.57&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Patent(s)</U>&rdquo;
means any granted patents and pending patent applications, together with all additions, divisionals, continuations, continuations-in-part,
substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, revalidations, supplementary protection
certificates, and renewals of any of the foregoing, and all foreign applications and patents corresponding to or claiming priority
from any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Patent
Term Extensions</U>&rdquo; has the meaning assigned to it in Section 5.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.59&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Pricing
Approval</U>&rdquo; means any pricing and reimbursement approvals that must be obtained before placing a Product on the market
for sale in a particular jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.60&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Prior
Fees</U>&rdquo; has the meaning assigned to it in Section 4.3.c.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.61&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Proceedings</U>&rdquo;
has the meaning assigned to it in Section 9.2.d.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.62&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Product</U>&rdquo;
means any and all products containing or constituting zolpidem tartrate oral spray (i) that incorporate or are otherwise made,
discovered, developed, conceived and/or reduced to practice as a direct result of use of the Licensor Know-How; or (ii) the manufacture,
use, sale, offer for sale or importation of which would, absent the license granted to the Licensee hereunder, infringe one or
more Valid Claims included in the Licensor Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.63&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Product
Problems</U>&rdquo; has the meaning assigned to it in Section 4.6.c.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.64&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Product
Supply</U>&rdquo; has the meaning assigned to it in Section 4.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Qualified
Sublicense</U>&rdquo; has the meaning assigned to it in Section 9.4.c.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Rechon</U>&rdquo;
means Rechon Life Science AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Rechon
Agreement</U>&rdquo; means that certain Manufacturing Agreement made and entered into on October 14, 2015 between Rechon and Licensor
related to the manufacture of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>Intentionally
omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.69&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Rechon
Product Supply</U>&rdquo; has the meaning assigned to it in Section 4.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.70&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Rechon
Purchase Orders</U>&rdquo; has the meaning assigned to it in Section 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.71&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Regulatory
Approval</U>&rdquo; means any and all approvals (including supplements, amendments, and pre- and post-approvals), licenses, registrations,
clearances, or authorizations of any national, supra-national (e.g., the European Commission or the Council of the European Union),
regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary
for the manufacture, distribution, use or, in Licensee&rsquo;s reasonable judgment, sale of a Product for human therapeutic use
in a particular jurisdiction, including Pricing Approvals. After the Transfer Date, the term &ldquo;<U>Regulatory Approvals</U>&rdquo;
shall include the Licensor Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.72&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Regulatory
Authority</U>&rdquo; means any Governmental Authority with responsibility for granting any licenses or approvals necessary for
the marketing and sale of pharmaceutical or biological products in a particular jurisdiction, including the FDA with respect to
the United States, and where applicable any ethics committee or any equivalent review board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.73&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Regulatory
Documents</U>&rdquo; has the meaning assigned to it in Section 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.74&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Regulatory
Filing</U>&rdquo; means, with respect to the United States, an NDA, IND, any foreign counterparts or equivalents of any of the
foregoing, any DMFs, and any other filings or submissions required by or provided to Regulatory Authorities relating to the manufacture,
Development or Commercialization of any Product, including any supporting documentation, data, correspondence, meeting minutes,
amendments, supplements, registrations, licenses, regulatory drug lists, advertising and promotion documents, adverse event files,
complaint files, and manufacturing, shipping, or storage records with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Reimbursement
Agreement</U>&rdquo; has the meaning assigned to it in Section 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.76&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Return
Date</U>&rdquo; has the meaning assigned to it in Section 9.4.a.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Reporting
Requirements</U>&rdquo; has the meaning assigned to it in Section 4.6.a.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.78&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Royalty
Term</U>&rdquo; has the meaning assigned to it in Section 3.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.79&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Secondary
Party</U>&rdquo; has the meaning assigned to it in Section 6.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.80&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Sublicense</U>&rdquo;
shall mean a sublicense under the rights granted to Licensee hereunder to Develop, make, have made, use, sell, have sold, offer
for sale, promote, market or import any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.81&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Sublicensee</U>&rdquo;
means a Third Party that has been granted a sublicense to any of the rights granted to Licensee and its Affiliates under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.82&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Suda
Agreement</U>&rdquo; means that certain Zolpimist License Agreement having an effective date of November 3, 2017 between Suda Ltd.
and Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Suda
Assignment</U>&rdquo; has the meaning assigned to it in Section 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.84&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Suda
Payment</U>&rdquo; has the meaning assigned to it in Section 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.85&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Term</U>&rdquo;
has the meaning assigned to it in Section 9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.86&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Termination
Date</U>&rdquo; has the meaning assigned to it in Section 9.4.b.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.87&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Territory</U>&rdquo;
means the United States and Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.88&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Third
Party</U>&rdquo; means any entity other than (a) Licensor, (b) Licensee, or (c) any Affiliate of either Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Transfer
Date</U>&rdquo; has the meaning assigned to it in Section 4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Transition
Quantities</U>&rdquo; has the meaning assigned to it in Section 4.4.a.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>United
States</U>&rdquo; or &ldquo;<U>U.S.</U>&rdquo; means the United States of America and its territories and protectorates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<U>Valid
Claim</U>&rdquo; means a claim of an issued and unexpired patent or a supplementary protection certificate, which claim has not
been held invalid or unenforceable by a court or other government agency of competent jurisdiction from which no appeal can be
or has been taken and has not been held or admitted to be invalid or unenforceable through re-examination or disclaimer, opposition
procedure, nullity suit or otherwise, provided that if a particular claim has not issued within five (5) years of its initial filing,
it shall not be considered a Valid Claim for purposes of this Agreement unless and until such claim is included in an issued Patent,
notwithstanding the foregoing definition.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Licenses;
Regulatory Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>License
Grant.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
hereby grants to Licensee (i) an exclusive license, with the right to sublicense as set forth in Section 2.3, to the Licensor Technology
and until such time as all Licensor Approvals are assigned to Licensee, to the Licensor Approvals to Develop, Commercialize, make,
have made, use, sell, have sold, offer for sale, promote, market or import Products in the Field and in the Territory, and (ii)
a nonexclusive license, with the right to sublicense as set forth in Section 2.3, to the Licensor Technology and, until such time
as all Licensor Approvals are assigned to Licensee, to the Licensor Approvals, including a right of reference with respect to the
Licensor Approvals, solely for the purpose of manufacturing the Products outside the Territory for the sole purposes of making,
having made, using, selling, or offering for sale the Products in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent Licensor or any Affiliate has the right to grant such rights to Licensee, Licensor hereby grants to Licensee an exclusive
right of reference (with the right to sublicense as set forth in Section 2.3) to any Regulatory Approvals or Regulatory Filings
outside the Territory for the purposes of obtaining and maintaining Regulatory Approvals in the Territory or exercising the rights
granted under Section 2.1.a.(ii), and Licensor shall use Commercially Reasonable Efforts, at no cost to Licensor, to obtain such
rights with respect to any Regulatory Approvals or Regulatory Filings following the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Licensor
Trademarks</B>. Licensor hereby assigns to Licensee all right, title and interest in and to the Licensor Trademarks, together with
all goodwill of Licensor associated with, and symbolized by, the Licensor Trademarks, including all applications, registrations,
issuances, extensions and renewals of the Licensor Trademarks. The foregoing assignment of the Licensor Trademarks does not include
Licensor&rsquo;s rights to the trademark ZOLPIMIST outside of the Territory. At any time and from time to time after the date hereof,
Licensor shall, at the request of Licensee, promptly execute and deliver such other instruments of sale, transfer, conveyance,
assignment, assumption and confirmation, and take such other action as Licensee may reasonably request to carry out the purpose
and intent of the foregoing assignment and to transfer, convey, assign and deliver to Licensee the title in and to the Licensor
Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Sublicensing.</B>
Licensee shall, through multiple tiers, have the right to sublicense the rights granted to it under Section 2.1 to its Affiliates
and Third Parties. No Sublicense shall convey any ownership interest in the rights conveyed to Licensee, nor diminish, reduce or
eliminate any of Licensee&rsquo;s obligations or Licensor&rsquo;s rights under this Agreement, and such Sublicense shall not impose
any additional obligations on Licensor in excess of those set forth in this Agreement. Each such Sublicense shall be in writing
and contain terms and conditions that are (i) not inconsistent with the terms of this Agreement applicable to the Sublicense and
(ii)&nbsp;reasonably sufficient to enable Licensee to comply with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Bankruptcy.</B>
If this Agreement is rejected by a Party as a debtor under Section 365 of the United States Bankruptcy Code or similar provision
in the bankruptcy laws of another jurisdiction (the &ldquo;<U>Code</U>&rdquo;), then, notwithstanding anything else in this Agreement
to the contrary, all licenses and rights to licenses granted under or pursuant to this Agreement by the Party in bankruptcy to
the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (or
similar provision in the bankruptcy laws of the jurisdiction), licenses of rights to &ldquo;intellectual property&rdquo; as defined
under Section 101(35A) of the United States Bankruptcy Code (or similar provision in the bankruptcy laws of the jurisdiction).
The Parties agree that a Party that is a licensee of rights under this Agreement shall retain and may fully exercise all of its
rights and elections under the Code. The foregoing provisions of this Section 2.3 are without prejudice to any rights a Party may
have arising under the Code.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Financial
Terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Initial
Compensation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the execution of this Agreement, the Licensee shall pay Licensor a licensee fee in the amount of Four Hundred Thousand Dollars
($400,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
on or before June 30, 2018, Licensor has (i) requested the removal of all Product from wholesaler distribution channels in the
U.S. (as requested and reasonably determined by Licensee) and (ii) used its Commercially Reasonable Efforts to assist wholesalers
and allow Licensee to assist to have such Product removed, then an additional license fee shall become due to Licensor in the amount
of Three Hundred Thousand Dollars ($300,000) (&ldquo;<U>July Payment</U>&rdquo;), provided, however, that such fee shall not become
payable until after July 1, 2018, but shall be paid in full prior to July 31, 2018. The failure of wholesalers to physically remove
all Product from their distribution channels shall not relieve Licensee of its obligation to timely pay the July Payment to Licensor
so long as Licensor has exercised Commercially Reasonable Efforts to assist wholesalers to remove such Product from the wholesaler
distribution channels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Royalty
Payments. </B>During the periods set forth below in this Section 3.2, Licensee shall pay to Licensor the following royalty payments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;twenty
percent (20%) of Net Sales during the period commencing on the Effective Date and continuing through May 31, 2020;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;fifteen
percent (15%) of Net Sales during the period commencing on June 1, 2020 and continuing through May 31, 2022; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ten
percent (10%) of Net Sales during the period commencing on June 1, 2022 and continuing through May 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Intentionally
Omitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Compulsory
Licenses</B>. Should a compulsory license be granted, or be the subject of a possible grant, to a Third Party under the Applicable
Laws of any country in the Territory under the Licensor Patents, the Party receiving notice thereof or otherwise becoming aware
thereof shall promptly notify the other Party thereof, including any material information concerning such compulsory license, and
the total amount payable under this Section 3 with respect to sales of Products in such country will be adjusted to match any lower
amount such Third Party may be allowed to pay with respect to the sales of such Products in such country, with such lower amount
subject to further adjustments pursuant to Section 3.3 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Royalty
Buyout</B>. Licensee may at any time terminate its obligation to pay royalties pursuant to Section 3.2 by paying Licensor a payment
in an amount equal to the different between Four Million Six Hundred Thousand Dollars ($4,600,000) and the amount of royalties
paid by Licensee to Licensor under this Agreement at the time such payment is made (the &ldquo;<U>Buyout Payment</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Royalty
Term.</B> Subject to any earlier termination of this Agreement, amounts due under Section 3.2 shall only be payable until the first
to occur of the following (i) the date Licensee pays to Licensor the Buyout Payment, (ii) the date seven (7) years from the Effective
Date or (iii)&nbsp;the date the aggregate royalty payments paid by Licensee hereunder equal Four Million Six Hundred Thousand Dollars
($4,600,000) (the period from the Effective Date until such date, the &ldquo;<U>Royalty Term</U>&rdquo;). Upon expiration of the
Royalty Term, (i) all licenses granted hereunder shall become perpetual, unrestricted, irrevocable, fully-paid and royalty-free,
and (ii) Licensor shall assign to Licensee all of its right, title and interest in and to the Licensor Patents. Licensor shall
take all actions reasonably requested by Licensee to effectuate and evidence such assignment, including the execution of assignment
agreements, in a form reasonably acceptable to Licensor, to be filed with the applicable Governmental Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Payments
and Payment Reports.</B> Except as otherwise provided in this Section 3, all royalties due under Section 3.2 shall be paid within
forty-five (45) Calendar Days of the end of the Calendar Quarter during which the applicable Net Sales occur. Each royalty payment
shall be accompanied by a statement stating (as applicable) the aggregate Net Sales and the respective royalty due for such Calendar
Quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Product
Supply and Delivered Inventory Payment</B>. In consideration for the Delivered Inventory and Product Supply (each as defined below)
delivered to Licensee pursuant to Section 4.2 Licensee shall pay Licensor (i) Fifty Thousand Dollars ($50,000) upon execution of
this Agreement and (ii)&nbsp;Fifty Thousand Dollars ($50,000) on or before July 31, 2018. On or before the Effective Date, Licensor
shall have submitted to Rechon Purchase Order number 409-634 for the purchase of 5,000 units of Product and Purchase Order number
409-633 for the purchase of 30,000 units of Product (&ldquo;<U>Rechon Purchase Orders</U>&rdquo;) subject to a Payment and Reimbursement
Agreement by and between Licensor and Licensee, as agreed to and acknowledged by Rechon, dated as of May 29, 2018 (&ldquo;<U>Reimbursement
Agreement</U>&rdquo;), and shall have paid the 2017 Maintenance Fee (as defined in the Reimbursement Agreement) by wire transfer.
In addition to the payments for Delivered Inventory and Product Supply, Licensee shall reimburse Licensor Fifty Thousand Dollars
($50,000) pursuant to the Reimbursement Agreement, and shall further reimburse Licensor Twleve Thousand Thirty Two Dollars ($12,032.00)
wired by Licensor to Rechon on May 9, 2018 for Schott vials. In accordance with the Reimbursement Agreement, within ten (10) Calendar
Days of the Effective Date, (i) Licensor shall pay Rechon an amount equal to Twenty Thousand Eighty Hundred Thirty Three Dollars
and 33/100 ($20,833.33), for its portion of the 2018 Maitenance Fee; and (ii) Licensee shall pay Rechon an amount equal to Twenty
Nine Thousand One Hundred Sixty Six Dollars and 67/100 ($29,166.67) for its portion of the 2018 Maintenance Fee. The Parties agree
that the 2018 Maintenance Fee payment shall be made by wire transfer to a bank account designated by Rechon. Licensee agrees that
it shall assume all obligations and liabilities of Licensor under the Rechon Agreement and the Rechon Purchase Orders. Notwithstanding
anything to the contrary herein, the failure to obtain Rechon&rsquo;s consent to assignment of the Rechon Agreement or Rechon Purchase
Orders shall not impair or otherwise diminish Licensor&rsquo;s rights herein and Rechon&rsquo;s consent to assignment shall not
be a condition precedent to any payment due to Licensor. Licensee agrees that it shall accept the Product manufactured by Rechon
pursuant to the Rechon Purchase Orders even if it is packaged under Licensor&rsquo;s labeling or labeler codes. All payments to
Licensor under this Section 3.8 shall not be considered royalty payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Payment
Method.</B> All payments due under this Agreement to Licensor shall be made by bank wire transfer in immediately available funds
to an account designated by Licensor in writing. All payments hereunder shall be made in the legal currency of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Taxes.</B>
In the event any tax or similar amount is paid or required to be withheld by Licensee or any Affiliate thereof for the benefit
of Licensor on account of any royalties or other payments payable to Licensor under this Agreement, the corresponding amounts payable
to Licensor shall be reduced by the amount of taxes or similar amounts deducted and withheld, and Licensee shall pay the amounts
of such taxes or similar amounts to the proper Governmental Authority in a timely manner and promptly transmit to Licensor an official
tax certificate or other evidence of such tax or other obligations together with proof of payment from the relevant Governmental
Authority of all amounts deducted and withheld sufficient to enable Licensor to claim such payment of taxes or similar amounts.
Any such withholding taxes or similar amounts required under applicable law to be paid or withheld shall be an expense of, and
borne solely by, Licensor. Licensee will provide Licensor with, at Licensor&rsquo;s expense, reasonable assistance to enable Licensor
to recover such taxes or amounts otherwise withheld as permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Foreign
Exchange. </B>With respect to Net Sales invoiced in a currency other than United States dollars, such Net Sales will be converted
into the United States dollar equivalent using the average conversion rate existing in the United States (as reported in <I>The
Wall Street Journal</I>, New York edition) during the applicable Calendar Quarter. If <I>The Wall Street Journal</I> ceases to
be published, then the rate of exchange to be used shall be that reported in such other business publication of national circulation
in the United States on which the Parties reasonably agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Blocked
Currency.</B> In each country where the local currency is blocked and cannot be removed from the country, payments under this Agreement
arising from activities in that country for which Licensee or an Affiliate thereof does not receive payment in United States&rsquo;
currency, freely useable outside of such country, shall, notwithstanding anything to the contrary, be paid to Licensor in the country
in local currency by deposit in a local bank designated by Licensee, unless the Parties otherwise mutually agree in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Interest.</B>
If Licensee fails to make any payment when due to Licensor under this Agreement, then interest shall accrue on the balance due
on a daily basis at a rate equal to eight percent (8%) per annum, or at the maximum rate permitted by applicable law, whichever
is the lower, until Licensee meets the full financial obligation due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Records;
Audits. </B>Licensee shall keep or cause to be kept such records as are reasonably required to determine, in a manner, with respect
to any financial records, consistent with generally accepted accounting principles in the United States, the amounts due under
this Agreement; such records must be kept for a minimum of three (3) years following the Calendar Year to which such records pertain.
At the request (and expense) of Licensor, Licensee shall permit Licensor to engage an independent certified public accounting firm
reasonably acceptable to Licensee, at reasonable times not more than once a year and upon reasonable notice, to examine only those
records as may be necessary to determine, with respect to any Calendar Year ending not more than three (3) years prior to Licensor&rsquo;s
request, the correctness or completeness of any royalty report or payment made under this Agreement. Licensor shall promptly provide
a copy of the results of any such audit or examination to Licensee. Licensor shall bear the full cost of the performance of any
such audit or examination, unless such audit or examination discloses an underpayment exceeding five percent (5%) of the amount
actually due hereunder with respect to any particular Calendar Year, in which case Licensee shall bear the reasonable, documented
cost of the performance of such audit or examination. Licensee shall promptly pay to Licensor the amount of any underpayment of
royalties revealed by such an examination and review. Any overpayment by Licensee of royalties or any other amount paid to Licensor
revealed by an examination and review shall, in Licensee&rsquo;s sole discretion, (i) be fully-creditable against future payments
under this Agreement or (ii) refunded to Licensee within thirty (30) Calendar Days of its request.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Technology
Transfer; Commercial Transition; Related Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Technology/Regulatory
Transfer</B>. Upon execution of this Agreement, Licensor shall transfer to Licensee, at no additional cost, all Licensor Know-How,
which shall include but not be limited to all clinical data, trade secrets, human safety data, and other regulatory data related
to the Products in its possession. Licensor shall, at Licensor&rsquo;s cost, take any and all actions reasonably requested by Licensee
to effect the purposes of the foregoing as promptly as practicable following the execution of this Agreement. Such actions shall
include providing Licensee with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;copies
of all Regulatory Filings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
communications with Governmental Authorities or Regulatory Authorities, and the minutes of any meetings with Governmental Authorities
or Regulatory Authorities, relating to any Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DMFs
and any trial, drug, device, or other master files relating to any Product, including copies of all case report forms;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;copies
of all adverse event reports relating to any Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
data, files and results of any chemistry, manufacturing, or control-related activities regarding any Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;current
market research, training, marketing, sales and medical information materials; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
other information that Licensee may reasonably request that may be useful to Licensee for the manufacturing of Products, obtaining
or maintaining Regulatory Approvals or Commercialization of Products (the documents listed in subsections 4.1.a. through 4.1.g.
shall be referred to herein as the &ldquo;<U>Regulatory Documents</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">From the Transfer Date to the earlier of
the Return Date or Termination Date, Licensee shall, and Licensee shall cause its Affiliates and/or Sublicensees to produce, maintain
and retain all Regulatory Documents. In the event of termination under Sections 9.2 or 9.3, Licensee and Licensor shall, subject
to the continued rights to any Regulatory Approvals in the Territory by any Sublicensee whose rights by Sublicense survive termination
of this Agreement in accordance with Section 9.4.c., within ten (10) Business Days of the termination of this Agreement pursuant
to Section 9.2 or 9.3, make such filings with the FDA as are necessary to transfer Regulatory Approvals in the Territory owned
by Licensee or any Affiliate thereof back to Licensor, and Licensee shall provide Licensor copies of all Regulatory Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Product
Inventory Transfer</B>. Licensor hereby assigns, transfers, and conveys to Licensee, as of the Effective Date, all of Licensor&rsquo;s
right, title, and interest in and to the Product inventory described on <U>Schedule&nbsp;4.2</U> (&ldquo;<U>Delivered Inventory</U>&rdquo;)
and unfinished materials and components described on <U>Schedule&nbsp;4.2</U> (the &ldquo;<U>Louisville Product Supply</U>&rdquo;
and &ldquo;<U>Rechon Product Supply</U>&rdquo; as identified on <U>Schedule&nbsp;4.2</U>; collectively, with the Delivered Inventory,
&ldquo;<U>Product Supply</U>&rdquo;). Within twenty (20) Calendar Days of the Effective Date, Licensor will deliver to Licensee
the Delivered Inventory and Louisville Product Supply F.O.B. at Licensor&rsquo;s Louisville warehouse. Licensor will assist Licensee
in the transfer and assignment to Licensee of Rechon Product Supply located at Rechon. Licensor will deliver to Licensee all material
information in Licensor&rsquo;s possession and control as of the Effective Date regarding the Delivered Inventory. Licensor represents
and warrants that, to its knowledge, the Delivered Inventory (including all packaging and labeling) (i) conforms to applicable
specifications and any requirements in Regulatory Approvals, (ii) was manufactured, packaged, tested, labeled and released in accordance
with Applicable Laws, GMP and Regulatory Approvals and (iii) will not at the time of delivery be adulterated or misbranded or otherwise
defective within the meaning of Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Transfer
of Regulatory Approvals.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provided
Licensee is not then in default under the terms of this Agreement, Licensor shall transfer and assign, and hereby assigns, to Licensee
all of Licensor&rsquo;s right, title and interest in and to all Licensor Approvals within three (3) Business Days following the
earlier of (a) receipt of notice from Suda, or other knowledge of Licensor, that an application for Regulatory Approval (or similar
regulatory documentation) has been accepted by the appropriate Chinese regulatory or governmental authorities for the authorization
of a clinical trial with Product in the People&rsquo;s Republic of China, or (b) December 31, 2018 (the &ldquo;<U>Transfer Date</U>&rdquo;).
Licensor and Licensee shall file the Licensor FDA Letter and the Licensee FDA Letter with the FDA within three (3) Business Days
after the Transfer Date. Transfer of title to the Regulatory Approvals for the Products in the U.S. will be effective as of the
Transfer Date. In addition to the filing of the Licensor FDA Letter and the Licensee FDA Letter, following the Transfer Date, each
Party shall, at the reasonable request of the other Party, promptly make any further filings and take any actions reasonably in
connection with the transfer of Licensor Approvals to Licensee, including, without limitation, filing with the FDA any other notices,
assignments, documents and/or other materials required by Applicable Laws, and change of labeler codes as required under 21 C.F.R.
&sect;&nbsp;201, <I>et seq</I>. During the Term, Licensee shall not sell, transfer, assign or otherwise encumber the Regulatory
Approvals, the Licensor Know-How, the Licensee Know-How or the Licensor Trademarks, except in accordance with Section 14.2. Any
sale, transfer, assignment or other encumbrance in violation of this Section 4.3.a. shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties shall provide each other with reasonable assistance in connection with the preparation, review and filings of all Regulatory
Filings with the relevant Regulatory Authorities and communications therewith for the purposes of obtaining the Regulatory Approvals
in the Territory as provided for in this Section 4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall assume and have responsibility for any fee or charge associated with the Product assessed by the FDA after the Effective
Date including fees and charges authorized pursuant to the Prescription Drug User Fee Act, and any reauthorization thereto, including
without limitation, the Food and Drug Administration Safety and Innovation Act, or such other fees which shall include all establishment,
user and product or application fee assessed under 21 U.S.C.S. &sect;&nbsp;379h. Licensor shall retain full responsibility and
liability for all fees or charges billed or invoiced to Licensor by the FDA on or prior to the Effective Date (&ldquo;<U>Prior
Fees</U>&rdquo;). Licensee may, in its sole discretion, pay Prior Fees. In the event Licensee pays any Prior Fees, Licensee shall
have the right to setoff such payments against amounts due hereunder until the amount of such setoff equals the amount of such
payments. Such setoff amounts shall be deemed payments made to Licensor hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Commercialization
Transition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
twenty (20) Calendar Days following the Effective Date, Licensor shall request that all wholesalers remove and use its Commercially
Reasonable Efforts to assist wholesalers to remove or have removed from all distribution channels in the U.S. all Products labeled
with Licensor&rsquo;s national drug codes (excluding Transition Quantities). &ldquo;<U>Transition Quantities</U>&rdquo; means a
quantity of Product to be identified in writing by Licensee that will remain in the distribution channels in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
shall remain responsible for all payments, cost reimbursements, discounts, rebates, refunds, chargeback claims and related fees
with respect to any Products labeled with Licensor&rsquo;s national drug codes (excluding Transition Quantities, Delivered Inventory
and any Product purchased under the Rechon Purchase Orders). Notwithstanding anything to the contrary herein, in no event shall
Licensee be liable in any manner for any audit, dispute, underpayment, act, error or omission with regard to such payments, cost
reimbursements, discounts, rebates, refunds, chargeback claims or related fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall not manufacture, use, Develop, promote, sell, distribute, or otherwise Commercialize any Product using the Licensor&rsquo;s
national drug code except for Transition Quantities, Delivered Inventory and any Product purchased under the Rechon Purchase Orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Diligence.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall, during the Term, use Commercially Reasonable Efforts, to Develop and Commercialize the Product in the U.S. From the Effective
Date to the Transfer Date, Licensee will provide Licensor&rsquo;s counsel (currently William A. Garvin, Buchanan Ingersoll &amp;
Rooney, PC and his colleagues, but in the even Licensor changes counsel, the appropriate counsel for Licensor at that time) a reasonable
opportunity to review and comment on any of Licensee&rsquo;s marketing or promotional material related to Products for the sole
purpose of ensuring compliance with the requirements of the FDA Office of Prescription Drug Promotion, and all other Applicable
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall, during the Term, use Commercially Reasonable Efforts to Develop and Commercialize the Product in Canada. Notwithstanding
anything to the contrary herein, in the event Licensee materially breaches this Section 4.5.b., and such breach is not cured within
ninety (90) Calendar Days&rsquo; of Licensee&rsquo;s receipt from Licensor of notice of such breach, Licensor shall, as its sole
and exclusive remedy for such breach, have the right to amend the definition of Territory to remove Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties agree that the efforts of Licensee&rsquo;s Affiliates, Sublicensees, and contractors or consultants of Licensee, its Affiliates,
or Sublicensees shall constitute the efforts of Licensee for purposes of satisfying Licensee&rsquo;s obligations under this Section
4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Licensor
and Licensee Regulatory Requirements. </B>From the Effective Date until the Transfer Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
shall (x) timely comply in all material respects with all reporting requirements with the FDA, including but not limited to those
required under 21 C.F.R. &sect;&sect;&nbsp;310, 314, <I>et seq</I>. (&ldquo;<U>Reporting Requirements</U>&rdquo;) and (y) take
all other steps and measures necessary to ensure that the Licensor Approvals remain in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
shall (i) promptly inform Licensee of all material communications with any Governmental Authorities in the U.S. concerning any
Product, (ii) provide Licensee copies of proposed material submissions to any Governmental Authorities in the U.S. concerning the
Licensed Product reasonably in advance of their submission to Governmental Authority, and (iii) not submit any information or materials
to any Governmental Authority in the U.S. without Licensee&rsquo;s prior written approval. Licensor will not respond substantively
to any material communication with a particular Governmental Authority in the U.S. or otherwise make any submissions to a Governmental
Authority in the U.S. concerning, in either case, a Product, without Licensee&rsquo;s prior written consent. Licensor shall enable
an employee or other designee of Licensee to attend, if and as requested by Licensee, lead all formal in person, telephonic, video,
or other electronic meetings with any Governmental Authority in the U.S. regarding any Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
shall use Commercially Reasonable Efforts to promptly provide all information coming into its possession that is necessary to enable
Licensor to comply with its obligations under clause a(x) above. In addition, Licensee shall (i) promptly inform Licensor of all
material communications Licensee may have with any Governmental Authorities in the U.S. concerning any Product, (ii) provide Licensor
copies of any material submissions being proposed by Licensee to be made to any Governmental Authorities in the U.S. concerning
the Licensed Product reasonably in advance of their submission to Governmental Authority, and (iii) not submit any information
or materials to any Governmental Authority in the U.S. without Licensor&rsquo;s prior written approval. Licensee will not respond
substantively to any material communication with a particular Governmental Authority in the U.S. or otherwise make any submissions
to a Governmental Authority in the U.S. concerning, in either case, a Product, without Licensee&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt">From the Transfer Date
to the earlier of the Return Date or Termination Date, Licensee shall timely comply in all material respects with all Reporting
Requirements and take all other steps and measures necessary to ensure that the Licensor Approvals remain in full force and effect.
In addition thereto, Licensee shall provide Licensor copies of annual reports to any Governmental Authorities in the U.S. concerning
the Licensed Product promptly after their submission to Governmental Authority. Each Party shall, to the extent it becomes aware
of any of the following, notify the other Party in writing, and on such timing is necessary to enable compliance with Applicable
Laws in the territory, of any reported adverse event with respect to any Product (&ldquo;<U>AE</U>&rdquo;), serious adverse event
with respect to any Product (&ldquo;<U>SAE</U>&rdquo;), Product problems and Product use errors (&ldquo;<U>Product Problems</U>&rdquo;)
and shall, during such period as a Party is a holder of title to any Regulatory Approvals in the Territory, otherwise ensure timely
reporting of any AE, SAE or Product Problems with the FDA in material compliance with applicable Reporting Requirements.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Patent
and Trademark Prosecution and Maintenance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Prosecution
and Maintenance by Licensee</B>. Except as provided in Section 5.2 below, Licensee shall assume and have primary responsibility
for the filing, prosecution, and maintenance of the Licensor Patents and Licensor Trademarks and, subject to Section 5.2, Licensee
will be responsible for all reasonable costs and expenses it incurs with respect its filing, prosecution, and maintenance of the
Licensor Patents and Licensor Trademarks. Licensee will, to the extent reasonably practicable, provide Licensor a reasonable opportunity
to review and comment on any material patent filings or correspondence with patent authorities pertaining to the Licensor Patents
and Licensor Trademarks, provided that all decisions with respect to the filing, prosecution, and maintenance of the Licensor Patents
and Licensor Trademarks under this Section&nbsp;5.1 shall be made by Licensee in its sole reasonable discretion. Licensee shall
not abandon prosecution or maintenance of any Licensor Patent or Licensor Trademark without first notifying Licensor in a reasonably
timely manner of Licensee&rsquo;s intention and reason therefor, and providing Licensor with reasonable opportunity to assume responsibility
for prosecution and maintenance of such Licensor Patent or Licensor Trademarks as set forth in Section 5.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Abandonment
by Licensee; Prosecution and maintenance by Licensor.</B> If Licensee provides Licensor with written notification that it will
no longer support or pursue the filing, prosecution, or maintenance of a specified Licensor Patent (an &ldquo;<U>Abandoned Patent</U>&rdquo;)
or Licensor Trademarks (an &ldquo;<U>Abandoned Trademark</U>&rdquo;) in a particular country, then (a) Licensee&rsquo;s responsibility
for such filing, prosecution, or maintenance of the Abandoned Patent or Abandoned Trademark in such country, and the fees and costs
related thereto, will terminate on the earlier of (x) the date sixty (60) Calendar Days after Licensor&rsquo;s receipt of such
written notice from Licensee or (y) Licensor&rsquo;s assumption of the filing, prosecution and maintenance of such Abandoned Patent
or Abandoned Trademark in such country, and (b) the specified Abandoned Patent or Abandoned Trademark shall no longer be deemed
a Licensor Patent or Licensor Trademark hereunder and in the case of an Abandoned Trademark, the respective Licensor Trademark
shall be assigned by Licensee to Licensor. For clarity, following the earlier of clause (x) or (y) in the preceding sentence with
respect to a particular Licensor Patent or Licensor Trademark in a particular country, Licensor shall not have any obligation to
Licensee under this Agreement with respect to such Licensor Patent or Licensor Trademark in such country. Notwithstanding anything
contained in Sections 5.1 or 5.2 to the contrary, Licensee shall not abandon prosecution or maintenance of any Licensor Patent
or Licensor Trademark if such abandoment will result in a breach of the Suda Agreement. Licensee acknolwedges and agrees that compliacne
with the terms of the Suda Agreement are its sole responsibility, and Licensor shall have no obligations to Licensee or Suda under
the terms of the Suda Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Patent
Term Extensions</B>. Licensee shall promptly notify Licensor of the issuance of each Regulatory Approval and, where reasonably
and legally possible and reasonably useful or materially valuable in the Commercialization of Products, use Commercially Reasonable
Efforts to apply (or cause its Affiliates or Sublicensee(s) to apply) for a patent term extension, adjustment or restoration, supplementary
protection certificate, or other form of market exclusivity conferred by Applicable Laws (collectively, &ldquo;<U>Patent Term Extensions</U>&rdquo;)
in the relevant country(ies) of the Territory. Licensor shall, if and as requested by Licensee, (a) use Commercially Reasonable
Efforts to, assist Licensee, its Affiliates, and Sublicensees in obtaining all available Patent Term Extensions and (b) take all
actions necessary to obtain all Patent Term Extensions. The Parties shall cooperate with each other in obtaining Patent Term Extensions
wherever and whenever applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Intentionally
Omitted</B></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
Patent Infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Notice.
</B>If either Party becomes aware of any actual, potential, or alleged infringement of any of the rights to Licensor Patents or
Licensor Trademarks granted to Licensee under this Agreement with respect to Products, such Party shall give to the other Party
prompt and reasonably detailed written notice of such actual, potential, or alleged infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Hatch-Waxman
Act Litigation.</B> Notwithstanding anything herein to the contrary, should a Party receive (a) a certification for a Product pursuant
to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417), as amended (the &ldquo;<U>Hatch-Waxman
Act</U>&rdquo;), including any notice under 21 U.S.C. &sect;&nbsp;355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) or a similar notice
with respect to, in either case, any Product, or (b) any reasonable equivalent in a country in the Territory other than the U.S.,
then such Party shall immediately (and in any event no later than within five (5) Business Days after such receipt) provide the
other Party with a copy of such certification or notice. The Party with the right to bring suit under the Hatch-Waxman Act or reasonable
equivalent in any country outside the United States, as applicable, on account of such certification or notice shall have fifteen
(15) Calendar Days from the date on which it receives a copy of the application for which Regulatory Approval is sought, but in
no event later than thirty-five (35) Calendar Days from the date of receipt of the certification or notice, to provide written
notice to the other Party (&ldquo;<U>H-W Suit Notice</U>&rdquo;) stating whether it will bring suit, at its expense, within a forty-five
(45) Calendar Day period from the date of such certification or notice, including any patent infringement suit (or other applicable
time limit for bringing such suit). Should the period referred to in the prior sentence for delivering an H-W Suit Notice expire
without the applicable Party providing such H-W Suit Notice, then the other Party shall be free immediately to bring suit in the
name of the Party that did not give the H-W Suit Notice. Notwithstanding the foregoing, (I) no Party shall take any action in the
course of exercising its rights under this Section 6.2 that (x) admits fault or wrongdoing, or incurs liability, on the part of
the other Party or (y) materially limits the scope, validity, or enforceability of any of the Licensor Patents in the Territory
without, in either case, the prior written consent of the other Party and (II)&nbsp;if Licensor is the party bringing the suit
hereunder, Licensor shall not take any action in the course of exercising its rights under this Section 6.2 that would reasonably
be expected to materially adversely affect the ability of Licensee to manufacture, Develop or Commercialize Products without Licensee&rsquo;s
prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Infringement.</B>
To comply with the Suda Agreement, with respect to any actual, potential, or alleged infringement of the rights to Licensor Patents
or Licensor Trademarks (an &ldquo;<U>Infringement</U>&rdquo;), Licensee shall initiate, prosecute, and control any action or legal
proceedings, and/or enter into a settlement, including any declaratory judgment action, with respect to such Infringement. In any
such litigation brought by Licensee, Licensee shall have the right to use and sue in Licensor&rsquo;s name and join Licensor as
a party to such litigation, and Licensor shall cooperate reasonably, as requested by Licensee and at Licensee&rsquo;s expense (which
expense shall be reasonable). If, within one hundred thirty five (135) Calendar Days of the notice in Section 6.1, Licensee shall,
(a) have been unsuccessful in persuading the actual, potential, or alleged infringer to desist, (b) shall not have brought and
shall not be diligently prosecuting an infringement action with respect to such Infringement, or (c) has not entered into settlement
discussions with respect to such Infringement, or if Licensee notifies Licensor that it has decided not to undertake any of the
foregoing against any such alleged, potential, or actual infringer, then Licensor shall have the right, but not the obligation,
to bring suit to enforce such Licensor Patents or Licensor Trademarks against such actual, alleged, or potential infringer at its
own expense, unless Licensee has provided Licensor with a strategic rationale for not taking action to terminate such Infringement.
In any such litigation brought by Licensor, Licensor shall have the right to use and sue in Licensee&rsquo;s name and join Licensee
as a party to such litigation, and Licensee shall cooperate reasonably, as requested by Licensor and at Licensor&rsquo;s expense
(which expense shall be reasonable). The Parties&rsquo; rights and obligations under this Section 6.3 shall be subject to, and
shall not be construed to limit or adversely affect, the Parties&rsquo; rights and obligations under Section 6.2. Notwithstanding
the foregoing, Licensee shall not take any action that would result in a breach of the Suda Agreement. For the avoidance of doubt,
Licensor shall have no obligations under this Section 6. 2 to bring suit to enforce such Licensor Patents or Licensor Trademarks
even if failure to do so would cause Licensee to be in breach of the Suda Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Infringement
of Third Party Rights. </B>In the event that a claim of infringement of a Third Party&rsquo;s Patents is made or brought against
either Party with respect to the manufacture, use, sale, or importation of the Product, the Party receiving such claim shall promptly
inform the other Party in writing, and the Parties shall consult with each other in order to develop a strategy for addressing
the alleged infringement. Each Party shall reasonably cooperate with the other in any investigations undertaken to determine any
potential infringement. As between the Parties, Licensee (and/or its Affiliates and Sublicensees) shall have the first and primary
right, but not the obligation, at its own expense to defend, control the defense of, and/or settle any such claim against Licensee,
its Affiliates, or Sublicensees, using counsel of its own choice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Litigation
Control</B>. The Party pursuing or controlling any action or defense under Section 6.2, 6.3 or 6.4 (the &ldquo;<U>Controlling Party</U>&rdquo;)
shall be free to enter into a settlement, consent judgment, or other voluntary disposition of any such action or defense, provided,
however, that (a)&nbsp;the Controlling Party shall consult with the other Party (the &ldquo;<U>Secondary Party</U>&rdquo;) prior
to entering into any settlement or voluntary disposition thereof, (b) any settlement, consent judgment or other voluntary disposition
of such actions which (1) subjects the Secondary Party to any non-indemnified liability or obligation or (2) admits fault or wrongdoing
on the part of Secondary Party must, in each case, be approved in advance and in writing by the Secondary Party, (c) any settlement,
consent judgment or other voluntary disposition of such actions which materially limits the scope, validity, or enforceability
of, or otherwise may adversely affect, any Licensor Patents or Licensor Trademarks or shall not be entered into, consented to,
approved, or agreed upon without the other Party&rsquo;s prior written approval, and (d) any settlement, consent judgment or other
voluntary disposition of such actions that would reasonably be expected to materially adversely affect the Licensor Patents or
Licensor Trademarks or ability of Licensee to manufacture, Develop or Commercialize Products shall not be entered into, consented
to, approved, or agreed upon without Licensee&rsquo;s prior written consent. With respect to clause (b) or (c) above in this Section&nbsp;6.5,
the Secondary Party shall provide the Controlling Party notice of its approval or denial of such approval within fifteen (15) Business
Days of any request for such approval by the Controlling Party, provided that (X) in the event Secondary Party wishes to deny such
approval, such notice shall include a written description summarizing the Secondary Party&rsquo;s reasonable objections to the
proposed settlement, consent judgment, or other voluntary disposition and (Y) Secondary Party shall be deemed to have approved
such proposed settlement, consent judgment, or other voluntary disposition in the event it fails to provide such notice within
such fifteen (15) Business Day period. Any recovery or damages received by the Controlling Party with respect to the infringement
of the rights to Licensor Patents or Licensor Trademarks granted under this Agreement, or in settlement of any matter subject to
Section 6.2 or 6.3, shall be used first to reimburse the Parties for unreimbursed reasonable, documented expenses incurred in connection
with such action or settlement, and the remainder shall be retained by the Controlling Party. Notwithstanding the foregoing, the
Secondary Party, at its expense, shall have the right to be represented by counsel of its choice in any proceeding governed by
this Section 6.5. Notwithstanding anything contained in Sections 6.2, 6.3 or this 6.5 to the contrary, Licensee acknolwedges and
agrees that compliance with the terms of the Suda Agreement are its sole responsibility, and Licensor shall have no obligations
to Licensee or Suda under the terms of the Suda Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Reimbursement.
</B>Each Party shall invoice the other Party for any reasonable, documented costs incurred that are to be borne by the other Party
pursuant to this Section 6. Each Party shall pay the other Party such amounts within thirty (30) Calendar Days of its receipt of
any such invoice, except to the extent such amounts are the subject of a good faith dispute, in which the amounts subject to such
dispute shall be due within thirty (30) Calendar Days of the resolution of such dispute.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Confidentiality
Obligations. </B>The Parties agree that, for the Term and for five (5) years thereafter, each Party will keep completely confidential
and will not publish, submit for publication or otherwise disclose, and will not use for any purpose except for the purposes contemplated
by this Agreement, any Confidential Information of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Authorized
Disclosure</B>. Each Party may disclose Confidential Information of the other Party to the extent that such disclosure is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;made
in response to a valid order of a court of competent jurisdiction; provided, however, that in each case such disclosing Party will,
to the extent reasonably practicable, (i) first have given written notice to the other Party and given such other Party a reasonable
opportunity to take appropriate action and (ii) cooperate with such other Party as necessary to obtain an appropriate protective
order or other protective remedy or treatment; provided, further, that in each case, the Confidential Information disclosed in
response to such court or governmental order will be limited to that information which is legally required to be disclosed in response
to such court or governmental order, as determined in good faith by counsel to the Party that is obligated to disclose Confidential
Information pursuant to such order;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;otherwise
required to be disclosed by Applicable Law or the requirements of any stock exchange to which a Party is subject; provided, however,
that the Party that is so required will provide such other Party with written notice of such disclosure reasonably in advance thereof
to the extent reasonably practicable and reasonable measures will be taken to assure confidential treatment of such information,
including such measures as may be reasonably requested by the disclosing Party with respect to such Confidential Information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;made
by such Party, in connection with the performance of this Agreement to such Party&rsquo;s Affiliates, licensees or sublicensees,
directors, officers, employees, consultants, representatives or agents, or to other Third Parties, in each case on a need to know
basis and solely to use such information for business purposes relevant to and permitted by this Agreement, and provided that (i)
each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure
obligations no less than substantially as restrictive as those set forth in this Agreement and (ii) the Party making such disclosure
shall be liable for such Third Parties&rsquo; compliance with such obligations; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;made
by such Party to existing or potential acquirers, existing or potential collaborators, investment bankers, accountants, attorneys,
existing or potential investors, merger candidates, partners, venture capital firms or other financial institutions or investors
for use of such information for business purposes relevant to this Agreement or for due diligence in connection with the financing,
licensing or acquisition of such Party (or such Party&rsquo;s acquisition of, or merger with, a Third Party), and provided that
(i) each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure
obligations (or in the case of attorneys or accountants, an equivalent professional duty of confidentiality) at least as restrictive
as those set forth in this Agreement and (ii) the Party making such disclosure shall be liable for such Third Parties&rsquo; compliance
with such obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Publicity.
</B>Press releases or other similar public communication by either Party not required by Applicable Law or the requirements of
any stock exchange to which a Party is subject and disclosing the existence or terms of this Agreement, will require the advance
written approval of the other Party, which approval will not be unreasonably withheld, conditioned or delayed. The foregoing notwithstanding,
communications required by Applicable Law or the requirements of any stock exchange to which a Party is subject, and disclosures
of information for which consent has previously been obtained, will not require advance approval, but will be provided to the other
Party as soon as practicable after the release or communication thereof, provided that, with respect to any such communications
required by Applicable Law or the requirements of any stock exchange to which a Party is subject, the Party required to make such
disclosure shall, to the extent reasonable practicable and such disclosure does not include information for which consent has previously
been obtained, provide the other Party a reasonable opportunity to review and comment on such communications.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Non-Competition.
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-variant: normal">Licensor shall (and shall ensure
that its Affiliates do):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
manufacture, use, develop, promote, sell, distribute, import, export, or otherwise Commercialize any Competing Product in the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
acquire from any Third Party the right to manufacture, use, develop, promote, sell, distribute, import, export, or otherwise Commercialize
any Competing Product in the Territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
enter into any agreement pursuant to which any Third Party may manufacture, use, develop, promote, sell, distribute, or otherwise
Commercialize any Competing Product in the Territory; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not
otherwise enable any Third Party, directly or indirectly, to manufacture, develop, promote, sell, distribute, or otherwise Commercialize
any Competing Product in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt">Notwithstanding the foregoing,
in the event that the Regulatory Approvals, Licensor Trademarks and Licensor Know-How are transferred to Licensor pursuant to Section
9.4, then the provisions of this Section 8 shall terminate as of the Return Date.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Term
and Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Term.
</B>This Agreement shall become effective on the Effective Date and shall continue until the earlier of (a) the expiration of the
Royalty Term or (b) the effective date of termination pursuant to Section 9.2 or 9.3 (the period from the Effective Date until
such expiration or termination, the &ldquo;<U>Term</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Termination
for Material Breach</B>. If either Party materially breaches this Agreement at any time, the non-breaching Party shall have the
right to terminate this Agreement by written notice to the breaching Party, if (a) such material breach is not cured within forty
five (45) Calendar Days of a default in making any undisputed payment when due under Section 3, or ninety (90) Calendar Days following
notice by the non-breaching Party to the breaching Party specifying the material breach (or, if such default is capable of being
cured but cannot be cured within such 90-day period, the breaching Party has commenced and diligently continued actions to cure
such default provided always that, in such instance, such cure must have occurred within one hundred eighty (180) Calendar Days
after notice thereof was provided to the breaching Party by the non-breaching Party to remedy such default) and (b) the non-breaching
Party provides notice confirming such termination within thirty (30) Calendar Days following the expiration of such forty-five
(45), ninety (90) or one hundred eighty (180) Calendar Day period, as applicable, without cure of such material breach. The foregoing
notwithstanding, if such material breach is cured or remedied or shown to be non-existent or not material within the aforesaid
forty-five (45), ninety (90) or one hundred eighty (180) Calendar Day period, the non-breaching Party&rsquo;s notice(s) hereunder
shall be automatically withdrawn and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Termination
for Convenience by Licensee</B>. This Agreement may be terminated by Licensee, in its sole discretion, upon (i) sixty (60) Calendar
Days prior written notice and (ii) Licensee paying Licensor a termination fee in the amount of Fifty Thousand Dollars ($50,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Effects
of Termination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of the termination of this agreement pursuant to Section 9.2 or Section 9.3, all licenses granted to Licensee hereunder
shall terminate, and, subject to the continued rights by any Sublicensee whose rights by Sublicense survive termination of this
Agreement in accordance with Section 9.4.c., (i) Licensee shall transfer title to all Regulatory Approvals, Licensor Trademarks
and Licensor Know-How owned by Licensee, its Affiliates, or any Sublicensee in the Territory to Licensor, free and clear of all
liens, claims, and encumbrances, and (ii) Licensee shall grant Licensor a perpetual, nonexclusive, royalty-free license to all
Licensee Know-How to make, use, or sell the Products in the Territory following such termination. Licensee shall, within ten (10)
Business Days of the termination of this Agreement pursuant to Section 9.2 or Section 9.3, file such documents with the FDA as
is reasonably required to effect the transfer of such Regulatory Approvals to Licensor. The filing date of such documentation shall
be referred to herein as the &ldquo;<U>Return Date</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary, in the event of termination of this Agreement pursuant to Section 9.2 or Section 9.3, Licensee and its
Affiliates shall (i) request within twenty (20) Calendar Days of the effective date of such termination (&ldquo;<U>Termination
Date</U>&rdquo;) that all wholesalers remove from all distribution channels in the Territory all Product labeled with Licensee&rsquo;s
national drug code (for Product within the U.S.) and (ii) use its best efforts to assist wholesalers to have such Product removed,
provided that the foregoing shall not apply with respect to any Sublicensee or its Commercialization of Products to the extent
such Sublicensee&rsquo;s rights by Sublicense survive termination of this Agreement in accordance with Section 9.4.c. During the
one hundred twenty (120) Calendar Days following the Termination Date, Licensee shall have the privilege, subject to the payment
of royalties as required under Section 3.2, of (i) completing the manufacture of any Products in the process of manufacture as
of the Termination Date, (ii)&nbsp;selling such Products and all finished Products in their possession or under their control as
of the Termination Date for a period of one hundred twenty (120) Calendar Days following the Termination Date upon commercially
reasonable conditions, and (iii) completing performance of all contracts entered into with Affiliates and Third Parties prior to
the Termination Date (1) for the marketing, sale, or manufacture of Products or (2) requiring the use of Products for a period
of one hundred twenty (120) Calendar Days following the Termination Date, provided that the foregoing shall not apply with respect
to, nor be construed to limit, any Sublicensee&rsquo;s Commercialization of Products to the extent such Sublicensee&rsquo;s rights
by Sublicense survive termination of this Agreement in accordance with Section 9.4.c. Licensee shall remain responsible for all
payments, cost reimbursements, discounts, rebates, refunds, chargeback claims and related fees with respect to any Products labeled
with Licensee&rsquo;s national drug codes and, in no event shall Licensor be liable in any manner for any audit, dispute, underpayment,
act, error or omission with regard to such payments, cost reimbursements, discounts, rebates, refunds, chargeback claims or related
fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any provision herein to the contrary, in the event (i) this Agreement is terminated, (ii) a Sublicense is in effect at the time
of termination and (iii) such Sublicense which complies with Section 2.3 and the royalty terms of such Sublicense are not less
favorable to Licensor than the royalty terms in this Agreement (&ldquo;<U>Qualified Sublicense</U>&rdquo;), such Qualified Sublicense
will, to the extent provided for therein, survive such termination and be automatically assigned to Licensor upon such termination
in order to provide for the applicable Sublicensee&rsquo;s continued enjoyment of its rights under such Qualified Sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Remedies.</B>
Any rights or remedies set forth in this Section 9 are not exclusive, and shall not limit any other legal or equitable remedies
that are available to the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Survival.</B>
Termination or expiration of this Agreement for any reason will be without prejudice to any rights that will have accrued to the
benefit of any Party prior to such termination or expiration, and any termination or expiration of this Agreement shall not relieve
either Party of any obligation that has accrued prior to the effective date of such termination or expiration (including, without
limitation payment obligations that have accrued prior to termination), which obligations shall remain in full force and effect.
The following provisions shall survive any expiration or termination of this Agreement: Sections 3.1, 3.6, 3.13, 4.1, 4.3, 7, 8
(except as otherwise provided therein), 9.4, 9.5, 9.6, 11, 12, and 14 together with any Sections referenced in such surviving provisions
or necessary to give them effect.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Representations
and Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Representations
and Warranties of Licensor</B>. Licensor represents and warrants to Licensee as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
is a corporation, duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation,
with full corporate power and authority to operate its properties and to carry on its business as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
has full power and authority to execute, deliver and perform this Agreement. This Agreement constitutes the legally binding and
valid obligation of Licensor, enforceable in accordance with its terms, except as such enforcement may be limited by applicable
bankruptcy, moratorium and other laws affecting creditors&rsquo; rights generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution, delivery and performance by Licensor of this Agreement and the consummation of the transactions contemplated hereby
will not result in any violation of, conflict with, result in a breach of or constitute a default under any contract or agreement
to which Licensor or any Affiliate thereof is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no action, suit, litigation, claim, administrative action or proceeding by a Governmental Authority or other person or investigation
by a Governmental Authority (&ldquo;<U>Proceedings</U>&rdquo;) pending or, to Licensor&rsquo;s and its Affiliates&rsquo; knowledge,
currently threatened in writing against or affecting Licensor or any Affiliate thereof that questions the validity of this Agreement
or the right of Licensor to enter into this Agreement or consummate the transactions contemplated hereby and, to Licensor&rsquo;s
and its Affiliates&rsquo; knowledge, there is no basis for the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority, or any Third Party, on the part of Licensor or any Affiliate thereof is required in connection
with the execution, delivery and performance of this Agreement except with respect to those applications, registrations, declarations
or other documents submitted to such Governmental Authority pursuant to Section 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
has disclosed in writing to Licensee all Patents owned or Controlled by Licensor or its Affiliates as of the Effective Date that
Cover any Products in the Field, or which relate to Developing, manufacturing or Commercializing Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Licensor and its Affiliates, no research or Development of the Licensor Technology, manufacture of Products, or
research leading to the inventions Covered by the Licensor Patents was supported in whole or part by funding or grants by any governmental
agency or philanthropic or charitable organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Licensor and its Affiliates, Licensor Technology, Licensor Trademarks and Regulatory Approvals are wholly-owned
by Licensor, free and clear of all mortgages, pledges, charges, liens, equities, security interests, or other encumbrances or similar
agreements or any other obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Licensor and its Affiliates, no Third Party or Affiliate of Licensor has any rights or ownership interest in any
Licensor Technology, Regulatory Approvals or Licensor Trademarks, and neither Licensor nor any Affiliate thereof obtained rights
to any of the Licensor Technology, Regulatory Approvals or Licensor Trademarks by license or any similar contract or agreement
with any Third Party or Affiliate of Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
Licensor nor any Affiliate thereof is aware of any Third Party intellectual property rights (including any Patent(s)) that were
(prior to the Effective Date) or would be (following the Effective Date) infringed, misappropriated, or otherwise violated by the
use, manufacture, sale, import, export, Development, or Commercialization of any Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Licensor and its Affiliates, Licensor and its Affiliates have taken all reasonable actions necessary or appropriate
to preserve the confidentiality of all trade secrets, proprietary and other confidential information material to Products and Licensor
Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
Licensor nor any Affiliate thereof is aware of any Third Party activities which would constitute misappropriation or infringement
of any Licensor Technology or Licensor Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Licensor and its Affiliates, all information provided to Licensee, its Affiliates, and their employees, officers,
directors, agents, and other representatives by or on behalf of Licensor or any Affiliate thereof with respect to Products, Regulatory
Approvals and the Licensor Technology has been accurate, and there is no material information known to, or in the possession or
control of, Licensor or any Affiliate thereof related to any Product, Regulatory Approval or the Licensor Technology that has not
been provided to Licensee prior to the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of Licensor and its Affiliates, all Development of Product was performed in accordance with GLP, GCP, and all Applicable
Laws, all human clinical studies of Products were performed in accordance with the protocols established therefor, and all Product
or placebo administered to patients or subjects in any such studies was manufactured, handled, shipped, and stored in accordance
with GMP, Applicable Laws, and the specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
has not received any written notice or, to Licensor&rsquo;s knowledge, other notice that any Governmental Authority has initiated,
or threatened to initiate, any action to recall, suspend or otherwise restrict the manufacture, sale, or distribution of any of
the Products. There are no pending or, to the knowledge of Licensor, threatened proceedings or requests for information, voluntary
or involuntary market withdrawals, field corrective actions (including recalls), safety alerts, or other regulatory enforcement
actions related to any of the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">p.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensor
has compiled and maintained all Regulatory Approvals in compliance with Applicable Laws. All Regulatory Approvals are in full force
and effect. There are no Proceedings pending or, to the knowledge of Licensor, threatened seeking the revocation or suspension
of any Regulatory Approval. All maintenance and other fees related to Regulatory Approvals have been paid, or are not chargeable
against Licensor as of the Effective Date. Licensor has not received: (i) any FDA Form 483&rsquo;s concerning the Products or (ii)
warning letters from the FDA concerning the Products (excluding a warning letter from the OPDP related solely to marketing materials
for the Product, which Licensor warrants has been resolved). There are no Proceedings by the FDA or any other Governmental Authority
pending or, to the knowledge of Licensor, threatened against Licensor relating to safety or efficacy of the Products. There are
no outstanding consent decrees with respect to any of the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Representations
and Warranties of Licensee</B>. Licensee represents and warrants to Licensor as follows as of the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
is a corporation, duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation,
with full corporate power and authority to operate its properties and to carry on its business as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licensee
has full power and authority to execute, deliver and perform this Agreement. This Agreement constitutes the legally binding and
valid obligations of Licensee, enforceable in accordance with their terms, except as such enforcement may be limited by applicable
bankruptcy, moratorium and other laws affecting creditors&rsquo; rights generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution, delivery and performance by Licensee of this Agreement and the consummation of the transactions contemplated thereby
will not result in any violation of, conflict with, result in a breach of or constitute a default under any contract or agreement
material to Licensee, its business or its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority on the part of Licensee is required in connection with the execution, delivery and performance
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 72pt">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no action, suit, proceeding or investigation pending or, to Licensee&rsquo;s knowledge, currently threatened against or affecting
Licensee or that questions the validity of this Agreement, or the right of Licensee to enter into this Agreement or consummate
the transactions contemplated hereby and, to Licensee&rsquo;s knowledge, there is no reasonable basis for the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Warranties
excluded</B>. Except as otherwise expressly set forth in this Agreement, the Licensor makes no representations or warranties of
any kind, express or implied, concerning the Product, Licensor Technology and Licensor Trademarks, and other materials licensed
hereunder, including, without limitation, warranties of merchantability, fitness for a particular purpose, and the absence of latent
or other defects, whether or not discoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Compliance
with Applicable Laws</B>. The Parties represent and warrant to each other that they will comply with, and will ensure that their
Affiliates (and in the case of Licensee, its Sublicensees) will comply with, all Applicable Laws, including without limitation
those local, state, federal and international laws, regulations, and treaties, related to the Development, manufacture, sale, importation,
and exportation of the Product during the Term of this Agreement. Licensee will require its Affiliates exercising rights hereunder
and any Sublicensee to comply with all such Applicable Laws, and Licensee bears full responsibility for any acts in violation of
Applicable Law by its Affiliates or Sublicensees.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Indemnities;
Limits on Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Indemnification
by Licensor.</B> Subject to Sections 11.3, Licensor hereby agrees to defend, indemnify and hold harmless Licensee, its Affiliates,
Sublicensees, any contractors of any of the foregoing, and each of their directors, officers, employees, agents, and other representatives
(each a &ldquo;<U>Licensee Indemnitee</U>&rdquo;) from and against all suits, claims, proceedings or causes of action brought
by Third Parties (&ldquo;<U>Claims</U>&rdquo;), and all associated damages, liabilities, expenses and/or loss, including reasonable
legal expenses and reasonable attorneys&rsquo; fees (&ldquo;<U>Losses</U>&rdquo;), to the extent arising out of a Licensor Indemnitee&rsquo;s
(i) negligence or willful misconduct, (ii) breach of this Agreement, (iii) failure to comply with any Applicable Law, (iv) all
payments, cost reimbursements, discounts, rebates, refunds, chargeback claims and related fees with respect to any Products labeled
with Licensor&rsquo;s national drug codes (excluding Transition Quantities, Delivered Inventory and any Product purchased under
Rechon Purchase Orders, if any), provided, however, that Licensor shall not be liable pursuant to this Section 11.1(iv) if any
Product is labeled with Licensor&rsquo;s national drug code in violation of Section 4.4.c., or (v) manufacture, use, Development,
Commercialization, import, or export of any Product(s) prior to the Effective Date (excluding Product manufactured by Rechon pursuant
to the Purchase Orders, Transition Quantities and Delivered Inventory), except to the extent such Losses result from the negligence
or willful misconduct, breach of this Agreement, or failure to comply with Applic<FONT STYLE="font-family: Times New Roman, Times, Serif">able
Laws on the part of, in each case, any Licensee Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification
by Licensee.</B> Subject to Section 11.3, Licensee hereby agrees to indemnify, defend and hold Licensor, its Affiliates, and Licensor&rsquo;s
and its Affiliates&rsquo; officers, directors, employees, contractors, agents, and other representatives (collectively, &ldquo;<U>Licensor
Indemnitees</U>&rdquo;) harmless from and against any Losses resulting from Claims brought against any Licensor Indemnitee(s)
resulting from Licensee Indemnitee&rsquo;s or Sublicensees&rsquo; (i) negligence or willful misconduct, (ii) breach of this Agreement,
(iii) failure to comply with Applicable Laws, (iv) breach of the Suda Agreement caused by Licensee&rsquo;s action or inaction,
(v) all payments, cost reimbursements, discounts, rebates, refunds, chargeback claims and related fees with respect to any Products
labeled with Licensee&rsquo;s national drug codes (including Delivered Inventory, Transition Quantities, and any Product purchased
under Rechon Purchase Orders, if any), (vi) all payments, cost reimbursements, discounts, rebates, refunds, chargeback claims
and related fees with respect to Delivered Inventory, Transition Quantities, and any Product purchased under Rechon Purchase Orders,
or (vii) manufacture, use, Development, Commercialization, import, or export of any Product(s) after the Effective Date (including
Product manufactured by Rechon pursuant to the Rechon Purchase Orders, Transition Quantities and Delivered Inventory), except
to the extent such Losses result from the negligence or willful misconduct, breach of this Agreement, or failure to comply with
Applicable Laws on the part of, in each case, any Licensor Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Indemnification
Procedures</B>. Each Party&rsquo;s agreement to indemnify, defend, and hold harmless under Section 11.1 or 11.2, as applicable,
is conditioned upon the indemnified party (a) providing written notice to the indemnifying Party of any claim, demand or action
arising out of the indemnified matter as soon as reasonably possible, and in any event no later than within thirty (30) Calendar
Days after the indemnified Party has actual knowledge of such claim, demand or action, (b) permitting the indemnifying Party to
assume control over the investigation of, preparation and defense against, and settlement or voluntary disposition of any such
claim, demand or action, (c) assisting the indemnifying Party, at the indemnifying Party&rsquo;s reasonable expense, in the investigation,
preparation, defense, and settlement or voluntary disposition of any such claim, demand or action, and (d) not compromising, settling,
or entering into any voluntary disposition of any such claim, demand or action without the indemnifying Party&rsquo;s prior written
consent, which consent shall not be unreasonably withheld; provided, however, that, if the party entitled to indemnification fails
to promptly notify the indemnifying Party pursuant to the foregoing clause (a), the indemnifying Party will only be relieved of
its indemnification obligation to the extent materially prejudiced by such failure. In no event may the indemnifying Party compromise,
settle, or enter into any voluntary disposition of any claim, demand or action in any manner that admits material fault or wrongdoing
on the part of the indemnified party or incurs non-indemnified liability on the part of the indemnified party without the prior
written consent of the indemnified party, and in no event may the indemnifying Party settle, compromise, or agree to any voluntary
disposition of any matter subject to indemnification hereunder in any manner which may adversely affect any portion of the Licensor
Technology in any material respect, or Licensee&rsquo;s ability to exploit Licensor Technology in any material respect, without
the other Party&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Limitation
of Liability</B>. IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL,
PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY
OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT, PROVIDED THAT, NOTWITHSTANDING ANYTHING TO THE CONTRARY, THE FOREGOING
SHALL NOT BE CONSTRUED TO LIMIT THE INDEMNITY OBLIGATIONS SET FORTH IN SECTIONS 11.1 AND 11.2 ABOVE OR EITHER PARTY&rsquo;S LIABILITY
FOR A BREACH OF SECTION 7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Insurance.
</B>Each Party shall carry and maintain insurance of the types and in amounts which are reasonable and customary in the U.S. pharmaceutical
industry for companies of comparable size and activities. Such insurance will insure against all liability, including but not limited
to, bodily injury or property damage arising out of the manufacture, sale, distribution, marketing, Development or Commercialization
of Products. Such insurance shall include (i) commercial general liability insurance and (ii) product liability insurance in the
amount of Ten Million Dollars ($10,000,000). Such coverage shall be maintained by each Party for not less than three (3) Calendar
Years following expiration or termination of this Agreement or if such coverage is of the &ldquo;claims made&rdquo; type, for five
(5) Calendar Years following expiration or termination of this Agreement. Upon written request from a Party, the other Party shall
promptly provide written evidence (e.g., certificates) of such insurance that is reasonably satisfactory to the requesting Party.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Dispute
Resolution. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-variant: normal">In the event that
a dispute arises between the Parties in the course of this Agreement, the dispute will be referred to the attention of the Chief
Executive Officer of Licensor and the Chief Executive Officer of Licensee or their designees (the &ldquo;<U>Executive Officers</U>&rdquo;).
The Executive Officers will meet as soon as reasonably possible thereafter and in good faith attempt to resolve such dispute. If,
within thirty (30) Calendar Days after referral of such dispute to the Executive Officers by either Party, the Executive Officers
are unable to resolve such dispute, either Party will have the right to have the dispute resolved by binding arbitration, initiated
by either Party on fifteen (15) Business Days&rsquo; notice to the other Party following the expiration of the thirty (30) Calendar
Day period referenced above (the &ldquo;<U>Initiation Notice</U>&rdquo;), under the Rules of the American Arbitration Association
then pertaining except where those rules conflict with this provision, in which case this provision controls, applying the laws
of Kentucky, without regards to its conflicts of law provisions, before three (3) independent, neutral arbitrators experienced
in the pharmaceutical industry and licensing transactions in such industry. The place of arbitration shall be Jefferson County,
Kentucky. Licensor and Licensee shall each be entitled to select one (1) such arbitrator, with the two (2) such arbitrators so
selected selecting the third (3<SUP>rd</SUP>) such arbitrator. In the event either Party fails to select its arbitrator within
fifteen (15) Business Days of the Initiation Notice, the arbitrator selected by the other Party within such fifteen (15) Business
Day period shall be entitled to select such arbitrator. The arbitration shall be conducted in English. The decision of the arbitrators
will be final and binding on the Parties, and any decision of the arbitrators may be enforced in any court of competent jurisdiction.
Each Party shall bear its own expenses and an equal share of the reasonable, documented expenses of the arbitration panel and any
fees required by ICC to submit such matter to arbitration, unless the panel determines that any such fees or expenses are to be
paid by the non-prevailing Party. Notwithstanding the foregoing, either Party may seek injunctive, equitable, or similar relief
from a court of competent jurisdiction without the requirement of arbitration.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Suda
Agreement. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-variant: normal">Subject to Suda&rsquo;s
approval, Licensee agrees that it shall assume all obligations and liabilities of Licensor under the Suda Agreement from and after
the Effective Date, with a full release of Licensor within three (3) Business Days of the Effective Date pursuant to the terms
of an assignment and assumption agreement to be executed by the Parties, in a form mutually agreed to by the Parties, in their
reasonable discretion (&ldquo;<U>Suda Assignment</U>&rdquo;). Effective as of the date of the Suda Assignment, Licensee shall have
the right to receive all compensation owed to Licensor under the Suda Agreement (the &ldquo;<U>Suda Payments</U>&rdquo;). Licensee
agrees to pay Licensor Seventy Five Thousand Dollars ($75,000) out of the first One Hundred Thousand Dollars ($100,000) in Suda
Payments that Licensee receives from Suda. Licensee acknowledges and agrees that in the event of any conflict between Licensee&rsquo;s
obligations under this Agreement and Licensee&rsquo;s obligations under the Suda Agreement, Licensee&rsquo;s obligations under
the Suda Agreement shall govern. </FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-variant: normal">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Miscellaneous.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Force
Majeure</B>. Neither Party shall be held liable or responsible to the other Party, nor be deemed to have defaulted under or breached
this Agreement, for failure or delay in fulfilling or performing any term of this Agreement, to the extent, and for so long as,
such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including fire,
floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil
commotions, strikes, lockouts or other labor disturbances, acts of God or any acts, omissions or delays in acting by any governmental
authority or the other Party, provided that, notwithstanding the foregoing, the payment of amounts due under this Agreement may
not be delayed due to a force majeure affecting the Party required to make such payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Assignment</B>.
Neither Party may assign this Agreement, or any of its rights or obligations hereunder without the other Party&rsquo;s prior written
consent, which consent shall not be unreasonably withheld, provided that, notwithstanding the foregoing, each Party shall be entitled,
without the other Party&rsquo;s prior written consent, to assign or transfer this Agreement: (a) in connection with the transfer
or sale of all or substantially all of such Party&rsquo;s assets or business (or that portion thereof related to the subject matter
of this Agreement) or (b) in the event of such Party&rsquo;s merger, consolidation, reorganization, change of control or similar
transaction. Any permitted assignee of either Party shall, as a condition to such assignment, assume all obligations of its assignor
arising under this Agreement following such assignment. Any purported assignment by a Party of this Agreement, or any of such Party&rsquo;s
rights or obligations hereunder, in violation of this Section 14.2 shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Severability</B>.
If one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the Parties shall substitute, by mutual
consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions are, in their economic effect,
sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this
Agreement with such provisions. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability
of one or more provisions of the Agreement shall not affect the validity of this Agreement as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Notices</B>.
Any notice, consent or report required or permitted to be given or made under this Agreement by one Party to the other Party shall
be in English and in writing, delivered personally or by U.S. first class mail or express courier providing evidence of receipt,
postage prepaid (where applicable), at the following address for a Party (or such other address for a Party as may be specified
by like notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-right: 0; padding-left: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>To Licensee</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Aytu BioScience, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Attn: Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">373 Inverness Parkway, Suite 206</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Englewood, CO 80112</P></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>To Licensor</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Magna Pharmaceuticals, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attn: Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10801 Electron Drive</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Louisville, KY 40299</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All such notices, consents or reports shall
be effective upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Applicable
Law</B>. This Agreement shall be governed by and construed in accordance with the laws of the State of Kentucky, without regard
to the conflicts of law principles that would provide for application of the law of a jurisdiction other than the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Entire
Agreement</B>. This Agreement (including the Suda Assignment, the Schedules or exhibits attached hereto) contains the entire agreement
by the Parties with respect to the subject matter hereof and supersedes any prior express or implied agreements, understandings
and representations, either oral or written, which may have related to the subject matter hereof in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B></B></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Interpretation</B>.
The captions to the several Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference
and shall not affect its meaning or interpretation. In this Agreement: (a) the word &ldquo;including&rdquo; shall be deemed to
be followed by the phrase &ldquo;without limitation&rdquo;, &ldquo;including but not limited to&rdquo;, or like expression; (b)&nbsp;the
singular shall include the plural and <I>vice versa</I>; and (c) masculine, feminine and neuter pronouns and expressions shall
be interchangeable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Independent
Contractors</B>. It is expressly agreed that Licensee and Licensor shall be independent contractors and that the relationship between
the two Parties shall not constitute a partnership, joint venture or agency or other fiduciary relationship. Neither Licensee nor
Licensor shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which
shall be binding on the other Party, without the prior written consent of the other Party to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Waiver;
Amendment</B>. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a written
instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any
time to require performance of any provision of this Agreement shall in no manner affect such Party&rsquo;s rights at a later time
to enforce the same. This Agreement may be amended, and any term of this Agreement may be modified, only by a written instrument
executed by a duly authorized representative of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Binding
Effect</B>. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives,
successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Counterparts</B>.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Facsimile and other electronically scanned signatures shall have the same effect
as their originals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>No
Strict Construction</B>. This Agreement has been prepared jointly and shall not be strictly construed against either Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Further
Assurances</B>. Each of the Parties hereto agrees, upon the request of the other Party hereto, from time to time to execute and
deliver to such other Party all such instruments and documents of further assurance or otherwise as shall be reasonable under the
circumstances, and to do any and all such acts and things as may reasonably be required to carry out the obligations of such requested
Party hereunder and to consummate the transactions provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature page to follow.]</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the Parties have executed this Agreement by their proper officers as of the date and year first above
written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">AYTU BIOSCIENCE, INC.</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: left">MAGNA PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps">By: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps">By: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps">Name: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps">Name: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps">Title: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-variant: small-caps">Title: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal"><U></U></FONT></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGE TO AMENDED AND RESTATED
EXCLUSIVE LICENSE AGREEMENT]</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SCHEDULE
1.32</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>Licensor
Trademarks</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Mark</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Serial #</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Filing Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USPTO Owner of Record</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; text-align: left; padding-left: 0">BETTER SLEEP. BETTER LIFE</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center; padding-left: 5.4pt">86/915,013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center; padding-left: 5.4pt">2/22/16</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center; padding-left: 5.4pt">MAGNA PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0">SLEEP REINVENTED. LIFE RETURNED.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">86/895,571</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">2/3/16</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 5.4pt">MAGNA PHARMACEUTICALS, INC.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SCHEDULE
2.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>Licensor
Approvals</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">New Drug Application No. 22-196 granted
to NovaDel by the FDA on December 19, 2008 for zolpidem tartrate oral spray.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>SCHEDULE
4.2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Delivered Inventory</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">10,000 Zolpimist 30 dose units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Rechon Product Supply</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">76,440 Aptar pumps</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">56,050 CR containers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Louisville Product Supply</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">16,100 CR containers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>f10k2018ex23-1_aytubio.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We consent to the incorporation by reference
in Aytu BioScience, Inc.&rsquo;s Registration Statements on Form S-8 (File No. 333-205462), Form S-3 (File No. 333-221735) and
Form S-1 (File Nos. 333-207421, 333-205414, 333-209874, 333-210144, 333-212100, 333-213738, 333-213489, 333-220351, 333-222994,
and 333-223385) of our report dated September 6, 2018, relating to the consolidated financial statements that appear in this Annual
Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our report dated September 6, 2018 contains
an explanatory paragraph that states that the Company's recurring losses from operations and accumulated deficit raise substantial
doubt about the Company's ability to continue as a going concern, as discussed in Note 3 to the consolidated financial statements.
The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    EKS&amp;H LLLP</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    6, 2018</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver,
    Colorado</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>f10k2018ex31-1_aytubio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE
OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Joshua R. Disbrow, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(1)</TD><TD>I have reviewed this annual report on Form 10-K for the year ended June 30, 2018 of Aytu BioScience, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(2)</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(3)</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(4)</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(d)</TD><TD>Disclosed in the report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(5)</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or
persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">Dated: September 6, 2018</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Joshua R. Disbrow&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Executive Officer <BR>
(Principal Executive Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>f10k2018ex31-2_aytubio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF FINANCIAL
OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, David A. Green, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(1)</TD><TD>I have reviewed this annual report on Form 10-K for the year ended June 30, 2018 of Aytu BioScience, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(2)</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(3)</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(4)</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(d)</TD><TD>Disclosed in the report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(5)</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 24.5pt">(b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">Dated: September 6, 2018</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ David A. Green</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">David A. Green</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer <BR>
(Principal Financial Officer and Principal Accounting Officer)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>f10k2018ex32-1_aytubio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE
OFFICER AND CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S. C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the annual report on Form 10-K of Aytu BioScience,
Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended June 30, 2018, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), each of Joshua R. Disbrow, Chief Executive Officer (Principal Executive Officer),
and David A. Green, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), of the Company, certify,
pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to his
knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(1)</TD><TD>The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">(2)</TD><TD>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 40%; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Dated: September 6, 2018</FONT></TD>
    <TD STYLE="padding-left: 0; font-size: 10pt; width: 60%; padding-right: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">/s/ Joshua R. Disbrow&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; font-size: 10pt; padding-bottom: 0; padding-right: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Joshua R. Disbrow</FONT></TD>
    <TD STYLE="padding-left: 0; font-size: 10pt; padding-right: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Chief Executive Officer <BR>
(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">/s/ David A. Green&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; font-size: 10pt; padding-bottom: 0; padding-right: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">David A. Green</FONT></TD>
    <TD STYLE="padding-left: 0; font-size: 10pt; padding-right: 0; text-indent: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-right: 0; padding-left: 0; text-indent: 0; padding-bottom: 0"><FONT STYLE="font-size: 10pt">Chief Financial Officer <BR>
(Principal Financial Officer and Principal Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




















































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &> :(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"P'4]L]">,X[
M>YIKN$QGN<=@!@9))/0  DGVKRCX@_%&U\*7MAX7T#2;KQG\1];B:30O!.ES
M1PS"UR8WUWQ)J,@:U\,>&+23BXUC4/GE;=;:9:7]X?) !Z5J>K:7HVGW6K:O
MJ-CI6EV,33WNI:E=P65A:0I]Z:YN[F2*"&)<C+R2*O(&<FO"E^-M]XL=X/@[
MX#U_XAQ!C&OBZ_8>#?ATK 8,EMXBUF$WVO11N?WC>&M'U."7HER0<B31_@Q=
M>);ZR\5?&[5K3X@:_;2"[TKPI%!+#\,O!]P267^QO#=PS+KVHVP(C7Q#XG6\
MOV*B6T@TWB,>^1PQQ*B(B1I$JQQI&JHB1H,(B*BJJHH "H!M4<#M0!X.OA3X
M_P#B$^9K_P 3_"W@: [,:7\._" U:Y5 <LDOB+QK/>^8^3M,EMH-F"!E%7NX
M? N>ZW/K/QD^-^IRN29/)\:P:%;,">46T\/Z5IT42GD?N\-M(!8D9KWNB@#P
M3_A0EC#DV7Q1^.5@^" \/Q-U:[4D@;6:/4XKZ,[>F#& 0,-D8I&^&OQ9T=<^
M%?CMK=V(T(CT_P"(7A/PWXIM9FR"!<ZAI-OX:UE<DE2T=XV%Z*2,U[Y10!\_
M/XZ^,?@S<_CWX9V?B_28PID\1_"&\FU&[A4 [I+OP1X@>TUID&"Q&CZCK3I@
M 1,/F'I'@CXD>"?B':3W7A'Q#9:J]HWEZEIN9+37-'G&T-;:WH=ZEOJVE7*,
MP4PW]G QX*%T*L>X89X[=P>_U]O;O[=:\K\<_!_PIXWNX-<Q>>%O&E@N=(\?
M>$IET?Q;I[C:1%)?1QR0ZOICE%%QHVMV^H:7<H"DMJ20R@'J0D1L88$'H>W!
MP?R/!].?0T^OG73?B)XI^'FJ6?A3XV?86LM1NH=.\,_&'3+:.P\+:]=SN%M-
M(\86(+)X*\47#96V8RMX;U>=L6%W9W933S]#AP6V@$D'!Q@@8YR>>.V >3D<
M8(- #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"< G_']
M<<X]?04M<WXP\5:-X'\+Z[XN\0W#6VCZ!IT^HWSQHTL[I"N([:U@3,EQ>WD[
M16EE;1@RW-W/#!$#)(HH X'XH?$#4=!?2/!O@JSMM8^)_C%;E?"VEW3L=/TB
MPMA''JGC3Q1Y9#V_AOP_Y\;R1AEN-7U![71[$&YN':#5^&WPTTKP!87DAO+O
MQ%XNUV9+[QEXWU8K)KOBC5?+ >6XD _T+2K4DP:/H5IY>G:19)';VL9(EFEY
MOX->#]9MXM6^)7CRVV?$GXBBWO\ 5K65Q,/!_AR)YI/#?@#3G&4BM=!M)1)J
MCPD?VEXAN-2OKC?_ *,5]P557(4 9))QW)ZGZF@  P,9)P.IY)Q_,^_<U\Z_
M&[]H_0/@AKGPL\)WO@WQUX\\8_&/7/$>A>"/"_@+3=*O=0NIO"7ARY\5Z_=W
MUSKFLZ%IEC:66C6SRH9+YI[JX:.WM8)7<[/HL]#_ )_GQ^=?%O[5/[+^H_'_
M ,7?L_\ C;3+WX737OP(\6^-/%%OX6^+_P .KKXC>"O$S^,/!5_X.$USIECX
MB\.7&G:IX?-V-6TG4H[BZ NHS&\*(X>@#RG4?^"G_P ";;XGWWPDTZTO-2\7
M0_M%>%OV7-.LY?$/A72VU/XKZIX4/C3Q?8-%>ZJLVEZ;X!T4"WOM0U)(%\1Z
MYOTCPO'J3QM/7UHW[3/[/BZ%K?B<_&OX7GP]X;\3P>"]=UA?&>B/8Z;XMNV;
M['X>GF2\8?VM=I'-+:62!Y;J&"XN+<206T\B?+K_ +"2WGC >,=6^)($EY^U
M=XI_:<U"RT_PHMK@^+?@%)\$[SP5IU[/JEQ<6<-A/<2^*=/UV2.:6&18]/FL
MG=6OCXO\+O\ @F'J?P9@^%NO^!_B3X1F^)OP8UO1;?PKXG\7>$?''B_1_'/@
M70/A_P"+_ASI.D_$S0-9^)ER$\0:3I/C+4M9T/5_ EWX3T_2]>^TO'I,UIJE
MQ!" ?7ND?MR_LZ>)?$MWH'ACXD>#]6M/#?Q#\5_"WXA>(+GQ7X>\.Z;X#\9^
M%M.M+U]-O+?Q+J.D:CXACU2ZO[+2[&\\)VNM6T5S=0W-]);6&^Y7V35OCW\%
M="U>ST'6/BQ\/-,UJ_\ &$WP^M=*O/%NBPZA+XY@M].N9_"GV5KP31:W;Q:O
MI)N+"5$GB;5=+B=5FU"TCE^$?$O_  3O@\5>+/$VK>/?B9X=U'P!J/C+]H+X
M@RZ/_P (,-/U.WN_V@_@Y:?#SQ5;7VN3^))M,33O">L:?!XP\+7EMIEG=VB1
MC3;VXD>&/4!Q1_X)D:=?1_"3Q1XZ^+&C?$37=)T#Q!IGQTU?Q'I?B?P[X5^,
M&K>./B=X?^*>L>/['2O!GQ#T$:-XBN?$FA:;96%KKNI^*M!FTV'3(3:R36%K
M-( ?<WP9_:R^#_QI\#0^-]+\1Z;X3'_"8W7@6_\ #'C'6-$TSQ3I/B1O&.O^
M"_#VE:EID.I7)M;_ ,::AX?NKSPC9,[7>LZ?+#);0/+YT4/TNC[P3Z''Z#_)
M'4="!7X[_#O_ ()_ZM\/?VA?V=_&UKX_L=?^"?PI\)?%SQ9\6-1E;1=-TGXB
M?%JQ^*_C'Q5^S_<7&CPZA>W5G>_!O3/BQ\65OM>GNVL[EDT>*1K:>W^RVW["
MP21R1J\3I)$ZJ\4B,K1R1LJLCQLA*-&5*E&1F4J1S0!G:WH.C^)-*U'0]?TZ
MSU?1=7M9K+5-+U""*ZL;ZTG7;+#<P2JR.K#!!(W(P#1E6 8?/WAK4-5^"GB;
M2_A[XHOKW5_AEXCO(].^%_C74[I[N\\-:JRN;7X:>+KZ<F2:&5 1X'UZY=IK
MU$.@W\TE['927/TQ7+^,?!^@^.?#.L^$_$=G]LT?7+-[.[C5C%<1,2'MKRSN
M!\]KJ%C<K%>:?>QD36EY##<1L'0&@#I48L,G QD$=P0?KZ8.",\X.""*?7B/
MP:\4:[-'X@^&WCF[-YX_^&EQ::;J.JNHC/B[PS?QRR^$O&T*_P 3ZQ86\EKK
M2QY2V\1:?JL)PAAS[=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?//Q!B;X@?%3P'\,Q\_A[PQ!%\6/'<9(9;Q]-OS8> -!N%VLCP7GB"*]U^
MYB<9:/PW;\;9=Q^AJ\ ^"2_V[JOQ9^(\A,C^+_B)J.C:7-E2O_",?#V)/".E
MQPX!5(7U&RUJ\948AYKN21OWC.* /?5!R2>^/3Z$<<\8]>_KFN;\977B"Q\*
M^)[[PEIUOJWBNS\.:Y=^&-+O)3!9ZIXAMM,NY=%TV[G#(8;:]U(6UO/(779%
M([AAM)KIJC=&8@J0,8Z@\8/)&,')4E>H !)P>E 'X5W7QI_:?F^%GPJU&3XA
M?M.6$^N^$OB'KOQ=\06OP 63QCX4_:CT[P5X7U#P5\!-)\.-X%VV_P *[[Q?
M=>+++^T8--U31K^]T72-"?X@VUAJEQ?-)#XA_P""C7C'6;_4?$/C;XK?#.XU
M'XC^/_!6K^#O"'PO\&ZCX>\,^&/#W[(GAOXG:+JWA76-5T74KVZ:^_:&&J>$
M[+Q3/?ZI8ZI9M<^#HHS+(MU']X?$W]JO5_!?[7G@3]F*Q@^%FE6WB3X467Q6
MO?$'Q#\>:GX?\0:]#<^/KOP7+X/^&WANRT2]A\1>(X([,ZD!>ZG8Q$W-M;M$
M0[S5XI\(O^"AVO:KX?\ A?X_^.OPX\-?#OX:?''X??&?XB_#OQ1X-\9:GXMN
M/#UG\#++6_$GBWPY\1]+U;PYX>:RU*[\$:->^(=)UCP]+JFDO=6%_HET+2<Z
M;/? '@>A^*O^"A'Q$\2>']3UKQW\7?AOIGB+XA>#O OB'P]H'PA\)0:1H/@G
M5?V)_#OQ1\3^*=)N=<\/ZAJVG:LG[1CW_AF'7;VYO[;1)8[SP.EC/)+YL?(6
MGQQ_X*4Z]>ZWJ]Z=4\'>(]*_9J?Q+HG@:7X:^(+RV\<W4O[,\^OW'B+0M#L_
MAU>Z'IWQ3LOVAB;%]#\0?%'2Q:6&FCPI'X'N8=0BU"X_2+]DO]KZQ_:%^& \
M3_$+0]$^"GQ+TWQYJ_PZ\4_"F_\ &>GZ[>Z7XF%CI_BOPQIVF:K-::&^OZAX
ME^'OB/PCXKCL-.T\W%I+K,^FH;EK%[A\&7_@HA\!4U#4_#$>E_%;4/B!IGQ-
MTKX3_P#"M=&\!76L^.=0\5^(/"?B/QOX?:TT[2KZZTV'3=8\.>$?$5^E]J.I
M:>-+FTFZL-=ATJ]:**4 ^/\ Q7XH_:DT?0/$7@?Q[XK^-GB/5A^QG9^)?A=9
MK\'=%\6>'?CW\:?&7@'Q_>_%;P_\6X-/\%W^B: /!NOP^#=%\/\ @&YD\+VD
M.C:I(BOXCFNKE(/G7XP>.?VO/BD/%'P;3X7_ !BC^'$GPD\%Z7XH\)WG@BXM
M-.L?&?P_\8_LXZOX<UWP%;>'_ VCZ=X7T/Q%#=^.KC3M-M_'/BW4M4TC1M2;
M5M#\)RZ%! /U,T3_ (*+_LU^(]:T#3=%U/QW>:3K]M\+7F\<KX%UN'P'X:OO
MC1:ZM)\-=#\4>(KGRX]+U[Q#J&AZCX?DT](;J32/$,$6F:XVFM?6+7.?I/\
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M%N)?@Q\)V5%C5?AYX/B\M> K0Z#91.!SG[T9SUSG)SUH ]7ICN5Q@;N"3TX
MZDDD 8SGN6P0.:?7P3_P44T/QKXC^"?@C1_ WA+Q9X]O;G]HS]GHZ]X+\'>(
M=7\)WWBCP9%\2](F\7Z)JOB32)K9]'\,ZAH<=W;^(;G4+B#1)=->>TUN>VTV
MXGN(P#Z5G^#/@6Y^,TOQXN-/O)O']Q\,[;X2&ZEOC)I<?A"V\2W?BZ**VTN5
M!##J[:S?3L^J0L+B2S6.VR4C0#XZG_X)U_LP>%?A7J_A;QQXA^*?B?X7>%O
MOB_P[86?C;XA7=]IOPX^&&O:Y;>+_B9X<\.'3-/L&M]&\96NB#PWXRN+Q=5U
MW4_! O/"L>H0Z=?WB7/R]X<_84_:A\OQKK;^*;KPCXC@_9@^*?@7]GU+CXL>
M(]9@^"OC/QQ\9_B%XJ\+>$1]FO+NRN[WPI\+/$&A^!;;XG)!J^HZ':23Z?H%
MS-:Z;;O-S/C;]BC]HWQ%X<\3Z=I/PH>P^"WB&]\;6WAS]D2Z^/C(?!?B+6?@
M39>!=#^*UW\18-6N;2ZMX?B/'J/B&Y\,V6KZA<:;#J/_  F=EI][XLGNM*A
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M^+=4^-/QWN/BOI&OWEX(D346\+Z/?7^D,=2,MW%J-S/)I[1V,TD8^E_VR_\
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M#&*[T #I_GZ>@]AQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLM#N-#\!V$PDR!$Z^%](M=46)4)"B/5$?."TIP0<#]ECGP5X^)Z_\+Y^-@_
M?$+5QC\@/Y]>:^F@ .@% 'FO@_X/?#7P+<-?^&_">G6^KOCS=?OS<ZYXCG(
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M6_\ !^NP?\2CQAI@$;2F?2I1>VL'.HZ;8N"J@'L=%%% !1110 4444 %%%%
M!113'+#D$<8)!Z8YSWSG'3.%&,D\4 /IC/M!8XVJI+$D #:,G+$@* .<M@>I
M&>/!=4^,E[K^J7?A?X,:!'\0]<LKB2TUCQ+<7<NF?#3PK<(P26'5O$\5O<OK
M.IPYW?V%X9AU"ZX*W=QI^"X@B^">I>+'6\^,OCG7?',DOS2>$=$GN?!WPYM
M0P-LNB:1<1:KKL2EB#+XDU?4$N@%,EJ@&P '5^(_CG\)/"D[6>L^/?#R:@AP
M^EZ9=/K^K(V0NQ]*T&/4=0C<ME0)+=<'!Y!S7/\ _#07AVY&_1O OQA\0P[@
M$N-)^%_B=+>7<&VM')JMMI@="OS!Q\N"#D9Q7J/AKP7X0\'6JV/A/PMH'ANT
M1%01:)I-CIJN$&%\PVD$32D#(WR,['NW//3X'O\ F?TYX_"@#X=^!?Q!U/X>
M^&?%>G>,/A+\:-)GU7XJ?$[Q;:NGP_OM4A.B^)O%^HZQI4\C:3<7LD<K65S"
MT]OY;2Q/N7##!'N5E^T=\'[BYCLK_P 5GPO?/MS9^-=%UWP=)'N8*/,G\1Z=
MIUFF20 #=<$C<1W]P"J.W]3P, Y/.0.,YJK>V%CJ-O)::C9VE_:2J4EMKVWA
MNK>5&&&62&='C=6'!#J01U!H BT[5=.U>TAO]*OK+5+"<%H;[3KNWOK.9>NZ
M*YM9)89%&0"5DZ\@$9(O@Y_I]/\ /ID>YKPS4_V?_ 0NIM5\%KJ_PL\02,9&
MUCX;Z@WAV.>4\HVHZ"J7'A?58\C$D>HZ-,TBDHLJ*0:Q)/&7Q9^%B%OB-I$7
MQ(\%PNRR_$#P#I4\'BG1[8,Q^W>+/A_&;AKRVB3YKS4_"$]T8(T,[Z($9V0
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MS^)T0^3K&LM#HD@DM+&_1_I6&)8(DB141(T5$CC54CC1%"JD<:@+'&B@*B*
MJJ  !0!GZ-HVD^'=+L-#T#3++1](TVVCM-/TW3K6*TLK*VB7;'%;V\*K'&H
MZ 9))9R68DZM%?&L/[?_ .R;<?MFW/\ P3]B^+&G/^U?:> Q\1Y_A@-+UKSD
M\-'3XM8_Y#_]G_\ ".MJZZ)/%K;:$NJ'55TEOMIM1$&( /LJBHC*H/W7([,
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M;:CIE]$T=WI>IV<F);/4;&>WO+650\,R<FO%M,\3>*/@]K&G^$_B;JMWXD\
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M[##I6L36?Q?\)( H@2U\432:;XRL(%4_NEL_%MBVI^6%"+_PD*%%"_*?H2@
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M8:%KT&G0ZC?P?$OX5ZK;>*[>SU74KOSK]7_LV.&*U:*OQ7_;Q^(?[3O[>_\
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MFK7>BN-(,>E^!_"OAZ'5++2H]0O[MKIP#ZC_ &P/@]\3/V,OV9?^"E'[3_\
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MO/@7%XIF\82:E'JUS\3-,U.V;XF7WATZ?%X</ARWN=">SB*/KR>,_#C]M_\
M;3^-7@WX\R?#K0/!OB;Q)^S7\0_!GP6\;6GPZ\/66M>-?BGH>G^*]>F^)7[5
M_P  _"OBK7M*T+Q3X2\0^#K"RT;X3?#^]UF6WU[QEX>^*-HGB&_N]!T72;P
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MG'Y44\DY/*?B3G\:* /!]8 L?VDO UR04CU_X2>.M'1NTDVC>)O"6J^2Q/\
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MQ9\./BY<^'K34?AC^S[\4O#5[X(\.^)/!OQ.^(GB>2]^%EWHNH6*:?H'C_\
ML>UGGOM(UZSU)0#X^\3?MG?M(>/? NK^)O$GCG2;7PC:_!_]NOPM'X#'@&./
M1/CWXQ^#'B;X?CX>ZM!XJ\#^([C4=(\1ZKX,U_5KQM/^&?C6ZTW4;+0]6O\
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M2NDZ-XW\ .V)_AS\2_&.C0QLW[W^Q]<OV\8Z#,Z#[D<NG>(D2$'/R6XP2<X
M/H"BBB@ K^=__@M+_P $N_VGOVT/B/\ !3XL?L:>-O!/PU\<:Y\-/BC^QO\
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MUW')';0)"D8^H:* /S=M/^"6_P"S%8W#WMLGQ*^WO\&_!'P0DNY/&K.'\+>
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MPWXZ\.[B9M!\7:4P@U2S*M\[65R1'J>C7(S%>:1?V=PCL&./3P<C(Z=O?WH
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M-T6,^$].+7?B"X^R@W$2?$O]F#XB1_\ !1O_ ((G_$#X4_L[:M\._@%^SO\
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MXBN'=(X;.?0+N1E2P<U]&^8N[;R,]"> ?3![YP2O9@#C.#0 K9P-O7(]<?B
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M3T.2#M.0!0(5  &< @_4@Y^;LW;!(R"-P.2:EHH B\E>>GWLX(^7 .0I48!
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M<].Y]SS^=.H 9&&V+YF-X!S@<9R>G)P"/0X] !@!]%% !1110 4444 %%%%
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M5M:O6/[S4=;UF\>XU35[^7),EUJ-W/,<E5\M JUV]%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(>H^O]#2TAZCZ_T- 'S1^RA_R2O4O^RK?&3_ -6AXHKZ8KYG_90_Y)7J7_95
MOC)_ZM#Q17TQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVI?B3I7Q$T?QMX5TFUN2[_$CP2FB0>'KJ>2>RMM1M[Y[JTO[);5K:[_9VF2
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M,%H6)_L;POI4;-8^$_#L>6":7I2H]RQ\_4[N_N,2CUD(!W)YSR2>?;.< 9.
M, 9QC@4^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $V ,X# 2(  A$! Q$!_\0
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MG*DG-=+;V>A['12 @_F1^(&:6OM4[['X^%%%% !1110 4444 %%%% !1110
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ME&U(U,BB0<2ECMVECP,UHJ!(KP2).))F,=M)%*"69!Y[G<IR\/R!8R9 44E
M#FL6!+2,2++<-&D+QX9W$DUPA8-)*JY4('7*\G!!P >E7IY+7R[A89(XUDRT
MJQW B01JI,20"0;H9VB9E9HU ,A W'-:TZL&N9RCH[:6UT/$Q<93E[.$?=75
MZ6Z6NOF_GIU-1;IF>62)I;>*2-D,;Y69I 5E15D.2SC<!Y3.H ^8$DTJ:BZ"
M1F2WA4!2(WW$O)(RJC.LA)-RISY,I(Y)W[A@UQ4FOX<(ID1DEB^SL4,UO%YB
MG)9 JFZE( )#953CYQR!'<>)+6%F::[^T[A(BI,B1S.BH'=FVEE!BDRR[22H
MP W45O'&X?X>>S2UU70XYX.IJU#F3V?5Z;[VTUO9]#;\4,DFF#]RR21Q2PM(
M)"@7<,W#;)-S;Y'VXQ@JI;'%?!_C(!+N;S,,$)*@$\ .<<#"YSW'S8Z]J^K?
M$7B:W:RWB7S%9=V2)&!9E(8ARQ8,V<QF4*"F<\XKXR\<ZS#+-*L;*KH[.78]
M0#DJ2"!CCH<^W/3SL54C7Y>17Y=TVM=U96;[_P!,]'*XSPT)N5KN]NRYE97[
MV\C+$T4ZE77=O0H5?D*,<J,X8 YQR3S]<U^_W_!*/Q_)K7P6U7P%>W#RW?@7
M7[B.VCD8EETW40UU;E02<1J"4&W !4 DG.?YX-*O/M4Y+L  =W&/FR!@CK^[
MQA<C'()R<5^R?_!*2XN[7XG_ !$T\'-GJ'A:RO)"A)C%S;76Q"%& -R''/3!
M'>OH>%XRHXU*-U&I!QDME9M-_P!?I<^&\4(4\3D,ZLU'VV%<90EYOW6T]]8M
MKY^A^\P*Y]\^_4Y_^O3JC4'<3VR<_P"?Q_G4E?HEK:?UK=G\W_\  ?IIU"BB
MB@84444 %%%% !1110 4444 %%%% '\)<\%WXT\;7C6CI+INCSI;S75RKF-[
MC8)#'$J$L\C)@;8QY(S\VT\5ZLVN_P!@I';3F00>6OV14'EQPR0NN8LL &/4
M@,63!Z@C-:WPL\#7'ASPI;7VH.G]HS;)M1=X]\T\FHL?.,<BJ29)%Q&IV(8V
M4@D#),/Q@^&USXD\/&;PY*8=0@L[D+;W4NPA<'R92#N1XU<H9&4JPSA2>E?B
M>'=.I0G1C[KBKQ>BE+6^JV?RMMTL?W%0K<M>6(J*4J<K7=_=2>G;\_([#PQ\
M2K(I]GDN _FLC7."1+$VXE @!$98G(R@QC->BP_$JS>X#KJ, Q%+"[F4[Y G
M#&2+=\Z@\$XSGU'7\$?$GQN\<_"_7KOPWK1EMM8TXO!<YC$D#PQ/O$EL&C!9
M71O,7:7<@X'/%<7XJ_;.ET^WB;3Y-1FNU"KY=I:/)?,\I.XI,SQPVJ;LD[\J
M 0&.>DTL%5JW46TT^RM;;MN;8S,,#!N?,Y1Y/A7+HUOMOHM/^ ?T1'XHZ?%,
M,W\4BRO&@C9@%C=%8I'*2<(6QA0Q&6 7[W!N0_$6UNS]F@N%NVDEDE<0D2.L
M3@8B>8G,:;QEAP0JG&:_G]_9&_:,\9?M/_M%^&OV?Y[;_A";OQA%<R>']7U:
MZ2X?6K[3=UZVE+A$CAO9+*.\O8-K227#1RQHN-I/]@GP _X)P?"K0;2PU#XA
MZUK/C/4)((4NK87DFG:6P#!F@:&S9))(O,RN7D9B58Y&<5]+EG!V89C"56->
M%/#PGR3G=-J7(I/1/7W6NC_,_->(_$/(\CG3IU:%:=:JFX0C%7DDY1373XDU
MO=>J/S];Q_8Q[WN9(8/+M6*2W$B ;X5*X61B,E0-@P,8P3U-?/>M_M*> _M$
MUMIGB;0-5-M*%E@TG7--O;RVG5BKQW<$%P\L(20%#YB*!(&0_,I6OZA!^RA^
MS_H%G;'1?AAX62U$2[//T]+YXV P<377FODD%FW,=PZ\'-?P'_\ !??_ ()W
M^*?V6?VTX/CS^SOHNI>'OAG\>8(_%-QI_AEY[+3]"^(%F5B\26%O%"RQ06&J
MW"+JT5JZO%!+<70CC&5!]/$\%4<'@WBOKGMK;NT==6KM)7Z;7MI<^3RSQ2_M
MC,*>!HY;5I1JR<*3G)IN5WIJ[/37J]=%8_2.X_:*36/.M82PB#%8C'@22$G:
M7E/"NJAB=I*G&"!Q7#W?BJ]UFYWW01D+\A&!4HA.UL#OCC.#G)'?C\G_ -E+
MQ[\5]9L5LOB1H]TUQ$8HX=0:.6+S8U.%,J;0IE"X+RL0#VK]/;1+>UM([P3(
MP*!CEN^WE5! R1DD@'<%&>F2/!EA(QDE!<ROZO9[+J_DS]!I9E4<$I4I1YKW
M]Y)*R;;;=E96V;/7O#<J85@K[R 5 P<*&/49.,#G! R.@ZBOWW_X)-^$YI+/
MXB>/G1S;2BQ\.V4K* C/#^_O/+8C+ -A6]#WSQ7X0?L[?#SQ_P#M">-[+P%\
M,=%O=1FFN8EUGQ$('71?#VGLVRYN[N[*M!))'"S&"$.9'D("KG%?V&_L\_!?
M0/@/\+/#?P\T&,-'I5LLFH7;+MFU'4YE5[R\F)&YFDER4#' 3"\=!]5D.#G&
MH\3.#A",;04E:4I-K?;W>79K5M=M#\P\1\]PM7"T\LH8B-2O5:G6C3=^2,4]
M+W<?CTL];]CW'G=_LXXZ=?YTM-.=P]!].O/XTZOJ4K'XTMEWLMO)6"BBBF,*
M*** "BBB@ HHHH **** "BBB@#^2?5[=C9QZ4+E(/->"XB6"#]Y,]N5>]M]N
MT;858>>LQX,;[02U8=\9(-88?;93I\L*9BPLJ2)OQ-!%E6"1RQ*9EC !"D;O
MF&!>OKF9;FZ<JT3O#+;V<1N2VX0O&]D?-D =5NX9&\P+D,H"X/RUB74T7VM)
MS#/%;VT"RW*P@M'%',Y%Y$\LL@*31G?+'"(]WDEBK[5"U^#4W)5;Q;C)/1K=
M?+;:ZV/[8=94,-[*:O":<7'>][65][7L]&M4NA\X_%[]GGP-\5Y+B:^T^&'4
M+AYC$J6YEN)Q BF!D? ,&S!+.I!<#!)  KY;N_V$? T.HPW"WB@M82S2W#1^
M;;PLF0^RW=0UQYQ'EL)W2%67*3 \#]'3K5JM]=PVX2Y2"/\ =O%*8I9I5C9O
M*28Y/E.O$@3J\38(!Q7)ZSXSL+*VN&FLC!>RVB)_JUN'N/,1TC>"U)&+>VDQ
M)+,8P&:,@J>0?>PN,HJ$FXJ\8>]OJ[K6]_Z\CY#'QJJ;49M)MN*[*WFF]N]S
M\(_VH?@[J?[,/B?P1\6/AQK4^E^)O!VOZ7XQ\%ZO;;8S#?Z->6UQ;"WCC;S[
MI))%DMYU^5&LY;B$@QLU?V_?\$\/VR/"?[8O[/7@3XQ>'[FVM]4U"UCT?Q_X
M=BF1[CPIX\TR)(/$&ESH'8_9Y[O=J&F2X\N;3IH&C)(<G^3']L]+76OA0+B]
MAEUFYMC):6%X()([J_O-7GEMM-M[*.)A+&&GD98HPJ!V(64(Q0#]6OV!?A=\
M,O\ @DM\ OA^_P ;O'MS_P -"_M*>(/#GBCQ;X$LM1$N@?#GPW>V\<>EVNJV
M0D:WM+ZVM[B,W]^%$IF+Q,?+@VC]"X)KUZF)KPC%_4JE%SK3=^7#RO954G>/
M-))0UYE;2W?\A\1J>%E@\+.LXSS&%3_98-)2KP6]-V47RQ?-/2SYG\70_K#T
M&^2_LFL9=K$HQB<GG<5SQ[<9 Z]?:OSX_P""B/[-#?M$? G6=!TO0;77/&OA
MB8Z]X0LIA")+C4( ?-LEGF 2#[6IQ\Y\H@YX/-?6'@OQ!%>6ME=03I/#<P07
M-O<1.&BGMIXDF@FC93AHIHW61'X#J0X 4\>FZM;0ZG:&5E\U+F-H;A" 0Z,I
M5U;/4%21VZY[\_98G#INM0K1BJ=5MJ-D[IQM&2LDES)J2:MJ[GY-A,=6P>(P
MN+HN4<1AL0Y4HJ35Y+XF]=D^:+OTC]_\DWPW_P""2/[;?C&:"63X=^#/AYI5
MUM$EWK7BK2;DPH0K.1:Z-)?2"1<[?*+;@P(; Y'ZF_!'_@B/X(T=K2_^/'Q&
MU7QS+&89I_#7AU7TC069,,(9KAF:ZGC1LJVP1*ZGYN#@_G%\=M5_:W_X)A_M
MC7OCGX2^+?%/B;]G7XDZP_B(_#_6[Z^UCPV(KZX$FLZ/80W,EPNEW$,C2R67
MV8Q(C +M\O K^H_]G7X[>$/VC?A9X:^*'@Z=&L-<L(9+[3BZM<Z1J@0"\TZZ
MC^^DEM*'C!8?O%&X'%?&4<KRJABJV'ASU<11:E.&(YN>&NCBDXK=KNK;K8_1
M,QXEXEKX+#8J56E0P6*I6A4P;TFWOS.7.XMI/5./E8V_A9\$/A=\&?#]OX:^
M&O@[1_"FDVP51#IMK%'-,4"[9+FYV>=/(=H<N[MR<#'->L@8  Z"@8QQT[8Z
M?Y_E2U[*2222225DEHDNVGH?&3J3JR<ZDY3F[WE)\TG=W>KUW=PHHIK$#J<=
M3[\#/ P<_IQSTS3(L.I"3G@9'?U_F/:OGGXN_M+_  S^#T3QZYJPU'6%QMT3
M2W2>\SAL>:$W+#EAM(?) Y(Z5\Q6G_!1OP;-,RS^ _$B0GE9(I87.WJ"5V@C
M(QG'OTQBN&OF."PT^2OBJ=.4MHMZIZ:-J]K?J>EALGS/&4_:X;!U:D.DE9*2
M[J_2]S](@6SR !_GW-.KX<T3]OOX)ZA-!!J1US03*RH9+VR+PH[G&'9"2J@D
M9(!]>!D'ZZ\*>-/"_C?3$UCPMK=CK6GR $364RR>66Y"RH/GC8="& YXZUK1
MQ5#$*]&M3FNR>K^5SGQ. QN#=L5AJM'SDM/FTFK=M5N=311172<H4444 %%%
M% !1110!_&_J.NOOD,9,Z>;&(I+G#WS%H"\/D2QMY=L(Y/,BV#/VF.$8(W 5
MQFM>(+PW4D5I%+)8!+3SXH3']J>ZU&"4[DC>4_:'>:'=))D&V ,1P&)K)NU@
M@ACFAM/)$T<3.T<[K=$S[4,LF^5HU)69Q;M&H-L<D9XKF[RZ=]B9&RW:6"\"
M[&,YF 5GEDC+21RRP +Y:@"%D:1&(EDV_B4*,8)RYDFMKK]/GWU/ZSQ&,G4O
MR/DCL[]M_,Z*?64BO!/%*T=O=2&#:\'^D1,BLCQ0H50^=+=&1YC@A8W!#8-8
MVMW4VH0VVFZ=+%)?3![=[BX0F5P8Q*)XYB0Q@2%Y(9W V*4. 2#7%7>OVL\3
M_:+H0?9G>1$VJLL\RLR>7(P(98F9XA(VY7!4D,QRHQM1U>[M&U+3]*,HN%@M
MS:W]Q)$\]I;RV[>?':2AP["0.2ML0"L2[B0SD4VG-QC&HHW;OHU?1Z72?KTT
M.15W&ZG4BTTM+]FG?7RO^!X+\8;K2[KQ=\$OAS=*A37?B9H5]JP:8"X%GX<$
MVO:E>.<E1!&EB;=9(L;Y9(9#@C%?-/[4GQ8\8?&/QSK9MTU34+>YO[W3GU>:
M6],BV]JJVT-G'=.VZ.."-6&U&"W#E67[N#F7?B75/$?[3WA>*:8W-KX$\+Z\
M6:9E 2_U2/[)-(G'^L\HG]VSLJLQVMWKSSQQKL_AKQ;<VT\\[Z:EW)J#6L1,
M:7$SONBCW%B"ASF4!<EN%QD$?IF13C@>'*R]I.E/$5'%SC;EY5",DWK=+F3W
M5OP/RK-H+->+:3Y(55A:5H1>M[U)7Y5MW[=?G_7Y_P $=_VCM:^(_P"SMIOP
MV\;:@][XY^#45KX;-Y=7/GW^K>#VA!\-7]U*_P"^ENK.&-M*G>09D:"-R<-F
MOW4T&^2: V[X*N,IGC(/W>A(X7C&<9&1GD5_#1_P1R^/6H^&/VRM+\+W]RUO
MI/Q7\(:[H_V,EEA74-+9-6TOYG9@CE8;R- [%L$@84G']K/AG4BRPMN!P$(;
M(!9<<9Y Y'3 Y&"1S7V&3XQ9GE4*SG[2MAJ_U*I4W;4=5)^L7';\#\ZXRRO^
MQ\ZG2LJ='$T?KT()62<K)PC9::Q>FF]CE_C[\#/"GQN\$ZEX.\3V=O*XB>YT
M>_DA1YM/U#:_DSQ/C*@-M#8Z*S<$\5^>/['-[KW[)WQNU'X3>)O,L?!OB^Z:
MV$3N?L=MJY=DL=2M&8!5BNP09#QDOM.*_8BX*W=K'<H%8A1OYS@C&5;'<CZX
M/2OE7]H'X+V/Q.T+[59#[!XLT=?M6BZO&,3B>W;S8899%4$IOP >2  .>*X,
MPRYU9QQM!^SQ>'?LYJ^M6BM')=]&]R,GS>%.C5RS'+VN Q<6Z2OI@ZSU@YMZ
MI1E&#]V_XGWLI# %<$-]U@1@JP')(ZYSG(X.?08J=<8&.GO7RO\ LL_%>_\
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M3I)$I;:9KFU8X:,#!(&& Y!.,5^FGA#QEX<\=Z)8^(_"^JVVK:3?Q"2"XM9
MZC*[O+E4$F*901OB?YE[U_/KJHT?5(G+PPJ3&0[;%!((Z],$C.?F&.!U[?1G
M[$7Q0E^'OQ)D\ 7M\_\ PB?C25AI\,TA,6G:SC= (T8D)]H *_+C.2,'&*^L
MRK/L3];IX/%3C7I57R4JR^*%E_R\;TMZ7=WH?"\1<,8!X.IC,MH3P^)H1]K7
MHI^Y.-W>5-;Z6_N[-69^TXSCGKWHIJG(SUY[=/P/<>YIU?;6MI_7]:GYLG=)
M_P!>?XA1110,_P ^N7QOX7T:"YBLKZTEEMXS:-<EXH9=K&-Y#)&I$,)BVMY>
MW#D#[O6O ?%W[0/A#2]3B@\T:DEO&9K@R2(T4DRN&C16##)#<@<G /':OG32
M?V0_VD==N%@UKXB0Z?;S$><]C;R-=^:2$9_.N&E^920 K L2?EE.>?5M _X)
ME63$7_BW6]:\27,UX //U>[6"258TGG5X()46/>C<R)@1N2$SMK\EC2HNRJ5
M$V]G)QO^%KZ_\#N?UQE^3RFU*RC%/F;GT\WIT;U/)_B'^V5I5I;W-KI2_:;Z
M54,=I8@7#*Y5F5?)BW/)Y8R&3 "8.<=O/O@?XWFU[XQ?#OQS\;O!OBKQ/\([
M;Q%I]WXHT?3KAK">XT..ZCEN(;<,O\:C>\;'$R@IQBOTJT']C7X4_#_1TO\
M2_!&F_VPDQCD23-T B',LT5U<>9(3+"KQS!GY;;(,L[ >G1?"/P=IUI<II^G
M1"RO;:WN-/B:$);PI. 60*V0IB;<ASA?EX)&,]V&J83#SC.,82E3]YWU6FVJ
M?>W4]^OP_4Q.'G!XYP56$J<8TW%.//%Q=^;LF[>:7H?T?_MFQ?!?]JO_ ()4
M^*;KX-?8KGX=6O@[3+CPSI]K%&LFC+I")$--GM\,UM=6OW)D.TD@]>*_S,OB
MC\/YO"OBO5-+FAECE@N77(79\K.Q7!'.,8'7N#[U_<!^P1\3O[(_9K_;2^!M
M[<.^AZ;X;'BG2(FW?9K"6XD^S75O$H(B0SE1(",<G@<YK^3_ /:P\/1?\+&U
M2\MP/(GG8H5CQGYP0=P)W #(/H?PK['%2CC,!A,=&/*Y7IV2LE%/F]V^K6M[
MN^]C^>,%ET\BXASO)JE7V]"G5<HSFTYS<]6ZG+[J=W;W4KI(^'/#VD:@EY&]
MK?7D4FY?+,,LD4@9<J2'0[AM1VP.!G\#7]:7_!'W]JK56\.V'P]\9ZQ-=:_X
M1DM-(>YO)G$^H^'9Y6.@:C-)D2RO;,'T&\D.3&\>G3-S<K7\T_@OPXDMS&[)
MT<GH>02/NGOGTZ]^<&ONSX!:MKGPL^)7AGQEIDD\=I;7"VNM01,46]T"^91?
M6[_*0&BVQ7UL_'EWUK%*& )->3E.;U<KSFA7E.2P]6I[*O'I"E=)35K>_K]J
MZ_,^ES7)Z.:9+6PL8+VJA[:F[)RB[/W8WTY=/6[W>A_H>^ ?$4=_9VMQ$P(E
MA0C+ _*!C.03P.!VSCBOHC0+Y 5CD&Z.8!&.3_$ ."!Q@\]!TQTK\D_V/OC%
M;^-/"6F*;V.XN8;>WBDD1Q^_4PK-:W*\X9;FUDBN >!LD ;$@*C]/?#MXKP0
MR-(%3 Y8E2" .,'!/..<8QTYK]@QU.%2G&K3:E3K1YZ4XM.\-'S7_!K;?K8_
MF^=*>&KU*%2,HU*=24'&2:=M=>FMTEL=MJ.G[))(OF8$G!QD%#\P/N.GKD\=
M0*\0^(WC[QO\(O"NOZEX*\/MXEO]4,4=I9H&<Z;J$N8!J9MHP[7"JN'DB&!*
M5#$@ @_0HN9=2M8Q:VX,D2CS+B0A0RXS\BY)/!X) &<UA2VJL2[@,ZL,LP#8
M*YQ@*V%&<Y !'3GI7D1<90<)JZO;TL]'ZZ>F_F:PDX3C-)-Q;T=[.ZMK;4_E
ML_;=\#?'#3_"GBKXO?%32M2^QZO!<*UY='SY8GN%=U-S$K-]C7G$)SLV'DCB
MOY9M/^*-QX0^(BQ7$LB6D^H[X)&(6./SW8E6/0$ CCC&1GJ,?Z:'Q6^&WACX
MG^#]>\%>,-)M=;\/>(--N].U/3[N-GBEMKF.1',1^9H941@8I(P6C=0ZCY<5
M_G7?\%6_V'?%G[&/QOU#PZ!<WOP_\5M=^(/AAXH>(I'J&C^>?M&E7,R@JFK:
M Y2WO(PQ9X##<JSH6V?)<28"KAWA\PH*56C!N%6ZUIMN]UR_95UON?J7!F=4
M,3&ME=?DIUY17L$FU&<;):\VKE=/X7M8_6_]D"X.LI'=S2*ZW4$,D398@I,$
M<$,IVX .<GD9!'7-?IGIVFV\42.9'8)A2J;\#&<'.2,?CT[=*_+#_@GHLE]\
M,?A_J3*7EU/PYILMSURB[%B5V(R%=A'AE)W*W!!/7]5(+:7/EH[11XY7.=V.
M 3@9!QR,]B3Q7Y'FDY/&U)2=^:HVX]$G;1==C]MRZC&EA*$5UIQO>VFLD[6Z
M?H;JVR!-S^:4. & X!R <].V>.<\XSQ3I82D8)D;+X#@@#:@& S<9P>N<=\]
MP:8L<UO 5:1FW+N.Y68X&2=JY))!YP<\ ^E1^=.I+EUG\]$$9 &X,#\HD4D%
M5!&2<$D ?2O-A.7-K3DH_9DT^SW[?YGH.A%*5JL7*&Z3BWVV7:Y@Z]%$H#%"
MLD2$@CH<KA3UP?EP1CJ.".M.\.R,VF1A8#A2X,FXX(!^]P>/? [?6C609+54
M,JJ8T>-LJ-[/AFX.,%<MP<],<<X%[P/;22^'XI)#N\R2XR,$9'F,H "CCE#W
MZ$<Y-=M)N2>BNUTNVK-;6UUV/%QCLG=O1M=.EM/3KTU1!<7VQSMD+A<[AU'.
M!S@>_'3_ !IZ?K5UI&JZ;K=G,8;W1]0MM2@D4L&WVLRN1\I!!90WX9YZUT-_
M8PAW**BY'*@8)P0< _S P>"/6O/M7MKFV#SVX8D8RKY*%1SM;C)&T-G&<DCM
MT[:%6=.I%I).+IOFU324]?O6CZ?,\;%4%5H2Y7[U2%2,D[>]%P>C79-W[W/Z
M8?ACXL@\<^ O"WBJ!MPUC1[.YEYR1.8468$GN9%+'_>KO*^+/V"?$4OB#]GS
M03*Q:33-1U'3L,<E5AFW*#R2 %.%! Q@#'4#[3'09]*_8L-5]MAZ-5?;IPE_
MY*E^A^!XV@L-B\302LJ5:I%;?S7Z?X@HHHK<Y3^+#[#:07%D+$*D<=M'<2N
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MO].OM,O+^2YN--U:^M'DDE+RMMN'>"1@V26:T>%E/#!7V@[17Z>^'-2++'G
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M:UU:4O/LKVV]4?JE_P $R;36;?X$ZC-J!==.NO%>H/HL3EB%MD4+*\6>-CR
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MR3-:>:9=A<=3:DJJ5.I&-FX8F*<:E)IJRES0D^624??5Y6N>4_M*>#?B#?\
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MSAR.<Y%@^*,'253$Y73A0Q4HJ7/7P&(<:F&K5+1OS89I4N:2YHTG=:JQ_/G
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M!SU_;#1]*MM%TK3-(LXUAL],L+2PMXD 54BMH4A10 ..%#' Y/U-?EA^T/\
M%A_AWHZZMX>MK;4=?\/7UKK),H'V6TBL+@2RI+*"-D]PB/%$#D[B!G!K])?A
MAXYM_B3\/?!OCNS@GM+;Q9X?T[6HH+A-L\)O( \D<B?PA9"54]P!Q@UXV:Y;
M'"U'CJ48I8W2?+I>JE=M]KJ*;M9:;;GM4<RK8NE0P5>4FL%"])R=[4GI&-TM
M;.[N[NSU>R/0****\PW/Y%/^"'/_  4:TSP%8K^S)\:/$26'AXR,_@;7-5N
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M\D$GKS[=.CBF"J?)PA4 NQPV!_L<\Y]/3..:^#?!7Q >]L[:19]KB-!@LPY
M&2<]B<GG@'ICM]%:+XVD6*-Y2D@7&%!9L_4?Q $_3V]/->-C><5)TIIR?*TM
M;-Q::OWUO\C[B"3ITYPY91E%77757;2VOKIKYGKPU6Z>9@L#M\R[_EPJA <%
M3QCG&!Q^.*W]-UJXAE2.218LDN1DL5;^^<'@C@8 QS[UYW;>,-/U)EB>00,<
M%\  D]\D="<8&.A_*O3_  ]X?L]5DC<3%U3:TC95M^X@A3CYE !P#D=,>M>/
MC<3.2;J)2=K)V2TU>RWZ_?V.[#X2-2<*D:DHNUFF[:K7I_P?,Z2S\>65G<+'
M L]_?LP4*,A2Q^4,5R!G((X.,#&.HKU?1=1\3WZOJ=S#<"&",M%;.A$2#J D
M>3N'3YF.>U>97N@:59ZCIPCA2W<2+B5 !O /W6+$DD$DY&#@^PS]M^!8=*M=
M-B),5[++ ,K(HD6- HR0H^7J1C(QZ>E?.5,4DJKY$[MM:+MI^B?D?24L(G"-
MY._*F[>6NC]+6OU/DOQ[X5\$?&&RL?"WQ+T+7)] @UC3M2N+G1Y_L.K6K0,T
M=Q<:?>>3.(?-MIITFC$+B=&V'#!"/M?X1_L._L'?"JXTKQ'J'@#3_&8,,6HV
M]SXYU:Z\9#RMBS"7^S+N\L-")V[',=Q9.T81@R%U(KG;F/2/M[F:TMP'F!.U
M8P<_>&T#& " <#'/8XYZ&*QT2"UF:&T@= A*AUC,<9.6RN=VP[N05*D$DKC-
M?=\)>)&;\,9;B<MP]-U:%6<:]!.<TZ%2<7[>$'=<E-RUARZNRND?%<3<%Y?Q
M#CL/CJ\W"I2IJC548I*O35[3J-*[J-VO>^C^(_0+_AXQX,^$WAR+P?\  _X?
M:;;06$+I9C1= LKJSM&@! >PTBRBTGPG;L<\2W3ZFT8=E\MW4 ?$'Q1_;<_:
M6^+.K>9?VFIV@9R8IK^\;4-0M("256"25(;+28@,#R=(L;)<':TCJHKB])\3
MPVDQLDLK43("@=8U4DY+9'?D$9(^]U)/-=+#;ZKK<GEQVT:B0E6985V[&/"[
MPH)89R021QV'3P<WXSS?.:DZF+Q-:,:DW>TFY6L_<C-RO;737S/:R7A+*LII
M1IX6G3Y4D]8)R<K]%9^;ON_/4^??$&I^/O$5RK:M/<RW8<2>4)7ED<[BQ:5B
MS-*P8X"NQ  #*,<5YG\?-8E\"_#66[UJ<QWEQ:GR8'8Y0R\8"@YW'K\PXZ=B
M:_1/3_A_IFB68U.\7[3.%9V  9DD'+-GJ8^2<GVK\2O^"CWQ$D:3^S8YU$4,
MFU5R%X504!1 H 7/ISQUYKR\MG'$XNE%1Y;5(-R<Y2YTI)N4V[OF>J:6FB/8
MSFBL+EU6JWR_NFH124>CMHK=^FY\S^$/']R\TUP)'0K*Y #':^7!WG!ZX.!C
MJ1S7]%/_  3.\=3^(_ >NOJ#><?#\Y>W)/S)&J[\Y[!N5XX (/7-?RK_  VU
ME)[619#\V696R1GY^PR>ISCUY XK^G?_ ()-^'B?@Q\2O%5TTBPRI=11!@P0
MM!&,E<C:01QT&0<GJ#7]1>'[G+B/"*E)O#SP?OVNU%T5%.,NB<W\&]U=NQ_.
M_%CA5X>K*HDJLL9'ED[<[]I=IPZN$7'WWNK[.Y_31^P%\=H?"GQCTC2%N@OA
M7XI6W]D7$1E'V>'7[8#['.J[MBS2$&)R.64X'6OZ%$;=GVX.0<_7\?Q^M?PP
M? #XG:II!DO+>X(O? _BJ#Q%II5\D16M^DLB+D'8/*5P< J!UX-?VR_"[QE9
M?$+X=^#/&VG2++:>)?#FE:JCHVX>9<VD;3IGUCF#J?<'ZGS?%[A[^R,\HYA3
MI<E+-*?/)I-0]JKR=M$M5?\ X!YW V:?7LOJX>K44Z^#J^SY;ZQI]+:MVO;2
MRW/X4?B?HWVF#S1L8H"2<9..",8SC/4=,_4U\PZAIFVTG#)\Z.P)QP!M8XQS
M@^WI]*^XO&5HMQ92(1N)C4/M4'RQC^(C(![ *3S@5\DZU9M;+J$.UHS\X /S
M,X)/S=0=V.#TXS]*_H]6E0G"23DXOW7?W4E=M==E8_*(:3BTVG=7:M=VN>'?
M8%PXX) 8,#U4DGK^?!/K[&N4U'16:5W10R8R<G\\8'3'?ID'I7H,<8:24('#
M@,"0N]<*<DDCH>3['Z=83 +F1E(/RJ !@ M@#.02.?7@^U?'XS"0E3=6,;N3
MD[=$TVM]]NC\V?4X7%^ZESZI:Z[J^YY--I@R<(/ICG' !X'0]_KGMFG+IJ(
M/E!.""H!P>3S]._Y^U>BW6F(V<JR <*Q! ) /4D9(/85A36'EL>X!_A&<<=^
M1C_'ID=?GJF'Y-5%IM7NI-:7>EEII^)Z4:\*J24E[KU3LG?\+]-?0RK2W:"0
M98%60Y['YL89<\[E()[>QK[S_9@_;Q_:&_9=U2SG\">,[^[\/I-&+OPEK4\]
M]HMQ"HPZI#)+^X!"X1$('7'%?#Z;5;81QU!(Y!]".@''<\DUJ6LJ!=C=,[MW
MMZ <$^_08Z=C7)6P>'Q5-T\72AB(V:Y:B3LGTNE=^KU.B%:5*2G2DZ<EJ^66
M[]'^1_:5^R5_P6%^!_QUCT[P]\2VB^%_C:=(XW:^F!\/WT^%5I+>]<@6ZN^?
MW39*L>:_GN_X.B+3P+\<M5\)7OP[U'2O$VJ^'/!4L>K:CH\L-[&K?:#/:0O/
M"&$DHBR?O9"MC XK\\-)N!;2QR1RA65MT9&-T8W!CL8Y9,$ Y!/3M7L]Q%8^
M,_"^H:;K$@N_MEI) 7G=Y6):/"[F<L< 'Y5R1G [5Y>5<$9='-*^(PCJ4_:X
M.I36'O%TDYQ>JYKRT:5DW9;+H:YAGV+CAL/"JX3C"K"I*HTU-V=DKK32[U23
M^5S^/?PYJ$^DW4EB^^.6WGECDC; 8/&Y5P0">A!'(X'7W^B/#7BPJ4$C+C'=
MAR,<Y&[]![8ZBLO]M+X&^(_@?\4[Z:.SN?\ A'-=OKBXT^^CA=+=&D+R/&S@
M8!Q@KEL'.,9Y/SKIOB::.)<LY8HNXC.X$8'()& 1VZ_C7XEQ/D5?+<RQ%*K0
ME1G3G.46TU&=.4GK>RU;L]-+:GZQP]F]'&8&A.-2$XJ$8OWKM2V::\OD?<MC
MX@MWD$C2!00 &5E5<G@9&0>IX[=:^K/A[JTZ)9)'<)B54#MD$E'(^]@\;02V
MX]O;-?E-8>*9P@=96!7!^^<@G('!)Z9]".,\\5]B_!GX@27*I9W$PW@*@=L#
M# <\@Y''//7@"OD<53FJ/-)\S2Z/I9K^NOIU^RP&(I^UY(RO=\_2ZNK66NRT
M\]6?>^NPF7['.SAOWH((&!D8& 3WP0<^A!SG%?5W@20?\([#):KONGMW0_Q
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I45[?'R4<CJ327-[5*[2>GM(='=?@<O"?OYG2YM;4M/+W9KIIMW3/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'R 58# 2(  A$! Q$!_\0
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MXL[U")X[?4([1-0AL=1CAU2PBN4M=1ABNXI%';ZM\'YYOA#IOPG\*_$CQUX
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MJ_8,^&GPT\(:]X)^(WCCQ5^T-\/-1U*[\4R>&_C_ *=\/_%FFZ=XNN[RXO\
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M@R\O]'^'^GZGXLN? ZR>/+ZUN)4T-K/Q1:2:9?");Y8BT=U&TUFWV@4_"?\
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MQ\/Z%HED]S9P:C<6\>JZA;WFI-9Q6=FUPT%JBL >&?!S_@H=\+?&?A;X/O\
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M)K:66/YJ /Q$^.GQ[_:4U/X2?&'X<?$#Q?X^\.V^C>"/C)X7\!^(_#WP8O\
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M1#]GMU3Z!^(?Q2\=>/[_ /9(\*+J.K?#S3_BUX"\6?%SQZ-$O)=,UV[G\#^
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M-]HNKM&K]6:* / ?&?P^^)WQ+_9WU'X>:SX[M?!GQ5\4>"+72];\;>%=,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!D GU.#CN .HH)QCW..W^>W;FB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117SW^T%^U?^SG^RGI7AS7/VBOB]X0^$6D>+M3
MNM&\-ZCXOO)[.UUC5+*U%[=6-I)#;7 ,\-J1,RR; 4^Z6/% 'T)TK^63_@LY
MI&I7'[1VHZ-X^\1?&VR\/_$SX1>#_#7P L?A]^TI\/?AA\*K#Q[8Z[J9\4:Q
M\9?!WCCQ#I5S'IJQW-J/[<TJRN8[K3HFM8Y/M^%7]_/@!^VC^RQ^U3?^(]+_
M &=OCAX'^+FH^$+2TOO$MIX0OKF\ET>TOY6@LYKT3VENL:W,J-'%@LQ93P!D
MU_/)^W!XN_9X^)7[8OBCXI:IX^_8@\,:LGA+PW\-]>^$O_!0S]E_XS>*/B/I
M/B'P7JFI2IK_ ,+OL=HEA/I6KV-[ UJOA1]4M]5DACNY#YF"0#]N/^":/@_X
MU> _V8=(\+?&FX\3W%QI7BKQ';_#@^-/%&C^,_%*?"A)+5?!AU/Q)H:BRU*"
M>!;JYT5F>6ZBT*?38KF5Y$('Z!5X-^S7\4_#?Q?^$/A7Q7X2TK6=-\/P6-MH
M>GS:GX%UWX<6&KIHUG:V;ZOX4\*^)8;77+'P?>2*Q\.G4+2UF>P2,>5M0.WO
M- !1110!^>^G_P#*5;Q5_P!H_P#P1_ZT1X[K]"*_([X]K\01^W-\=+OX5^/8
M/AGX]TC_ ()K^&O$&@>-+GPEIOCFWTR3P_\ '_Q_K-S;2^&-6O+"PU&/5;6R
METQWENXGLUNC=P%IH44_*W_!/[PI\0O'7[7GP<^,7QD^.?Q7^(WC+XI_L)>&
M?VK=8T.S\;>-?!WPAT_QU\2O'5]X4_L[3O@U9^+M4\$QZ9X<\*&/2+%/L@M[
MB]A37C96VI?. #^AJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH /I7Q'_P %#;ZW
MTC]E#XL:S8ZAX$T7QSI_AJX_X5_KGC>#P?.VE:Y=W5E:7D_AK_A-K.^TA?$K
MZ3+>1Z1YEM*C:@;3SU\H$K]N5\"?\%-?A9X(^*'[&GQCC\8_!;P_\=;GP?X>
MD\7^%/!^OZ/?:W':>(M,G@6'Q':Z?I4L&JW<OAVTFNM:GT_3YXIM5M+"?3B2
MMR10!^<?_!'G3_BKX2_:"_:*^'GQ.\<>./&-UX:^'7@RY@N/&5S\(38WJ:KX
MDU.ZTW7/"*?"K3K1;_2+[16L8]1O=>D^V6.LQ7.G0P+!M<_1?[8G[<?QG^'/
M[2[? ;X*?LU?L]_$_5/"O@;PUXX\0>+/V@?VC? ?P-F%GXHO;^VM/^$$T[Q-
MI.I:AXBM],^P7":K=6TMNMO>,EN%&X.?G#_@B%9^!-"\6?'[P[\*;KX/_%[P
M'%X?\"ZK)^TE\*_V?]9^ AO?%%_)?#5/@SK6GZME/$+^#%C&H6][9K&]G]JE
MM-2\V]!,?B7_  5UT&RUW]K5+_QEX%\.:?J_A[X5>$'_ &<Q+^QMH?[1DG[2
M_C^;7;Z35/AKXQ\>ZAX<UF]\%:#HSB"RM]+L-2\/SVD>H77B![R5$$1 /Z:O
M"VH7VK^&O#VJZG;6%EJ6I:)I5_?V>E:A%JVF6M[=V,,]U;Z?JD"K#J5C#-(\
M=K?1*(KJ%$GC 5Q7Y"?M 6'Q!\"?M6?M->+/'GQ$_::\0? W7OV'M4U6ST7X
M3:9JUO/X,UBU^(D%D/"7PC?PWHNJ&3XCZ[IT;L^IRQW?B 6MW)<0I:6L(E7]
M9OARNHI\/O ZZOX=L?"&JKX1\.#4O"FEJB:;X:OQI%I]KT*P2,"-+/2;CS+&
MV1!M2&!%&0,UV?X__7]O\]_;@@'\BVAZW\<Y_!?P OO#6O?M8+8ZOKFOZK^S
M_P"";4?'QX_A_P#&"[^)OA%K+X9?$_Q#XNLK'Q!XOTW1/A@==N+W5O'HE\&S
M75SJ\.EW#&"&OTC_ & =2^-5U^V/\:;?QO<_&N;48M'^)A^.UKXZ;QG_ ,*W
MT_QL/BE$/@]%\.XO$ 'A:"TD^&)F:W/@,_8Y].$<NK#[;\Q_<:B@#\4XM)^-
MFE?MW?M7K\;/%_@'Q?=7?_!./4+KP(_@+PMJGA:/1?!+_%_XI"QT?Q&FJ:MJ
M[:QK\+;6GU6UDM+21<B.RBR,<S_P3L_Y+9^R?_VAQ^!?_JV+VOH'XK?\G[_M
M ?\ :+9O_5P?$^OG[_@G9_R6S]D__M#C\"__ %;%[2Z_+]6!^Z5%%%, HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW@O1-2O=;MUU:/\ L_PR^KZ\^E06=G>6U@8VU:\:XDM7NV:(W!@B /8****
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M9Q'*A#Q,=Z,&%?AS_P $Z/V4/!?_  20_:W_ &R?CWX?O-?\8?LPW_[0E_\
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M",_Q+^#C%#M$EM\6?A:GB32K:U9@P^U>)=)\,Q1J8WE*+(" #S']L_\ 9_\
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M-_/'%_/HEO?6D<MIJ?BKQE+XOO--ALVG^TK/ ^L3#R]I=@AZC+5^F?[*Y/\
MPTW^U\N&!3]D+]B(-N!ZGX8_$@X)Q@MUW 9QWZUZA\</^"5G['W[1'A.WLO%
M'@>7P5XVN_#V@>'M7^,7PJ.B>$_BSJWA[2_"C>$9_#EQXRNM$UZ==!UC0I38
M:G9P0I+/ D/DW<+)O;RW]E[]F3]J'X _&WX^Z]XX/@SQ%\$O%7P?\+?#?PKX
MMUCXC:_XS^-<^D_!:P\6:;X$U'Q?-+X8T#0M0U'Q%HWB64ZXUK!;+I!TRPM+
M0WFZ>=P#YP\)6EK=_P#!.O\ X(YVM[:6M_;3?M+_ +)L4MM>V\-S;S12V/Q
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MAS5(=6T32H196NG^%+/5+?4H6$\]WJ5U:R6Z16\+G]%Z* /SO_:<_P"3YO\
M@FU_V'/VJ/\ U2]E7Z(5^>'[38)_;F_X)M8&0-;_ &J<X[?\66LSGH>F#D<<
M<YX /Z'T %1300W,4EO<0Q7$$R-'+#-&DL4L;##))'(&1T8<,K*5(X(J6CKU
MH _F9_X*4?\ !'#]C_\ :5_X*.?L$^.=;TG6/A_+\2]7^)FD_$_1/ABUCX1T
M_P ;VGP=\%W_ ,4_#=W+/I%O:7FB:[?:K =)UCQ%I4L6IW>DF%8IH+RVCN6_
M58_\$R_@)8.O_")?$3]JWP'!&%6WL?"_[5WQQ?3[:)5(\JWL?$GC#Q#;1QM)
MB=OW9<R@?/Y9:-K/[2R'_AM__@FP0I(7Q7^U,"0"0!_PSQK6,GG ^O3\*_0>
M@#\\G_8'\1Z:A;P;^W;^W-X7N%QY*W?Q0\#^,].CR<3-+IWC'X9ZP+EGAS%&
M9;C$#;9HU\U=QC3]DS]KG2#GPU_P4?\ BJ^P?N1XZ^"GP;\9KNC_ ./<W(LM
M-\*?:!R?MBKY/VKC8;;'/Z(T4 ?R+_\ !6W]G+_@LG=?M"_\$\V^&/[7GA3Q
MQX9'[0&C:)X+U[2_AYH?P?;PC\9)])\0:E;>+_'_ (9M-8\2Z?XRTZ'P'I_B
MZVMH8IK?3UMQ>Z7)I*W.K&[FZS_@MY_P2X_:._:#_9B\ ^)OB7^W]XZ\;ZIX
M%^,'PLTF7PE<_#GPOX%^&=S/\5/'OA?X:MXCLM \'RM?CQ!X6N_$=OJ^D/JV
MIZI;&WMKB%$M;ETED_:[]NK_ )*3_P $[NO_ "?1X4Z$C_FBOQNZ^H]CQ^5)
M_P %1?\ DTV?I_R7G]E+J ?^;F?A3Z_YS0!]?_!+X;R?!WX/?"_X43>*=:\;
MR_#CP'X6\%2>+_$<@EUWQ*_AO1K/26UK5'#./MFH&U-Q*H=Q&7$8=]NXR?&.
MX^(5K\,/&LOPI\*Z+XW^(+:+/;^&?"OB+Q$?"FBZQ>WCQVDL&H>(19Z@=,AA
MLY[FZ$JVDQDD@2W 0S"1?3** /YV]2\)?MA?!G]EK_@GS\"O&O[(7CSXA^,_
MV=?C]\)?'?BB^_9YUSPQX^\,1_#SX3)K=I>W][J?B;5_!=Q:^*M:D\0QSZ7X
M<@M+V*6UM;J634(&B$#_ -!GVMK_ ,/_ &Y[.[T][W1_M;V%^B17UBUS9><U
MG>QQ2311W=L7,-RD<TJ),CJDCJ QV*X3XG:?\0=5\ ^*=.^%6M^&?#GQ#O-+
MD@\*ZYXQT>\\0>&--U)Y(A]HUG1;"]T^\U&T%OYZ?9X+VW8RO&Q<HK*P!\=_
M\$L?^4?/[+7_ &3IO_4BUROO^OC?]A+X _%C]F#]GKPI\#?BIX^\&?$63P )
MM(\(Z[X-\+ZCX5C'A<RR7<%OK5KJ&I:D;O5UO;J\:2[MFMX&@:",0>8CR/\
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M4/B!XDL=;M]6TVPN'D3QUXGU_1GMM1L+VZMKR"#2[8*LN^U:W=2&_;7]E;X
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MPH$O+Q+@:Z-/\12&\FM+:33H;-KB[C_6G_/^?_K_ (4 ?G?_ ,(3_P %2_\
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M]-\(:23XN^'NM1ZI)\,?'M_XLE75]+TY-%L%\86U_))+8&">U0MX4[?M(_\
M"#_!R/1H?VO#X(C\6?$!/V/!YGQ;_MB3QJ/B-X-7PY_PM.2YD3Q&?#0\)#Q?
M_9B_%=SI!L1=^6@/D@?US_Y]?Z_Y]** /SL_:/\ BC^U!\'/C=^S#J.D^,/A
MC<?!3XO?&7X>_!CQ=X O/!&J3^-K;4/$OA_Q'J&KZ_I/C6+7(["*WCOM$1;6
MSFT5RD,N#)(22OZ)\_Y_'_ZW_P!:OSS_ &]_^1A_85_[/F^$W_J+^/Z_0R@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBLG7M>T7POHFK>)/$>J6.B:!H.G7
MFKZUK&IW,5GIVEZ7I\$EU?7]]=S,D-O:VEM%)-/-(RI'&C,Q % &M7Y^?\%/
MM-^(&I?L<_$0?#W5_&FBW>GZGX0U;Q5=_#?XDZ;\)OB#)\/]-\26%UXTM/!?
MCG6K_2]%TGQ%=:*D\6GIJ]_;:?>2$VLTF944^A^&?^"@?[#_ (TU_1?"OA+]
MJ_X"^(_$OB34+;2= T+1OB7X8O\ 5-8U.\D$5I8:=96^H//=W=Q(PCB@A1I'
M<[0N:^5_^"N?BOX9:C\!;7X(>//'WP_^%NK>/]<\.>*/"OC'X[> _&WBO]GB
MYN_ GB73=4O/#'Q-O/"UG/IZ6VKVVZ)=$\075E8ZK"SEG=8CM /SC_X)+> O
MB8?VJ]:^+'P;U;X[R?LT^+KGQE#X\LOC/^T)\/?C-KJV-IX3L$\"Q>.-)\$^
M(O$-OH7C*;Q?+J=YX;N%N8KV;PNEZ-160;6;^H2OQ(_X):?%;X,Z1KOC/X1^
M#+_]B77_ !1XNGM?$AN_^">WP1\:>#/A?9Z=H>EW?GWOQ3\5W]K)X:?7;J64
M6WAJ"'4Y+HQFXM_)S(A/[933P6T;37$T5O"FW?+-(D4:;F"+N>1E5=SLJKDC
M+,%') H EHJM]ML_/EM3=6PNH81<S6QGB^T16Y)47$L._P R.$D$"5U"$@C=
MD$4U=0L&CM95OK-HKYE2QE6YA,=X[JSJEJX<K<,R*SJL)<LJLP! ) !^?O[?
M'_(Q?L*^W[<_PG_]1;X@#^M?H;7YY_M\$#Q#^PKG//[<_P )@,#//_"+_$ \
M^@P#SZXK]#* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN_&NA^-+K6++POKNJ^%=8U*:;0X8(],\GQ'H>JV,-I<H99[>"*]0^3.E?7M
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M>*+1KV(10Z7X>;2H+>*:179Y;1W!_1C_ (+!>$M?OOV<=$\>^&/BO^T)\/\
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M]0T3X3:CJ7QAF\2Z;;^%=>M->UJ+6M)^&^D7'B$17.IZJ5NET>Q>>.W?YU(
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M2)'7?Z*6_P"'4/[)I!VL/VW/A20P ./^-@>KX(R.N/Q&:\%_:3_8!\&^"/\
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M>TFL)[G]DG]GRXGL;AHVN+*6:]^),LEI.T+/$TUL[M#*T3O&71BC,I!/??\
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M:'X&E\,?LO?'71/ 5_XM\7-^RYX&NWO;+4OV;/&E[XR\ 7MMX\\<Z(WB!Y_
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M#[*U;3?AAX>NKO7=(T>P^(,/CE9H=5M?%5Y-?C4QX6-O_8_EZ''IT8B2]'Z
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M.H6NJZ-J^GW-I$]O?:;J-E+-:WEI.OS13P2O&Z\AC0!\-/XP_P""I.@L%O\
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ML;BX/Q.^!3>1!>VT\X6'X'Z)%*?*BD:15BD_=R;A^[EW(VU@17QS_P %:?V
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M6-_X@\+^'];OK)5D06EYJNDVE]<VH27]Z@MYIWA"R_O%"8?Y@: /AC_A7O\
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MO#^AZG9CXR2K<W/C@:UJBZ9,;ZV^RMX>N]\-QYT:C]7Z_%S]H+]KWX]>!?\
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M>$X4T^3X9>,='\.Q'3/['SXVTIX[/4)EUQOB%';P:Y>F*\\+F>S1W !])_\
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*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %$ ;@# 2(  A$! Q$!_\0
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M1W.E0?;/-U"WD<%$FM$FC9@55B1BOPS^(WP-^*NI>(_@QX@TGX1>+3X&\&_
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MD^0*6XK\ #^R=\9+/0_@QX9G\&^.?"6A>'M*^)7@;5;+P/X#\/:[J5CXXO\
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M;>WDT][L7%K+>2M'# UQ$BEGW<@&O,/B3^U$? 7P)^'/QEL_ <_B:\^)FN>
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M>688^CEEH5HTH4L#@,%7A3@L'EM6J_;5*N(DZ^)KU%6Y7'#6=)TI?T)M\0/
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M:*JK-*ICP8F5V#HP-=!)(D2/+*Z1QQHTDDDC!$C1 6=W=B%5%4%F9B H!)(
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M[V43720VXQ;H9Y0'D<1;V;JU._XJK_J7_P#RHT?\55_U+_\ Y4: .@HKG_\
MBJO^I?\ _*C7SI\4OC[XE^&K7"OH&AZGY&[)6YOX=VWT!!QT]:UHT:N(FJ=*
M//-[*Z7ENVEU[B;2W/JNBOPC^*?_  6*U_X<?$KX>> %^#>CZDOCC4KK3Y-0
M.O7L+6/V:-G\Q(A&1)NVXPQ&*^Q_AQ^VYXA^(#P*G@C1M/\ /VX+:A?2[=Q
MYPO.,UZM?A_-\-1I5ZV%Y*5:#J4Y>UHRO",W!MJ,VT^:+5FKVUV9$:U.<IPC
M*\J<E&2LU:3BII7:L_=:>GIN?HK17%:+J?BG6--MM0$7A^$7"[O++:BVW@'&
M>_6M7_BJO^I?_P#*C7C---I[IM/U3LS0Z"BN?_XJK_J7_P#RHT?\55_U+_\
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MEEXEAU0W=]<V]L9].GTYM9O7M;>WNMQ@EAMHY7D9A.D4:J* /M;4O^0=?_\
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M,\CUG_DL_@W_ +%'Q%_Z/BKURO(]9_Y+/X-_[%'Q%_Z/BKUR@ HHHH ****
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M>-.KTJR_X\[3_KV@_P#124 6:*** "OSA_:I_P!;J/\ VT_K7Z/5^</[5/\
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M#S7F$OPE_P"";7@L^=>Z%^RUHKQ<[]5UGP-YV4'?^T=4DE<@#D$,?6N=U/\
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M]FC]G3Q3J47_  C>N6]CXS^,[2?#?PG<6\LT?F:C:V$XDUV_A@&'6-(86G!
M &:]'7]EK]I7XN-]H_:._:>UG3]%N3NN?AO\!;%O V@F!SN-E>^)YS-XAO@@
M_=O(A@\W!8$9%8?6>?\ @4JE;^\E[*EZ^TJJ*DO\$)^39X?^L:Q6F297F.<W
MT6)A2_LW*U_>_M+-(8:%6'6^"P6,NM82EI?V+XK_ +2?PL^"@:+XA_'CPGI.
MJG<(/#EIIUGK'B:[E7@6]KH&DR7FIR3N>$C:W0L2!GFOG4?M0_M1_%AE@_9K
M^!/B&_TJ=U$'Q$^->FVOPX\(M 3@W-MI#O+XCOUVGS(@D4/F#@A<UUUSI_\
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MO^QQX)MW+;);G6_&OB2>%?X?-CLHHHY'_O>6VWTK=_X5G_P5>UE/^)C^TO\
MLN>$0YR8_#/P=\1:U+&I'*";7;Y%++V=1@XY%?IS11_:;7\/ 933],OA4?WU
M\16?K=!['O5KO_N*U_Z1")^3WAO]E/\ ;L\26%\^M?\ !1#6_#>_5=0CFM_
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M<?M7?M;6MM/<S^*]&,<5FVH+/%IUC);&TAG:WN)'FX"^7*IC QDN"/>O/O\
MAO;]I4?\S=8?^"6T_P :J.0XN=^6IAG;1VJ2_P#D ]M'LS^B6BOYVO\ AO?]
MI3_H;K#_ ,$MI_C7;_#?]O+X_P!QXZ\*V6NZWIFKZ1J&N:=I]_82:5!#YUO>
MW45O)LFC.^.11)N1@#A@,@BB608V,92YJ#Y8N5E.5VDFVE>%KV3M<%6C?9_<
M?O=13(W\R-'QC>BOCTW*#C]:*\0V'T444 %%%% !1110 R169'5',;LC*L@
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M_8GB7_H<9O\ P2V'_P 70!UU%<C_ &)XE_Z'&;_P2V'_ ,71_8GB7_H<9O\
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MTK-.\7)#C@<552J1IQ49/F3E.,7VMJ[V;5ULWI;H?=5WJB:?\+-+\;:IX?\
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MG@/QK\*-%_:RU#QWH/P&OR=4N=7.GZ;HVEZD?$6BWUDJ0MXJ;PU(L5I:3:K
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M&_$_Q-\-](U>36?A^FN?$&VT*[L+<R^&M?\ %>G^']8MH=%\57K>6]Q#9Z1
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MN7+WSKLDF^SY:)>JI@ 'G->I_P#"G],_Z'/XD?\ A77'_P C4FE_\EK\4_\
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MY%I?_):_%/\ V)&B?^E[UZ[7D6E_\EK\4_\ 8D:)_P"E[UZ[0 4444 %%%%
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M_%/_ &)&B?\ I>]>NUY%I?\ R6OQ3_V)&B?^E[UZ[0 4444 %%%% '(^#/\
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M##Q#JFJ?M*>.[4-JEEI/V[6I8])U/PKKNFS0RPV5O!<,=9DO+K0KM+FY5;R
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MQ$*SB;:&(Y )!/85ZS_PD&@_]!O2/_!E9?\ QZ@#7HK(_P"$@T'_ *#>D?\
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MZ9:1I NQ?L[&%))+<QHS+"89'9# "1#@1CA10!TE%%% !1110 4444 %%%%
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M?#KQ)J6N0:H+N&[\/V>BP6HA*,)%GAO=1O;B0D[I;F^B:5 G432-)A\"O<Z
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MOSJNDZ9JAMIK(ZEIUE?FSN0!<6AO+:*X-M.!@": R>5*!P'1L5H4  # & .
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M7^(]O-X7NO!]OI=[:78:XN+7Q%;>'TT]=5LR(U*//J?F:A<R+GS9RLNU2-M
M'E-KHG[=,T-W8ZCK'@F*Q?6%EBN+2ZLTUG^R7UNUN'MX+L(88GATM)X$:1"[
MAC&>2I'1_$#3_P!LRX\5^+&\"7WA"+PM_:UM-X/%W<:=%<)IL84S1:@DB&9W
MD;>"LAP5QSD5E:_\-OVN3IDVG^'OBC;B-Q=10SWEW&=9AD?4X7MKQM4-OMDB
MBT])XWM#%N+2IAMR$U]KZ/!>6ND:7;:A.]S?V^G6,%]<R/YCW%Y#;11W,[R
M*'>697D9PHW%BV!G% 'Q9]A_:X\16NC7B:CIFF:EH'Q,NHM<TR86-CI6M^#K
M9+'RV =)6NX'9[LQJA220HC$@ 9V-<T#]KR^U3P7+8Z_X8LK-M'\2V7CE;:6
MU6!;N37FN?#=WI=O,C,UU%HZ1VUQ,IV[Y'5U^4&OLRB@#X1.G_MUPW<3B_\
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MO<2VL0;Y[>ROKR"*TB7++:/,TH!&0.FTC3_VF)]"\20^(=4==5G\1Z-/H_\
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MT92K*P#*RL,,K*<@J02""""#@\444 (B)&JI&JHB*%1$4*JJ!@*JJ %4#@
M #@4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #V 9,# 2(  A$! Q$!_\0
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M[6+^T;SP(XHL^6F#/+^Q#\,[*Q\6Q^&?$7CK2=0\2>%=>\(:;<:EKS>(-/\
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MS+FV;VO?9-[;)O9-JS114<LL4$4DT\B0PQ(TDLLKJD<<: LSN[$*JJ 2S,0
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M%_T/&E_]^=1_^0J /7**\L\:_%[PKX)T'0O$EP+_ %C2O$5R;?3;C1;<70D
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MA4CWBT[>36Z?DTBQ1117":A1110 4444 %%%% !1110 4444 %%%% !1110
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M>:M;6L'A;3PT%E8P1S7$EX7B46S*9!"(VRS3*R@8&XP_ /QY\"_&O@S0M/\
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M)(:_RYOA%_R5CX8?]E#\%?\ J2:97^HSH?\ R!='_P"P7I__ *20U^*>+O\
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MZ[JWBN_TR?2Y_']PF+;4M(DGM+N'2M-D0+'&+R"66%A*5P77'L$5[^S!X?\
M$^BZZMUHUZ([_19M8BL+G4[ZUN[<Z<)/$L;V]S;A&^T:LDB1#:JO;R VNP,
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M*;J5VK2Q6(G+$8J2ZIUZSG.,7_)25"FNE.P_X<@#P7HH   6^  & !_:=[P
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M_P!!CP[_ ."^Z_\ BJ/L?Q!_Z#'AW_P7W7_Q5 '<4U_N-_NM_(UQ/V/X@_\
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MLS^%/'6DZ-H/B?3-86WU@:EHN@R0/I^ERW-_%-=&S6.VAM)HC,PFLHUM7)B
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MK\,:D9?\912A:4=:N6YO!.Z>B?U&=WUM9:=>A^>]%?I7_9G[#O\ T1;XM_\
MASHO_D2H;C3/V)?*?[+\%OBKY^/W?VCXG+Y6?]OR[3?C_=YK3_B+G!W_ #^S
M+_PW5/\ Y>-^-'ABDW_K9A79-V6!S=MVZ)?V<KM]%=7?4_-JBOT-_LS]D3_H
MBWCW_P .==__ ")1_9G[(G_1%O'O_ASKO_Y$H_XB[P=_S]S+_P -U3_Y>8?\
M1O\ #'_HI?\ S%9O_P#,9^>5%?H;_9G[(G_1%O'O_ASKO_Y$H_LS]D3_ *(M
MX]_\.==__(E'_$7>#O\ G[F7_ANJ?_+P_P"(W^&/_12_^8K-_P#YC/SRHK]#
M?[,_9$_Z(MX]_P##G7?_ ,B4?V9^R)_T1;Q[_P"'.N__ )$H_P"(N\'?\_<R
M_P##=4_^7A_Q&_PQ_P"BE_\ ,5F__P QGYY45^AO]F?LB?\ 1%O'O_ASKO\
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M %06GP1\5V_Q\N?BX?'UT/#4Z3(/ T;WQL0\FGK:?;&628VWVJ21=TH6,0A
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M1C2R]MZ6J4L;3G%<DY4_DUOV'_C.(]5N8XM#GL=&\9_#WP/J%[%J,;0P:O\
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M_A:!M'L[(SZ/J,6L6_GZM>*A/V)[1DW66]P%6>5FC&<MP#4'_"$?]3?XX_\
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M+N_2&9K6]1&56QNKWHKD4:"Q>'<*=.DXOEAKS5)P<;^U2YHIJ;U5TH[)-O\
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M%:NGT?3?#=WH/BB]U;Q!+I>MZ;#IC^&M(33I;N/Q!-<7C1:C!+>1NJ:=]BM
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MDU=4^127QSX]\,P>#?&/B#PO;:I;ZU!HNH/9Q:I:$-;WBJD;^;&PP" 7,;$
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M:Z@^9@&!-:_[8/[+WPA^$G[,GA7QUX0\,ZAI7BV[^,OBKPS=ZO>:I-=B^T>
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M:[FGEN_(EACD(:.  ;@,.>:/^%+?"G_H0O#G_@"O_P 51_PI;X4_]"%X<_\
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M0MWBB@\16,VFF(LUT79='L[B6'1,G-BI',I%<'XG_;<^./BYO!CZS>>&Y)/
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M43Y1@ "L2OK?_A@[]L+_ *-[^(__ ()3_P#':/\ A@[]L+_HWOXC_P#@E/\
M\=HY*G\D_P#P&7_R),^$>,JCYJG#'$]25DN:IDF=3E9;*\\!)V5W97LKNR1\
MD45];_\ #!W[87_1O?Q'_P#!*?\ X[1_PP=^V%_T;W\1_P#P2G_X[2]G/^2?
M_@$O_D2/]3N+O^B5XD_\,.;_ /SN/F:+Q5XE@+M#K^L1-(I1S'J-TI928V*D
MB4$C=%&WU13U44D?BCQ)%&T46O:O'$[K(T::A=*C2)*9E<J)<;A*S/G'+$DY
MR:^FO^&#OVPO^C>_B/\ ^"4__':/^&#OVPO^C>_B/_X)3_\ ':?)4_DG_P"
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M#_\ )-'LZG_/N?\ X!+_ .1#_4KC+_HDN)__ !'\Y_\ G:?-WPN_Y*9\._\
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M-?%#P/H'CO1]%2RTWQ#:->6EM?V5LEW%$)I(E$ZB/"N1'N*]4+;#\RF@#?\
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MGZ[JTND2ZW-864BS7%A90W*VDBZFD;/]@NA,ZA;6XV3.A\Q%9,M0!ZW1110
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MRX7BN\^"_P"T5^T-\2_B5X7T3Q3\$X/ ?@*^\//JNMZ]=_VO)>6^J2V :'1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &= A<# 2(  A$! Q$!_\0
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M &X;W7YO@_$?AS!:CXI?M=?%?]F"5AXB:7^Q;;X:6?Q!NHO&*C^S4^V2ZO\
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MU^$/ WA7QCKOPTU#XI:M?>.M&\<Z5IOBSPK\'=+M-8T.\L/C-H^J0:*LFGV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*M.N3X?\4ZJ-:\4>$M=U#3-9L[WQ-X/\1:DD-QK'AC7I[_1[TVULDEKLB44
M?!'QE\>>-OAY8_\ !2GQ'X$\0:F?%T_BO]CCPS:>)_"]QIVDZY>KXP\$?#CP
MKJVI^'+V1SI6B:OK.G:S>'1M2\Q;'2;V^M[V*9(K5)%^T_V++'XI:+X&^*?A
MCXM)XJL],\/_ !/UZU^'^G?$+XD>'_BA\1= ^'=[X>T'48-"\;>+?#NK:R)K
M_3]4N=:GT^+5=0FU>#1+K34GFEB2WD/K?B?]EGX$>,=8\=:UK_@&PNKGXF^
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M+!\'V]Q9:/XZT1M#UNQ/AKQ8^G7,FF:OK?A\Z;>:]IXCMM9DODC7%BR_8_\
MV?M-^'O@7X7Z?X*ELO"GPR\<R?$CX?+:^(_$MOKGA+QE+K.H:Y<ZOI'B:+5E
MU^,WEUJVIV^H6LVHSVFHZ;?W6FZA!=64S0T ?EM%KGQ$^*EI\!O">K_&3XP:
M!9>)?BE_P4O37=2\%^/=7\-:_J=C\,O$7B&X\!Z3<:Q:,US_ &3X7:TLX])L
MD*QVMK;1V416T>:&3SGXF?%CXQ?$3X'Z#XJU?XR_$WPYKW@7_@FK\*OCQIUY
MX+\7WO@[_A(OBEXQ\>2>'/$/BCQ1'I#6R>(VFTK1[?3197PEL+:34[^YMX(K
MZ\CGC_:/2_V6_@KH]UX8O=.\+S03^#]7^,>N>'W_ +:UAULM2^/=Q=W/Q0G*
M->E)UU^:^N6@BG$D6D^8%TQ+5551\0_M4?L%ZM\1-!^'GPJ^$OP\^#\GP[\-
M_"G3_A#X;\8>+_$?C72OB+\';&R\2Z3?2ZK9RZ>-2L_BIX<70-/7^S/!OB4V
MK:=XOM+37EU(I-<!0#T3_@HRVO3_ +-GPP?P[-IB>*)?VA_V86T*X\0I>7&B
MKKK_ !)\/'3Y=;CL72_FTT7AC?4$M)$NG@\P0N)"IKXPL-4^,EGXP_:B\&^,
MO&=EX5\;?%C]O#]DOX3_ !%\4?!&ZUOPQ%;^#_&7P_\ "D>J6G@W5=:EN_$6
M@7^IZ):VVCW6J+<F]AGN[Q]/FC,D1'[0^/\ X1>!_BEX8\.^$_'6F3:UH_AG
MQ-X-\9:7"+V\TZ2/Q)X#U2TUKPWJ+RV$\$CBTU.R@N9+5W:VN IBN(Y(F9#P
MGB;]E7X&^+[;XLVWB+P@]\OQK\2>&/&/CNX76]<LK^;Q9X+TW3-*\)^)- U&
MQU&VOO"NLZ!;Z/ILFFW_ (>N-.GANK9;G>TDDQD /S5\$:M\1_'?BG]F;X.:
MS\8/B]9>']$_:A_;4^%.I>(-,\9WEAXT\=^ O@]8ZU<^"M'\8>)X$6]U>2R2
MUM-,OM7;R]6NHM.E)NXKJYN)6X'1['Q_X^^-/A^RU/X_?M!Z3H_Q3_;>_:\^
M"/B/0O#/Q2U?1M)L_AMX"\*^)?%7AG0O#%M''(?#,]CK>B64BZOI4D&J_8I+
MO3$NX["?R4_7;PG^S-\&? \?PFC\+>$_[+'P3N?&.H?#^0:OK-W<66J?$&QN
M['QIK&L7=[?W%UXEU?Q&FH7USJ>I:]/?WD]]=S7IF%PP<1:5^S%\&]$U[0_$
MNF^&IX-9\.?%3X@?&G2+IM9U>5;;XB?%#2M0T7QIK1@DO'AFBU33]3O8H].E
M1["R:7S;.WAD1&4 _'&+XE_&7XH? _X62:U\;?BKH>J?#S]@SX__ +1%KX@\
M)>*9/#NM^+/BC\+_ !]%X4\':WXZO+* 'Q7I^E:38A]3T744.E:O<:A=76IP
M2RRJR='XE^(OQ7U3XM^*?BVGQ8^*&@:AX:^,7_!./2-.\":7XLO;/X;#3/CM
MX/\ !T/Q.T[5/!+(VEZC%KZ:U>.R7*8LKH17=H(;D222?ICKO["_[,?B7P;\
M// 6L_#V6Y\-?#"TUG2O"MM!XH\5Z==?\(YXDU+^U_$GA'7=2TS6K._\3>$/
M$&H+%<:QX:UZXU#2+TP0++:E4P>WUW]EWX+>(]6\4ZUJOA5Y+_QGXP^$WCO7
MFMM6U6R@N/$GP02PC^&MW;6UK>106,'A^+3;*/[!9QPV5\D(6^@G#,& /SL^
M!GBK]HKQ=^U]K7C5;KXB3_#]/VE?VB?A'XPG\2_%3PG%\*;KX?>![+5-,\">
M&? 7PEGU9/$%OXP\+ZWI%GJ>HZWI^BQ7FHPW6N7=_>7NGS*+<_X*,?$[QCX0
M\7^)M:^&/C;X[GQG\%OA1X,^(TGA[P'KV@>$OA%\/(]>^(]SI5IXT^)RW^HV
MFI_$Z?QA;:9J?AR/P-%8:Q;6&AZ=?ZA%!:W=X+E?T0T3]E7X%>'OC)J/Q[TK
MP3';_$O4KO5M4?4VUC79]'LM?\0V$6E>)?%&C^%+C4I?#.C>*?$NEV\&G:_X
MATW2K;5M4LXS#=74@FN3-B_&S]C?]GK]H7Q OBGXI^"KG6M</AN+PC>7FG>*
M/%7AQ-8\.VFK#7M+TS7[/P_K.FV.OP:)K?F:KHO]KVUX=,O9YY;8H9&! /ST
M^*'B7XBZ?^U#\4?&^E_%GXH:5%X#_:Q_8G^'NB>!;+Q??)\-9O"7Q?\ "OA*
MS^(&EZIX,</INH#7(]7N)UGF"S6-]';WMDT%SYTDV/\ L]'Q%XL_:B_9=^,W
MB[QQX[\4^)?B3XJ_X*#V&H:3XC\17&H^$?#&G^!/%MAX2\-:5X(\./&EEX5M
M].T#2[+3KV*P(&HO$+F]5[K]Z?U(UG]FCX/^(-<\2^(M5\.7%QJ_BWQ]\,/B
M;KUTNLZO#]K\9?!VVTZT^'^IK%%>)%;IHT&E6*R6<"QVFHF(MJ$-P7<M@^$O
MV0?@#X$^+#_&KPIX.N=(\>MJ?C?6(;F+Q/XHGT+3]0^)'V:3QU/I'A2[UB?P
MUHQ\37EJFIZHFE:79I/J;2WI7S9&- 'E5O\ \I,=3//'[#^F$X!./^+Z7_IZ
M]AU.#CI7RY/\2/B,?B?>62^.?%HTY?\ @K/HOPV%LNMWXM4\!W'P&;5I_!"H
M)0B^&Y-4/]IMHRXM3? 77E^8NX?>OQ<_9%^#/QL\>Z3\3O&5MXUM/&VC>&XO
M"%IKG@OXD>.? 4\OAN#6)=>CTF_7PAKND1:C:+JTTEWLO$F!<A3E5 J+4?V-
MOV>]4^+EI\<;GP7=I\1K/Q?HOQ CU&U\4^*K31Y/'&@Z+/X=L_%MQX4M]93P
MO<>()M"F&E:AJLNDM>:C:06Z7<TC1[B ?E-:6FO_  N^!7CS0OA==_%R]N_B
M]_P4W\8_"/Q+:^%OB=?Z?XUU'PA!X[\62W6B^%/%GBO6(['PAKOB2/3(M-U?
MQ'%>Z9?ZFDTS7FHM=M;RQ^J^'O%WQ\\*Q_ 'PQ\0?%_B^QUZ#X/?\% SJ&G7
MOC[2_%^K7.G>!;K0!\*9/'/B'PK?7>BZ_P".O!NA7$-C>:DMS-J%EJL=XUS(
M+Z2X9OT.U_\ 9#^ 7B2U^*-EJ/@R>.U^,/BC0_'?C2'3?$OB?24_X3_P[,;G
M2O'WAK^SM7MCX-\:1W0AN[OQ#X4.D7^I75M!<:C)=2JS-9T?]DWX$>']-\$:
M1HG@L:9I_P //"7Q'\%^&(+?6-:8P:+\7/LK?$:34+B?4);G6=8\57%JE[J6
MNZM->:L]_)/>+=K//*[@'X\VGC7XK_#WX"_%D6'QM^,/B"Y\5?\ !.W]GO\
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MX%^&'C;1?&SKH6E:7H4_B.>YN]0\.Z=INN:V=9\)?;UU..VFCG@/TW%^R!X
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M'?1N?V*?AS<WOCJ[_P"$S^)\$7C""YBTC3K;7=!BL/AQ+<_%>T^-QN? 4?\
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M[N]L(M5UCQ!X0TF_T:TD\4M::7!8:I9:K::E<OKVGVUAI]KJ%P8Y%2W6-8Z
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M..E '+?\)WXI_P"B3>-/_!CX+_\ FGH_X3OQ3_T2;QI_X,?!?_S3UY!^U?\
MM6:%^RWX=\"3OX$\9_%?XA?%CQQ:?#GX4?"OP%'IJ^)/&WBZYT^]U>2TCO\
M6[RPT?2-/L-+TZ[O=0U+4+I8X(T15CD+G;Y;X$_X*+?!OQ9X&^!?BW7/"WQ*
M\!:O\<OCGJO[-]EX*\4>'[2VU_P3\6M 36SKVD^,6;4HK2#0M.DT&Z0>)-+D
MU.QN?M.GF%";K;& ?6/_  G?BG_HDWC3_P &/@O_ .:>C_A._%/_ $2;QI_X
M,?!?_P T]<GX*^-EUK7B'XM:7X_\!ZE\']#^'GQ"MO OA+Q?XX\1>&(=$^+-
MM=Z1;:E#XE\)_9]0,]E927$T^FQ:;K M]5FN+.:6*W:#:]>IZ?XU\':O=6-C
MI/BOPUJE]JFGOJ^F66FZ[I5]=ZCI,<C0OJEA;6MW+->:<DJM$U[;I);K(K(9
M P( !S'_  G?BG_HDWC3_P &/@O_ .:>C_A._%/_ $2;QI_X,?!?_P T]6M>
M^*/@S2/#>J>(;/Q#H.N&ST#Q;K^FZ;I6OZ1<7GB"+P5:7-UKUKHX2ZE%W+I\
MEJUGJ#PK*FFW#!+WR6!6O,_V??VF/!?QU_9U^$O[1MW'!\,_#OQ:\.:;K^F:
M1XSU[1H+C3)=5FN(+72+G5//@TV[U"1[=O+2U<F8G;$K$&@#T+_A._%/_1)O
M&G_@Q\%__-/1_P )WXI_Z)-XT_\ !CX+_P#FGKC?$_[1_@+PS\<_#/[.LMOK
ME]\3/&/PN\7_ !8\.V]G:V7]B7>@^#=1T[2KW3I]5FOXWMM<U"\U2U&E6?V&
M6*ZMQ<7)N$2W<%_PJ^.]EXQ^&?@_QS\4?#__  S[XF\56.J7]Q\,OB7XK\))
MXGT*#3-;N='+W=UI^IR:7>Q7 2RO!/83S0P)J=G;SO'<LT= '7_\)WXI_P"B
M3>-/_!CX+_\ FGH_X3OQ3_T2;QI_X,?!?_S3UU.N>,_"'AF.TE\2^*O#GAV*
M_2>2PDUW7-+TA+Z.VB6>YDLWO[JW6YCMX76:=X2ZQ1,LCD(P)\'_ &JOVG-#
M_9:^%^A?%+5/#.I>-],U[XE?##X;VVGZ!J.G6<RS_$_Q7IWA;3];%W?%K6:P
MTV348[^XBB)EN;9&6V8NR4 >G_\ "=^*?^B3>-/_  8^"_\ YIZ/^$[\4_\
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M6FV.F:A)?J&L8['4+FZBM+M[Q2&M4MYI&N%(,(<$4 <G_P )WXI_Z)-XT_\
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M#4/"WB"Q\5V5W'''IVNZ7XKTV;[ NF^9:7&C2Q22.;A'W?8- 'F/_"=^*?\
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MWA36/"VI:;)XL^*VD67@_P ,ZG<_$%K.VMK&WN?$MA?Q6^G^(KLP06=E!?\
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M?"O_ ,.!X4_^6U'_  OSX&?]%F^%?_AP/"G_ ,MJ_B#^SV__ #PA_P"_2?\
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MG_19OA7_ .' \*?_ "VH_P"%^? S_HLWPK_\.!X4_P#EM7\0?V>W_P">$/\
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MJ&J>&+:PTW3?&WAN]O[VYD\4:-Y=O:6EMJ4MQ<3R8(2*&-W8]%-?Q>_9[?\
MYX0_]^D_^)KU7X$6\"_'/X+,((0P^+/P\(81H&!'BS2L$$+D$>U ']P-%%%
M!1110 4444 %?S*_\%D5Q^T[X,.?O?![2>/3;XG\1CK[Y%?TU5^47[7W[&W@
MG]I_XYSZ]XJ\8^+/#%QX1\ >%=%LX/#MMI$\-W!J&J>)K^2:Y.I0R.DL<B>6
M@B.QD.6&X @ _F,HK]W/^'3/P@_Z*Q\3O_!?X6_^1:/^'3/P@_Z*Q\3O_!?X
M6_\ D6@#\(Z*_=S_ (=,_"#_ **Q\3O_  7^%O\ Y%H_X=,_"#_HK'Q._P#!
M?X6_^1: /PCHK]W/^'3/P@_Z*Q\3O_!?X6_^1:/^'3/P@_Z*Q\3O_!?X6_\
MD6@#\(Z*_=S_ (=,_"#_ **Q\3O_  7^%O\ Y%H_X=,_"#_HK'Q._P#!?X6_
M^1: /PCHK]W/^'3/P@_Z*Q\3O_!?X6_^1:/^'3/P@_Z*Q\3O_!?X6_\ D6@#
M\(Z*_=S_ (=,_"#_ **Q\3O_  7^%O\ Y%H_X=,_"#_HK'Q._P#!?X6_^1:
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M^+A_:&\.7'@6'PWHZZ:+GP_;^+M/\4>-GT75[C7M0'Q0\/6=MXK@LK2&!5C
M/V%HHHH **** "BBB@ JGJ/_ "#=3_[!NH?^D<]7*IZC_P @W4_^P;J'_I'/
M0!B^"O\ D3/"/_8K^'__ $T6==-7,^"O^1,\(_\ 8K^'_P#TT6==-0 4444
M%%%% !1110!S7C3QCX:^'?@WQ9\0/&FJP:#X/\#>&];\7^*M;N@[6^D^'O#N
MG7&JZOJ$J1JTL@MK*UFD6&)7FGD"00H\LB(VAH.M6/B30="\2:7]J_LOQ'HF
MD^(=+-]9W&G7K:9K>GV^J:>UYI]VD=U873V=U ]Q974<=S:2LT%Q&DL;J/@G
M_@J!,T_[*\'A74_$VH> OAW\1_CO^S]\._C9\2=-MK:ZE^&_P6U_XDZ5<>.O
M&%VM]9ZCI<&DV<>F:=8:O=:U87>B0Z=J-RNJPO:22"O:/V)?B7\1?C)^R;\"
MOBA\64'_  L'QCX/N-0UZ\70QX977(+7Q%KFE>'_ !0/#R100Z1_PEGAG3]&
M\2?8[:WMK)?[4\RQMK>TDAA0 ^HZ*** "BBB@ HHHH *Y;QI_P B]/\ ]A7P
MO_ZE>AUU-<MXT_Y%Z?\ ["OA?_U*]#H ^R:*** "BBB@ HHHH *^8?$__)5_
M&?\ V+/@;_T;XHKZ>K\]/C]KOB?2/C1K46@^(KW0X)_!7A"2XCM+/2+H7,JW
MWB5$DD;4K"]=#&F458FC0AB65F^:@#VNBOCW_A-/B)_T/VL?^"KPM_\ *.C_
M (33XB?]#]K'_@J\+?\ RCH ^PJ1E1U*R)'(C<-'+&DL;#T>.161U/=64J>X
M-?'W_":?$3_H?M8_\%7A;_Y1T?\ ":?$3_H?M8_\%7A;_P"4= 'V"%0,'\N+
M>JE%D,49D6-AAXE<J76)QC?$"(WP-ZMM&&^3;^7#%]DLO)ME*VL/V*T\JU4C
M:5M(O)\NU!'!%NL8(QG.!7R!_P )I\1/^A^UC_P5>%O_ )1T?\)I\1/^A^UC
M_P %7A;_ .4= 'V (XE.Y885;YCO2&)7!D.9"'5 P,K /,0?WS@/+O< TD<-
MO"\TD-K:0R7.W[5+#:6T4MT%S@7<L<2R70&3Q<-("22<DU\@?\)I\1/^A^UC
M_P %7A;_ .4='_":?$3_ *'[6/\ P5>%O_E'0!]?K#;HB1I:V:11O'+'$EG:
MI#%-",0SQ1+"(XKB$<0SQJLT0XC=13U"*\DBQ0B694CGE$$/FW,<:LD<=S+L
M\RYCC1W1(YVD1$=U50K,#\>_\)I\1/\ H?M8_P#!5X6_^4='_":?$3_H?M8_
M\%7A;_Y1T ?7OD6V,?9+/&TK@6EL!L90KH0(L%'1421#\LB(B.&1$ D"1AFD
M6*%96CCA>988EF>&$DPP/,J"5X(2S&&%G,41),:*37Q]_P )I\1/^A^UC_P5
M>%O_ )1T?\)I\1/^A^UC_P %7A;_ .4= 'U!8^#_  AIFI^)=:T_PGX:L]7\
M9ZAI^K^+]3@T/35O?%&KZ3IT&CZ7JVOSFV+:IJ>GZ1:VNEVFH7?F7<-A;06J
MS>5$BC>N(Q<!V;8ET89HK>_%O;27UB\RD+/93W$,QAE@EV7,(PT(N(HG>)PN
M#\@_\)I\1/\ H?M8_P#!5X6_^4='_":?$3_H?M8_\%7A;_Y1T >S? [X*^#_
M -G[P&O@'P3=>)-4MKGQ3XN\=^(O$_C+63X@\9^,_'?CW7;KQ+XP\8^*M;%O
M9I?ZWK>KW;RRM;V=G9VMM#:6-E:6]K:Q1COM4\*>%M<OO#.IZSX9\/ZIJ/@O
M6+KQ%X/O;[1["XN/"WB&^L+S2KW7M =X#_9>LW6F:C?V$^IV@BO9+6]NHFFV
MS/GY;_X33XB?]#]K'_@J\+?_ "CH_P"$T^(G_0_:Q_X*O"W_ ,HZ /J1_"GA
M:3Q.GC:3PWH,OC*/P^_A-/%<FE64GB$>%I-3BUIO#AU5X3>-HO\ ;$,6JIIS
M2M:QZC&+R.-)R7*^*/"WACQMH6J^%_&7AS0_%7AO7K>UM-<T/7],M-3TS6K2
MQNX;^RM-5M;F)TU"UM+VW@N[>VNO-ABGACD1 RBOEK_A-/B)_P!#]K'_ (*O
M"W_RCH_X33XB?]#]K'_@J\+?_*.@#ZYN;*PO2S7NGZ?>.T<D/FW=A:7,ZQ2H
MT<D<<\T+S1(Z,RE8I$&&8#&36;X;\->'/!OA_1O"?A#0-'\+>%O#NGP:5H'A
MOP_IUKI.AZ+IEL"+?3]+TRRCAM;*TARQ2&"-%W,[G+NS'Y8_X33XB?\ 0_:Q
M_P""KPM_\HZ/^$T^(G_0_:Q_X*O"W_RCH ^PJ*^/?^$T^(G_ $/VL?\ @J\+
M?_*.C_A-/B)_T/VL?^"KPM_\HZ /L*N0U_\ Y&?X=_\ 89\1?^HEJM?-G_":
M?$3_ *'[6/\ P5>%O_E'7-ZQXQ\?OKO@QG\=:L[QZGK#0N=+\,!H6;P]?H[(
M%T0*Q>,F,B0.H5B5 <!@ ?<U%?'O_":?$3_H?M8_\%7A;_Y1T?\ ":?$3_H?
MM8_\%7A;_P"4= 'V%17Q[_PFGQ$_Z'[6/_!5X6_^4='_  FGQ$_Z'[6/_!5X
M6_\ E'0!]A45\>_\)I\1/^A^UC_P5>%O_E'1_P )I\1/^A^UC_P5>%O_ )1T
M ?85%?'O_":?$3_H?M8_\%7A;_Y1T?\ ":?$3_H?M8_\%7A;_P"4= 'V T<+
M^;OM[9_/=)+C?;0-]IDB4)%)=;HS]IDA156*2?S'B55$;*%&'84-)($C62;R
MQ/*L4:S3^2I2'[1,JB6?R4)2'SG?RD)6/:I(KX]_X33XB?\ 0_:Q_P""KPM_
M\HZ/^$T^(G_0_:Q_X*O"W_RCH ^PJ*^/?^$T^(G_ $/VL?\ @J\+?_*.C_A-
M/B)_T/VL?^"KPM_\HZ /L*BOCW_A-/B)_P!#]K'_ (*O"W_RCH_X33XB?]#]
MK'_@J\+?_*.@#["HKX]_X33XB?\ 0_:Q_P""KPM_\HZ/^$T^(G_0_:Q_X*O"
MW_RCH ^PJIZC_P @W4_^P;J'_I'/7R3_ ,)I\1/^A^UC_P %7A;_ .4=5K[Q
MG\0C8WP;Q[K#*;*\#*=*\+@,IMI05)&A@X89!P0<'@@\T ?4O@K_ )$SPC_V
M*_A__P!-%G735\0>%_&7Q!3PSX<6/QWJ\<:Z!HPCC72O#!6-!IUL%C4OHC.5
M10%4NS.0,LS')K=_X33XB?\ 0_:Q_P""KPM_\HZ /L*BOCW_ (33XB?]#]K'
M_@J\+?\ RCH_X33XB?\ 0_:Q_P""KPM_\HZ /L*BOCW_ (33XB?]#]K'_@J\
M+?\ RCH_X33XB?\ 0_:Q_P""KPM_\HZ /L*BOCW_ (33XB?]#]K'_@J\+?\
MRCH_X33XB?\ 0_:Q_P""KPM_\HZ /L%E1U>.2..6*1&CEBFC2:&6-QAXY895
M>*6-APR2(RL.H-.)SZ#    "JJJ %55  55 "JJ@*J@!0  *^//^$T^(G_0_
M:Q_X*O"W_P HZ/\ A-/B)_T/VL?^"KPM_P#*.@#["HKX]_X33XB?]#]K'_@J
M\+?_ "CH_P"$T^(G_0_:Q_X*O"W_ ,HZ /L*BOCW_A-/B)_T/VL?^"KPM_\
M*.C_ (33XB?]#]K'_@J\+?\ RCH ^PJ*^/?^$T^(G_0_:Q_X*O"W_P HZ/\
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MO2KZ;1-5O=#U9+6YVH)18:QIU]I\[J-GVBUE",Z@,?RB_;>\ _&CQ?\ MP_
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M  JGXD?\^O@__P *74O_ )F: / _#GPB^%W@_P 21^+O"?@#PIX8\0V_A)?
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M #,T </17<?\*I^)'_/KX/\ _"EU+_YF:/\ A5/Q(_Y]?!__ (4NI?\ S,T
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M^4\Y7T]L5%0 4444 %%%% !7+>-/^1>G_P"PKX7_ /4KT.NIKEO&G_(O3_\
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M>'O!V@/K;Z[J5O\ 9-5U+7KNQM;2>^M;4RE_NWZU@?\ "0Q?]"_X[_\ #?\
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M^B:5/!9Z7:O=:)X*CO[Z]\*PS2M>VVI7'VN^OKYH8!'V/_"0Q?\ 0O\ CO\
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M6,]QJ][_ ,%!? ][KFO7/A#2_P!NC_@F]X1T72!XFUI;31O#.JZ=X2L+W3-
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MW-KI%O:V-M:QV(@619 #^E%9HGDDA62-I80C2QJZ-)$)0QB,B*Q9!(%8QE@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "O-OBY_P B#K'_ %^^&_\
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M"5N)29@ >BZ-X&_X)_>%/#/Q7\8Z!H?[,_A[PA\6M3U+X?\ QA\3Z6_@72]
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MBBB@ HHHH *\V^+G_(@:Q_U^^&__ %*-%KTFO-OBY_R(&L?]?OAO_P!2C1:
M/2:*** "BBB@ HHHH *_!S_@I)^U?\>OV=OVBM,T7X/^-8?"VF^)OAAX=U;6
MK>;P_H>M?:[^RUSQ+96TZR:O974EOLMF,92%D1_O,"W-?O'7\RG_  61&/VG
MO!AS][X/:3QZ;?%'B,?KD?E0!X=_P\W_ &V?^BNV?_A">#/_ )44?\/-_P!M
MG_HKMG_X0G@S_P"5%?!=% 'WI_P\W_;9_P"BNV?_ (0G@S_Y44?\/-_VV?\
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M]!_*EH ^]/\ AYO^VS_T5VS_ /"$\&?_ "HH_P"'F_[;/_17;/\ \(3P9_\
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MJJ"S,?0* 23[ 4 ?S"?\,'_M<_\ 1%=;_P#!QX:_^6]'_#!_[7/_ $176_\
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M;_\ !QX:_P#EO7]/-% '\PW_  P?^US_ -$5UO\ \''AK_Y;T?\ #!_[7/\
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MA-<R16VIS3R+'O7*PQ.Y)&%/-?T<5RWC3_D7I_\ L*^%_P#U*]#H ^R:***
M"BBB@ HHHH *^8?$_P#R5?QG_P!BSX&_]&^**^GJ^8?$_P#R5?QG_P!BSX&_
M]&^** &T444 %?$O_!2C5/$.B_\ !/S]L;5/"/B+5/"'BJS^ ?C63PYXLT2^
MNM,UCPUK4D-M!I^MZ;J%C+!>6=UIUQ,ERD]M+',JQL%8;CG[:KS#XU_"/PG\
M??A%\1O@GX[?5H_!GQ1\*ZAX/\3OH-ZNFZTND:D8C<G2]0>&Y6SO!Y*>5.UO
M,$YS&<T ?SK^#_\ @H9\=]+^.%]\>?B3INLCPW^S7_P3R^)_PLU_X8:IJ.L>
M'O"_C[]JWX3_ !(^#/A7XO?$'4XXK>7S]"7Q7XVT'3M.\06^F:AJ,&A0ZT=)
MWRW1BD^R[G_@J;\0-$\,?#_Q)XC\!_ Z"UE^,^L?";QEL\9?$;1M8^+5O:?%
MKP!\-M-\7?LP>"-?\*6_BJ]\)76C^/$\7W?C7XEPZ9X0BO-#N_!UIJ5SJM];
M7$?Z#_%[]CKX*?''51JWCVPU]Y/^%&^-_P!G]K;0-8&@6[>#_'NN^#_$VJZ\
M&L;5;F/QYI^O^!/#>K:+XH2<36E[:-+/;W8DVCQCQ%_P36^#7BZ[T/5_%/Q7
M_:9\1>*+2(6WC7Q=K7Q=?4M>^+VG6_Q4\/?&C2M#^([7>@RV$OAW0?'_ (7T
M?4=#T#PC9>%-)L+"*;2EM9+2YF5P!G[._P"V+\4?BE^TI>?"+QO\//AWHG@7
M7;W]JNW^&_B/PGXA\37_ (N)_93^-_A_X1ZVWCS2=:L8M%@7QG;^);'6M)7P
M]>7']F36-[;7OFQW$!B_*KX'?&/QQX$_:W\>^,]+M?BK8:O:_&+_ (*C)XA\
M0_&?XQ:EX:_9F_:"TCX6O!J7PN^$?AB]U_Q3XA\->!]6^$=U!)XCU?Q%/X/\
M')X?\):7K\6FW7B:2=;./]T?A_\ LJ?"WX:?$?1/BEX;E\4MXGT"X_:#N;!=
M2UF.[TLR_M,?$?0_BG\2?M%FMG"TJQ>)_#]@OAL"9?[)TLW%G)]K:43+\YZK
M_P $M?V;/$VJ_$JZ\:^(?C5XU\/?$:[^/6JV_P /M=^(,4?@7X<^(OVEG1OB
MWXK^'6EZ3H>G7NF>)M7CC6WTK4M:U+75T&W:>+3K>-;JY\P ^>M/_P""GOQ2
MUKX9^%O%NA?#SX%:A(O[0OQ1^!'C?XL:AXR^)?AW]FF?5_ 6D^!]9\':=H'C
MK4/"<FM>!-5^-(\:3:!X(\0_%FRT;P/8:_X8OX]3U.6'5](CD\@_:G_X*$>.
M_B)X<_:G^$'AW0M,\)Z-X0\4:MX9\->,O >M?$(?$?P7K/P1_:4^"'@O6E^)
MNLIH>G^!-,M/BQ;>)]??P1;>$?$MW?-I6AZC9:Q%<"_98?OV[_X)N_!W4O F
MO> M7^*O[2NJ6?C?QOX[\:?%+7;CXLB'7_B_%\4-#\(^'OB#X.^)/V/0+?1-
M<\'^(M-\#^'DBM;?1=/U;P]+;W$GAG6-(-Y/NZ37_P#@GU\#/$T7QCTC5?$G
MQJ/@;XRVOBIKOX7V7Q0U.P^'7P\\1^-O$'AKQ=XF\=_#/P_;6B-HGC6\\6>$
M- \1V&KZS=^(8O#^I6][_85II]OK&JP78!\;?&;]N_XJ? GXG_M%>'/A7\+_
M  /XI3PS\2/VR/B)XQE^*7Q*^(]REUX9_9@^%WP$\9:II_@.WM+?5+7PE?\
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MG[0OQJ^/_P 1O&]X;"XFDLX]0U&W\2V6C:C<0Q++<6&F6=C)(T%I#'']-_\
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MO33_ /H2/&'_ '^\,?\ R^H_X7II_P#T)'C#_O\ >&/_ )?5XC2A6(+ $JI
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M'_R^KQ&B@#V[_A>FG_\ 0D>,/^_WAC_Y?4?\+TT__H2/&'_?[PQ_\OJ\1HH
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MU>(T4 >W?\+TT_\ Z$CQA_W^\,?_ "^H_P"%Z:?_ -"1XP_[_>&/_E]7B-%
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M/_IP\35^C=?G)^T7_P EIU7_ +$CPC_Z</$U 'C5%%% !1110 4444 ?F/\
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M_P )+X=_Z#NE?^!L'_Q5'_"2^'?^@[I7_@;!_P#%5]Z_9K;_ )];7_P&@_\
MC='V:V_Y];7_ ,!H/_C= 'P5_P )+X=_Z#NE?^!L'_Q5'_"2^'?^@[I7_@;!
M_P#%5]Z_9K;_ )];7_P&@_\ C='V:V_Y];7_ ,!H/_C= 'P5_P )+X=_Z#NE
M?^!L'_Q5'_"2^'?^@[I7_@;!_P#%5]Z_9K;_ )];7_P&@_\ C='V:V_Y];7_
M ,!H/_C= 'P5_P )+X=_Z#NE?^!L'_Q5'_"2^'?^@[I7_@;!_P#%5]Z_9K;_
M )];7_P&@_\ C='V:V_Y];7_ ,!H/_C= 'P5_P )+X=_Z#NE?^!L'_Q5'_"2
M^'?^@[I7_@;!_P#%5]Z_9K;_ )];7_P&@_\ C='V:V_Y];7_ ,!H/_C= 'P5
M_P )+X=_Z#NE?^!L'_Q5'_"2^'?^@[I7_@;!_P#%5]Z_9K;_ )];7_P&@_\
MC='V:V_Y];7_ ,!H/_C= 'P5_P )+X=_Z#NE?^!L'_Q5+%K^AW.H:#;VVL:=
M/<3>*O""1017<+RRN?%6CX6-%8LS=3@ G )[5]Z?9K;_ )];7_P&@_\ C=<O
MXR@@3P_,R6]NC#5?"Y#)!"K*?^$KT/E65 RGW!!H ^SJ*** "BBB@ HHHH *
M^8?$_P#R5?QG_P!BSX&_]&^**^GJ^8?$_P#R5?QG_P!BSX&_]&^** &T444
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MO/".H6.M6>AVK+KJSVD?W'\ OV1OC;X2_8T_:W^''C+P-K>B_&'XI_LR:/\
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MA>%IK2ZB(EMKJ)7+V]S$1)!,J2QD.@- 'BOBWXJ>*/#7QX^$7PI7P1!)X/\
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MY12: /?:*** "BBB@ HHHH *Y;QI_P B]/\ ]A7PO_ZE>AUU-<MXT_Y%Z?\
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7TBN8(9O*F1XF:-0Z,N00#U2BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D A,# 2(  A$! Q$!_\0
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M_#]MX9\2^'_!FMZ7X(M+F"*_AO\ 1?%-N'EU6RAN(I)[2*[60W#"SA2:0AR
M?HK]G^+/_06^'?\ X3WB7_YIZ/L_Q9_Z"WP[_P#">\2__-/7YW>,_P#@HW'?
M?!+]D;]J/X0>&].UKX+?&CX[^$_@W\6=$\6B]TWXD>"KCQIJFH>";:WT:TLI
MI=).L^%?'5LT7B"&]EGAN]-AB?3RJW#30_JH!@ >@H \\^S_ !9_Z"WP[_\
M">\2_P#S3T?9_BS_ -!;X=_^$]XE_P#FGKT2B@#SO[/\6?\ H+?#O_PGO$O_
M ,T]'V?XL_\ 06^'?_A/>)?_ )IZ]$HH \[^S_%G_H+?#O\ \)[Q+_\ -/1]
MG^+/_06^'?\ X3WB7_YIZ]$HH \[^S_%G_H+?#O_ ,)[Q+_\T]'V?XL_]!;X
M=_\ A/>)?_FGKT2B@#SO[/\ %G_H+?#O_P )[Q+_ /-/1]G^+/\ T%OAW_X3
MWB7_ .:>O1** /._L_Q9_P"@M\.__">\2_\ S3T?9_BS_P!!;X=_^$]XE_\
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M);A=.T;7X?$1:0_Z(-&:\RHMR:_J3KRW1_@K\+] ^+7C'XZZ/X0L+'XL>/\
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MS7C/_D3_ !9_V+6N_P#IKNJZ6N:\9_\ (G^+/^Q:UW_TUW5 #/ __(E^$/\
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M/]M;_HH/A7_PW'A3_P"0Z/\ AZG^VM_T4'PK_P"&X\*?_(=?G;7U5^R5\+O
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M[*_B7X?:'\78O%WAKP5\2EC^"7A;XG>!?B+X5^(5S%X:T;1?$7B^+PY;^+M
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M_P#*JC_AV%^U#_<^&_\ X6A_^55 'YXT5^AW_#L+]J'^Y\-__"T/_P JJ/\
MAV%^U#_<^&__ (6A_P#E50!^>-%?H=_P["_:A_N?#?\ \+0__*JC_AV%^U#_
M '/AO_X6A_\ E50!^>-%?H=_P["_:A_N?#?_ ,+0_P#RJH_X=A?M0_W/AO\
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M-;SX5VO@[1_$EU'96ETHDU'4K0!M-MWN-1MQ(&F@" L/G7_AV%^U#_<^&_\
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M9ZU;:5IUY:&[TZTT_27WB;51:Q2M')#%+)(J"3S+_AV%^U#_ '/AO_X6A_\
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MK4[*+[38PW%J_G;TF9$=AY]_P["_:A_N?#?_ ,+0_P#RJH_X=A?M0_W/AO\
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M^D&D5NUA:9_R,7Q-_P"RDZY_Z0:16[0 4444 %%%% !117@W[4WQ@U+]GO\
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MU[_D</AQ_P!?7C'_ -1Q:[*N-U[_ )'#X<?]?7C'_P!1Q:[*@ HHHH ****
M"BBOG?QQ\9M:T;]I3X#?L^>%-$TW6;KX@^$/BI\5/B;J=Y+<^?X'^%W@"UTK
M1-%U.PAMG$;ZIXN^(OB'2?#]D-04V@L;+69HP;B&/ !]$45\]?"3XSZO\5_C
M)^TOX-T_1-,@^&WP$\8>!_A3IGC**XN);_Q5\4[KPA;^,?BAI<B;C90Z5X'B
MU[PMHL30@W4FJ3ZHET5$$2CX UK_ (*7?$+PY\9/C9X;U#X4^";OX:^"'_;+
M\.>!H;/Q!K\/Q1C\6_L:^"O"7B[6O$'Q+LYK9]#TCX>?$^7Q2;#PG=Z6@O\
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M_CWKWQ-\(Z?\=_@Y=_!^_P#&^G6?P6\2:XVM?%CX\>/?VA?&?C+7[O2/#GQ
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M=+MYCX.T/QA'X/U>VMO$%^;6Q2:W:U28730PR?HO3E=U#A691( KA20'4$,
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MZ* /3/\ A=OC+_H2/"__ (5.J_\ RCH_X7;XR_Z$CPO_ .%3JO\ \HZ\SHH
M],_X7;XR_P"A(\+_ /A4ZK_\HZ/^%V^,O^A(\+_^%3JO_P HZ\SHH ],_P"%
MV^,O^A(\+_\ A4ZK_P#*.C_A=OC+_H2/"_\ X5.J_P#RCKS.B@#TS_A=OC+_
M *$CPO\ ^%3JO_RCH_X7;XR_Z$CPO_X5.J__ "CKS.B@#TS_ (7;XR_Z$CPO
M_P"%3JO_ ,HZ/^%V^,O^A(\+_P#A4ZK_ /*.O,Z* /3/^%V^,O\ H2/"_P#X
M5.J__*.C_A=OC+_H2/"__A4ZK_\ *.O,Z* /3/\ A=OC+_H2/"__ (5.J_\
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M4ZK_ /*.O,Z* /3/^%V^,O\ H2/"_P#X5.J__*.C_A=OC+_H2/"__A4ZK_\
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M@ HHHH **** .8U?_D9/!G_77Q+_ .F9:Z>N8U?_ )&3P9_UU\2_^F9:Z>@
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M):]XYB^*.@7GB[Q'KWP:MHY+N+2_AN-*AO[/3_$=U)]DL-2O-7\FS*F6X60
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M* "BBB@#EM4_Y&SP=_UR\4_^FF&NIKEM4_Y&SP=_UR\4_P#IIAKJ: "BBB@
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M$7B+7;J\U35;^=(;6RMS//Y%AIMG9Z?90P6MO'&/2/-N_P#H >+O_"/\2_\
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MO5Q&&,:_,^%YKI?-N_\ H >+O_"/\2__ "LH L457\V[_P"@!XN_\(_Q+_\
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M@!XN_P#"/\2__*R@"Q15?S;O_H >+O\ PC_$O_RLH\V[_P"@!XN_\(_Q+_\
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MX8;NZ:V3R[9KJYB1)[EK:/\ =VQGDD-O'^[A*)\M,\V[_P"@!XN_\(_Q+_\
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M[.[R](5D!)N"1M8[A@CGKFND_P"$1\,?] 6U_P"_EY_\DT ?H%Q_>7_OI?\
M&CC^\O\ WTO^-?G[_P (CX8_Z MK_P!_+S_Y)H_X1'PQ_P! 6U_[^7G_ ,DT
M ?H%Q_>7_OI?\:./[R_]]+_C7Y^_\(CX8_Z MK_W\O/_ ))H_P"$1\,?] 6U
M_P"_EY_\DT ?H%Q_>7_OI?\ &CC^\O\ WTO^-?G[_P (CX8_Z MK_P!_+S_Y
M)H_X1'PQ_P! 6U_[^7G_ ,DT ?H%Q_>7_OI?\:./[R_]]+_C7Y^_\(CX8_Z
MMK_W\O/_ ))H_P"$1\,?] 6U_P"_EY_\DT ?H%Q_>7_OI?\ &CC^\O\ WTO^
M-?G[_P (CX8_Z MK_P!_+S_Y)H_X1'PQ_P! 6U_[^7G_ ,DT ?H%Q_>7_OI?
M\:./[R_]]+_C7Y^_\(CX8_Z MK_W\O/_ ))H_P"$1\,?] 6U_P"_EY_\DT ?
MH%Q_>7_OI?\ &CC^\O\ WTO^-?G[_P (CX8_Z MK_P!_+S_Y)H_X1'PQ_P!
M6U_[^7G_ ,DT ?H%Q_>7_OI?\:./[R_]]+_C7Y^_\(CX8_Z MK_W\O/_ ))H
M_P"$1\,?] 6U_P"_EY_\DT ?H%Q_>7_OI?\ &CC^\O\ WTO^-?G[_P (CX8_
MZ MK_P!_+S_Y)H_X1'PQ_P! 6U_[^7G_ ,DT ?9NMX_X3GX><K_J/&_\2_\
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M^_EY_P#)- 'Z!<?WE_[Z7_&CC^\O_?2_XU^?O_"(^&/^@+:_]_+S_P"2:/\
MA$?#'_0%M?\ OY>?_)- 'Z!<?WE_[Z7_ !HX_O+_ -]+_C7Y^_\ "(^&/^@+
M:_\ ?R\_^2:/^$1\,?\ 0%M?^_EY_P#)- 'Z!<?WE_[Z7_&CC^\O_?2_XU^?
MO_"(^&/^@+:_]_+S_P"2:/\ A$?#'_0%M?\ OY>?_)- 'Z!<?WE_[Z7_ !HX
M_O+_ -]+_C7Y^_\ "(^&/^@+:_\ ?R\_^2:/^$1\,?\ 0%M?^_EY_P#)- 'Z
M!<?WE_[Z7_&CC^\O_?2_XU^?O_"(^&/^@+:_]_+S_P"2:/\ A$?#'_0%M?\
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M !U^W#^SEX!B\0ZEX8EN_P!EC]L2\\-^(M-6.XOO WC?5&^&O@RP^(?AZVN
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M;)Z#:0#D]N.>U.,$X8H890ZKN93&^X+_ 'BN,A?<C%?%?P,MO#/QC_9;\<>
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MV^#>KOKWAZ[\,#Q1K&K1ZI8:CJ@@CU7P[K$;Z0V@K>>&[6.WTK4KN%_T2HH
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M]QOF'-7?^%(Z1_T-_C7_ +_>%?\ YE*** #_ (4CI'_0W^-?^_WA7_YE*/\
MA2.D?]#?XU_[_>%?_F4HHH /^%(Z1_T-_C7_ +_>%?\ YE*/^%(Z1_T-_C7_
M +_>%?\ YE*** #_ (4CI'_0W^-?^_WA7_YE*/\ A2.D?]#?XU_[_>%?_F4H
MHH /^%(Z1_T-_C7_ +_>%?\ YE*/^%(Z1_T-_C7_ +_>%?\ YE*** #_ (4C
MI'_0W^-?^_WA7_YE*/\ A2.D?]#?XU_[_>%?_F4HHH /^%(Z1_T-_C7_ +_>
M%?\ YE*/^%(Z1_T-_C7_ +_>%?\ YE*** #_ (4CI'_0W^-?^_WA7_YE*/\
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<TK06=I%;Q&5E5%:0QQJ7940,V2%4' *** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "4 ' # 2(  A$! Q$!_\0
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MR>#Z?4$<U]#? +]W>^(H<_>M+&0@#@8GN%Z^V[ QCCMW/SA=/<S2K<6EQ9Q
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M3S@\<=QQ@UY/XK0^5<.<D*0<8"G 9<CN?7K@XX/I7KUUND1N & S@#.<8//
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MWA;2N#GCCD<8^I/)^R-$Y2,=@Q)/UR,>WKWSTX[_ (EB$XXC$1:LXXBO%_\
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;+'"B =.@4 #H.@K62..,;8T5!Z* ***"C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- 8H# 2(  A$! Q$!_\0
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M X?!XFIF%+,*V7YC2<'['%8>AAHXIX22J.F?RY_\*)^"'_1&_A5_X;SPC_\
M*>C_ (43\$/^B-_"K_PWGA'_ .4]?JA_P40_9W\,?L_>*/A=K'P[^'^E^"/
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MX4>W_P!$;P]%XB32?L7^A?9?LO[FO$_B'\7?B1\5['X>Z=\0?%%QXDL_A1X
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MJRLOA+2 RLI<%64@@@@$$$$9KU/^TM._Y_[+_P "H/\ XY7[#E"E_9.4Z/\
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MO=^!])O8])TO7M;N=.O[H64.HL+349KBXDZ+X._\%7-+\ ZE\ ?B!\1OV1_
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M?_*.O9:*/KN-_P"@W&?^%F+_ /FH/[7S;_H;9K_X=,S_ /GD>-?\,Y_L]_\
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M_P"4='_#.?[/?_1"/@U_X;#P1_\ *.O7[=F>W@=SEGAB9CP,LR*2<# &22>
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M_-0?VOFW_0VS7_PZ9G_\\CQK_AG/]GO_ *(1\&O_  V'@C_Y1T?\,Y_L]_\
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M  Z9G_\ /(\:_P"&<_V>_P#HA'P:_P##8>"/_E'7^*]_P50TW3M'_P""GO\
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MQ_\ H"TZNCV-/L_O9GSR[_@C];_^'FGAS_HD'B/_ ,*G1_\ Y H_X>:>'/\
MHD'B/_PJ='_^0*_)"BCV-/L_O8<\N_X(_6__ (>:>'/^B0>(_P#PJ='_ /D"
MC_AYIX<_Z)!XC_\ "IT?_P"0*_)"BCV-/L_O8<\N_P""/Z _V</VIM,_:*U#
MQ98:?X,U/PJWA2ST>\EEU#5K+4EO1J\^HPI'$MI;P&$P'3F9V<L'$JA0"IS]
M6U^1O_!,S_D8OB__ -@7P7_Z7>):_7 N@94+*'?=L4L S[0"VU2<MM!!; .
M1FN:HE&;2V5O/HF:1=TF_P"M1U%1K-"TDD*RQM-$$:6)74R1K("8VDC!+('
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M?\$T_P#LP#]C?_UG7X<U]_U\ ?\ !)W_ )19?\$T_P#LP#]C?_UG7X<U]_T
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M&&!SQUY/N<8R?P 'T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5_B#?\%8O^4IO_!2S_L__P#;(_\
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M#]CX?U+6M3T*&QTSP@7T9O$>HWFKZ]I&F7-SX;N+NR\(ZQJFH7U]?^!+>=/
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MU*\,/5P5.I*I&-3FI\M6,:T*\8_O]1117\R'^>(4444 %%%% !1110 4444
M%%%% !1110 5_B#?\%8O^4IO_!2S_L__ /;(_P#6BOB-7^WS7^(-_P %8O\
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MI]Q;7%MK5W+%=:''-Y/ES?+7Q%_X* ^#O%?AWXO>#-"\.?%2WTK4OV,/AO\
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MH^*'B/X%_&#1O$?@[XAZ?X@3Q7KOB/X*^(=3L+GXM?"WQK)XT\36<^I:N([
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MX>*E@ &(+V;.1G."S%B/O$G)I_\ P[__ &(_^C5?@7_X;KPY_P#(5+W/[_\
MY*/7R_$Z#_AMC]C[_HZ'X!_^'7\$_P#RZH_X;8_8^_Z.A^ ?_AU_!/\ \NJY
M_P#X=_\ [$?_ $:K\"__  W7AS_Y"H_X=_\ [$?_ $:K\"__  W7AS_Y"H]S
M^_\ ^2AKY?B=!_PVQ^Q]_P!'0_ /_P .OX)_^75'_#;'['W_ $=#\ __  Z_
M@G_Y=5S_ /P[_P#V(_\ HU7X%_\ ANO#G_R%1_P[_P#V(_\ HU7X%_\ ANO#
MG_R%1[G]_P#\E#7R_$Z#_AMC]C[_ *.A^ ?_ (=?P3_\NJ/^&U_V/AU_:A^
M8_[JOX)_^75<=J__  3W_8ON])U2UT[]E[X%6>H7.G7MO879^'F@H+6\FMI8
M[6Y+PV0F003LDI:(B1=N4.X"OD#]B+_@DW\.O@I\._%'A[]J'P/\"OCSXQU/
MQ@VL:%XF_P"$2FUDZ3X<.@:+8#0S/XJTR&[B"ZO9:GJ0BMD-O_Q,"Y8RNX5V
MA9N\KJVGNZW_  T#WO+UU/O#_AMC]C[_ *.A^ ?_ (=?P3_\NJ/^&V/V/O\
MHZ'X!_\ AU_!/_RZKG_^'?\ ^Q'_ -&J_ O_ ,-UX<_^0J/^'?\ ^Q'_ -&J
M_ O_ ,-UX<_^0J7N?W__ "4-?+\3H/\ AMC]C[_HZ'X!_P#AU_!/_P NJ/\
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M._\ ]B/_ *-5^!?_ (;KPY_\A4?\._\ ]B/_ *-5^!?_ (;KPY_\A4O<_O\
M_DH]?+\3H/\ AMC]C[_HZ'X!_P#AU_!/_P NJ/\ AMC]C[_HZ'X!_P#AU_!/
M_P NJY__ (=__L1_]&J_ O\ \-UX<_\ D*C_ (=__L1_]&J_ O\ \-UX<_\
MD*CW/[__ )*&OE^)T'_#;'['W_1T/P#_ /#K^"?_ )=4?\-L?L??]'0_ /\
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MV/O^CH?@'_X=?P3_ /+JC_AMC]C[_HZ'X!_^'7\$_P#RZKG_ /AW_P#L1_\
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MNEZ;;16=A86=O&!'!:VEK#%;P1( L<4:(H  K_$8_P""L7_*4W_@I9_V?_\
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M<5*+7DT_DU)-)QDD^K76,I1?E*+LU\G;U3BUI),*_P 0;_@K%_RE-_X*6?\
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M[U.X675I[2:VNKNWD?3;>VM+6WM"G\A/_$<Y_P!8NO\ S=G_ /)'H_XCG/\
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M!J9GU>PF+ Z-;.NDPP&)!+7\.7_$<Y_UBZ_\W9__ "1Z/^(YS_K%U_YNS_\
MDCT2?-&<)1A*-2,X23BOAJ0G3E%;-+DG**L[I6L[JX]4XM-J49*:DG9\T9QF
MFWY2BG:R3VMT/ZY=/_9G\9^(? $G@?6=+\.1:AX)_9Q^(7[,VDWWB""1[/61
M?:UX8F\*^*=-FCL+]?\ A'=<\)Z'ITFNF-AJ-AKL=QI<NGS-8F>NA^)_[*WB
MOQIK/C.;2V\$0:%XCU37+FTTN]:[BMUL-6^'/PC\'&VNK*WT:>T427G@+5C=
M0H)8I-/FTXL9)))X+?\ CY_XCG/^L77_ )NS_P#DCT?\1SG_ %BZ_P#-V?\
M\D>FIR4_:7YIMJ4I22:G/FYY3E'2+E.?-.6EG*<[:.RF45)-;+EE"*C[O+"6
MG*FKOW8VC&3?-RQBF]#^S/Q-\(?%5[X\;2+'3X%\.>*OVB/!'QOOM8L4>'3_
M  [X9^&'@_P7 FG7;-%;)_PD_BCQIX:L[*UL=.%X'T&74=4O;F'[.UN]3XX?
M!'XL>.OB-%XD\+3^%_[!AU#X/ZS%#-X@NO"ES<'X9>/(_&.HZ7XF33?!^MZC
MXL>^19(?"#W'B#3M \-W5Y?7-YH-[<,+FX_C7_XCG/\ K%U_YNS_ /DCT?\
M$<Y_UBZ_\W9__)'J8^[[%K>C-5(MZWE!48PY_P";EA0IQZ.5I.5W+W7)*2JI
MK2M3E3FEI:,Y59S46K./-.M.6GPW2C91U_L(O/V5O%C^#O"VA:?-X(LK_0O"
M?Q-LM1B_TU-)U[6O$_QD\%_%/1]+U;[/I,=Q=^'-9B\-7^E^+9I(GN8WU6:>
MWL=3$DP;U3P3\'O$VH^&?VA]*^(NG^%?"I^/&O:Q=G2O >IW>M0Z'I&L_#/P
MQX"N9+O4K_0?#BW_ (@>?1KV_N;F+3(K6<2VN6+B4#^*/_B.<_ZQ=?\ F[/_
M .2/1_Q'.?\ 6+K_ ,W9_P#R1Z5E[.=*WN3IRIM=H3C1C)1:LTW'#T8IW?*H
M7@HR<I.FVYQJ7]^-6%92[SIRJSBVM4TIUJDVK>\Y6DW%*)_:QIGA[]I:\\,Z
M?X'U6Z^'?A2RT/PNV@77C7PKK^OWWB/Q=>VUO::;I>JZ1I]YX:L+7X>J+:*X
MU34DEN_&=PE\\&F:=(MNCZHV#<_#/]HO2YM 70_B')J]G9^(['6=4_MOQC?I
M>W%I:ZR6O=&,I\*745SI6I>&(X]/%O,N;75V;45S-++=K_&+_P 1SG_6+K_S
M=G_\D>C_ (CG/^L77_F[/_Y(]6YRE.523YISFJDY-+WY\TYMR5N6TI3DY1C&
M$'>RBHZ$*$5#V<4XP4%"$8MKV<%!TU&#^)6A9)N4I>[!\W-"+/[7-:^$?Q&\
M9?L__$KX8>./%-IK7C#Q1;^(5T'Q US+/96XD>'4?!ME>)_9FGM'#H<]KI^D
MZK.D$SZV;*\\02+;W&L2Z;9\1-\'?%GCUO%OCZ\TC3_"&N>._'/P%\9W-E>1
MS+XL\/6_PLMM(M/%.F&Z@T^<3ZA;W-CK8\)2V5U<:=J4-Y%="ZM;;4I2?XVO
M^(YS_K%U_P";L_\ Y(]'_$<Y_P!8NO\ S=G_ /)'J7JIK1<\8*]F^5TZ<*2D
MM4VY0ITU4U3FXN3DIU)LKK%Z^[*;T=KJI.=1QM9I*,YSE35FJ=U&,7&$4?U2
M?#"W\8>,/$/A[1/A/<_#*QU7PQ^RKJGPQT_XA:!=ZO)JVCR:MX^\"VAU[QII
M<OAJQN_!WC"VTK2_$/B/2OAUJ\M[JB^,K'6X]5OH;'S+^;WSXA_LG0:U9:KH
M'A'3_",/AR+]G_P[\&O#5OX@6:>[MVTCQY!XGO6U"9=+O&DL=2L;2VEOKI7E
MNM0UB/[1=6Y;%S7\;:?\'R\49<Q_\$MHXS*YDD*?MK*IDD( +N5_9&!=R  6
M;+$ #. *D_XCG/\ K%U_YNS_ /DCUI[1IJ22YFW.;=GS3<ZE1NUDE%3JSDHJ
M,5S2E-Q3?+%-7;Z*RC%*ZY8J,8K6[;GRPC'F;;48J*;5Y2_LKD^#WQ4\'?%O
M_A9?@S0_ OB6Q?Q;\6-1'A_4/%NI>#WM])\?>%_@YI>G7$=Q;>#/$=LU[;ZE
M\.M7;4;(6\<9@O[*YBO9YVN88O1?"6@^,_$?QQNOB9XI\-KX2MO#'PJ@^'%O
M91:DVJVNL>(?$/B*S\6^)[K2=0DL=)N=2\/Z';Z1X=TRPU:[T?3&O]4NM=CM
MK18+$3W/\1__ !'.?]8NO_-V?_R1Z/\ B.<_ZQ=?^;L__DCU$6TH+22IQJ1I
M\VKC[2'))WNKOE<[<R>LV[Z)!)*3J2M9U94Y3MHI>SG&<?=M9:PA\-M(VL[M
MG]8'A+X-?$WXC>#=2_L31OAAX<TS0O'?[3]QH.KW;7&H:MXXO/&OQ1\5Z9<Z
M3XJT.^\)S:5I-J+:.\OKK4[F;QA:7VMV7A+4WT"XM=-N+.3T/X=_LW?%#1?%
M=WXG\2S>$)[I==^+GB;1+W6_$&J^/]4M-0^)/P[^'OA'3AJ\][X8\-QWMSIM
M[X-OVUM],&EV5WI6J)8Z7!;PK+&?X^Q_P?. <#_@ET .>!^VSCJ<G_FT?N>3
M[TO_ !'.?]8NO_-V?_R1Z44HP4$E;V"H-O5M?5Z>'G)7NHRE&FFK)1B^6T=)
M<]-MR<GUK3K)+9-XBIB(Q:^U&+J<KN[S7-=J\>3^N/P-^RU\4[/Q1H.J>,5\
M&W>DZ=KOP+UB2VG\3W6O-8GX.#XA0R0Z+H\'@+PQX>T;3)V\8V%UX0T;2;.T
M@T&WTHPWD\][*+H6K[]D'Q?+X4\*Z+I]_P"%M*N/#>B^(6O(-'U#4]$AU_6)
MOV@/#?Q@TS2;C4K#11=V>E:IIFC7EAJ.JK;7%UI6L7<-U;Z9J=NLRR_R)?\
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MBV]_:IXH\#Z_)<?\(S>3ZJNM:_?Z ?[7OI&UB)8&_D?_ .(YS_K%U_YNS_\
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8C^W?^$?T+^U_L?\ :']CZ9]H^Q0(#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #^ 8 # 2(  A$! Q$!_\0
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M5AH4][?W;1Q22+;VT,DI2-V"X4D8]Q\ O@O:7%Q:77P5^%]M=6EQ/:7=M/\
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M2GC:3E@<+7<<%C*V'Q<X4W-3C?P_IUYX7_43+JV+A5I8/V&#RWPVQ_/F=:>
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M>)=1^$WAZST+Q:OAZ]33-?;PWJL^A)9ZRNAZC(EAJQL)IQ87CK;W/ERL%/\
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M5U,_Q4<%0CF.9N6#PN8U%G%3#_S!R_&'XJZGX)L_AW/\6?B1J/PVL9X+C3_
M4WQ \4WG@2TGLYA/:RVGA:35Y= @>TN%6:V\FQ7[-,J21!'12*^J?$SXE:XW
MC%];^(GCO67^(B:7'\0GU7Q?X@U%O'L>B-$^BIXU:\U"8^*DT=X('TI-=-^N
MGM#$UH(3&F/T5_X*2FR\7_"#]@;]I/7?!_A3P)\<OV@?V>?$^O\ QET7PEX5
ML? ^F:UJ'A+Q5!I7A7QG<>$=/@M+73;S7-,N[F-I8[:%;JVM+>-=T=I&$^^_
M$W_!//\ X)Q^#K+XH:3X@T#]JB7Q/\&OV(_A]^V?XMU/P]\4/"?]DZYI6M+?
M-J_@?PS9:QX;FDM-3U272+B$ZAJWFV>F0:C%+IQCFL62X[JO$^4X+!8;&8S*
MJM.KBL;G&%J4,!@\'CW#%9/CJ&$S"LZ].."C7HRQ"P-2CBXIU,2Y8:;A[2A&
M=#T*GB#PUEV79%CL9PYC*>*S[$9Q&&!R7*<JS:6'QV3\2X;(<QJSQ=!Y11KT
MZO$%;+)83,*2<\;/%8/&S5*K0J8C"?@GIGQS^/NFW6M:IHGQH^-.GWNL:5I&
MD>)-2T?XC^.[2YU/0]!MQ9:!IFO7MAK,<EUI.B6B+9Z-::C*]IIMJ@M;)(85
M$8X'5_%'B?Q!XBN_&&O>)?$.M^+[_48]8OO%FK:UJ6H^)[S5X6B:+5KKQ!=W
M,NK3ZI$T$+1ZA)=M=QM#$R3 QJ1_0SXZ_8W^%?P+^'W[<4GP/\<_&SPM\./%
M7_!/CX"?M"6'@K4?%^DW4M^?B%XA\8VEQX-^(5\F@2/XLT&R2QBO+2&VDTJY
MM+J\U"#[?=6[0/%S/[2O_!/#]BOP/HO[8WA#X9Z+\=="^)_[+/P"^"/QTM_%
MWB3XG:3XE\&^)E^*$Y^V>%1X7/ABQU"UBM;2UF#ZG/JLDXNKY);,6]O8?9KO
M#"\99#/$7I8"O!UI8>A"K1RVC#$4X5'1I5UC[.BZ5+#8O$4J$HT:V-BU*514
MY6][SLL\6.":N*A]6RG%48YC/ 8;#XG!Y!AJ558+%4>':4'G6N#GAZ5''\1Y
M=EWU?#SS:A&+<U34*53D_#?5/C)\8M<\7Z/\0=:^+OQ2UCQ_X>ABMO#WCK5/
MB%XNU#QEH-O"K)%;:)XGNM8EUK2K=$=T$%A>V\15V4H0Q%9UW\5_B7K>I^+?
M$%_\3_'VLZUX]TN3P]X\UV^\;^(M2U7QKH9>&270/%^J7.ISW?B/1_-M[>1]
M(UB>\L1)!"YMPT:$?MC\;?\ @G3^S#\+_'7_  47T^#2/BEJGA#]DO\ 9O\
M@1\8_ 6G/\0);34=3UCQ[IMSJ?C+2M;\0_V#*EY#?PVTEKH["T4Z*Y>X6*Z\
MORU^R?VC?V,?V8/VCOVF/&.NZ]X/U;X8^$/V>?V)/@U\4?%%A8?$[2/A[H/Q
M*_X3*RU6W\$Z->>(V\ W]C\/M-\%)H^LS?$3X@VVE>(-0\02:EHYEL-)AL3'
M<95.->':2PLX9;6E@Y8.I5J8B.7X*'U2A/!X;-,/0CA_XE7ZS.M14Z%!1IT<
M2Z5:I"J^:K1P7B[P-"6 K8?(L;++*V44Z[Q]/),KI3PE.KA>$,YR;*J.!@_K
M%7ZY/B_*91HX=T\)EV81=2=%SA+&T/YE-)^,7Q?T#6]$\2Z!\6?B?H7B3PSX
M<M_!WAOQ#HOC_P 5Z5KGA_P?:!A:>$M$U6QU:"^TKPO:!W%KX?L9X-)M][&&
MT0L26>&OB[\7/!>I>(M9\&_%?XG>$=8\8"8>+]7\,>/_ !9H&J>+/M#RR3GQ
M-J&E:O:W>OM,\TSR/JLUV[M+(2QWMG]Z=,_X)J_\$_;/XAZO>ZS\:]2OO"'B
M;X,_#7QW\+OAQJ_Q>3P1X5C\:^,-:U;1]?\ #VK?M3S_  UN/#6KZ-&^FVTG
MPYOSX=TN;QG+?7:8F@T]YH_QO_;)^!<O[-O[2OQ0^#?_  B?BKP3I_A;4]/F
MT#P_XU\3>'?&7B2'PYK6DV6JZ/>WOB?PI:V6A:Q#J$%RUQ8W-K:6UPMH8H-1
MA348KH5ZN5\19!G>,E@,-A*BKU,%.O-8W*Z.'A6HTL1)U\.G7IMXF6'Q,Y5*
M].%.OAZ=6K[:4E4JJK4^FX9XUX+XPS#$Y3EF75%B/[*PV/JPS7AW"Y=3Q>"I
MXB/[FE#&8=U<<LLQN(<:\88;$X+!8RI.5.K2K555Q/BMA\1?B'I2>&8]+\?^
M-]-C\%:[J'BGP8EAXKUZT7PCXGU:2.;5O$OA<07Z?V!XAU6:&&;4M:TK[+J5
M_+%')=74KHK#<T?XV_&KP[IJZ-X?^,?Q6T+1EUW4/%*:1HWQ$\7Z7I:>)]7A
MO;?5O$::?8ZQ!:)KVJV^I:E#J6L+"-0OXM1OX[JXE2\N!)YE17TL\-AJB:J8
M;#33=VIX?#S3?,Y7:G0FF^9N5VF^9N5^9N3^]J8# 55:K@,#57-SVJX'!55S
M\]6ISVJX*HN?VE>M4Y[<_M*U:IS>TK5IU?2?!_QG^,GP\TJ;0OA]\7OBEX#T
M*XU.'6Y]$\%?$+Q=X5T>;6K<QM!J\NF:%J]A8R:I$T43)?M ;I6C0B7*J1-H
MWQO^-GAW3TTCP]\9/BQH&DQ:]?\ BJ+2M$^(OB_2M,A\3ZK#>V^J^)(;"PUB
M"UBU_5+?4M2@U'6(XEU"]AU&_CN;B5+RX$GF%%*6$PDW.4\)A)RJ.+J2GA<+
M-U'&ZBZCGAI.HXIM1=1S<4VHN*;3F>6Y;4E4G4RW+JDZU15JTZF79?4E6K14
ME&M6E/ 3E6K14YJ-6M*K5BIS4:L5.:GVUE\3/B7IO@O4?AMIWQ'\?Z?\.-8G
MDN=7^'MCXT\2V?@;5;B9Q)-/J/A&WU./0+V6:0"29[C3Y#,_SR[VYJ3_ (6C
M\3_M1O?^%D_$#[:?!8^&QO/^$R\1_:S\.5A^SCX?&Y_M+SCX'%O_ *./">_^
MP1!^Z%AL^6N%HJGAL,W-O#8=NI*4JC>'H-U)3A&G*4VZ#<Y2IPA3E*;G*5.$
M(2E*$(0C?U' WF_J."O4J5*M1_4L'>I5JNBZM6H_J=ZE6J\-AW5JU'4JU7A\
M.ZE2H\/0=!          ,  <  #@ #H*\K^.W_)$/C)_V2KXA_\ J(ZQ7JM>
M5?';_DB'QD_[)5\0_P#U$=8KES?_ )%.;?\ 8JS3_P!5F9'G<3_\DSQ+_P!D
MWQ%_ZS^?!\"?^2(?!O\ [)5\//\ U$='K]$_AK^WY^V7\'O 6B_"_P"&W[07
MC+POX \-Q:I;:#X9BLO"NJVFDV&M-<OJFD65UKWA[5-3BT&\EN[BYDT$7QT=
M+MUNX;*.XBADC_6[]@K_ (-Z_AW\:?V&/V+_ (QWO[4'Q#\/WOQ9_9._9T^)
MEWH-E\/_  G>V>B77CSX/^#O%-QI%I>7.HI<7=KILNJO9V]S.B33Q0I+*BN[
M ?6'_$,_\,O^CM_B9_X;;P;_ /+2OS6CXB>'M?*LOP.9XB.+6'P6 IU*&*R3
M%8NE#$8? 87#5'&-7#U:;E&4*]-5(KWH.5FX3L_Y_P )XZ^!V+X>X?RO/\?3
MS&6695DM.>&S'A#,<RHX;'X+)<JP-:I16(P.(I*K3J8;$4HXBBHN4%>,W3E"
MW\Y,W[;W[6\_PE3X%R_'OQS_ ,*KC\/V_A%/#$;:+!.G@^T='M?!Z^*8-(C\
M9#PE;>6D</AH>(?[&2!%MA9_9QY52?$C]N/]KWXO>$M-\#?$C]H'Q_XG\,:5
MJF@ZY;V4L^DZ3>W>M^%GAE\,ZQKFOZ!I6E>(O$VI^'I[>WN=%O?$>K:K/IMW
M;V]W:O'<P12I_1E_Q#/_  R_Z.W^)G_AMO!O_P M*/\ B&?^&7_1V_Q,_P##
M;>#?_EI6BX_\,(U%6C]556.(>+C57#=55(XN2M+$J?U/G5=K>JI<[>M^;WC>
M'C;]'>G5IUZ;RVG7I8JOC:5:' .(C5IXS%*2Q.+A464*<<1B%*2KUE+GJ\TN
M>[E)R_G+^*'[<7[7WQHM?!MG\3OVAOB-XI@^'VOZ;XM\'@ZA8Z)-I/B[1T2/
M2/%TEUX;T_1KK5_%>EH@6P\1ZW-J6L6@,GDWB&63=K>+OV_/VS?'VN:1XB\9
M?M#>.?$&JZ#X:\8>$=)>\A\-QV%IH7Q!T:3P]XWC.B6F@VVB76J^)]$FETW5
M?$EYIUQXDEMW;R]6BD)<_P!#W_$,_P##+_H[?XF?^&V\&_\ RTH_XAG_ (9?
M]';_ !,_\-MX-_\ EI4QX^\+HQIPBL'&%%XATHQX:J1C2>*7+BG3BL$E!XB-
MHUW!1=5)*=TDD4_&SZ.M*.&A2_LRE'!1Q$,'&GP!B(+"0QE2%;%PPRAE$?J\
M<55ITZN(5%T_;5(0G4;E%-?SP:A^WW^V5J_PMN?@GJW[0/C+5?A;>^!6^&=_
MX2U*R\*WT.I>!/L::=%X=U/6+GP])XBU*WM+"-;+3KR]UB?4],M6DAL+ZV2:
M4/H:3_P41_;>T/Q)X9\7Z3^TCX]LO$GA'P2GPWT75$M_"\K-X'BDMYH/#VN6
MD_AZ6P\6V]K-:6\MG=^++76]2LI8R]I>PM+,9/Z#_P#B&?\ AE_T=O\ $S_P
MVW@W_P"6E'_$,_\ #+_H[?XF?^&V\&__ "TI/CSPL:J)QP;56I4JU4^&JC52
MK6A.E6J5$\%:=2K3J3IU)R3E.$Y1DVGIE_Q&;Z.#IU*3IY0Z5:>(J5:7_$/J
MWLZE3&0A3Q<YT_[(Y)3Q,*5*&(DX\U6-*E&;:I4_9_SJ^&_V[OVR/"7Q \>_
M%30?VC/B3;?$#XH6NGV7Q \1WFH:?K4GB>VT='BT*.\TS7--U+1+8^'8I'A\
M-2:;IEE+X=A=H=%>QC9E/BGQ6^+_ ,3?CEX]U/XI?%SQEJGCKXAZS!HMOJOB
MW5DL8-4OX_#NF66C:*9_[+L]/M?-L-,TZRMDN$MDGE^SK/<2S7+23/\ U*_\
M0S_PR_Z.W^)G_AMO!O\ \M*/^(9_X9?]';_$S_PVW@W_ .6E;T?$7PUPU:.(
MPU6CA\1"A'#0KT.'\11K0PT(QA##QJTL)3J1H0C"$8TE)4U&$$HVC&W;A?'C
MP!P.*ECL%B\-@L;/"T\#/&8/@C'87%3P5*G1I4L'+$8;+*%66%I4L/AZ=/#N
M;HPIT*,(TU&E34/YN?%7[9'[47CB?XMW/BWXU^+M=G^//A'PQX"^,#W::(@\
M=^#_  9#-;^&-"U2.VTF".TM]*AN+J-9]'33;Z\6\OO[1NKPWMT9;>@_MJ_M
M5>%]5BUO0?C5XDT[4HO@YHO[/@E73?"US;R_!?PY]J.@?#^ZTZ]T"YTV\TO1
MVO;QK"]N[2;6X'N9F&J%G)K^CO\ XAG_ (9?]';_ !,_\-MX-_\ EI1_Q#/_
M  R_Z.W^)G_AMO!O_P M*A^(/ABZ?LG+#.DX>S=-\.UO9N'L5A^1P^J<O+[!
M*ARVM[%*DDH)162\</H]*BL.JN 6'48P5!<"XQ45"%# X6$5266*FHPPV69;
MAH)1]VAE^!HQ<:>#PT*/\T5_^U/^T+J?B;Q]XRO_ (I:Y<^*/BE\*H/@?\0M
M9>Q\/K<>*?A-;:9I6C0>"+Z.+1H[6'38]+T32K/[786]GJ[)9)(^HM-)-))+
M\#_VK_VC?V;+77;#X&?%GQ#\/=-\37=EJ.NZ38V7A[6=(U'5=,C,6FZR^D^*
M-&US3[?6]/B/E66LV=M;ZG;1@)#=(%&/Z6/^(9_X9?\ 1V_Q,_\ #;>#?_EI
M1_Q#/_#+_H[?XF?^&V\&_P#RTJI>(OAK.E5P\ZM*5"M&C"M1ED&)E2JPP[J/
M#QJ4WAG"<:#JU714HM474J.E[-SDWI4\=OH_U<)5P%7%86K@:ZPD:V"J<$8^
MIA*T<OI>PP"JX:>72H36!H?N<'S4W]5H_NL.Z5-N$OYU/AI^W;^V-\'KWX@Z
ME\-_VB_B3X;O_BKKMYXI^(5TVH:?KLGB;Q5J "WOBFY'B73=92Q\2W"+%%)K
MNDKI^I^5;VD0N1':6JPVOAE^WU^VA\&]+U?1OAM^TA\2/#NG:]XNO?'NKPSW
M>E>))KSQCJMS]LUGQ#]N\5Z5KNH6U]K]R7E\1"SNK>W\0&:X76(+U+B=9/Z(
M?^(9_P"&7_1V_P 3/_#;>#?_ ):4?\0S_P ,O^CM_B9_X;;P;_\ +2LI\>^%
MM3VOM(X.?MHT(5N?AF<O:PPJ4<-"I? ^_'#QC&-",O=I*,5345&*CSUO&KZ.
MF)^L_6%E=?Z[/#5,9[;P_K5/K<\'3]CA)XGGR=^WEA:7[K#2J<SHT_<I\L;)
M?SZ>"?\ @HK^V_\ #GP^GA7P5^T=XWT/P]%J_B76X-+6P\(:E%:WWC'4K[6?
M$\=I/K'AK4+RSTG6M7U*^U.[T"UN(=!6^N#<V^FPR1PF/DM$_;9_:L\.?#C2
M_A#HWQK\26GPVT/PUXQ\&:/X5?3/"EY;:;X2^(%I>6'C'PW::A?^'KK68]'U
MNSO[N![,:D8[%90VF"RDB@>/^CC_ (AG_AE_T=O\3/\ PVW@W_Y:4?\ $,_\
M,O\ H[?XF?\ AMO!O_RTI/COPL;FW#!WJSIU*C_U:J7J5*2E&E4F_J=Y3IJ4
ME"<FY14I*+2E+F7_ !&KZ.G/4J6RSVE7%0Q]6?\ J#B5.ICJ?-R8RI)94I3Q
M<.>7+B)-UH\TK5/>=_YO=1_;/_:MU;X*+^SGJ7QY\?WOP570[;PNW@6>^L6A
MF\*V>/LGA.Y\0+8+XMN_"MLJK%#X;NM?FT5(%6W%E]G BKG=:_:?^/OB/4/B
M/JVN?$W6=1U'XO?#GP[\(OB5=36'AZ.3Q=\-O"<&EVWASPE?K!H\,=M8Z5;Z
M+I44-UI:6&J3+9I]JOYS).9?Z9/^(9_X9?\ 1V_Q,_\ #;>#?_EI1_Q#/_#+
M_H[?XF?^&V\&_P#RTK:/B)X:0=1PJT8.M5J5ZSAP_B(NK6JNE*K6J..%C[2K
M4E0H2G4GS3E*C2;=X19T4?'7Z/V&Y_J^(P>']IB*N*G[#@?&T.?%5\1A<76Q
M,_8Y92YJ]7%8'!8FI6E>I/$8/"UG+VF'HRI_S7?!#]KK]IK]FO2?%&A? ?XT
M^,OAAHWC.>UN_$NF^'I-+DM-0O[*+R+75(8]6TW4O[+U>&W"VXU;1S8:BT$<
M4,ER\<,2IT*?MR?M;1ZI\:]93XZ>*UU#]HW3X=*^.#BQ\,?9OB+96_A]_"D"
MZOIQT$Z;8W,7AN1]&34-"M-)OQ9,4^TEL./Z,/\ B&?^&7_1V_Q,_P##;>#?
M_EI1_P 0S_PR_P"CM_B9_P"&V\&__+2HJ^('AC7JUJ]>6&K5\1&,,16J\.UJ
ME6O"$J,X0K5)X24ZL83PV'E&-24U&6'H2C:5&FX15\<?H]U\3B<96JX&MC,;
M*A/&8NKP+BZF)Q<\+6PV)PT\5B)Y6ZV(GAL1@\)B*$ZU2I.C7PN'K4I0JT*=
M2/\ +A\'/C-\4?V??'%C\2?@QXRU#P!XZTS3-5T>P\2:5:Z5>7EKIFMV9T_5
MK1(-:L-4L&2]LR8)'DM'FC&'@DBD <=]\&OVNOVG/V>-#\9>&O@?\;O'/PST
M#X@2R7/BW2O#=[9QVNIWTL+6TNJVPOK&]DT/6Y+8BW;6_#\FE:J8(X(C>;;>
M 1_TH_\ $,_\,O\ H[?XF?\ AMO!O_RTH_XAG_AE_P!';_$S_P -MX-_^6E:
MXCQ'\-\7[;ZUB*>*^L4Z5&O]8R'$U_;TL/5G7H4JWML-456G1K5*E:C":E&E
M5G.I",9SG*71C/'OP$S#ZQ_:&.H8_P"M_4OK7UW@O,,7]9_LZI4JY?\ 6%B<
MNKJM]0JUJU3!>U4_JLZU:6']DZM7VG\W?Q+_ &FO$WQ(_9R_9U_9MO=/FC\-
M?L_:I\3O$-GKNI:M_:NJ:[KOQ/UU=5O8K>);"R31M T>WC*VEC//K&I7VKZG
MK>JWVK-%<V5A8^:V?QG^*>G_  BU;X"V/C34[7X/ZYXWL/B3JO@:&#35T^[\
M=Z5:VEEIWB;^T/L)URWO[.UL+**%+758+/\ T:*1K9I5WG^H[_B&?^&7_1V_
MQ,_\-MX-_P#EI1_Q#/\ PR_Z.W^)G_AMO!O_ ,M**7B1X=4:<J5/&3]G/&U,
MQE"648^<?KU7$+%2Q24Z34:RQ"C5IR@H^QE&+I<G*FYP_CWX#X7#PPM'-:BP
M]/,\5G-.G4X6SJO&GFV,QV,S+$9C3]OAJGL\7/&YAC:\:U-0G2EB*D:/LX2E
M&7\X7Q<_;5_:R^/7@+1/A=\9/CYX^^(7P_\ #\]C=Z?X8UV[TY;.:\TN(P:;
M>ZW<:=IUCJ/B>]T^,DV=WXEO=6GMY2;B.1;C]Z%^"G[:W[5_[./A74? _P #
M?CMXU^&_A'5-=7Q/=^']%_L6[T]?$ CMX9M5L%UO2-5ETFYOH+2WMM5_LJ6R
MBU>UC^S:G'=P.Z-_1Y_Q#/\ PR_Z.W^)G_AMO!O_ ,M*/^(9_P"&7_1V_P 3
M/_#;>#?_ ):5G_Q$'PQ^K3P7-AOJ=2L\14PBX<K+#5,0YJHZ\\.L&J,ZSFE/
MVLJ;J<R3YEL8/QO^CP\N_L=SRYY1]8>+_LI\!8G^S?K;G*;Q2P']DK"+$N<Y
MR==8=5KR?[RSY%_-Y-^V5^T_.+)9?C#K[+IWQWN/VG;)1I?A9%M_C[=7$MW<
M?$U F@*&UF6YGFF:PDW^'P\LA71U#$5U'@;_ (* _MI?#34OB#JW@+]HOQ[X
M8OOBIXUO?B/X^:P3P[+;:]X\U.>.XU3Q4FGWVA7>G:+JNK/#%'JTGAZUTF+4
M[2-;&]AGLQY%?T-_\0S_ ,,O^CM_B9_X;;P;_P#+2C_B&?\ AE_T=O\ $S_P
MVW@W_P"6E2^/_"^4)4I?594Y)1E3EPY5E"45/#U%&4)8.46E/"86:3BTI8;#
MR6M&FXS6\;?H[XBE4H8B675Z-5152C7X"Q5:E44<1#%14Z=7*ZD)<N*IPQ,;
MQTKPC63]HE(_F9\+?M-_'KP3\<=3_:5\*?$K5]%^.VM:GXFUK5/B1;Z=X>GU
M>\U3QE!<6OBB]DT^]T>YT!)-8M[JXBN$BTB.*)93]DCMV"D>F>/?^"@7[:'Q
M.\7_  U\?^-OVA?&>K>-O@[JFL:S\,_$]I8^%/#NJ^$M1\06UO9:]/:2^&?#
MNC)?Q:S96L-GJ5GK,>I65Y:"2WFMVBGG63^AK_B&?^&7_1V_Q,_\-MX-_P#E
MI1_Q#/\ PR_Z.W^)G_AMO!O_ ,M*J?B#X8U*E"K.6'G5PU!87#5)\.UYU,/A
M52G06&H3EA92I8=4:M6BJ%-QI*E4J4_9\DY1E=;QP^CUB<13QF(JX'$8NC@?
M[,HXJOP+C*V(I9;]7J8/^SJ=:KEE2I# ?5*M7"_4XR6&^KU*E#V/LIR@_P"7
MGXU?'/XP?M&^,[CXA_'3XA>(?B;XSN-.MM'_ +;\12VP>UTBS:9[;2M,L--M
MK#2M(TV*6XN)_L6E6-G;O<W%Q=21O<322MZ#K/[9'[3WB&X\876M?&'Q!J%Q
MX^^#FG_L^^,99=,\+HVO?!?2OMG]G_#^Y$&@Q+!I=M_:%[MOK%;76Y/M,OG:
MI)D8_I%_XAG_ (9?]';_ !,_\-MX-_\ EI1_Q#/_  R_Z.W^)G_AMO!O_P M
M*O\ XB+X:^RH4/;4O88:$J>&H?ZOXCV.'A-TW.%"E]55.E&;HTG.-.$%-TJ;
MES.$6M_^(]> GLL'1^O4/8Y=25#+Z/\ J7F"I8"@JN$KJC@J2R]4\)25? 8&
MLJ>'A2A[;!82KRNIAZ-2'\WVM_MF_M1^)-(\0Z#KGQD\0ZCH_BSX4^%_@=XB
ML)M,\*QQ:K\)?!5S?WGA7P1.\&@131:=HUUJFHS07EK)!K$[7DPO-2N5*JL'
MBG]L/]IOQM=_%:^\5_%_Q!K5Y\<? WAOX:?%JXN--\,0OXW\">$$GC\->'-2
M%IH5NMI:Z0ES<+!=:.NFZC+YTANKVX9LC^DC_B&?^&7_ $=O\3/_  VW@W_Y
M:4?\0S_PR_Z.W^)G_AMO!O\ \M*F/B%X9P=X3H1=[WCP]B(N[G&HW=85.[J0
MA.][\\(S^**:PI>./T>Z#A*C6P-&4'!P=+@;&TW!TJF$K4G!PRV+BZ=;+\!5
MIN-N2I@<'.-IX6A*E_/5XM_X*$?MJ^/?AQK/PC\:?M$^-?$WPX\1^#X? /B#
MPOJUEX3N(-:\)6Z"*'2=3U(>'$UN\9(AY1U.;4WU=XF>-[]E=PQ9?\%"?VVM
M.UGX=^(;+]I+XA6^M_"GPM?>"/ FHJ= :;2O"&I1Z5'?>'=1C?1&M_%6F7"Z
M%H[&'Q?#KS1S:;:W$+QW"&5OZ%?^(9_X9?\ 1V_Q,_\ #;>#?_EI1_Q#/_#+
M_H[?XF?^&V\&_P#RTK)<>>%BC**A@E&52I6E%<,U.656M2J4*M64?J7*ZE6A
M5JT:DVN:=*I.G)N$G%<\?&;Z.$*+P\:641P[EB)NA'P]K*BYXRA##8N?LEE'
ML^;%8:G2P^(DH)UJ-*E2J.4*5)4OY^=&_P""CW[=N@>./%'Q&TS]J/XGIXN\
M:6NF67B:[O;K1-7TC4;31!<#1;>+PEK&BW_A#2X](^UW?]F#1]"T\V9N[IH"
MK7$K-\L>/OB!XX^*GC'7_B%\2?%>N>./''BF]_M#Q#XI\27TFHZQJUV(HX(W
MN;B3 6.WMH8;6TM8$AM+.UAAM;6"&")(U_JM_P"(9_X9?]';_$S_ ,-MX-_^
M6E'_ !#/_#+_ *.W^)G_ (;;P;_\M*VP_B)X:8.K[;"5*&%K>QCA_:X;AZOA
MZOU>%N2A[2CA*4_91LK4^;ET5U*RMVX'QW\ ,KKU,5EF*PN6XFKAZ.%JXC+^
M!\;@:]3"X=1C0PU2MA,KPU6>'HQA!4J,ING!0A:+<(./\D=%?UN?\0S_ ,,O
M^CM_B9_X;;P;_P#+2C_B&?\ AE_T=O\ $S_PVW@W_P"6E=W_ !%?@;_H:XC_
M ,-68_\ RL]7_B97P=_Z*7&_^(WGO_R@_DCHK^MS_B&?^&7_ $=O\3/_  VW
M@W_Y:4?\0S_PR_Z.W^)G_AMO!O\ \M*/^(K\#?\ 0UQ'_AJS'_Y6'_$RO@[_
M -%+C?\ Q&\]_P#E!_)'17];G_$,_P##+_H[?XF?^&V\&_\ RTH_XAG_ (9?
M]';_ !,_\-MX-_\ EI1_Q%?@;_H:XC_PU9C_ /*P_P")E?!W_HI<;_XC>>__
M "@_DCKRKX[?\D0^,G_9*OB'_P"HCK%?V8_\0S_PR_Z.W^)G_AMO!O\ \M*^
M3_V]?^#>OX=_!;]AC]M#XQV7[4'Q#\07OPF_9._:+^)EIH-[\/\ PG96>MW7
M@/X/^,?%-OI%W>6VHO<6EKJ4NE)9W%S CS013/+$C.B@\>8>*/!6(R_,,/2S
M3$2JU\!CZ%*+RS,(J56O@<;1I1<I4^6*E4K4XN3TBFY/1,\O//I&>$>-R/.\
M%AN(L;/$XW)<YP>'@^'L[@IXC&9/FV$P\'.=!0@IU\50@YS:C!3<Y-1C)K]U
M?V!_BEI?P3_X(O?L$_%36=-OM8T_P9_P3G_8YU.32]/DMX+F_GD_9]^&-C96
MOVN\>.RTZVFOKNV2]U6]D2RTJR-QJ5XPMK64U[%_PV=JMT]WX2T/X1P^(_C!
MH&O?$'3?&'@71?B;H=UX;T?2?AKX2\&^-M>UG3/B!_8BPZQ+?:/\1/!5CH6C
MW/AS1;N?Q%JUWI>M2:#::5=:J>%_X)I^$].\>?\ !(+_ ()]>"M8N-2M=*\5
M_P#!.3]DKP_J-SH]X=/U2"RU7]FKX?6=Q)8W@240W"Q2L8S)#/ Q^2XMYX&D
MA?U'2_V$/A#X?\*6?ASPMK_Q \'ZK;ZSXSU:\\<>$+_PEX9\4:K!\0M T?PK
MXQT&ZM-'\&6G@RQT'5_#_ASPW81V>A>$='N-)G\/:3K&C7FGZ]#/JEQ_)WO?
MO-O@C[)O5>TY:B7.E9JG&K[*=:S<ZM#VE*C[.KRU'_FK[EJ=T[J<O:6OK3O3
MOR].=T_:QI;1A6=.I5YZ:E X?P__ ,%%_A;KJZ'J+Z'>Z;X<\:W.CW/@/4KC
M4Q<ZMJWAF?7M9T#Q%K/B#PO8:7<ZOX:U/19="O+W2O#$2ZYJ/BBRO-&^P2VU
MWJ+VMI]UQ>,/"\^DZ/KT&OZ7-HOB"RM]2T35([N)[+5;"[MXKNVN[&X5C'<0
M3VT\,\<B$JT<B,#@BO M;_9%^$6I7.DWNB6=]X%U#PSX<\):!X.U3P7%H.GZ
MGX4G\%ZCI%YHOB&QN]1T/5O[5U]++P[X?\/37/BB/7K5_#NE)I2V:17=\US[
MSX*\(:)\/_"'ACP/X;AFM] \):%I?A[1XKB=KFX73])LXK*V-S<. UQ</%"K
MSS,%,LS.^U=V!M+V=I\O-=5)>SOJY4N:HH\_::C&G)VO>51QU5-REE[]XZ))
MTUSW=[5+0;Y;)7CS.4>BM3YU;VD8Q/\ A-/"?_0PZ5_X%Q?XT?\ ":>$_P#H
M8=*_\"XO\:Z>BHT\_P /\AZ]U]S_ ,SF/^$T\)_]##I7_@7%_C1_PFGA/_H8
M=*_\"XO\:Z>BC3S_  _R#7NON?\ F<Q_PFGA/_H8=*_\"XO\:/\ A-/"?_0P
MZ5_X%Q?XUT]%&GG^'^0:]U]S_P SF/\ A-/"?_0PZ5_X%Q?XT?\ ":>$_P#H
M8=*_\"XO\:Z>BC3S_#_(->Z^Y_YG,?\ ":>$_P#H8=*_\"XO\:/^$T\)_P#0
MPZ5_X%Q?XUT]%&GG^'^0:]U]S_S.8_X33PG_ -##I7_@7%_C1_PFGA/_ *&'
M2O\ P+B_QKIZ*-//\/\ (->Z^Y_YG,?\)IX3_P"AATK_ ,"XO\:/^$T\)_\
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M2O\ P+B_QKIZ*-//\/\ (->Z^Y_YG,?\)IX3_P"AATK_ ,"XO\:/^$T\)_\
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MTAKX _X*Q?\ *++_ (*6?]F ?MD?^LZ_$:C3S_ ->Z^[_@GEW[!/Q.MO@O\
M\$5OV&/BQ>:/<^(+7X>_\$T_V3_%=QHUG=V]C/J$6D?LU?#RZ>W%[<K)#:1E
M4+3W)AN9((%ED@L[R=8[6;O_  M^W3JOCK26M? GPQ\.^-?'%MXE^*FGW%EH
M7Q/EB\"7_AGX/^&/!'B?Q3XDT'QAJW@/3M;N;F\E^(/ASPIHFC:QX'T-9_$S
M:D]WJ=KX?T]=:N^8_P""='PZ\+_%K_@CO_P3Z^'/C2UN;SPSXL_X)W?L<Z;J
M<=E>W&G7\0'[/7PTNK2^T[4+1TN+'4M-O[>UU'3[N)MUO>VL$NUPA1O=)OV)
M_AG<Z?>M<>,OB[+XVUC7]=UWQ)\5U\;16_Q*\31^)O"6C> ]=T#6-7M-%M](
M'AN_\'>&_#FAIIFF:#IITY=!TK5=)GL->MO[6>$I7JZK6$51NM(U%&I:4[>]
M*'M72E6C=2G0A4ITI*K.+A=X6I:-M3E[9W:;IWINT-;<[IJK&FWI"M*G4FI4
MX24O*?#/_!1SX=>(6\/7C>&[JRT/QU>:)/X'E74[O5/$MQX;N==U?0]>O_%7
M@[1_#]_K/A_Q!8#19=6\.^%=-7Q'>>+M.U70?L=U93WTJ6_WE;^-?"MWHNB>
M([37+*[T+Q)86VJ:%JEJSW%IJFGWEM%>6MW:RPHX>&>UGAFC8A<HXX!R!XIX
M@_92^$FM2:;<:=8:CX-O?#WAKPKX;\(:CX,FT[2+_P 'KX-U'2;_ $/6]#N9
M]+OS+KT$'A_0-$DO-<768)?#^C6FCFT%I)>+=>W^#O">B> _"?AOP5X:MGL_
M#_A31--\/Z-;2327$L.G:5:165JLUQ*3+<3&&%6FGD)>:4O(YW,:VE[.T^52
M351^SOK>ES5%'G[348TY.U[RJ2CK&GS2S][FCMRNFN=7NU4M!OELDG%R<X]%
M:GSI)U%&$'_"<>%?^@Q!_P!^KK_XQ1_PG'A7_H,0?]^KK_XQ75T5F4<I_P )
MQX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ
M_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?
M^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_X
MQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )
MQX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ
M_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?
M^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_X
MQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )
MQX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ
M_P#C%'_"<>%?^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?
M^@Q!_P!^KK_XQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_X
MQ75T4 <I_P )QX5_Z#$'_?JZ_P#C%'_"<>%?^@Q!_P!^KK_XQ75U_/SXN_X.
M)OV6?!WB_P 7>#K_ ."7[0UU?^#O%GB;PC?W5GI_PW:SNK[POKE_H-Y<V9F^
M(,,QM+BYT^6:U,T,,Q@>,RPQ2;HU]C*.'\ZSZ5>&3Y=B,PEA8TYXB.']E>E&
MK*4*<I>UKT-)RA.*Y7+6+NEHW]5POP1Q9QK4QM+A7(L;GE3+J="KCH8+ZM?#
M4\34J4J$ZGUG&8-6JU*52$>1U'>#NHJS?[M_\)QX5_Z#$'_?JZ_^,4?\)QX5
M_P"@Q!_WZNO_ (Q7X"?\1)'[)W_1"_VCO_!=\,__ )XM'_$21^R=_P!$+_:.
M_P#!=\,__GBU[?\ Q#SC;_HF\Q^["_\ S<?7_P#$"?%[_H@<\^_+/_GT?OW_
M ,)QX5_Z#$'_ 'ZNO_C%'_"<>%?^@Q!_WZNO_C%?@)_Q$D?LG?\ 1"_VCO\
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M_3_^"K5__D"C_A-O#7_/]/\ ^"K5_P#Y KJZ* .4_P"$V\-?\_T__@JU?_Y
MH_X3;PU_S_3_ /@JU?\ ^0*ZNB@#E/\ A-O#7_/]/_X*M7_^0*/^$V\-?\_T
M_P#X*M7_ /D"NKHH Y3_ (3;PU_S_3_^"K5__D"C_A-O#7_/]/\ ^"K5_P#Y
M KJZ* .4_P"$V\-?\_T__@JU?_Y H_X3;PU_S_3_ /@JU?\ ^0*ZNB@#E/\
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M]_5?_"<\1_\ RIH_X3+0?[^J_P#A.>(__E374T4 <M_PF6@_W]5_\)SQ'_\
M*FC_ (3+0?[^J_\ A.>(_P#Y4UU-% '+CQCH1( ?5<D@#/AWQ$!D\<DZ4 ![
MD@#N:_S)?C>ZR?'#XWR)DI)\:?BW(A971BK_ !#\2,I9)%61"5(RCJKJ<JZJ
MP('^H%7^7_\ '+_DN?QS_P"RV?%W_P!6+XEK]X\#/][XD_[!,L_]2\6?V?\
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M^*O_ )34?\)5I7_/#7__  D_%7_RFKHZ*-.WX_\  #7NON?^9SG_  E6E?\
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M#7__  D_%7_RFH_X2K2O^>&O_P#A)^*O_E-71T5_&^G;\?\ @'^4FO=?<_\
M,YS_ (2K2O\ GAK_ /X2?BK_ .4U'_"5:5_SPU__ ,)/Q5_\IJZ.BC3M^/\
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MBC3M^/\ P U[_A_P3F?^$JL?^@=XF_\ "4\1?_*VC_A*K'_H'>)O_"4\1?\
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M?_H">*O_  G-2_\ C-=511IV_'_@!KW_  _X)RO_  EEO_T!/%7_ (3FI?\
MQFC_ (2RW_Z GBK_ ,)S4O\ XS7544:=OQ_X :]_P_X)RO\ PEEO_P! 3Q5_
MX3FI?_&:/^$LM_\ H">*O_"<U+_XS7544:=OQ_X :]_P_P""<K_PEEO_ - 3
MQ5_X3FI?_&:_F6_X.4-7CU3P!^R.$L=6L_)\?_%,DZGIMUIXDW>%?#8Q$;A$
M$C#&65<D#D\5_4G7\P/_  <Q?\B!^R#_ -E ^*O_ *BGANON_#+_ )+G(/\
MK]B^O_4MQY^T?1YO_P 1CX)U_P"8K-.G_4@SKS/Y+:***_L0_P!40KH_!AQX
MV\#-@G;XX\&-A068[?$^E'"J.68XPJCEF( Y-<Y72>"_^1X\"_\ 8]>"_P#U
M*-)J*O\ "J_]>JW_ *9K&.)_W;$_]@V)_P#4;$G^H&?%=N#C^Q/%1^GAS4L?
M^B:3_A++?_H">*O_  G-2_\ C-=517\!Z=OQ_P" ?XF:]_P_X)RO_"66_P#T
M!/%7_A.:E_\ &:/^$LM_^@)XJ_\ "<U+_P",UU5%&G;\?^ &O?\ #_@G*_\
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M$XOVM[=O#WB&S63X72 W-Y;6"6T7_%0:&=TK1:E-(%[$K&Y'H:_SZZ_T-/\
M@KK_ ,HV?VN_^R6R?^I#H5?YY=?TUX)?\DYFW_8[?_JNPQ_H5]$/_D@^)O\
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MJK.I%1IR2VO>W:\D[+LELET2[ME)N4DWO9*_5VC:[[MZMON^UC]2O^$GN/\
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M:%#X@G\2+>:QJ7VPW>F^'-#U>73X5NY$O;+SC_@D[_RBR_X)I_\ 9@'[&_\
MZSK\.:^P_'_PO^'/Q5TRRT;XD^"/#/CG2M.U"/5;"P\3Z/9ZO;6>H112VXNK
M>.\BE$3R6T\]I<A<)=V5Q<6=TLUK/+"\24G;EERM-ZVO:].M&,K/27LZDZ-?
MDE[E7ZO[&;5.M-JXN*=Y+F6FG=*=*4HW^S[2G"K2YU[U/V_M8)SI03_,KPG^
MW#\=M2O/AW)K'PUOEO/C _@G7M'\&IX8ET<^%-*U77%MH/#>E^,?$6HZ3H'B
M]?'>@ZIX(N[;Q?)=VVG>%=7\77%A>QM=V":-#^FGA7X@Z;XU\$^#_'OAC2M;
MU70_&N@:9XCTQ(X=.MKZVL-6L8+^U74(+[4[1(K@1SB*1+>:Z59HY )&CV2.
MWQ-\*_AQXSBU*#Q5X*\.Z_#J^@:=X6U&+4]-@N8[CP]I.IOK6EZ2%=<06FGZ
MN_\ :=HMN(F@OHX+F-EEMK=HNST_3[#2+"RTK2K*UTW3--M+:PT[3[&"*ULK
M&QLX4M[2SM+6!4AM[:V@CCA@@B1(XHD6-%55 &TI4VIJ,'']XY4]?AI-U+0E
MOS.,/9+F6\_:2O;D1G:=XNZM[-*:LW>HE#WXM[)RY]&D^6---<TJC,7_ (2"
M^_Z%'Q-^?AW_ .:&C_A(+[_H4?$WY^'?_FAKIJ*CY?BQ_/\ !'PU^WW\,?B/
M^TA^QS\?O@=\-/!]X_COXD>!WT#PROB+5/#VBZ(=1.K:9>@:CJBZO>M90>1:
M3?O1:3G?L4(=V1_)3_PX3_X*/_\ 0C?"K_P[NB?_ "!7]W=%?:<-<>Y[PI@Z
M^!RJ.7NAB<3];J?6\(\1/VOL84/=G]8H\L.2G'W>5^]=WULOUOP_\:>,_#7*
M\;D_#<<DEA,?F']IUWF>5O'5OK/U6E@[4ZBQ^%4*7L:,/<Y)>_S2Y]>5?PB?
M\.$_^"C_ /T(WPJ_\.[HG_R!1_PX3_X*/_\ 0C?"K_P[NB?_ "!7]C?[66E^
M,M0^'OA&?P5K7C?3;W3/CA\ [W5]-\#QJ]SXB\,?\+C\$V_B;2]>:#2[_6$\
M,1:'/?ZEKIT>[TAS864HU2^;1?[1M9_G+X%6GQ&C_:-@EN[;XE0^)AJW[2[?
MM%W?B.+QHO@._P!!D^(=C_PS2OAFXUS_ (HRZ,7@SR1X03P*S7-CX:C\1P>)
M%AOWD63Z*'C+QA-S3CDT5!U$V\L;OR8>->\4L<KI\SC+K'W)6DYJ$?NI_2O\
M5(*/[OA.5XPEIP_)6YJU2ERM_P!KOWO<O!;3D^2\>5S?\N/_  X3_P""C_\
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MS_PD%]_T*/B;\_#O_P T-'_"07W_ $*/B;\_#O\ \T-=-14?+\6/Y_@CF?\
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M+^(;=9?V!?VQ8VN)SH/DP*_[/'Q%4S3>3KLTWE1 EY/*BEDV*=D;MA3^D%?
M'_!6+_E%E_P4L_[, _;(_P#6=?B-4_+\Q_/\@_X)._\ *++_ ()I_P#9@'[&
M_P#ZSK\.:^_Z^ /^"3O_ "BR_P"":?\ V8!^QO\ ^LZ_#FOO^D,**** "BBB
M@ HHHH **** "BBB@ HHHH *^;OVO?VA8OV4?V;/BU^T/-X2F\=1?"SP[!K[
M^$H-9C\/3:X)M8TS2?LB:U+INKQZ>5.HB?SGTV[!$)C\L%PZ_2->$?M.? #P
MS^U-\!OB5^S]XRUG7_#WACXGZ'#H.L:UX7?3HM?T^VAU33]56;3)-6L-4TY9
MS-IT49-U87,?E/(!&'VNO9ESP<<PP#S&,I9>L;A7CHP4W.6#6(I/%1BJ4HU'
M)X=55%4Y1G=KDDI6:]7(995#/,FEGL*E3)(YMELLYA259U9Y5'&X9YC"FL/.
MG7=26"6)C!4*D*SDXJE.-3EDORK_ &!?^"TUA^W-^T39? &W_9RU'X927G@C
MQ;XS_P"$JN?BA9>+(HU\+/HZ-IQT>#P1H$C-??VL"MT-0"V_V<@P2^8"GZ 6
M'[4?B+2?BM\0?!?Q'\%>#/#_ (#^'&F:6WB+XD>$?B#XB\;O8>,O%^MV%A\.
MOA?)X07X8:'J6J?$3Q=HU]%XAE\.>%[WQ#?:+;7GA^VFAO)/$^CR3?*'[&/_
M  1M^ W[$GQQM/CO\/?BA\8O%?B2T\(^)?!Z:/XUN_!4^A-8>)VTM[RZ9-#\
M'Z+J'VRW.E0?9B+X0 22^;#+\FSZQ\.?L4^"O#>E:CHD/Q3^-^JZ9>^,+WXD
M6L.M^*_#-_<Z1\2[OQBGCJ/XA6>JCP5#K%_XHL==0K:2^(M0US3&TASH=[IE
MYI,<%I#[7%E3AFIG,9\)T:U+)U@**E3Q$<4IRQSG.-=\N+K5*Z4*3C5IR]K[
M*=6-.FXQI^VE+[#Q/K>'=?B*,_#+#XS"\._V;E\94\9#,J=99E#Z]+'S2S7$
M8S$NG4?U"GI4]FH.O4HQ52*BX[7]NKX$KXI\3Z%K?B(:3I6FG3G\+:[:Z;XI
M\02^*[-?"EEXG\87ESH.B^&+K5?"47@#[:NG^*QXB2V.CS0W+ZL=,>UNH(-<
M?MM?LZZ>TMIX@^)&BQZFESJ@2+PMI7COQEILUG;:KXQL]+,&KZ3X+6UGU75=
M/\#>)-131[83W$BZ'KDFDR:QI>FMJTWF&I_L">$X_B!X>\0>$?&_C_PIH-YH
MWQ)M_BE=:9XPDA\8^.-6\=6'A73[BXGOI]"OK(VOB(:;XBU'Q@T:Z;>+K.H:
M?J'AJ727LXDM?3O#/[%'P0\'P_9?#MMXJTVQCU>VUBTL(O$<S6EA)9:5\5M%
MLK*S1[=I(].M=-^,?BZWBMWDD?$>BL\SOIN9_FOL)Z<_LY)Q5^5U8.23N[2C
M3J-KEJ-<[IJ\J,'O^=:<[2YN3GBU)\MU"5KZ)M2E"*DW!/E5224:LUHK9_;(
M^!]N/$D,_C/2=8U31;?Q)J]CI'@B#Q-XNN]2T#0M.O-4M)Y[BV\,V>G:9J^N
MVVG7\>D:9/>RVFJW5NUMHFK:M(LPA^@/ ?C'3/B'X(\(>/=%@U&UT?QIX9T/
MQ3I=MJ]C<:9JD%AKVFVVJ6D.H:?=)'/:7D<%TB7$$BY20,%9TVNWRGI_[ OP
M)TV\T:YMYO';0Z*UV\%C-XGBDBDDN])?19"M]_98UO3(9+&0IJ-EX?U;1]/\
M1!+>'Q5::[:V=G;P?6'@CPG8^ _!OA7P1IEYJ>H:9X0\.Z/X9TV]UF>WN=6N
M=/T/3[?3;*34;FUM;*WN+PVMM$)YXK2W660-(8U9C5/V=I\KDWS14+I+W$ZJ
M;DE?WI1]BWK9-3:MS<L97/>-U&W+)SM_,U2<5&_V8R]LN]G!._+S2ZBBBBH*
M"OS^_:0_;LM_V>_B9)\.9/AA=>+&C\/:/KW]KQ>+8-&0C5I+^,6OV*30-18&
M#[#N,WVG$GF@"--A+?H#7Q9\=OV'_AW\??'TGQ"\3>+/&^C:I)HFEZ$;+09M
M!CT\6VE27LD,P74-$O[GSY#?2"4FX,9")L1/FW5#EO[][6>U]^FUA2O;3?\
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MUQ4G:%=\LG!-S46Z,9RBFKNIRV=-<BH.49WJ04ZG*Q?MN_ /7K;1=1\%^/\
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M$+QMX!UCP3<_%2UT[]HOP39>#[G6;2U^)'C#X,>(_#F@"Y\ >)9-(M;ZQO\
MP5XI\675EH/BCPOK<L5W;W.J1Z3J^+OVWM+\*?M0M^SC<^ +J*QLM:^&OA_5
M_BCK&N7^D>%;+6?B?ITNH>'M*BGC\(ZGH8U:\9(=,TC2]9\4Z%>^(-8N(M-T
MJ*6XDMUGM:=^QMJ4WC3X8ZWXX^./BWXB>%_@[\0+SXF^ M'\2>&?#4OCBQ\1
MW,6NBUTC4OBULE\6ZEX%T:?Q-K*Z5X85+.X;21I/A_6=;UC2-+^S777?$O\
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M=?\ Z*J@#^OVBOY O^(U;_@EE_T0/]O_ /\ #6?LZ_\ T55'_$:M_P $LO\
MH@?[?_\ X:S]G7_Z*J@#^OVBOY O^(U;_@EE_P!$#_;_ /\ PUG[.O\ ]%51
M_P 1JW_!++_H@?[?_P#X:S]G7_Z*J@#^OVBOY O^(U;_ ()9?]$#_;__ /#6
M?LZ__154?\1JW_!++_H@?[?_ /X:S]G7_P"BJH _K]HK^0+_ (C5O^"67_1
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MK^0+_B-6_P""67_1 _V__P#PUG[.O_T55'_$:M_P2R_Z('^W_P#^&L_9U_\
MHJJ /Z_:*_D"_P"(U;_@EE_T0/\ ;_\ _#6?LZ__ $55'_$:M_P2R_Z('^W_
M /\ AK/V=?\ Z*J@#^OVBOY O^(U;_@EE_T0/]O_ /\ #6?LZ_\ T55'_$:M
M_P $LO\ H@?[?_\ X:S]G7_Z*J@#^OVBOY O^(U;_@EE_P!$#_;_ /\ PUG[
M.O\ ]%51_P 1JW_!++_H@?[?_P#X:S]G7_Z*J@#^OVO@#_@K%_RBR_X*6?\
M9@'[9'_K.OQ&K\ ?^(U;_@EE_P!$#_;_ /\ PUG[.O\ ]%57R3^WC_P=T?L"
M?M-_L;?M0_LT_!WX$_M@V'CO]HG]GWXS? O1-:^)?@?X+:'X2T&^^+/PX\2>
F [35]5N/"_[0/B[6'M+.YUZ.6Y:TTFXFM8%>[BM-3D@73;H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "6 .$# 2(  A$! Q$!_\0
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M?V-1F9<9+  CVZ9QV[].G./:HS=1K_&,#ONQV'\ACZ=Z )6C X('/H<_S_\
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M_P R>;RC]R/IRQT]E9-L;*0%S@'[P4!E 4E<,5Y4?>#'DC@=;9V3K][=E?F
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MI%.#:RP2'6,DTGW^?G_2Z=2XRYO7MKI\^I]'A,C("_E_]:H'B!!X.?< ]_\
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M'Z4RBFX[_GR!_P#7S]/2JDB<<<C/3C^?Y]NV*ON1SC &#CH.U4W'0_A_G]:
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M4++48+FPO;&YM(;ZUN[*='6.YMKZUEBN;::%ECE@8HA\N0[OO#]AK]JR&_\
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M3WZ9^F/U[4 5F7'0<=>GKVS_ "^M0OC_ &NG;IWQFK3=,^A!_456;[I_#^=
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M>0 ].F!QP.?_ -=%% %62X(Q@8SD<<=L^OM[TV-RY.>,#IV_S^OO110!="@
M<#C^?K3&7 SGIUS]?\]:** (7.!]>/T-5V;!QBBB@"-FW>V*B<< ^^/S_P#U
L445,FTKKN!"PX)Y^Z1CM_P#KJJ_3\_T!/\L_CBBBLW)OK]V@$5%%%2!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= ),# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^U--)'\2
MY/(('W2000!@YS@XY'//(P%_LA-WW=PZC=D-P<@%B&(Z=",=#7:_8_8?-A<C
M(. ,D<<\9.?7MBE%G[<'(Y!SU([CT'(]">ISD XE=''4J"IS@87/)W'CD$9
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M_!'B:_OKC0]35XL13>*/&,UO>W8:.UGMM9T^RMA'.5KZ-U/69_BO_P %_?\
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M;Z&!)O,DNH0O]=$@R.O&"/S]/\]J_@._X/$OB3<ZG\?_ -C;X/P74DMKX/\
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MG:_^0+1/LTU]]ONO;3YG]'ZKT'H!V[9 Z>PJ49P,DCGID\^Q_$?T],-'/!(
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MH*0#<5P'8,[NXP#'M1MPWXHY7V=_5?ENQ\[^7E;\F_0_1/\ X)(?"N3XN_\
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MXXZ8]>GY=:3CG.<]O_K_ $IP4YXV\9'7DCZ G'I_]?!H(/3Y>.>/PZCWXYX
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MESP!G@9Q]>?U_P ^M1@'N./^^3^GU[FG $$CMU')SGOG/K[?UH <#C_]>/\
M/Z4$Y_S[?Y/XTE ^G/'7&/QSQ_GO0 X. ,;@/8D#_P!E/\_\**;10!8H/^?\
MX/\ *BB@!A!SGID8/3CD9Y&.@[]?YAC') !R!^'^ _+ J4C(Q_3/Z&F8!/N?
M<GCH<-G!ZYQST(Q0!$1D$?YX]ZK21@@DX'!'/)(Q_+\,]*ND#!V\X/)[X^F.
M![]>O:HR >M &2UNK$C (&&)(SD=QSC'X?UJN;)"20 /?&,G''OWSG/![UNE
M%/M]*:8@>Y_S^7Y&@#E[W2;7487M=2M+75+9U97M-2MH-0MG5A\RM;WD<T+*
MV>04(QP<C@Y.B^ O!^A3S7&B^%]$T::Y.ZX_LK3[?3HY6P 6:VLDAM@Q"C<4
MB4D!=Q(Z][Y*#U)SW/O_ (4Y4"G([GT_SS[_ %XYJ7"#:?)"ZV?+&Z^=F^_7
MJQW=K7=NUW;[KV_ @BM88U 2-4QV"C&?5?3\.,]JLJD77 ZX^7!Z?IU[4FT]
M.H.<YYX'IC ^OI3BF5],_3 &0..0>W?U]!5"#:GI_P".C_&G!4P/4=O7)!P!
M^'!'?DXXI0!D@8X'&>1Z'/<_YQQ4@ '0?Y_G0 S9_G/09^G/'<_E2A2#D'].
MV1QUST__ %BGT4 19 )..<GD>O?&>GX@]>U&T'OC..,=R!TYSW_SBI>E% $9
MVY.0,]^6_H**<0V>,?FP_D<44 .HHHH /\_G[_A2$ _AZ'V/'Z_K[FEI,#GT
M/7_'ZT -..".<')QR>P('7VXR,<4W9UQSZ8/O[_X\8J3'Y?K^G3M0,<@=OZT
M ,VXSU;\."?S(R#G)/Y4FWUZ8X/;.>/7@]<\5)C.<\\]!T_^N?7/0]*.@XR3
MCKUY[?YZ?2@",!>>O;'.".>2>GX8R/6E'0G@\\ G/&/0?Q'OZG/%+SGW(ST'
M ]SWZ8_7TIV/4>I(///MV]?3\.: &8P <' SD'MGKU'(]/UI<#!V@@^ASV[8
MY!]NO6EQC).,8YP,#C/U]:=^'_U_>@!H&,9Z\GC&/P'';J<>V:=1]** "BBB
M@ HHHH 0J,__ %A_4$_YXXHI:* "BBB@ HHHH **** "BD()Z''X9I: $.3P
M,CU..@YZ>_\ 3FE^M-W?/LQ_ 6SGN&P>,=\COVIU "=>YQCI@CGUSP:6BF[O
IFVX_'\,T .HHI <Y]O\ $C^E "YSTHHI!R ?4?SH 6BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>21
<FILENAME>aytu-20180630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aytu%2D20180630.xfr; Date: 2018%2D09%2D06T20:07:56Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:aytu="http://aytubio.com/20180630">
    <link:schemaRef xlink:href="aytu-20180630.xsd" xlink:type="simple" />
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-01</xbrli:startDate>
        <xbrli:endDate>2017-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2017-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Oct_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember_StatementBusinessSegmentsAxis_AytuBioscienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:AwhAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:AytuCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:AwhAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-05-01</xbrli:startDate>
        <xbrli:endDate>2015-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jul_2015T00_00_00_TO_30_Jun_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DiscountedCashFlowMethodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:DiscountedCashFlowMethodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_BusinessCombinationSeparatelyRecognizedTransactionsAxis_ThirdUpfrontMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">aytu:ThirdUpfrontMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FirstMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FirstMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_SecondMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:SecondMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ThirdMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ThirdMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ForthMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:ForthMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FifthMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:FifthMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_StatementEquityComponentsAxis_AytuCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aytu:AytuCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Oct_2017T00_00_00_TO_31_Dec_2017T00_00_00_BusinessAcquisitionAxis_AytuMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:AytuMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">aytu:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:LuoxisPatentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">aytu:LuoxisPatentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember_SubsidiarySaleOfStockAxis_NoteWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:AytuCommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:PrescriptionDatabaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_03_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-06-03</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-09-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:PrescriptionDatabaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-05-01</xbrli:startDate>
        <xbrli:endDate>2016-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2017-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">aytu:ExecutiveOfficerOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_GreenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">aytu:GreenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-01</xbrli:startDate>
        <xbrli:endDate>2017-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_01_Jun_2015T00_00_00_TO_01_Jun_2015T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_05_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-09-05</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_02_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-02</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_02_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember_TitleOfIndividualAxis_ExecutiveOfficerDirectorAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">aytu:ExecutiveOfficerDirectorAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-02</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_04_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-04</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_02_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:SponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-02</xbrli:startDate>
        <xbrli:endDate>2015-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AgreementAxis_ServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:ServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:SponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-03-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:SponsoredResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-04-28_custom_NatestoMember_custom_CADMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">aytu:CADMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-01to2018-08-10_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-01</xbrli:startDate>
        <xbrli:endDate>2018-08-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_custom_JazzPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:JazzPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember_us-gaap_CustomerContractsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ProstascintBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_SalesRevenueNetMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_SalesRevenueNetMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_OtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:OtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_PrimsolBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-31_custom_PrimsolBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-03-01to2017-03-31_custom_PrimsolBusinessMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:PrimsolBusinessMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-03-01</xbrli:startDate>
        <xbrli:endDate>2017-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-04-01to2016-04-30_custom_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-04-01</xbrli:startDate>
        <xbrli:endDate>2016-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_NatestoMember_custom_LicenseAndSupplyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NatestoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aytu:LicenseAndSupplyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_NuelleIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:NuelleIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ContingentConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_custom_ContingentConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aytu:ContingentConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-27to2018-03-06_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-27</xbrli:startDate>
        <xbrli:endDate>2018-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_SupplyOrderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:SupplyOrderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30_custom_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-09-30_custom_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-31_custom_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_OfficeLeaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:OfficeLeaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-04-30_custom_NatestoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:NatestoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_SupplyOrderMember_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">aytu:SupplyOrderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-07-31_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LincolnParkCapitalFundLlcPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LincolnParkCapitalFundLlcPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-01to2016-11-30_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-01</xbrli:startDate>
        <xbrli:endDate>2016-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-01to2016-11-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-01</xbrli:startDate>
        <xbrli:endDate>2016-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-01to2016-11-30_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-01</xbrli:startDate>
        <xbrli:endDate>2016-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-30_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-02-28_custom_MayTwoZeroOneSixWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:MayTwoZeroOneSixWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-02-03to2017-02-28_custom_OctoberTwoZeroOneSixWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:OctoberTwoZeroOneSixWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-02-03</xbrli:startDate>
        <xbrli:endDate>2017-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-02-28_custom_OctoberTwoZeroOneSixWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:OctoberTwoZeroOneSixWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_ExercisePriceRangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_ExercisePriceRangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">aytu:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_ServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:AgreementAxis">aytu:ServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_AytuBioscienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_AytuWomensHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_AytuBioscienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_AytuWomensHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuWomensHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-02to2018-07-31_us-gaap_SubsequentEventMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-02</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-04to2018-01-31_custom_TwoThousandFifteenPlanMember_us-gaap_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-04</xbrli:startDate>
        <xbrli:endDate>2018-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_custom_TwoThousandFifteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aytu:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_custom_AytuBioscienceIncMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_WarrantMember110589561">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:NovemberTwoThousandSixTeenPublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aytu:NovemberTwoThousandSixTeenPublicOfferingOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-05-01to2016-05-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-05-01</xbrli:startDate>
        <xbrli:endDate>2016-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-10-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-02-03to2017-02-28_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-02-03</xbrli:startDate>
        <xbrli:endDate>2017-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_WarrantMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-03to2018-05-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-03</xbrli:startDate>
        <xbrli:endDate>2018-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_srt_ParentCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_srt_ParentCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerMember183079934">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_CustomerMember_us-gaap_SalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">aytu:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_ConvertibleAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:ConvertibleAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_custom_ConvertibleBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">aytu:ConvertibleBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2016-07-31_custom_ExecutiveOfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">aytu:ExecutiveOfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2016-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_ExecutiveOfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">aytu:ExecutiveOfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_custom_ExecutiveOfficersAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">aytu:ExecutiveOfficersAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2016-08-31_us-gaap_ExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2016-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-05-01to2017-05-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-05-01</xbrli:startDate>
        <xbrli:endDate>2017-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-10-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-01to2018-02-28_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-01</xbrli:startDate>
        <xbrli:endDate>2018-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_AytuBioscienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_custom_AytuBioscienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aytu:AytuBioscienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_us-gaap_WarrantMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-03-01to2018-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-03-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2016-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aytu:LincolnParkCapitalFundLlcPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_custom_CounterpartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:CounterpartiesAxis">aytu:CounterpartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-01to2017-06-30_custom_CounterpartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="aytu:CounterpartiesAxis">aytu:CounterpartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-01-31_custom_AmpioPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">aytu:AmpioPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-07-31_us-gaap_SubsequentEventMember_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-31_us-gaap_SubsequentEventMember_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-11_custom_ZolpiMistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aytu:ZolpiMistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-01to2017-12-22_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-01</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-01to2017-12-22_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-01</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-02to2018-07-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-02</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USD_per_Share">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segments">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>aytu:Segments</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>aytu:Segment</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Customers">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>aytu:Customers</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>aytu:Number</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">AYTU BIOSCIENCE, INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">0001385818</dei:EntityCentralIndexKey>
    <dei:TradingSymbol contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">AYTU</dei:TradingSymbol>
    <dei:AmendmentFlag contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">2018-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityFilerCategory contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">271278</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">245944</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">246000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">7912000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">3208000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">41244</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1794762</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">38738</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3660120</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">100000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" decimals="0">243000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">3221590</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-07-01to2017-06-30_custom_AytuBioscienceIncMember" unitRef="USD" decimals="0">3175000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2016-07-01to2017-06-30_custom_AytuWomensHealthMember" unitRef="USD" decimals="0">47000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2017-07-01to2018-06-30_custom_AytuBioscienceIncMember" unitRef="USD" decimals="0">3417000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-10187863</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" decimals="0">-2405000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-10187863</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-22508304</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-22508304</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30_custom_AytuBioscienceIncMember" unitRef="USD" decimals="0">-22349000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-07-01to2017-06-30_custom_AytuWomensHealthMember" unitRef="USD" decimals="0">-159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-07-01to2018-06-30_custom_AytuBioscienceIncMember" unitRef="USD" decimals="0">-7783000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">394839</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">-274</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">37500</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2018-03-01to2018-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">161</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2017-10-01to2017-10-31_us-gaap_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">18</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2018-02-01to2018-02-28_us-gaap_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">95</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-4633</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-4633</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-64690</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-64690</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantAmendments>
    <us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">348515</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Oct_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="USD" decimals="0">36000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">74000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">14000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">2502092</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-03-31_custom_AytuBioscienceIncMember_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">37000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">10500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2018-06-11" unitRef="USD" decimals="0">3200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember" unitRef="USD" decimals="0">1940000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">4694000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="AsOf2016-06-30_custom_ContingentConsiderationMember" unitRef="USD" decimals="0">3869000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">-266000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember" unitRef="USD" decimals="0">-250000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">6900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">801000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember" unitRef="USD" decimals="0">64000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">2500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh contextRef="From2016-07-01to2017-06-30_custom_ContingentConsiderationMember" unitRef="USD" decimals="0">306000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">677000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="From2016-07-01to2017-06-30_custom_NatestoMember_custom_LicenseAndSupplyAgreementMember" unitRef="USD" decimals="0">1100000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity contextRef="From2018-02-27to2018-03-06_us-gaap_IPOMember" unitRef="USD" decimals="0">12000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity>
    <aytu:RevenueEarnOutPayment contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">12000</aytu:RevenueEarnOutPayment>
    <aytu:RevenueEarnOutPayment contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_StatementEquityComponentsAxis_AytuCommonStockMember" unitRef="USD" decimals="0">1000000</aytu:RevenueEarnOutPayment>
    <aytu:RevenueEarnOutPayment contextRef="Context_3ME_01_Oct_2017T00_00_00_TO_31_Dec_2017T00_00_00_BusinessAcquisitionAxis_AytuMember" unitRef="USD" decimals="0">1000000</aytu:RevenueEarnOutPayment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="USD" decimals="0">405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="USD" decimals="0">111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">287000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember" unitRef="USD" decimals="0">90000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="USD" decimals="0">213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="USD" decimals="0">112000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">344000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentMember" unitRef="USD" decimals="0">90000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:DepreciationAndAmortization contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">294000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">134000</us-gaap:DepreciationAndAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">109000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">134000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2017-10-01to2017-12-31_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">6600000</us-gaap:IncomeTaxExpenseBenefit>
    <aytu:PreferredStockConversionPricePerShare contextRef="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">60.00</aytu:PreferredStockConversionPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="shares" decimals="INF">4167</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerOneMember" unitRef="shares" decimals="INF">4167</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-09-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="shares" decimals="INF">500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-11-01to2016-11-30_us-gaap_IPOMember" unitRef="shares" decimals="INF">14338</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <aytu:SecuritiesPurchaseAgreementCashFeePercentage contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="INF">0.09</aytu:SecuritiesPurchaseAgreementCashFeePercentage>
    <aytu:ClassOfWarrantOrRightPercentageOfSharesToBeIssued contextRef="Context_As_Of_11_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="INF">0.10</aytu:ClassOfWarrantOrRightPercentageOfSharesToBeIssued>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">80750</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">315755</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">315755</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="From2017-02-03to2017-02-28_custom_OctoberTwoZeroOneSixWarrantsMember" unitRef="shares" decimals="INF">7477</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember110589561" unitRef="shares" decimals="INF">221</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingMember" unitRef="shares" decimals="INF">1009</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingOneMember" unitRef="shares" decimals="INF">15051</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="From2018-03-01to2018-03-31_custom_AytuBioscienceIncMember" unitRef="shares" decimals="INF">75000</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsToPurchaseOfCommonStockShares contextRef="From2018-03-01to2018-03-31_us-gaap_WarrantMember_us-gaap_IPOMember" unitRef="shares" decimals="INF">1533356</aytu:WarrantsToPurchaseOfCommonStockShares>
    <aytu:WarrantsIssuedToUnderwritersAsCompensationForTransaction contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">19749</aytu:WarrantsIssuedToUnderwritersAsCompensationForTransaction>
    <us-gaap:SharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">151</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">2961055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">1197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-11-01to2016-11-30_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF">2151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EquityFairValueDisclosure contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">179000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure contextRef="AsOf2016-11-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">293000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure contextRef="AsOf2016-11-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4400000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure contextRef="AsOf2016-11-30" unitRef="USD" decimals="0">4200000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:EquityFairValueDisclosure contextRef="AsOf2016-11-30_us-gaap_OverAllotmentOptionMember" unitRef="USD" decimals="0">208000</us-gaap:EquityFairValueDisclosure>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Contingent Consideration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; font-size: 10pt"&gt;Balance as of June 30, 2016&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,869,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to purchase of assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,927,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to accretion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;306,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to remeasurement&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,256,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(710,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to purchase of assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,846,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to accretion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;801,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to contractual payment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(266,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(6,335,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Balance as of June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;4,694,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Contingent Consideration&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; font-size: 10pt"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;1,940,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to accretion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;64,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to contractual payment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(250,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(1,754,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Balance as of June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; white-space: nowrap; font-size: 10pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;173.40% - 188.00%&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;156.64% - 169.22%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; white-space: nowrap; font-size: 10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;1.83% - 2.69%&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;1.63% - 1.87%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; white-space: nowrap; font-size: 10pt"&gt;Contractual term (years)&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;4.13 - 5&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;3.46 - 4.67&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; white-space: nowrap; font-size: 10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt"&gt;0%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30, &lt;br /&gt;&#13;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;At Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;Warrants:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-indent: 20pt; font-size: 10pt"&gt;Volatility&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;173.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;188.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: 20pt; font-size: 10pt"&gt;Equivalent term (years)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: 20pt; font-size: 10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2.69&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1.83&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: 20pt; font-size: 10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended&amp;#160; June&amp;#160;30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 84%; text-align: left; font-size: 10pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: center; font-size: 10pt"&gt;178% - 185%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;0.97% - 1.88%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Expected term (years)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;5.0 - 6.5&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;0%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="AsOf2018-06-11" unitRef="USD" decimals="0">3200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">464000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">464000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">464000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">464000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1319000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">464000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="USD" decimals="0">121000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1317000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">888000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">297000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">2000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_BusinessCombinationSeparatelyRecognizedTransactionsAxis_ThirdUpfrontMember" unitRef="USD" decimals="0">4000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="From2016-04-01to2016-04-30_custom_NatestoMember" unitRef="USD" decimals="0">2000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="From2018-07-01to2018-07-31_us-gaap_SubsequentEventMember_custom_ZolpiMistMember" unitRef="USD" decimals="0">400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">1900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">2846000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">664000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="Context_FYE_01_Jul_2015T00_00_00_TO_30_Jun_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">3200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="From2017-07-01to2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">3200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1 contextRef="From2016-07-01to2017-06-30_custom_ContingentConsiderationMember" unitRef="USD" decimals="0">1927000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <aytu:BusinessCombinationContingentConsiderationRevalued contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember_FiniteLivedIntangibleAssetsByMajorClassAxis_DiscountedCashFlowMethodMember" unitRef="USD" decimals="0">54000</aytu:BusinessCombinationContingentConsiderationRevalued>
    <aytu:BusinessCombinationContingentConsiderationRevalued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">0</aytu:BusinessCombinationContingentConsiderationRevalued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_JazzPharmaceuticalsIncMember" unitRef="USD" decimals="0">9000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="From2018-01-01to2018-03-31_custom_JazzPharmaceuticalsIncMember" unitRef="USD" decimals="0">7400</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;239,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;442,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Work in process&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;442,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,100,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;738,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;Reserve&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(310,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,339,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,312,000&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Principals of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;These consolidated financial statements&#13;include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&amp;#8217;s Health. All material intercompany transactions&#13;and balances have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents and Restricted Cash &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu considers all highly liquid instruments purchased with&#13;an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a certificate of deposit&#13;investment account. Aytu&amp;#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors&#13;its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year,&#13;and as of June 30, 2018, Aytu has maintained balances in excess of federally insured limits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Product&amp;#160;&amp;#38; Service Sales&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The Company recognizes revenue only when&#13;all of the following criteria have been met:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -0.2in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;Persuasive evidence&#13;of an arrangement exists,&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;Delivery has occurred,&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;The fee for the arrangement&#13;is fixed or determinable, and&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;Collectability is&#13;reasonably assured.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Persuasive evidence of an arrangement exists&#13;- The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue. Certain&#13;contracts allow for revenue recognition at the time of shipment and others at the time of delivery.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Delivery has occurred - The Company recognizes&#13;revenue when delivery of certain products occurs at the customers&amp;#8217; designated location.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Device sales are typically recorded when&#13;products are shipped to customers. Drug sales are typically recorded when the product arrives at the customer&amp;#8217;s dock. Provisions&#13;for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period&#13;the related sales are recorded and are estimated at the time of sale.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The fee for the arrangement is fixed or&#13;determinable - Prior to recognizing revenue, a customer&amp;#8217;s fee is either fixed or determinable under the terms of the written contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Collectability is reasonably assured -&#13;The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a&#13;customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which&#13;evaluates the customer&amp;#8217;s financial position and ultimately its ability to pay. The Company does not enter into arrangements unless&#13;collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment&#13;history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is&#13;recognized on a cash basis.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueRecognitionSalesReturns contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Estimated Sales Returns and Allowances &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu records estimated reductions in revenue for potential returns&#13;of products by customers. As a result, management must make estimates of potential future product returns and other allowances&#13;related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends&#13;and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different&#13;estimates, material differences in the amount of the Company&amp;#8217;s reported revenue could result. As of June 30, 2018, and 2017,&#13;we accrued $17,000 and $58,000, respectively, in our estimated returns allowance. Estimates of potential returns and allowances&#13;are trued up each quarter for the difference between estimates made in the prior quarter and actual results that become available&#13;after the end of each reporting period.&lt;/p&gt;</us-gaap:RevenueRecognitionSalesReturns>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Shipping and Handling&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The Company&amp;#8217;s shipping and handling costs&#13;are included in cost of goods sold for all periods presented.&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Inventories &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventories consist of raw materials, work in process and finished&#13;goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu&#13;periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items.&#13;If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable&#13;value in the period that the impairment is first recognized. Inventory for our abandoned products was written down during fiscal&#13;2018. Therefore, we currently have a reserve of $0 for slow moving inventory as of June 30, 2018 and $310,000 at June 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventory balances consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;239,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;442,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Work in process&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;442,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,100,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;738,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;Reserve&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(310,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,339,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,312,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fixed Assets &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fixed assets are recorded at cost. After being placed in service,&#13;the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;in years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; text-align: left; font-size: 10pt"&gt;Manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; font-size: 10pt"&gt;2 - 5&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;213,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;405,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;112,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Office equipment, furniture and other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;2 - 5&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Lab equipment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;3 - 5&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(540,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(246,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;219,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;647,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu recorded the following depreciation and amortization expense&#13;in the respective periods:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Depreciation and amortization expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;294,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;134,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Patents &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Costs of establishing patents, consisting of legal and filing&#13;fees paid to third parties, are expensed as incurred. The cost of the Luoxis patents were $380,000 when they were acquired in connection&#13;with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which&#13;expires in March 2028. Patents consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(134,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(109,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Patents, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;271,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu recorded the following amortization expense in the respective&#13;periods:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;26,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Future amortization from the year ended June 30, 2018 is as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;121,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:BusinessCombinationsPolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Business Combinations &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for its business acquisitions under the&#13;acquisition method of accounting as indicated in the Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;) Accounting&#13;Standards Codification (&amp;#8220;ASC&amp;#8221;) 805, &amp;#8220;Business Combinations&amp;#8221;, which requires the acquiring entity in a business&#13;combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired&#13;business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets&#13;acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest&#13;in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes&#13;and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value&#13;of the identified net assets acquired.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Goodwill &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Nuelle, ProstaScint and Primsol&amp;#160;purchase price allocations&#13;were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted&#13;up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities&#13;acquired required the use of estimates by management, and were based upon currently available data, as noted below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company allocated the excess of purchase price over the&#13;identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the&#13;value placed on entering new markets and expanding market share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company tests its goodwill for impairment annually, or whenever&#13;events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair&#13;value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market&#13;conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that&#13;an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating&#13;expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company&#13;must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets.&#13;Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to&#13;the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&amp;#160;20, 2015,&#13;Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $74,000 related to&#13;the ProstaScint goodwill for the year ended June 30, 2017. There was an impairment of $238,000 related to the Fiera goodwill during&#13;the year ended June 30, 2018.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of financial statements in accordance with Generally&#13;Accepted Accounting Principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of&#13;the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject&#13;to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation,&#13;valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable,&#13;and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu accounts for share-based payments by recognizing compensation&#13;expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair&#13;value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the&#13;graded method. Forfeitures are adjusted for as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <aytu:RestrictedStocksPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company is recognizing compensation cost equal to the fair&#13;value of the stock at the grant dates prorated over the vesting period of each award.&lt;/p&gt;</aytu:RestrictedStocksPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and development costs are expensed as incurred with&#13;expenses recorded in the respective period.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments and Derivative Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of financial instruments, including cash&#13;and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate&#13;their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated&#13;discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable&#13;securities was based on quoted market prices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu accounts for liability warrants by recording the fair value&#13;of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial&#13;instruments and related warrants were calculated using a lattice valuation model. We recorded a derivative expense at the inception&#13;of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods&#13;was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income&#13;or expense for the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;The fair value of the&#13;warrants issued to the placement agents in connection with the registered offering were valued using the lattice valuation methodology.&#13;Changes in the fair value in subsequent periods were recorded to derivative income or expense.&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_us-gaap_SalesRevenueNetMember_custom_CustomerCMember" unitRef="pure" decimals="INF">0.3</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_us-gaap_SalesRevenueNetMember_custom_CustomerCMember" unitRef="pure" decimals="INF">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember" unitRef="pure" decimals="INF">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_custom_CustomerOneMember_us-gaap_AccountsReceivableMember" unitRef="pure" decimals="INF">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerTwoMember" unitRef="pure" decimals="INF">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerTwoMember" unitRef="pure" decimals="INF">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerCMember" unitRef="pure" decimals="INF">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_OtherMember" unitRef="pure" decimals="INF">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_OtherMember" unitRef="pure" decimals="INF">0.00</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerMember" unitRef="pure" decimals="INF">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerMember183079934" unitRef="pure" decimals="INF">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_custom_CustomerMember_us-gaap_SalesRevenueNetMember" unitRef="pure" decimals="INF">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerCMember" unitRef="pure" decimals="INF">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2017-07-01to2018-06-30_custom_CounterpartiesMember" unitRef="pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-07-01to2017-06-30_custom_CounterpartiesMember" unitRef="pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryRawMaterials contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">442000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">239000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">442000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">738000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1100000</us-gaap:InventoryFinishedGoods>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2018-08-31" unitRef="shares" decimals="INF">1801411</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">Yes</dei:EntityCurrentReportingStatus>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;1,317,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;7,912,000&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;121,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2017-07-01to2018-06-30_custom_ZolpiMistMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;888,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,208,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2017-07-01to2018-06-30_custom_ZolpiMistMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;&amp;#160;Intangible assets&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,200,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;Total assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,200,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1553705</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="USD" decimals="0">61000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_PrimsolBusinessMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">110000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-07-01to2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">39000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember_us-gaap_TradeNamesMember" unitRef="USD" decimals="0">7000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember_us-gaap_DevelopedTechnologyRightsMember" unitRef="USD" decimals="0">54000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember_us-gaap_CustomerContractsMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_custom_ProstascintBusinessMember" unitRef="USD" decimals="0">159000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_custom_PrimsolBusinessMember" unitRef="USD" decimals="0">184000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1708771</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_custom_NuelleIncMember" unitRef="USD" decimals="0">22000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-07-01to2018-06-30_srt_ParentCompanyMember" unitRef="USD" decimals="0">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-07-01to2017-06-30_srt_ParentCompanyMember" unitRef="USD" decimals="0">25000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Cash contextRef="AsOf2017-03-31_custom_PrimsolBusinessMember" unitRef="USD" decimals="0">1750000</us-gaap:Cash>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">62000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="From2017-03-01to2017-03-31_custom_PrimsolBusinessMember" unitRef="USD" decimals="0">428000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="shares" decimals="INF">6250</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">159834</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="shares" decimals="INF">12245411</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="From2017-05-01to2017-05-05" unitRef="shares" decimals="INF">6250</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">2000000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="AsOf2016-04-28_custom_NatestoMember_custom_CADMember" unitRef="USD" decimals="0">2500000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessAcquisitionSharePrice contextRef="Context_As_Of_28_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD_per_Share" decimals="INF">0.16</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice contextRef="AsOf2016-04-28_custom_NatestoMember_custom_CADMember" unitRef="USD_per_Share" decimals="INF">0.207</us-gaap:BusinessAcquisitionSharePrice>
    <aytu:CostOfSaleForInvestment contextRef="From2016-07-01to2017-06-30_custom_NatestoMember_custom_LicenseAndSupplyAgreementMember" unitRef="USD" decimals="0">92000</aytu:CostOfSaleForInvestment>
    <us-gaap:RevenueRecognitionMilestoneMethodDescription contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember">One-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million.</us-gaap:RevenueRecognitionMilestoneMethodDescription>
    <aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FirstMilestoneMember" unitRef="USD" decimals="0">2500000</aytu:OneTimeNonRefundablePayments>
    <aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_SecondMilestoneMember" unitRef="USD" decimals="0">5000000</aytu:OneTimeNonRefundablePayments>
    <aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ThirdMilestoneMember" unitRef="USD" decimals="0">7500000</aytu:OneTimeNonRefundablePayments>
    <aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ForthMilestoneMember" unitRef="USD" decimals="0">10000000</aytu:OneTimeNonRefundablePayments>
    <aytu:OneTimeNonRefundablePayments contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FifthMilestoneMember" unitRef="USD" decimals="0">12500000</aytu:OneTimeNonRefundablePayments>
    <aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FirstMilestoneMember" unitRef="USD" decimals="0">25000000</aytu:SalesRevenueTarget>
    <aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_SecondMilestoneMember" unitRef="USD" decimals="0">50000000</aytu:SalesRevenueTarget>
    <aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ThirdMilestoneMember" unitRef="USD" decimals="0">75000000</aytu:SalesRevenueTarget>
    <aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_ForthMilestoneMember" unitRef="USD" decimals="0">100000000</aytu:SalesRevenueTarget>
    <aytu:SalesRevenueTarget contextRef="Context_Custom_01_Apr_2016T00_00_00_TO_28_Apr_2016T00_00_00_BusinessAcquisitionAxis_NatestoMember_RelatedPartyTransactionAxis_LicenseAndSupplyAgreementMember_TypeOfArrangementAxis_FifthMilestoneMember" unitRef="USD" decimals="0">125000000</aytu:SalesRevenueTarget>
    <us-gaap:AccretionExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">694000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NuelleIncMember" unitRef="USD" decimals="0">64000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="Context_FYE_01_Jul_2016T00_00_00_TO_30_Jun_2017T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">228000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="From2017-07-01to2018-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">23000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="From2016-07-01to2017-06-30_custom_ZolpiMistMember" unitRef="USD" decimals="0">0</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense contextRef="From2016-07-01to2017-06-30_custom_NuelleIncMember" unitRef="USD" decimals="0">12000</us-gaap:AccretionExpense>
    <aytu:PercentageofNetSalesDescriptions contextRef="From2017-07-01to2018-06-30_custom_ZolpiMistMember">Twenty percent (20%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2020,  Fifteen percent (15%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2022, Ten percent (10%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2025.</aytu:PercentageofNetSalesDescriptions>
    <aytu:SubsidiariesPaymentDescription contextRef="Context_Custom_01_May_2017T00_00_00_TO_31_May_2017T00_00_00_BusinessAcquisitionAxis_NuelleIncMember">The first $1.0 million of revenue earn-out payments was paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.</aytu:SubsidiariesPaymentDescription>
    <us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">528039</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">578782</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1312221</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1338973</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">310760</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">440009</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3028562</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">9470291</us-gaap:AssetsCurrent>
    <aytu:CoreAndDevelopedTechnologyNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1337333</aytu:CoreAndDevelopedTechnologyNet>
    <aytu:CoreAndDevelopedTechnologyNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IndefiniteLivedContractualRights contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">77667</us-gaap:IndefiniteLivedContractualRights>
    <us-gaap:IndefiniteLivedContractualRights contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IndefiniteLivedTradeNames contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">164037</us-gaap:IndefiniteLivedTradeNames>
    <us-gaap:IndefiniteLivedTradeNames contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">9231072</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">11120086</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Goodwill contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">238426</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">2888</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">5088</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">11969955</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">11589802</us-gaap:AssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">2220400</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2119672</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">782536</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">185882</us-gaap:AccruedLiabilitiesCurrent>
    <aytu:AccruedCompensationCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">339704</aytu:AccruedCompensationCurrent>
    <aytu:AccruedCompensationCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">540674</aytu:AccruedCompensationCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">6673</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1450</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">261155</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">547100</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3610468</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3394778</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1451</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">10998701</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7635588</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">4</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">179</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">73069541</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">92681918</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2018-07-31_us-gaap_SubsequentEventMember_custom_ZolpiMistMember" unitRef="USD" decimals="0">300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2018-06-11_custom_ZolpiMistMember" unitRef="USD" decimals="0">2600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">-69069729</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-79257592</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3999816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">13424505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">4</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">73069541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-69069729</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">179</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">92681918</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-79257592</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="USD" decimals="0">10085253</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2016-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">56646677</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-46561425</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">14998517</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">21060093</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" xsi:nil="true" />
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">41244</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1794762</us-gaap:CommonStockSharesIssued>
    <us-gaap:CostOfRevenue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2050544</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1417355</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">167595</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">959857</us-gaap:ResearchAndDevelopmentExpense>
    <aytu:ResearchAndDevelopmentRelatedParty contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:ResearchAndDevelopmentRelatedParty contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">387960</aytu:ResearchAndDevelopmentRelatedParty>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">17732490</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">17442627</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-07-01to2017-06-30_custom_ExecutiveOfficersAndDirectorsMember" unitRef="USD" decimals="0">725000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CostsAndExpensesRelatedParty contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">165131</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1856020</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1265125</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">23360354</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">23346826</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-19700234</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-20125236</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">749423</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">2534358</us-gaap:InterestExpense>
    <us-gaap:GainLossOnInvestments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnInvestments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-61519</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncome contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">6277873</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">9512371</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-2383068</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">665605</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-07-01to2017-06-30" unitRef="shares" decimals="INF">466024</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">-15.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-07-01to2017-06-30" unitRef="USD_per_Share" decimals="INF">-48.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">41244</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1794762</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2016-06-30_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2016-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">9355</us-gaap:SharesOutstanding>
    <aytu:StockIssuanceNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">648933</aytu:StockIssuanceNetOfIssuanceCostsValue>
    <aytu:StockIssuanceNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:StockIssuanceNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:StockIssuanceNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">648933</aytu:StockIssuanceNetOfIssuanceCostsValue>
    <aytu:StockIssuanceNetOfIssuanceCostsShares contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <aytu:StockIssuanceNetOfIssuanceCostsShares contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">966</aytu:StockIssuanceNetOfIssuanceCostsShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">348515</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">348515</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">2502092</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2502092</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">248419</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">4</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">248415</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">724613</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">724613</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">38350</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">2500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2016-07-01to2016-07-31_custom_ExecutiveOfficersAndDirectorsMember" unitRef="shares" decimals="INF">2500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <aytu:CommonStockIssuedToExecutivesValue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">509996</aytu:CommonStockIssuedToExecutivesValue>
    <aytu:CommonStockIssuedToExecutivesValue contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:CommonStockIssuedToExecutivesValue contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:CommonStockIssuedToExecutivesValue contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">509996</aytu:CommonStockIssuedToExecutivesValue>
    <aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">3671581</aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue>
    <aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue>
    <aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3671580</aytu:IssuanceOfCommonStockNetOfIssuanceCostsValue>
    <aytu:IssuanceOfCommonStockNetOfIssuanceCostsShares contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <aytu:IssuanceOfCommonStockNetOfIssuanceCostsShares contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">14338</aytu:IssuanceOfCommonStockNetOfIssuanceCostsShares>
    <aytu:WarrantTenderOfferNetIssuanceCostsValue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1931123</aytu:WarrantTenderOfferNetIssuanceCostsValue>
    <aytu:WarrantTenderOfferNetIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:WarrantTenderOfferNetIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</aytu:WarrantTenderOfferNetIssuanceCostsValue>
    <aytu:WarrantTenderOfferNetIssuanceCostsValue contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1931122</aytu:WarrantTenderOfferNetIssuanceCostsValue>
    <aytu:WarrantTenderOfferNetIssuanceCostsShares contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <aytu:WarrantTenderOfferNetIssuanceCostsShares contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">7478</aytu:WarrantTenderOfferNetIssuanceCostsShares>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">250000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">250000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3208</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">6319167</aytu:IssuanceOfPreferredAndCommonStockNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">16</aytu:IssuanceOfPreferredAndCommonStockNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6319150</aytu:IssuanceOfPreferredAndCommonStockNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:IssuanceOfPreferredAndCommonStockNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">1</aytu:IssuanceOfPreferredAndCommonStockNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockNetShare contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">159834</aytu:IssuanceOfPreferredAndCommonStockNetShare>
    <aytu:IssuanceOfPreferredAndCommonStockNetShare contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">113</aytu:IssuanceOfPreferredAndCommonStockNetShare>
    <aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">9166425</aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">108</aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9166316</aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">1</aytu:IssuanceOfPreferredAndCommonStockAndWarrantNetCost>
    <aytu:IssuanceOfPreferredAndCommonStockWarrantNetShare contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1076000</aytu:IssuanceOfPreferredAndCommonStockWarrantNetShare>
    <aytu:IssuanceOfPreferredAndCommonStockWarrantNetShare contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">161</aytu:IssuanceOfPreferredAndCommonStockWarrantNetShare>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2439360</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2439360</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">3470646</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3470646</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">39</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-37</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" decimals="0">-2</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <aytu:RegisteredOfferingCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-60450</aytu:RegisteredOfferingCost>
    <aytu:RegisteredOfferingCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-60450</aytu:RegisteredOfferingCost>
    <aytu:WarrantExercisesValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">677100</aytu:WarrantExercisesValue>
    <aytu:WarrantExercisesValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">8</aytu:WarrantExercisesValue>
    <aytu:WarrantExercisesValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">677092</aytu:WarrantExercisesValue>
    <aytu:WarrantExercisesValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:WarrantExercisesValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">179287</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">179287</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">596434</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">596434</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">40096</aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant>
    <aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">40096</aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant>
    <aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentForRoundingOfValueDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentForRoundingOfSharesDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">537</aytu:AdjustmentForRoundingOfSharesDueToConversion>
    <aytu:AdjustmentForRoundingOfSharesDueToConversion contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1402831</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <aytu:PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1294235</aytu:PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash>
    <aytu:PrepaymentofCommonStock contextRef="Context_3ME_01_Oct_2017T00_00_00_TO_31_Dec_2017T00_00_00_BusinessAcquisitionAxis_AytuMember" unitRef="USD" decimals="0">238000</aytu:PrepaymentofCommonStock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2018-08-01to2018-08-10_us-gaap_SubsequentEventMember">Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the &amp;#8220;Reverse Stock Splits&amp;#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2018-07-02to2018-07-31_us-gaap_SubsequentEventMember_us-gaap_DirectorMember">A reverse stock split in which&#13;each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 10, 2018.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RestrictedStockExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">248419</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">724613</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2016-07-01to2017-06-30_custom_ExecutiveOfficersAndDirectorsMember" unitRef="USD" decimals="0">430000</us-gaap:RestrictedStockExpense>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">74707</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">111608</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7385</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:PaymentsToAcquireOtherProductiveAssetsOne contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">400000</aytu:PaymentsToAcquireOtherProductiveAssetsOne>
    <aytu:PaymentsToAcquireOtherProductiveAssetsOne contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">6000000</aytu:PaymentsToAcquireOtherProductiveAssetsOne>
    <us-gaap:PaymentsToAcquireInvestments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireInvestments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">91864</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-484292</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-3534538</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">11839995</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1402831</aytu:PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost>
    <aytu:PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepurchaseOfEquity contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">12900020</us-gaap:ProceedsFromRepurchaseOfEquity>
    <us-gaap:ProceedsFromRepurchaseOfEquity contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1294235</aytu:RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost>
    <aytu:RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">677100</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">90924</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2016-09-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="USD" decimals="0">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2016-11-01to2016-11-30_us-gaap_IPOMember" unitRef="USD" decimals="0">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <aytu:PaymentsForRegisteredOfferingCosts contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:PaymentsForRegisteredOfferingCosts contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-8602499</aytu:PaymentsForRegisteredOfferingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">22659599</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">10187542</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">6234985</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-7176648</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <aytu:WarrantsIssuedToInvestorsAndUnderwriters contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4117997</aytu:WarrantsIssuedToInvestorsAndUnderwriters>
    <aytu:WarrantsIssuedToInvestorsAndUnderwriters contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:WarrantExerciseOfDerivativeWarrants contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">40096</aytu:WarrantExerciseOfDerivativeWarrants>
    <aytu:WarrantExerciseOfDerivativeWarrants contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:EarnOutPaymentToOtherShareholders contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">250000</aytu:EarnOutPaymentToOtherShareholders>
    <aytu:EarnOutPaymentToOtherShareholders contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAcquiredFromAcquisition contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAcquiredFromAcquisition contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">613309</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherPaymentsToAcquireBusinesses contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">16082</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">750000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-1750000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1071707</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <aytu:PaymentsForDepositsInvestingActivities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2200</aytu:PaymentsForDepositsInvestingActivities>
    <aytu:PaymentsForDepositsInvestingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:OverallotmentWarrantsPurchased contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:OverallotmentWarrantsPurchased contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">2852</aytu:OverallotmentWarrantsPurchased>
    <aytu:RepaymentsForRegisteredOfferingCosts contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:RepaymentsForRegisteredOfferingCosts contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-997865</aytu:RepaymentsForRegisteredOfferingCosts>
    <aytu:ProceedsFromWarrantTenderOffer contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:ProceedsFromWarrantTenderOffer contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-312159</aytu:ProceedsFromWarrantTenderOffer>
    <aytu:ProceedsOfWarrantTenderOffer contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:ProceedsOfWarrantTenderOffer contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">2243282</aytu:ProceedsOfWarrantTenderOffer>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">739857</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-09-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="USD" decimals="0">649000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <aytu:PaymentForRegisteredOfferingCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">60450</aytu:PaymentForRegisteredOfferingCost>
    <aytu:PaymentForRegisteredOfferingCost contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:WarrantsAmendedInConnectionWithWarrantTenderOffer contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:WarrantsAmendedInConnectionWithWarrantTenderOffer contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">63182</aytu:WarrantsAmendedInConnectionWithWarrantTenderOffer>
    <aytu:WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">292630</aytu:WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents>
    <aytu:FixedAssetsIncludedInAccountsPayable contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:FixedAssetsIncludedInAccountsPayable contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">10789</aytu:FixedAssetsIncludedInAccountsPayable>
    <aytu:IssuanceOfCommonStockToNuelleShareHolders contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:IssuanceOfCommonStockToNuelleShareHolders contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1837500</aytu:IssuanceOfCommonStockToNuelleShareHolders>
    <aytu:BusinessCombinationContingentCconsideration contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2553169</aytu:BusinessCombinationContingentCconsideration>
    <aytu:BusinessCombinationContingentCconsideration contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:Purchaseofassetincludedincontingentconsideration contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">293216</aytu:Purchaseofassetincludedincontingentconsideration>
    <aytu:Purchaseofassetincludedincontingentconsideration contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:ContingentConsiderationIncludedInAccountsPayable contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">8980</aytu:ContingentConsiderationIncludedInAccountsPayable>
    <aytu:ContingentConsiderationIncludedInAccountsPayable contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">246000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">540000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">647254</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">218684</us-gaap:PropertyPlantAndEquipmentNet>
    <aytu:CommonStockIssuedToExecutivesShare contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="shares" xsi:nil="true" />
    <aytu:CommonStockIssuedToExecutivesShare contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">357</aytu:CommonStockIssuedToExecutivesShare>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3660120</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">3221590</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockholdersEquityOther contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">13500000</us-gaap:StockholdersEquityOther>
    <us-gaap:PaymentsForOperatingActivities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4000000</us-gaap:PaymentsForOperatingActivities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Fair Value Measurements Using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;June 30, 2018&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;LIABILITIES&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 52%; text-align: left; font-size: 10pt"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;94,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;94,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4,694,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4,694,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;LIABILITIES&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Derivative Instruments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; font-size: 10pt"&gt;Balance as of June 30, 2016&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;276,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Warrant issuances&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Change in fair value included in earnings (February 28, 2017)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(213,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Reclassification of warrant from liability to equity upon amendment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(63,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Warrant issuances&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4,118,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Warrant exercises&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(40,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Change in fair value included in earnings&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(3,984,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Balance as of June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;94,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">93981</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">94000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">94000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">7386782</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4146829</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">7648000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">4694000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">4694000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <aytu:FairValueAssumptionsExpectedVolatilityRates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="INF">1.734</aytu:FairValueAssumptionsExpectedVolatilityRates>
    <aytu:FairValueAssumptionsExpectedVolatilityRates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember_SubsidiarySaleOfStockAxis_NoteWarrantMember" unitRef="pure" decimals="INF">1.880</aytu:FairValueAssumptionsExpectedVolatilityRates>
    <aytu:FairValueAssumptionsExpectedTerms contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember">P4Y1M16D</aytu:FairValueAssumptionsExpectedTerms>
    <aytu:FairValueAssumptionsExpectedTerms contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember_SubsidiarySaleOfStockAxis_NoteWarrantMember">P5Y0M0D</aytu:FairValueAssumptionsExpectedTerms>
    <aytu:FairValueAssumptionsRiskFreeInterestRates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="INF">0.0269</aytu:FairValueAssumptionsRiskFreeInterestRates>
    <aytu:FairValueAssumptionsRiskFreeInterestRates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember_SubsidiarySaleOfStockAxis_NoteWarrantMember" unitRef="pure" decimals="INF">0.0183</aytu:FairValueAssumptionsRiskFreeInterestRates>
    <aytu:FairValueAssumptionsExpectedDividendRates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="INF">0.0000</aytu:FairValueAssumptionsExpectedDividendRates>
    <aytu:FairValueAssumptionsExpectedDividendRates contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_AytuCommonStockMember_SubsidiarySaleOfStockAxis_NoteWarrantMember" unitRef="pure" decimals="INF">0.0000</aytu:FairValueAssumptionsExpectedDividendRates>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">94000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="USD" decimals="0">276000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4118000</aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances>
    <aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-40000</aytu:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-3984000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-213000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <aytu:ReclassificationOfWarrantLiabilityToEquityUponExercise contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-63000</aytu:ReclassificationOfWarrantLiabilityToEquityUponExercise>
    <aytu:BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_ContingentConsiderationByTypeAxis_ContingentConsiderationMember" unitRef="USD" decimals="0">-6335000</aytu:BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">The&#13;contingent consideration related to the AWH assets was prepaid up to the first $1.0 million in net revenue. Since we will not be&#13;able to manufacture more product (see Note 1), we will not generate any additional revenue. Therefore, we will not exceed $1.0&#13;million and thus, we have adjusted the remaining contingent consideration balance to zero.</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <aytu:AdjustmentOfContingentConsideration contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">0</aytu:AdjustmentOfContingentConsideration>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">16000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <aytu:BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement contextRef="From2016-07-01to2017-06-30_custom_ContingentConsiderationMember" unitRef="USD" decimals="0">2256000</aytu:BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">101000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-2745000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">7922000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:CumulativeEffectOnRetainedEarningsTax1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">891000</us-gaap:CumulativeEffectOnRetainedEarningsTax1>
    <us-gaap:CumulativeEffectOnRetainedEarningsTax1 contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <aytu:RemeasurementOfDeferredTaxes contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">6648000</aytu:RemeasurementOfDeferredTaxes>
    <aytu:RemeasurementOfDeferredTaxes contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-31000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-11000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <aytu:IncomeTaxReconciliationContingentConsideration contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-465000</aytu:IncomeTaxReconciliationContingentConsideration>
    <aytu:IncomeTaxReconciliationContingentConsideration contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">4000</aytu:IncomeTaxReconciliationContingentConsideration>
    <aytu:IncomeTaxReconciliationOfFeringCosts contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:IncomeTaxReconciliationOfFeringCosts contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">203000</aytu:IncomeTaxReconciliationOfFeringCosts>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">22000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">116000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-585000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-681000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-2807000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-7653000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.0097</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.0044</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <aytu:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">-0.1010</aytu:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage>
    <aytu:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.00</aytu:DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">-0.2694</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.3520</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <aytu:CumulativeEffectOnRetainedEarningsTaxPercentage contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.0875</aytu:CumulativeEffectOnRetainedEarningsTaxPercentage>
    <aytu:CumulativeEffectOnRetainedEarningsTaxPercentage contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.00</aytu:CumulativeEffectOnRetainedEarningsTaxPercentage>
    <aytu:RemeasurementOfDeferredTaxesPercentage contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.6525</aytu:RemeasurementOfDeferredTaxesPercentage>
    <aytu:RemeasurementOfDeferredTaxesPercentage contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.00</aytu:RemeasurementOfDeferredTaxesPercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">-0.0030</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">-0.0005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2017-12-01to2017-12-22_srt_MaximumMember" unitRef="pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2017-12-01to2017-12-22_srt_MinimumMember" unitRef="pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.0456</aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.0002</aytu:EffectiveIncomeTaxrateReconciliationContingentConsideration>
    <aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.00</aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts>
    <aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.0090</aytu:EffectiveIncomeTaxRateReconciliationOfferingCosts>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.0022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.0052</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">-0.0574</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">-0.0303</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="pure" decimals="INF">0.2755</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-07-01to2017-06-30" unitRef="pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-1029000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">3000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">127000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">136000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">15435000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">14458000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2016-01-31_custom_AmpioPharmaceuticalsMember" unitRef="USD" decimals="0">4500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1559000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">651000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">1362000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1044000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">191000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">139000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">385000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">204000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">41000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">29000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">75000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">53000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">174000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">4000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">17000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">19369000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">16718000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">19369000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">16718000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-06-30_us-gaap_ForeignCountryMember" unitRef="USD" decimals="0">59300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-06-30_us-gaap_ForeignCountryMember" unitRef="USD" decimals="0">42300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-06-30_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">50300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-06-30_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">32800000</us-gaap:OperatingLossCarryforwards>
    <aytu:NetOperatingLossesExpirationDescription contextRef="From2016-07-01to2017-06-30_us-gaap_ForeignCountryMember">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The available federal net operating&#13;losses, if not utilized to offset taxable income in future periods, will begin to expire in 2031 through 2037.&lt;/font&gt;&lt;/p&gt;</aytu:NetOperatingLossesExpirationDescription>
    <aytu:NetOperatingLossesExpirationDescription contextRef="From2017-07-01to2018-06-30_us-gaap_StateAndLocalJurisdictionMember">&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The available state net operating&#13;losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2037.&lt;/font&gt;&lt;/p&gt;</aytu:NetOperatingLossesExpirationDescription>
    <aytu:NetOperatingLossesExpirationDescription contextRef="From2016-07-01to2017-06-30_us-gaap_StateAndLocalJurisdictionMember">&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The available state net operating&#13;losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2037.</aytu:NetOperatingLossesExpirationDescription>
    <aytu:CommonStockTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 7 &amp;#8211; Common Stock &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Capital Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At June 30, 2018 and June 30, 2017, Aytu had 1,794,762 and 41,244&#13;common shares outstanding, respectively, and no preferred shares outstanding. The Company has 100&amp;#160;million shares of common&#13;stock authorized with a par value of $0.0001&amp;#160;per share and 50&amp;#160;million shares of preferred stock authorized with a par&#13;value of $0.0001 per share, of which 500 were designated Series A Convertible Preferred Stock and 161 were designated as Series&#13;B Convertible Preferred Stock. Included in the common stock outstanding are 38,738 shares of restricted stock granted to executives,&#13;directors, employees and consultants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In July 2016, we entered into a purchase agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;), together with a registration rights agreement (the &amp;#8220;Registration Rights Agreement&amp;#8221;),&#13;with Lincoln Park Capital Fund, LLC (&amp;#8220;Lincoln Park&amp;#8221;). Upon signing the Purchase Agreement, Lincoln Park&#13;agreed to purchase 335 shares of our common stock for $500,000 as an initial purchase under the agreement. We also issued as a&#13;commitment fee to Lincoln Park of 131 shares of common stock. Between September 2016 and June 2017, Lincoln Park purchased an additional&#13;500 shares for $240,000, the issuance costs related to these purchases totaled $91,000, resulting in net proceeds of $649,000.&#13;We terminated the Purchase Agreement effective August 16, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In July 2016, we issued 2,500 shares of restricted stock as&#13;compensation to certain executive officers and directors, which vest in July 2026. This expense is included in sales, general and&#13;administrative. For the year ended June 30, 2017, the expense was $725,000. The original fair value of the restricted stock was&#13;$3.2 million. As of June 30, 2017, the remaining unrecognized expense is $2.5 million. During fiscal 2017, one of the Company&amp;#8217;s&#13;executive officers resigned and his restricted stock vested in full upon this event. This resulted in the Company recognizing the&#13;remainder of the expense related to this executive&amp;#8217;s restricted stock grant of $430,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In August 2016, we issued an aggregate of 357 shares of common&#13;stock as bonuses for performance in 2016 to three executive officers.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In November 2016, we raised gross proceeds of approximately&#13;$8.6 million through a public offering of 14,338 Units. Offering costs totaled $1.0 million resulting in net cash proceeds of $7.6&#13;million. We also issued underwriter warrants in connection with the offering with a fair value of $293,000, resulting in net proceeds&#13;of $7.3 million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock.&#13;The common stock issued had a relative fair value of $3.7 million and a fair value of $4.4 million. The investor warrants have&#13;an exercise price of $744.00 per share and will expire five years from the date of issuance. These investor warrants have a relative&#13;fair value of $3.5 million and a fair value of $4.2 million. We also granted the underwriters a 45-day option (the Over-Allotment&#13;Option) to purchase up to an additional 2,151 shares of common stock and/or warrants. The underwriters purchased 714 of this Over-Allotment&#13;Option for the warrants and paid $4.00 per over-allotment warrant. These warrants have the same terms as the warrants sold in the&#13;registered offering. These warrants have a relative fair value of $173,000, a fair value of $208,000, and proceeds of $3,000, which&#13;was the purchase price per the underwriting agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2017, the Company consummated its warrant tender&#13;offer to exercise, at a temporarily reduced exercise price of $300.00 per share, (i) outstanding warrants to purchase 4,334 shares&#13;of common stock with an exercise price of $2,400.00 per share, which were originally issued to investors in the Company&amp;#8217;s&#13;May 2016 financing (the &amp;#8220;May 2016 Warrants&amp;#8221;), and (ii) outstanding warrants to purchase 15,051 shares of common stock&#13;with an exercise price of $744.00 per share, which were originally issued to investors in the Company&amp;#8217;s October 2016 financing&#13;(the &amp;#8220;October 2016 Warrants&amp;#8221; and together with the May 2016 Warrants, the &amp;#8220;Original Warrants&amp;#8221;). Original&#13;warrants to purchase an aggregate of 7,477 shares of common stock were tendered and exercised in the warrant tender offer, for&#13;aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not tendered and exercised remain&#13;in effect at the pre-tender offer exercise prices of $2,400.00 per share and $744.00 per share, respectively (see Note 11).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2017, we entered into a Merger Agreement with Nuelle,&#13;Inc. and its stockholders, pursuant to which Nuelle would become our wholly owned subsidiary (the &amp;#8220;Merger&amp;#8221;). The Merger&#13;closed on May 5, 2017. As part of the Merger, we issued to the Nuelle preferred stockholders an aggregate of 6,250 shares of our&#13;common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On August 11, 2017, we entered into a Securities Purchase Agreement&#13;with various accredited investors pursuant to which, upon closing on August 15, 2017, we sold Class A and Class B equity units&#13;for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase&#13;one and one-half (1.5) shares of common stock and were sold at a price of $60.00 per unit. Class B units consist of one (1) share&#13;of our newly created Series A Preferred Stock and warrants to purchase one and one-half (1.5) shares of common stock for each share&#13;of common stock into which the Series A Preferred Stock is convertible and were sold at a price of $20,000.00 per unit to those&#13;purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding&#13;common stock following the offering. These Series A Preferred stock were convertible into common shares at $60.00 per common share,&#13;or an aggregate of 37,500 shares of common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the offering, we issued an aggregate of 159,834 shares of&#13;our common stock, 113 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 315,755 shares of our common&#13;stock, which included 19,749 warrants issued to the placement agents as compensation for the transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We incurred certain expenses related to this transaction to&#13;attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in&#13;the transaction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with the closing of the financing, we terminated&#13;the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective&#13;on August 16, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In September 2017, Aytu issued 151 shares of common stock in&#13;connection with the Nuelle earn-out (see Note 1). In October 2017, we made a $238,000 prepayment in Aytu common stock, which represented&#13;the revenue earn-out payment for the remaining balance due on the first $1.0 million in net revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In October 2017, investors holding Aytu Series A Preferred shares&#13;exercised their right to convert 18 Aytu Series A Preferred shares into 5,834 shares of Aytu common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2018, investors holding Aytu Series A Preferred&#13;shares exercised their right to convert 95 Aytu Series A Preferred shares into 31,667 shares of Aytu common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On March 6, 2018, Aytu completed an underwritten public offering&#13;for total gross proceeds of $12 million, before deducting cash offering costs inclusive of underwriting discounts, commissions&#13;and other offering expenses totaling $1.2 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The securities sold by the Company consist of (i) Class A Units&#13;consisting of an aggregate of 976,000 shares of our common stock and warrants to purchase an aggregate of 976,000 shares of common&#13;stock, at a public offering price of $9.00 per Class A Unit, and (ii) Class B Units consisting of 161 shares of our Series B Preferred&#13;Stock, with a stated value of $20,000 per share, and convertible into an aggregate of 357,356 shares of common stock, and warrants&#13;to purchase an aggregate of 357,356 shares of common stock, at a public offering price of $20,000 per Class B Unit. The warrants&#13;have an exercise price of $10.80, are exercisable upon issuance and will expire five years from the date of issuance. The Company&#13;granted the underwriters a 45-day option to purchase an additional 200,000 shares of common stock and/or warrants to purchase an&#13;additional 200,000 shares of common stock. In connection with the closing of this offering, the underwriters partially exercised&#13;their over-allotment option and purchased an additional 200,000 warrants. On March 26, 2018, the underwriters exercised their over-allotment&#13;option to purchase an additional 100,000 shares of common stock, resulting in gross proceeds of approximately $900,000, before&#13;deducting costs of $63,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In March 2018, investors holding Aytu Series B Preferred shares&#13;exercised their right to convert 161 Aytu Series B Preferred shares into 357,356 shares of Aytu common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In fiscal 2018, warrants issued from the registered offerings&#13;to purchase an aggregate of 80,750 shares of common stock were exercised for aggregate gross proceeds to our Company of approximately&#13;$677,000.&lt;/p&gt;</aytu:CommonStockTextBlock>
    <us-gaap:OtherUnderwritingExpense contextRef="From2018-02-27to2018-03-06_us-gaap_IPOMember" unitRef="USD" decimals="0">1200000</us-gaap:OtherUnderwritingExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Commitments and contingencies are described below and summarized&#13;by the following table as of June&amp;#160;30, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 23%; text-align: left; font-size: 10pt"&gt;Prescription database&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;774,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;774,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Natesto&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Supply order&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;167,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;167,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Office lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;258,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;122,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;109,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;27,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,699,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,063,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;109,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;27,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Prescription Database&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2016, Aytu entered into an agreement with a vendor that&#13;will provide Aytu with prescription database information. Aytu agreed to pay approximately $1.9 million over three years for access&#13;to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Natesto&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In April 2016, the Company entered into an agreement with Acerus,&#13;whereby Aytu is required to make milestone payments to Acerus. The first milestone payment of $2.5 million must be paid even if&#13;the milestone is not reached.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Supply Order&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In June 2018, Aytu submitted a purchase order for 45,000 units&#13;of ZolpiMist, which are expected to arrive in fiscal 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Office Lease &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In June 2015, Aytu entered into a 37-month operating lease for&#13;office space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term&#13;of the lease of approximately $112,000. In June 2018, the Company entered into a 12-month operating lease, beginning on August&#13;1, 2018, for a new office space in Raleigh. This lease has base rent of $1,100 a month, with total rent over the term of the lease&#13;of approximately $13,200. In September 2015, the Company entered into a 37-month operating lease in Englewood, Colorado. This lease&#13;has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000. In October&#13;2017, the Company signed an amendment to the 37-month operating lease in Englewood, Colorado. The amendment extended the lease&#13;for an additional 24 months beginning October 1, 2018. The base rent will remain at $9,000 a month. The Company recognizes rent&#13;expense on a straight-line basis over the term of each lease. Differences between the straight-line net expenses on rent payments&#13;are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods&#13;was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Rent expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;142,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <aytu:CommitmentsAndContingenciesDisclosureTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 23%; text-align: left; font-size: 10pt"&gt;Prescription database&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;774,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;774,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Natesto&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Supply order&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;167,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;167,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Office lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;258,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;122,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;109,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;27,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,699,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,063,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;109,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;27,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;2,500,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:CommitmentsAndContingenciesDisclosureTableTextBlock>
    <us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Rent expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;142,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1063000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">122000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="0">774000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" decimals="0">167000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">109000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">109000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInSecondYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInSecondYear contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">27000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">27000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInThirdYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInThirdYear contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFourthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFourthYear contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueInFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueInFifthYear contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueAfterFifthYear contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligationDueAfterFifthYear contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractualObligation contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3699000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">258000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_NatestoMember" unitRef="USD" decimals="0">2500000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="0">774000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="AsOf2018-06-30_custom_SupplyOrderMember" unitRef="USD" decimals="0">167000</us-gaap:ContractualObligation>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">142000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">139000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:PaymentsForRent contextRef="Context_Custom_03_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">3000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">9000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">9000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="From2017-07-01to2018-06-30_custom_OfficeLeaseMember" unitRef="USD" decimals="0">1100</us-gaap:PaymentsForRent>
    <us-gaap:LeaseAndRentalExpense contextRef="Context_Custom_03_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">112000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="Context_Custom_01_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember" unitRef="USD" decimals="0">318000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-07-01to2018-06-30_custom_OfficeLeaseMember" unitRef="USD" decimals="0">13200</us-gaap:LeaseAndRentalExpense>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_PrescriptionDatabaseMember" unitRef="USD" decimals="0">1900000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aytu:FirstMilestonePayable contextRef="AsOf2016-04-30_custom_NatestoMember" unitRef="USD" decimals="0">2500000</aytu:FirstMilestonePayable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2017-07-01to2018-06-30_custom_SupplyOrderMember_custom_ZolpiMistMember" unitRef="shares" decimals="INF">45000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_OfficeLeaseMember">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2015-06-30_custom_OfficeLeaseMember">P37M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2015-09-30_custom_OfficeLeaseMember">P37M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2017-10-31_custom_OfficeLeaseMember">P37M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <aytu:FairValueAssumptionsExpectedVolatilityRate1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">1.78</aytu:FairValueAssumptionsExpectedVolatilityRate1>
    <aytu:FairValueAssumptionsExpectedVolatilityRate1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">1.85</aytu:FairValueAssumptionsExpectedVolatilityRate1>
    <aytu:FairValueAssumptionsExpectedTerm1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y0M0D</aytu:FairValueAssumptionsExpectedTerm1>
    <aytu:FairValueAssumptionsExpectedTerm1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y6M0D</aytu:FairValueAssumptionsExpectedTerm1>
    <aytu:FairValueAssumptionsRiskFreeInterestRate1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0097</aytu:FairValueAssumptionsRiskFreeInterestRate1>
    <aytu:FairValueAssumptionsRiskFreeInterestRate1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0188</aytu:FairValueAssumptionsRiskFreeInterestRate1>
    <aytu:FairValueAssumptionsExpectedDividendRate1 contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember" unitRef="pure" decimals="INF">0.00</aytu:FairValueAssumptionsExpectedDividendRate1>
    <aytu:CommonStockSharesAgreedToPurchase contextRef="From2016-07-01to2016-07-31_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="shares" decimals="INF">335</aytu:CommonStockSharesAgreedToPurchase>
    <aytu:CommonStockValueAgreedToPurchase contextRef="From2016-07-01to2016-07-31_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="USD" decimals="0">500000</aytu:CommonStockValueAgreedToPurchase>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2016-07-01to2016-07-31_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="shares" decimals="INF">131</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2016-08-01to2016-08-31_us-gaap_ExecutiveOfficerMember" unitRef="shares" decimals="INF">357</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-09-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="USD" decimals="0">240000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2016-11-01to2016-11-30_us-gaap_IPOMember" unitRef="USD" decimals="0">7600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2016-11-01to2016-11-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">8600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2016-11-01to2016-11-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">7300000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2016-11-01to2016-11-30_us-gaap_OverAllotmentOptionMember" unitRef="USD" decimals="0">3000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2017-02-03to2017-02-28_custom_OctoberTwoZeroOneSixWarrantsMember" unitRef="USD" decimals="0">2200000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <aytu:EquityRelativeFairValue contextRef="AsOf2016-11-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3700000</aytu:EquityRelativeFairValue>
    <aytu:EquityRelativeFairValue contextRef="AsOf2016-11-30" unitRef="USD" decimals="0">3500000</aytu:EquityRelativeFairValue>
    <aytu:EquityRelativeFairValue contextRef="AsOf2016-11-30_us-gaap_OverAllotmentOptionMember" unitRef="USD" decimals="0">173000</aytu:EquityRelativeFairValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-11-30_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">744.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-11-30_us-gaap_OverAllotmentOptionMember" unitRef="USD_per_Share" decimals="INF">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-02-28_custom_MayTwoZeroOneSixWarrantsMember" unitRef="USD_per_Share" decimals="INF">2400.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-02-28" unitRef="USD_per_Share" decimals="INF">300.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2017-02-28_custom_OctoberTwoZeroOneSixWarrantsMember" unitRef="USD_per_Share" decimals="INF">744</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentTerm contextRef="From2016-11-01to2016-11-30_us-gaap_WarrantMember">P5Y</us-gaap:DebtInstrumentTerm>
    <aytu:UnderwritersExercisedOfOverallotmentOption contextRef="From2016-11-01to2016-11-30_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF">714</aytu:UnderwritersExercisedOfOverallotmentOption>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-02-28_custom_MayTwoZeroOneSixWarrantsMember" unitRef="shares" decimals="INF">4334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-02-28_custom_OctoberTwoZeroOneSixWarrantsMember" unitRef="shares" decimals="INF">15051</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">1947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">1798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">-20</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="shares" decimals="INF">-4</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">1375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">326.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">325.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">7204.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">364.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">328.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">1664.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">328.00</aytu:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember" unitRef="USD_per_Share" decimals="INF">1292.00</aytu:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="USD_per_Share" decimals="INF">325.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P6Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-07-01to2017-06-30_us-gaap_StockOptionMember">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-07-01to2016-06-30_us-gaap_StockOptionMember">P9Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember">P6Y8M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_DerivativeInstrumentRiskAxis_StockOptionMember" unitRef="shares" decimals="INF">2961002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2018-06-30_custom_ExercisePriceRangeOneMember" unitRef="USD_per_Share" decimals="INF">280.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2018-06-30_custom_ExercisePriceRangeTwoMember" unitRef="USD_per_Share" decimals="INF">328.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1798</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2018-06-30_custom_ExercisePriceRangeOneMember" unitRef="shares" decimals="INF">76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2018-06-30_custom_ExercisePriceRangeTwoMember" unitRef="shares" decimals="INF">1722</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">325.97</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2017-07-01to2018-06-30_custom_ExercisePriceRangeOneMember" unitRef="USD_per_Share" decimals="INF">280.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2017-07-01to2018-06-30_custom_ExercisePriceRangeTwoMember" unitRef="USD_per_Share" decimals="INF">328.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">P6Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2017-07-01to2018-06-30_custom_ExercisePriceRangeOneMember">P8Y10M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2017-07-01to2018-06-30_custom_ExercisePriceRangeTwoMember">P6Y10M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1375</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2018-06-30_custom_ExercisePriceRangeOneMember" unitRef="shares" decimals="INF">76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2018-06-30_custom_ExercisePriceRangeTwoMember" unitRef="shares" decimals="INF">1299</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">325.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2017-07-01to2018-06-30_custom_ExercisePriceRangeOneMember" unitRef="USD_per_Share" decimals="INF">280.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2017-07-01to2018-06-30_custom_ExercisePriceRangeTwoMember" unitRef="USD_per_Share" decimals="INF">328.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">37200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">39150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">1150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">-800</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="INF">72.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="INF">39.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember110589561" unitRef="USD_per_Share" decimals="INF">1600.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingMember" unitRef="USD_per_Share" decimals="INF">744.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingOneMember" unitRef="USD_per_Share" decimals="INF">744.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-05-01to2016-05-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">2400.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-10-01to2016-10-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">744.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-02-03to2017-02-28_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">300.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-05-03to2018-05-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">21744.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-03-01to2018-03-31_custom_AytuBioscienceIncMember" unitRef="USD_per_Share" decimals="INF">72.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-03-01to2018-03-31_us-gaap_WarrantMember_us-gaap_IPOMember" unitRef="USD_per_Share" decimals="INF">10.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-03-01to2018-03-31_us-gaap_WarrantMember" unitRef="USD_per_Share" decimals="INF">10.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="INF">40.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="INF">40.40</aytu:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="INF">39.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember">P9Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">3227000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-07-01to2018-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-07-01to2017-06-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">725000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-07-01to2017-06-30_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">2502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="shares" decimals="INF">14342</aytu:ShareBasedCompensationShareWarrantsOutstanding>
    <aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1882661</aytu:ShareBasedCompensationShareWarrantsOutstanding>
    <aytu:ShareBasedCompensationShareWarrantsOutstanding contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="shares" decimals="INF">5538</aytu:ShareBasedCompensationShareWarrantsOutstanding>
    <aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement contextRef="From2016-07-01to2017-06-30" unitRef="shares" decimals="INF">221</aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering contextRef="From2016-07-01to2017-06-30" unitRef="shares" decimals="INF">15051</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering contextRef="From2016-07-01to2017-06-30" unitRef="shares" decimals="INF">1009</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">296006</aytu:ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwriter contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">19749</aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwriter>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnConnection contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1533356</aytu:ShareBasedCompensationShareWarrantsIssuedOnConnection>
    <aytu:ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">100000</aytu:ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsExpired contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">-42</aytu:ShareBasedCompensationShareWarrantsExpired>
    <aytu:ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">-80750</aytu:ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30" unitRef="shares" decimals="INF">-7477</aytu:ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD_per_Share" decimals="INF">1005.80</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">25.94</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="USD_per_Share" decimals="INF">2480.40</aytu:ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30" unitRef="USD_per_Share" decimals="INF">1600.00</aytu:ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30" unitRef="USD_per_Share" decimals="INF">744.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30" unitRef="USD_per_Share" decimals="INF">300.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">72.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">72.00</aytu:ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">10.80</aytu:ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">10.80</aytu:ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">21744.00</aytu:ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares>
    <aytu:ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD_per_Share" decimals="INF">8.20</aytu:ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice>
    <aytu:ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice contextRef="From2016-07-01to2017-06-30" unitRef="USD_per_Share" decimals="INF">300.00</aytu:ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice>
    <aytu:FairValueAssumptionWeightedAverageExpectedDividend contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MinimumMember" unitRef="pure" decimals="INF">1.7340</aytu:FairValueAssumptionWeightedAverageExpectedDividend>
    <aytu:FairValueAssumptionWeightedAverageExpectedDividend contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MaximumMember" unitRef="pure" decimals="INF">1.8800</aytu:FairValueAssumptionWeightedAverageExpectedDividend>
    <aytu:FairValueAssumptionWeightedAverageExpectedDividend contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MaximumMember" unitRef="pure" decimals="INF">1.6922</aytu:FairValueAssumptionWeightedAverageExpectedDividend>
    <aytu:FairValueAssumptionWeightedAverageExpectedDividend contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MinimumMember" unitRef="pure" decimals="INF">1.5664</aytu:FairValueAssumptionWeightedAverageExpectedDividend>
    <aytu:FairValueAssumptionExpectedTerm contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MinimumMember">P4Y1M16D</aytu:FairValueAssumptionExpectedTerm>
    <aytu:FairValueAssumptionExpectedTerm contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MaximumMember">P5Y</aytu:FairValueAssumptionExpectedTerm>
    <aytu:FairValueAssumptionExpectedTerm contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MaximumMember">P4Y8M2D</aytu:FairValueAssumptionExpectedTerm>
    <aytu:FairValueAssumptionExpectedTerm contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MinimumMember">P3Y5M16D</aytu:FairValueAssumptionExpectedTerm>
    <aytu:FairValueAssumptionRiskFreeInterestRate contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0183</aytu:FairValueAssumptionRiskFreeInterestRate>
    <aytu:FairValueAssumptionRiskFreeInterestRate contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0269</aytu:FairValueAssumptionRiskFreeInterestRate>
    <aytu:FairValueAssumptionRiskFreeInterestRate contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MaximumMember" unitRef="pure" decimals="INF">0.0187</aytu:FairValueAssumptionRiskFreeInterestRate>
    <aytu:FairValueAssumptionRiskFreeInterestRate contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember_srt_MinimumMember" unitRef="pure" decimals="INF">0.0163</aytu:FairValueAssumptionRiskFreeInterestRate>
    <aytu:FairValueAssumptionExpectedDividendRate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember" unitRef="pure" decimals="INF">0</aytu:FairValueAssumptionExpectedDividendRate>
    <aytu:FairValueAssumptionExpectedDividendRate contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember" unitRef="pure" decimals="INF">0</aytu:FairValueAssumptionExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_01_Jun_2015T00_00_00_TO_01_Jun_2015T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">161000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="USD" decimals="0">1593000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <aytu:WarrantsExercisePriceTerm contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</aytu:WarrantsExercisePriceTerm>
    <aytu:WarrantsExercisePriceTerm contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember110589561">P5Y</aytu:WarrantsExercisePriceTerm>
    <aytu:WarrantsExercisePriceTerm contextRef="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingMember">P5Y</aytu:WarrantsExercisePriceTerm>
    <aytu:WarrantsExercisePriceTerm contextRef="From2017-07-01to2018-06-30_custom_NovemberTwoThousandSixTeenPublicOfferingOneMember">P5Y</aytu:WarrantsExercisePriceTerm>
    <aytu:WarrantsExercisePriceTerm contextRef="From2018-05-03to2018-05-31_us-gaap_WarrantMember">P5Y</aytu:WarrantsExercisePriceTerm>
    <aytu:WarrantsExercisePriceTerm contextRef="From2018-03-01to2018-03-31_us-gaap_WarrantMember_us-gaap_IPOMember">P5Y</aytu:WarrantsExercisePriceTerm>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME_01_Oct_2017T00_00_00_TO_31_Dec_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">413</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="shares" decimals="INF">23000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">1538</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_05_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_02_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">150</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_02_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember_TitleOfIndividualAxis_ExecutiveOfficerDirectorAndConsultantsMember" unitRef="shares" decimals="INF">24750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_04_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">3750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember" unitRef="shares" decimals="INF">650</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2018-01-04to2018-01-31_custom_TwoThousandFifteenPlanMember_us-gaap_OfficerMember" unitRef="shares" decimals="INF">3750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2018-03-01to2018-03-31_custom_TwoThousandFifteenPlanMember" unitRef="shares" decimals="INF">650</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2018-01-01to2018-03-31_custom_AytuBioscienceIncMember_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF">200</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">5750</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-03-31_us-gaap_WarrantMember_us-gaap_IPOMember" unitRef="shares" decimals="INF">1533356</us-gaap:ClassOfWarrantOrRightOutstanding>
    <aytu:VestingExpiryDate contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">July 2026</aytu:VestingExpiryDate>
    <aytu:VestingExpiryDate contextRef="Context_Custom_05_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">September 2027</aytu:VestingExpiryDate>
    <aytu:VestingExpiryDate contextRef="Context_Custom_02_Nov_2017T00_00_00_TO_30_Nov_2017T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember_TitleOfIndividualAxis_ExecutiveOfficerDirectorAndConsultantsMember">November 2027</aytu:VestingExpiryDate>
    <aytu:VestingExpiryDate contextRef="Context_Custom_04_Jan_2018T00_00_00_TO_31_Jan_2018T00_00_00_PlanNameAxis_TwoThousandFifteenStockOptionAndIncentivePlanMember">January 2028</aytu:VestingExpiryDate>
    <aytu:VestingExpiryDate contextRef="From2018-01-04to2018-01-31_custom_TwoThousandFifteenPlanMember_us-gaap_OfficerMember">January 2028</aytu:VestingExpiryDate>
    <aytu:VestingExpiryDate contextRef="From2018-03-01to2018-03-31_custom_TwoThousandFifteenPlanMember">March 2028</aytu:VestingExpiryDate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2945000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">1288</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">P8Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockOptionPlanExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">139000</us-gaap:StockOptionPlanExpense>
    <aytu:NewWarrantsToPurchaseOfCommonStock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">100000</aytu:NewWarrantsToPurchaseOfCommonStock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 9 &amp;#8211; Related Party Transactions &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Executive Stock Purchases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Two Aytu executive officers, Joshua Disbrow and Jarrett Disbrow,&#13;participated in the August 2017 offering. Each officer purchased 4,167 units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Three Aytu executive officers, Joshua Disbrow, Jarrett Disbrow&#13;and David Green, participated in the March 2018 offering. Joshua Disbrow and Jarrett Disbrow each purchased 11,306 units. Mr. Green&#13;purchased 3,330 units.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Services Agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In July 2015, Aytu entered into an agreement with Ampio, whereby&#13;Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff&#13;and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016, July 2016, and again in January&#13;2017 resulting in an amount of $12,000 per month. This agreement was terminated in June 2017. Ampio was the Company&amp;#8217;s largest&#13;stockholder during part of this period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Sponsored Research Agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In June 2013, Luoxis entered into a sponsored research agreement&#13;with TRLLC, an entity controlled by Ampio&amp;#8217;s director and Chief Scientific Officer, Dr.&amp;#160;Bar-Or. The agreement, which&#13;was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related&#13;to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000&#13;which was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance&#13;sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Co-Pay Support&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In June 2018, the Company entered into a master services agreement&#13;with TrialCard Incorporated (&amp;#8220;TCI&amp;#8221;), a vendor selected to support the Company sponsored co-pay program. In supporting&#13;the program, TCI will make disbursements to qualified patients presenting valid prescriptions for Natesto and ZolpiMist on behalf&#13;of Aytu. Disbursements will be based upon business rules determined by Aytu. The Company agreed to pay fees monthly to TCI for&#13;account management, data analytics, implementation, and technology and to reimburse TCI for certain direct costs incurred by TCI&#13;to support the Company&amp;#8217;s program. Expenses are expected to be approximately $19,000 per month based on volumes and performance&#13;of our program. One of the Aytu directors, Mr. Donofrio, is an executive officer of TCI and has no direct interest in the arrangement.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_Custom_02_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_AgreementAxis_SponsoredResearchAgreementMember" unitRef="USD" decimals="0">6000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AgreementAxis_ServicesAgreementMember" unitRef="USD" decimals="0">12000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="From2017-07-01to2018-06-30_custom_ServicesAgreementMember" unitRef="USD" decimals="0">19000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AgreementAxis_ServicesAgreementMember">This agreement was terminated in June 2017.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">This agreement was terminated in March 2017.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember" unitRef="USD" decimals="0">615000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <aytu:PrepaidExpensesAmortizationPeriod contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_AgreementAxis_SponsoredResearchAgreementMember">P60M15D</aytu:PrepaidExpensesAmortizationPeriod>
    <us-gaap:Assets contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">14998517</us-gaap:Assets>
    <us-gaap:Assets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">21060093</us-gaap:Assets>
    <us-gaap:Assets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuBioscienceIncMember" unitRef="USD" decimals="0">21053000</us-gaap:Assets>
    <us-gaap:Assets contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_StatementBusinessSegmentsAxis_AytuWomensHealthMember" unitRef="USD" decimals="0">7000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2017-06-30_custom_AytuBioscienceIncMember" unitRef="USD" decimals="0">11779000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2017-06-30_custom_AytuWomensHealthMember" unitRef="USD" decimals="0">3220000</us-gaap:Assets>
    <us-gaap:NumberOfReportableSegments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="Segments" decimals="INF">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 11 &amp;#8211; Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu has a 401(k) plan that allows participants to contribute&#13;a portion of their salary, subject to eligibility requirements and annual IRS limits. The Company matches 50% of the first 6% contributed&#13;to the plan by employees. In fiscal 2018, the Company&amp;#8217;s match was $119,000.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">The Company matches 50% of the first 6% contributed&#13;to the plan by employees.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">119000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <aytu:WarrantsGeneratedNoncashExpense contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember110589561" unitRef="USD" decimals="0">596000</aytu:WarrantsGeneratedNoncashExpense>
    <aytu:IncrementalFairValueOfWarrant contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">23000</aytu:IncrementalFairValueOfWarrant>
    <aytu:IncrementalFairValueOfWarrant contextRef="From2017-02-03to2017-02-28_us-gaap_WarrantMember" unitRef="USD" decimals="0">178000</aytu:IncrementalFairValueOfWarrant>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">428374</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">596434</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">509996</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-61519</us-gaap:UnrealizedGainLossOnInvestments>
    <aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">335454</aytu:AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3983921</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">212809</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">183920</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1507</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">6277873</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments contextRef="From2016-07-01to2017-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetImpairmentCharges contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">1856020</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1265125</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">2591270</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">4364680</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-15940322</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-13829652</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <aytu:IncreaseDecreaseInAccruedCompensation contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">200970</aytu:IncreaseDecreaseInAccruedCompensation>
    <aytu:IncreaseDecreaseInAccruedCompensation contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-861226</aytu:IncreaseDecreaseInAccruedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-596654</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-414570</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-109707</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">493217</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">129249</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">95202</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">26752</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-195427</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">50743</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">355031</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;Accounts receivable are recorded at&#13;their estimated net realizable value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation&#13;allowance accordingly. As of June 30, 2018, we had an allowance for doubtful accounts of $0, and as of June 30, 2017, there had&#13;been an allowance for doubtful accounts of $44,000.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Adoption of Newly Issued Accounting Pronouncements &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2017, the FASB issued ASU No. 2017-09,&#13;&amp;#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&amp;#160;(ASU 2017-09).&amp;#8221; ASU 2017-09&#13;clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification&#13;accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15,&#13;2017, with early adoption permitted. In the quarter ended March 31, 2018, the Company adopted this pronouncement, the impact&#13;of which was immaterial.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business&#13;Combinations (Topic 805) Clarifying the Definition of a Business.&amp;#8221; The amendment clarifies the definition of a business,&#13;which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets&#13;or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance&#13;is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively&#13;for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods.&#13;Early adoption is permitted. As of the quarter ended June 30, 2018, the pronouncement does not apply to the Company, however, if&#13;Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business&#13;combination or an asset purchase.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2017, the FASB issued ASU 2017-04, &amp;#8220;Intangibles&#13;- Goodwill and Other (Topic 350).&amp;#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second&#13;step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test&#13;by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount&#13;by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the&#13;total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment&#13;for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective&#13;basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal&#13;years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1,&#13;2017. The Company early adopted this standard in fiscal 2018. There was no impact on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements, Not Adopted as&#13;of June 30, 2018 &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;From March 2016 through&#13;December 2016, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued ASU 2016-20, ASU 2016-12, ASU 2016-11,&#13;ASU 2016-10 and ASU 2016-08. These updates all clarify aspects of the guidance in ASU 2014-09, Revenue from Contracts with Customers&#13;(Topic 606), which represents comprehensive reform to revenue recognition principals related to customer contracts. The effective&#13;date of these updates for the Company is July 1, 2018. Adoption of this ASU is either full retrospective to each prior period presented&#13;or modified retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;We finalized our assessment&#13;of the new standard and will be adopting using the modified retrospective method as we have concluded that the impact of adopting&#13;the new standard is not significant as it relates to historical revenues, future revenues, or accounting for incremental costs&#13;of obtaining a contract with a customer. Going forward we will need to have disclosures de-segregating revenue to comply with this&#13;standard. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;We have analyzed the five-steps&#13;for each type of contract with our customers and concluded that: (1) The new guidance will not change our existing policy and practice&#13;for identifying contracts with customers, nor give rise to changes to our existing policy and practice or create new concern surrounding&#13;the collectability of our receivables from customers, (2) none of our contracts with customers contain multiple performance obligations&#13;that are not fulfilled at the same time, and (3) the new guidance will not change our existing policy and practice regarding the&#13;recording of variable consideration. Our financial reporting process will remain essentially unchanged. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;Additionally, Subtopic&#13;340-40 requires the capitalization of all incremental costs that we incur to obtain a contract with a customer that would not have&#13;been incurred if the contract had not been obtained, provided we expect to recover those costs. We performed an analysis and noted&#13;that there are no material customer acquisition costs that are incremental and that are expected to be recovered at a future time.&#13;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 10pt; background-color: white"&gt;The aforementioned&#13;modified retrospective method of transition will not result in a cumulative adjustment as of July 1, 2018. Additionally, no other&#13;line items in the statement of operations or the balance sheet will reflect any changes due to the adoption of the new standard.&#13;Adoption of the standards related to revenue recognition had no material impact to cash from or used in operating, financing, or&#13;investing on our consolidated cash flows statements. &lt;/font&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;In June 2016, the FASB&#13;issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses&amp;#8221; to require the measurement of expected credit losses&#13;for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts.&#13;The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected&#13;credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.&#13;The standard is effective for interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted&#13;for interim and annual reporting periods beginning after December 15, 2018. The Company is currently assessing the impact that&#13;ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases&#13;(Topic 842).&amp;#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a&#13;lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance&#13;or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective&#13;for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective&#13;transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of&#13;the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018,&#13;the FASB issued ASU 2018-10, &amp;#8220;Codification Improvements to Topic 842, Leases.&amp;#8221; The improvements in this amendment will&#13;be effective at the same time as ASU 2016-02. Also, in July 2018, the FASB issued ASU 2018-11, &amp;#8220;Leases (Topic 842): Targeted&#13;Improvements.&amp;#8221; The Board decided to provide another transition method, in addition to the existing transition method, by&#13;allowing entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment&#13;to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of its adoption&#13;of these standards on its consolidated financial statements.&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryValuationReserves contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">310000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember" unitRef="USD" decimals="0">380000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">58000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">17000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">44000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">P15Y0M0D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <aytu:FiniteLivedIntangibleAssetsExpirationMonthYear contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_LuoxisPatentMember">2028-03</aytu:FiniteLivedIntangibleAssetsExpirationMonthYear>
    <us-gaap:GoodwillImpairmentLoss contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">238000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">74000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="shares" decimals="INF">1923199</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-07-01to2017-06-30" unitRef="shares" decimals="INF">18366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <aytu:NumberOfcustomers contextRef="From2017-07-01to2018-06-30_us-gaap_AccountsReceivableMember_custom_CustomerMember" unitRef="Customers" decimals="INF">3</aytu:NumberOfcustomers>
    <aytu:NumberOfcustomers contextRef="From2016-07-01to2017-06-30_us-gaap_AccountsReceivableMember_custom_CustomerMember183079934" unitRef="Customers" decimals="INF">3</aytu:NumberOfcustomers>
    <aytu:NumberOfcustomers contextRef="From2017-07-01to2018-06-30_custom_CustomerMember_us-gaap_SalesRevenueNetMember" unitRef="Customers" decimals="INF">3</aytu:NumberOfcustomers>
    <aytu:BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment contextRef="From2016-07-01to2017-06-30_custom_ContingentConsiderationMember" unitRef="USD" decimals="0">-710000</aytu:BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">57000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_NatestoMember" unitRef="USD" decimals="0">1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;in years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; text-align: left; font-size: 10pt"&gt;Manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; font-size: 10pt"&gt;2 - 5&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;213,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;405,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;112,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Office equipment, furniture and other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;2 - 5&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Lab equipment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;3 - 5&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(540,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(246,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;219,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;647,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Depreciation and amortization expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;294,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;134,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(134,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(109,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Patents, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;271,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <aytu:PreferredStockSharesDesignated contextRef="AsOf2018-06-30_custom_ConvertibleAPreferredStockMember" unitRef="shares" decimals="INF">500</aytu:PreferredStockSharesDesignated>
    <aytu:PreferredStockSharesDesignated contextRef="AsOf2018-06-30_custom_ConvertibleBPreferredStockMember" unitRef="shares" decimals="INF">161</aytu:PreferredStockSharesDesignated>
    <us-gaap:RestrictedInvestmentsAtFairValue contextRef="AsOf2017-06-30_custom_ExecutiveOfficersAndDirectorsMember" unitRef="USD" decimals="0">3200000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:SignificantPurchaseCommitmentDescription contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_11_Aug_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">We entered into a Securities Purchase Agreement&#13;with various accredited investors pursuant to which, upon closing on August 15, 2017, we sold Class A and Class B equity units&#13;for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase&#13;one and one-half (1.5) shares of common stock and were sold at a price of $60.00 per unit. Class B units consist of one (1) share&#13;of our newly created Series A Preferred Stock and warrants to purchase one and one-half (1.5) shares of common stock for each share&#13;of common stock into which the Series A Preferred Stock is convertible and were sold at a price of $20,000.00 per unit to those&#13;purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding&#13;common stock following the offering.</us-gaap:SignificantPurchaseCommitmentDescription>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2018-03-01to2018-03-31_us-gaap_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">357356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2017-10-01to2017-10-31_us-gaap_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">5834</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2018-02-01to2018-02-28_us-gaap_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">31667</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">&lt;p style="margin: 0pt"&gt;The securities sold by the Company consist of (i) Class A Units&#13;consisting of an aggregate of 976,000 shares of our common stock and warrants to purchase an aggregate of 976,000 shares of common&#13;stock, at a public offering price of $9.00 per Class A Unit, and (ii) Class B Units consisting of 161 shares of our Series B Preferred&#13;Stock, with a stated value of $20,000 per share, and convertible into an aggregate of 357,356 shares of common stock, and warrants&#13;to purchase an aggregate of 357,356 shares of common stock, at a public offering price of $20,000 per Class B Unit. The warrants&#13;have an exercise price of $10.80, are exercisable upon issuance and will expire five years from the date of issuance. The Company&#13;granted the underwriters a 45-day option to purchase an additional 200,000 shares of common stock and/or warrants to purchase an&#13;additional 200,000 shares of common stock. In connection with the closing of this offering, the underwriters partially exercised&#13;their over-allotment option and purchased an additional 200,000 warrants. On March 26, 2018, the underwriters exercised their over-allotment&#13;option to purchase an additional 100,000 shares of common stock, resulting in gross proceeds of approximately $900,000, before&#13;deducting costs of $63,000.&lt;/p&gt;</us-gaap:SaleOfStockDescriptionOfTransaction>
    <aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">P4Y7M10D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne>
    <aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne contextRef="From2016-07-01to2017-06-30">P4Y2M23D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne>
    <aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne contextRef="From2015-07-01to2016-06-30">P4Y8M16D</aytu:ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2018-03-01to2018-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">615000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_ExecutiveOfficerOneMember" unitRef="shares" decimals="INF">11306</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_TitleOfIndividualAxis_GreenMember" unitRef="shares" decimals="INF">3330</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:DerivativeGainOnDerivative contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">3983921</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">212809</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">-6674</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">-4200</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <aytu:WarrantExercisesShares contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">80750</aytu:WarrantExercisesShares>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">172629</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">172629</aytu:AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption>
    <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">292630</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>
    <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">292630</aytu:Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-07-01to2017-06-30" unitRef="USD" decimals="0">1837500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-07-01to2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="From2016-07-01to2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1837499</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="shares" decimals="INF">6250</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2016-07-01to2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">997865</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2016-07-01to2017-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">312159</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2016-07-01to2017-06-30_custom_LincolnParkCapitalFundLlcPurchaseAgreementMember" unitRef="USD" decimals="0">90924</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Amortization expense&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;26,000&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <aytu:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_BusinessAcquisitionAxis_AwhAssetsMember" unitRef="USD" decimals="0">-1754000</aytu:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement>
    <aytu:BusinessCombinationContingentConsiderationPercentage contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_BusinessAcquisitionAxis_ProstascintBusinessMember" unitRef="pure" decimals="INF">0.08</aytu:BusinessCombinationContingentConsiderationPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2016-01-31_custom_AmpioPharmaceuticalsMember" unitRef="pure" decimals="INF">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2016-07-01to2016-07-31_custom_ExecutiveOfficersAndDirectorsMember">July 2026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_31_Oct_2017T00_00_00">We made a $238,000 prepayment in Aytu common stock, which represented the revenue earn-out payment for the remaining balance due on the first $1.0 million in net revenue.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <aytu:UnrecognizedExpense contextRef="From2016-07-01to2017-06-30_custom_ExecutiveOfficersAndDirectorsMember" unitRef="USD" decimals="0">2500000</aytu:UnrecognizedExpense>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Number of &lt;br /&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average Grant &lt;br /&gt; Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual Life in &lt;br /&gt; Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Unvested at June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;39,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;39.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Vested&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(1,150&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;40.40&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt"&gt;40.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Unvested at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;37,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right; font-size: 10pt"&gt;39.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00_FinancialInstrumentAxis_WarrantMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Number of &lt;br /&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Outstanding June 30, 2016&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;5,538&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;2,480.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center; font-size: 10pt"&gt;4.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Issuance of settlement warrants to initial investors&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;221&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,600.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Warrants issued to investors in connection with the registered offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;15,051&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;744.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Warrants issued to placement agents for the registered offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,009&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;300.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(7,477&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;300.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;14,342&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right; font-size: 10pt"&gt;1,005.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;4.23&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued in connection with the August 2017 private offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;296,006&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;72.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued to underwriters in connection with the August 2017 private offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;19,749&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;72.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued in connection with the March 2018 public offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,533,356&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;10.80&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued to investor&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;10.80&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants expired&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(42&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;21,744.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(80,750&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;8.20&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Outstanding June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,882,661&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right; font-size: 10pt"&gt;25.94&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;4.61&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <dei:EntityPublicFloat contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">7900000</dei:EntityPublicFloat>
    <us-gaap:RestrictedCashCurrent contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">75214</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">802328</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7012527</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="0">877542</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_31_Mar_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">7112527</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="USD" decimals="0">8054190</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 1 &amp;#8211; Business, Basis of Presentation, Business&#13;Combinations, Divestitures, License/Supply Agreement and Merger&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu BioScience, Inc. (&amp;#8220;Aytu&amp;#8221;, the &amp;#8220;Company&amp;#8221;&#13;or &amp;#8220;we&amp;#8221;) was incorporated as Rosewind Corporation on August&amp;#160;9, 2002 in the State of Colorado. Aytu was re-incorporated&#13;in the state of Delaware on June&amp;#160;8, 2015. &lt;font style="background-color: white"&gt;Aytu is an emerging specialty pharmaceutical&#13;company focused on commercializing novel products that address significant medical needs. Aytu is focused on commercializing products&#13;that address hypogonadism (low testosterone), insomnia, and male infertility and plans to expand into other therapeutic areas.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Basis of Presentation &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The audited consolidated financial statements include the operations&#13;of Aytu and its wholly-owned subsidiary, Aytu Women&amp;#8217;s Health, LLC. All significant inter-company balances and transactions&#13;have been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accompanying consolidated financial statements of the Company&#13;have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;). On August 10, 2018,&#13;Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding&#13;(herein referred to collectively as the &amp;#8220;Reverse Stock Splits&amp;#8221;). All share and per share amounts in this report have&#13;been adjusted to reflect the effect of these Reverse Stock Splits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Business Combination&amp;#8212;ProstaScint&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2015, Aytu completed an asset purchase agreement with&#13;Jazz Pharmaceuticals, Inc. (&amp;#8220;Jazz Pharmaceuticals&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to the&#13;Jazz Pharmaceuticals&amp;#8217; product known as ProstaScint&lt;sup&gt;&amp;#174;&lt;/sup&gt; (capromab pendetide), a late life cycle imaging agent,&#13;including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the&#13;&amp;#8220;ProstaScint Business&amp;#8221;), and assumed certain of Jazz Pharmaceuticals&amp;#8217; liabilities, including those&#13;related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront payment of $1.0&#13;million. We will pay a revenue share of 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment&#13;of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017&#13;at $54,000 using a discounted cash flow. As of June 30, 2018, the value for the contingent consideration was adjusted to $0 based&#13;upon the abandonment of ProstaScint in the quarter ended June 30, 2018, thus resulting in no future revenues around this product.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the asset purchase agreement, we were required to&#13;make our first revenue share payment to Jazz Pharmaceuticals during the March 31, 2018 quarter which was approximately $7,400.&#13;We will make our final revenue share payment to Jazz Pharmaceuticals in the first quarter of fiscal 2019, which is approximately&#13;$9,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At June 30, 2017, the ProstaScint asset was determined to be&#13;impaired based upon sales projections at that time and because we were planning to discontinue sales of ProstaScint in fiscal 2019,&#13;consistent with product expiry dating. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000&#13;for trade names and $0 for customer contracts. At June 30, 2018, we reevaluated the ProstaScint asset and abandoned sales of ProstaScint&#13;in the current fiscal year, and we recognized the remainder of the amortization expense in the quarter ended June 30, 2018. The&#13;amortization expense was $61,000 and $159,000 for fiscal 2018 and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Business Combination&amp;#8212;Primsol&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In October 2015, Aytu entered into and closed on an Asset Purchase&#13;Agreement with FSC Laboratories, Inc. (&amp;#8220;FSC&amp;#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&amp;#8217;s&#13;product known as Primsol&amp;#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in&#13;progress and all marketing and sales assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Business&amp;#8221;),&#13;and assumed certain of FSC&amp;#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the&#13;closing.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Amortization expense of $0 and $184,000 was recognized in fiscal&#13;2018 and fiscal 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Divestiture &amp;#8211; Primsol&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In March 2017, we entered into and closed on an Asset Purchase&#13;Agreement with Allegis Holdings, LLC (the &amp;#8220;Purchaser&amp;#8221;). Pursuant to the agreement, we sold to the Purchaser all of&#13;our assets related to our Primsol product, including certain intellectual property and contracts, inventory, work in process and&#13;all marketing assets and materials related solely to Primsol (together, the &amp;#8220;Primsol Asset&amp;#8221;). We retain any liability&#13;associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol&#13;Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense&#13;on our statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;License and Supply Agreement&amp;#8212;Natesto&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In April 2016, Aytu entered into and closed a license and supply&#13;agreement to acquire the exclusive U.S. rights to Natesto&amp;#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation&#13;(&amp;#8220;Acerus&amp;#8221;). We acquired the right effective upon the expiration of the former licensee&amp;#8217;s rights, which occurred&#13;on June 30, 2016. The licensee&amp;#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent&#13;including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu made an upfront payment of $2.0 million to Acerus upon&#13;execution of the agreement. In October 2016, we paid an additional $2.0 million. In January 2017, Aytu paid the final upfront payment&#13;of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5&#13;million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share.&#13;These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares&#13;until after August 29, 2016. During fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1&#13;million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $0 and $62,000 during fiscal 2018 and&#13;2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In addition to the upfront payments, we must make the following&#13;one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum&#13;aggregate amount payable under such milestone payments will be $37.5 million):&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &amp;#8220;First Milestone&amp;#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The fair value of the net identifiable asset acquired totaled&#13;$10.5 million which is being amortized over eight years. The amortization expense for fiscal 2018 and fiscal 2017 was $1.3 million,&#13;respectively. The estimated future amortization of Natesto after June 30, 2018 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,319,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;1,317,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;7,912,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The contingent consideration was initially valued at $3.2 million&#13;using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2018, the contingent consideration was revalued at $1.8 million&#13;using the same Monte Carlo simulation methodology, and based on current interest rates, expected sales potential, and Aytu stock&#13;trading variables. The contingent consideration accretion expense for fiscal 2018 and 2017 was $694,000, and $228,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;License and Supply Agreement&amp;#8212;ZolpiMist &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In June 2018, Aytu signed an exclusive license agreement for&#13;ZolpiMist&amp;#8482; (Zolpidem Tartrate Oral Spray) from Magna Pharmaceuticals, Inc., (&amp;#8220;Magna&amp;#8221;). This agreement allows&#13;for Aytu&amp;#8217;s exclusive commercialization of ZolpiMist in the U.S. and Canada.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu made an upfront payment of $400,000 to Magna upon execution of the agreement. In July 2018, we paid&#13;an additional $300,000, of which, $297,000 was included in current contingent consideration at June 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The intangible asset was valued at $3.2 million and will be&#13;amortized over the life of the license agreement up to seven years. The Company&amp;#8217;s allocation on consideration transferred&#13;for ZolpiMist as of the purchase date of June 11, 2018 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;&amp;#160;Intangible assets&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,200,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;Total assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,200,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The amortization expense for fiscal 2018 was $39,000. The estimated&#13;future amortization of ZolpiMist after June 30, 2018 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;464,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;888,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,208,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We also agreed to make certain royalty payments to Magna which&#13;will be calculated as a percentage of our ZolpiMist net sales which will be payable within 45 days of the end of the quarter during&#13;which the applicable net sales occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Twenty percent (20%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Fifteen percent (15%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2022&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Ten percent (10%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2025&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The contingent consideration, related to these royalty payments, was valued at $2.6 million using a Monte&#13;Carlo simulation, as of June 11, 2018. The contingent consideration accretion expense for fiscal 2018 and 2017 was $23,000, and&#13;$0, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Merger/Subsidiary&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2017, Aytu Women&amp;#8217;s Health, LLC., (&amp;#8220;AWH&amp;#8221;)&#13;a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc. (&amp;#8220;Nuelle&amp;#8221;), a women&amp;#8217;s sexual health company. This transaction&#13;expanded our product portfolio with the addition of the Fiera&lt;sup&gt;&amp;#174;&lt;/sup&gt; personal care device for women.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In the Merger, (i) each share of Nuelle common stock and each&#13;option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the&#13;right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 6,250 shares of our&#13;common stock and agreed to make future revenue earn-out and milestone payments subject to certain performance criteria.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Nuelle preferred stockholders were entitled to revenue earn-out&#13;payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all&#13;tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The first $1.0 million of revenue earn-out payments was paid&#13;in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.&#13;The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&amp;#8217;s portion of the revenue earn-out&#13;by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to&#13;the Nuelle stockholders of the revenue earn-out or any public disclosure by us of the earn-out being due and payable.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Amortization expense of $110,000 and $22,000 was recognized&#13;in fiscal 2018 and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The contingent consideration was valued at $1.9 million using&#13;a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for fiscal 2018 and 2017 was $64,000,&#13;and 12,000 respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the quarter ended September 30, 2017, we paid the first&#13;revenue earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which represented the revenue earn-out&#13;payment for fiscal 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the quarter ended December 31, 2017, we made a $238,000&#13;prepayment, issued in Aytu common stock, which represented the revenue earn-out payment for the remaining balance due on the first&#13;$1.0 million in net revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;At March 31, 2018, the AWH assets were determined to be impaired&#13;based upon sales performance and the manufacturer no longer supporting the product. The value for all AWH intangible assets were&#13;adjusted to zero. The contingent consideration was revalued to zero as well.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Contingent Consideration&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; font-size: 10pt"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;1,940,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to accretion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;64,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to contractual payment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(250,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(1,754,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Balance as of June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 2 &amp;#8211; Summary of Significant Accounting Policies&#13;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&lt;i&gt;Principals of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;These consolidated financial statements&#13;include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&amp;#8217;s Health. All material intercompany transactions&#13;and balances have been eliminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents and Restricted Cash &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu considers all highly liquid instruments purchased with&#13;an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a certificate of deposit&#13;investment account. Aytu&amp;#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors&#13;its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year,&#13;and as of June 30, 2018, Aytu has maintained balances in excess of federally insured limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Product&amp;#160;&amp;#38; Service Sales&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The Company recognizes revenue only when&#13;all of the following criteria have been met:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -0.2in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;Persuasive evidence&#13;of an arrangement exists,&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;Delivery has occurred,&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;The fee for the arrangement&#13;is fixed or determinable, and&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; font-size: 10pt"&gt;&#13;&lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; font-size: 10pt"&gt;&amp;#9679;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;font style="color: windowtext"&gt;Collectability is&#13;reasonably assured.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Persuasive evidence of an arrangement exists&#13;- The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue. Certain&#13;contracts allow for revenue recognition at the time of shipment and others at the time of delivery.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Delivery has occurred - The Company recognizes&#13;revenue when delivery of certain products occurs at the customers&amp;#8217; designated location.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Device sales are typically recorded when&#13;products are shipped to customers. Drug sales are typically recorded when the product arrives at the customer&amp;#8217;s dock. Provisions&#13;for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period&#13;the related sales are recorded and are estimated at the time of sale.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The fee for the arrangement is fixed or&#13;determinable - Prior to recognizing revenue, a customer&amp;#8217;s fee is either fixed or determinable under the terms of the written contract.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Collectability is reasonably assured -&#13;The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a&#13;customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which&#13;evaluates the customer&amp;#8217;s financial position and ultimately its ability to pay. The Company does not enter into arrangements unless&#13;collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment&#13;history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is&#13;recognized on a cash basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Estimated Sales Returns and Allowances &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu records estimated reductions in revenue for potential returns&#13;of products by customers. As a result, management must make estimates of potential future product returns and other allowances&#13;related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends&#13;and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different&#13;estimates, material differences in the amount of the Company&amp;#8217;s reported revenue could result. As of June 30, 2018, and 2017,&#13;we accrued $17,000 and $58,000, respectively, in our estimated returns allowance. Estimates of potential returns and allowances&#13;are trued up each quarter for the difference between estimates made in the prior quarter and actual results that become available&#13;after the end of each reporting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Shipping and Handling&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;The Company&amp;#8217;s shipping and handling costs&#13;are included in cost of goods sold for all periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;Accounts receivable are recorded at&#13;their estimated net realizable value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation&#13;allowance accordingly. As of June 30, 2018, we had an allowance for doubtful accounts of $0, and as of June 30, 2017, there had&#13;been an allowance for doubtful accounts of $44,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Concentration of Business Risks&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;The following counterparties contributed&#13;greater than&amp;#160;10%&amp;#160;of the Company&amp;#8217;s gross revenue during the year ended June 30, 2018 and 2017, respectively. The counterparties,&#13;sometimes referred to as partners or customers, are large wholesale distributors that resell our products to retailers. As of June&#13;30, 2018, three customers accounted for 84% of gross revenue. The revenue from these counterparties as a percentage of gross revenue&#13;was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;32&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer C&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;30&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;18&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer B&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;24&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;22&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The loss of one or more of the Company&amp;#8217;s significant partners&#13;or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company&#13;is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit&#13;risk exists as of&amp;#160;June&amp;#160;30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;We are also subject to credit risk&#13;from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our&#13;accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse&#13;effect on our financial position, liquidity or results of operations. As of June 30, 2018, three customers accounted for 81% of&#13;gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Customer C&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;35&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer A&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;27&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer B&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;19&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;17&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;12&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Inventories &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventories consist of raw materials, work in process and finished&#13;goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu&#13;periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items.&#13;If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable&#13;value in the period that the impairment is first recognized. Inventory for our abandoned products was written down during fiscal&#13;2018. Therefore, we currently have a reserve of $0 for slow moving inventory as of June 30, 2018 and $310,000 at June 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventory balances consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;239,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;442,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Work in process&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;442,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,100,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;738,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;Reserve&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(310,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,339,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,312,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fixed Assets &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fixed assets are recorded at cost. After being placed in service,&#13;the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt"&gt;Estimated Useful Lives&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;in years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; text-align: left; font-size: 10pt"&gt;Manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; font-size: 10pt"&gt;2 - 5&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;213,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;405,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;112,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;111,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Office equipment, furniture and other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;2 - 5&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;287,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Lab equipment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;3 - 5&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Less accumulated depreciation and amortization&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(540,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(246,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Fixed assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;219,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;647,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu recorded the following depreciation and amortization expense&#13;in the respective periods:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Depreciation and amortization expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;294,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;134,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Patents &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Costs of establishing patents, consisting of legal and filing&#13;fees paid to third parties, are expensed as incurred. The cost of the Luoxis patents were $380,000 when they were acquired in connection&#13;with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which&#13;expires in March 2028. Patents consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30,&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(134,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(109,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Patents, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;271,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu recorded the following amortization expense in the respective&#13;periods:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Amortization expense&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;26,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Future amortization from the year ended June 30, 2018 is as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; text-align: left; font-size: 10pt"&gt;2019&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2020&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2021&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2022&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;121,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;246,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Business Combinations &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for its business acquisitions under the&#13;acquisition method of accounting as indicated in the Financial Accounting Standards Board&amp;#8217;s (&amp;#8220;FASB&amp;#8221;) Accounting&#13;Standards Codification (&amp;#8220;ASC&amp;#8221;) 805, &amp;#8220;Business Combinations&amp;#8221;, which requires the acquiring entity in a business&#13;combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired&#13;business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets&#13;acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest&#13;in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes&#13;and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value&#13;of the identified net assets acquired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Goodwill &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Nuelle, ProstaScint and Primsol&amp;#160;purchase price allocations&#13;were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted&#13;up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities&#13;acquired required the use of estimates by management, and were based upon currently available data, as noted below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company allocated the excess of purchase price over the&#13;identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the&#13;value placed on entering new markets and expanding market share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company tests its goodwill for impairment annually, or whenever&#13;events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair&#13;value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market&#13;conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that&#13;an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating&#13;expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company&#13;must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets.&#13;Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to&#13;the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&amp;#160;20, 2015,&#13;Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $74,000 related to&#13;the ProstaScint goodwill for the year ended June 30, 2017. There was an impairment of $238,000 related to the Fiera goodwill during&#13;the year ended June 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The preparation of financial statements in accordance with Generally&#13;Accepted Accounting Principles in the United States of America (&amp;#8220;GAAP&amp;#8221;) requires management to make estimates and assumptions&#13;that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of&#13;the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject&#13;to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation,&#13;valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable,&#13;and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu has been included in the consolidated tax returns of Ampio&#13;for tax years ending on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&amp;#8217;s ownership percentage of&#13;Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu&amp;#8217;s taxes were&#13;computed and reported on a &amp;#8220;separate return&amp;#8221; basis for these financial statements. Deferred taxes are provided on an&#13;asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and&#13;tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are&#13;the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation&#13;allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will&#13;not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date&#13;of enactment. &amp;#9;&amp;#9;&amp;#9;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The amount of income taxes and related income tax positions&#13;taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax&#13;positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining&#13;the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized&#13;upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&amp;#8217;s&#13;policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB&#13;ASC 740-10. &amp;#8220;Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109&amp;#8221; (ASC 740-10) and tax&#13;position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes,&#13;the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and&#13;penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant&#13;tax position requires recognition under ASC 740-10. &amp;#9;&amp;#9;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu accounts for share-based payments by recognizing compensation&#13;expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair&#13;value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the&#13;graded method. Forfeitures are adjusted for as they occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company is recognizing compensation cost equal to the fair&#13;value of the stock at the grant dates prorated over the vesting period of each award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Research and development costs are expensed as incurred with&#13;expenses recorded in the respective period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income (Loss) Per Common Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic income (loss) per common share is calculated by dividing&#13;the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during&#13;that period. &lt;font style="background-color: white"&gt;Diluted net loss per share reflects the potential of securities that could&#13;share in the net loss of Aytu. Basic and diluted loss per share was the same in 2018 and 2017. Although there were common stock&#13;equivalents of 1,923,199 and 18,366 shares outstanding at June 30, 2018 and 2017, respectively, consisting of stock options, unvested&#13;restricted stock and warrants; they were not included in the calculation of the diluted net loss per share because they would&#13;have been anti-dilutive.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments and Derivative Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of financial instruments, including cash&#13;and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate&#13;their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated&#13;discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable&#13;securities was based on quoted market prices.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu accounts for liability warrants by recording the fair value&#13;of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial&#13;instruments and related warrants were calculated using a lattice valuation model. We recorded a derivative expense at the inception&#13;of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods&#13;was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income&#13;or expense for the warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;The fair value of the&#13;warrants issued to the placement agents in connection with the registered offering were valued using the lattice valuation methodology.&#13;Changes in the fair value in subsequent periods were recorded to derivative income or expense.&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Adoption of Newly Issued Accounting Pronouncements &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2017, the FASB issued ASU No. 2017-09,&#13;&amp;#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&amp;#160;(ASU 2017-09).&amp;#8221; ASU 2017-09&#13;clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification&#13;accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15,&#13;2017, with early adoption permitted. In the quarter ended March 31, 2018, the Company adopted this pronouncement, the impact&#13;of which was immaterial.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2017, the FASB issued ASU 2017-01, &amp;#8220;Business&#13;Combinations (Topic 805) Clarifying the Definition of a Business.&amp;#8221; The amendment clarifies the definition of a business,&#13;which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets&#13;or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance&#13;is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively&#13;for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods.&#13;Early adoption is permitted. As of the quarter ended June 30, 2018, the pronouncement does not apply to the Company, however, if&#13;Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business&#13;combination or an asset purchase.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2017, the FASB issued ASU 2017-04, &amp;#8220;Intangibles&#13;- Goodwill and Other (Topic 350).&amp;#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second&#13;step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test&#13;by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount&#13;by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the&#13;total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment&#13;for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective&#13;basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal&#13;years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1,&#13;2017. The Company early adopted this standard in fiscal 2018. There was no impact on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements, Not Adopted as&#13;of June 30, 2018 &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;From March 2016 through&#13;December 2016, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued ASU 2016-20, ASU 2016-12, ASU 2016-11,&#13;ASU 2016-10 and ASU 2016-08. These updates all clarify aspects of the guidance in ASU 2014-09, Revenue from Contracts with Customers&#13;(Topic 606), which represents comprehensive reform to revenue recognition principals related to customer contracts. The effective&#13;date of these updates for the Company is July 1, 2018. Adoption of this ASU is either full retrospective to each prior period presented&#13;or modified retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;We finalized our assessment&#13;of the new standard and will be adopting using the modified retrospective method as we have concluded that the impact of adopting&#13;the new standard is not significant as it relates to historical revenues, future revenues, or accounting for incremental costs&#13;of obtaining a contract with a customer. Going forward we will need to have disclosures de-segregating revenue to comply with this&#13;standard. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;We have analyzed the five-steps&#13;for each type of contract with our customers and concluded that: (1) The new guidance will not change our existing policy and practice&#13;for identifying contracts with customers, nor give rise to changes to our existing policy and practice or create new concern surrounding&#13;the collectability of our receivables from customers, (2) none of our contracts with customers contain multiple performance obligations&#13;that are not fulfilled at the same time, and (3) the new guidance will not change our existing policy and practice regarding the&#13;recording of variable consideration. Our financial reporting process will remain essentially unchanged. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;Additionally, Subtopic&#13;340-40 requires the capitalization of all incremental costs that we incur to obtain a contract with a customer that would not have&#13;been incurred if the contract had not been obtained, provided we expect to recover those costs. We performed an analysis and noted&#13;that there are no material customer acquisition costs that are incremental and that are expected to be recovered at a future time.&#13;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="font-size: 10pt; background-color: white"&gt;The aforementioned&#13;modified retrospective method of transition will not result in a cumulative adjustment as of July 1, 2018. Additionally, no other&#13;line items in the statement of operations or the balance sheet will reflect any changes due to the adoption of the new standard.&#13;Adoption of the standards related to revenue recognition had no material impact to cash from or used in operating, financing, or&#13;investing on our consolidated cash flows statements. &lt;/font&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;In June 2016, the FASB&#13;issued ASU 2016-13, &amp;#8220;Financial Instruments &amp;#8211; Credit Losses&amp;#8221; to require the measurement of expected credit losses&#13;for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts.&#13;The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected&#13;credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.&#13;The standard is effective for interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted&#13;for interim and annual reporting periods beginning after December 15, 2018. The Company is currently assessing the impact that&#13;ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2016, the FASB issued ASU 2016-02, &amp;#8220;Leases&#13;(Topic 842).&amp;#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a&#13;lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance&#13;or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective&#13;for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective&#13;transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of&#13;the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018,&#13;the FASB issued ASU 2018-10, &amp;#8220;Codification Improvements to Topic 842, Leases.&amp;#8221; The improvements in this amendment will&#13;be effective at the same time as ASU 2016-02. Also, in July 2018, the FASB issued ASU 2018-11, &amp;#8220;Leases (Topic 842): Targeted&#13;Improvements.&amp;#8221; The Board decided to provide another transition method, in addition to the existing transition method, by&#13;allowing entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment&#13;to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of its adoption&#13;of these standards on its consolidated financial statements.&amp;#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Concentration of Business Risks&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;The following counterparties contributed&#13;greater than&amp;#160;10%&amp;#160;of the Company&amp;#8217;s gross revenue during the year ended June 30, 2018 and 2017, respectively. The counterparties,&#13;sometimes referred to as partners or customers, are large wholesale distributors that resell our products to retailers. As of June&#13;30, 2018, three customers accounted for 84% of gross revenue. The revenue from these counterparties as a percentage of gross revenue&#13;was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;32&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer C&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;30&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;18&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer B&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;24&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;22&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The loss of one or more of the Company&amp;#8217;s significant partners&#13;or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company&#13;is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit&#13;risk exists as of&amp;#160;June&amp;#160;30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;We are also subject to credit risk&#13;from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our&#13;accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse&#13;effect on our financial position, liquidity or results of operations. As of June 30, 2018, three customers accounted for 81% of&#13;gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Customer C&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;35&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer A&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;27&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer B&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;19&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;17&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;12&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu has been included in the consolidated tax returns of Ampio&#13;for tax years ending on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&amp;#8217;s ownership percentage of&#13;Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu&amp;#8217;s taxes were&#13;computed and reported on a &amp;#8220;separate return&amp;#8221; basis for these financial statements. Deferred taxes are provided on an&#13;asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and&#13;tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are&#13;the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation&#13;allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will&#13;not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date&#13;of enactment. &amp;#9;&amp;#9;&amp;#9;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The amount of income taxes and related income tax positions&#13;taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax&#13;positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining&#13;the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized&#13;upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&amp;#8217;s&#13;policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB&#13;ASC 740-10. &amp;#8220;Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109&amp;#8221; (ASC 740-10) and tax&#13;position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes,&#13;the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and&#13;penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant&#13;tax position requires recognition under ASC 740-10. &amp;#9;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Income (Loss) Per Common Share &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic income (loss) per common share is calculated by dividing&#13;the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during&#13;that period. &lt;font style="background-color: white"&gt;Diluted net loss per share reflects the potential of securities that could&#13;share in the net loss of Aytu. Basic and diluted loss per share was the same in 2018 and 2017. Although there were common stock&#13;equivalents of 1,923,199 and 18,366 shares outstanding at June 30, 2018 and 2017, respectively, consisting of stock options, unvested&#13;restricted stock and warrants; they were not included in the calculation of the diluted net loss per share because they would&#13;have been anti-dilutive.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&lt;td style="font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Customer A&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;32&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer C&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;30&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;18&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer B&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;24&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;22&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; font-size: 10pt"&gt;Customer C&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;35&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer A&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;27&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;25&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Customer B&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;19&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;17&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;12&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4 &amp;#8211; Fair Value Considerations &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The carrying amounts of financial instruments, including cash&#13;and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate&#13;their fair value due to their short maturities. The fair value of the warrant derivative liability was valued using the lattice&#13;valuation methodology. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash&#13;flows and assessment of the probability of occurrence of potential future events. The valuation policies are determined by the&#13;Chief Financial Officer and approved by the Company&amp;#8217;s Board of Directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Authoritative guidance defines fair value as the price that&#13;would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants&#13;at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of&#13;observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.&#13;Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data&#13;obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&amp;#8217;s assumptions of what market&#13;participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&#13;The hierarchy is broken down into three levels based on reliability of the inputs as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="font-size: 10pt"&gt;&#13;    &lt;td style="vertical-align: top; width: 8%; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Level&amp;#160;1:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-size: 10pt"&gt;&#13;    &lt;td style="vertical-align: top; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Level&amp;#160;2:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font-size: 10pt"&gt;&#13;    &lt;td style="vertical-align: top; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Level&amp;#160;3:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font-size: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Unobservable inputs that are supported by little or no market activity.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu&amp;#8217;s assets and liabilities which are measured at fair&#13;value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.&#13;Aytu&amp;#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change&#13;in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table presents Aytu&amp;#8217;s financial liabilities&#13;that were accounted for at fair value on a recurring basis as of June 30, 2018 and 2017, by level within the fair value hierarchy:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Fair Value Measurements Using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;June 30, 2018&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;LIABILITIES&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 52%; text-align: left; font-size: 10pt"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;94,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;94,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4,694,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4,694,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;LIABILITIES&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Warrant derivative liability&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The warrant derivative liability was valued using the lattice valuation methodology because that model&#13;embodies the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative&#13;liability are not actively traded and are, therefore, classified as Level 3 liabilities. Significant assumptions in valuing the&#13;warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants,&#13;were as follows as of issuance and as of June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;June 30, &lt;br /&gt;&#13;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;At Issuance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-decoration: underline; font-size: 10pt"&gt;Warrants:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-indent: 20pt; font-size: 10pt"&gt;Volatility&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;173.4&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;188.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: 20pt; font-size: 10pt"&gt;Equivalent term (years)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: 20pt; font-size: 10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2.69&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1.83&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: 20pt; font-size: 10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table sets forth a reconciliation of changes in&#13;the warrant derivative liability for the period ended June 30, 2018&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Derivative Instruments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; font-size: 10pt"&gt;Balance as of June 30, 2016&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;276,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Warrant issuances&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Change in fair value included in earnings (February 28, 2017)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(213,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Reclassification of warrant from liability to equity upon amendment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(63,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Warrant issuances&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;4,118,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Warrant exercises&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(40,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Change in fair value included in earnings&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(3,984,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Balance as of June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;94,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;We classify our contingent consideration liability in connection with the acquisition of ProstaScint,&#13;Natesto, ZolpiMist and the merger with Nuelle within Level 3 as factors used to develop the estimated fair value are unobservable&#13;inputs that are not supported by market activity. We estimate the fair value of our contingent consideration liability based on&#13;contractual payment obligations, discount rates, probabilities of payment, and expected future performance. Contingent payment&#13;amounts are discounted back to the current period using a discounted cash flow methodology. The contingent consideration related&#13;to the AWH assets was prepaid up to the first $1.0 million in net revenue. Since we will not be able to manufacture more product&#13;(see Note 1), we will not generate any additional revenue. Therefore, we will not exceed $1.0 million and thus, we have adjusted&#13;the remaining contingent consideration balance to zero. This adjustment is reflected in Other Gain on the Consolidated Statement&#13;of Operations. We also reduced the contingent consideration for ProstaScint by $57,000 to reflect that product&amp;#8217;s abandonment.&#13;As of June 30, 2018, the value for the contingent consideration was adjusted to $0 based upon the abandonment of ProstaScint in&#13;June 2018. Also, as of June 30, 2018, the contingent consideration related to Natesto was revalued at $1.8 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table sets forth a summary of changes in the contingent&#13;consideration for the period ended June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Contingent Consideration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 88%; font-size: 10pt"&gt;Balance as of June 30, 2016&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,869,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to purchase of assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,927,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to accretion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;306,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to remeasurement&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,256,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(710,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Balance as of June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;7,648,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to purchase of assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;2,846,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Increase due to accretion&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;801,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to contractual payment&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(266,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Decrease due to remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(6,335,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Balance as of June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;4,694,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The contingent consideration was valued using the Monte-Carlo&#13;valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments.&#13;Contingent consideration is not actively traded and therefore classified as Level 3.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%; text-align: left"&gt;Benefit at statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-27.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,653,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-34.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(585,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-5.74&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(681,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-3.03&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Offering costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Contingent consideration&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(465,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-4.56&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Change in taxrate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Remeasurement of deferred taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,648,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Effect of phased-in taxrate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;891,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,745,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-26.94&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,922,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Derivative income&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,029,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-10.10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Net income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;Deferred rent&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,458,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,435,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Intangibles&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,559,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,044,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,362,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Unrealized loss on investment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Capital loss carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Contribution carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Inventory&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Total deferred income tax assets (liabilities)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,718,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,369,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,718,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,369,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred income tax assets (liabilities)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 8 &amp;#8211; Equity Instruments &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On June&amp;#160;1, 2015, Aytu&amp;#8217;s stockholders approved the&#13;2015 Stock Option and Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;), which, as amended in July 2017, provides for the award of stock&#13;options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common&#13;stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied&#13;without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back&#13;to the shares of common stock available for issuance under the 2015 Plan. As of June 30, 2018, we have 2,961,055 shares that are&#13;available for grant under the 2015 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the 2015 Stock Plan, 3.0 million shares of its common&#13;stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model.&#13;In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including&#13;the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected&#13;option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based&#13;on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury&#13;yield in effect at the time of the grant for treasury securities of similar maturity. There&amp;#8217;s no issuances during the year&#13;ended June 30, 2018, therefore, no assumptions are used for fiscal 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The assumptions used for the year ended June 30, 2017, as none were issued in fiscal 2018, are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year Ended&lt;/p&gt;&#13;                                                                           &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June&amp;#160;30,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 84%; text-align: left; font-size: 10pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: center; font-size: 10pt"&gt;178% - 185%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;0.97% - 1.88%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Expected term (years)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;5.0 - 6.5&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;0%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock option activity is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br /&gt;&#13; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise&amp;#160;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;&#13;                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;br /&gt; Remaining&amp;#160;Contractual&lt;br /&gt; Life in Years&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%"&gt;Outstanding June 30, 2016&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,204.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;364.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,664.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,292.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,947&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;326.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(129&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Outstanding June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;325.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Exercisable at June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;325.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Available for grant at June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,961,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table details the options outstanding at June&#13;30, 2018 by range of exercise prices:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Range of Exercise Prices&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br /&gt;&#13; Options&lt;br /&gt;&#13; Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise&lt;br /&gt;&#13; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Remaining&lt;br /&gt;&#13; Contractual&lt;br /&gt;&#13; Life of&lt;br /&gt;&#13; Options&lt;br /&gt;&#13; Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br /&gt;&#13; Options&lt;br /&gt;&#13; Exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise&lt;br /&gt;&#13; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;280.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;280.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;280.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,722&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;6.86&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,299&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,798&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;325.97&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,375&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;325.35&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In September 2017, Aytu issued 10,000 shares of restricted stock&#13;to employees pursuant to the 2015 Plan, which vest in September 2027. In November 2017, 150 of these restricted shares were cancelled.&#13;Also, in November 2017, Aytu issued 24,750 shares of restricted stock to executives, directors and consultants pursuant to the&#13;2015 Plan, which vest in November 2027.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In January 2018, Aytu issued 3,750 shares of restricted stock&#13;to an officer pursuant to the 2015 Plan, which vest in January 2028. In March 2018, Aytu issued 650 shares of restricted stock&#13;to employees pursuant to the 2015 Plan, which vest in March 2028. During the three months ended March 31, 2018, 650 shares of restricted&#13;stock were cancelled.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During fiscal 2018, we modified 2,000 shares of restricted stock&#13;for accelerated vesting and recognized an increase in aggregate stock compensation expense of $14,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Restricted stock activity is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Number of &lt;br /&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted &lt;br /&gt; Average Grant &lt;br /&gt; Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted Average &lt;br /&gt; Remaining &lt;br /&gt; Contractual Life in &lt;br /&gt; Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Unvested at June 30, 2017&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;39,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;39.80&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;Vested&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(1,150&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;40.40&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt"&gt;40.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;Unvested at June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;37,200&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right; font-size: 10pt"&gt;39.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;9.4&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Aytu previously issued 1,538 shares of restricted stock outside the Aytu BioScience 2015 Stock Option&#13;and Inventive Plan, which vest in July 2026. The unrecognized expense related to these shares was $1,593,000 as of June 30, 2018&#13;and will be recognized over the 10-year vesting period. During fiscal 2018, the expense related to these awards was $139,000. During&#13;the quarter ended December 31, 2017, we modified 413 shares of restricted stock for accelerated vesting and recognized a reduction&#13;in aggregate stock compensation expense of $36,000. During the quarter ended March 31, 2018, we modified 200 shares of restricted&#13;stock for accelerated vesting and recognized a reduction in aggregate stock compensation expense of $37,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-based compensation expense related to the fair value of&#13;stock options and restricted stock was included in the statements of operations as selling, general and administrative expenses&#13;as set forth in the table below. Aytu determined the fair value of stock compensation as of the date of grant using the Black-Scholes&#13;option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation&#13;expense for the stock option and restricted stock issuances for fiscal 2018 and 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Sales, general and administrative:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;349,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;2,502,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt"&gt;Restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;248,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;725,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;Total share-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;597,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,227,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;As of&amp;#160;June 30, 2018, there was&amp;#160;$161,000 of total unrecognized option-based compensation expense&#13;related to non-vested stock options. The Company expects to recognize this expense over a weighted-average period of 6.95 years.&#13;As of June 30, 2018, there was $2,945,000 of total unrecognized share-based compensation expense related to the non-vested restricted&#13;stock. The Company expects to recognize this expense over a weighted-average period of 8.63 years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Warrants &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;A summary of all warrants is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Number of &lt;br /&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 64%; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Outstanding June 30, 2016&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;5,538&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;2,480.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center; font-size: 10pt"&gt;4.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Issuance of settlement warrants to initial investors&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;221&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,600.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Warrants issued to investors in connection with the registered offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;15,051&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;744.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Warrants issued to placement agents for the registered offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,009&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;300.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(7,477&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;300.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;14,342&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right; font-size: 10pt"&gt;1,005.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;4.23&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued in connection with the August 2017 private offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;296,006&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;72.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued to underwriters in connection with the August 2017 private offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;19,749&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;72.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued in connection with the March 2018 public offering&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;1,533,356&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;10.80&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants issued to investor&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;10.80&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants expired&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(42&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;21,744.00&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Warrants exercised&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(80,750&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;8.20&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt"&gt;Outstanding June 30, 2018&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;1,882,661&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right; font-size: 10pt"&gt;25.94&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center; font-size: 10pt"&gt;4.61&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During fiscal 2017, Aytu issued warrants to purchase 221 shares&#13;of common stock to initial investors of the Company at an exercise price of $1,600.00 and a term of five years from July 2016.&#13;These warrants generated a non-cash expense of $596,000 for the year ended June 30, 2017, which is included in sales, general and&#13;administrative expense. These warrants are accounted for under equity treatment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with our November 2016 public offering, we issued&#13;to the underwriters of the public offering warrants to purchase an aggregate of 1,009 shares of common stock at an exercise price&#13;of $744.00 and a term of five years. These warrants are accounted for under equity treatment. In February 2017, we reduced the&#13;exercise price of these warrants to $300.00.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Also, in connection with our November 2016 public offering,&#13;we issued to investors warrants to purchase an aggregate of 15,051 shares of common stock, which includes the over-allotment warrants,&#13;at an exercise price of $744.00 with a term of five years. These warrants are accounted for under equity treatment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In February 2017, the Company consummated its warrant tender&#13;offer to exercise, at a temporarily reduced exercise price of $300.00 per share, (i) outstanding warrants to purchase 4,334 shares&#13;of common stock with an exercise price of $2,400.00 per share, which were originally issued to investors in the Company&amp;#8217;s&#13;May 2016 financing (the &amp;#8220;May 2016 Warrants&amp;#8221;), and (ii) outstanding warrants to purchase 15,051 shares of common stock&#13;with an exercise price of $744.00 per share, which were originally issued to investors in the Company&amp;#8217;s October 2016 financing&#13;(the &amp;#8220;October 2016 Warrants&amp;#8221; and together with the May 2016 Warrants, the &amp;#8220;Original Warrants&amp;#8221;). Original&#13;Warrants to purchase an aggregate of 7,477 shares of common stock were tendered and exercised in the warrant tender offer, for&#13;aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not exercised remain in effect&#13;at the pre-tender offer exercise prices of $2,400.00 per share and $744.00 per share, respectively. The incremental fair value,&#13;which had no book impact, was $178,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company also reduced the exercise prices of an aggregate&#13;of 1,288 warrants to purchase shares of common stock, which were originally issued as underwriters&amp;#8217; compensation in the May&#13;2016 and October 2016 financings, from $2,400.00 per share and $744.00 per share, respectively, to $300.00 per share. The amended&#13;warrants related to the May 2016 financing adjusted the accounting for these warrants from liability classification to equity.&#13;The incremental fair value of these warrant modifications, which had no book impact, was $23,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with our August 2017 private offering, we issued&#13;warrants to purchase an aggregate of 315,755 shares of common stock at an exercise price of $72.00 and a term of five years to&#13;investors and underwriters. The remaining outstanding warrants from that offering are accounted for using derivative liability&#13;treatment (see Note 5).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In connection with our March 2018 public offering,&amp;#160;we issued&#13;to investors and underwriters warrants to purchase an aggregate of 1,533,356 shares of common stock&amp;#160;at an exercise price of&#13;$10.80 with a term of five years from March 6, 2018. These warrants are accounted for under equity treatment. Of the 1,533,356&#13;warrants issued in the March 2018 public offering, 5,750 were exercised in fiscal 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In March 2018, Aytu BioScience, Inc. entered into a warrant&#13;exercise agreement with an investor of the Company&amp;#8217;s outstanding warrants. Pursuant to the exercise agreement, the Company&#13;agreed to reduce the exercise price of the investor&amp;#8217;s warrant to purchase 75,000 shares of the Company&amp;#8217;s common stock&#13;from $72.00 to one cent less than the closing price on the last trading day prior to the exercise date; provided that the investor&#13;exercised the warrant for cash by March 23, 2018, and the Company also agreed to issue the investor a new warrant to purchase 100,000&#13;shares of the Company&amp;#8217;s common stock at an exercise price of $10.80 per share. In accordance with the exercise agreement,&#13;the investor exercised the warrant and the Company received net proceeds of $615,000. The new warrant to purchase 100,000 shares&#13;of the Company&amp;#8217;s common stock are accounted for under equity treatment and have a fair value of $179,000. &amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In May 2018, the warrants we issued to the placement agent,&#13;in connection with our private placement in 2013, expired. &amp;#160;The 42 placement agent warrants have a term of five years from&#13;the date of issuance and an exercise price of $21,744.00.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The warrants related to the August Financing issued in fiscal&#13;2018 were valued using the lattice option pricing model. These warrants were accounted for as liability warrants (see Note 5).&#13;The warrants related to the March Financing in fiscal 2018 were valued using the Black Scholes pricing model and were accounted&#13;for as equity warrants. In order to calculate the fair value of the warrants, certain assumptions were made, including the selling&#13;price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and contractual&#13;life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing&#13;a weighted average of comparable published betas of peer companies. The risk-free interest rate is based on the U.S. Treasury yield&#13;in effect at the time of the grant for treasury securities of similar maturity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Significant assumptions in valuing the warrants issued and modified&#13;during the year ended June 30, 2018 were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; white-space: nowrap; font-size: 10pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;173.40% - 188.00%&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;156.64% - 169.22%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; white-space: nowrap; font-size: 10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;1.83% - 2.69%&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;1.63% - 1.87%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; white-space: nowrap; font-size: 10pt"&gt;Contractual term (years)&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;4.13 - 5&lt;/td&gt;&lt;td style="white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; white-space: nowrap; font-size: 10pt"&gt;3.46 - 4.67&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; white-space: nowrap; font-size: 10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; white-space: nowrap; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt"&gt;0%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br /&gt;&#13; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise&amp;#160;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;&#13;                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average&lt;br /&gt; Remaining&amp;#160;Contractual&lt;br /&gt; Life in Years&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 64%"&gt;Outstanding June 30, 2016&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,204.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,197&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;364.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,664.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,292.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Outstanding June 30, 2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,947&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;326.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(129&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td&gt;Outstanding June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;325.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td&gt;Exercisable at June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,375&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;325.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Available for grant at June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,961,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <aytu:ScheduleOfOptionsOutstanding contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom"&gt;&lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Range of Exercise Prices&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br /&gt;&#13; Options&lt;br /&gt;&#13; Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise&lt;br /&gt;&#13; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Remaining&lt;br /&gt;&#13; Contractual&lt;br /&gt;&#13; Life of&lt;br /&gt;&#13; Options&lt;br /&gt;&#13; Outstanding&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br /&gt;&#13; Options&lt;br /&gt;&#13; Exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br /&gt;&#13; Average&lt;br /&gt;&#13; Exercise&lt;br /&gt;&#13; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;280.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;280.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;280.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,722&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;6.86&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,299&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;328.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,798&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;325.97&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;6.95&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1.5pt solid"&gt;1,375&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt"&gt;325.35&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</aytu:ScheduleOfOptionsOutstanding>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;tr style="vertical-align: bottom; font-size: 10pt; background-color: White"&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Sales, general and administrative:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;349,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;2,502,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt"&gt;Restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;248,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;725,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;Total share-based compensation expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;597,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,227,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:OtherTaxExpenseBenefit contextRef="Context_3ME_01_Jan_2018T00_00_00_TO_31_Mar_2018T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 5 &amp;#8211; Income Taxes &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As previously discussed in Note 2 - Summary of Significant Accounting&#13;Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ending on or before December 31,&#13;2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company&amp;#8217;s&#13;taxes have been computed and reported on a &amp;#8220;separate return&amp;#8221; basis. Ampio and Aytu did not have a tax sharing agreement&#13;for the consolidated return periods. Accordingly, certain tax attributes, e.g. net operating loss carryforwards, reflected in these&#13;financial statements, may or may not be available to Aytu. In January 2016, Ampio&amp;#8217;s ownership interest in Aytu fell below 80% so&#13;that Aytu will no longer be included in the Ampio consolidated tax return. The deconsolidation resulted in approximately $4.5 million&#13;of net operating loss carryforwards originating prior to the incorporation of Vyrix and Luoxis no longer being available to Aytu.&#13;Upon deconsolidation, the deferred tax asset and related valuation allowance for these pre-incorporation net operating losses have&#13;been removed. &lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 6.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0"&gt;&lt;font style="font-size: 10pt"&gt;Income tax benefit resulting from applying statutory rates in jurisdictions&#13;in which Aytu is taxed (Federal and various states) differs from the income tax provision (benefit) in the Aytu financial statements.&#13;The following table reflects the reconciliation for the respective periods.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 52%; text-align: left"&gt;Benefit at statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,807,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-27.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,653,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-34.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(585,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-5.74&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(681,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-3.03&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Offering costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Contingent consideration&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(465,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-4.56&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.02&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Change in taxrate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Remeasurement of deferred taxes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,648,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;65.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Effect of phased-in taxrate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;891,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,745,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-26.94&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,922,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;Derivative income&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,029,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-10.10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;101,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Net income tax provision (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"&gt;Deferred income taxes arise from temporary differences in the recognition of certain items for income&#13;tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred&#13;tax assets &amp;#9;and liabilities are as follows for the respective periods:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;6/30/2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in"&gt;Deferred rent&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,458,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,435,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Intangibles&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;651,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,559,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,044,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,362,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;191,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Unrealized loss on investment&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Capital loss carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;204,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;385,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Contribution carry forward&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 0.125in"&gt;Inventory&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"&gt;Allowance for doubtful accounts&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;Total deferred income tax assets (liabilities)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,718,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,369,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,718,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,369,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total deferred income tax assets (liabilities)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In assessing the realizability of deferred tax assets, management&#13;considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate&#13;realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary&#13;differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable&#13;income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than&#13;not it will realize the benefits of these deductible differences, net of the valuation allowance provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company has federal net operating losses of approximately&#13;$59.3 million and $42.3 million as of June 30, 2018 and June 30, 2017, respectively that, subject to limitation, may be available&#13;in future tax years to offset taxable income. The available federal net operating losses, if not utilized to offset taxable income&#13;in future periods, will begin to expire in 2031 through 2037. The Company has state net operating losses of approximately $50.3&#13;million and $32.8 million as of June 30, 2018 and June 30, 2017, respectively that, subject to limitation, may be available in&#13;future tax years to offset taxable income. The available state net operating losses, if not utilized to offset taxable income in&#13;future periods, will begin to expire in 2025 through 2037. Under the provisions of the Internal Revenue Code, substantial changes&#13;in the Company&amp;#8217;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. Net&#13;operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which&#13;they are generated has been closed by statute. The amount &amp;#9;subject to disallowance is limited to the NOL utilized. Accordingly,&#13;the Company may be subject to examination for prior NOLs generated as such NOLs are utilized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;As of June 30, 2018, and 2017, the Company has no&#13;liability for gross unrecognized tax benefits or related interest and penalties. Aytu has made its best estimates of certain&#13;income tax amounts included in the financial statements. Application of the Company&amp;#8217;s accounting policies and estimates,&#13;however, involves the exercise of judgement and use of assumptions as to future uncertainties and, as a result, could differ&#13;from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or&#13;assumptions have been in the past, how much the estimates or assumptions have changed and how likely such changes may have a&#13;material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of&#13;limitations, the Company would not be subject to federal or Colorado income tax examinations for tax years prior to 2014 and&#13;2013, respectively. However, given the net operating losses generated since inception, all tax years since inception are&#13;subject to examination.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0"&gt;&lt;font style="font-size: 10pt"&gt;On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the &amp;#8220;Tax Reform&#13;Act&amp;#8221;) was signed into law by the President of the United States. The Tax Reform Act significantly revised the U.S. corporate&#13;income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. GAAP&#13;requires that the impact of tax legislation be recognized in the period in which the law was enacted. As a result of the Tax Reform&#13;Act, the Company recorded a tax expense of $6.6 million due to a re-measurement of deferred tax assets and liabilities at a blended&#13;rate in the three months ended December 31, 2017, which is fully offset by a reduction in valuation allowance. The Company recorded&#13;additional tax expense of $0.1 million related to re- measurement of deferred tax assets and liabilities in the three months ended&#13;March 31, 2018. The tax expense is a provisional amount and the Company&amp;#8217;s current best estimate. Any adjustments recorded to the&#13;provisional amounts will be included in income from operations as an adjustment to tax expense, net of any related valuation allowance.&#13;The provisional amount incorporates assumptions made based upon the Company&amp;#8217;s current interpretation of the Tax Reform Act and&#13;may change as the Company receives additional clarification and implementation guidance.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 3 &amp;#8211; Going Concern &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;As reflected in the accompanying&#13;financial statements, for the year ended June 30, 2018, the Company had a net loss of $10.2 million and net cash used in&#13;operations of $16.0 million. At June 30, 2018, Aytu had $7.1 million of cash, cash equivalents and restricted cash,&#13;stockholders&amp;#8217; equity of $13.5 million and an accumulated deficit of $79.3 million. In addition, the Company is in the&#13;early stage of commercialization and has not yet generated profits for the most recent four quarters ended June 30, 2018. We&#13;used an average of $4.0 million of cash per quarter for operating activities. These factors raised substantial doubt about&#13;the Company&amp;#8217;s ability to continue as a going concern.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;Looking forward, we expect cash used in&#13;operating activities to be in the range of historical amounts, and we expect our revenue to increase. We also expect to raise new&#13;capital if and when needed. Therefore, it is uncertain as to whether the Company is sufficiently capitalized. Since the Company&#13;does not have a cash balance as of June 30, 2018, sufficient to cover potential operating losses for the twelve months following&#13;the expected filing date of this Annual Report, ASU 2014-15, Presentation of Financial Statements&amp;#8212;Going Concern (Subtopic&#13;205-40) requires us to report that there is an indication that substantial doubt about the Company&amp;#8217;s ability to continue&#13;as a going concern exists.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The ability of the Company to continue its operations is dependent&#13;on management&amp;#8217;s plans, which include continuing to build on the historical growth trajectory of Natesto, launching the recently&#13;licensed ZolpiMist product, seeking to acquire cash generating assets and if needed, accessing the capital markets through the&#13;sale of our securities. Based on our ability to raise capital in the past as well as our continued growth, the Company believes&#13;additional financing will be available and will continue to be available to support the current level of operations for at least&#13;the next 12 months from the date of this report. There can be no assurance, however, that such financing will be available on terms&#13;which are favorable to the Company, or at all.&amp;#160;While Company management believes that its plan to fund ongoing operations&#13;will be successful, there is uncertainty due to the Company&amp;#8217;s limited operating history and therefore no assurance that its&#13;plan will be successfully realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The accompanying financial statements have been prepared on&#13;a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of&#13;business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification&#13;of the liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 12 &amp;#8211; Subsequent Events&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On July 31, we made the second payment towards an asset purchase totaling $300,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Our board of directors approved a reverse stock split in which&#13;each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 10, 2018.&#13;This adjustment is reflected in this Annual Report.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In August, the Aytu sales force began promotions of ZolpiMist&#13;to U.S. clinicians.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;On September 5, 2018, Aytu and Magna Pharmaceuticals, Inc. agreed to amend and restate the license agreement&#13;effective as of June 11, 2018.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <aytu:AssetPurchase contextRef="From2018-07-02to2018-07-31_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">300000</aytu:AssetPurchase>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 10 &amp;#8211; Segment Information&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="background-color: white"&gt;Aytu manages our Company&#13;and aggregated our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&amp;#8217;s&#13;Health. The Aytu segment consists of our core male urology products. The Aytu Women&amp;#8217;s Health segment contains our women&amp;#8217;s&#13;health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Consolidated revenue:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; padding-left: 9pt; font-size: 10pt"&gt;Aytu&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,417,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,175,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;243,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;47,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;Consolidated revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,660,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,222,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Consolidated net loss:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-left: 9pt; font-size: 10pt"&gt;Aytu&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(7,783,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(22,349,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(2,405,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(159,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;Consolidated net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;(10,188,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;(22,508,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Total assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-left: 9pt; font-size: 10pt"&gt;Aytu&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;21,053,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;11,779,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;3,220,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;21,060,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;14,999,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="Context_9ME_01_Jul_2017T00_00_00_TO_31_Mar_2018T00_00_00">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;Year Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Consolidated revenue:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="width: 76%; padding-left: 9pt; font-size: 10pt"&gt;Aytu&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,417,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-size: 10pt"&gt;3,175,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;243,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;47,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;Consolidated revenue&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,660,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;3,222,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;Consolidated net loss:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-left: 9pt; font-size: 10pt"&gt;Aytu&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(7,783,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;(22,349,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(2,405,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;(159,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt"&gt;Consolidated net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;(10,188,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;(22,508,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt"&gt;Total assets:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="padding-left: 9pt; font-size: 10pt"&gt;Aytu&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;21,053,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;11,779,000&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt"&gt;Aytu Women&amp;#8217;s Health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt"&gt;3,220,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"&gt;&#13;    &lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font-size: 10pt"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;21,060,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt"&gt;14,999,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-size: 10pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>aytu-20180630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aytu%2D20180630.xfr; Date: 2018%2D09%2D06T20:07:56Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +qpZs7xRiXgen8uAaHxMWaaImcOdx5ZzmYlBvWp0fUl63yYhnToOcy7IVTM2wZ0N -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:aytu="http://aytubio.com/20180630" elementFormDefault="qualified" targetNamespace="http://aytubio.com/20180630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://aytubio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" id="ConsolidatedStatementOfStockholdersEquityUnaudited">
	  <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" id="ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited">
	  <link:definition>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger">
	  <link:definition>00000008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/GoingConcern" id="GoingConcern">
	  <link:definition>00000010 - Disclosure - Going Concern</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderations" id="FairValueConsiderations">
	  <link:definition>00000011 - Disclosure - Fair Value Considerations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000012 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommonStock" id="CommonStock">
	  <link:definition>00000014 - Disclosure - Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstruments" id="EquityInstruments">
	  <link:definition>00000015 - Disclosure - Equity Instruments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000016 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SegmentInformation" id="SegmentInformation">
	  <link:definition>00000017 - Disclosure - Segment Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
	  <link:definition>00000018 - Disclosure - Employee Benefit Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000019 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables">
	  <link:definition>00000021 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderationsTables" id="FairValueConsiderationsTables">
	  <link:definition>00000023 - Disclosure - Fair Value Considerations (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000024 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000025 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsTables" id="EquityInstrumentsTables">
	  <link:definition>00000026 - Disclosure - Equity Instruments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SegmentInformationTables" id="SegmentInformationTables">
	  <link:definition>00000027 - Disclosure - Segment Information (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails">
	  <link:definition>00000028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1">
	  <link:definition>00000029 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2">
	  <link:definition>00000030 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" id="BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual">
	  <link:definition>00000031 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000032 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
	  <link:definition>00000033 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" id="SummaryOfSignificantAccountingPoliciesDetails2">
	  <link:definition>00000034 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" id="SummaryOfSignificantAccountingPoliciesDetails3">
	  <link:definition>00000035 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" id="SummaryOfSignificantAccountingPoliciesDetails4">
	  <link:definition>00000036 - Disclosure - Summary of Significant Accounting Policies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" id="SummaryOfSignificantAccountingPoliciesDetails5">
	  <link:definition>00000037 - Disclosure - Summary of Significant Accounting Policies (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" id="SummaryOfSignificantAccountingPoliciesDetails6">
	  <link:definition>00000038 - Disclosure - Summary of Significant Accounting Policies (Details 6)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
	  <link:definition>00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/GoingConcernDetails" id="GoingConcernDetails">
	  <link:definition>00000040 - Disclosure - Going Concern (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderationsDetails" id="FairValueConsiderationsDetails">
	  <link:definition>00000041 - Disclosure - Fair Value Considerations (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderationsDetails1" id="FairValueConsiderationsDetails1">
	  <link:definition>00000042 - Disclosure - Fair Value Considerations (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderationsDetails2" id="FairValueConsiderationsDetails2">
	  <link:definition>00000043 - Disclosure - Fair Value Considerations (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderationsDetails3" id="FairValueConsiderationsDetails3">
	  <link:definition>00000044 - Disclosure - Fair Value Considerations (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" id="FairValueConsiderationsDetailsTextual">
	  <link:definition>00000045 - Disclosure - Fair Value Considerations (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000046 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000047 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
	  <link:definition>00000048 - Disclosure - Income Taxes (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000049 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000050 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
	  <link:definition>00000051 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/CommonStockDetails" id="CommonStockDetails">
	  <link:definition>00000052 - Disclosure - Common Stock (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails" id="EquityInstrumentsDetails">
	  <link:definition>00000053 - Disclosure - Equity Instruments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails1" id="EquityInstrumentsDetails1">
	  <link:definition>00000054 - Disclosure - Equity Instruments (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails2" id="EquityInstrumentsDetails2">
	  <link:definition>00000055 - Disclosure - Equity Instruments (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails3" id="EquityInstrumentsDetails3">
	  <link:definition>00000056 - Disclosure - Equity Instruments (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails4" id="EquityInstrumentsDetails4">
	  <link:definition>00000057 - Disclosure - Equity Instruments (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails5" id="EquityInstrumentsDetails5">
	  <link:definition>00000058 - Disclosure - Equity Instruments (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetails6" id="EquityInstrumentsDetails6">
	  <link:definition>00000059 - Disclosure - Equity Instruments (Details 6)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EquityInstrumentsDetailsTextual" id="EquityInstrumentsDetailsTextual">
	  <link:definition>00000060 - Disclosure - Equity Instruments (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
	  <link:definition>00000061 - Disclosure - Related Party Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SegmentInformationDetails" id="SegmentInformationDetails">
	  <link:definition>00000062 - Disclosure - Segment Information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SegmentInformationDetailsTextual" id="SegmentInformationDetailsTextual">
	  <link:definition>00000063 - Disclosure - Segment Information (Details Textual)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/EmployeeBenefitPlanDetails" id="EmployeeBenefitPlanDetails">
	  <link:definition>00000064 - Disclosure - Employee Benefit Plan (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aytubio.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
	  <link:definition>00000065 - Disclosure - Subsequent Events (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20180630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20180630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20180630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20180630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
    <element id="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" name="AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RevenueEarnOutPayment" name="RevenueEarnOutPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PreferredStockConversionPricePerShare" name="PreferredStockConversionPricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SecuritiesPurchaseAgreementCashFeePercentage" name="SecuritiesPurchaseAgreementCashFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" name="ClassOfWarrantOrRightPercentageOfSharesToBeIssued" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsToPurchaseOfCommonStockShares" name="WarrantsToPurchaseOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" name="WarrantsIssuedToUnderwritersAsCompensationForTransaction" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentConsiderationRevalued" name="BusinessCombinationContingentConsiderationRevalued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RestrictedStocksPolicyTextBlock" name="RestrictedStocksPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CostOfSaleForInvestment" name="CostOfSaleForInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_OneTimeNonRefundablePayments" name="OneTimeNonRefundablePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SalesRevenueTarget" name="SalesRevenueTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PercentageofNetSalesDescriptions" name="PercentageofNetSalesDescriptions" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SubsidiariesPaymentDescription" name="SubsidiariesPaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CoreAndDevelopedTechnologyNet" name="CoreAndDevelopedTechnologyNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AccruedCompensationCurrent" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ResearchAndDevelopmentRelatedParty" name="ResearchAndDevelopmentRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_StockIssuanceNetOfIssuanceCostsValue" name="StockIssuanceNetOfIssuanceCostsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_StockIssuanceNetOfIssuanceCostsShares" name="StockIssuanceNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommonStockIssuedToExecutivesValue" name="CommonStockIssuedToExecutivesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" name="IssuanceOfCommonStockNetOfIssuanceCostsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" name="IssuanceOfCommonStockNetOfIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantTenderOfferNetIssuanceCostsValue" name="WarrantTenderOfferNetIssuanceCostsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantTenderOfferNetIssuanceCostsShares" name="WarrantTenderOfferNetIssuanceCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfPreferredAndCommonStockNetCost" name="IssuanceOfPreferredAndCommonStockNetCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfPreferredAndCommonStockNetShare" name="IssuanceOfPreferredAndCommonStockNetShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" name="IssuanceOfPreferredAndCommonStockAndWarrantNetCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" name="IssuanceOfPreferredAndCommonStockWarrantNetShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" name="AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RegisteredOfferingCost" name="RegisteredOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantExercisesValue" name="WarrantExercisesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" name="AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AdjustmentForRoundingOfValueDueToConversion" name="AdjustmentForRoundingOfValueDueToConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AdjustmentForRoundingOfSharesDueToConversion" name="AdjustmentForRoundingOfSharesDueToConversion" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" name="PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PrepaymentofCommonStock" name="PrepaymentofCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaymentsToAcquireOtherProductiveAssetsOne" name="PaymentsToAcquireOtherProductiveAssetsOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" name="PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" name="RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaymentsForRegisteredOfferingCosts" name="PaymentsForRegisteredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsIssuedToInvestorsAndUnderwriters" name="WarrantsIssuedToInvestorsAndUnderwriters" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantExerciseOfDerivativeWarrants" name="WarrantExerciseOfDerivativeWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_EarnOutPaymentToOtherShareholders" name="EarnOutPaymentToOtherShareholders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaymentsForDepositsInvestingActivities" name="PaymentsForDepositsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_OverallotmentWarrantsPurchased" name="OverallotmentWarrantsPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RepaymentsForRegisteredOfferingCosts" name="RepaymentsForRegisteredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ProceedsFromWarrantTenderOffer" name="ProceedsFromWarrantTenderOffer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ProceedsOfWarrantTenderOffer" name="ProceedsOfWarrantTenderOffer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaymentForRegisteredOfferingCost" name="PaymentForRegisteredOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer" name="WarrantsAmendedInConnectionWithWarrantTenderOffer" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" name="WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FixedAssetsIncludedInAccountsPayable" name="FixedAssetsIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IssuanceOfCommonStockToNuelleShareHolders" name="IssuanceOfCommonStockToNuelleShareHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentCconsideration" name="BusinessCombinationContingentCconsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_Purchaseofassetincludedincontingentconsideration" name="Purchaseofassetincludedincontingentconsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ContingentConsiderationIncludedInAccountsPayable" name="ContingentConsiderationIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommonStockIssuedToExecutivesShare" name="CommonStockIssuedToExecutivesShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsExpectedVolatilityRates" name="FairValueAssumptionsExpectedVolatilityRates" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsExpectedTerms" name="FairValueAssumptionsExpectedTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsRiskFreeInterestRates" name="FairValueAssumptionsRiskFreeInterestRates" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsExpectedDividendRates" name="FairValueAssumptionsExpectedDividendRates" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise" name="ReclassificationOfWarrantLiabilityToEquityUponExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" name="BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AdjustmentOfContingentConsideration" name="AdjustmentOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" name="BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RemeasurementOfDeferredTaxes" name="RemeasurementOfDeferredTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IncomeTaxReconciliationContingentConsideration" name="IncomeTaxReconciliationContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IncomeTaxReconciliationOfFeringCosts" name="IncomeTaxReconciliationOfFeringCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" name="DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CumulativeEffectOnRetainedEarningsTaxPercentage" name="CumulativeEffectOnRetainedEarningsTaxPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RemeasurementOfDeferredTaxesPercentage" name="RemeasurementOfDeferredTaxesPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" name="EffectiveIncomeTaxrateReconciliationContingentConsideration" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" name="EffectiveIncomeTaxRateReconciliationOfferingCosts" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NetOperatingLossesExpirationDescription" name="NetOperatingLossesExpirationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommonStockTextBlock" name="CommonStockTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" name="CommitmentsAndContingenciesDisclosureTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FirstMilestonePayable" name="FirstMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsExpectedVolatilityRate1" name="FairValueAssumptionsExpectedVolatilityRate1" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsExpectedTerm1" name="FairValueAssumptionsExpectedTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsRiskFreeInterestRate1" name="FairValueAssumptionsRiskFreeInterestRate1" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionsExpectedDividendRate1" name="FairValueAssumptionsExpectedDividendRate1" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommonStockSharesAgreedToPurchase" name="CommonStockSharesAgreedToPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommonStockValueAgreedToPurchase" name="CommonStockValueAgreedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_EquityRelativeFairValue" name="EquityRelativeFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_UnderwritersExercisedOfOverallotmentOption" name="UnderwritersExercisedOfOverallotmentOption" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsOutstanding" name="ShareBasedCompensationShareWarrantsOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" name="ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" name="ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" name="ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" name="ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" name="ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection" name="ShareBasedCompensationShareWarrantsIssuedOnConnection" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsExpired" name="ShareBasedCompensationShareWarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" name="ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" name="ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" name="ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionWeightedAverageExpectedDividend" name="FairValueAssumptionWeightedAverageExpectedDividend" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionExpectedTerm" name="FairValueAssumptionExpectedTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionRiskFreeInterestRate" name="FairValueAssumptionRiskFreeInterestRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueAssumptionExpectedDividendRate" name="FairValueAssumptionExpectedDividendRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsExercisePriceTerm" name="WarrantsExercisePriceTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_VestingExpiryDate" name="VestingExpiryDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NewWarrantsToPurchaseOfCommonStock" name="NewWarrantsToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PrepaidExpensesAmortizationPeriod" name="PrepaidExpensesAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsGeneratedNoncashExpense" name="WarrantsGeneratedNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IncrementalFairValueOfWarrant" name="IncrementalFairValueOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" name="AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IncreaseDecreaseInAccruedCompensation" name="IncreaseDecreaseInAccruedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" name="FiniteLivedIntangibleAssetsExpirationMonthYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NumberOfcustomers" name="NumberOfcustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" name="BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PreferredStockSharesDesignated" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" name="ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" name="AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" name="Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" name="BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationContingentConsiderationPercentage" name="BusinessCombinationContingentConsiderationPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_UnrecognizedExpense" name="UnrecognizedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ScheduleOfOptionsOutstanding" name="ScheduleOfOptionsOutstanding" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AssetPurchase" name="AssetPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ProstascintBusinessMember" name="ProstascintBusinessMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PrimsolBusinessMember" name="PrimsolBusinessMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NuelleMember" name="NuelleMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AytuBioscienceIncMember" name="AytuBioscienceIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AytuWomensHealthMember" name="AytuWomensHealthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NuelleIncMember" name="NuelleIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NatestoMember" name="NatestoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" name="TwoThousandFifteenStockOptionAndIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ContingentConsiderationMember" name="ContingentConsiderationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AwhAssetsMember" name="AwhAssetsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AytuCommonStockMember" name="AytuCommonStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ProstaScintMember" name="ProstaScintMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_JazzPharmaceuticalsIncMember" name="JazzPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PrimsolMember" name="PrimsolMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PaidOnAprilTwoThousandSixteenMember" name="PaidOnAprilTwoThousandSixteenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NoLaterThanJuly012016Member" name="NoLaterThanJuly012016Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NoLaterThanSeptember302016Member" name="NoLaterThanSeptember302016Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_DiscountedCashFlowMethodMember" name="DiscountedCashFlowMethodMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ThirdUpfrontMember" name="ThirdUpfrontMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_LicenseAndSupplyAgreementMember" name="LicenseAndSupplyAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FirstMilestoneMember" name="FirstMilestoneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SecondMilestoneMember" name="SecondMilestoneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ThirdMilestoneMember" name="ThirdMilestoneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ForthMilestoneMember" name="ForthMilestoneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FifthMilestoneMember" name="FifthMilestoneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AytuMember" name="AytuMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_LabEquipmentMember" name="LabEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AwhManufacturingEquipmentMember" name="AwhManufacturingEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_LuoxisPatentMember" name="LuoxisPatentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_OfficeLeaseMember" name="OfficeLeaseMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_PrescriptionDatabaseMember" name="PrescriptionDatabaseMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SeriesConvertiblePreferredStockMember" name="SeriesConvertiblePreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ClassUnitsMember" name="ClassUnitsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ClassBUnitsMember" name="ClassBUnitsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ExecutiveOfficerOneMember" name="ExecutiveOfficerOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_GreenMember" name="GreenMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ExecutiveOfficerDirectorAndConsultantsMember" name="ExecutiveOfficerDirectorAndConsultantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SponsoredResearchAgreementMember" name="SponsoredResearchAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ServicesAgreementMember" name="ServicesAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CADMember" name="CADMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ZolpiMistMember" name="ZolpiMistMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_OtherMember" name="OtherMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CustomerMember" name="CustomerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AmpioPharmaceuticalsMember" name="AmpioPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SupplyOrderMember" name="SupplyOrderMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" name="LincolnParkCapitalFundLlcPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ExecutiveOfficersAndDirectorsMember" name="ExecutiveOfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_MayTwoZeroOneSixWarrantsMember" name="MayTwoZeroOneSixWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_OctoberTwoZeroOneSixWarrantsMember" name="OctoberTwoZeroOneSixWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ExercisePriceRangeOneMember" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ExercisePriceRangeTwoMember" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NovemberTwoThousandSixTeenPublicOfferingMember" name="NovemberTwoThousandSixTeenPublicOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember" name="NovemberTwoThousandSixTeenPublicOfferingOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ConvertibleAPreferredStockMember" name="ConvertibleAPreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ConvertibleBPreferredStockMember" name="ConvertibleBPreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CounterpartiesMember" name="CounterpartiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_GoingConcernDisclosureAbstract" name="GoingConcernDisclosureAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessDescriptionAndBasisOfPresentationTable" name="BusinessDescriptionAndBasisOfPresentationTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="aytu_BusinessDescriptionAndBasisOfPresentationLineItems" name="BusinessDescriptionAndBasisOfPresentationLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ContingentConsiderationAbstract" name="ContingentConsiderationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" name="BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_BusinessCombinationConsiderationTransferredInventory" name="BusinessCombinationConsiderationTransferredInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CounterpartiesAxis" name="CounterpartiesAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="aytu_CounterpartiesDomain" name="CounterpartiesDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SummaryOfSignificantAccountingPoliciesTextual" name="SummaryOfSignificantAccountingPoliciesTextual" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_GoingConcernTextualAbstract" name="GoingConcernTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_FairValueConsiderationsTextualAbstract" name="FairValueConsiderationsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_CommonStockTextualAbstract" name="CommonStockTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" name="IncrementalCommonSharesDueToConversionOfPreferredStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_UnrecognizedShareBasedCompensationExpenses" name="UnrecognizedShareBasedCompensationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_DescriptionOfUnrecognizedExpense" name="DescriptionOfUnrecognizedExpense" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_OptionsAbstract" name="OptionsAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_EquityInstrumentsTextualAbstract" name="EquityInstrumentsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_WarrantTenderOfferDescription" name="WarrantTenderOfferDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" name="StockIssuedDuringPeriodValueRestrictedStockCancelled" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_AgreementAxis" name="AgreementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="aytu_AgreementDomain" name="AgreementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_RelatedPartyTransactionsTextualAbstract" name="RelatedPartyTransactionsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SegmentInformationTextualAbstract" name="SegmentInformationTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_EmployeeBenefitPlanTextualAbstract" name="EmployeeBenefitPlanTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aytu_SubsequentEventsTextualAbstract" name="SubsequentEventsTextualAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>aytu-20180630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aytu%2D20180630.xfr; Date: 2018%2D09%2D06T20:07:56Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aytubio.com/role/DocumentAndEntityInformation" xlink:href="aytu-20180630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedBalanceSheets" xlink:href="aytu-20180630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="aytu-20180630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/StatementsOfCashFlows" xlink:href="aytu-20180630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/GoingConcern" xlink:href="aytu-20180630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderations" xlink:href="aytu-20180630.xsd#FairValueConsiderations" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxes" xlink:href="aytu-20180630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingencies" xlink:href="aytu-20180630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommonStock" xlink:href="aytu-20180630.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstruments" xlink:href="aytu-20180630.xsd#EquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/RelatedPartyTransactions" xlink:href="aytu-20180630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformation" xlink:href="aytu-20180630.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EmployeeBenefitPlan" xlink:href="aytu-20180630.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SubsequentEvents" xlink:href="aytu-20180630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsTables" xlink:href="aytu-20180630.xsd#FairValueConsiderationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesTables" xlink:href="aytu-20180630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesTables" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsTables" xlink:href="aytu-20180630.xsd#EquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationTables" xlink:href="aytu-20180630.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/GoingConcernDetails" xlink:href="aytu-20180630.xsd#GoingConcernDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails1" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails2" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails3" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetails" xlink:href="aytu-20180630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetails1" xlink:href="aytu-20180630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetailsTextual" xlink:href="aytu-20180630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommonStockDetails" xlink:href="aytu-20180630.xsd#CommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails1" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails2" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails3" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails4" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails5" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails6" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetailsTextual" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/RelatedPartyTransactionsDetails" xlink:href="aytu-20180630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationDetails" xlink:href="aytu-20180630.xsd#SegmentInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationDetailsTextual" xlink:href="aytu-20180630.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EmployeeBenefitPlanDetails" xlink:href="aytu-20180630.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SubsequentEventsDetails" xlink:href="aytu-20180630.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytuCoreAndDevelopedTechnologyNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_aytuCoreAndDevelopedTechnologyNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaapIndefiniteLivedContractualRights" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIndefiniteLivedContractualRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaapIndefiniteLivedTradeNames" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIndefiniteLivedTradeNames" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytuAccruedCompensationCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_aytuAccruedCompensationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytuResearchAndDevelopmentRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_aytuResearchAndDevelopmentRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfOtherInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytuAmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_aytuAmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaapAdjustmentOfWarrantsGrantedForServices" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAdjustmentOfWarrantsGrantedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytuIncreaseDecreaseInAccruedCompensation" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_aytuIncreaseDecreaseInAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="loc_aytuPaymentsForDepositsInvestingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_aytuPaymentsForDepositsInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsToAcquireOtherProductiveAssetsOne" xlink:label="loc_aytuPaymentsToAcquireOtherProductiveAssetsOne" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_aytuPaymentsToAcquireOtherProductiveAssetsOne" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfOtherInvestments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfOtherInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaapOtherPaymentsToAcquireBusinesses" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapOtherPaymentsToAcquireBusinesses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_aytuPaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuPaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="loc_us-gaapProceedsFromRepurchaseOfEquity" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepurchaseOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_aytuRepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuRepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentForRegisteredOfferingCost" xlink:label="loc_aytuPaymentForRegisteredOfferingCost" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuPaymentForRegisteredOfferingCost" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProceedsOfWarrantTenderOffer" xlink:label="loc_aytuProceedsOfWarrantTenderOffer" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuProceedsOfWarrantTenderOffer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProceedsFromWarrantTenderOffer" xlink:label="loc_aytuProceedsFromWarrantTenderOffer" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuProceedsFromWarrantTenderOffer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsForRegisteredOfferingCosts" xlink:label="loc_aytuPaymentsForRegisteredOfferingCosts" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuPaymentsForRegisteredOfferingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RepaymentsForRegisteredOfferingCosts" xlink:label="loc_aytuRepaymentsForRegisteredOfferingCosts" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuRepaymentsForRegisteredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OverallotmentWarrantsPurchased" xlink:label="loc_aytuOverallotmentWarrantsPurchased" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aytuOverallotmentWarrantsPurchased" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:title="00000008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/GoingConcern" xlink:title="00000010 - Disclosure - Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderations" xlink:title="00000011 - Disclosure - Fair Value Considerations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommonStock" xlink:title="00000014 - Disclosure - Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstruments" xlink:title="00000015 - Disclosure - Equity Instruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformation" xlink:title="00000017 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EmployeeBenefitPlan" xlink:title="00000018 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:title="00000021 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsTables" xlink:title="00000023 - Disclosure - Fair Value Considerations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsTables" xlink:title="00000026 - Disclosure - Equity Instruments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationTables" xlink:title="00000027 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:title="00000028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:title="00000029 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:title="00000030 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:title="00000031 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000032 - Disclosure - Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000033 - Disclosure - Summary of Significant Accounting Policies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="00000035 - Disclosure - Summary of Significant Accounting Policies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details 6)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/GoingConcernDetails" xlink:title="00000040 - Disclosure - Going Concern (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails" xlink:title="00000041 - Disclosure - Fair Value Considerations (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails1" xlink:title="00000042 - Disclosure - Fair Value Considerations (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails2" xlink:title="00000043 - Disclosure - Fair Value Considerations (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails3" xlink:title="00000044 - Disclosure - Fair Value Considerations (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" xlink:title="00000045 - Disclosure - Fair Value Considerations (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetails" xlink:title="00000046 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetails1" xlink:title="00000047 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetailsTextual" xlink:title="00000048 - Disclosure - Income Taxes (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapContractualObligationDueInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapContractualObligation" xlink:to="loc_us-gaapContractualObligationDueInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaapContractualObligationDueInSecondYear" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapContractualObligation" xlink:to="loc_us-gaapContractualObligationDueInSecondYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaapContractualObligationDueInThirdYear" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapContractualObligation" xlink:to="loc_us-gaapContractualObligationDueInThirdYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaapContractualObligationDueInFourthYear" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapContractualObligation" xlink:to="loc_us-gaapContractualObligationDueInFourthYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaapContractualObligationDueInFifthYear" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapContractualObligation" xlink:to="loc_us-gaapContractualObligationDueInFifthYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaapContractualObligationDueAfterFifthYear" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapContractualObligation" xlink:to="loc_us-gaapContractualObligationDueAfterFifthYear" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000050 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000051 - Disclosure - Commitments and Contingencies (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommonStockDetails" xlink:title="00000052 - Disclosure - Common Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails" xlink:title="00000053 - Disclosure - Equity Instruments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails1" xlink:title="00000054 - Disclosure - Equity Instruments (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails2" xlink:title="00000055 - Disclosure - Equity Instruments (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails3" xlink:title="00000056 - Disclosure - Equity Instruments (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails4" xlink:title="00000057 - Disclosure - Equity Instruments (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails5" xlink:title="00000058 - Disclosure - Equity Instruments (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails6" xlink:title="00000059 - Disclosure - Equity Instruments (Details 6)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetailsTextual" xlink:title="00000060 - Disclosure - Equity Instruments (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/RelatedPartyTransactionsDetails" xlink:title="00000061 - Disclosure - Related Party Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationDetails" xlink:title="00000062 - Disclosure - Segment Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationDetailsTextual" xlink:title="00000063 - Disclosure - Segment Information (Details Textual)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EmployeeBenefitPlanDetails" xlink:title="00000064 - Disclosure - Employee Benefit Plan (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SubsequentEventsDetails" xlink:title="00000065 - Disclosure - Subsequent Events (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>aytu-20180630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aytu%2D20180630.xfr; Date: 2018%2D09%2D06T20:07:56Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aytubio.com/role/DocumentAndEntityInformation" xlink:href="aytu-20180630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedBalanceSheets" xlink:href="aytu-20180630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="aytu-20180630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/StatementsOfCashFlows" xlink:href="aytu-20180630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/GoingConcern" xlink:href="aytu-20180630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderations" xlink:href="aytu-20180630.xsd#FairValueConsiderations" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxes" xlink:href="aytu-20180630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingencies" xlink:href="aytu-20180630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommonStock" xlink:href="aytu-20180630.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstruments" xlink:href="aytu-20180630.xsd#EquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/RelatedPartyTransactions" xlink:href="aytu-20180630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformation" xlink:href="aytu-20180630.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EmployeeBenefitPlan" xlink:href="aytu-20180630.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SubsequentEvents" xlink:href="aytu-20180630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsTables" xlink:href="aytu-20180630.xsd#FairValueConsiderationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesTables" xlink:href="aytu-20180630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesTables" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsTables" xlink:href="aytu-20180630.xsd#EquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationTables" xlink:href="aytu-20180630.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/GoingConcernDetails" xlink:href="aytu-20180630.xsd#GoingConcernDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails1" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails2" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails3" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetails" xlink:href="aytu-20180630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetails1" xlink:href="aytu-20180630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetailsTextual" xlink:href="aytu-20180630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommonStockDetails" xlink:href="aytu-20180630.xsd#CommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails1" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails2" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails3" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails4" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails5" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails6" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetailsTextual" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/RelatedPartyTransactionsDetails" xlink:href="aytu-20180630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationDetails" xlink:href="aytu-20180630.xsd#SegmentInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationDetailsTextual" xlink:href="aytu-20180630.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EmployeeBenefitPlanDetails" xlink:href="aytu-20180630.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SubsequentEventsDetails" xlink:href="aytu-20180630.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuanceNetOfIssuanceCostsValue" xlink:label="loc_aytuStockIssuanceNetOfIssuanceCostsValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuStockIssuanceNetOfIssuanceCostsValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuanceNetOfIssuanceCostsShares" xlink:label="loc_aytuStockIssuanceNetOfIssuanceCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuStockIssuanceNetOfIssuanceCostsShares_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockIssuedToExecutivesValue" xlink:label="loc_aytuCommonStockIssuedToExecutivesValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuCommonStockIssuedToExecutivesValue_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockIssuedToExecutivesShare" xlink:label="loc_aytuCommonStockIssuedToExecutivesShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuCommonStockIssuedToExecutivesShare_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" xlink:label="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsValue_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" xlink:label="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:label="loc_aytuAdjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferNetIssuanceCostsValue" xlink:label="loc_aytuWarrantTenderOfferNetIssuanceCostsValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantTenderOfferNetIssuanceCostsValue_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferNetIssuanceCostsShares" xlink:label="loc_aytuWarrantTenderOfferNetIssuanceCostsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantTenderOfferNetIssuanceCostsShares_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockNetCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockNetCost_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockNetShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockNetShare_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockAndWarrantNetCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockAndWarrantNetCost_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockWarrantNetShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockWarrantNetShare_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RegisteredOfferingCost" xlink:label="loc_aytuRegisteredOfferingCost_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuRegisteredOfferingCost_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExercisesValue" xlink:label="loc_aytuWarrantExercisesValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantExercisesValue_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExercisesShares" xlink:label="loc_aytuWarrantExercisesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantExercisesShares_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantAmendments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantAmendments_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytuAdjustmentForRoundingOfValueDueToConversion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentForRoundingOfValueDueToConversion_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytuAdjustmentForRoundingOfSharesDueToConversion_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentForRoundingOfSharesDueToConversion_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="35" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:label="loc_aytuPaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuPaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:title="00000008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/GoingConcern" xlink:title="00000010 - Disclosure - Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderations" xlink:title="00000011 - Disclosure - Fair Value Considerations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommonStock" xlink:title="00000014 - Disclosure - Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstruments" xlink:title="00000015 - Disclosure - Equity Instruments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformation" xlink:title="00000017 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EmployeeBenefitPlan" xlink:title="00000018 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:title="00000021 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)">
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuZolpiMistMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AwhAssetsMember" xlink:label="loc_aytuAwhAssetsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuAwhAssetsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsTables" xlink:title="00000023 - Disclosure - Fair Value Considerations (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_aytuContingentConsiderationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_aytuContingentConsiderationMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="loc_aytuAytuCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuAytuCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsTables" xlink:title="00000026 - Disclosure - Equity Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaapNonvestedRestrictedStockSharesActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNonvestedRestrictedStockSharesActivityTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ScheduleOfOptionsOutstanding" xlink:label="loc_aytuScheduleOfOptionsOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuScheduleOfOptionsOutstanding_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationTables" xlink:title="00000027 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:title="00000028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuZolpiMistMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:title="00000029 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:title="00000030 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AwhAssetsMember" xlink:label="loc_aytuAwhAssetsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuAwhAssetsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_aytuContingentConsiderationAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_aytuContingentConsiderationAbstract_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_20" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_20" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_20" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_20" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:title="00000031 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytuProstascintBusinessMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuProstascintBusinessMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytuJazzPharmaceuticalsIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuJazzPharmaceuticalsIncMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytuPrimsolBusinessMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuPrimsolBusinessMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuZolpiMistMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NuelleIncMember" xlink:label="loc_aytuNuelleIncMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNuelleIncMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuMember" xlink:label="loc_aytuAytuMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuAytuMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DiscountedCashFlowMethodMember" xlink:label="loc_aytuDiscountedCashFlowMethodMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_aytuDiscountedCashFlowMethodMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaapDevelopedTechnologyRightsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapDevelopedTechnologyRightsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaapCustomerContractsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerContractsMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytuThirdUpfrontMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_aytuThirdUpfrontMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CADMember" xlink:label="loc_aytuCADMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_aytuCADMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytuLicenseAndSupplyAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aytuLicenseAndSupplyAgreementMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytuFirstMilestoneMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuFirstMilestoneMember_250" xlink:type="arc" order="253" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytuSecondMilestoneMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuSecondMilestoneMember_260" xlink:type="arc" order="263" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytuThirdMilestoneMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuThirdMilestoneMember_270" xlink:type="arc" order="273" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytuForthMilestoneMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuForthMilestoneMember_280" xlink:type="arc" order="283" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytuFifthMilestoneMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuFifthMilestoneMember_290" xlink:type="arc" order="293" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:label="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytuBusinessCombinationContingentConsiderationPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuBusinessCombinationContingentConsiderationPercentage_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationRevalued" xlink:label="loc_aytuBusinessCombinationContingentConsiderationRevalued_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuBusinessCombinationContingentConsiderationRevalued_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytuBusinessCombinationConsiderationTransferredInventory_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuBusinessCombinationConsiderationTransferredInventory_450" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapCash_450" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaapGainLossOnSaleOfBusiness_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapGainLossOnSaleOfBusiness_450" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_450" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_450" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaapBusinessAcquisitionSharePrice_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapBusinessAcquisitionSharePrice_450" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity_450" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytuCostOfSaleForInvestment_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuCostOfSaleForInvestment_450" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodDescription_450" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OneTimeNonRefundablePayments" xlink:label="loc_aytuOneTimeNonRefundablePayments_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuOneTimeNonRefundablePayments_450" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytuSalesRevenueTarget_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuSalesRevenueTarget_450" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_450" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapAccretionExpense_450" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PercentageofNetSalesDescriptions" xlink:label="loc_aytuPercentageofNetSalesDescriptions_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuPercentageofNetSalesDescriptions_450" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapRevenues_450" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SubsidiariesPaymentDescription" xlink:label="loc_aytuSubsidiariesPaymentDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuSubsidiariesPaymentDescription_450" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RevenueEarnOutPayment" xlink:label="loc_aytuRevenueEarnOutPayment_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuRevenueEarnOutPayment_450" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrepaymentofCommonStock" xlink:label="loc_aytuPrepaymentofCommonStock_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_aytuPrepaymentofCommonStock_450" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_450" xlink:to="loc_us-gaapAdditionalPaidInCapital_450" xlink:type="arc" order="27" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000032 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerOneMember" xlink:label="loc_aytuCustomerOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerTwoMember" xlink:label="loc_aytuCustomerTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerCMember" xlink:label="loc_aytuCustomerCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerCMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OtherMember" xlink:label="loc_aytuOtherMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuOtherMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000033 - Disclosure - Summary of Significant Accounting Policies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaapManufacturingFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapManufacturingFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytuLabEquipmentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_aytuLabEquipmentMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_180" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="00000035 - Disclosure - Summary of Significant Accounting Policies (Details 3)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srtParentCompanyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtParentCompanyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details 6)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LuoxisPatentMember" xlink:label="loc_aytuLuoxisPatentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_aytuLuoxisPatentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerMember" xlink:label="loc_aytuCustomerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesAxis" xlink:label="loc_aytuCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_aytuCounterpartiesAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesDomain" xlink:label="loc_aytuCounterpartiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aytuCounterpartiesAxis" xlink:to="loc_aytuCounterpartiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesDomain" xlink:label="loc_aytuCounterpartiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_aytuCounterpartiesAxis" xlink:to="loc_aytuCounterpartiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesMember" xlink:label="loc_aytuCounterpartiesMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCounterpartiesDomain" xlink:to="loc_aytuCounterpartiesMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SummaryOfSignificantAccountingPoliciesTextual" xlink:label="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapInventoryValuationReserves_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="loc_aytuFiniteLivedIntangibleAssetsExpirationMonthYear_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_aytuFiniteLivedIntangibleAssetsExpirationMonthYear_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapGoodwillImpairmentLoss_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_us-gaapConcentrationRiskPercentage1_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NumberOfcustomers" xlink:label="loc_aytuNumberOfcustomers_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual_120" xlink:to="loc_aytuNumberOfcustomers_120" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/GoingConcernDetails" xlink:title="00000040 - Disclosure - Going Concern (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails" xlink:title="00000041 - Disclosure - Fair Value Considerations (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract_110" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract_110" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails1" xlink:title="00000042 - Disclosure - Fair Value Considerations (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="loc_aytuAytuCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuAytuCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_us-gaapNoteWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapNoteWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAbstract" xlink:label="loc_aytuWarrantsAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_aytuWarrantsAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_aytuFairValueAssumptionsExpectedVolatilityRates_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_30" xlink:to="loc_aytuFairValueAssumptionsExpectedVolatilityRates_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedTerms" xlink:label="loc_aytuFairValueAssumptionsExpectedTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_30" xlink:to="loc_aytuFairValueAssumptionsExpectedTerms_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_aytuFairValueAssumptionsRiskFreeInterestRates_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_30" xlink:to="loc_aytuFairValueAssumptionsRiskFreeInterestRates_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_aytuFairValueAssumptionsExpectedDividendRates_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_30" xlink:to="loc_aytuFairValueAssumptionsExpectedDividendRates_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails2" xlink:title="00000043 - Disclosure - Fair Value Considerations (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails3" xlink:title="00000044 - Disclosure - Fair Value Considerations (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_aytuContingentConsiderationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_aytuContingentConsiderationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_aytuContingentConsiderationAbstract_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_aytuContingentConsiderationAbstract_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuContingentConsiderationAbstract_60" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" xlink:title="00000045 - Disclosure - Fair Value Considerations (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueConsiderationsTextualAbstract" xlink:label="loc_aytuFairValueConsiderationsTextualAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuFairValueConsiderationsTextualAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuFairValueConsiderationsTextualAbstract_30" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentOfContingentConsideration" xlink:label="loc_aytuAdjustmentOfContingentConsideration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuFairValueConsiderationsTextualAbstract_30" xlink:to="loc_aytuAdjustmentOfContingentConsideration_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuFairValueConsiderationsTextualAbstract_30" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetails" xlink:title="00000046 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetails1" xlink:title="00000047 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetailsTextual" xlink:title="00000048 - Disclosure - Income Taxes (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AmpioPharmaceuticalsMember" xlink:label="loc_aytuAmpioPharmaceuticalsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_aytuAmpioPharmaceuticalsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxesTextualAbstract" xlink:label="loc_aytuIncomeTaxesTextualAbstract_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIncomeTaxesTextualAbstract_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_us-gaapOperatingLossCarryforwards_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NetOperatingLossesExpirationDescription" xlink:label="loc_aytuNetOperatingLossesExpirationDescription_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_aytuNetOperatingLossesExpirationDescription_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuIncomeTaxesTextualAbstract_230" xlink:to="loc_us-gaapOtherTaxExpenseBenefit_230" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytuPrescriptionDatabaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuPrescriptionDatabaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuNatestoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SupplyOrderMember" xlink:label="loc_aytuSupplyOrderMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuSupplyOrderMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytuOfficeLeaseMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuOfficeLeaseMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapContractualObligationDueInNextTwelveMonths_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInNextTwelveMonths_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaapContractualObligationDueInSecondYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInSecondYear_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaapContractualObligationDueInThirdYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInThirdYear_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaapContractualObligationDueInFourthYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInFourthYear_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaapContractualObligationDueInFifthYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInFifthYear_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaapContractualObligationDueAfterFifthYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueAfterFifthYear_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligation_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000050 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000051 - Disclosure - Commitments and Contingencies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytuOfficeLeaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuOfficeLeaseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytuPrescriptionDatabaseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuPrescriptionDatabaseMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuNatestoMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SupplyOrderMember" xlink:label="loc_aytuSupplyOrderMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuSupplyOrderMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_aytuZolpiMistMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:to="loc_us-gaapPaymentsForRent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:to="loc_us-gaapLeaseAndRentalExpense_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytuFirstMilestonePayable_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:to="loc_aytuFirstMilestonePayable_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract_120" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommonStockDetails" xlink:title="00000052 - Disclosure - Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="loc_aytuAytuCommonStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_aytuAytuCommonStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytuClassUnitsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuClassUnitsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytuClassBUnitsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuClassBUnitsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SeriesConvertiblePreferredStockMember" xlink:label="loc_aytuSeriesConvertiblePreferredStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuSeriesConvertiblePreferredStockMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SeriesBConvertiblePreferredStockMember" xlink:label="loc_aytuSeriesBConvertiblePreferredStockMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuSeriesBConvertiblePreferredStockMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuMayTwoZeroOneSixWarrantsMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuMayTwoZeroOneSixWarrantsMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuOctoberTwoZeroOneSixWarrantsMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuOctoberTwoZeroOneSixWarrantsMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ConvertibleAPreferredStockMember" xlink:label="loc_aytuConvertibleAPreferredStockMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuConvertibleAPreferredStockMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ConvertibleBPreferredStockMember" xlink:label="loc_aytuConvertibleBPreferredStockMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuConvertibleBPreferredStockMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficersAndDirectorsMember" xlink:label="loc_aytuExecutiveOfficersAndDirectorsMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuExecutiveOfficersAndDirectorsMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaapExecutiveOfficerMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveOfficerMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockTextualAbstract" xlink:label="loc_aytuCommonStockTextualAbstract_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_aytuCommonStockTextualAbstract_570" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_570" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapCommonStockSharesAuthorized_570" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapCommonStockSharesOutstanding_570" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_570" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_570" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapPreferredStockSharesIssued_570" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_570" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity_570" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_570" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytuPreferredStockConversionPricePerShare_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuPreferredStockConversionPricePerShare_570" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_570" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_570" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytuIncrementalCommonSharesDueToConversionOfPreferredStock_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuIncrementalCommonSharesDueToConversionOfPreferredStock_570" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_570" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytuSecuritiesPurchaseAgreementCashFeePercentage_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuSecuritiesPurchaseAgreementCashFeePercentage_570" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytuClassOfWarrantOrRightPercentageOfSharesToBeIssued_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuClassOfWarrantOrRightPercentageOfSharesToBeIssued_570" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytuWarrantsToPurchaseOfCommonStockShares_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuWarrantsToPurchaseOfCommonStockShares_570" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:label="loc_aytuWarrantsIssuedToUnderwritersAsCompensationForTransaction_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuWarrantsIssuedToUnderwritersAsCompensationForTransaction_570" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytuUnrecognizedShareBasedCompensationExpenses_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuUnrecognizedShareBasedCompensationExpenses_570" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnrecognizedExpense" xlink:label="loc_aytuUnrecognizedExpense_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuUnrecognizedExpense_570" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_570" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_570" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaapRestrictedInvestmentsAtFairValue_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapRestrictedInvestmentsAtFairValue_570" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:label="loc_us-gaapInvestmentOwnedRestrictedAcquisitionDate_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapInvestmentOwnedRestrictedAcquisitionDate_570" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RevenueEarnOutPayment" xlink:label="loc_aytuRevenueEarnOutPayment_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuRevenueEarnOutPayment_570" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DescriptionOfUnrecognizedExpense" xlink:label="loc_aytuDescriptionOfUnrecognizedExpense_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuDescriptionOfUnrecognizedExpense_570" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapOtherUnderwritingExpense_570" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapSharesIssued_570" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockSharesAgreedToPurchase" xlink:label="loc_aytuCommonStockSharesAgreedToPurchase_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuCommonStockSharesAgreedToPurchase_570" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockValueAgreedToPurchase" xlink:label="loc_aytuCommonStockValueAgreedToPurchase_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuCommonStockValueAgreedToPurchase_570" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_570" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_570" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_570" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_570" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapRestrictedStockExpense_570" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_570" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_570" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapEquityFairValueDisclosure_570" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_570" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EquityRelativeFairValue" xlink:label="loc_aytuEquityRelativeFairValue_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuEquityRelativeFairValue_570" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_570" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapDebtInstrumentTerm_570" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_570" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnderwritersExercisedOfOverallotmentOption" xlink:label="loc_aytuUnderwritersExercisedOfOverallotmentOption_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuUnderwritersExercisedOfOverallotmentOption_570" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_570" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PreferredStockSharesDesignated" xlink:label="loc_aytuPreferredStockSharesDesignated_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_aytuPreferredStockSharesDesignated_570" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_570" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="loc_us-gaapSignificantPurchaseCommitmentDescription_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapSignificantPurchaseCommitmentDescription_570" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="loc_us-gaapRevenuePerformanceObligationDescriptionOfPaymentTerms_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapRevenuePerformanceObligationDescriptionOfPaymentTerms_570" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuCommonStockTextualAbstract_570" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_570" xlink:type="arc" order="51" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails" xlink:title="00000053 - Disclosure - Equity Instruments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OptionsAbstract" xlink:label="loc_aytuOptionsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuOptionsAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedVolatilityRate1" xlink:label="loc_aytuFairValueAssumptionsExpectedVolatilityRate1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuOptionsAbstract_40" xlink:to="loc_aytuFairValueAssumptionsExpectedVolatilityRate1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_aytuFairValueAssumptionsRiskFreeInterestRate1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuOptionsAbstract_40" xlink:to="loc_aytuFairValueAssumptionsRiskFreeInterestRate1_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedTerm1" xlink:label="loc_aytuFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuOptionsAbstract_40" xlink:to="loc_aytuFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedDividendRate1" xlink:label="loc_aytuFairValueAssumptionsExpectedDividendRate1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuOptionsAbstract_40" xlink:to="loc_aytuFairValueAssumptionsExpectedDividendRate1_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails1" xlink:title="00000054 - Disclosure - Equity Instruments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_aytuShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_70" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_70" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails2" xlink:title="00000055 - Disclosure - Equity Instruments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="loc_aytuExercisePriceRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_aytuExercisePriceRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="loc_aytuExercisePriceRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_aytuExercisePriceRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails3" xlink:title="00000056 - Disclosure - Equity Instruments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_30" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_30" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails4" xlink:title="00000057 - Disclosure - Equity Instruments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails5" xlink:title="00000058 - Disclosure - Equity Instruments (Details 5)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails6" xlink:title="00000059 - Disclosure - Equity Instruments (Details 6)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAbstract" xlink:label="loc_aytuWarrantsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuWarrantsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionWeightedAverageExpectedDividend" xlink:label="loc_aytuFairValueAssumptionWeightedAverageExpectedDividend_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_70" xlink:to="loc_aytuFairValueAssumptionWeightedAverageExpectedDividend_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_aytuFairValueAssumptionRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_70" xlink:to="loc_aytuFairValueAssumptionRiskFreeInterestRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionExpectedTerm" xlink:label="loc_aytuFairValueAssumptionExpectedTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_70" xlink:to="loc_aytuFairValueAssumptionExpectedTerm_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionExpectedDividendRate" xlink:label="loc_aytuFairValueAssumptionExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuWarrantsAbstract_70" xlink:to="loc_aytuFairValueAssumptionExpectedDividendRate_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetailsTextual" xlink:title="00000060 - Disclosure - Equity Instruments (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytuTwoThousandFifteenStockOptionAndIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aytuTwoThousandFifteenStockOptionAndIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_TwoThousandFifteenPlanMember" xlink:label="loc_aytuTwoThousandFifteenPlanMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aytuTwoThousandFifteenPlanMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficerDirectorAndConsultantsMember" xlink:label="loc_aytuExecutiveOfficerDirectorAndConsultantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuExecutiveOfficerDirectorAndConsultantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaapExecutiveOfficerMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveOfficerMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaapOfficerMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapOfficerMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytuAytuBioscienceIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aytuAytuBioscienceIncMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NovemberTwoThousandSixTeenPublicOfferingMember" xlink:label="loc_aytuNovemberTwoThousandSixTeenPublicOfferingMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_aytuNovemberTwoThousandSixTeenPublicOfferingMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember" xlink:label="loc_aytuNovemberTwoThousandSixTeenPublicOfferingOneMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_aytuNovemberTwoThousandSixTeenPublicOfferingOneMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuMayTwoZeroOneSixWarrantsMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuMayTwoZeroOneSixWarrantsMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuOctoberTwoZeroOneSixWarrantsMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuOctoberTwoZeroOneSixWarrantsMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EquityInstrumentsTextualAbstract" xlink:label="loc_aytuEquityInstrumentsTextualAbstract_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytuWarrantsToPurchaseOfCommonStockShares_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuWarrantsToPurchaseOfCommonStockShares_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_400" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsExercisePriceTerm" xlink:label="loc_aytuWarrantsExercisePriceTerm_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuWarrantsExercisePriceTerm_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsGeneratedNoncashExpense" xlink:label="loc_aytuWarrantsGeneratedNoncashExpense_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuWarrantsGeneratedNoncashExpense_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferDescription" xlink:label="loc_aytuWarrantTenderOfferDescription_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuWarrantTenderOfferDescription_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_400" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_400" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_400" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapShareBasedCompensation_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_400" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_VestingExpiryDate" xlink:label="loc_aytuVestingExpiryDate_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuVestingExpiryDate_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_400" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapStockOptionPlanExpense_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NewWarrantsToPurchaseOfCommonStock" xlink:label="loc_aytuNewWarrantsToPurchaseOfCommonStock_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuNewWarrantsToPurchaseOfCommonStock_400" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapEquityFairValueDisclosure_400" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" xlink:label="loc_aytuStockIssuedDuringPeriodValueRestrictedStockCancelled_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuStockIssuedDuringPeriodValueRestrictedStockCancelled_400" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_400" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_400" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_400" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_400" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncrementalFairValueOfWarrant" xlink:label="loc_aytuIncrementalFairValueOfWarrant_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuEquityInstrumentsTextualAbstract_400" xlink:to="loc_aytuIncrementalFairValueOfWarrant_400" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/RelatedPartyTransactionsDetails" xlink:title="00000061 - Disclosure - Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficerOneMember" xlink:label="loc_aytuExecutiveOfficerOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuExecutiveOfficerOneMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaapExecutiveOfficerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveOfficerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GreenMember" xlink:label="loc_aytuGreenMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuGreenMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementAxis" xlink:label="loc_aytuAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_aytuAgreementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementDomain" xlink:label="loc_aytuAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_aytuAgreementAxis" xlink:to="loc_aytuAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementDomain" xlink:label="loc_aytuAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_aytuAgreementAxis" xlink:to="loc_aytuAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SponsoredResearchAgreementMember" xlink:label="loc_aytuSponsoredResearchAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuAgreementDomain" xlink:to="loc_aytuSponsoredResearchAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ServicesAgreementMember" xlink:label="loc_aytuServicesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuAgreementDomain" xlink:to="loc_aytuServicesAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_aytuRelatedPartyTransactionsTextualAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:to="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:to="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:to="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytuPrepaidExpensesAmortizationPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:to="loc_aytuPrepaidExpensesAmortizationPeriod_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract_110" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationDetails" xlink:title="00000062 - Disclosure - Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytuAytuWomensHealthMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aytuAytuWomensHealthMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytuAytuBioscienceIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aytuAytuBioscienceIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_130" xlink:to="loc_us-gaapRevenues_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:label="loc_us-gaapMinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_130" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_130" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationDetailsTextual" xlink:title="00000063 - Disclosure - Segment Information (Details Textual)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/EmployeeBenefitPlanDetails" xlink:title="00000064 - Disclosure - Employee Benefit Plan (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aytubio.com/role/SubsequentEventsDetails" xlink:title="00000065 - Disclosure - Subsequent Events (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapDirectorMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SubsequentEventsTextualAbstract" xlink:label="loc_aytuSubsequentEventsTextualAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuSubsequentEventsTextualAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSubsequentEventsTextualAbstract_30" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AssetPurchase" xlink:label="loc_aytuAssetPurchase_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_aytuSubsequentEventsTextualAbstract_30" xlink:to="loc_aytuAssetPurchase_30" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>aytu-20180630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aytu%2D20180630.xfr; Date: 2018%2D09%2D06T20:07:56Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuBioscienceIncMember" xlink:label="aytu_AytuBioscienceIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuBioscienceIncMember" xlink:to="aytu_AytuBioscienceIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AytuBioscienceIncMember_lbl" xml:lang="en-US">Aytu Bioscience Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuWomensHealthMember" xlink:label="aytu_AytuWomensHealthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuWomensHealthMember" xlink:to="aytu_AytuWomensHealthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AytuWomensHealthMember_lbl" xml:lang="en-US">Aytu Womens Health [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NuelleIncMember" xlink:label="aytu_NuelleIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NuelleIncMember" xlink:to="aytu_NuelleIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NuelleIncMember_lbl" xml:lang="en-US">Nuelle, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProstascintBusinessMember" xlink:label="aytu_ProstascintBusinessMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProstascintBusinessMember" xlink:to="aytu_ProstascintBusinessMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProstascintBusinessMember_lbl" xml:lang="en-US">Prostascint Business [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrimsolBusinessMember" xlink:label="aytu_PrimsolBusinessMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrimsolBusinessMember" xlink:to="aytu_PrimsolBusinessMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PrimsolBusinessMember_lbl" xml:lang="en-US">Primsol Business [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="aytu_NatestoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NatestoMember" xlink:to="aytu_NatestoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NatestoMember_lbl" xml:lang="en-US">Natesto [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Statement Class Of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:to="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Fifteen Stock Option And Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationMember" xlink:label="aytu_ContingentConsiderationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationMember" xlink:to="aytu_ContingentConsiderationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationMember_lbl" xml:lang="en-US">Contingent Consideration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AwhAssetsMember" xlink:label="aytu_AwhAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AwhAssetsMember" xlink:to="aytu_AwhAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AwhAssetsMember_lbl" xml:lang="en-US">Awh Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="aytu_AytuCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuCommonStockMember" xlink:to="aytu_AytuCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AytuCommonStockMember_lbl" xml:lang="en-US">Aytu Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DiscountedCashFlowMethodMember" xlink:label="aytu_DiscountedCashFlowMethodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DiscountedCashFlowMethodMember" xlink:to="aytu_DiscountedCashFlowMethodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DiscountedCashFlowMethodMember_lbl" xml:lang="en-US">Discounted Cash Flow Method [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="aytu_JazzPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_JazzPharmaceuticalsIncMember" xlink:to="aytu_JazzPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_JazzPharmaceuticalsIncMember_lbl" xml:lang="en-US">Jazz Pharmaceuticals Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ThirdUpfrontMember" xlink:label="aytu_ThirdUpfrontMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ThirdUpfrontMember" xlink:to="aytu_ThirdUpfrontMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ThirdUpfrontMember_lbl" xml:lang="en-US">Third Upfront [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="aytu_LicenseAndSupplyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAndSupplyAgreementMember" xlink:to="aytu_LicenseAndSupplyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LicenseAndSupplyAgreementMember_lbl" xml:lang="en-US">License And Supply Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FirstMilestoneMember" xlink:label="aytu_FirstMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FirstMilestoneMember" xlink:to="aytu_FirstMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FirstMilestoneMember_lbl" xml:lang="en-US">First Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SecondMilestoneMember" xlink:label="aytu_SecondMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecondMilestoneMember" xlink:to="aytu_SecondMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SecondMilestoneMember_lbl" xml:lang="en-US">Second Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ThirdMilestoneMember" xlink:label="aytu_ThirdMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ThirdMilestoneMember" xlink:to="aytu_ThirdMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ThirdMilestoneMember_lbl" xml:lang="en-US">Third Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ForthMilestoneMember" xlink:label="aytu_ForthMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ForthMilestoneMember" xlink:to="aytu_ForthMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ForthMilestoneMember_lbl" xml:lang="en-US">Forth Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FifthMilestoneMember" xlink:label="aytu_FifthMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FifthMilestoneMember" xlink:to="aytu_FifthMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FifthMilestoneMember_lbl" xml:lang="en-US">Fifth Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuMember" xlink:label="aytu_AytuMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuMember" xlink:to="aytu_AytuMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AytuMember_lbl" xml:lang="en-US">Aytu [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="us-gaap_ManufacturingFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LabEquipmentMember" xlink:label="aytu_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LabEquipmentMember" xlink:to="aytu_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LuoxisPatentMember" xlink:label="aytu_LuoxisPatentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LuoxisPatentMember" xlink:to="aytu_LuoxisPatentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LuoxisPatentMember_lbl" xml:lang="en-US">Luoxis Patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="us-gaap_NoteWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoteWarrantMember" xlink:to="us-gaap_NoteWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoteWarrantMember_lbl" xml:lang="en-US">Note Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OfficeLeaseMember" xlink:label="aytu_OfficeLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeLeaseMember" xlink:to="aytu_OfficeLeaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OfficeLeaseMember_lbl" xml:lang="en-US">Office Lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="aytu_PrescriptionDatabaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrescriptionDatabaseMember" xlink:to="aytu_PrescriptionDatabaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PrescriptionDatabaseMember_lbl" xml:lang="en-US">Prescription Database [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="us-gaap_ExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveOfficerMember" xlink:to="us-gaap_ExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficerOneMember" xlink:label="aytu_ExecutiveOfficerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExecutiveOfficerOneMember" xlink:to="aytu_ExecutiveOfficerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExecutiveOfficerOneMember_lbl" xml:lang="en-US">Executive Officer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GreenMember" xlink:label="aytu_GreenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GreenMember" xlink:to="aytu_GreenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_GreenMember_lbl" xml:lang="en-US">Green [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficerDirectorAndConsultantsMember" xlink:label="aytu_ExecutiveOfficerDirectorAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExecutiveOfficerDirectorAndConsultantsMember" xlink:to="aytu_ExecutiveOfficerDirectorAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExecutiveOfficerDirectorAndConsultantsMember_lbl" xml:lang="en-US">Executive Officer Director And Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementAxis" xlink:label="aytu_AgreementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AgreementAxis" xlink:to="aytu_AgreementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SponsoredResearchAgreementMember" xlink:label="aytu_SponsoredResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SponsoredResearchAgreementMember" xlink:to="aytu_SponsoredResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SponsoredResearchAgreementMember_lbl" xml:lang="en-US">Sponsored Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ServicesAgreementMember" xlink:label="aytu_ServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ServicesAgreementMember" xlink:to="aytu_ServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ServicesAgreementMember_lbl" xml:lang="en-US">Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CADMember" xlink:label="aytu_CADMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CADMember" xlink:to="aytu_CADMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CADMember_lbl" xml:lang="en-US">CAD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="aytu_ZolpiMistMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ZolpiMistMember" xlink:to="aytu_ZolpiMistMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ZolpiMistMember_lbl" xml:lang="en-US">ZolpiMist [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Trade Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="us-gaap_CustomerContractsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerContractsMember" xlink:to="us-gaap_CustomerContractsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerContractsMember_lbl" xml:lang="en-US">Customer Contracts [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk By Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerOneMember" xlink:label="aytu_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerOneMember" xlink:to="aytu_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerOneMember_lbl" xml:lang="en-US">CustomerOne</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk By Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">SalesRevenueNetMember</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerTwoMember" xlink:label="aytu_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerTwoMember" xlink:to="aytu_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerTwoMember_lbl" xml:lang="en-US">CustomerTwo</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerCMember" xlink:label="aytu_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerCMember" xlink:to="aytu_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerCMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">AccountsReceivableMember</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OtherMember" xlink:label="aytu_OtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OtherMember" xlink:to="aytu_OtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OtherMember_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">Statel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IPOMember_2_lbl" xml:lang="en-US">Public offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SupplyOrderMember" xlink:label="aytu_SupplyOrderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyOrderMember" xlink:to="aytu_SupplyOrderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SupplyOrderMember_lbl" xml:lang="en-US">Supply order [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:to="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="aytu_MayTwoZeroOneSixWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_MayTwoZeroOneSixWarrantsMember" xlink:to="aytu_MayTwoZeroOneSixWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_MayTwoZeroOneSixWarrantsMember_lbl" xml:lang="en-US">May 2016 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="aytu_OctoberTwoZeroOneSixWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:to="aytu_OctoberTwoZeroOneSixWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OctoberTwoZeroOneSixWarrantsMember_lbl" xml:lang="en-US">October 2016 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="aytu_ExercisePriceRangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeOneMember" xlink:to="aytu_ExercisePriceRangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="aytu_ExercisePriceRangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeTwoMember" xlink:to="aytu_ExercisePriceRangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_TwoThousandFifteenPlanMember" xlink:label="aytu_TwoThousandFifteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TwoThousandFifteenPlanMember" xlink:to="aytu_TwoThousandFifteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_TwoThousandFifteenPlanMember_lbl" xml:lang="en-US">2015 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficerMember" xlink:to="us-gaap_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NovemberTwoThousandSixTeenPublicOfferingMember" xlink:label="aytu_NovemberTwoThousandSixTeenPublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NovemberTwoThousandSixTeenPublicOfferingMember" xlink:to="aytu_NovemberTwoThousandSixTeenPublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NovemberTwoThousandSixTeenPublicOfferingMember_lbl" xml:lang="en-US">November 2016 Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember" xlink:label="aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember" xlink:to="aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember_lbl" xml:lang="en-US">November 2016 Public Offering One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Aytu [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerMember" xlink:label="aytu_CustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerMember" xlink:to="aytu_CustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ConvertibleAPreferredStockMember" xlink:label="aytu_ConvertibleAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConvertibleAPreferredStockMember" xlink:to="aytu_ConvertibleAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ConvertibleAPreferredStockMember_lbl" xml:lang="en-US">ConvertibleAPreferredStock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ConvertibleBPreferredStockMember" xlink:label="aytu_ConvertibleBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConvertibleBPreferredStockMember" xlink:to="aytu_ConvertibleBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ConvertibleBPreferredStockMember_lbl" xml:lang="en-US">ConvertibleAPreferredStock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficersAndDirectorsMember" xlink:label="aytu_ExecutiveOfficersAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExecutiveOfficersAndDirectorsMember" xlink:to="aytu_ExecutiveOfficersAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ExecutiveOfficersAndDirectorsMember_lbl" xml:lang="en-US">Executive Officers and directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesAxis" xlink:label="aytu_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CounterpartiesAxis" xlink:to="aytu_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesMember" xlink:label="aytu_CounterpartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CounterpartiesMember" xlink:to="aytu_CounterpartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CounterpartiesMember_lbl" xml:lang="en-US">Counterparties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AmpioPharmaceuticalsMember" xlink:label="aytu_AmpioPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AmpioPharmaceuticalsMember" xlink:to="aytu_AmpioPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AmpioPharmaceuticalsMember_lbl" xml:lang="en-US">Ampio's [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DocumentAndEntityInformationAbstract" xlink:label="aytu_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DocumentAndEntityInformationAbstract" xlink:to="aytu_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="aytu_CoreAndDevelopedTechnologyNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CoreAndDevelopedTechnologyNet" xlink:to="aytu_CoreAndDevelopedTechnologyNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CoreAndDevelopedTechnologyNet_lbl" xml:lang="en-US">Developed technology, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="us-gaap_IndefiniteLivedContractualRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedContractualRights" xlink:to="us-gaap_IndefiniteLivedContractualRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedContractualRights_lbl" xml:lang="en-US">Customer contracts, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="us-gaap_IndefiniteLivedTradeNames" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTradeNames" xlink:to="us-gaap_IndefiniteLivedTradeNames_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTradeNames_lbl" xml:lang="en-US">Trade names, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Licensed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AccruedCompensationCurrent" xlink:label="aytu_AccruedCompensationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedCompensationCurrent" xlink:to="aytu_AccruedCompensationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AccruedCompensationCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Current deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Current contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Long-term deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Warrant derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 1,794,762 and 41,244, respectively as of June 30, 2018 and 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Product revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total product revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="aytu_ResearchAndDevelopmentRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ResearchAndDevelopmentRelatedParty" xlink:to="aytu_ResearchAndDevelopmentRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ResearchAndDevelopmentRelatedParty_lbl" xml:lang="en-US">Research and development - related party (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Sales, general and administrative - related party (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">(Loss) on investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other gain</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Derivative income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_2_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_2_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_2_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuanceNetOfIssuanceCostsValue" xlink:label="aytu_StockIssuanceNetOfIssuanceCostsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuanceNetOfIssuanceCostsValue" xlink:to="aytu_StockIssuanceNetOfIssuanceCostsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuanceNetOfIssuanceCostsValue_lbl" xml:lang="en-US">Lincoln Park stock issuance, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuanceNetOfIssuanceCostsShares" xlink:label="aytu_StockIssuanceNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuanceNetOfIssuanceCostsShares" xlink:to="aytu_StockIssuanceNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuanceNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Lincoln Park stock issuance, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockIssuedToExecutivesValue" xlink:label="aytu_CommonStockIssuedToExecutivesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockIssuedToExecutivesValue" xlink:to="aytu_CommonStockIssuedToExecutivesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockIssuedToExecutivesValue_lbl" xml:lang="en-US">Common stock issued to executives</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockIssuedToExecutivesShare" xlink:label="aytu_CommonStockIssuedToExecutivesShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockIssuedToExecutivesShare" xlink:to="aytu_CommonStockIssuedToExecutivesShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockIssuedToExecutivesShare_lbl" xml:lang="en-US">Common stock issued to executives, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issurance of warrants to initial investors</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" xlink:label="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" xlink:to="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue_lbl" xml:lang="en-US">Issuance of common stock, net of in issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" xlink:label="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" xlink:to="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of common stock, net of in issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_lbl" xml:lang="en-US">Warrants issued in connection with registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_lbl" xml:lang="en-US">Warrants issued in connection with registered offering to the placement agents for the over-allotment option</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:label="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:to="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_lbl" xml:lang="en-US">Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferNetIssuanceCostsValue" xlink:label="aytu_WarrantTenderOfferNetIssuanceCostsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantTenderOfferNetIssuanceCostsValue" xlink:to="aytu_WarrantTenderOfferNetIssuanceCostsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantTenderOfferNetIssuanceCostsValue_lbl" xml:lang="en-US">Warrant tender offer, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferNetIssuanceCostsShares" xlink:label="aytu_WarrantTenderOfferNetIssuanceCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantTenderOfferNetIssuanceCostsShares" xlink:to="aytu_WarrantTenderOfferNetIssuanceCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantTenderOfferNetIssuanceCostsShares_lbl" xml:lang="en-US">Warrant tender offer, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Earn-out payment to Nuelle shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Earn-out payment to Nuelle shareholders, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:label="aytu_IssuanceOfPreferredAndCommonStockNetCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:to="aytu_IssuanceOfPreferredAndCommonStockNetCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfPreferredAndCommonStockNetCost_lbl" xml:lang="en-US">Issuance of preferred and common stock, net of cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:label="aytu_IssuanceOfPreferredAndCommonStockNetShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:to="aytu_IssuanceOfPreferredAndCommonStockNetShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfPreferredAndCommonStockNetShare_lbl" xml:lang="en-US">Issuance of preferred and common stock, net of cash issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:label="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:to="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost_lbl" xml:lang="en-US">Issuance of preferred and common stock, net of cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:label="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:to="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare_lbl" xml:lang="en-US">Issuance of preferred and common stock, net of cash issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Preferred stock converted in common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Preferred stock converted in common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RegisteredOfferingCost" xlink:label="aytu_RegisteredOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RegisteredOfferingCost" xlink:to="aytu_RegisteredOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RegisteredOfferingCost_lbl" xml:lang="en-US">S-3 registered offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExercisesValue" xlink:label="aytu_WarrantExercisesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExercisesValue" xlink:to="aytu_WarrantExercisesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantExercisesValue_lbl" xml:lang="en-US">Warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExercisesShares" xlink:label="aytu_WarrantExercisesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExercisesShares" xlink:to="aytu_WarrantExercisesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantExercisesShares_lbl" xml:lang="en-US">Warrant exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments_lbl" xml:lang="en-US">Warrant amendments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Investment in Subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Investment in Subsidiary, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" xlink:label="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" xlink:to="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant_lbl" xml:lang="en-US">Warrant exercise of derivative warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="aytu_AdjustmentForRoundingOfValueDueToConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:to="aytu_AdjustmentForRoundingOfValueDueToConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentForRoundingOfValueDueToConversion_lbl" xml:lang="en-US">Adjustment for rounding of shares due to stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="aytu_AdjustmentForRoundingOfSharesDueToConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:to="aytu_AdjustmentForRoundingOfSharesDueToConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentForRoundingOfSharesDueToConversion_lbl" xml:lang="en-US">Adjustment for rounding of shares due to stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_2_lbl" xml:lang="en-US">Warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:to="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember_2_lbl" xml:lang="en-US">LincolnPark</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Issuance of preferred and common stock, net of cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:label="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:to="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_lbl" xml:lang="en-US">Issuance of preferred and common stock, net of cash issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, amortization and accretion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Issuance of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="us-gaap_GainLossOnSaleOfOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="us-gaap_GainLossOnSaleOfOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherInvestments_lbl" xml:lang="en-US">Other gain</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Warrants issuance and amendments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainOnDerivative_lbl" xml:lang="en-US">Derivative income</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:to="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_lbl" xml:lang="en-US">Amortization of prepaid research and development - related party (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Loss on investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Common stock issued to executives</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US">Issuance of warrants to initial investors</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Gain on sale of asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">(Increase) in accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">(Increase) decrease in inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">(Increase) in prepaid expenses and other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">(Decrease) increase in accounts payable and other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">(Decrease) in accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="aytu_IncreaseDecreaseInAccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncreaseDecreaseInAccruedCompensation" xlink:to="aytu_IncreaseDecreaseInAccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncreaseDecreaseInAccruedCompensation_lbl" xml:lang="en-US">Increase (decrease) in accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">(Decrease) in deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows used in investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="aytu_PaymentsForDepositsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsForDepositsInvestingActivities" xlink:to="aytu_PaymentsForDepositsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_PaymentsForDepositsInvestingActivities_lbl" xml:lang="en-US">Deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xml:lang="en-US">Contingent consideration payment</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsToAcquireOtherProductiveAssetsOne" xlink:label="aytu_PaymentsToAcquireOtherProductiveAssetsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsToAcquireOtherProductiveAssetsOne" xlink:to="aytu_PaymentsToAcquireOtherProductiveAssetsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_PaymentsToAcquireOtherProductiveAssetsOne_lbl" xml:lang="en-US">Purchase of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfOtherInvestments_lbl" xml:lang="en-US">Investment in Acerus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Sale of investment in Acerus cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Sales of Primsol assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US">Purchase of Primsol asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash proceed from Nuelle</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xml:lang="en-US">Cost related to Nuelle acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Issuance of preferred, common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_lbl" xml:lang="en-US">Issuance costs related to preferred, common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfEquity" xlink:to="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity_lbl" xml:lang="en-US">Issuance of preferred, common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_lbl" xml:lang="en-US">Issuance costs related to preferred, common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentForRegisteredOfferingCost" xlink:label="aytu_PaymentForRegisteredOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentForRegisteredOfferingCost" xlink:to="aytu_PaymentForRegisteredOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_PaymentForRegisteredOfferingCost_lbl" xml:lang="en-US">S-3 registered offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock to Lincoln Park</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Costs related to the sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProceedsOfWarrantTenderOffer" xlink:label="aytu_ProceedsOfWarrantTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsOfWarrantTenderOffer" xlink:to="aytu_ProceedsOfWarrantTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProceedsOfWarrantTenderOffer_lbl" xml:lang="en-US">Warrant tender offer</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProceedsFromWarrantTenderOffer" xlink:label="aytu_ProceedsFromWarrantTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsFromWarrantTenderOffer" xlink:to="aytu_ProceedsFromWarrantTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ProceedsFromWarrantTenderOffer_lbl" xml:lang="en-US">Warrant tender offer cost</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsForRegisteredOfferingCosts" xlink:label="aytu_PaymentsForRegisteredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsForRegisteredOfferingCosts" xlink:to="aytu_PaymentsForRegisteredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aytu_PaymentsForRegisteredOfferingCosts_lbl" xml:lang="en-US">Registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RepaymentsForRegisteredOfferingCosts" xlink:label="aytu_RepaymentsForRegisteredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RepaymentsForRegisteredOfferingCosts" xlink:to="aytu_RepaymentsForRegisteredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RepaymentsForRegisteredOfferingCosts_lbl" xml:lang="en-US">Registered offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OverallotmentWarrantsPurchased" xlink:label="aytu_OverallotmentWarrantsPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OverallotmentWarrantsPurchased" xlink:to="aytu_OverallotmentWarrantsPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OverallotmentWarrantsPurchased_lbl" xml:lang="en-US">Over-allotment warrants purchased by placement agents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:label="aytu_WarrantsIssuedToInvestorsAndUnderwriters" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:to="aytu_WarrantsIssuedToInvestorsAndUnderwriters_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsIssuedToInvestorsAndUnderwriters_lbl" xml:lang="en-US">Warrants issued to investors and underwriters (see Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExerciseOfDerivativeWarrants" xlink:label="aytu_WarrantExerciseOfDerivativeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExerciseOfDerivativeWarrants" xlink:to="aytu_WarrantExerciseOfDerivativeWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_WarrantExerciseOfDerivativeWarrants_lbl" xml:lang="en-US">Warrant exercise of derivative warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationIncludedInAccountsPayable" xlink:label="aytu_ContingentConsiderationIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationIncludedInAccountsPayable" xlink:to="aytu_ContingentConsiderationIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationIncludedInAccountsPayable_lbl" xml:lang="en-US">Contingent consideration included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EarnOutPaymentToOtherShareholders" xlink:label="aytu_EarnOutPaymentToOtherShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EarnOutPaymentToOtherShareholders" xlink:to="aytu_EarnOutPaymentToOtherShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EarnOutPaymentToOtherShareholders_lbl" xml:lang="en-US">Earn-out payment to Nuelle Shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_Purchaseofassetincludedincontingentconsideration" xlink:label="aytu_Purchaseofassetincludedincontingentconsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Purchaseofassetincludedincontingentconsideration" xlink:to="aytu_Purchaseofassetincludedincontingentconsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_Purchaseofassetincludedincontingentconsideration_lbl" xml:lang="en-US">Purchase of asset included in contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentCconsideration" xlink:label="aytu_BusinessCombinationContingentCconsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentCconsideration" xlink:to="aytu_BusinessCombinationContingentCconsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentCconsideration_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:label="aytu_IssuanceOfCommonStockToNuelleShareHolders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:to="aytu_IssuanceOfCommonStockToNuelleShareHolders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfCommonStockToNuelleShareHolders_lbl" xml:lang="en-US">Issuance of common stock to Nuelle share holders</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FixedAssetsIncludedInAccountsPayable" xlink:label="aytu_FixedAssetsIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedAssetsIncludedInAccountsPayable" xlink:to="aytu_FixedAssetsIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Fixed assets included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" xlink:label="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" xlink:to="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents_lbl" xml:lang="en-US">Warrants issued in connection with the equity financing to the placement agents</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer" xlink:label="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer" xlink:to="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer_lbl" xml:lang="en-US">Warrants amended in connection with warrant tender offer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GoingConcernDisclosureAbstract" xlink:label="aytu_GoingConcernDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GoingConcernDisclosureAbstract" xlink:to="aytu_GoingConcernDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_GoingConcernDisclosureAbstract_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Considerations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockTextBlock" xlink:label="aytu_CommonStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockTextBlock" xlink:to="aytu_CommonStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockTextBlock_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principals of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionSalesReturns" xlink:label="us-gaap_RevenueRecognitionSalesReturns" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionSalesReturns" xlink:to="us-gaap_RevenueRecognitionSalesReturns_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionSalesReturns_lbl" xml:lang="en-US">Estimated Sales Returns and Allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Business Risks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RestrictedStocksPolicyTextBlock" xlink:label="aytu_RestrictedStocksPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RestrictedStocksPolicyTextBlock" xlink:to="aytu_RestrictedStocksPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RestrictedStocksPolicyTextBlock_lbl" xml:lang="en-US">Restricted Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Income (Loss) Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Adoption of Newly Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="aytu_BusinessDescriptionAndBasisOfPresentationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="aytu_BusinessDescriptionAndBasisOfPresentationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessDescriptionAndBasisOfPresentationTable_lbl" xml:lang="en-US">Business Description And Basis Of Presentation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="aytu_BusinessDescriptionAndBasisOfPresentationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="aytu_BusinessDescriptionAndBasisOfPresentationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessDescriptionAndBasisOfPresentationLineItems_lbl" xml:lang="en-US">Business Description And Basis Of Presentation [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AwhAssetsMember" xlink:to="aytu_AwhAssetsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_AwhAssetsMember_2_lbl" xml:lang="en-US">AWH Assets [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated future amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of allocation on consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">Schedule of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedules of concentration of business risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2_lbl" xml:lang="en-US">Schedule of future amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_2_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of significant assumptions in valuing the warrant derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of changes in the warrant derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_2_lbl" xml:lang="en-US">Schedule of changes in the contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax benefit resulting from applying statutory rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:to="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRentExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_2_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_3_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock activity</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ScheduleOfOptionsOutstanding" xlink:label="aytu_ScheduleOfOptionsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ScheduleOfOptionsOutstanding" xlink:to="aytu_ScheduleOfOptionsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ScheduleOfOptionsOutstanding_lbl" xml:lang="en-US">Schedule of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of all warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2_lbl" xml:lang="en-US">Schedule of significant assumptions used in valuing options/warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of financial information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationAbstract" xlink:label="aytu_ContingentConsiderationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationAbstract" xlink:to="aytu_ContingentConsiderationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ContingentConsiderationAbstract_lbl" xml:lang="en-US">Contingent Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Balance as of June 30, 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" xml:lang="en-US">Increase due to accretion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow_lbl" xml:lang="en-US">Decrease due to contractual payment</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement_lbl" xml:lang="en-US">Decrease due to remeasurement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Balance as of June 30, 2018</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuMember" xlink:to="aytu_AytuMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_AytuMember_2_lbl" xml:lang="en-US">Aytu BioScience, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LicenseAndSupplyAgreementMember" xlink:to="aytu_LicenseAndSupplyAgreementMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_LicenseAndSupplyAgreementMember_2_lbl" xml:lang="en-US">License and Supply Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:label="aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual_lbl" xml:lang="en-US">Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' equity, reverse stock split, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xml:lang="en-US">Upfront amount</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="aytu_BusinessCombinationContingentConsiderationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationPercentage" xlink:to="aytu_BusinessCombinationContingentConsiderationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationPercentage_lbl" xml:lang="en-US">Percentage of a revenue share net sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_2_lbl" xml:lang="en-US">Maximum aggregate payout for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_lbl" xml:lang="en-US">Contingent consideration valued</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationRevalued" xlink:label="aytu_BusinessCombinationContingentConsiderationRevalued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationRevalued" xlink:to="aytu_BusinessCombinationContingentConsiderationRevalued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationRevalued_lbl" xml:lang="en-US">Contingent consideration was initially revalued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_lbl" xml:lang="en-US">Share-based payment</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="aytu_BusinessCombinationConsiderationTransferredInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationConsiderationTransferredInventory" xlink:to="aytu_BusinessCombinationConsiderationTransferredInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationConsiderationTransferredInventory_lbl" xml:lang="en-US">Inventory from primsol business</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xml:lang="en-US">Recognized gain loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Stock issued aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_lbl" xml:lang="en-US">Purchase of common stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_lbl" xml:lang="en-US">Gross proceeds from the sales</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CostOfSaleForInvestment" xlink:label="aytu_CostOfSaleForInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CostOfSaleForInvestment" xlink:to="aytu_CostOfSaleForInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CostOfSaleForInvestment_lbl" xml:lang="en-US">Total of cost of sale</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodDescription_lbl" xml:lang="en-US">Maximum aggregate amount payable milestone payments, description</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OneTimeNonRefundablePayments" xlink:label="aytu_OneTimeNonRefundablePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OneTimeNonRefundablePayments" xlink:to="aytu_OneTimeNonRefundablePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OneTimeNonRefundablePayments_lbl" xml:lang="en-US">One-time, non-refundable payments</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SalesRevenueTarget" xlink:label="aytu_SalesRevenueTarget" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SalesRevenueTarget" xlink:to="aytu_SalesRevenueTarget_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SalesRevenueTarget_lbl" xml:lang="en-US">Sales revenue target</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2_lbl" xml:lang="en-US">Net identifiable asset acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US">Contingent consideration accretion expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PercentageofNetSalesDescriptions" xlink:label="aytu_PercentageofNetSalesDescriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PercentageofNetSalesDescriptions" xlink:to="aytu_PercentageofNetSalesDescriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PercentageofNetSalesDescriptions_lbl" xml:lang="en-US">Percentage of net sales, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SubsidiariesPaymentDescription" xlink:label="aytu_SubsidiariesPaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SubsidiariesPaymentDescription" xlink:to="aytu_SubsidiariesPaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SubsidiariesPaymentDescription_lbl" xml:lang="en-US">Subsidiaries payment, description</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RevenueEarnOutPayment" xlink:label="aytu_RevenueEarnOutPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RevenueEarnOutPayment" xlink:to="aytu_RevenueEarnOutPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RevenueEarnOutPayment_lbl" xml:lang="en-US">Revenue earn out payment</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrepaymentofCommonStock" xlink:label="aytu_PrepaymentofCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrepaymentofCommonStock" xlink:to="aytu_PrepaymentofCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PrepaymentofCommonStock_lbl" xml:lang="en-US">Prepayment of common stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_2_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_2_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerOneMember" xlink:to="aytu_CustomerOneMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_CustomerOneMember_2_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerTwoMember" xlink:to="aytu_CustomerTwoMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_CustomerTwoMember_2_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerCMember" xlink:to="aytu_CustomerCMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_CustomerCMember_2_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OtherMember" xlink:to="aytu_OtherMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_OtherMember_2_lbl" xml:lang="en-US">Other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_2_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNetMember_2_lbl" xml:lang="en-US">Revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableMember_2_lbl" xml:lang="en-US">Accounts receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of concentration risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ManufacturingFacilityMember_2_lbl" xml:lang="en-US">Manufacturing equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_2_lbl" xml:lang="en-US">Leasehold improvements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_2_lbl" xml:lang="en-US">Office equipment, furniture and other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LabEquipmentMember" xlink:to="aytu_LabEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_LabEquipmentMember_2_lbl" xml:lang="en-US">Lab equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Useful Lives in years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2_lbl" xml:lang="en-US">2019</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2_lbl" xml:lang="en-US">2020</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2_lbl" xml:lang="en-US">2021</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2_lbl" xml:lang="en-US">2023</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Future amortization expense, Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LuoxisPatentMember" xlink:to="aytu_LuoxisPatentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_LuoxisPatentMember_2_lbl" xml:lang="en-US">Luoxis patents [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_3_lbl" xml:lang="en-US">Gross revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CounterpartiesAxis" xlink:to="aytu_CounterpartiesAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_CounterpartiesAxis_2_lbl" xml:lang="en-US">CounterpartiesAxis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SummaryOfSignificantAccountingPoliciesTextual" xlink:label="aytu_SummaryOfSignificantAccountingPoliciesTextual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SummaryOfSignificantAccountingPoliciesTextual" xlink:to="aytu_SummaryOfSignificantAccountingPoliciesTextual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_SummaryOfSignificantAccountingPoliciesTextual_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Estimated returns allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Inventory reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_2_lbl" xml:lang="en-US">Costs of establishing patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Patent lives</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:to="aytu_FiniteLivedIntangibleAssetsExpirationMonthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FiniteLivedIntangibleAssetsExpirationMonthYear_lbl" xml:lang="en-US">Patents expires</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Common stock equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Percentage of concentration business risks</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NumberOfcustomers" xlink:label="aytu_NumberOfcustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NumberOfcustomers" xlink:to="aytu_NumberOfcustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NumberOfcustomers_lbl" xml:lang="en-US">Number of customers</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GoingConcernTextualAbstract" xlink:label="aytu_GoingConcernTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GoingConcernTextualAbstract" xlink:to="aytu_GoingConcernTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_GoingConcernTextualAbstract_lbl" xml:lang="en-US">Going Concern (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xml:lang="en-US">Net cash used in operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="us-gaap_StockholdersEquityOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="us-gaap_PaymentsForOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOperatingActivities" xlink:to="us-gaap_PaymentsForOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForOperatingActivities_lbl" xml:lang="en-US">Cash for operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_2_lbl" xml:lang="en-US">Level 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_2_lbl" xml:lang="en-US">Level 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_2_lbl" xml:lang="en-US">Level 3 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_2_lbl" xml:lang="en-US">Fair Value Measurements Using [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuCommonStockMember" xlink:to="aytu_AytuCommonStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_AytuCommonStockMember_2_lbl" xml:lang="en-US">At Issuance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoteWarrantMember" xlink:to="us-gaap_NoteWarrantMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NoteWarrantMember_2_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAbstract" xlink:label="aytu_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsAbstract" xlink:to="aytu_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedVolatilityRates" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedVolatilityRates" xlink:to="aytu_FairValueAssumptionsExpectedVolatilityRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedTerms" xlink:label="aytu_FairValueAssumptionsExpectedTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedTerms" xlink:to="aytu_FairValueAssumptionsExpectedTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsExpectedTerms_lbl" xml:lang="en-US">Equivalent term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsRiskFreeInterestRates" xlink:label="aytu_FairValueAssumptionsRiskFreeInterestRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsRiskFreeInterestRates" xlink:to="aytu_FairValueAssumptionsRiskFreeInterestRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedDividendRates" xlink:label="aytu_FairValueAssumptionsExpectedDividendRates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedDividendRates" xlink:to="aytu_FairValueAssumptionsExpectedDividendRates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Balance, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_lbl" xml:lang="en-US">Warrant issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises_lbl" xml:lang="en-US">Warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Change in fair value included in earnings</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise" xlink:label="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise" xlink:to="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise_lbl" xml:lang="en-US">Reclassification of warrant from liability to equity upon amendment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Balance, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_2_lbl" xml:lang="en-US">Increase due to purchase of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement_lbl" xml:lang="en-US">Increase due to remeasurement</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment_lbl" xml:lang="en-US">Decrease due to impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_lbl" xml:lang="en-US">Decrease due to remeasurement</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueConsiderationsTextualAbstract" xlink:label="aytu_FairValueConsiderationsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueConsiderationsTextualAbstract" xlink:to="aytu_FairValueConsiderationsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueConsiderationsTextualAbstract_lbl" xml:lang="en-US">Fair Value Considerations (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Contingent consideration, description</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentOfContingentConsideration" xlink:label="aytu_AdjustmentOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentOfContingentConsideration" xlink:to="aytu_AdjustmentOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentOfContingentConsideration_lbl" xml:lang="en-US">Adjusted amount of contingent consideration for ProstaScint</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Contingent consideration reduced</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of income tax benefit resulting from applying statutory rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Benefit at statutory rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxReconciliationOfFeringCosts" xlink:label="aytu_IncomeTaxReconciliationOfFeringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxReconciliationOfFeringCosts" xlink:to="aytu_IncomeTaxReconciliationOfFeringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncomeTaxReconciliationOfFeringCosts_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:to="aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts_lbl" xml:lang="en-US">Offering costs, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxReconciliationContingentConsideration" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:label="aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:to="aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration_lbl" xml:lang="en-US">Contingent consideration, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Change in taxrate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Change in tax rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RemeasurementOfDeferredTaxes" xlink:label="aytu_RemeasurementOfDeferredTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RemeasurementOfDeferredTaxes" xlink:to="aytu_RemeasurementOfDeferredTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RemeasurementOfDeferredTaxes_lbl" xml:lang="en-US">Remeasurement of deferred taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RemeasurementOfDeferredTaxesPercentage" xlink:label="aytu_RemeasurementOfDeferredTaxesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RemeasurementOfDeferredTaxesPercentage" xlink:to="aytu_RemeasurementOfDeferredTaxesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RemeasurementOfDeferredTaxesPercentage_lbl" xml:lang="en-US">Remeasurement of deferred taxes, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:to="us-gaap_CumulativeEffectOnRetainedEarningsTax1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEffectOnRetainedEarningsTax1_lbl" xml:lang="en-US">Effect of phased-in taxrate</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CumulativeEffectOnRetainedEarningsTaxPercentage" xlink:label="aytu_CumulativeEffectOnRetainedEarningsTaxPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CumulativeEffectOnRetainedEarningsTaxPercentage" xlink:to="aytu_CumulativeEffectOnRetainedEarningsTaxPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CumulativeEffectOnRetainedEarningsTaxPercentage_lbl" xml:lang="en-US">Effect of phased-in tax rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_lbl" xml:lang="en-US">Derivative income</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" xlink:label="aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" xlink:to="aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage_lbl" xml:lang="en-US">Derivative income, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Net income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Net income tax provision (benefit), percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax assets (liabilities):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl" xml:lang="en-US">Unrealized loss on investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Capital loss carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Contribution carry forward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDerivativeInstruments_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax assets (liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total deferred income tax assets (liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxesTextualAbstract" xlink:label="aytu_IncomeTaxesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxesTextualAbstract" xlink:to="aytu_IncomeTaxesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncomeTaxesTextualAbstract_lbl" xml:lang="en-US">Income Taxes (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership interest, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Deferred tax asset and related valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NetOperatingLossesExpirationDescription" xlink:label="aytu_NetOperatingLossesExpirationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NetOperatingLossesExpirationDescription" xlink:to="aytu_NetOperatingLossesExpirationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NetOperatingLossesExpirationDescription_lbl" xml:lang="en-US">Net operating loss carryforwards begin to expire, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_2_lbl" xml:lang="en-US">U.S. corporate income tax percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="us-gaap_OtherTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTaxExpenseBenefit" xlink:to="us-gaap_OtherTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherTaxExpenseBenefit_lbl" xml:lang="en-US">Additional tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrescriptionDatabaseMember" xlink:to="aytu_PrescriptionDatabaseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_PrescriptionDatabaseMember_2_lbl" xml:lang="en-US">Prescription database [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OfficeLeaseMember" xlink:to="aytu_OfficeLeaseMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_OfficeLeaseMember_2_lbl" xml:lang="en-US">Office lease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationTable_lbl" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_lbl" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SupplyOrderMember" xlink:to="aytu_SupplyOrderMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_SupplyOrderMember_2_lbl" xml:lang="en-US">Purchase order [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommitmentsAndContingenciesTextualAbstract" xlink:label="aytu_CommitmentsAndContingenciesTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommitmentsAndContingenciesTextualAbstract" xlink:to="aytu_CommitmentsAndContingenciesTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommitmentsAndContingenciesTextualAbstract_lbl" xml:lang="en-US">Commitments and Contingencies (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Initial base rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Installment payments</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FirstMilestonePayable" xlink:label="aytu_FirstMilestonePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FirstMilestonePayable" xlink:to="aytu_FirstMilestonePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FirstMilestonePayable_lbl" xml:lang="en-US">First milestone payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of purchase order</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Operating leases, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xml:lang="en-US">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassUnitsMember" xlink:label="aytu_ClassUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassUnitsMember" xlink:to="aytu_ClassUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassUnitsMember_lbl" xml:lang="en-US">Class A Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassBUnitsMember" xlink:label="aytu_ClassBUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassBUnitsMember" xlink:to="aytu_ClassBUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassBUnitsMember_lbl" xml:lang="en-US">Class B Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SeriesConvertiblePreferredStockMember" xlink:label="aytu_SeriesConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SeriesConvertiblePreferredStockMember" xlink:to="aytu_SeriesConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SeriesBConvertiblePreferredStockMember" xlink:label="aytu_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SeriesBConvertiblePreferredStockMember" xlink:to="aytu_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConvertibleAPreferredStockMember" xlink:to="aytu_ConvertibleAPreferredStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ConvertibleAPreferredStockMember_2_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConvertibleBPreferredStockMember" xlink:to="aytu_ConvertibleBPreferredStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aytu_ConvertibleBPreferredStockMember_2_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockTextualAbstract" xlink:label="aytu_CommonStockTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockTextualAbstract" xlink:to="aytu_CommonStockTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockTextualAbstract_lbl" xml:lang="en-US">Common Stock (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Sale of stock, description</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="aytu_PreferredStockConversionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PreferredStockConversionPricePerShare" xlink:to="aytu_PreferredStockConversionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xml:lang="en-US">Preferred stocks converted in common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Aytu conversion of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:to="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_lbl" xml:lang="en-US">Increase common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issues during period</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="aytu_SecuritiesPurchaseAgreementCashFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:to="aytu_SecuritiesPurchaseAgreementCashFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SecuritiesPurchaseAgreementCashFeePercentage_lbl" xml:lang="en-US">Cash fee, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_lbl" xml:lang="en-US">Warrants purchase, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="aytu_WarrantsToPurchaseOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseOfCommonStockShares" xlink:to="aytu_WarrantsToPurchaseOfCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsToPurchaseOfCommonStockShares_lbl" xml:lang="en-US">Warrants to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:label="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:to="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_lbl" xml:lang="en-US">Warrants issued to underwriters as compensation for transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="aytu_UnrecognizedShareBasedCompensationExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_UnrecognizedShareBasedCompensationExpenses" xlink:to="aytu_UnrecognizedShareBasedCompensationExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_UnrecognizedShareBasedCompensationExpenses_lbl" xml:lang="en-US">Aggregate stock compensation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnrecognizedExpense" xlink:label="aytu_UnrecognizedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_UnrecognizedExpense" xlink:to="aytu_UnrecognizedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_UnrecognizedExpense_lbl" xml:lang="en-US">Unrecognized expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Issued of common stock payment to Nuelle Shareholders for fiscal 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xml:lang="en-US">Fair value of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:label="us-gaap_InvestmentOwnedRestrictedAcquisitionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:to="us-gaap_InvestmentOwnedRestrictedAcquisitionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedRestrictedAcquisitionDate_lbl" xml:lang="en-US">Restricted vest</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DescriptionOfUnrecognizedExpense" xlink:label="aytu_DescriptionOfUnrecognizedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DescriptionOfUnrecognizedExpense" xlink:to="aytu_DescriptionOfUnrecognizedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_DescriptionOfUnrecognizedExpense_lbl" xml:lang="en-US">Description of unrecognized expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="us-gaap_OtherUnderwritingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Other offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Aytu issued shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockSharesAgreedToPurchase" xlink:label="aytu_CommonStockSharesAgreedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockSharesAgreedToPurchase" xlink:to="aytu_CommonStockSharesAgreedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockSharesAgreedToPurchase_lbl" xml:lang="en-US">Purchase of stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockValueAgreedToPurchase" xlink:label="aytu_CommonStockValueAgreedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockValueAgreedToPurchase" xlink:to="aytu_CommonStockValueAgreedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CommonStockValueAgreedToPurchase_lbl" xml:lang="en-US">Purchase of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock issued during period, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of stock issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_2_lbl" xml:lang="en-US">Restricted stock expense, grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="us-gaap_EquityFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityFairValueDisclosure_lbl" xml:lang="en-US">Issued stock at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EquityRelativeFairValue" xlink:label="aytu_EquityRelativeFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EquityRelativeFairValue" xlink:to="aytu_EquityRelativeFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EquityRelativeFairValue_lbl" xml:lang="en-US">Stock issued during relative fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt instrument, term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Purchase of additional common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnderwritersExercisedOfOverallotmentOption" xlink:label="aytu_UnderwritersExercisedOfOverallotmentOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_UnderwritersExercisedOfOverallotmentOption" xlink:to="aytu_UnderwritersExercisedOfOverallotmentOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_UnderwritersExercisedOfOverallotmentOption_lbl" xml:lang="en-US">Underwriters exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Aggregate shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PreferredStockSharesDesignated" xlink:label="aytu_PreferredStockSharesDesignated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PreferredStockSharesDesignated" xlink:to="aytu_PreferredStockSharesDesignated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PreferredStockSharesDesignated_lbl" xml:lang="en-US">Preferred stock shares designated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_2_lbl" xml:lang="en-US">Aggregate of shares common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantPurchaseCommitmentDescription" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xml:lang="en-US">Securities purchase agreement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xml:lang="en-US">Description of Aytu common stock of net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Issuance of restricted stock, shares vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_2_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OptionsAbstract" xlink:label="aytu_OptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OptionsAbstract" xlink:to="aytu_OptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_OptionsAbstract_lbl" xml:lang="en-US">Options:</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedVolatilityRate1" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedVolatilityRate1" xlink:to="aytu_FairValueAssumptionsExpectedVolatilityRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRate1_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsRiskFreeInterestRate1" xlink:label="aytu_FairValueAssumptionsRiskFreeInterestRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsRiskFreeInterestRate1" xlink:to="aytu_FairValueAssumptionsRiskFreeInterestRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsRiskFreeInterestRate1_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedTerm1" xlink:label="aytu_FairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedTerm1" xlink:to="aytu_FairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedDividendRate1" xlink:label="aytu_FairValueAssumptionsExpectedDividendRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedDividendRate1" xlink:to="aytu_FairValueAssumptionsExpectedDividendRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_FairValueAssumptionsExpectedDividendRate1_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_lbl" xml:lang="en-US">Number of options, Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeOneMember" xlink:to="aytu_ExercisePriceRangeOneMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ExercisePriceRangeOneMember_2_lbl" xml:lang="en-US">280.00 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExercisePriceRangeTwoMember" xlink:to="aytu_ExercisePriceRangeTwoMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ExercisePriceRangeTwoMember_2_lbl" xml:lang="en-US">328.00 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Range of Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of Options Outstanding | shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life of Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of Options Exercisable | shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Unvested, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Unvested, Weighted Average Remaining Contractual Life in Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_2_lbl" xml:lang="en-US">Restricted stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_3_lbl" xml:lang="en-US">Stock options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2_lbl" xml:lang="en-US">Number of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstanding_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_lbl" xml:lang="en-US">Issuance of settlement warrants to initial investors</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_lbl" xml:lang="en-US">Warrants issued to investors in connection with the registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_lbl" xml:lang="en-US">Warrants issued to placement agents for the registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering_lbl" xml:lang="en-US">Warrants issued in connection with the August 2017 private offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter_lbl" xml:lang="en-US">Warrants issued to underwriters in connection with the August 2017 private offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection_lbl" xml:lang="en-US">Warrants issued in connection with the March 2018 public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued to investor</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsExpired" xlink:label="aytu_ShareBasedCompensationShareWarrantsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsExpired" xlink:to="aytu_ShareBasedCompensationShareWarrantsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsExpired_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstanding_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_lbl" xml:lang="en-US">Issuance of settlement warrants to initial investors</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued to investors in connection with the registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued to placement agents for the registered offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued in connection with the August 2017 private offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued to underwriters in connection with the August 2017 private offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued in connection with the March 2018 public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants issued to investor</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" xlink:label="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" xlink:to="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" xlink:label="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" xlink:label="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" xlink:to="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionWeightedAverageExpectedDividend" xlink:label="aytu_FairValueAssumptionWeightedAverageExpectedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionWeightedAverageExpectedDividend" xlink:to="aytu_FairValueAssumptionWeightedAverageExpectedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionRiskFreeInterestRate" xlink:label="aytu_FairValueAssumptionRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionRiskFreeInterestRate" xlink:to="aytu_FairValueAssumptionRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_FairValueAssumptionRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionExpectedTerm" xlink:label="aytu_FairValueAssumptionExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionExpectedTerm" xlink:to="aytu_FairValueAssumptionExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionExpectedTerm_lbl" xml:lang="en-US">Contractual term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionExpectedDividendRate" xlink:label="aytu_FairValueAssumptionExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionExpectedDividendRate" xlink:to="aytu_FairValueAssumptionExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionExpectedDividendRate_lbl" xml:lang="en-US">Dividend yields</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:to="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember_2_lbl" xml:lang="en-US">2015 Stock Option and Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EquityInstrumentsTextualAbstract" xlink:label="aytu_EquityInstrumentsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EquityInstrumentsTextualAbstract" xlink:to="aytu_EquityInstrumentsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EquityInstrumentsTextualAbstract_lbl" xml:lang="en-US">Equity Instruments (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Aggregate shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized expense share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsExercisePriceTerm" xlink:label="aytu_WarrantsExercisePriceTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsExercisePriceTerm" xlink:to="aytu_WarrantsExercisePriceTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsExercisePriceTerm_lbl" xml:lang="en-US">Warrants exercise price term</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsGeneratedNoncashExpense" xlink:label="aytu_WarrantsGeneratedNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsGeneratedNoncashExpense" xlink:to="aytu_WarrantsGeneratedNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantsGeneratedNoncashExpense_lbl" xml:lang="en-US">Warrants generated non-cash expense</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferDescription" xlink:label="aytu_WarrantTenderOfferDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantTenderOfferDescription" xlink:to="aytu_WarrantTenderOfferDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantTenderOfferDescription_lbl" xml:lang="en-US">Warrant tender offer, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Grant purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting expiry date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Unrecognized expense, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_VestingExpiryDate" xlink:label="aytu_VestingExpiryDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_VestingExpiryDate" xlink:to="aytu_VestingExpiryDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_VestingExpiryDate_lbl" xml:lang="en-US">Vesting expiry date, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Expense related to awards</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NewWarrantsToPurchaseOfCommonStock" xlink:label="aytu_NewWarrantsToPurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NewWarrantsToPurchaseOfCommonStock" xlink:to="aytu_NewWarrantsToPurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_NewWarrantsToPurchaseOfCommonStock_lbl" xml:lang="en-US">New warrant to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityFairValueDisclosure" xlink:to="us-gaap_EquityFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityFairValueDisclosure_2_lbl" xml:lang="en-US">Equity fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" xlink:label="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" xlink:to="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled_lbl" xml:lang="en-US">Cancelled of restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US">Restricted stock for accelerated vesting</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncrementalFairValueOfWarrant" xlink:label="aytu_IncrementalFairValueOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncrementalFairValueOfWarrant" xlink:to="aytu_IncrementalFairValueOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncrementalFairValueOfWarrant_lbl" xml:lang="en-US">Incremental fair value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExecutiveOfficerOneMember" xlink:to="aytu_ExecutiveOfficerOneMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_ExecutiveOfficerOneMember_2_lbl" xml:lang="en-US">Jarrett Disbrow [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExecutiveOfficerMember" xlink:to="us-gaap_ExecutiveOfficerMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExecutiveOfficerMember_2_lbl" xml:lang="en-US">Joshua Disbrow [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_GreenMember" xlink:to="aytu_GreenMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_GreenMember_2_lbl" xml:lang="en-US">Mr. Green [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RelatedPartyTransactionsTextualAbstract" xlink:label="aytu_RelatedPartyTransactionsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RelatedPartyTransactionsTextualAbstract" xlink:to="aytu_RelatedPartyTransactionsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RelatedPartyTransactionsTextualAbstract_lbl" xml:lang="en-US">Related Party Transactions (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock purchases offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Monthly payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Agreement term, description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Amount agreed to pay</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="aytu_PrepaidExpensesAmortizationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrepaidExpensesAmortizationPeriod" xlink:to="aytu_PrepaidExpensesAmortizationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PrepaidExpensesAmortizationPeriod_lbl" xml:lang="en-US">Contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Share purchased of executive</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuWomensHealthMember" xlink:to="aytu_AytuWomensHealthMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_AytuWomensHealthMember_2_lbl" xml:lang="en-US">Aytu Women's Health [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuBioscienceIncMember" xlink:to="aytu_AytuBioscienceIncMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aytu_AytuBioscienceIncMember_2_lbl" xml:lang="en-US">Aytu [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Consolidated revenue:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Consolidated revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:label="us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:to="us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_lbl" xml:lang="en-US">Consolidated net loss:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Consolidated net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_2_lbl" xml:lang="en-US">Total assets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SegmentInformationTextualAbstract" xlink:label="aytu_SegmentInformationTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SegmentInformationTextualAbstract" xlink:to="aytu_SegmentInformationTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SegmentInformationTextualAbstract_lbl" xml:lang="en-US">Segment Information (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EmployeeBenefitPlanTextualAbstract" xlink:label="aytu_EmployeeBenefitPlanTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EmployeeBenefitPlanTextualAbstract" xlink:to="aytu_EmployeeBenefitPlanTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_EmployeeBenefitPlanTextualAbstract_lbl" xml:lang="en-US">Employee Benefit Plan (Textual)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xml:lang="en-US">Description of contributed to plan by employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Employees contributed plan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SubsequentEventsTextualAbstract" xlink:label="aytu_SubsequentEventsTextualAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SubsequentEventsTextualAbstract" xlink:to="aytu_SubsequentEventsTextualAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_SubsequentEventsTextualAbstract_lbl" xml:lang="en-US">Subsequent Events (Textual)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_2_lbl" xml:lang="en-US">Description of reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AssetPurchase" xlink:label="aytu_AssetPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AssetPurchase" xlink:to="aytu_AssetPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AssetPurchase_lbl" xml:lang="en-US">Asset purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AccruedCompensationCurrent" xlink:to="aytu_AccruedCompensationCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AccruedCompensationCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable pertaining to costs that are statutory in nature of accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:to="aytu_AdjustmentForRoundingOfSharesDueToConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentForRoundingOfSharesDueToConversion_doc" xml:lang="en-US">It refers to adjustment for rounding of shares due to conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:to="aytu_AdjustmentForRoundingOfValueDueToConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentForRoundingOfValueDueToConversion_doc" xml:lang="en-US">It refers to adjustment for rounding of values due to conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentOfContingentConsideration" xlink:to="aytu_AdjustmentOfContingentConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentOfContingentConsideration_doc" xml:lang="en-US">Amount of adjusted the contingent consideration for revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments_doc" xml:lang="en-US">Amount of increase in additional paid up capital resulting from warrants amendments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing_doc" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" xlink:to="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant_doc" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to warrant exercise of derivative warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AgreementAxis" xlink:to="aytu_AgreementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AgreementAxis_doc" xml:lang="en-US">Agreement axis</link:label>
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementDomain" xlink:label="aytu_AgreementDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AgreementDomain" xlink:to="aytu_AgreementDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AgreementDomain_doc" xml:lang="en-US">Agreement domin</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:to="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties_doc" xml:lang="en-US">Amortization of prepaid research and development due to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AytuMember" xlink:to="aytu_AytuMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AytuMember_doc" xml:lang="en-US">Aytu</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationConsiderationTransferredInventory" xlink:to="aytu_BusinessCombinationConsiderationTransferredInventory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationConsiderationTransferredInventory_doc" xml:lang="en-US">Represents the amount of business combination consideration transferred to inventory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentCconsideration" xlink:to="aytu_BusinessCombinationContingentCconsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentCconsideration_doc" xml:lang="en-US">It represents the contingent consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment_doc" xml:lang="en-US">Decrease due to impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_doc" xml:lang="en-US">This element represents the amount of decrease due to impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement_doc" xml:lang="en-US">This element represents the amount of increase due to impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement_doc" xml:lang="en-US">This element represents the amount of any change recognized during the period in the low-end of the estimated range of outcomes decrease due to remeasurement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationPercentage" xlink:to="aytu_BusinessCombinationContingentConsiderationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationPercentage_doc" xml:lang="en-US">Business combination contingent consideration percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationRevalued" xlink:to="aytu_BusinessCombinationContingentConsiderationRevalued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_BusinessCombinationContingentConsiderationRevalued_doc" xml:lang="en-US">Revalued amount of recognized arising from contingent consideration in a business combination.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:to="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued_doc" xml:lang="en-US">The warrants to be issued as a percentage of shares issued in the transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" xlink:to="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne_doc" xml:lang="en-US">Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:to="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommitmentsAndContingenciesDisclosureTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockIssuedToExecutivesShare" xlink:to="aytu_CommonStockIssuedToExecutivesShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockIssuedToExecutivesShare_doc" xml:lang="en-US">Number of common stock issued to executives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockIssuedToExecutivesValue" xlink:to="aytu_CommonStockIssuedToExecutivesValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockIssuedToExecutivesValue_doc" xml:lang="en-US">Value of common stock issued to executives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockSharesAgreedToPurchase" xlink:to="aytu_CommonStockSharesAgreedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockSharesAgreedToPurchase_doc" xml:lang="en-US">The number of common stock shares agreed to purchase in the purchase agreement entered during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockTextBlock" xlink:to="aytu_CommonStockTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockTextBlock_doc" xml:lang="en-US">The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CommonStockValueAgreedToPurchase" xlink:to="aytu_CommonStockValueAgreedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CommonStockValueAgreedToPurchase_doc" xml:lang="en-US">The amount of common stock agreed to purchase in the purchase agreement entered during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ContingentConsiderationIncludedInAccountsPayable" xlink:to="aytu_ContingentConsiderationIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ContingentConsiderationIncludedInAccountsPayable_doc" xml:lang="en-US">Non cash amount of contingent consideration included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CoreAndDevelopedTechnologyNet" xlink:to="aytu_CoreAndDevelopedTechnologyNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CoreAndDevelopedTechnologyNet_doc" xml:lang="en-US">Amount of rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CostOfSaleForInvestment" xlink:to="aytu_CostOfSaleForInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_CostOfSaleForInvestment_doc" xml:lang="en-US">The cost of sale of investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_DescriptionOfUnrecognizedExpense" xlink:to="aytu_DescriptionOfUnrecognizedExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_DescriptionOfUnrecognizedExpense_doc" xml:lang="en-US">Description of unrecognized expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EarnOutPaymentToOtherShareholders" xlink:to="aytu_EarnOutPaymentToOtherShareholders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EarnOutPaymentToOtherShareholders_doc" xml:lang="en-US">Earn-out payment to the shareholders of subsidiary company or on merger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_EquityRelativeFairValue" xlink:to="aytu_EquityRelativeFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_EquityRelativeFairValue_doc" xml:lang="en-US">Stock issued during relative fair value for the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ExecutiveOfficerOneMember" xlink:to="aytu_ExecutiveOfficerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ExecutiveOfficerOneMember_doc" xml:lang="en-US">One of the ranking officers of the entity, appointed to the position by the board of directors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionExpectedDividendRate" xlink:to="aytu_FairValueAssumptionExpectedDividendRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionExpectedDividendRate_doc" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionExpectedTerm" xlink:to="aytu_FairValueAssumptionExpectedTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionExpectedTerm_doc" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionRiskFreeInterestRate" xlink:to="aytu_FairValueAssumptionRiskFreeInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionRiskFreeInterestRate_doc" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionWeightedAverageExpectedDividend" xlink:to="aytu_FairValueAssumptionWeightedAverageExpectedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionWeightedAverageExpectedDividend_doc" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedDividendRate1" xlink:to="aytu_FairValueAssumptionsExpectedDividendRate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsExpectedDividendRate1_doc" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedDividendRates" xlink:to="aytu_FairValueAssumptionsExpectedDividendRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsExpectedDividendRates_doc" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedTerm1" xlink:to="aytu_FairValueAssumptionsExpectedTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsExpectedTerm1_doc" xml:lang="en-US">Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedTerms" xlink:to="aytu_FairValueAssumptionsExpectedTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsExpectedTerms_doc" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedVolatilityRate1" xlink:to="aytu_FairValueAssumptionsExpectedVolatilityRate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRate1_doc" xml:lang="en-US">The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedVolatilityRates" xlink:to="aytu_FairValueAssumptionsExpectedVolatilityRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRates_doc" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsRiskFreeInterestRate1" xlink:to="aytu_FairValueAssumptionsRiskFreeInterestRate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsRiskFreeInterestRate1_doc" xml:lang="en-US">The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsRiskFreeInterestRates" xlink:to="aytu_FairValueAssumptionsRiskFreeInterestRates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueAssumptionsRiskFreeInterestRates_doc" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises_doc" xml:lang="en-US">Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances_doc" xml:lang="en-US">Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FirstMilestonePayable" xlink:to="aytu_FirstMilestonePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FirstMilestonePayable_doc" xml:lang="en-US">It represents the amount of first milestone payment which is require to make.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FixedAssetsIncludedInAccountsPayable" xlink:to="aytu_FixedAssetsIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_FixedAssetsIncludedInAccountsPayable_doc" xml:lang="en-US">The fair value of fixed assets included in accounts payable in noncash investing or financing activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncreaseDecreaseInAccruedCompensation" xlink:to="aytu_IncreaseDecreaseInAccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IncreaseDecreaseInAccruedCompensation_doc" xml:lang="en-US">Increase decrease in accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:to="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IncrementalCommonSharesDueToConversionOfPreferredStock_doc" xml:lang="en-US">The number of shares by which the common shares outstanding will increase in case of conversion of preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncrementalFairValueOfWarrant" xlink:to="aytu_IncrementalFairValueOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IncrementalFairValueOfWarrant_doc" xml:lang="en-US">Amount of incremental fair value of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" xlink:to="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares_doc" xml:lang="en-US">Number of stock issued during the reporting period,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" xlink:to="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue_doc" xml:lang="en-US">Amount of stock issued during the reporting period,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:to="aytu_IssuanceOfCommonStockToNuelleShareHolders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfCommonStockToNuelleShareHolders_doc" xml:lang="en-US">Issuance of common stock to Nuelle share holders for non cash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:to="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost_doc" xml:lang="en-US">Issuance of preferred and common stock and warrant net cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:to="aytu_IssuanceOfPreferredAndCommonStockNetCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfPreferredAndCommonStockNetCost_doc" xml:lang="en-US">Issuance of preferred and common stock net cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:to="aytu_IssuanceOfPreferredAndCommonStockNetShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfPreferredAndCommonStockNetShare_doc" xml:lang="en-US">Issuance of preferred and common stock net share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:to="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare_doc" xml:lang="en-US">Issuance of preferred and common stock and warrant net share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_LabEquipmentMember" xlink:to="aytu_LabEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_LabEquipmentMember_doc" xml:lang="en-US">Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_NewWarrantsToPurchaseOfCommonStock" xlink:to="aytu_NewWarrantsToPurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_NewWarrantsToPurchaseOfCommonStock_doc" xml:lang="en-US">New Warrants to purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OneTimeNonRefundablePayments" xlink:to="aytu_OneTimeNonRefundablePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OneTimeNonRefundablePayments_doc" xml:lang="en-US">Amount represents the one time non-refundable payments based on sales revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_OverallotmentWarrantsPurchased" xlink:to="aytu_OverallotmentWarrantsPurchased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_OverallotmentWarrantsPurchased_doc" xml:lang="en-US">The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentForRegisteredOfferingCost" xlink:to="aytu_PaymentForRegisteredOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PaymentForRegisteredOfferingCost_doc" xml:lang="en-US">S-3 registered offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:to="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_doc" xml:lang="en-US">The total of the cash outflow during the period issuance of preferred stock, common stock and warrants, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsForRegisteredOfferingCosts" xlink:to="aytu_PaymentsForRegisteredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PaymentsForRegisteredOfferingCosts_doc" xml:lang="en-US">The amount of cash outflow for the payment of costs on issuance of registered offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_doc" xml:lang="en-US">The cash outflow for cost incurred directly with the issuance of preferred, common stock and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsToAcquireOtherProductiveAssetsOne" xlink:to="aytu_PaymentsToAcquireOtherProductiveAssetsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PaymentsToAcquireOtherProductiveAssetsOne_doc" xml:lang="en-US">Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PreferredStockConversionPricePerShare" xlink:to="aytu_PreferredStockConversionPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PreferredStockConversionPricePerShare_doc" xml:lang="en-US">The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PreferredStockSharesDesignated" xlink:to="aytu_PreferredStockSharesDesignated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PreferredStockSharesDesignated_doc" xml:lang="en-US">Preferred stock shares designated for the during period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PrepaidExpensesAmortizationPeriod" xlink:to="aytu_PrepaidExpensesAmortizationPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_PrepaidExpensesAmortizationPeriod_doc" xml:lang="en-US">Prepaid expenses amortization period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsFromWarrantTenderOffer" xlink:to="aytu_ProceedsFromWarrantTenderOffer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProceedsFromWarrantTenderOffer_doc" xml:lang="en-US">Amount of warrant tender offer for the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ProceedsOfWarrantTenderOffer" xlink:to="aytu_ProceedsOfWarrantTenderOffer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ProceedsOfWarrantTenderOffer_doc" xml:lang="en-US">The cash inflow from issuance of warrant tender offer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Purchaseofassetincludedincontingentconsideration" xlink:to="aytu_Purchaseofassetincludedincontingentconsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_Purchaseofassetincludedincontingentconsideration_doc" xml:lang="en-US">It represents the purchase of asset included in contingent consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise" xlink:to="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise_doc" xml:lang="en-US">Amount of reclassification of warrant liability to equity upon exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RegisteredOfferingCost" xlink:to="aytu_RegisteredOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RegisteredOfferingCost_doc" xml:lang="en-US">Value of registered offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RepaymentsForRegisteredOfferingCosts" xlink:to="aytu_RepaymentsForRegisteredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RepaymentsForRegisteredOfferingCosts_doc" xml:lang="en-US">The amount of registered offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_doc" xml:lang="en-US">The cash outflow for cost incurred directly with the issuance of preferred, common stock and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ResearchAndDevelopmentRelatedParty" xlink:to="aytu_ResearchAndDevelopmentRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ResearchAndDevelopmentRelatedParty_doc" xml:lang="en-US">Amount of research and development related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RestrictedStocksPolicyTextBlock" xlink:to="aytu_RestrictedStocksPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RestrictedStocksPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy for restricted stock for the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RevenueEarnOutPayment" xlink:to="aytu_RevenueEarnOutPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_RevenueEarnOutPayment_doc" xml:lang="en-US">The amount of revenue earn-out payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SalesRevenueTarget" xlink:to="aytu_SalesRevenueTarget_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SalesRevenueTarget_doc" xml:lang="en-US">The amount sales revenue target for non-refundable payment criteria.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ScheduleOfOptionsOutstanding" xlink:to="aytu_ScheduleOfOptionsOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ScheduleOfOptionsOutstanding_doc" xml:lang="en-US">Tabular disclosure of options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:to="aytu_SecuritiesPurchaseAgreementCashFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SecuritiesPurchaseAgreementCashFeePercentage_doc" xml:lang="en-US">The percentage of cash fee to underwriters incurred in securities purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested in period weighted average cancelled date fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" xlink:to="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares_doc" xml:lang="en-US">It represents share based compensation share warrants weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation share warrants issued to investor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsExpired" xlink:to="aytu_ShareBasedCompensationShareWarrantsExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsExpired_doc" xml:lang="en-US">Number of share based compensation share warrants expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation share warrants investor weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement_doc" xml:lang="en-US">Number of warrants issued as part of a settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price of warrants issued as part of a settlement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection_doc" xml:lang="en-US">Share based compensation share warrants issued on connection.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation share warrants issued on connection with private offering weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price of warrants issued upon investor private offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering_doc" xml:lang="en-US">Warrants issued to placement agents for the registered offering for the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price of warrants issued upon the registered offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering_doc" xml:lang="en-US">Number of warrants issued upon the private offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering_doc" xml:lang="en-US">Number of warrants issued upon placement agents for registered offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price of warrants issued upon the registered offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter_doc" xml:lang="en-US">Number of warrants issued upon underwritters.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price of warrants issued upon underwriter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstanding_doc" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation warrants exercised weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation warrants issued to investor weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuanceNetOfIssuanceCostsShares" xlink:to="aytu_StockIssuanceNetOfIssuanceCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuanceNetOfIssuanceCostsShares_doc" xml:lang="en-US">Number of stock issuance, net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuanceNetOfIssuanceCostsValue" xlink:to="aytu_StockIssuanceNetOfIssuanceCostsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuanceNetOfIssuanceCostsValue_doc" xml:lang="en-US">Value of stock issuance, net of issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" xlink:to="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled_doc" xml:lang="en-US">Aggregate value of stock related to restricted stock were cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_SubsidiariesPaymentDescription" xlink:to="aytu_SubsidiariesPaymentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_SubsidiariesPaymentDescription_doc" xml:lang="en-US">Subsidiaries payment description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_UnderwritersExercisedOfOverallotmentOption" xlink:to="aytu_UnderwritersExercisedOfOverallotmentOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_UnderwritersExercisedOfOverallotmentOption_doc" xml:lang="en-US">Number of underwriters exercised of this over-allotment option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_UnrecognizedExpense" xlink:to="aytu_UnrecognizedExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_UnrecognizedExpense_doc" xml:lang="en-US">Unrecognized expense yearsrelated to these shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_UnrecognizedShareBasedCompensationExpenses" xlink:to="aytu_UnrecognizedShareBasedCompensationExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_UnrecognizedShareBasedCompensationExpenses_doc" xml:lang="en-US">Unrecognized share based compensation expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_VestingExpiryDate" xlink:to="aytu_VestingExpiryDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_VestingExpiryDate_doc" xml:lang="en-US">vesting expiry date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExerciseOfDerivativeWarrants" xlink:to="aytu_WarrantExerciseOfDerivativeWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantExerciseOfDerivativeWarrants_doc" xml:lang="en-US">The amount non cash warrant exercise of derivative warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExercisesShares" xlink:to="aytu_WarrantExercisesShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantExercisesShares_doc" xml:lang="en-US">Number of shares warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExercisesValue" xlink:to="aytu_WarrantExercisesValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantExercisesValue_doc" xml:lang="en-US">Value of stock related to issuance of warrants exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantTenderOfferDescription" xlink:to="aytu_WarrantTenderOfferDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantTenderOfferDescription_doc" xml:lang="en-US">Description of warrant tender offer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantTenderOfferNetIssuanceCostsShares" xlink:to="aytu_WarrantTenderOfferNetIssuanceCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantTenderOfferNetIssuanceCostsShares_doc" xml:lang="en-US">Number of warrant tender offer, net of in issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantTenderOfferNetIssuanceCostsValue" xlink:to="aytu_WarrantTenderOfferNetIssuanceCostsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantTenderOfferNetIssuanceCostsValue_doc" xml:lang="en-US">Value of warrant tender offer, net of in issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer" xlink:to="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer_doc" xml:lang="en-US">Warrants amended in connection with warrant tender offer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsExercisePriceTerm" xlink:to="aytu_WarrantsExercisePriceTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsExercisePriceTerm_doc" xml:lang="en-US">Warrants exercise price term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsGeneratedNoncashExpense" xlink:to="aytu_WarrantsGeneratedNoncashExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsGeneratedNoncashExpense_doc" xml:lang="en-US">Amount of warrants generated a non-cash expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" xlink:to="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents_doc" xml:lang="en-US">Fair value of warrants issued in connection with equity financing to the placement agents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:to="aytu_WarrantsIssuedToInvestorsAndUnderwriters_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsIssuedToInvestorsAndUnderwriters_doc" xml:lang="en-US">Amount of warrants issued to investors and underwriters.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:to="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction_doc" xml:lang="en-US">Warrants issued to the underwriters as compensation for the transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantsToPurchaseOfCommonStockShares" xlink:to="aytu_WarrantsToPurchaseOfCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_WarrantsToPurchaseOfCommonStockShares_doc" xml:lang="en-US">Number of warrants to purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption_doc" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing to the placement agents for the over-allotment option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:to="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts_doc" xml:lang="en-US">The value of adjustment made to the additional paid in capital with regard to issuance of Warrants issued in connection with equity financing to the placement agents, non-cash issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_2_lbl" xml:lang="en-US">Parent Company [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_CustomerMember" xlink:to="aytu_CustomerMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_CustomerMember_2_lbl" xml:lang="en-US">Income Taxes Textual [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ConvertibleBPreferredStockMember" xlink:to="aytu_ConvertibleBPreferredStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ConvertibleBPreferredStockMember_3_lbl" xml:lang="en-US">First Milestone [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:to="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost_3_lbl" xml:lang="en-US">Issuance Of Preferred And Common Stock And Warrant Net Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:to="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare_3_lbl" xml:lang="en-US">Issuance Of Preferred And Common Stock Warrant Net Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:to="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments_3_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrant Amendments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:to="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash_3_lbl" xml:lang="en-US">Payment Of Stock Issuance Of Preferred Stock Common Stock And Warrants Costs Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_2_lbl" xml:lang="en-US">Asset Impairment Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="us-gaap_GainLossOnSaleOfOtherInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherInvestments_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainOnDerivative_2_lbl" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_2_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_2_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsForDepositsInvestingActivities" xlink:to="aytu_PaymentsForDepositsInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentsForDepositsInvestingActivities_2_lbl" xml:lang="en-US">Payments For Registered Offering Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_2_lbl" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsToAcquireOtherProductiveAssetsOne" xlink:to="aytu_PaymentsToAcquireOtherProductiveAssetsOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentsToAcquireOtherProductiveAssetsOne_3_lbl" xml:lang="en-US">Payments To Acquire Other Productive Assets One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_2_lbl" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_3_lbl" xml:lang="en-US">Payments Of Preferred Common Stock And Warrants Issuance Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfEquity" xlink:to="us-gaap_ProceedsFromRepurchaseOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepurchaseOfEquity_2_lbl" xml:lang="en-US">Proceeds from (Repurchase of) Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:to="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost_3_lbl" xml:lang="en-US">Repayments Of Preferred Common Stock And Warrants Issuance Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentForRegisteredOfferingCost" xlink:to="aytu_PaymentForRegisteredOfferingCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentForRegisteredOfferingCost_3_lbl" xml:lang="en-US">Payment Of Stock Issuance Of Preferred Stock Common Stock And Warrants Costs Cash [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_PaymentsForRegisteredOfferingCosts" xlink:to="aytu_PaymentsForRegisteredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_PaymentsForRegisteredOfferingCosts_3_lbl" xml:lang="en-US">Payments For Registered Offering Costs [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_3_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_WarrantExerciseOfDerivativeWarrants" xlink:to="aytu_WarrantExerciseOfDerivativeWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_WarrantExerciseOfDerivativeWarrants_3_lbl" xml:lang="en-US">Warrant Exercise Of Derivative Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2_lbl" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOther_2_lbl" xml:lang="en-US">Stockholders' Equity, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" xlink:to="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises_3_lbl" xml:lang="en-US">Reclassification Of Warrant Liability To Equity Upon Exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:to="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement_3_lbl" xml:lang="en-US">Class B Units [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_IncomeTaxReconciliationContingentConsideration" xlink:to="aytu_IncomeTaxReconciliationContingentConsideration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_IncomeTaxReconciliationContingentConsideration_2_lbl" xml:lang="en-US">Services Agreement [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:to="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_2_lbl" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Provision for Loan Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_2_lbl" xml:lang="en-US">Contractual Obligation, Due in Next Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_2_lbl" xml:lang="en-US">Contractual Obligation, Due in Second Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_2_lbl" xml:lang="en-US">Contractual Obligation, Due in Third Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFourthYear_2_lbl" xml:lang="en-US">Contractual Obligation, Due in Fourth Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInFifthYear_2_lbl" xml:lang="en-US">Contractual Obligation, Due in Fifth Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_2_lbl" xml:lang="en-US">Contractual Obligation, Due after Fifth Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_2_lbl" xml:lang="en-US">Contractual Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedVolatilityRate1" xlink:to="aytu_FairValueAssumptionsExpectedVolatilityRate1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsExpectedVolatilityRate1_3_lbl" xml:lang="en-US">Primsol [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionsExpectedDividendRate1" xlink:to="aytu_FairValueAssumptionsExpectedDividendRate1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionsExpectedDividendRate1_3_lbl" xml:lang="en-US">Preferred Stock Conversion Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:to="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue_3_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Cancelled Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstanding_4_lbl" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Investors In Connection With Private Offering Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Underwriters For Private Offering Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Share Warrants Issued On Connection With Private Offering Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Warrants Issued To Investor Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" xlink:to="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares_3_lbl" xml:lang="en-US">ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" xlink:to="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share Based Compensation Warrants Exercised Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aytu_FairValueAssumptionRiskFreeInterestRate" xlink:to="aytu_FairValueAssumptionRiskFreeInterestRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aytu_FairValueAssumptionRiskFreeInterestRate_3_lbl" xml:lang="en-US">Payments Of Preferred Common Stock And Warrants Issuance Cost [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>aytu-20180630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: aytu%2D20180630.xfr; Date: 2018%2D09%2D06T20:07:56Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80090002 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aytubio.com/role/DocumentAndEntityInformation" xlink:href="aytu-20180630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedBalanceSheets" xlink:href="aytu-20180630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="aytu-20180630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:href="aytu-20180630.xsd#ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/StatementsOfCashFlows" xlink:href="aytu-20180630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/GoingConcern" xlink:href="aytu-20180630.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderations" xlink:href="aytu-20180630.xsd#FairValueConsiderations" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxes" xlink:href="aytu-20180630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingencies" xlink:href="aytu-20180630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommonStock" xlink:href="aytu-20180630.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstruments" xlink:href="aytu-20180630.xsd#EquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/RelatedPartyTransactions" xlink:href="aytu-20180630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformation" xlink:href="aytu-20180630.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EmployeeBenefitPlan" xlink:href="aytu-20180630.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SubsequentEvents" xlink:href="aytu-20180630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsTables" xlink:href="aytu-20180630.xsd#FairValueConsiderationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesTables" xlink:href="aytu-20180630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesTables" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsTables" xlink:href="aytu-20180630.xsd#EquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationTables" xlink:href="aytu-20180630.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:href="aytu-20180630.xsd#BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:href="aytu-20180630.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/GoingConcernDetails" xlink:href="aytu-20180630.xsd#GoingConcernDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails1" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails2" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetails3" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" xlink:href="aytu-20180630.xsd#FairValueConsiderationsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetails" xlink:href="aytu-20180630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetails1" xlink:href="aytu-20180630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/IncomeTaxesDetailsTextual" xlink:href="aytu-20180630.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="aytu-20180630.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/CommonStockDetails" xlink:href="aytu-20180630.xsd#CommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails1" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails2" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails3" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails4" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails5" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetails6" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetails6" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EquityInstrumentsDetailsTextual" xlink:href="aytu-20180630.xsd#EquityInstrumentsDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/RelatedPartyTransactionsDetails" xlink:href="aytu-20180630.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationDetails" xlink:href="aytu-20180630.xsd#SegmentInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SegmentInformationDetailsTextual" xlink:href="aytu-20180630.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/EmployeeBenefitPlanDetails" xlink:href="aytu-20180630.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aytubio.com/role/SubsequentEventsDetails" xlink:href="aytu-20180630.xsd#SubsequentEventsDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DocumentAndEntityInformationAbstract" xlink:label="loc_aytuDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CoreAndDevelopedTechnologyNet" xlink:label="loc_aytuCoreAndDevelopedTechnologyNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_aytuCoreAndDevelopedTechnologyNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedContractualRights" xlink:label="loc_us-gaapIndefiniteLivedContractualRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIndefiniteLivedContractualRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedTradeNames" xlink:label="loc_us-gaapIndefiniteLivedTradeNames" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIndefiniteLivedTradeNames" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AccruedCompensationCurrent" xlink:label="loc_aytuAccruedCompensationCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_aytuAccruedCompensationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ResearchAndDevelopmentRelatedParty" xlink:label="loc_aytuResearchAndDevelopmentRelatedParty" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_aytuResearchAndDevelopmentRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuanceNetOfIssuanceCostsValue" xlink:label="loc_aytuStockIssuanceNetOfIssuanceCostsValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuStockIssuanceNetOfIssuanceCostsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuanceNetOfIssuanceCostsShares" xlink:label="loc_aytuStockIssuanceNetOfIssuanceCostsShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuStockIssuanceNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockIssuedToExecutivesValue" xlink:label="loc_aytuCommonStockIssuedToExecutivesValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuCommonStockIssuedToExecutivesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockIssuedToExecutivesShare" xlink:label="loc_aytuCommonStockIssuedToExecutivesShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuCommonStockIssuedToExecutivesShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue" xlink:label="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares" xlink:label="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfCommonStockNetOfIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:label="loc_aytuAdjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferNetIssuanceCostsValue" xlink:label="loc_aytuWarrantTenderOfferNetIssuanceCostsValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantTenderOfferNetIssuanceCostsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferNetIssuanceCostsShares" xlink:label="loc_aytuWarrantTenderOfferNetIssuanceCostsShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantTenderOfferNetIssuanceCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockNetCost" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockNetCost" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockNetCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockNetShare" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockNetShare" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockNetShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockAndWarrantNetCost" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockAndWarrantNetCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:label="loc_aytuIssuanceOfPreferredAndCommonStockWarrantNetShare" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIssuanceOfPreferredAndCommonStockWarrantNetShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RegisteredOfferingCost" xlink:label="loc_aytuRegisteredOfferingCost" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuRegisteredOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExercisesValue" xlink:label="loc_aytuWarrantExercisesValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantExercisesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExercisesShares" xlink:label="loc_aytuWarrantExercisesShares" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuWarrantExercisesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantAmendments" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInCapitalWarrantAmendments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" xlink:label="loc_aytuAdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentForRoundingOfValueDueToConversion" xlink:label="loc_aytuAdjustmentForRoundingOfValueDueToConversion" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentForRoundingOfValueDueToConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentForRoundingOfSharesDueToConversion" xlink:label="loc_aytuAdjustmentForRoundingOfSharesDueToConversion" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuAdjustmentForRoundingOfSharesDueToConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:label="loc_aytuPaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuPaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfOtherInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaapDerivativeGainOnDerivative" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainOnDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:label="loc_aytuAmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_aytuAmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaapAdjustmentOfWarrantsGrantedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentOfWarrantsGrantedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_aytuIncreaseDecreaseInAccruedCompensation" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_aytuIncreaseDecreaseInAccruedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsForDepositsInvestingActivities" xlink:label="loc_aytuPaymentsForDepositsInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuPaymentsForDepositsInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentForContingentConsiderationLiabilityInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsToAcquireOtherProductiveAssetsOne" xlink:label="loc_aytuPaymentsToAcquireOtherProductiveAssetsOne" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuPaymentsToAcquireOtherProductiveAssetsOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="loc_us-gaapProceedsFromSaleOfOtherInvestments" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfOtherInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="loc_us-gaapOtherPaymentsToAcquireBusinesses" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapOtherPaymentsToAcquireBusinesses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_aytuPaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuPaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepurchaseOfEquity" xlink:label="loc_us-gaapProceedsFromRepurchaseOfEquity" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromRepurchaseOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:label="loc_aytuRepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuRepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentForRegisteredOfferingCost" xlink:label="loc_aytuPaymentForRegisteredOfferingCost" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuPaymentForRegisteredOfferingCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProceedsOfWarrantTenderOffer" xlink:label="loc_aytuProceedsOfWarrantTenderOffer" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuProceedsOfWarrantTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProceedsFromWarrantTenderOffer" xlink:label="loc_aytuProceedsFromWarrantTenderOffer" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuProceedsFromWarrantTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PaymentsForRegisteredOfferingCosts" xlink:label="loc_aytuPaymentsForRegisteredOfferingCosts" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuPaymentsForRegisteredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RepaymentsForRegisteredOfferingCosts" xlink:label="loc_aytuRepaymentsForRegisteredOfferingCosts" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuRepaymentsForRegisteredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OverallotmentWarrantsPurchased" xlink:label="loc_aytuOverallotmentWarrantsPurchased" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_aytuOverallotmentWarrantsPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents_2" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedToInvestorsAndUnderwriters" xlink:label="loc_aytuWarrantsIssuedToInvestorsAndUnderwriters" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuWarrantsIssuedToInvestorsAndUnderwriters" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantExerciseOfDerivativeWarrants" xlink:label="loc_aytuWarrantExerciseOfDerivativeWarrants" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuWarrantExerciseOfDerivativeWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationIncludedInAccountsPayable" xlink:label="loc_aytuContingentConsiderationIncludedInAccountsPayable" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuContingentConsiderationIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EarnOutPaymentToOtherShareholders" xlink:label="loc_aytuEarnOutPaymentToOtherShareholders" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuEarnOutPaymentToOtherShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_Purchaseofassetincludedincontingentconsideration" xlink:label="loc_aytuPurchaseofassetincludedincontingentconsideration" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuPurchaseofassetincludedincontingentconsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentCconsideration" xlink:label="loc_aytuBusinessCombinationContingentCconsideration" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuBusinessCombinationContingentCconsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IssuanceOfCommonStockToNuelleShareHolders" xlink:label="loc_aytuIssuanceOfCommonStockToNuelleShareHolders" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuIssuanceOfCommonStockToNuelleShareHolders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FixedAssetsIncludedInAccountsPayable" xlink:label="loc_aytuFixedAssetsIncludedInAccountsPayable" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuFixedAssetsIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" xlink:label="loc_aytuWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer" xlink:label="loc_aytuWarrantsAmendedInConnectionWithWarrantTenderOffer" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_aytuWarrantsAmendedInConnectionWithWarrantTenderOffer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger" xlink:title="00000008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/GoingConcern" xlink:title="00000010 - Disclosure - Going Concern">
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GoingConcernDisclosureAbstract" xlink:label="loc_aytuGoingConcernDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernDisclosureAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderations" xlink:title="00000011 - Disclosure - Fair Value Considerations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommonStock" xlink:title="00000014 - Disclosure - Common Stock">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockTextBlock" xlink:label="loc_aytuCommonStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_aytuCommonStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstruments" xlink:title="00000015 - Disclosure - Equity Instruments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformation" xlink:title="00000017 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EmployeeBenefitPlan" xlink:title="00000018 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionSalesReturns" xlink:label="loc_us-gaapRevenueRecognitionSalesReturns" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionSalesReturns" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RestrictedStocksPolicyTextBlock" xlink:label="loc_aytuRestrictedStocksPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_aytuRestrictedStocksPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables" xlink:title="00000021 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" xlink:to="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuZolpiMistMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AwhAssetsMember" xlink:label="loc_aytuAwhAssetsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuAwhAssetsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsTables" xlink:title="00000023 - Disclosure - Fair Value Considerations (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_aytuContingentConsiderationMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_aytuContingentConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="loc_aytuAytuCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuAytuCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesTables" xlink:title="00000025 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommitmentsAndContingenciesDisclosureTableTextBlock" xlink:label="loc_aytuCommitmentsAndContingenciesDisclosureTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_aytuCommitmentsAndContingenciesDisclosureTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleOfRentExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfRentExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsTables" xlink:title="00000026 - Disclosure - Equity Instruments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaapNonvestedRestrictedStockSharesActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapNonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ScheduleOfOptionsOutstanding" xlink:label="loc_aytuScheduleOfOptionsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuScheduleOfOptionsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationTables" xlink:title="00000027 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails" xlink:title="00000028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuZolpiMistMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1" xlink:title="00000029 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2" xlink:title="00000030 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AwhAssetsMember" xlink:label="loc_aytuAwhAssetsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuAwhAssetsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_aytuContingentConsiderationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_aytuContingentConsiderationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual" xlink:title="00000031 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ProstascintBusinessMember" xlink:label="loc_aytuProstascintBusinessMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuProstascintBusinessMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_JazzPharmaceuticalsIncMember" xlink:label="loc_aytuJazzPharmaceuticalsIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuJazzPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrimsolBusinessMember" xlink:label="loc_aytuPrimsolBusinessMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuPrimsolBusinessMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuZolpiMistMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NuelleIncMember" xlink:label="loc_aytuNuelleIncMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNuelleIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuMember" xlink:label="loc_aytuAytuMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuAytuMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DiscountedCashFlowMethodMember" xlink:label="loc_aytuDiscountedCashFlowMethodMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_aytuDiscountedCashFlowMethodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaapDevelopedTechnologyRightsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapDevelopedTechnologyRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CustomerContractsMember" xlink:label="loc_us-gaapCustomerContractsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerContractsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ThirdUpfrontMember" xlink:label="loc_aytuThirdUpfrontMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_aytuThirdUpfrontMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CADMember" xlink:label="loc_aytuCADMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_aytuCADMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LicenseAndSupplyAgreementMember" xlink:label="loc_aytuLicenseAndSupplyAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aytuLicenseAndSupplyAgreementMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FirstMilestoneMember" xlink:label="loc_aytuFirstMilestoneMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuFirstMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SecondMilestoneMember" xlink:label="loc_aytuSecondMilestoneMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuSecondMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ThirdMilestoneMember" xlink:label="loc_aytuThirdMilestoneMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuThirdMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ForthMilestoneMember" xlink:label="loc_aytuForthMilestoneMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuForthMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FifthMilestoneMember" xlink:label="loc_aytuFifthMilestoneMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuFifthMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:label="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationPercentage" xlink:label="loc_aytuBusinessCombinationContingentConsiderationPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuBusinessCombinationContingentConsiderationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationRevalued" xlink:label="loc_aytuBusinessCombinationContingentConsiderationRevalued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuBusinessCombinationContingentConsiderationRevalued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationConsiderationTransferredInventory" xlink:label="loc_aytuBusinessCombinationConsiderationTransferredInventory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuBusinessCombinationConsiderationTransferredInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaapGainLossOnSaleOfBusiness" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapGainLossOnSaleOfBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaapBusinessAcquisitionSharePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapBusinessAcquisitionSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CostOfSaleForInvestment" xlink:label="loc_aytuCostOfSaleForInvestment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuCostOfSaleForInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodDescription" xlink:label="loc_us-gaapRevenueRecognitionMilestoneMethodDescription" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapRevenueRecognitionMilestoneMethodDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OneTimeNonRefundablePayments" xlink:label="loc_aytuOneTimeNonRefundablePayments" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuOneTimeNonRefundablePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SalesRevenueTarget" xlink:label="loc_aytuSalesRevenueTarget" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuSalesRevenueTarget" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PercentageofNetSalesDescriptions" xlink:label="loc_aytuPercentageofNetSalesDescriptions" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuPercentageofNetSalesDescriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SubsidiariesPaymentDescription" xlink:label="loc_aytuSubsidiariesPaymentDescription" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuSubsidiariesPaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RevenueEarnOutPayment" xlink:label="loc_aytuRevenueEarnOutPayment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuRevenueEarnOutPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrepaymentofCommonStock" xlink:label="loc_aytuPrepaymentofCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_aytuPrepaymentofCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuBusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000032 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerOneMember" xlink:label="loc_aytuCustomerOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerTwoMember" xlink:label="loc_aytuCustomerTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerCMember" xlink:label="loc_aytuCustomerCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerCMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OtherMember" xlink:label="loc_aytuOtherMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuOtherMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1" xlink:title="00000033 - Disclosure - Summary of Significant Accounting Policies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2" xlink:title="00000034 - Disclosure - Summary of Significant Accounting Policies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaapManufacturingFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapManufacturingFacilityMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LabEquipmentMember" xlink:label="loc_aytuLabEquipmentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_aytuLabEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3" xlink:title="00000035 - Disclosure - Summary of Significant Accounting Policies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5" xlink:title="00000037 - Disclosure - Summary of Significant Accounting Policies (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srtParentCompanyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtParentCompanyMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6" xlink:title="00000038 - Disclosure - Summary of Significant Accounting Policies (Details 6)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" xlink:title="00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LuoxisPatentMember" xlink:label="loc_aytuLuoxisPatentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_aytuLuoxisPatentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CustomerMember" xlink:label="loc_aytuCustomerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_aytuCustomerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesAxis" xlink:label="loc_aytuCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_aytuCounterpartiesAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesDomain" xlink:label="loc_aytuCounterpartiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCounterpartiesAxis" xlink:to="loc_aytuCounterpartiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CounterpartiesMember" xlink:label="loc_aytuCounterpartiesMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCounterpartiesDomain" xlink:to="loc_aytuCounterpartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SummaryOfSignificantAccountingPoliciesTextual" xlink:label="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FiniteLivedIntangibleAssetsExpirationMonthYear" xlink:label="loc_aytuFiniteLivedIntangibleAssetsExpirationMonthYear" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_aytuFiniteLivedIntangibleAssetsExpirationMonthYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NumberOfcustomers" xlink:label="loc_aytuNumberOfcustomers" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSummaryOfSignificantAccountingPoliciesTextual" xlink:to="loc_aytuNumberOfcustomers" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/GoingConcernDetails" xlink:title="00000040 - Disclosure - Going Concern (Details)">
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GoingConcernDisclosureAbstract" xlink:label="loc_aytuGoingConcernDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GoingConcernTextualAbstract" xlink:label="loc_aytuGoingConcernTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernDisclosureAbstract" xlink:to="loc_aytuGoingConcernTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernTextualAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="loc_us-gaapOtherOperatingActivitiesCashFlowStatement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernTextualAbstract" xlink:to="loc_us-gaapOtherOperatingActivitiesCashFlowStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernTextualAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaapStockholdersEquityOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernTextualAbstract" xlink:to="loc_us-gaapStockholdersEquityOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernTextualAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForOperatingActivities" xlink:label="loc_us-gaapPaymentsForOperatingActivities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuGoingConcernTextualAbstract" xlink:to="loc_us-gaapPaymentsForOperatingActivities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails" xlink:title="00000041 - Disclosure - Fair Value Considerations (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails1" xlink:title="00000042 - Disclosure - Fair Value Considerations (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="loc_aytuAytuCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuAytuCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoteWarrantMember" xlink:label="loc_us-gaapNoteWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapNoteWarrantMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAbstract" xlink:label="loc_aytuWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_aytuWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_aytuFairValueAssumptionsExpectedVolatilityRates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionsExpectedVolatilityRates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedTerms" xlink:label="loc_aytuFairValueAssumptionsExpectedTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionsExpectedTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_aytuFairValueAssumptionsRiskFreeInterestRates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionsRiskFreeInterestRates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_aytuFairValueAssumptionsExpectedDividendRates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionsExpectedDividendRates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails2" xlink:title="00000043 - Disclosure - Fair Value Considerations (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:label="loc_aytuFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_aytuFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" xlink:label="loc_aytuFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_aytuFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise" xlink:label="loc_aytuReclassificationOfWarrantLiabilityToEquityUponExercise" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_aytuReclassificationOfWarrantLiabilityToEquityUponExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetails3" xlink:title="00000044 - Disclosure - Fair Value Considerations (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationMember" xlink:label="loc_aytuContingentConsiderationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_aytuContingentConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ContingentConsiderationAbstract" xlink:label="loc_aytuContingentConsiderationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_aytuContingentConsiderationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:label="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_aytuBusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuContingentConsiderationAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/FairValueConsiderationsDetailsTextual" xlink:title="00000045 - Disclosure - Fair Value Considerations (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_aytuNatestoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueConsiderationsTextualAbstract" xlink:label="loc_aytuFairValueConsiderationsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuFairValueConsiderationsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuFairValueConsiderationsTextualAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AdjustmentOfContingentConsideration" xlink:label="loc_aytuAdjustmentOfContingentConsideration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuFairValueConsiderationsTextualAbstract" xlink:to="loc_aytuAdjustmentOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuFairValueConsiderationsTextualAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetails" xlink:title="00000046 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxReconciliationOfFeringCosts" xlink:label="loc_aytuIncomeTaxReconciliationOfFeringCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuIncomeTaxReconciliationOfFeringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:label="loc_aytuEffectiveIncomeTaxRateReconciliationOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuEffectiveIncomeTaxRateReconciliationOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxReconciliationContingentConsideration" xlink:label="loc_aytuIncomeTaxReconciliationContingentConsideration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuIncomeTaxReconciliationContingentConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:label="loc_aytuEffectiveIncomeTaxrateReconciliationContingentConsideration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuEffectiveIncomeTaxrateReconciliationContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RemeasurementOfDeferredTaxes" xlink:label="loc_aytuRemeasurementOfDeferredTaxes" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuRemeasurementOfDeferredTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RemeasurementOfDeferredTaxesPercentage" xlink:label="loc_aytuRemeasurementOfDeferredTaxesPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuRemeasurementOfDeferredTaxesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsTax1" xlink:label="loc_us-gaapCumulativeEffectOnRetainedEarningsTax1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapCumulativeEffectOnRetainedEarningsTax1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CumulativeEffectOnRetainedEarningsTaxPercentage" xlink:label="loc_aytuCumulativeEffectOnRetainedEarningsTaxPercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuCumulativeEffectOnRetainedEarningsTaxPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaapDerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" xlink:label="loc_aytuDerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_aytuDerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetails1" xlink:title="00000047 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnTradingSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCharitableContributionCarryforwards" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaapDeferredTaxAssetsDerivativeInstruments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDerivativeInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaapDeferredTaxAssetsInventory" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/IncomeTaxesDetailsTextual" xlink:title="00000048 - Disclosure - Income Taxes (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AmpioPharmaceuticalsMember" xlink:label="loc_aytuAmpioPharmaceuticalsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_aytuAmpioPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncomeTaxesTextualAbstract" xlink:label="loc_aytuIncomeTaxesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuIncomeTaxesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NetOperatingLossesExpirationDescription" xlink:label="loc_aytuNetOperatingLossesExpirationDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_aytuNetOperatingLossesExpirationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuIncomeTaxesTextualAbstract" xlink:to="loc_us-gaapOtherTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000049 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytuPrescriptionDatabaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuPrescriptionDatabaseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuNatestoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SupplyOrderMember" xlink:label="loc_aytuSupplyOrderMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuSupplyOrderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytuOfficeLeaseMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuOfficeLeaseMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaapContractualObligationDueInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaapContractualObligationDueInSecondYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInSecondYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="loc_us-gaapContractualObligationDueInThirdYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInThirdYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="loc_us-gaapContractualObligationDueInFourthYear" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInFourthYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="loc_us-gaapContractualObligationDueInFifthYear" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueInFifthYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="loc_us-gaapContractualObligationDueAfterFifthYear" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligationDueAfterFifthYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000050 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:title="00000051 - Disclosure - Commitments and Contingencies (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:label="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OfficeLeaseMember" xlink:label="loc_aytuOfficeLeaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuOfficeLeaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrescriptionDatabaseMember" xlink:label="loc_aytuPrescriptionDatabaseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuPrescriptionDatabaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NatestoMember" xlink:label="loc_aytuNatestoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuNatestoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SupplyOrderMember" xlink:label="loc_aytuSupplyOrderMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="loc_aytuSupplyOrderMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationTable" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ZolpiMistMember" xlink:label="loc_aytuZolpiMistMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="loc_aytuZolpiMistMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_aytuCommitmentsAndContingenciesTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapUnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FirstMilestonePayable" xlink:label="loc_aytuFirstMilestonePayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_aytuFirstMilestonePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommitmentsAndContingenciesTextualAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/CommonStockDetails" xlink:title="00000052 - Disclosure - Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuCommonStockMember" xlink:label="loc_aytuAytuCommonStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_aytuAytuCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassUnitsMember" xlink:label="loc_aytuClassUnitsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuClassUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassBUnitsMember" xlink:label="loc_aytuClassBUnitsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuClassBUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SeriesConvertiblePreferredStockMember" xlink:label="loc_aytuSeriesConvertiblePreferredStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuSeriesConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SeriesBConvertiblePreferredStockMember" xlink:label="loc_aytuSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuMayTwoZeroOneSixWarrantsMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuMayTwoZeroOneSixWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuOctoberTwoZeroOneSixWarrantsMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuOctoberTwoZeroOneSixWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ConvertibleAPreferredStockMember" xlink:label="loc_aytuConvertibleAPreferredStockMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuConvertibleAPreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ConvertibleBPreferredStockMember" xlink:label="loc_aytuConvertibleBPreferredStockMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuConvertibleBPreferredStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:label="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aytuLincolnParkCapitalFundLlcPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficersAndDirectorsMember" xlink:label="loc_aytuExecutiveOfficersAndDirectorsMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuExecutiveOfficersAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaapExecutiveOfficerMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockTextualAbstract" xlink:label="loc_aytuCommonStockTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_aytuCommonStockTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:label="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfAvailableForSaleSecuritiesEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PreferredStockConversionPricePerShare" xlink:label="loc_aytuPreferredStockConversionPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuPreferredStockConversionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncrementalCommonSharesDueToConversionOfPreferredStock" xlink:label="loc_aytuIncrementalCommonSharesDueToConversionOfPreferredStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuIncrementalCommonSharesDueToConversionOfPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SecuritiesPurchaseAgreementCashFeePercentage" xlink:label="loc_aytuSecuritiesPurchaseAgreementCashFeePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuSecuritiesPurchaseAgreementCashFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:label="loc_aytuClassOfWarrantOrRightPercentageOfSharesToBeIssued" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuClassOfWarrantOrRightPercentageOfSharesToBeIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytuWarrantsToPurchaseOfCommonStockShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuWarrantsToPurchaseOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:label="loc_aytuWarrantsIssuedToUnderwritersAsCompensationForTransaction" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuWarrantsIssuedToUnderwritersAsCompensationForTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnrecognizedShareBasedCompensationExpenses" xlink:label="loc_aytuUnrecognizedShareBasedCompensationExpenses" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuUnrecognizedShareBasedCompensationExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnrecognizedExpense" xlink:label="loc_aytuUnrecognizedExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuUnrecognizedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaapRestrictedInvestmentsAtFairValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapRestrictedInvestmentsAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentOwnedRestrictedAcquisitionDate" xlink:label="loc_us-gaapInvestmentOwnedRestrictedAcquisitionDate" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapInvestmentOwnedRestrictedAcquisitionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RevenueEarnOutPayment" xlink:label="loc_aytuRevenueEarnOutPayment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuRevenueEarnOutPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_DescriptionOfUnrecognizedExpense" xlink:label="loc_aytuDescriptionOfUnrecognizedExpense" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuDescriptionOfUnrecognizedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaapOtherUnderwritingExpense" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapOtherUnderwritingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockSharesAgreedToPurchase" xlink:label="loc_aytuCommonStockSharesAgreedToPurchase" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuCommonStockSharesAgreedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_CommonStockValueAgreedToPurchase" xlink:label="loc_aytuCommonStockValueAgreedToPurchase" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuCommonStockValueAgreedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapEquityFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EquityRelativeFairValue" xlink:label="loc_aytuEquityRelativeFairValue" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuEquityRelativeFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_UnderwritersExercisedOfOverallotmentOption" xlink:label="loc_aytuUnderwritersExercisedOfOverallotmentOption" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuUnderwritersExercisedOfOverallotmentOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PreferredStockSharesDesignated" xlink:label="loc_aytuPreferredStockSharesDesignated" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_aytuPreferredStockSharesDesignated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="loc_us-gaapSignificantPurchaseCommitmentDescription" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapSignificantPurchaseCommitmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="loc_us-gaapRevenuePerformanceObligationDescriptionOfPaymentTerms" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapRevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuCommonStockTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails" xlink:title="00000053 - Disclosure - Equity Instruments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OptionsAbstract" xlink:label="loc_aytuOptionsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedVolatilityRate1" xlink:label="loc_aytuFairValueAssumptionsExpectedVolatilityRate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuOptionsAbstract" xlink:to="loc_aytuFairValueAssumptionsExpectedVolatilityRate1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_aytuFairValueAssumptionsRiskFreeInterestRate1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuOptionsAbstract" xlink:to="loc_aytuFairValueAssumptionsRiskFreeInterestRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedTerm1" xlink:label="loc_aytuFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuOptionsAbstract" xlink:to="loc_aytuFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionsExpectedDividendRate1" xlink:label="loc_aytuFairValueAssumptionsExpectedDividendRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuOptionsAbstract" xlink:to="loc_aytuFairValueAssumptionsExpectedDividendRate1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails1" xlink:title="00000054 - Disclosure - Equity Instruments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails2" xlink:title="00000055 - Disclosure - Equity Instruments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExercisePriceRangeOneMember" xlink:label="loc_aytuExercisePriceRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_aytuExercisePriceRangeOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExercisePriceRangeTwoMember" xlink:label="loc_aytuExercisePriceRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_aytuExercisePriceRangeTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails3" xlink:title="00000056 - Disclosure - Equity Instruments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails4" xlink:title="00000057 - Disclosure - Equity Instruments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails5" xlink:title="00000058 - Disclosure - Equity Instruments (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytuShareBasedCompensationShareWarrantsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnPrivateOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnUnderwriter" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnUnderwriter" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnConnection" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnConnection" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsExpired" xlink:label="loc_aytuShareBasedCompensationShareWarrantsExpired" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstanding" xlink:label="loc_aytuShareBasedCompensationShareWarrantsOutstanding_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" xlink:label="loc_aytuShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice" xlink:label="loc_aytuShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_aytuShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" xlink:label="loc_aytuClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract" xlink:to="loc_aytuClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetails6" xlink:title="00000059 - Disclosure - Equity Instruments (Details 6)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsAbstract" xlink:label="loc_aytuWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionWeightedAverageExpectedDividend" xlink:label="loc_aytuFairValueAssumptionWeightedAverageExpectedDividend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionWeightedAverageExpectedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionRiskFreeInterestRate" xlink:label="loc_aytuFairValueAssumptionRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionExpectedTerm" xlink:label="loc_aytuFairValueAssumptionExpectedTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_FairValueAssumptionExpectedDividendRate" xlink:label="loc_aytuFairValueAssumptionExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuWarrantsAbstract" xlink:to="loc_aytuFairValueAssumptionExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EquityInstrumentsDetailsTextual" xlink:title="00000060 - Disclosure - Equity Instruments (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:label="loc_aytuTwoThousandFifteenStockOptionAndIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aytuTwoThousandFifteenStockOptionAndIncentivePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_TwoThousandFifteenPlanMember" xlink:label="loc_aytuTwoThousandFifteenPlanMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aytuTwoThousandFifteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficerDirectorAndConsultantsMember" xlink:label="loc_aytuExecutiveOfficerDirectorAndConsultantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuExecutiveOfficerDirectorAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaapExecutiveOfficerMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaapOfficerMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytuAytuBioscienceIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aytuAytuBioscienceIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NovemberTwoThousandSixTeenPublicOfferingMember" xlink:label="loc_aytuNovemberTwoThousandSixTeenPublicOfferingMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_aytuNovemberTwoThousandSixTeenPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember" xlink:label="loc_aytuNovemberTwoThousandSixTeenPublicOfferingOneMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_aytuNovemberTwoThousandSixTeenPublicOfferingOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_MayTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuMayTwoZeroOneSixWarrantsMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuMayTwoZeroOneSixWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_OctoberTwoZeroOneSixWarrantsMember" xlink:label="loc_aytuOctoberTwoZeroOneSixWarrantsMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_aytuOctoberTwoZeroOneSixWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EquityInstrumentsTextualAbstract" xlink:label="loc_aytuEquityInstrumentsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_aytuEquityInstrumentsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsToPurchaseOfCommonStockShares" xlink:label="loc_aytuWarrantsToPurchaseOfCommonStockShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuWarrantsToPurchaseOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsExercisePriceTerm" xlink:label="loc_aytuWarrantsExercisePriceTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuWarrantsExercisePriceTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantsGeneratedNoncashExpense" xlink:label="loc_aytuWarrantsGeneratedNoncashExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuWarrantsGeneratedNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_WarrantTenderOfferDescription" xlink:label="loc_aytuWarrantTenderOfferDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuWarrantTenderOfferDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_VestingExpiryDate" xlink:label="loc_aytuVestingExpiryDate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuVestingExpiryDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_NewWarrantsToPurchaseOfCommonStock" xlink:label="loc_aytuNewWarrantsToPurchaseOfCommonStock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuNewWarrantsToPurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaapEquityFairValueDisclosure" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapEquityFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_StockIssuedDuringPeriodValueRestrictedStockCancelled" xlink:label="loc_aytuStockIssuedDuringPeriodValueRestrictedStockCancelled" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuStockIssuedDuringPeriodValueRestrictedStockCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_IncrementalFairValueOfWarrant" xlink:label="loc_aytuIncrementalFairValueOfWarrant" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEquityInstrumentsTextualAbstract" xlink:to="loc_aytuIncrementalFairValueOfWarrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/RelatedPartyTransactionsDetails" xlink:title="00000061 - Disclosure - Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ExecutiveOfficerOneMember" xlink:label="loc_aytuExecutiveOfficerOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuExecutiveOfficerOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaapExecutiveOfficerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapExecutiveOfficerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_GreenMember" xlink:label="loc_aytuGreenMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aytuGreenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementAxis" xlink:label="loc_aytuAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_aytuAgreementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AgreementDomain" xlink:label="loc_aytuAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuAgreementAxis" xlink:to="loc_aytuAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SponsoredResearchAgreementMember" xlink:label="loc_aytuSponsoredResearchAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuAgreementDomain" xlink:to="loc_aytuSponsoredResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_ServicesAgreementMember" xlink:label="loc_aytuServicesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuAgreementDomain" xlink:to="loc_aytuServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_aytuRelatedPartyTransactionsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapDueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_PrepaidExpensesAmortizationPeriod" xlink:label="loc_aytuPrepaidExpensesAmortizationPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:to="loc_aytuPrepaidExpensesAmortizationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuRelatedPartyTransactionsTextualAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationDetails" xlink:title="00000062 - Disclosure - Segment Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuWomensHealthMember" xlink:label="loc_aytuAytuWomensHealthMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aytuAytuWomensHealthMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AytuBioscienceIncMember" xlink:label="loc_aytuAytuBioscienceIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aytuAytuBioscienceIncMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:label="loc_us-gaapMinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SegmentInformationDetailsTextual" xlink:title="00000063 - Disclosure - Segment Information (Details Textual)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SegmentInformationTextualAbstract" xlink:label="loc_aytuSegmentInformationTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_aytuSegmentInformationTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSegmentInformationTextualAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/EmployeeBenefitPlanDetails" xlink:title="00000064 - Disclosure - Employee Benefit Plan (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_EmployeeBenefitPlanTextualAbstract" xlink:label="loc_aytuEmployeeBenefitPlanTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_aytuEmployeeBenefitPlanTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="loc_us-gaapDescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEmployeeBenefitPlanTextualAbstract" xlink:to="loc_us-gaapDescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuEmployeeBenefitPlanTextualAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/SubsequentEventsDetails" xlink:title="00000065 - Disclosure - Subsequent Events (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_SubsequentEventsTextualAbstract" xlink:label="loc_aytuSubsequentEventsTextualAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aytuSubsequentEventsTextualAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSubsequentEventsTextualAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aytu-20180630.xsd#aytu_AssetPurchase" xlink:label="loc_aytuAssetPurchase" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aytuSubsequentEventsTextualAbstract" xlink:to="loc_aytuAssetPurchase" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840660160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOSCIENCE, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,801,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841142736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,012,527<span></span>
</td>
<td class="nump">$ 802,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">75,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">578,782<span></span>
</td>
<td class="nump">528,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,338,973<span></span>
</td>
<td class="nump">1,312,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">440,009<span></span>
</td>
<td class="nump">310,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,470,291<span></span>
</td>
<td class="nump">3,028,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">218,684<span></span>
</td>
<td class="nump">647,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CoreAndDevelopedTechnologyNet', window );">Developed technology, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,337,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedContractualRights', window );">Customer contracts, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">77,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTradeNames', window );">Trade names, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">164,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Licensed assets, net</a></td>
<td class="nump">11,120,086<span></span>
</td>
<td class="nump">9,231,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">238,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">245,944<span></span>
</td>
<td class="nump">271,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">5,088<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">11,589,802<span></span>
</td>
<td class="nump">11,969,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,060,093<span></span>
</td>
<td class="nump">14,998,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and other</a></td>
<td class="nump">2,119,672<span></span>
</td>
<td class="nump">2,220,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">185,882<span></span>
</td>
<td class="nump">782,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">540,674<span></span>
</td>
<td class="nump">339,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current deferred rent</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="nump">6,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current contingent consideration</a></td>
<td class="nump">547,100<span></span>
</td>
<td class="nump">261,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,394,778<span></span>
</td>
<td class="nump">3,610,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Long-term contingent consideration</a></td>
<td class="nump">4,146,829<span></span>
</td>
<td class="nump">7,386,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Long-term deferred rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">93,981<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,635,588<span></span>
</td>
<td class="nump">10,998,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 1,794,762 and 41,244, respectively as of June 30, 2018 and 2017</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">92,681,918<span></span>
</td>
<td class="nump">73,069,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(79,257,592)<span></span>
</td>
<td class="num">(69,069,729)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">13,424,505<span></span>
</td>
<td class="nump">3,999,816<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 21,060,093<span></span>
</td>
<td class="nump">$ 14,998,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable pertaining to costs that are statutory in nature of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CoreAndDevelopedTechnologyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CoreAndDevelopedTechnologyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedContractualRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date of rights with an indefinite period of benefit that arose from a contractual arrangement with a third party (not including franchise rights and license agreements).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedContractualRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTradeNames">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trade name to gain or protect exclusive use thereof for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTradeNames</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818219440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">1,794,762<span></span>
</td>
<td class="nump">41,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">1,794,762<span></span>
</td>
<td class="nump">41,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841140672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Product revenue, net</a></td>
<td class="nump">$ 3,660,120<span></span>
</td>
<td class="nump">$ 3,221,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total product revenue</a></td>
<td class="nump">3,660,120<span></span>
</td>
<td class="nump">3,221,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">2,050,544<span></span>
</td>
<td class="nump">1,417,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">167,595<span></span>
</td>
<td class="nump">959,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ResearchAndDevelopmentRelatedParty', window );">Research and development - related party (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">387,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">17,732,490<span></span>
</td>
<td class="nump">17,442,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Sales, general and administrative - related party (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">165,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">1,856,020<span></span>
</td>
<td class="nump">1,265,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,553,705<span></span>
</td>
<td class="nump">1,708,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,360,354<span></span>
</td>
<td class="nump">23,346,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,700,234)<span></span>
</td>
<td class="num">(20,125,236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(749,423)<span></span>
</td>
<td class="num">(2,534,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">(Loss) on investment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(61,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other gain</a></td>
<td class="nump">6,277,873<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative income</a></td>
<td class="nump">3,983,921<span></span>
</td>
<td class="nump">212,809<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense)</a></td>
<td class="nump">9,512,371<span></span>
</td>
<td class="num">(2,383,068)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,187,863)<span></span>
</td>
<td class="num">$ (22,508,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">665,605<span></span>
</td>
<td class="nump">466,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (15.31)<span></span>
</td>
<td class="num">$ (48.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ResearchAndDevelopmentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ResearchAndDevelopmentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842181728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 56,646,677<span></span>
</td>
<td class="num">$ (46,561,425)<span></span>
</td>
<td class="nump">$ 10,085,253<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_StockIssuanceNetOfIssuanceCostsValue', window );">Lincoln Park stock issuance, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">648,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_StockIssuanceNetOfIssuanceCostsShares', window );">Lincoln Park stock issuance, net of issuance costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,502,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,502,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">724,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockIssuedToExecutivesValue', window );">Common stock issued to executives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">509,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockIssuedToExecutivesShare', window );">Common stock issued to executives, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issurance of warrants to initial investors</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">596,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue', window );">Issuance of common stock, net of in issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,671,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,671,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares', window );">Issuance of common stock, net of in issuance costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing', window );">Warrants issued in connection with registered offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,470,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,470,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption', window );">Warrants issued in connection with registered offering to the placement agents for the over-allotment option</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">172,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts', window );">Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">292,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantTenderOfferNetIssuanceCostsValue', window );">Warrant tender offer, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,931,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,931,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantTenderOfferNetIssuanceCostsShares', window );">Warrant tender offer, net of issuance costs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments', window );">Warrant amendments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Investment in Subsidiary</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,837,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Investment in Subsidiary, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,508,304)<span></span>
</td>
<td class="num">(22,508,304)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">73,069,541<span></span>
</td>
<td class="num">(69,069,729)<span></span>
</td>
<td class="nump">3,999,816<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">41,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">348,515<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">348,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">248,415<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">248,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issurance of warrants to initial investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing', window );">Warrants issued in connection with registered offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,439,360<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,439,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Earn-out payment to Nuelle shareholders</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Earn-out payment to Nuelle shareholders, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfPreferredAndCommonStockNetCost', window );">Issuance of preferred and common stock, net of cash issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">6,319,150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,319,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfPreferredAndCommonStockNetShare', window );">Issuance of preferred and common stock, net of cash issuance costs, shares</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">159,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost', window );">Issuance of preferred and common stock, net of cash issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">9,166,316<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,166,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare', window );">Issuance of preferred and common stock, net of cash issuance costs, shares</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">1,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Preferred stock converted in common stock</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Preferred stock converted in common stock, shares</a></td>
<td class="num">(274)<span></span>
</td>
<td class="nump">394,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RegisteredOfferingCost', window );">S-3 registered offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantExercisesValue', window );">Warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">677,092<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">677,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments', window );">Warrant amendments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,633<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant', window );">Warrant exercise of derivative warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,096<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentForRoundingOfValueDueToConversion', window );">Adjustment for rounding of shares due to stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentForRoundingOfSharesDueToConversion', window );">Adjustment for rounding of shares due to stock split, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,187,863)<span></span>
</td>
<td class="num">(10,187,863)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 92,681,918<span></span>
</td>
<td class="num">$ (79,257,592)<span></span>
</td>
<td class="nump">$ 13,424,505<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,794,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentForRoundingOfSharesDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to adjustment for rounding of shares due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentForRoundingOfSharesDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentForRoundingOfValueDueToConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to adjustment for rounding of values due to conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentForRoundingOfValueDueToConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid up capital resulting from warrants amendments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInCapitalWarrantAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of warrants in connection with equity financing to the placement agents for the over-allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to warrant exercise of derivative warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentsToAdditionalPaidInWarrantExerciseOfDerivativeWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of adjustment made to the additional paid in capital with regard to issuance of Warrants issued in connection with equity financing to the placement agents, non-cash issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockIssuedToExecutivesShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued to executives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockIssuedToExecutivesShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockIssuedToExecutivesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued to executives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockIssuedToExecutivesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the reporting period,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfCommonStockNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock issued during the reporting period,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfCommonStockNetOfIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred and common stock and warrant net cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfPreferredAndCommonStockAndWarrantNetCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfPreferredAndCommonStockNetCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred and common stock net cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfPreferredAndCommonStockNetCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfPreferredAndCommonStockNetShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred and common stock net share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfPreferredAndCommonStockNetShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of preferred and common stock and warrant net share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfPreferredAndCommonStockWarrantNetShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RegisteredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of registered offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RegisteredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuanceNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issuance, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuanceNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_StockIssuanceNetOfIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issuance, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_StockIssuanceNetOfIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantExercisesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to issuance of warrants exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantExercisesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantTenderOfferNetIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant tender offer, net of in issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantTenderOfferNetIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantTenderOfferNetIssuanceCostsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of warrant tender offer, net of in issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantTenderOfferNetIssuanceCostsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823036448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Issuance of preferred and common stock, net of cash issuance costs</a></td>
<td class="nump">$ 1,402,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash', window );">Issuance of preferred and common stock, net of cash issuance costs</a></td>
<td class="nump">$ 1,294,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember', window );">LincolnPark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 997,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period issuance of preferred stock, common stock and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentOfStockIssuanceOfPreferredStockCommonStockAndWarrantsCostsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841957600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,187,863)<span></span>
</td>
<td class="num">$ (22,508,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and accretion</a></td>
<td class="nump">2,591,270<span></span>
</td>
<td class="nump">4,364,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of intangible assets</a></td>
<td class="nump">1,856,020<span></span>
</td>
<td class="nump">1,265,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">348,515<span></span>
</td>
<td class="nump">2,502,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Issuance of restricted stock</a></td>
<td class="nump">248,419<span></span>
</td>
<td class="nump">724,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Other gain</a></td>
<td class="num">(6,277,873)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrants issuance and amendments</a></td>
<td class="nump">183,920<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative income</a></td>
<td class="num">(3,983,921)<span></span>
</td>
<td class="num">(212,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties', window );">Amortization of prepaid research and development - related party (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">335,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Loss on investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">61,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued to executives</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">509,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Issuance of warrants to initial investors</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">596,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of asset</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(428,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) in accounts receivable</a></td>
<td class="num">(50,743)<span></span>
</td>
<td class="num">(355,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="num">(26,752)<span></span>
</td>
<td class="nump">195,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">(Increase) in prepaid expenses and other</a></td>
<td class="num">(129,249)<span></span>
</td>
<td class="num">(95,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">(Decrease) increase in accounts payable and other</a></td>
<td class="num">(109,707)<span></span>
</td>
<td class="nump">493,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease) in accrued liabilities</a></td>
<td class="num">(596,654)<span></span>
</td>
<td class="num">(414,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncreaseDecreaseInAccruedCompensation', window );">Increase (decrease) in accrued compensation</a></td>
<td class="nump">200,970<span></span>
</td>
<td class="num">(861,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">(Decrease) in deferred rent</a></td>
<td class="num">(6,674)<span></span>
</td>
<td class="num">(4,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,940,322)<span></span>
</td>
<td class="num">(13,829,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentsForDepositsInvestingActivities', window );">Deposit</a></td>
<td class="num">(2,200)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(74,707)<span></span>
</td>
<td class="num">(111,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Contingent consideration payment</a></td>
<td class="num">(7,385)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentsToAcquireOtherProductiveAssetsOne', window );">Purchase of assets</a></td>
<td class="num">(400,000)<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Investment in Acerus</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,071,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Sale of investment in Acerus cost</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(91,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sales of Primsol assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Purchase of Primsol asset</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash proceed from Nuelle</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">613,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cost related to Nuelle acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,082)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(484,292)<span></span>
</td>
<td class="num">(3,534,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance of preferred, common stock and warrants</a></td>
<td class="nump">11,839,995<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost', window );">Issuance costs related to preferred, common stock and warrants</a></td>
<td class="num">(1,402,831)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfEquity', window );">Issuance of preferred, common stock and warrants</a></td>
<td class="nump">12,900,020<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost', window );">Issuance costs related to preferred, common stock and warrants</a></td>
<td class="num">(1,294,235)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises</a></td>
<td class="nump">677,100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentForRegisteredOfferingCost', window );">S-3 registered offering cost</a></td>
<td class="num">(60,450)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock to Lincoln Park</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">739,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Costs related to the sale of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(90,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ProceedsOfWarrantTenderOffer', window );">Warrant tender offer</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,243,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ProceedsFromWarrantTenderOffer', window );">Warrant tender offer cost</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(312,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PaymentsForRegisteredOfferingCosts', window );">Registered offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,602,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RepaymentsForRegisteredOfferingCosts', window );">Registered offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(997,865)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OverallotmentWarrantsPurchased', window );">Over-allotment warrants purchased by placement agents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">22,659,599<span></span>
</td>
<td class="nump">10,187,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">6,234,985<span></span>
</td>
<td class="num">(7,176,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash and cash equivalents restricted cash at beginning of period</a></td>
<td class="nump">877,542<span></span>
</td>
<td class="nump">8,054,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash and cash equivalents restricted cash at end of period</a></td>
<td class="nump">7,112,527<span></span>
</td>
<td class="nump">877,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsIssuedToInvestorsAndUnderwriters', window );">Warrants issued to investors and underwriters (see Note 4)</a></td>
<td class="nump">4,117,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantExerciseOfDerivativeWarrants', window );">Warrant exercise of derivative warrants</a></td>
<td class="nump">40,096<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ContingentConsiderationIncludedInAccountsPayable', window );">Contingent consideration included in accounts payable</a></td>
<td class="nump">8,980<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EarnOutPaymentToOtherShareholders', window );">Earn-out payment to Nuelle Shareholders</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_Purchaseofassetincludedincontingentconsideration', window );">Purchase of asset included in contingent consideration</a></td>
<td class="nump">293,216<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentCconsideration', window );">Contingent consideration</a></td>
<td class="nump">2,553,169<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IssuanceOfCommonStockToNuelleShareHolders', window );">Issuance of common stock to Nuelle share holders</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,837,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FixedAssetsIncludedInAccountsPayable', window );">Fixed assets included in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents', window );">Warrants issued in connection with the equity financing to the placement agents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">292,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer', window );">Warrants amended in connection with warrant tender offer</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 63,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of prepaid research and development due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentCconsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentCconsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash amount of contingent consideration included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EarnOutPaymentToOtherShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earn-out payment to the shareholders of subsidiary company or on merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EarnOutPaymentToOtherShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FixedAssetsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of fixed assets included in accounts payable in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FixedAssetsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IssuanceOfCommonStockToNuelleShareHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to Nuelle share holders for non cash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IssuanceOfCommonStockToNuelleShareHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OverallotmentWarrantsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OverallotmentWarrantsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentForRegisteredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>S-3 registered offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentForRegisteredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsForDepositsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsForDepositsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsForRegisteredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for the payment of costs on issuance of registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsForRegisteredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of preferred, common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsOfPreferredCommonStockAndWarrantsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PaymentsToAcquireOtherProductiveAssetsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PaymentsToAcquireOtherProductiveAssetsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProceedsFromWarrantTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrant tender offer for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProceedsFromWarrantTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ProceedsOfWarrantTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of warrant tender offer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ProceedsOfWarrantTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_Purchaseofassetincludedincontingentconsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the purchase of asset included in contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_Purchaseofassetincludedincontingentconsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RepaymentsForRegisteredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of registered offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RepaymentsForRegisteredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of preferred, common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RepaymentsOfPreferredCommonStockAndWarrantsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantExerciseOfDerivativeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount non cash warrant exercise of derivative warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantExerciseOfDerivativeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants amended in connection with warrant tender offer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsAmendedInConnectionWithWarrantTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued in connection with equity financing to the placement agents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsIssuedInConnectionWithEquityFinancingToPlacementAgents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsIssuedToInvestorsAndUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued to investors and underwriters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsIssuedToInvestorsAndUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow resulting from the entity's share transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831793424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 &#8211; Business, Basis of Presentation, Business
Combinations, Divestitures, License/Supply Agreement and Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience, Inc. (&#8220;Aytu&#8221;, the &#8220;Company&#8221;
or &#8220;we&#8221;) was incorporated as Rosewind Corporation on August&#160;9, 2002 in the State of Colorado. Aytu was re-incorporated
in the state of Delaware on June&#160;8, 2015. <font style="background-color: white">Aytu is an emerging specialty pharmaceutical
company focused on commercializing novel products that address significant medical needs. Aytu is focused on commercializing products
that address hypogonadism (low testosterone), insomnia, and male infertility and plans to expand into other therapeutic areas.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis of Presentation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The audited consolidated financial statements include the operations
of Aytu and its wholly-owned subsidiary, Aytu Women&#8217;s Health, LLC. All significant inter-company balances and transactions
have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements of the Company
have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). On August 10, 2018,
Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding
(herein referred to collectively as the &#8220;Reverse Stock Splits&#8221;). All share and per share amounts in this report have
been adjusted to reflect the effect of these Reverse Stock Splits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Combination&#8212;ProstaScint</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2015, Aytu completed an asset purchase agreement with
Jazz Pharmaceuticals, Inc. (&#8220;Jazz Pharmaceuticals&#8221;). Pursuant to the agreement, Aytu purchased assets related to the
Jazz Pharmaceuticals&#8217; product known as ProstaScint<sup>&#174;</sup> (capromab pendetide), a late life cycle imaging agent,
including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the
&#8220;ProstaScint Business&#8221;), and assumed certain of Jazz Pharmaceuticals&#8217; liabilities, including those
related to product approvals and the sale and marketing of ProstaScint. The purchase price consists of the upfront payment of $1.0
million. We will pay a revenue share of 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment
of an additional $2.5 million. The contingent consideration was initially valued at $664,000 and was revalued as of June 30, 2017
at $54,000 using a discounted cash flow. As of June 30, 2018, the value for the contingent consideration was adjusted to $0 based
upon the abandonment of ProstaScint in the quarter ended June 30, 2018, thus resulting in no future revenues around this product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the asset purchase agreement, we were required to
make our first revenue share payment to Jazz Pharmaceuticals during the March 31, 2018 quarter which was approximately $7,400.
We will make our final revenue share payment to Jazz Pharmaceuticals in the first quarter of fiscal 2019, which is approximately
$9,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2017, the ProstaScint asset was determined to be
impaired based upon sales projections at that time and because we were planning to discontinue sales of ProstaScint in fiscal 2019,
consistent with product expiry dating. The value for the intangible assets were adjusted to $54,000 for developed technology, $7,000
for trade names and $0 for customer contracts. At June 30, 2018, we reevaluated the ProstaScint asset and abandoned sales of ProstaScint
in the current fiscal year, and we recognized the remainder of the amortization expense in the quarter ended June 30, 2018. The
amortization expense was $61,000 and $159,000 for fiscal 2018 and 2017, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Combination&#8212;Primsol</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2015, Aytu entered into and closed on an Asset Purchase
Agreement with FSC Laboratories, Inc. (&#8220;FSC&#8221;). Pursuant to the agreement, Aytu purchased assets related to FSC&#8217;s
product known as Primsol&#174; (trimethoprim solution), including certain intellectual property and contracts, inventory, work in
progress and all marketing and sales assets and materials related solely to Primsol (together, the &#8220;Primsol Business&#8221;),
and assumed certain of FSC&#8217;s liabilities, including those related to the sale and marketing of Primsol arising after the
closing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense of $0 and $184,000 was recognized in fiscal
2018 and fiscal 2017, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Divestiture &#8211; Primsol</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2017, we entered into and closed on an Asset Purchase
Agreement with Allegis Holdings, LLC (the &#8220;Purchaser&#8221;). Pursuant to the agreement, we sold to the Purchaser all of
our assets related to our Primsol product, including certain intellectual property and contracts, inventory, work in process and
all marketing assets and materials related solely to Primsol (together, the &#8220;Primsol Asset&#8221;). We retain any liability
associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol
Asset. We recognized a gain of approximately $428,000 on the sale which is included in sales, general and administrative expense
on our statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License and Supply Agreement&#8212;Natesto</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, Aytu entered into and closed a license and supply
agreement to acquire the exclusive U.S. rights to Natesto&#174; (testosterone) nasal gel from Acerus Pharmaceuticals Corporation
(&#8220;Acerus&#8221;). We acquired the right effective upon the expiration of the former licensee&#8217;s rights, which occurred
on June 30, 2016. The licensee&#8217;s term runs for the greater of eight years or until the expiry of the latest to expire patent
including claims covering Natesto and until the entry on the market of at least one AB-rated generic product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu made an upfront payment of $2.0 million to Acerus upon
execution of the agreement. In October 2016, we paid an additional $2.0 million. In January 2017, Aytu paid the final upfront payment
of $4.0 million. Aytu also purchased, on April 28, 2016, an aggregate of 12,245,411 shares of Acerus common stock for Cdn. $2.5
million (approximately US $2.0 million), with a purchase price per share equal to Cdn. $0.207 or approximately US $0.16 per share.
These shares were a held for sale trading security and were valued at fair market value. Aytu could not dispose of these shares
until after August 29, 2016. During fiscal 2017, Aytu sold all of these shares. The gross proceeds from the sales totaled $1.1
million, the cost of the sales totaled $92,000, and we recognized a loss on investment of $0 and $62,000 during fiscal 2018 and
2017, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the upfront payments, we must make the following
one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum
aggregate amount payable under such milestone payments will be $37.5 million):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; font-size: 10pt">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">$2.5 million if net sales during any four consecutive calendar quarter period equal or exceed $25.0 million (the &#8220;First Milestone&#8221;); the First Milestone payment is required to be paid even if the threshold is not met in the event that the agreement is terminated for any reason other than material breach by Acerus, bankruptcy of either party, or termination by Acerus because it believes the amounts payable to Aytu for agreed upon trial work would no longer make the agreement economically viable for Acerus;</font></td></tr>
<tr style="vertical-align: top; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">$5.0 million if net sales during any four consecutive calendar quarter period equal or exceed $50.0 million;</font></td></tr>
<tr style="vertical-align: top; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">$7.5 million if net sales during any four consecutive calendar quarter period equal or exceed $75.0 million;</font></td></tr>
<tr style="vertical-align: top; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">$10.0 million if net sales during any four consecutive calendar quarter period equal or exceed $100.0 million; and</font></td></tr>
<tr style="vertical-align: top; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">$12.5 million if net sales during any four consecutive calendar quarter period equal or exceed $125.0 million.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of the net identifiable asset acquired totaled
$10.5 million which is being amortized over eight years. The amortization expense for fiscal 2018 and fiscal 2017 was $1.3 million,
respectively. The estimated future amortization of Natesto after June 30, 2018 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">1,319,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">1,317,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">7,912,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was initially valued at $3.2 million
using a Monte Carlo simulation, as of June 30, 2016. As of June 30, 2018, the contingent consideration was revalued at $1.8 million
using the same Monte Carlo simulation methodology, and based on current interest rates, expected sales potential, and Aytu stock
trading variables. The contingent consideration accretion expense for fiscal 2018 and 2017 was $694,000, and $228,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>License and Supply Agreement&#8212;ZolpiMist </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, Aytu signed an exclusive license agreement for
ZolpiMist&#8482; (Zolpidem Tartrate Oral Spray) from Magna Pharmaceuticals, Inc., (&#8220;Magna&#8221;). This agreement allows
for Aytu&#8217;s exclusive commercialization of ZolpiMist in the U.S. and Canada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu made an upfront payment of $400,000 to Magna upon execution of the agreement. In July 2018, we paid
an additional $300,000, of which, $297,000 was included in current contingent consideration at June 30, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The intangible asset was valued at $3.2 million and will be
amortized over the life of the license agreement up to seven years. The Company&#8217;s allocation on consideration transferred
for ZolpiMist as of the purchase date of June 11, 2018 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Fair Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; text-align: left; font-size: 10pt">&#160;Intangible assets</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">3,200,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">&#160;Total assets acquired</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,200,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amortization expense for fiscal 2018 was $39,000. The estimated
future amortization of ZolpiMist after June 30, 2018 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">464,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">888,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,208,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also agreed to make certain royalty payments to Magna which
will be calculated as a percentage of our ZolpiMist net sales which will be payable within 45 days of the end of the quarter during
which the applicable net sales occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; font-size: 10pt">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Twenty percent (20%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2020</font></td></tr>
<tr style="vertical-align: top; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Fifteen percent (15%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2022</font></td></tr>
<tr style="vertical-align: top; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="font-size: 10pt"><font style="font-size: 10pt">Ten percent (10%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2025</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration, related to these royalty payments, was valued at $2.6 million using a Monte
Carlo simulation, as of June 11, 2018. The contingent consideration accretion expense for fiscal 2018 and 2017 was $23,000, and
$0, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Merger/Subsidiary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, Aytu Women&#8217;s Health, LLC., (&#8220;AWH&#8221;)
a wholly-owned subsidiary of Aytu, acquired Nuelle, Inc. (&#8220;Nuelle&#8221;), a women&#8217;s sexual health company. This transaction
expanded our product portfolio with the addition of the Fiera<sup>&#174;</sup> personal care device for women.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the Merger, (i) each share of Nuelle common stock and each
option or warrant to purchase Nuelle stock was cancelled, and (ii) each share of Nuelle preferred stock was converted into the
right to receive shares of our common stock. We issued to the Nuelle preferred stockholders an aggregate of 6,250 shares of our
common stock and agreed to make future revenue earn-out and milestone payments subject to certain performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nuelle preferred stockholders were entitled to revenue earn-out
payments equal to a designated percentage of net sales on tiers of net sales up to $100.0 million, with an average rate for all
tiers in the mid-single digit range and a maximum aggregate payout of $6.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The first $1.0 million of revenue earn-out payments was paid
in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.
The stock portion of any earn-out will be calculated by dividing each Nuelle stockholder&#8217;s portion of the revenue earn-out
by the average closing price of our common stock for the 10 trading days prior to the earlier of the date we deliver notice to
the Nuelle stockholders of the revenue earn-out or any public disclosure by us of the earn-out being due and payable.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expense of $110,000 and $22,000 was recognized
in fiscal 2018 and 2017, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was valued at $1.9 million using
a Monte Carlo simulation, as of May 2017. The contingent consideration accretion expense for fiscal 2018 and 2017 was $64,000,
and 12,000 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the quarter ended September 30, 2017, we paid the first
revenue earn-out payment to Nuelle shareholders of $12,000 issued in Aytu common stock, which represented the revenue earn-out
payment for fiscal 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the quarter ended December 31, 2017, we made a $238,000
prepayment, issued in Aytu common stock, which represented the revenue earn-out payment for the remaining balance due on the first
$1.0 million in net revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At March 31, 2018, the AWH assets were determined to be impaired
based upon sales performance and the manufacturer no longer supporting the product. The value for all AWH intangible assets were
adjusted to zero. The contingent consideration was revalued to zero as well.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Contingent Consideration</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; font-size: 10pt">Balance as of June 30, 2017</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">1,940,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">64,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Decrease due to contractual payment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(250,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to remeasurement</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(1,754,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822929648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 &#8211; Summary of Significant Accounting Policies
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Principals of Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">These consolidated financial statements
include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&#8217;s Health. All material intercompany transactions
and balances have been eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash, Cash Equivalents and Restricted Cash </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu considers all highly liquid instruments purchased with
an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a certificate of deposit
investment account. Aytu&#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors
its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year,
and as of June 30, 2018, Aytu has maintained balances in excess of federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue Recognition </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Product&#160;&#38; Service Sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company recognizes revenue only when
all of the following criteria have been met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -0.2in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">Persuasive evidence
of an arrangement exists,</font></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">Delivery has occurred,</font></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">The fee for the arrangement
is fixed or determinable, and</font></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">Collectability is
reasonably assured.</font></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Persuasive evidence of an arrangement exists
- The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue. Certain
contracts allow for revenue recognition at the time of shipment and others at the time of delivery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Delivery has occurred - The Company recognizes
revenue when delivery of certain products occurs at the customers&#8217; designated location.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Device sales are typically recorded when
products are shipped to customers. Drug sales are typically recorded when the product arrives at the customer&#8217;s dock. Provisions
for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period
the related sales are recorded and are estimated at the time of sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fee for the arrangement is fixed or
determinable - Prior to recognizing revenue, a customer&#8217;s fee is either fixed or determinable under the terms of the written contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collectability is reasonably assured -
The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a
customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which
evaluates the customer&#8217;s financial position and ultimately its ability to pay. The Company does not enter into arrangements unless
collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment
history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is
recognized on a cash basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Estimated Sales Returns and Allowances </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu records estimated reductions in revenue for potential returns
of products by customers. As a result, management must make estimates of potential future product returns and other allowances
related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends
and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different
estimates, material differences in the amount of the Company&#8217;s reported revenue could result. As of June 30, 2018, and 2017,
we accrued $17,000 and $58,000, respectively, in our estimated returns allowance. Estimates of potential returns and allowances
are trued up each quarter for the difference between estimates made in the prior quarter and actual results that become available
after the end of each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shipping and Handling</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&#8217;s shipping and handling costs
are included in cost of goods sold for all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounts Receivable </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Accounts receivable are recorded at
their estimated net realizable value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation
allowance accordingly. As of June 30, 2018, we had an allowance for doubtful accounts of $0, and as of June 30, 2017, there had
been an allowance for doubtful accounts of $44,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentration of Business Risks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following counterparties contributed
greater than&#160;10%&#160;of the Company&#8217;s gross revenue during the year ended June 30, 2018 and 2017, respectively. The counterparties,
sometimes referred to as partners or customers, are large wholesale distributors that resell our products to retailers. As of June
30, 2018, three customers accounted for 84% of gross revenue. The revenue from these counterparties as a percentage of gross revenue
was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Customer A</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">32</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">34</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer C</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">30</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">18</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer B</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">24</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">22</td><td style="text-align: left; font-size: 10pt">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The loss of one or more of the Company&#8217;s significant partners
or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company
is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit
risk exists as of&#160;June&#160;30, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We are also subject to credit risk
from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our
accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse
effect on our financial position, liquidity or results of operations. As of June 30, 2018, three customers accounted for 81% of
gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Customer C</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">35</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">18</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer A</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">27</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer B</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">19</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">17</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Other</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">12</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0</td><td style="text-align: left; font-size: 10pt">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inventories </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories consist of raw materials, work in process and finished
goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu
periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items.
If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable
value in the period that the impairment is first recognized. Inventory for our abandoned products was written down during fiscal
2018. Therefore, we currently have a reserve of $0 for slow moving inventory as of June 30, 2018 and $310,000 at June 30, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory balances consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Raw materials</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">239,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">442,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Work in process</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">442,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Finished goods</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,100,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">738,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">Reserve</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(310,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,339,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,312,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fixed Assets </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are recorded at cost. After being placed in service,
the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt">Estimated Useful Lives</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">in years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 64%; text-align: left; font-size: 10pt">Manufacturing equipment</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; font-size: 10pt">2 - 5</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">213,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">405,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Leasehold improvements</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">3</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">112,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">111,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Office equipment, furniture and other</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">2 - 5</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">344,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">287,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Lab equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">3 - 5</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">90,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">90,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Less accumulated depreciation and amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(540,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(246,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Fixed assets, net</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">219,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">647,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu recorded the following depreciation and amortization expense
in the respective periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Depreciation and amortization expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">294,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">134,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patents </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costs of establishing patents, consisting of legal and filing
fees paid to third parties, are expensed as incurred. The cost of the Luoxis patents were $380,000 when they were acquired in connection
with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which
expires in March 2028. Patents consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">Patents</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">380,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">380,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Less accumulated amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(134,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(109,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Patents, net</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">271,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu recorded the following amortization expense in the respective
periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Amortization expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">26,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future amortization from the year ended June 30, 2018 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">25,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">121,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business Combinations </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for its business acquisitions under the
acquisition method of accounting as indicated in the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting
Standards Codification (&#8220;ASC&#8221;) 805, &#8220;Business Combinations&#8221;, which requires the acquiring entity in a business
combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired
business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets
acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest
in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes
and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value
of the identified net assets acquired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Goodwill </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Nuelle, ProstaScint and Primsol&#160;purchase price allocations
were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted
up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities
acquired required the use of estimates by management, and were based upon currently available data, as noted below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company allocated the excess of purchase price over the
identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the
value placed on entering new markets and expanding market share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company tests its goodwill for impairment annually, or whenever
events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair
value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market
conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that
an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating
expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company
must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets.
Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to
the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&#160;20, 2015,
Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $74,000 related to
the ProstaScint goodwill for the year ended June 30, 2017. There was an impairment of $238,000 related to the Fiera goodwill during
the year ended June 30, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in accordance with Generally
Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of
the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject
to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation,
valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable,
and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu has been included in the consolidated tax returns of Ampio
for tax years ending on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&#8217;s ownership percentage of
Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu&#8217;s taxes were
computed and reported on a &#8220;separate return&#8221; basis for these financial statements. Deferred taxes are provided on an
asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and
tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are
the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation
allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will
not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date
of enactment. &#9;&#9;&#9;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount of income taxes and related income tax positions
taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax
positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining
the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized
upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&#8217;s
policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB
ASC 740-10. &#8220;Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109&#8221; (ASC 740-10) and tax
position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes,
the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and
penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant
tax position requires recognition under ASC 740-10. &#9;&#9;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu accounts for share-based payments by recognizing compensation
expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair
value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the
graded method. Forfeitures are adjusted for as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restricted Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is recognizing compensation cost equal to the fair
value of the stock at the grant dates prorated over the vesting period of each award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred with
expenses recorded in the respective period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income (Loss) Per Common Share </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic income (loss) per common share is calculated by dividing
the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during
that period. <font style="background-color: white">Diluted net loss per share reflects the potential of securities that could
share in the net loss of Aytu. Basic and diluted loss per share was the same in 2018 and 2017. Although there were common stock
equivalents of 1,923,199 and 18,366 shares outstanding at June 30, 2018 and 2017, respectively, consisting of stock options, unvested
restricted stock and warrants; they were not included in the calculation of the diluted net loss per share because they would
have been anti-dilutive.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value of Financial Instruments and Derivative Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of financial instruments, including cash
and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate
their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated
discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable
securities was based on quoted market prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu accounts for liability warrants by recording the fair value
of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial
instruments and related warrants were calculated using a lattice valuation model. We recorded a derivative expense at the inception
of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods
was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income
or expense for the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">The fair value of the
warrants issued to the placement agents in connection with the registered offering were valued using the lattice valuation methodology.
Changes in the fair value in subsequent periods were recorded to derivative income or expense.&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Adoption of Newly Issued Accounting Pronouncements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, the FASB issued ASU No. 2017-09,
&#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&#160;(ASU 2017-09).&#8221; ASU 2017-09
clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification
accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15,
2017, with early adoption permitted. In the quarter ended March 31, 2018, the Company adopted this pronouncement, the impact
of which was immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-01, &#8220;Business
Combinations (Topic 805) Clarifying the Definition of a Business.&#8221; The amendment clarifies the definition of a business,
which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets
or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance
is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively
for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods.
Early adoption is permitted. As of the quarter ended June 30, 2018, the pronouncement does not apply to the Company, however, if
Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business
combination or an asset purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-04, &#8220;Intangibles
- Goodwill and Other (Topic 350).&#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second
step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test
by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount
by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the
total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment
for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective
basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal
years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1,
2017. The Company early adopted this standard in fiscal 2018. There was no impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements, Not Adopted as
of June 30, 2018 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">From March 2016 through
December 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2016-20, ASU 2016-12, ASU 2016-11,
ASU 2016-10 and ASU 2016-08. These updates all clarify aspects of the guidance in ASU 2014-09, Revenue from Contracts with Customers
(Topic 606), which represents comprehensive reform to revenue recognition principals related to customer contracts. The effective
date of these updates for the Company is July 1, 2018. Adoption of this ASU is either full retrospective to each prior period presented
or modified retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">We finalized our assessment
of the new standard and will be adopting using the modified retrospective method as we have concluded that the impact of adopting
the new standard is not significant as it relates to historical revenues, future revenues, or accounting for incremental costs
of obtaining a contract with a customer. Going forward we will need to have disclosures de-segregating revenue to comply with this
standard. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">We have analyzed the five-steps
for each type of contract with our customers and concluded that: (1) The new guidance will not change our existing policy and practice
for identifying contracts with customers, nor give rise to changes to our existing policy and practice or create new concern surrounding
the collectability of our receivables from customers, (2) none of our contracts with customers contain multiple performance obligations
that are not fulfilled at the same time, and (3) the new guidance will not change our existing policy and practice regarding the
recording of variable consideration. Our financial reporting process will remain essentially unchanged. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">Additionally, Subtopic
340-40 requires the capitalization of all incremental costs that we incur to obtain a contract with a customer that would not have
been incurred if the contract had not been obtained, provided we expect to recover those costs. We performed an analysis and noted
that there are no material customer acquisition costs that are incremental and that are expected to be recovered at a future time.
</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; background-color: white">The aforementioned
modified retrospective method of transition will not result in a cumulative adjustment as of July 1, 2018. Additionally, no other
line items in the statement of operations or the balance sheet will reflect any changes due to the adoption of the new standard.
Adoption of the standards related to revenue recognition had no material impact to cash from or used in operating, financing, or
investing on our consolidated cash flows statements. </font><font style="font-size: 10pt">&#160;</font>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">In June 2016, the FASB
issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses&#8221; to require the measurement of expected credit losses
for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts.
The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected
credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.
The standard is effective for interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted
for interim and annual reporting periods beginning after December 15, 2018. The Company is currently assessing the impact that
ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases
(Topic 842).&#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a
lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance
or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective
for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective
transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of
the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018,
the FASB issued ASU 2018-10, &#8220;Codification Improvements to Topic 842, Leases.&#8221; The improvements in this amendment will
be effective at the same time as ASU 2016-02. Also, in July 2018, the FASB issued ASU 2018-11, &#8220;Leases (Topic 842): Targeted
Improvements.&#8221; The Board decided to provide another transition method, in addition to the existing transition method, by
allowing entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment
to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of its adoption
of these standards on its consolidated financial statements.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831862240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_GoingConcernDisclosureAbstract', window );"><strong>Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 &#8211; Going Concern </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As reflected in the accompanying
financial statements, for the year ended June 30, 2018, the Company had a net loss of $10.2 million and net cash used in
operations of $16.0 million. At June 30, 2018, Aytu had $7.1 million of cash, cash equivalents and restricted cash,
stockholders&#8217; equity of $13.5 million and an accumulated deficit of $79.3 million. In addition, the Company is in the
early stage of commercialization and has not yet generated profits for the most recent four quarters ended June 30, 2018. We
used an average of $4.0 million of cash per quarter for operating activities. These factors raised substantial doubt about
the Company&#8217;s ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Looking forward, we expect cash used in
operating activities to be in the range of historical amounts, and we expect our revenue to increase. We also expect to raise new
capital if and when needed. Therefore, it is uncertain as to whether the Company is sufficiently capitalized. Since the Company
does not have a cash balance as of June 30, 2018, sufficient to cover potential operating losses for the twelve months following
the expected filing date of this Annual Report, ASU 2014-15, Presentation of Financial Statements&#8212;Going Concern (Subtopic
205-40) requires us to report that there is an indication that substantial doubt about the Company&#8217;s ability to continue
as a going concern exists.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ability of the Company to continue its operations is dependent
on management&#8217;s plans, which include continuing to build on the historical growth trajectory of Natesto, launching the recently
licensed ZolpiMist product, seeking to acquire cash generating assets and if needed, accessing the capital markets through the
sale of our securities. Based on our ability to raise capital in the past as well as our continued growth, the Company believes
additional financing will be available and will continue to be available to support the current level of operations for at least
the next 12 months from the date of this report. There can be no assurance, however, that such financing will be available on terms
which are favorable to the Company, or at all.&#160;While Company management believes that its plan to fund ongoing operations
will be successful, there is uncertainty due to the Company&#8217;s limited operating history and therefore no assurance that its
plan will be successfully realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared on
a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification
of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_GoingConcernDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_GoingConcernDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822936528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Considerations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 &#8211; Fair Value Considerations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of financial instruments, including cash
and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate
their fair value due to their short maturities. The fair value of the warrant derivative liability was valued using the lattice
valuation methodology. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash
flows and assessment of the probability of occurrence of potential future events. The valuation policies are determined by the
Chief Financial Officer and approved by the Company&#8217;s Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authoritative guidance defines fair value as the price that
would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants
at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of
observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.
Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data
obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu&#8217;s assumptions of what market
participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
The hierarchy is broken down into three levels based on reliability of the inputs as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font-size: 10pt">
    <td style="vertical-align: top; width: 8%; font-size: 10pt"><font style="font-size: 10pt">Level&#160;1:</font></td>
    <td style="vertical-align: bottom; font-size: 10pt"><font style="font-size: 10pt">Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities;</font></td></tr>
<tr style="font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="font-size: 10pt">
    <td style="vertical-align: top; font-size: 10pt"><font style="font-size: 10pt">Level&#160;2:</font></td>
    <td style="vertical-align: bottom; font-size: 10pt"><font style="font-size: 10pt">Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and</font></td></tr>
<tr style="font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="font-size: 10pt">
    <td style="vertical-align: top; font-size: 10pt"><font style="font-size: 10pt">Level&#160;3:</font></td>
    <td style="vertical-align: bottom; font-size: 10pt"><font style="font-size: 10pt">Unobservable inputs that are supported by little or no market activity.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu&#8217;s assets and liabilities which are measured at fair
value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement.
Aytu&#8217;s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change
in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents Aytu&#8217;s financial liabilities
that were accounted for at fair value on a recurring basis as of June 30, 2018 and 2017, by level within the fair value hierarchy:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Fair Value Measurements Using</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 1</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 2</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 3</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Total</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-decoration: underline; font-size: 10pt">June 30, 2018</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">LIABILITIES</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 52%; text-align: left; font-size: 10pt">Warrant derivative liability</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">94,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">94,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Contingent consideration</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">4,694,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">4,694,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-decoration: underline; font-size: 10pt">June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">LIABILITIES</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Warrant derivative liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Contingent consideration</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">7,648,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">7,648,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrant derivative liability was valued using the lattice valuation methodology because that model
embodies the relevant assumptions that address the features underlying these instruments. The warrants related to the warrant derivative
liability are not actively traded and are, therefore, classified as Level 3 liabilities. Significant assumptions in valuing the
warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants,
were as follows as of issuance and as of June 30, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30, <br />
2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">At Issuance</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-decoration: underline; font-size: 10pt">Warrants:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-indent: 20pt; font-size: 10pt">Volatility</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">173.4</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">188.0</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: 20pt; font-size: 10pt">Equivalent term (years)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">4.13</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">5.00</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: 20pt; font-size: 10pt">Risk-free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2.69</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1.83</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: 20pt; font-size: 10pt">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0.00</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0.00</td><td style="text-align: left; font-size: 10pt">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth a reconciliation of changes in
the warrant derivative liability for the period ended June 30, 2018</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Derivative Instruments</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; font-size: 10pt">Balance as of June 30, 2016</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">276,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant issuances</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Change in fair value included in earnings (February 28, 2017)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(213,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Reclassification of warrant from liability to equity upon amendment</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(63,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">Balance as of June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant issuances</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">4,118,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant exercises</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(40,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Change in fair value included in earnings</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(3,984,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">94,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We classify our contingent consideration liability in connection with the acquisition of ProstaScint,
Natesto, ZolpiMist and the merger with Nuelle within Level 3 as factors used to develop the estimated fair value are unobservable
inputs that are not supported by market activity. We estimate the fair value of our contingent consideration liability based on
contractual payment obligations, discount rates, probabilities of payment, and expected future performance. Contingent payment
amounts are discounted back to the current period using a discounted cash flow methodology. The contingent consideration related
to the AWH assets was prepaid up to the first $1.0 million in net revenue. Since we will not be able to manufacture more product
(see Note 1), we will not generate any additional revenue. Therefore, we will not exceed $1.0 million and thus, we have adjusted
the remaining contingent consideration balance to zero. This adjustment is reflected in Other Gain on the Consolidated Statement
of Operations. We also reduced the contingent consideration for ProstaScint by $57,000 to reflect that product&#8217;s abandonment.
As of June 30, 2018, the value for the contingent consideration was adjusted to $0 based upon the abandonment of ProstaScint in
June 2018. Also, as of June 30, 2018, the contingent consideration related to Natesto was revalued at $1.8 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth a summary of changes in the contingent
consideration for the period ended June 30, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Contingent Consideration</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; font-size: 10pt">Balance as of June 30, 2016</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">3,869,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to purchase of assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,927,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">306,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to remeasurement</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,256,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to impairment</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(710,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Balance as of June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">7,648,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to purchase of assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,846,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">801,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Decrease due to contractual payment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(266,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to remeasurement</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(6,335,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">4,694,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The contingent consideration was valued using the Monte-Carlo
valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments.
Contingent consideration is not actively traded and therefore classified as Level 3.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831777616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 &#8211; Income Taxes </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously discussed in Note 2 - Summary of Significant Accounting
Policies, the Company has been included in the consolidated tax returns of Ampio for tax years ending on or before December 31,
2015. Beginning in January 2016, Aytu will file tax returns separate from Ampio. For all consolidated tax return periods, the Company&#8217;s
taxes have been computed and reported on a &#8220;separate return&#8221; basis. Ampio and Aytu did not have a tax sharing agreement
for the consolidated return periods. Accordingly, certain tax attributes, e.g. net operating loss carryforwards, reflected in these
financial statements, may or may not be available to Aytu. In January 2016, Ampio&#8217;s ownership interest in Aytu fell below 80% so
that Aytu will no longer be included in the Ampio consolidated tax return. The deconsolidation resulted in approximately $4.5 million
of net operating loss carryforwards originating prior to the incorporation of Vyrix and Luoxis no longer being available to Aytu.
Upon deconsolidation, the deferred tax asset and related valuation allowance for these pre-incorporation net operating losses have
been removed. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 6.5in">&#160;</p>

<p style="margin: 0pt 0"><font style="font-size: 10pt">Income tax benefit resulting from applying statutory rates in jurisdictions
in which Aytu is taxed (Federal and various states) differs from the income tax provision (benefit) in the Aytu financial statements.
The following table reflects the reconciliation for the respective periods.</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Benefit at statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,807,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-27.55</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,653,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-34.00</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(585,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5.74</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(681,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-3.03</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.22</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.52</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.90</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(465,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-4.56</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in taxrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.30</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.05</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remeasurement of deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,648,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of phased-in taxrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.75</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,745,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-26.94</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,922,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.20</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,029,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-10.10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.97</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.44</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net income tax provision (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">Deferred income taxes arise from temporary differences in the recognition of certain items for income
tax and financial reporting purposes. The approximate tax effects of significant temporary differences which comprise the deferred
tax assets &#9;and liabilities are as follows for the respective periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Deferred rent</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Net operating loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,458,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,435,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,559,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,044,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,362,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Unrealized loss on investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Capital loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Contribution carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred income tax assets (liabilities)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,718,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,369,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,718,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,369,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred income tax assets (liabilities)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In assessing the realizability of deferred tax assets, management
considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate
realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary
differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable
income, carry back opportunities and tax planning strategies in making the assessment. The Company believes it is more likely than
not it will realize the benefits of these deductible differences, net of the valuation allowance provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has federal net operating losses of approximately
$59.3 million and $42.3 million as of June 30, 2018 and June 30, 2017, respectively that, subject to limitation, may be available
in future tax years to offset taxable income. The available federal net operating losses, if not utilized to offset taxable income
in future periods, will begin to expire in 2031 through 2037. The Company has state net operating losses of approximately $50.3
million and $32.8 million as of June 30, 2018 and June 30, 2017, respectively that, subject to limitation, may be available in
future tax years to offset taxable income. The available state net operating losses, if not utilized to offset taxable income in
future periods, will begin to expire in 2025 through 2037. Under the provisions of the Internal Revenue Code, substantial changes
in the Company&#8217;s ownership may result in limitations on the amount of NOL carryforwards that can be utilized in future years. Net
operating loss carryforwards are subject to examination in the year they are utilized regardless of whether the tax year in which
they are generated has been closed by statute. The amount &#9;subject to disallowance is limited to the NOL utilized. Accordingly,
the Company may be subject to examination for prior NOLs generated as such NOLs are utilized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2018, and 2017, the Company has no
liability for gross unrecognized tax benefits or related interest and penalties. Aytu has made its best estimates of certain
income tax amounts included in the financial statements. Application of the Company&#8217;s accounting policies and estimates,
however, involves the exercise of judgement and use of assumptions as to future uncertainties and, as a result, could differ
from these estimates. In arriving at its estimates, factors the Company considers include how accurate the estimates or
assumptions have been in the past, how much the estimates or assumptions have changed and how likely such changes may have a
material impact. Aytu has been historically included in the Ampio consolidated tax return. Under the general statute of
limitations, the Company would not be subject to federal or Colorado income tax examinations for tax years prior to 2014 and
2013, respectively. However, given the net operating losses generated since inception, all tax years since inception are
subject to examination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="margin: 0pt 0"><font style="font-size: 10pt">On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the &#8220;Tax Reform
Act&#8221;) was signed into law by the President of the United States. The Tax Reform Act significantly revised the U.S. corporate
income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. GAAP
requires that the impact of tax legislation be recognized in the period in which the law was enacted. As a result of the Tax Reform
Act, the Company recorded a tax expense of $6.6 million due to a re-measurement of deferred tax assets and liabilities at a blended
rate in the three months ended December 31, 2017, which is fully offset by a reduction in valuation allowance. The Company recorded
additional tax expense of $0.1 million related to re- measurement of deferred tax assets and liabilities in the three months ended
March 31, 2018. The tax expense is a provisional amount and the Company&#8217;s current best estimate. Any adjustments recorded to the
provisional amounts will be included in income from operations as an adjustment to tax expense, net of any related valuation allowance.
The provisional amount incorporates assumptions made based upon the Company&#8217;s current interpretation of the Tax Reform Act and
may change as the Company receives additional clarification and implementation guidance.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822929648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 &#8211; Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commitments and contingencies are described below and summarized
by the following table as of June&#160;30, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Total</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2019</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2021</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2022</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2023</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 23%; text-align: left; font-size: 10pt">Prescription database</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">774,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">774,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Natesto</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,500,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,500,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Supply order</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">167,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">167,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Office lease</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">258,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">122,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">109,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">27,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,699,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,063,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">109,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">27,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">2,500,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Prescription Database</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2016, Aytu entered into an agreement with a vendor that
will provide Aytu with prescription database information. Aytu agreed to pay approximately $1.9 million over three years for access
to the database of prescriptions written for Natesto. The payments have been broken down into quarterly payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Natesto</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, the Company entered into an agreement with Acerus,
whereby Aytu is required to make milestone payments to Acerus. The first milestone payment of $2.5 million must be paid even if
the milestone is not reached.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Supply Order</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, Aytu submitted a purchase order for 45,000 units
of ZolpiMist, which are expected to arrive in fiscal 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Office Lease </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2015, Aytu entered into a 37-month operating lease for
office space in Raleigh, North Carolina. This lease has initial base rent of $3,000 a month, with total base rent over the term
of the lease of approximately $112,000. In June 2018, the Company entered into a 12-month operating lease, beginning on August
1, 2018, for a new office space in Raleigh. This lease has base rent of $1,100 a month, with total rent over the term of the lease
of approximately $13,200. In September 2015, the Company entered into a 37-month operating lease in Englewood, Colorado. This lease
has an initial base rent of $9,000 a month with a total base rent over the term of the lease of approximately $318,000. In October
2017, the Company signed an amendment to the 37-month operating lease in Englewood, Colorado. The amendment extended the lease
for an additional 24 months beginning October 1, 2018. The base rent will remain at $9,000 a month. The Company recognizes rent
expense on a straight-line basis over the term of each lease. Differences between the straight-line net expenses on rent payments
are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods
was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Rent expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">142,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">139,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822888192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7 &#8211; Common Stock </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Capital Stock </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2018 and June 30, 2017, Aytu had 1,794,762 and 41,244
common shares outstanding, respectively, and no preferred shares outstanding. The Company has 100&#160;million shares of common
stock authorized with a par value of $0.0001&#160;per share and 50&#160;million shares of preferred stock authorized with a par
value of $0.0001 per share, of which 500 were designated Series A Convertible Preferred Stock and 161 were designated as Series
B Convertible Preferred Stock. Included in the common stock outstanding are 38,738 shares of restricted stock granted to executives,
directors, employees and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we entered into a purchase agreement (the &#8220;Purchase
Agreement&#8221;), together with a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). Upon signing the Purchase Agreement, Lincoln Park
agreed to purchase 335 shares of our common stock for $500,000 as an initial purchase under the agreement. We also issued as a
commitment fee to Lincoln Park of 131 shares of common stock. Between September 2016 and June 2017, Lincoln Park purchased an additional
500 shares for $240,000, the issuance costs related to these purchases totaled $91,000, resulting in net proceeds of $649,000.
We terminated the Purchase Agreement effective August 16, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2016, we issued 2,500 shares of restricted stock as
compensation to certain executive officers and directors, which vest in July 2026. This expense is included in sales, general and
administrative. For the year ended June 30, 2017, the expense was $725,000. The original fair value of the restricted stock was
$3.2 million. As of June 30, 2017, the remaining unrecognized expense is $2.5 million. During fiscal 2017, one of the Company&#8217;s
executive officers resigned and his restricted stock vested in full upon this event. This resulted in the Company recognizing the
remainder of the expense related to this executive&#8217;s restricted stock grant of $430,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2016, we issued an aggregate of 357 shares of common
stock as bonuses for performance in 2016 to three executive officers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In November 2016, we raised gross proceeds of approximately
$8.6 million through a public offering of 14,338 Units. Offering costs totaled $1.0 million resulting in net cash proceeds of $7.6
million. We also issued underwriter warrants in connection with the offering with a fair value of $293,000, resulting in net proceeds
of $7.3 million. Each Unit consisted of one share of Aytu common stock and a warrant to purchase one share of Aytu common stock.
The common stock issued had a relative fair value of $3.7 million and a fair value of $4.4 million. The investor warrants have
an exercise price of $744.00 per share and will expire five years from the date of issuance. These investor warrants have a relative
fair value of $3.5 million and a fair value of $4.2 million. We also granted the underwriters a 45-day option (the Over-Allotment
Option) to purchase up to an additional 2,151 shares of common stock and/or warrants. The underwriters purchased 714 of this Over-Allotment
Option for the warrants and paid $4.00 per over-allotment warrant. These warrants have the same terms as the warrants sold in the
registered offering. These warrants have a relative fair value of $173,000, a fair value of $208,000, and proceeds of $3,000, which
was the purchase price per the underwriting agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2017, the Company consummated its warrant tender
offer to exercise, at a temporarily reduced exercise price of $300.00 per share, (i) outstanding warrants to purchase 4,334 shares
of common stock with an exercise price of $2,400.00 per share, which were originally issued to investors in the Company&#8217;s
May 2016 financing (the &#8220;May 2016 Warrants&#8221;), and (ii) outstanding warrants to purchase 15,051 shares of common stock
with an exercise price of $744.00 per share, which were originally issued to investors in the Company&#8217;s October 2016 financing
(the &#8220;October 2016 Warrants&#8221; and together with the May 2016 Warrants, the &#8220;Original Warrants&#8221;). Original
warrants to purchase an aggregate of 7,477 shares of common stock were tendered and exercised in the warrant tender offer, for
aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not tendered and exercised remain
in effect at the pre-tender offer exercise prices of $2,400.00 per share and $744.00 per share, respectively (see Note 11).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, we entered into a Merger Agreement with Nuelle,
Inc. and its stockholders, pursuant to which Nuelle would become our wholly owned subsidiary (the &#8220;Merger&#8221;). The Merger
closed on May 5, 2017. As part of the Merger, we issued to the Nuelle preferred stockholders an aggregate of 6,250 shares of our
common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 11, 2017, we entered into a Securities Purchase Agreement
with various accredited investors pursuant to which, upon closing on August 15, 2017, we sold Class A and Class B equity units
for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase
one and one-half (1.5) shares of common stock and were sold at a price of $60.00 per unit. Class B units consist of one (1) share
of our newly created Series A Preferred Stock and warrants to purchase one and one-half (1.5) shares of common stock for each share
of common stock into which the Series A Preferred Stock is convertible and were sold at a price of $20,000.00 per unit to those
purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding
common stock following the offering. These Series A Preferred stock were convertible into common shares at $60.00 per common share,
or an aggregate of 37,500 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the offering, we issued an aggregate of 159,834 shares of
our common stock, 113 shares of Series A Preferred Stock and warrants to purchase up to an aggregate of 315,755 shares of our common
stock, which included 19,749 warrants issued to the placement agents as compensation for the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incurred certain expenses related to this transaction to
attorneys and underwriters inclusive of a 9% cash fee and warrants to purchase 10% of the aggregate number of shares issued in
the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the closing of the financing, we terminated
the Purchase Agreement, dated as of July 27, 2016, by and between us and Lincoln Park Capital Fund, LLC. The termination was effective
on August 16, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2017, Aytu issued 151 shares of common stock in
connection with the Nuelle earn-out (see Note 1). In October 2017, we made a $238,000 prepayment in Aytu common stock, which represented
the revenue earn-out payment for the remaining balance due on the first $1.0 million in net revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2017, investors holding Aytu Series A Preferred shares
exercised their right to convert 18 Aytu Series A Preferred shares into 5,834 shares of Aytu common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2018, investors holding Aytu Series A Preferred
shares exercised their right to convert 95 Aytu Series A Preferred shares into 31,667 shares of Aytu common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 6, 2018, Aytu completed an underwritten public offering
for total gross proceeds of $12 million, before deducting cash offering costs inclusive of underwriting discounts, commissions
and other offering expenses totaling $1.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities sold by the Company consist of (i) Class A Units
consisting of an aggregate of 976,000 shares of our common stock and warrants to purchase an aggregate of 976,000 shares of common
stock, at a public offering price of $9.00 per Class A Unit, and (ii) Class B Units consisting of 161 shares of our Series B Preferred
Stock, with a stated value of $20,000 per share, and convertible into an aggregate of 357,356 shares of common stock, and warrants
to purchase an aggregate of 357,356 shares of common stock, at a public offering price of $20,000 per Class B Unit. The warrants
have an exercise price of $10.80, are exercisable upon issuance and will expire five years from the date of issuance. The Company
granted the underwriters a 45-day option to purchase an additional 200,000 shares of common stock and/or warrants to purchase an
additional 200,000 shares of common stock. In connection with the closing of this offering, the underwriters partially exercised
their over-allotment option and purchased an additional 200,000 warrants. On March 26, 2018, the underwriters exercised their over-allotment
option to purchase an additional 100,000 shares of common stock, resulting in gross proceeds of approximately $900,000, before
deducting costs of $63,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2018, investors holding Aytu Series B Preferred shares
exercised their right to convert 161 Aytu Series B Preferred shares into 357,356 shares of Aytu common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In fiscal 2018, warrants issued from the registered offerings
to purchase an aggregate of 80,750 shares of common stock were exercised for aggregate gross proceeds to our Company of approximately
$677,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822929648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 &#8211; Equity Instruments </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June&#160;1, 2015, Aytu&#8217;s stockholders approved the
2015 Stock Option and Incentive Plan (the &#8220;2015 Plan&#8221;), which, as amended in July 2017, provides for the award of stock
options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common
stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied
without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back
to the shares of common stock available for issuance under the 2015 Plan. As of June 30, 2018, we have 2,961,055 shares that are
available for grant under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the 2015 Stock Plan, 3.0 million shares of its common
stock, are reserved for issuance. The fair value of options granted was calculated using the Black-Scholes option pricing model.
In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including
the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected
option life. Changes to the assumptions could cause significant adjustments to valuation. Aytu estimates the expected term based
on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury
yield in effect at the time of the grant for treasury securities of similar maturity. There&#8217;s no issuances during the year
ended June 30, 2018, therefore, no assumptions are used for fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The assumptions used for the year ended June 30, 2017, as none were issued in fiscal 2018, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt"><p style="margin-top: 0; margin-bottom: 0">Year Ended</p>
                                                                           <p style="margin-top: 0; margin-bottom: 0">June&#160;30,</p></td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 84%; text-align: left; font-size: 10pt">Expected volatility</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 15%; text-align: center; font-size: 10pt">178% - 185%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Risk free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">0.97% - 1.88%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Expected term (years)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">5.0 - 6.5</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">0%</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock option activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of<br />
 Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Exercise&#160;Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average<br /> Remaining&#160;Contractual<br /> Life in Years</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding June 30, 2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,204.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">364.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,664.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,292.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding June 30, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">326.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.40</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(129</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">328.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">328.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">325.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.95</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable at June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">325.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.69</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available for grant at June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,961,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table details the options outstanding at June
30, 2018 by range of exercise prices:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Range of Exercise Prices</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of<br />
 Options<br />
 Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Exercise<br />
 Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Remaining<br />
 Contractual<br />
 Life of<br />
 Options<br />
 Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of<br />
 Options<br />
 Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Exercise<br />
 Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">280.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">280.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">280.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">328.00</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,722</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">328.00</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt">6.86</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,299</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">328.00</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,798</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">325.97</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt">6.95</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,375</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">325.35</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2017, Aytu issued 10,000 shares of restricted stock
to employees pursuant to the 2015 Plan, which vest in September 2027. In November 2017, 150 of these restricted shares were cancelled.
Also, in November 2017, Aytu issued 24,750 shares of restricted stock to executives, directors and consultants pursuant to the
2015 Plan, which vest in November 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2018, Aytu issued 3,750 shares of restricted stock
to an officer pursuant to the 2015 Plan, which vest in January 2028. In March 2018, Aytu issued 650 shares of restricted stock
to employees pursuant to the 2015 Plan, which vest in March 2028. During the three months ended March 31, 2018, 650 shares of restricted
stock were cancelled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2018, we modified 2,000 shares of restricted stock
for accelerated vesting and recognized an increase in aggregate stock compensation expense of $14,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted stock activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Number of <br /> Shares</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted <br /> Average Grant <br /> Date Fair Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average <br /> Remaining <br /> Contractual Life in <br /> Years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">Unvested at June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 64%; font-size: 10pt">Granted</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">39,150</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">39.80</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: center; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: center; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">Vested</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(1,150</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">40.40</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">Cancelled</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(800</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">40.40</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Unvested at June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">37,200</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 4pt; text-align: right; font-size: 10pt">39.80</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">9.4</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu previously issued 1,538 shares of restricted stock outside the Aytu BioScience 2015 Stock Option
and Inventive Plan, which vest in July 2026. The unrecognized expense related to these shares was $1,593,000 as of June 30, 2018
and will be recognized over the 10-year vesting period. During fiscal 2018, the expense related to these awards was $139,000. During
the quarter ended December 31, 2017, we modified 413 shares of restricted stock for accelerated vesting and recognized a reduction
in aggregate stock compensation expense of $36,000. During the quarter ended March 31, 2018, we modified 200 shares of restricted
stock for accelerated vesting and recognized a reduction in aggregate stock compensation expense of $37,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense related to the fair value of
stock options and restricted stock was included in the statements of operations as selling, general and administrative expenses
as set forth in the table below. Aytu determined the fair value of stock compensation as of the date of grant using the Black-Scholes
option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation
expense for the stock option and restricted stock issuances for fiscal 2018 and 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt; background-color: White">
    <td style="padding-bottom: 1.5pt; font-size: 10pt"></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Sales, general and administrative:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt">Stock options</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">349,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">2,502,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Restricted stock</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">248,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">725,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">Total share-based compensation expense</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">597,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,227,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of&#160;June 30, 2018, there was&#160;$161,000 of total unrecognized option-based compensation expense
related to non-vested stock options. The Company expects to recognize this expense over a weighted-average period of 6.95 years.
As of June 30, 2018, there was $2,945,000 of total unrecognized share-based compensation expense related to the non-vested restricted
stock. The Company expects to recognize this expense over a weighted-average period of 8.63 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Warrants </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of all warrants is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Number of <br /> Warrants</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 64%; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2016</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">5,538</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">2,480.40</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: center; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: center; font-size: 10pt">4.71</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Issuance of settlement warrants to initial investors</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">221</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">1,600.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants issued to investors in connection with the registered offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">15,051</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">744.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants issued to placement agents for the registered offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,009</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">300.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(7,477</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">300.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2017</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,342</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 4pt; text-align: right; font-size: 10pt">1,005.80</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">4.23</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued in connection with the August 2017 private offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">296,006</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">72.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued to underwriters in connection with the August 2017 private offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">19,749</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">72.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued in connection with the March 2018 public offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,533,356</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">10.80</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued to investor</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">100,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">10.80</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants expired</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(42</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">21,744.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(80,750</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">8.20</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,882,661</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 4pt; text-align: right; font-size: 10pt">25.94</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">4.61</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During fiscal 2017, Aytu issued warrants to purchase 221 shares
of common stock to initial investors of the Company at an exercise price of $1,600.00 and a term of five years from July 2016.
These warrants generated a non-cash expense of $596,000 for the year ended June 30, 2017, which is included in sales, general and
administrative expense. These warrants are accounted for under equity treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our November 2016 public offering, we issued
to the underwriters of the public offering warrants to purchase an aggregate of 1,009 shares of common stock at an exercise price
of $744.00 and a term of five years. These warrants are accounted for under equity treatment. In February 2017, we reduced the
exercise price of these warrants to $300.00.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Also, in connection with our November 2016 public offering,
we issued to investors warrants to purchase an aggregate of 15,051 shares of common stock, which includes the over-allotment warrants,
at an exercise price of $744.00 with a term of five years. These warrants are accounted for under equity treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2017, the Company consummated its warrant tender
offer to exercise, at a temporarily reduced exercise price of $300.00 per share, (i) outstanding warrants to purchase 4,334 shares
of common stock with an exercise price of $2,400.00 per share, which were originally issued to investors in the Company&#8217;s
May 2016 financing (the &#8220;May 2016 Warrants&#8221;), and (ii) outstanding warrants to purchase 15,051 shares of common stock
with an exercise price of $744.00 per share, which were originally issued to investors in the Company&#8217;s October 2016 financing
(the &#8220;October 2016 Warrants&#8221; and together with the May 2016 Warrants, the &#8220;Original Warrants&#8221;). Original
Warrants to purchase an aggregate of 7,477 shares of common stock were tendered and exercised in the warrant tender offer, for
aggregate gross proceeds to the Company of approximately $2.2 million. Original warrants that were not exercised remain in effect
at the pre-tender offer exercise prices of $2,400.00 per share and $744.00 per share, respectively. The incremental fair value,
which had no book impact, was $178,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company also reduced the exercise prices of an aggregate
of 1,288 warrants to purchase shares of common stock, which were originally issued as underwriters&#8217; compensation in the May
2016 and October 2016 financings, from $2,400.00 per share and $744.00 per share, respectively, to $300.00 per share. The amended
warrants related to the May 2016 financing adjusted the accounting for these warrants from liability classification to equity.
The incremental fair value of these warrant modifications, which had no book impact, was $23,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our August 2017 private offering, we issued
warrants to purchase an aggregate of 315,755 shares of common stock at an exercise price of $72.00 and a term of five years to
investors and underwriters. The remaining outstanding warrants from that offering are accounted for using derivative liability
treatment (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our March 2018 public offering,&#160;we issued
to investors and underwriters warrants to purchase an aggregate of 1,533,356 shares of common stock&#160;at an exercise price of
$10.80 with a term of five years from March 6, 2018. These warrants are accounted for under equity treatment. Of the 1,533,356
warrants issued in the March 2018 public offering, 5,750 were exercised in fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2018, Aytu BioScience, Inc. entered into a warrant
exercise agreement with an investor of the Company&#8217;s outstanding warrants. Pursuant to the exercise agreement, the Company
agreed to reduce the exercise price of the investor&#8217;s warrant to purchase 75,000 shares of the Company&#8217;s common stock
from $72.00 to one cent less than the closing price on the last trading day prior to the exercise date; provided that the investor
exercised the warrant for cash by March 23, 2018, and the Company also agreed to issue the investor a new warrant to purchase 100,000
shares of the Company&#8217;s common stock at an exercise price of $10.80 per share. In accordance with the exercise agreement,
the investor exercised the warrant and the Company received net proceeds of $615,000. The new warrant to purchase 100,000 shares
of the Company&#8217;s common stock are accounted for under equity treatment and have a fair value of $179,000. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2018, the warrants we issued to the placement agent,
in connection with our private placement in 2013, expired. &#160;The 42 placement agent warrants have a term of five years from
the date of issuance and an exercise price of $21,744.00.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The warrants related to the August Financing issued in fiscal
2018 were valued using the lattice option pricing model. These warrants were accounted for as liability warrants (see Note 5).
The warrants related to the March Financing in fiscal 2018 were valued using the Black Scholes pricing model and were accounted
for as equity warrants. In order to calculate the fair value of the warrants, certain assumptions were made, including the selling
price or fair market value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield, and contractual
life. Changes to the assumptions could cause significant adjustments to valuation. The Company estimated a volatility factor utilizing
a weighted average of comparable published betas of peer companies. The risk-free interest rate is based on the U.S. Treasury yield
in effect at the time of the grant for treasury securities of similar maturity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant assumptions in valuing the warrants issued and modified
during the year ended June 30, 2018 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">Year Ended June 30,</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">2017</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; white-space: nowrap; font-size: 10pt">Expected volatility</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">173.40% - 188.00%</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">156.64% - 169.22%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; white-space: nowrap; font-size: 10pt">Risk free interest rate</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">1.83% - 2.69%</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">1.63% - 1.87%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; white-space: nowrap; font-size: 10pt">Contractual term (years)</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">4.13 - 5</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">3.46 - 4.67</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; text-align: left; white-space: nowrap; font-size: 10pt">Dividend yield</td><td style="width: 1%; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt">0%</td><td style="width: 1%; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt">0%</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822999552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 &#8211; Related Party Transactions </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Executive Stock Purchases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two Aytu executive officers, Joshua Disbrow and Jarrett Disbrow,
participated in the August 2017 offering. Each officer purchased 4,167 units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Three Aytu executive officers, Joshua Disbrow, Jarrett Disbrow
and David Green, participated in the March 2018 offering. Joshua Disbrow and Jarrett Disbrow each purchased 11,306 units. Mr. Green
purchased 3,330 units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Services Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2015, Aytu entered into an agreement with Ampio, whereby
Aytu agreed to pay Ampio a set amount per month for shared overhead, which includes costs related to the shared corporate staff
and other miscellaneous overhead expenses. This agreement was amended in November 2015, April 2016, July 2016, and again in January
2017 resulting in an amount of $12,000 per month. This agreement was terminated in June 2017. Ampio was the Company&#8217;s largest
stockholder during part of this period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sponsored Research Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2013, Luoxis entered into a sponsored research agreement
with TRLLC, an entity controlled by Ampio&#8217;s director and Chief Scientific Officer, Dr.&#160;Bar-Or. The agreement, which
was amended in January 2015 and provided for Luoxis (now Aytu) to pay $6,000 per month to TRLLC in consideration for services related
to research and development of the Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000
which was being amortized over the contractual term of 60.5 months and was divided between current and long-term on the balance
sheet; as of September 2014, this amount had been paid in full. This agreement was terminated in March 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Co-Pay Support</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2018, the Company entered into a master services agreement
with TrialCard Incorporated (&#8220;TCI&#8221;), a vendor selected to support the Company sponsored co-pay program. In supporting
the program, TCI will make disbursements to qualified patients presenting valid prescriptions for Natesto and ZolpiMist on behalf
of Aytu. Disbursements will be based upon business rules determined by Aytu. The Company agreed to pay fees monthly to TCI for
account management, data analytics, implementation, and technology and to reimburse TCI for certain direct costs incurred by TCI
to support the Company&#8217;s program. Expenses are expected to be approximately $19,000 per month based on volumes and performance
of our program. One of the Aytu directors, Mr. Donofrio, is an executive officer of TCI and has no direct interest in the arrangement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812538416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10 &#8211; Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">Aytu manages our Company
and aggregated our operational and financial information in accordance with two reportable segments: Aytu and Aytu Women&#8217;s
Health. The Aytu segment consists of our core male urology products. The Aytu Women&#8217;s Health segment contains our women&#8217;s
health platform which consists of sexual wellness platform. Select financial information for these segments is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Consolidated revenue:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; padding-left: 9pt; font-size: 10pt">Aytu</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">3,417,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">3,175,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&#8217;s Health</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">243,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">47,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">Consolidated revenue</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,660,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,222,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Consolidated net loss:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-left: 9pt; font-size: 10pt">Aytu</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">(7,783,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">(22,349,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&#8217;s Health</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(2,405,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(159,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">Consolidated net loss</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(10,188,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(22,508,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Total assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-left: 9pt; font-size: 10pt">Aytu</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">21,053,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">11,779,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&#8217;s Health</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">7,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,220,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Total assets</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">21,060,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,999,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822955808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11 &#8211; Employee Benefit Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu has a 401(k) plan that allows participants to contribute
a portion of their salary, subject to eligibility requirements and annual IRS limits. The Company matches 50% of the first 6% contributed
to the plan by employees. In fiscal 2018, the Company&#8217;s match was $119,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812538416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 12 &#8211; Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 31, we made the second payment towards an asset purchase totaling $300,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors approved a reverse stock split in which
each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 10, 2018.
This adjustment is reflected in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August, the Aytu sales force began promotions of ZolpiMist
to U.S. clinicians.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 5, 2018, Aytu and Magna Pharmaceuticals, Inc. agreed to amend and restate the license agreement
effective as of June 11, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842167056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principals of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Principals of Consolidation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">These consolidated financial statements
include the accounts of Aytu and its wholly-owned subsidiary, Aytu Women&#8217;s Health. All material intercompany transactions
and balances have been eliminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash, Cash Equivalents and Restricted Cash </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu considers all highly liquid instruments purchased with
an original maturity of three months or less to be cash equivalents. Restricted cash consist primarily of a certificate of deposit
investment account. Aytu&#8217;s investment policy is to preserve principal and maintain liquidity. The Company periodically monitors
its positions with, and the credit quality of the financial institutions with which it invests. Periodically, throughout the year,
and as of June 30, 2018, Aytu has maintained balances in excess of federally insured limits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue Recognition </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Product&#160;&#38; Service Sales</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company recognizes revenue only when
all of the following criteria have been met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -0.2in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">Persuasive evidence
of an arrangement exists,</font></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">Delivery has occurred,</font></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">The fee for the arrangement
is fixed or determinable, and</font></td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; font-size: 10pt">
<td style="width: 0.25in; font-size: 10pt"></td><td style="width: 0.25in; text-align: left; font-size: 10pt">&#9679;</td><td style="font-size: 10pt"><font style="color: windowtext">Collectability is
reasonably assured.</font></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Persuasive evidence of an arrangement exists
- The Company documents all terms of an arrangement in a written contract by the customer prior to recognizing revenue. Certain
contracts allow for revenue recognition at the time of shipment and others at the time of delivery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Delivery has occurred - The Company recognizes
revenue when delivery of certain products occurs at the customers&#8217; designated location.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Device sales are typically recorded when
products are shipped to customers. Drug sales are typically recorded when the product arrives at the customer&#8217;s dock. Provisions
for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period
the related sales are recorded and are estimated at the time of sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The fee for the arrangement is fixed or
determinable - Prior to recognizing revenue, a customer&#8217;s fee is either fixed or determinable under the terms of the written contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Collectability is reasonably assured -
The Company determines that collectability is reasonably assured prior to recognizing revenue. Collectability is assessed on a
customer-by-customer basis based on criteria outlined by management. New customers are subject to a credit review process, which
evaluates the customer&#8217;s financial position and ultimately its ability to pay. The Company does not enter into arrangements unless
collectability is reasonably assured at the outset. Existing customers are subject to ongoing credit evaluations based on payment
history and other factors. If it is determined during the arrangement that collectability is not reasonably assured, revenue is
recognized on a cash basis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSalesReturns', window );">Estimated Sales Returns and Allowances</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Estimated Sales Returns and Allowances </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu records estimated reductions in revenue for potential returns
of products by customers. As a result, management must make estimates of potential future product returns and other allowances
related to current period product revenue. In making such estimates, management analyzes historical returns, current economic trends
and changes in customer demand and acceptance of our products. If management were to make different judgments or utilize different
estimates, material differences in the amount of the Company&#8217;s reported revenue could result. As of June 30, 2018, and 2017,
we accrued $17,000 and $58,000, respectively, in our estimated returns allowance. Estimates of potential returns and allowances
are trued up each quarter for the difference between estimates made in the prior quarter and actual results that become available
after the end of each reporting period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Shipping and Handling</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&#8217;s shipping and handling costs
are included in cost of goods sold for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Accounts Receivable </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Accounts receivable are recorded at
their estimated net realizable value. Aytu evaluates collectability of accounts receivable on a quarterly basis and records a valuation
allowance accordingly. As of June 30, 2018, we had an allowance for doubtful accounts of $0, and as of June 30, 2017, there had
been an allowance for doubtful accounts of $44,000.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Business Risks</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentration of Business Risks</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following counterparties contributed
greater than&#160;10%&#160;of the Company&#8217;s gross revenue during the year ended June 30, 2018 and 2017, respectively. The counterparties,
sometimes referred to as partners or customers, are large wholesale distributors that resell our products to retailers. As of June
30, 2018, three customers accounted for 84% of gross revenue. The revenue from these counterparties as a percentage of gross revenue
was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Customer A</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">32</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">34</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer C</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">30</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">18</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer B</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">24</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">22</td><td style="text-align: left; font-size: 10pt">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The loss of one or more of the Company&#8217;s significant partners
or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company
is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit
risk exists as of&#160;June&#160;30, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We are also subject to credit risk
from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our
accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse
effect on our financial position, liquidity or results of operations. As of June 30, 2018, three customers accounted for 81% of
gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Customer C</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">35</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">18</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer A</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">27</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer B</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">19</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">17</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Other</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">12</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0</td><td style="text-align: left; font-size: 10pt">%</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inventories </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories consist of raw materials, work in process and finished
goods and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Aytu
periodically reviews the composition of its inventories in order to identify obsolete, slow-moving or otherwise unsaleable items.
If unsaleable items are observed and there are no alternate uses for the inventory, Aytu will record a write-down to net realizable
value in the period that the impairment is first recognized. Inventory for our abandoned products was written down during fiscal
2018. Therefore, we currently have a reserve of $0 for slow moving inventory as of June 30, 2018 and $310,000 at June 30, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory balances consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b>&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Raw materials</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">239,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">442,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Work in process</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">442,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Finished goods</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,100,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">738,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">Reserve</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(310,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,339,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,312,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fixed Assets </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets are recorded at cost. After being placed in service,
the fixed assets are depreciated using the straight-line method over estimated useful lives. Fixed assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt">Estimated Useful Lives</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">in years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 64%; text-align: left; font-size: 10pt">Manufacturing equipment</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; font-size: 10pt">2 - 5</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">213,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">405,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Leasehold improvements</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">3</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">112,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">111,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Office equipment, furniture and other</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">2 - 5</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">344,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">287,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Lab equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">3 - 5</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">90,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">90,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Less accumulated depreciation and amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(540,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(246,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Fixed assets, net</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">219,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">647,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu recorded the following depreciation and amortization expense
in the respective periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Depreciation and amortization expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">294,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">134,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patents </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Costs of establishing patents, consisting of legal and filing
fees paid to third parties, are expensed as incurred. The cost of the Luoxis patents were $380,000 when they were acquired in connection
with the 2013 formation of Luoxis and are being amortized over the remaining U.S. patent lives of approximately 15 years, which
expires in March 2028. Patents consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">Patents</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">380,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">380,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Less accumulated amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(134,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(109,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Patents, net</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">271,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu recorded the following amortization expense in the respective
periods:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Amortization expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">26,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future amortization from the year ended June 30, 2018 is as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">25,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">121,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Business Combinations </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for its business acquisitions under the
acquisition method of accounting as indicated in the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting
Standards Codification (&#8220;ASC&#8221;) 805, &#8220;Business Combinations&#8221;, which requires the acquiring entity in a business
combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquired
business; and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets
acquired and liabilities assumed in business combinations, including contingent assets and liabilities and non-controlling interest
in the acquiree, based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes
and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value
of the identified net assets acquired.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Goodwill </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Nuelle, ProstaScint and Primsol&#160;purchase price allocations
were based upon an analysis of the fair value of the assets and liabilities acquired. The final purchase price may be adjusted
up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities
acquired required the use of estimates by management, and were based upon currently available data, as noted below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company allocated the excess of purchase price over the
identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the
value placed on entering new markets and expanding market share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company tests its goodwill for impairment annually, or whenever
events or changes in circumstances indicate an impairment may have occurred, by comparing the carrying value to its implied fair
value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market
conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that
an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating
expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company
must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets.
Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to
the recorded balances. The goodwill was recorded as part of the acquisition of ProstaScint that occurred on May&#160;20, 2015,
Primsol that occurred on October 5, 2015 and Nuelle that occurred on May 5, 2017. There was an impairment of $74,000 related to
the ProstaScint goodwill for the year ended June 30, 2017. There was an impairment of $238,000 related to the Fiera goodwill during
the year ended June 30, 2018.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in accordance with Generally
Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of
the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject
to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation,
valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable,
and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu has been included in the consolidated tax returns of Ampio
for tax years ending on or before December 31, 2015. As of January 2016, due to the decrease in Ampio&#8217;s ownership percentage of
Aytu stock, Aytu will begin to file tax returns separate from Ampio. For all consolidated tax return periods, Aytu&#8217;s taxes were
computed and reported on a &#8220;separate return&#8221; basis for these financial statements. Deferred taxes are provided on an
asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and
tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are
the differences between the reported amounts of assets and liabilities and their tax bases. Deferred taxes are reduced by a valuation
allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will
not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date
of enactment. &#9;&#9;&#9;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The amount of income taxes and related income tax positions
taken are subject to audits by federal and state tax authorities. The Company has adopted accounting guidance for uncertain tax
positions which provides that in order to recognize an uncertain tax position, the taxpayer must be more likely than not of sustaining
the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized
upon settlement with the taxing authority. The Company believes that it has no material uncertain tax positions. The Company&#8217;s
policy is to record a liability for the difference between the benefits that are both recognized and measured pursuant to FASB
ASC 740-10. &#8220;Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement 109&#8221; (ASC 740-10) and tax
position taken or expected to be taken on the tax return. Then, to the extent that the assessment of such tax positions changes,
the change in estimate is recorded in the period in which the determination is made. The Company reports tax-related interest and
penalties as a component of income tax expense. During the periods reported, management of the Company has concluded that no significant
tax position requires recognition under ASC 740-10. &#9;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu accounts for share-based payments by recognizing compensation
expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant fair
value using the Black-Scholes option pricing model and recognizes compensation costs ratably over the period of service using the
graded method. Forfeitures are adjusted for as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RestrictedStocksPolicyTextBlock', window );">Restricted Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restricted Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is recognizing compensation cost equal to the fair
value of the stock at the grant dates prorated over the vesting period of each award.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs are expensed as incurred with
expenses recorded in the respective period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income (Loss) Per Common Share </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic income (loss) per common share is calculated by dividing
the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during
that period. <font style="background-color: white">Diluted net loss per share reflects the potential of securities that could
share in the net loss of Aytu. Basic and diluted loss per share was the same in 2018 and 2017. Although there were common stock
equivalents of 1,923,199 and 18,366 shares outstanding at June 30, 2018 and 2017, respectively, consisting of stock options, unvested
restricted stock and warrants; they were not included in the calculation of the diluted net loss per share because they would
have been anti-dilutive.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments and Derivative Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fair Value of Financial Instruments and Derivative Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of financial instruments, including cash
and cash equivalents, restricted cash, accounts receivable, accounts payable, and other current assets and other liabilities approximate
their fair value due to their short maturities. The fair value of acquisition-related contingent consideration is based on estimated
discounted future cash flows and assessment of the probability of occurrence of potential future events. The fair values of marketable
securities was based on quoted market prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu accounts for liability warrants by recording the fair value
of each instrument in its entirety and recording the fair value of the warrant derivative liability. The fair value of the financial
instruments and related warrants were calculated using a lattice valuation model. We recorded a derivative expense at the inception
of the instrument reflecting the difference between the fair value and cash received. Changes in the fair value in subsequent periods
was recorded as unrealized gain or loss on fair value of debt instruments for the financial instruments and to derivative income
or expense for the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">The fair value of the
warrants issued to the placement agents in connection with the registered offering were valued using the lattice valuation methodology.
Changes in the fair value in subsequent periods were recorded to derivative income or expense.&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of Newly Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Adoption of Newly Issued Accounting Pronouncements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, the FASB issued ASU No. 2017-09,
&#8220;Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting&#160;(ASU 2017-09).&#8221; ASU 2017-09
clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification
accounting in Topic 718. The standard is effective for interim and annual reporting periods beginning after December 15,
2017, with early adoption permitted. In the quarter ended March 31, 2018, the Company adopted this pronouncement, the impact
of which was immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-01, &#8220;Business
Combinations (Topic 805) Clarifying the Definition of a Business.&#8221; The amendment clarifies the definition of a business,
which is fundamental in the determination of whether transactions should be accounted for as acquisitions (or disposals) of assets
or businesses. This determination is important given the diverging accounting models used for each type of transaction. The guidance
is generally expected to result in fewer transactions qualifying as business combinations. The amendment is effective prospectively
for public business entities for annual periods beginning after December 15, 2017, including interim periods within those periods.
Early adoption is permitted. As of the quarter ended June 30, 2018, the pronouncement does not apply to the Company, however, if
Aytu seeks to purchase additional assets in the future it could have an impact if that purchase is accounted for as a business
combination or an asset purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2017, the FASB issued ASU 2017-04, &#8220;Intangibles
- Goodwill and Other (Topic 350).&#8221; The amendment simplifies the subsequent measurement of goodwill by removing the second
step of the two-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test
by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount
by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the
total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment
for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective
basis. ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal
years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1,
2017. The Company early adopted this standard in fiscal 2018. There was no impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Issued Accounting Pronouncements, Not Adopted as
of June 30, 2018 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">From March 2016 through
December 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU 2016-20, ASU 2016-12, ASU 2016-11,
ASU 2016-10 and ASU 2016-08. These updates all clarify aspects of the guidance in ASU 2014-09, Revenue from Contracts with Customers
(Topic 606), which represents comprehensive reform to revenue recognition principals related to customer contracts. The effective
date of these updates for the Company is July 1, 2018. Adoption of this ASU is either full retrospective to each prior period presented
or modified retrospective with a cumulative adjustment to retained earnings or accumulated deficit as of the adoption date. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">We finalized our assessment
of the new standard and will be adopting using the modified retrospective method as we have concluded that the impact of adopting
the new standard is not significant as it relates to historical revenues, future revenues, or accounting for incremental costs
of obtaining a contract with a customer. Going forward we will need to have disclosures de-segregating revenue to comply with this
standard. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">We have analyzed the five-steps
for each type of contract with our customers and concluded that: (1) The new guidance will not change our existing policy and practice
for identifying contracts with customers, nor give rise to changes to our existing policy and practice or create new concern surrounding
the collectability of our receivables from customers, (2) none of our contracts with customers contain multiple performance obligations
that are not fulfilled at the same time, and (3) the new guidance will not change our existing policy and practice regarding the
recording of variable consideration. Our financial reporting process will remain essentially unchanged. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">Additionally, Subtopic
340-40 requires the capitalization of all incremental costs that we incur to obtain a contract with a customer that would not have
been incurred if the contract had not been obtained, provided we expect to recover those costs. We performed an analysis and noted
that there are no material customer acquisition costs that are incremental and that are expected to be recovered at a future time.
</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 10pt; background-color: white">The aforementioned
modified retrospective method of transition will not result in a cumulative adjustment as of July 1, 2018. Additionally, no other
line items in the statement of operations or the balance sheet will reflect any changes due to the adoption of the new standard.
Adoption of the standards related to revenue recognition had no material impact to cash from or used in operating, financing, or
investing on our consolidated cash flows statements. </font><font style="font-size: 10pt">&#160;</font>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="background-color: white">In June 2016, the FASB
issued ASU 2016-13, &#8220;Financial Instruments &#8211; Credit Losses&#8221; to require the measurement of expected credit losses
for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts.
The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected
credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date.
The standard is effective for interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted
for interim and annual reporting periods beginning after December 15, 2018. The Company is currently assessing the impact that
ASU 2016-13 will have on its consolidated financial statements but does not anticipate there to be a material impact.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases
(Topic 842).&#8221; The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a
lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance
or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective
for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective
transition approach is required for leases for capital and operating leases existing at, or entered into after, the beginning of
the earliest comparative period presented in the financial statements, with certain practical expedients available. In July 2018,
the FASB issued ASU 2018-10, &#8220;Codification Improvements to Topic 842, Leases.&#8221; The improvements in this amendment will
be effective at the same time as ASU 2016-02. Also, in July 2018, the FASB issued ASU 2018-11, &#8220;Leases (Topic 842): Targeted
Improvements.&#8221; The Board decided to provide another transition method, in addition to the existing transition method, by
allowing entities to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment
to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of its adoption
of these standards on its consolidated financial statements.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RestrictedStocksPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for restricted stock for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RestrictedStocksPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823414176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember', window );">ZolpiMist [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated future amortization</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"><td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">464,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">464,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">888,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,208,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of allocation on consideration transferred</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="font-size: 10pt"></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Fair Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; text-align: left; font-size: 10pt">&#160;Intangible assets</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">3,200,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">&#160;Total assets acquired</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,200,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_AwhAssetsMember', window );">AWH Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of contingent consideration</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; background-color: White; font-size: 10pt"><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Contingent Consideration</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; font-size: 10pt">Balance as of June 30, 2017</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">1,940,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">64,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Decrease due to contractual payment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(250,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to remeasurement</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(1,754,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated future amortization</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"><td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">1,319,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,319,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">1,317,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">7,912,000</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessDescriptionAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessDescriptionAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_AwhAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_AwhAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828304112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of concentration of business risk</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="font-size: 10pt"></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Customer A</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">32</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">34</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer C</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">30</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">18</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer B</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">24</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">22</td><td style="text-align: left; font-size: 10pt">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Customer C</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">35</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">18</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer A</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">27</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Customer B</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">19</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">17</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Other</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">12</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0</td><td style="text-align: left; font-size: 10pt">%</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; font-size: 10pt">Raw materials</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">239,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">442,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Work in process</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">442,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Finished goods</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,100,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">738,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">Reserve</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(310,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,339,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,312,000</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; font-size: 10pt">Estimated Useful Lives</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">in years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 64%; text-align: left; font-size: 10pt">Manufacturing equipment</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; font-size: 10pt">2 - 5</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">213,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">405,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Leasehold improvements</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">3</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">112,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">111,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Office equipment, furniture and other</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">2 - 5</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">344,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">287,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Lab equipment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">3 - 5</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">90,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">90,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Less accumulated depreciation and amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(540,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(246,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Fixed assets, net</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">219,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">647,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Depreciation and amortization expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">294,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">134,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of patents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30,</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">Patents</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">380,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">380,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Less accumulated amortization</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(134,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(109,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Patents, net</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">271,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td>
    <td style="font-size: 10pt">&#160;</td>
</tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td>
    <td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td>
    <td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Amortization expense</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td>
    <td style="text-align: right; font-size: 10pt">25,000</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td>
    <td style="text-align: right; font-size: 10pt">26,000</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt"><td style="width: 88%; text-align: left; font-size: 10pt">2019</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">25,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2020</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2021</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2022</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">2023</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">25,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">121,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">246,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828062464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Fair Value Measurements Using</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 1</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 2</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Level 3</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Total</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-decoration: underline; font-size: 10pt">June 30, 2018</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">LIABILITIES</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 52%; text-align: left; font-size: 10pt">Warrant derivative liability</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">94,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">94,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Contingent consideration</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">4,694,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">4,694,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-decoration: underline; font-size: 10pt">June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">LIABILITIES</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Warrant derivative liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Contingent consideration</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">7,648,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">7,648,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of changes in the warrant derivative liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Derivative Instruments</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; font-size: 10pt">Balance as of June 30, 2016</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">276,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant issuances</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Change in fair value included in earnings (February 28, 2017)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(213,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Reclassification of warrant from liability to equity upon amendment</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(63,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">Balance as of June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant issuances</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">4,118,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Warrant exercises</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(40,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Change in fair value included in earnings</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(3,984,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">94,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_AytuCommonStockMember', window );">Aytu Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant assumptions in valuing the warrant derivative liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">June 30, <br />
2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">At Issuance</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-decoration: underline; font-size: 10pt">Warrants:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-indent: 20pt; font-size: 10pt">Volatility</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">173.4</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">188.0</td><td style="width: 1%; text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: 20pt; font-size: 10pt">Equivalent term (years)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">4.13</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">5.00</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: 20pt; font-size: 10pt">Risk-free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2.69</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1.83</td><td style="text-align: left; font-size: 10pt">%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: 20pt; font-size: 10pt">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0.00</td><td style="text-align: left; font-size: 10pt">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">0.00</td><td style="text-align: left; font-size: 10pt">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember', window );">Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of changes in the contingent consideration</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Contingent Consideration</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 88%; font-size: 10pt">Balance as of June 30, 2016</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">3,869,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to purchase of assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,927,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">306,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to remeasurement</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,256,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to impairment</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(710,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Balance as of June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">7,648,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to purchase of assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,846,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Increase due to accretion</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">801,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Decrease due to contractual payment</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(266,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Decrease due to remeasurement</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(6,335,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Balance as of June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">4,694,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_AytuCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_AytuCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823019664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of income tax benefit resulting from applying statutory rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Benefit at statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,807,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-27.55</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,653,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-34.00</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(585,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5.74</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(681,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-3.03</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.22</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.52</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.90</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(465,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-4.56</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in taxrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.30</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.05</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remeasurement of deferred taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,648,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.25</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of phased-in taxrate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.75</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,745,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-26.94</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,922,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.20</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,029,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-10.10</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.97</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.44</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net income tax provision (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.00</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2018</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">6/30/2017</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Deferred rent</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Net operating loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,458,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,435,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">651,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,559,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,044,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,362,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Unrealized loss on investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Capital loss carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">204,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Contribution carry forward</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total deferred income tax assets (liabilities)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,718,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,369,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,718,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,369,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total deferred income tax assets (liabilities)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822929360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock', window );">Schedule of commitments and contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Total</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2019</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2021</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2022</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2023</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 23%; text-align: left; font-size: 10pt">Prescription database</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">774,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">774,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 8%; text-align: right; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">Natesto</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,500,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">2,500,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Supply order</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">167,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">167,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt">Office lease</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">258,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">122,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">109,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">27,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,699,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,063,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">109,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">27,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">2,500,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">-</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of rent expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Rent expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">142,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">139,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommitmentsAndContingenciesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommitmentsAndContingenciesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823218896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Number of <br /> Shares</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted <br /> Average Grant <br /> Date Fair Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average <br /> Remaining <br /> Contractual Life in <br /> Years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">Unvested at June 30, 2017</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">-</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 64%; font-size: 10pt">Granted</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">39,150</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">39.80</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: center; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: center; font-size: 10pt">&#160;</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">Vested</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(1,150</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">40.40</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">Cancelled</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(800</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">40.40</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; font-size: 10pt">Unvested at June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">37,200</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 4pt; text-align: right; font-size: 10pt">39.80</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">9.4</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ScheduleOfOptionsOutstanding', window );">Schedule of options outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Range of Exercise Prices</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of<br />
 Options<br />
 Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Exercise<br />
 Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Remaining<br />
 Contractual<br />
 Life of<br />
 Options<br />
 Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of<br />
 Options<br />
 Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Exercise<br />
 Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">280.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">280.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">8.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">280.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">328.00</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,722</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">328.00</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt">6.86</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,299</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">328.00</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,798</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">325.97</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="text-align: right; padding-bottom: 1.5pt">6.95</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1.5pt solid">1,375</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">$</td><td style="text-align: right; padding-bottom: 1.5pt">325.35</td><td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt; background-color: White"><td style="padding-bottom: 1.5pt; font-size: 10pt"></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Sales, general and administrative:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; text-align: left; text-indent: 10pt; font-size: 10pt">Stock options</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">349,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">2,502,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; font-size: 10pt">Restricted stock</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">248,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">725,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">Total share-based compensation expense</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">597,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,227,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Number of<br />
 Options</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted<br />
 Average<br />
 Exercise&#160;Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average<br /> Remaining&#160;Contractual<br /> Life in Years</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Outstanding June 30, 2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,204.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">364.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,664.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,292.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding June 30, 2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">326.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.40</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(129</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">328.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">328.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">325.97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.95</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable at June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">325.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.69</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Available for grant at June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,961,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant assumptions used in valuing options/warrants issued</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended&#160; June&#160;30,</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 84%; text-align: left; font-size: 10pt">Expected volatility</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 15%; text-align: center; font-size: 10pt">178% - 185%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Risk free interest rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">0.97% - 1.88%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Expected term (years)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">5.0 - 6.5</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Dividend yield</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">0%</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of all warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Number of <br /> Warrants</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 64%; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2016</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: right; font-size: 10pt">5,538</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">2,480.40</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: center; font-size: 10pt">&#160;</td><td style="width: 9%; text-align: center; font-size: 10pt">4.71</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Issuance of settlement warrants to initial investors</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">221</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">1,600.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants issued to investors in connection with the registered offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">15,051</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">744.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants issued to placement agents for the registered offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,009</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">300.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; font-size: 10pt">Warrants exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(7,477</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">300.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2017</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,342</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 4pt; text-align: right; font-size: 10pt">1,005.80</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">4.23</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued in connection with the August 2017 private offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">296,006</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">72.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued to underwriters in connection with the August 2017 private offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">19,749</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">72.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued in connection with the March 2018 public offering</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">1,533,356</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">10.80</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants issued to investor</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">100,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">10.80</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants expired</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(42</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">21,744.00</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Warrants exercised</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">(80,750</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">8.20</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: center; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in; font-size: 10pt">Outstanding June 30, 2018</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">1,882,661</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">$</td><td style="padding-bottom: 4pt; text-align: right; font-size: 10pt">25.94</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; text-align: center; font-size: 10pt">4.61</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant assumptions used in valuing options/warrants issued</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom; font-size: 10pt"><td style="white-space: nowrap; font-size: 10pt"></td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">Year Ended June 30,</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt">2017</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; white-space: nowrap; font-size: 10pt">Expected volatility</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">173.40% - 188.00%</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">156.64% - 169.22%</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; white-space: nowrap; font-size: 10pt">Risk free interest rate</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">1.83% - 2.69%</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">1.63% - 1.87%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="text-align: left; white-space: nowrap; font-size: 10pt">Contractual term (years)</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">4.13 - 5</td><td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="text-align: center; white-space: nowrap; font-size: 10pt">3.46 - 4.67</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="width: 76%; text-align: left; white-space: nowrap; font-size: 10pt">Dividend yield</td><td style="width: 1%; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt">0%</td><td style="width: 1%; white-space: nowrap; font-size: 10pt">&#160;</td>
    <td style="width: 11%; text-align: center; white-space: nowrap; font-size: 10pt">0%</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ScheduleOfOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ScheduleOfOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831971504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of financial information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">Year Ended June 30,</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2018</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-size: 10pt">2017</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Consolidated revenue:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="width: 76%; padding-left: 9pt; font-size: 10pt">Aytu</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">3,417,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; text-align: left; font-size: 10pt">$</td><td style="width: 9%; text-align: right; font-size: 10pt">3,175,000</td><td style="width: 1%; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&#8217;s Health</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">243,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">47,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">Consolidated revenue</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,660,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">3,222,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; font-size: 10pt">Consolidated net loss:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-left: 9pt; font-size: 10pt">Aytu</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">(7,783,000</td><td style="text-align: left; font-size: 10pt">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">(22,349,000</td><td style="text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&#8217;s Health</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(2,405,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">(159,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; font-size: 10pt">Consolidated net loss</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(10,188,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">(22,508,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-left: 9pt; font-size: 10pt">Total assets:</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="padding-left: 9pt; font-size: 10pt">Aytu</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">21,053,000</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">$</td><td style="text-align: right; font-size: 10pt">11,779,000</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-size: 10pt">Aytu Women&#8217;s Health</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">7,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-size: 10pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right; font-size: 10pt">3,220,000</td><td style="padding-bottom: 1.5pt; text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font-size: 10pt">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: left; font-size: 10pt">&#160;</td><td style="text-align: right; font-size: 10pt">&#160;</td><td style="text-align: left; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font-size: 10pt">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-size: 10pt">Total assets</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">21,060,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left; font-size: 10pt">$</td><td style="border-bottom: Black 4pt double; text-align: right; font-size: 10pt">14,999,000</td><td style="padding-bottom: 4pt; text-align: left; font-size: 10pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828221440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 245,944<span></span>
</td>
<td class="nump">$ 271,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2019</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2020</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2021</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2022</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2023</a></td>
<td class="nump">1,319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">7,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember', window );">ZolpiMist [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2019</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2020</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2021</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2022</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2023</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6668008480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 11, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6667529408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2) - AWH Assets [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ContingentConsiderationAbstract', window );"><strong>Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance as of June 30, 2017</a></td>
<td class="nump">$ 1,940,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Increase due to accretion</a></td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow', window );">Decrease due to contractual payment</a></td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement', window );">Decrease due to remeasurement</a></td>
<td class="num">$ (1,754,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance as of June 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the low-end of the estimated range of outcomes decrease due to remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityDecreaseDueRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the low-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_AwhAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_AwhAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6852671968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2018</div></th>
<th class="th"><div>May 05, 2017</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Apr. 28, 2016</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 11, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,553,705<span></span>
</td>
<td class="nump">$ 1,708,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock issued aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,660,120<span></span>
</td>
<td class="nump">3,221,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,681,918<span></span>
</td>
<td class="nump">73,069,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember', window );">Third Upfront [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationPercentage', window );">Percentage of a revenue share net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum aggregate payout for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationRevalued', window );">Contingent consideration was initially revalued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Discounted Cash Flow Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationRevalued', window );">Contingent consideration was initially revalued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember', window );">Prostascint Business [Member] | Customer Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember', window );">Jazz Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Share-based payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember', window );">Primsol Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Recognized gain loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Recognized gain loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock issued aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,245,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Purchase of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodDescription', window );">Maximum aggregate amount payable milestone payments, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event (provided that, the maximum aggregate amount payable under such milestone payments will be $37.5 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net identifiable asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Contingent consideration accretion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
<td class="nump">228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Gross proceeds from the sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CostOfSaleForInvestment', window );">Total of cost of sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member] | First Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member] | Second Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member] | Third Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member] | Forth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | License and Supply Agreement [Member] | Fifth Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_OneTimeNonRefundablePayments', window );">One-time, non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SalesRevenueTarget', window );">Sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member] | CAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Purchase of common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember', window );">ZolpiMist [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Contingent consideration accretion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PercentageofNetSalesDescriptions', window );">Percentage of net sales, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Twenty percent (20%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2020,  Fifteen percent (15%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2022, Ten percent (10%) of Net Sales during the period commencing on the effective date and continuing through May 31, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember', window );">Nuelle, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum aggregate payout for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Contingent consideration valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock issued aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Contingent consideration accretion expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SubsidiariesPaymentDescription', window );">Subsidiaries payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first $1.0 million of revenue earn-out payments was paid in shares of our common stock and all other earn-out payments will be comprised of 60% cash and 40% shares of our common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueEarnOutPayment', window );">Revenue earn out payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_AytuMember', window );">Aytu BioScience, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueEarnOutPayment', window );">Revenue earn out payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaymentofCommonStock', window );">Prepayment of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split, description</a></td>
<td class="text">Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the &#8220;Reverse Stock Splits&#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | ZolpiMist [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual', window );"><strong>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessBasisofPresentationBusinessCombinationsDivestituresLicenseSupplyAgreementMergerTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationRevalued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revalued amount of recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationRevalued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CostOfSaleForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cost of sale of investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CostOfSaleForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_OneTimeNonRefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the one time non-refundable payments based on sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_OneTimeNonRefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PercentageofNetSalesDescriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PercentageofNetSalesDescriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrepaymentofCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrepaymentofCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueEarnOutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue earn-out payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueEarnOutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SalesRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount sales revenue target for non-refundable payment criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SalesRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SubsidiariesPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiaries payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SubsidiariesPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the overall arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized and expensed compensation cost from equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ThirdUpfrontMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ProstascintBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_DiscountedCashFlowMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_DiscountedCashFlowMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_JazzPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_PrimsolBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aytu_LicenseAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aytu_LicenseAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_SecondMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_SecondMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_ThirdMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_ThirdMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_ForthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_ForthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_FifthMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_FifthMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=aytu_CADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=aytu_CADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_ZolpiMistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NuelleIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_AytuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_AytuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828098624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember', window );">Customer A [Member] | Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember', window );">Customer A [Member] | Accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember', window );">Customer B [Member] | Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember', window );">Customer B [Member] | Accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerCMember', window );">Customer C [Member] | Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerCMember', window );">Customer C [Member] | Accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_OtherMember', window );">Other [Member] | Accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration risk</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828599536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 239,000<span></span>
</td>
<td class="nump">$ 442,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">442,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">738,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(310,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 1,338,973<span></span>
</td>
<td class="nump">$ 1,312,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818389056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">$ (540,000)<span></span>
</td>
<td class="num">$ (246,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">218,684<span></span>
</td>
<td class="nump">647,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment, furniture and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment, furniture and other [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment, furniture and other [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=aytu_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831901360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 294,000<span></span>
</td>
<td class="nump">$ 134,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822901680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 4) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="nump">$ 380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(134,000)<span></span>
</td>
<td class="num">(109,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 245,944<span></span>
</td>
<td class="nump">$ 271,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815571760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 5) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,553,705<span></span>
</td>
<td class="nump">$ 1,708,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Aytu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827958560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 6) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Future amortization expense, Total</a></td>
<td class="nump">$ 245,944<span></span>
</td>
<td class="nump">$ 271,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2019</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2020</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2021</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2022</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2023</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Future amortization expense, Total</a></td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6854400256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>Customers / Number </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Customers / Number </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPoliciesTextual', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Estimated returns allowance</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Costs of establishing patents</a></td>
<td class="nump">380,000<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 238,000<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents | shares</a></td>
<td class="nump">1,923,199<span></span>
</td>
<td class="nump">18,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CounterpartiesAxis=aytu_CounterpartiesMember', window );">Counterparties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPoliciesTextual', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration business risks</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerMember', window );">Customer [Member] | Gross revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPoliciesTextual', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration business risks</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NumberOfcustomers', window );">Number of customers | Customers / Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerMember', window );">Customer [Member] | Accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPoliciesTextual', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration business risks</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NumberOfcustomers', window );">Number of customers | Customers / Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LuoxisPatentMember', window );">Luoxis patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SummaryOfSignificantAccountingPoliciesTextual', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Costs of establishing patents</a></td>
<td class="nump">$ 380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Patent lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear', window );">Patents expires</a></td>
<td class="text">2028-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FiniteLivedIntangibleAssetsExpirationMonthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FiniteLivedIntangibleAssetsExpirationMonthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NumberOfcustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NumberOfcustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SummaryOfSignificantAccountingPoliciesTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SummaryOfSignificantAccountingPoliciesTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CounterpartiesAxis=aytu_CounterpartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CounterpartiesAxis=aytu_CounterpartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=aytu_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LuoxisPatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=aytu_LuoxisPatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823239680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,187,863)<span></span>
</td>
<td class="num">$ (22,508,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Net cash used in operations</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders' equity</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(79,257,592)<span></span>
</td>
<td class="num">$ (69,069,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForOperatingActivities', window );">Cash for operating activities</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_GoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_GoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount of cash paid for operating activities during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840625600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Considerations (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 93,981<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">4,146,829<span></span>
</td>
<td class="nump">7,386,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Using [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">4,694,000<span></span>
</td>
<td class="nump">7,648,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value Measurements Using [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value Measurements Using [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Fair Value Measurements Using [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 4,694,000<span></span>
</td>
<td class="nump">$ 7,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828157984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">173.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedTerms', window );">Equivalent term (years)</a></td>
<td class="text">4 years 1 month 16 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsRiskFreeInterestRates', window );">Risk-free interest rate</a></td>
<td class="nump">2.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedDividendRates', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_AytuCommonStockMember', window );">At Issuance [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">188.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedTerms', window );">Equivalent term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsRiskFreeInterestRates', window );">Risk-free interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedDividendRates', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsExpectedTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsExpectedTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsExpectedVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsExpectedVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_AytuCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_AytuCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_NoteWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6666303104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances', window );">Warrant issuances</a></td>
<td class="nump">4,118,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises', window );">Warrant exercises</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value included in earnings</a></td>
<td class="num">(3,984,000)<span></span>
</td>
<td class="num">(213,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise', window );">Reclassification of warrant from liability to equity upon amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, Ending</a></td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityWarrantIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification of warrant liability to equity upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ReclassificationOfWarrantLiabilityToEquityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829464784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details 3) - Contingent Consideration [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ContingentConsiderationAbstract', window );"><strong>Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance as of June 30, 2017</a></td>
<td class="nump">$ 7,648,000<span></span>
</td>
<td class="nump">$ 3,869,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Increase due to purchase of assets</a></td>
<td class="nump">2,846,000<span></span>
</td>
<td class="nump">1,927,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Increase due to accretion</a></td>
<td class="nump">801,000<span></span>
</td>
<td class="nump">306,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement', window );">Increase due to remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment', window );">Decrease due to impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(710,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow', window );">Decrease due to contractual payment</a></td>
<td class="num">(266,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement', window );">Decrease due to remeasurement</a></td>
<td class="num">(6,335,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance as of June 30, 2018</a></td>
<td class="nump">$ 4,694,000<span></span>
</td>
<td class="nump">$ 7,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease due to impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of decrease due to impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationArrangementsChangeInDecreaseDueToRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of increase due to impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_BusinessCombinationContingentConsiderationArrangementsChangeInIncreaseDueToRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ContingentConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ContingentConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the low-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=aytu_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804657072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Considerations (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueConsiderationsTextualAbstract', window );"><strong>Fair Value Considerations (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Contingent consideration, description</a></td>
<td class="text">The
contingent consideration related to the AWH assets was prepaid up to the first $1.0 million in net revenue. Since we will not be
able to manufacture more product (see Note 1), we will not generate any additional revenue. Therefore, we will not exceed $1.0
million and thus, we have adjusted the remaining contingent consideration balance to zero.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AdjustmentOfContingentConsideration', window );">Adjusted amount of contingent consideration for ProstaScint</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reduced</a></td>
<td class="nump">57,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueConsiderationsTextualAbstract', window );"><strong>Fair Value Considerations (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reduced</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AdjustmentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of adjusted the contingent consideration for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AdjustmentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueConsiderationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueConsiderationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6846700544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Schedule of income tax benefit resulting from applying statutory rates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit at statutory rate</a></td>
<td class="num">$ (2,807,000)<span></span>
</td>
<td class="num">$ (7,653,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Benefit at statutory rate, percentage</a></td>
<td class="num">(27.55%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">$ (585,000)<span></span>
</td>
<td class="num">$ (681,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit, percentage</a></td>
<td class="num">(5.74%)<span></span>
</td>
<td class="num">(3.03%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation, percentage</a></td>
<td class="nump">0.22%<span></span>
</td>
<td class="nump">0.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxReconciliationOfFeringCosts', window );">Offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 203,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts', window );">Offering costs, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxReconciliationContingentConsideration', window );">Contingent consideration</a></td>
<td class="num">$ (465,000)<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration', window );">Contingent consideration, percentage</a></td>
<td class="nump">4.56%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in taxrate</a></td>
<td class="num">$ (31,000)<span></span>
</td>
<td class="num">$ (11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate, percentage</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RemeasurementOfDeferredTaxes', window );">Remeasurement of deferred taxes</a></td>
<td class="nump">$ 6,648,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RemeasurementOfDeferredTaxesPercentage', window );">Remeasurement of deferred taxes, percentage</a></td>
<td class="nump">65.25%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsTax1', window );">Effect of phased-in taxrate</a></td>
<td class="nump">$ 891,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CumulativeEffectOnRetainedEarningsTaxPercentage', window );">Effect of phased-in tax rate, percentage</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">$ (2,745,000)<span></span>
</td>
<td class="nump">$ 7,922,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, percentage</a></td>
<td class="num">(26.94%)<span></span>
</td>
<td class="nump">35.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Derivative income</a></td>
<td class="num">$ (1,029,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage', window );">Derivative income, percentage</a></td>
<td class="num">(10.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, percentage</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.44%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Net income tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax provision (benefit), percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CumulativeEffectOnRetainedEarningsTaxPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CumulativeEffectOnRetainedEarningsTaxPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_DerivativeInstrumentsGainReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxRateReconciliationOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EffectiveIncomeTaxrateReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxReconciliationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxReconciliationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxReconciliationOfFeringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxReconciliationOfFeringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RemeasurementOfDeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RemeasurementOfDeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RemeasurementOfDeferredTaxesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RemeasurementOfDeferredTaxesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the related income tax effect of a cumulative effect on retained earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829663136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">14,458,000<span></span>
</td>
<td class="nump">15,435,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">651,000<span></span>
</td>
<td class="nump">1,559,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">1,044,000<span></span>
</td>
<td class="nump">1,362,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities', window );">Unrealized loss on investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carry forward</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Contribution carry forward</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Warrant liability</a></td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses', window );">Allowance for doubtful accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets (liabilities)</a></td>
<td class="nump">16,718,000<span></span>
</td>
<td class="nump">19,369,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(16,718,000)<span></span>
</td>
<td class="num">(19,369,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred income tax assets (liabilities)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the provision for loan losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829648080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax asset and related valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,458,000<span></span>
</td>
<td class="nump">$ 15,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">U.S. corporate income tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Additional tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">U.S. corporate income tax percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">U.S. corporate income tax percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=aytu_AmpioPharmaceuticalsMember', window );">Ampio's [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax asset and related valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,300,000<span></span>
</td>
<td class="nump">$ 42,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NetOperatingLossesExpirationDescription', window );">Net operating loss carryforwards begin to expire, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">The available federal net operating
losses, if not utilized to offset taxable income in future periods, will begin to expire in 2031 through 2037.</font></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Statel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,300,000<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NetOperatingLossesExpirationDescription', window );">Net operating loss carryforwards begin to expire, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">The available state net operating
losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2037.</font></p><span></span>
</td>
<td class="text"><font style="font: 10pt Times New Roman, Times, Serif">The available state net operating
losses, if not utilized to offset taxable income in future periods, will begin to expire in 2025 through 2037.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NetOperatingLossesExpirationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NetOperatingLossesExpirationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=aytu_AmpioPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=aytu_AmpioPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828074704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 1,063,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2020</a></td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2021</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2023</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">3,699,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember', window );">Prescription database [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2019</a></td>
<td class="nump">774,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2021</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">774,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2019</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2021</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2023</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SupplyOrderMember', window );">Supply order [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2019</a></td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2020</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2021</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">167,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember', window );">Office lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2019</a></td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2020</a></td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2021</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2022</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 258,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SupplyOrderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SupplyOrderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816526528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841354992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember', window );">Office Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Initial base rent</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leases, Term</a></td>
<td class="text">37 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">37 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember', window );">Prescription Database [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember', window );">Natesto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FirstMilestonePayable', window );">First milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SupplyOrderMember', window );">Purchase order [Member] | ZolpiMist [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of purchase order</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FirstMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the amount of first milestone payment which is require to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FirstMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_PrescriptionDatabaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_NatestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SupplyOrderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=aytu_SupplyOrderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ZolpiMistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=aytu_ZolpiMistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842927312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2018</div></th>
<th class="th"><div>Aug. 11, 2017</div></th>
<th class="th"><div>May 05, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,244<span></span>
</td>
<td class="nump">1,794,762<span></span>
</td>
<td class="nump">41,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aytu issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 739,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock expense, grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,419<span></span>
</td>
<td class="nump">724,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,732,490<span></span>
</td>
<td class="nump">17,442,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Issued stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityRelativeFairValue', window );">Stock issued during relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate of shares common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of Aytu common stock of net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We made a $238,000 prepayment in Aytu common stock, which represented the revenue earn-out payment for the remaining balance due on the first $1.0 million in net revenue.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficersAndDirectorsMember', window );">Executive Officers and directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_UnrecognizedExpense', window );">Unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Fair value of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock expense, grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Issuance of restricted stock, shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember', window );">Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockSharesAgreedToPurchase', window );">Purchase of stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockValueAgreedToPurchase', window );">Purchase of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0pt">The securities sold by the Company consist of (i) Class A Units
consisting of an aggregate of 976,000 shares of our common stock and warrants to purchase an aggregate of 976,000 shares of common
stock, at a public offering price of $9.00 per Class A Unit, and (ii) Class B Units consisting of 161 shares of our Series B Preferred
Stock, with a stated value of $20,000 per share, and convertible into an aggregate of 357,356 shares of common stock, and warrants
to purchase an aggregate of 357,356 shares of common stock, at a public offering price of $20,000 per Class B Unit. The warrants
have an exercise price of $10.80, are exercisable upon issuance and will expire five years from the date of issuance. The Company
granted the underwriters a 45-day option to purchase an additional 200,000 shares of common stock and/or warrants to purchase an
additional 200,000 shares of common stock. In connection with the closing of this offering, the underwriters partially exercised
their over-allotment option and purchased an additional 200,000 warrants. On March 26, 2018, the underwriters exercised their over-allotment
option to purchase an additional 100,000 shares of common stock, resulting in gross proceeds of approximately $900,000, before
deducting costs of $63,000.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Preferred stocks converted in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Aytu conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PreferredStockConversionPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Preferred stocks converted in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Aytu conversion of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,667<span></span>
</td>
<td class="nump">5,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SecuritiesPurchaseAgreementCashFeePercentage', window );">Cash fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued', window );">Warrants purchase, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction', window );">Warrants issued to underwriters as compensation for transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate of shares common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_MayTwoZeroOneSixWarrantsMember', window );">May 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_OctoberTwoZeroOneSixWarrantsMember', window );">October 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_ConvertibleAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PreferredStockSharesDesignated', window );">Preferred stock shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_ConvertibleBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PreferredStockSharesDesignated', window );">Preferred stock shares designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Preferred stocks converted in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,350<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued of common stock payment to Nuelle Shareholders for fiscal 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Issued stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityRelativeFairValue', window );">Stock issued during relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantPurchaseCommitmentDescription', window );">Securities purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We entered into a Securities Purchase Agreement
with various accredited investors pursuant to which, upon closing on August 15, 2017, we sold Class A and Class B equity units
for gross proceeds of approximately $11.8 million. Class A units consist of one (1) share of common stock and a warrant to purchase
one and one-half (1.5) shares of common stock and were sold at a price of $60.00 per unit. Class B units consist of one (1) share
of our newly created Series A Preferred Stock and warrants to purchase one and one-half (1.5) shares of common stock for each share
of common stock into which the Series A Preferred Stock is convertible and were sold at a price of $20,000.00 per unit to those
purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of our outstanding
common stock following the offering.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Preferred stocks converted in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued of common stock payment to Nuelle Shareholders for fiscal 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=aytu_AytuCommonStockMember', window );">Aytu Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RevenueEarnOutPayment', window );">Revenue earn out payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Issued stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issues during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Other offering expenses</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Public offering [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_CommonStockTextualAbstract', window );"><strong>Common Stock (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Issued stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityRelativeFairValue', window );">Stock issued during relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Purchase of additional common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_UnderwritersExercisedOfOverallotmentOption', window );">Underwriters exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrants to be issued as a percentage of shares issued in the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightPercentageOfSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockSharesAgreedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock shares agreed to purchase in the purchase agreement entered during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockSharesAgreedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_CommonStockValueAgreedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock agreed to purchase in the purchase agreement entered during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_CommonStockValueAgreedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EquityRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during relative fair value for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EquityRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated for the during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RevenueEarnOutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue earn-out payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RevenueEarnOutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SecuritiesPurchaseAgreementCashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of cash fee to underwriters incurred in securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SecuritiesPurchaseAgreementCashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_UnderwritersExercisedOfOverallotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of underwriters exercised of this over-allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_UnderwritersExercisedOfOverallotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_UnrecognizedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized expense yearsrelated to these shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_UnrecognizedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to the underwriters as compensation for the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsIssuedToUnderwritersAsCompensationForTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsToPurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsToPurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.9(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aytu_LincolnParkCapitalFundLlcPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_MayTwoZeroOneSixWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_MayTwoZeroOneSixWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_OctoberTwoZeroOneSixWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_OctoberTwoZeroOneSixWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_ConvertibleAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_ConvertibleAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_ConvertibleBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_ConvertibleBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=aytu_AytuCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=aytu_AytuCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828090592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details) - Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedDividendRate1', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedVolatilityRate1', window );">Expected volatility</a></td>
<td class="nump">178.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsRiskFreeInterestRate1', window );">Risk free interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedVolatilityRate1', window );">Expected volatility</a></td>
<td class="nump">185.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsRiskFreeInterestRate1', window );">Risk free interest rate</a></td>
<td class="nump">1.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsExpectedDividendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsExpectedDividendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsExpectedVolatilityRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsExpectedVolatilityRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionsRiskFreeInterestRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionsRiskFreeInterestRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829186656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 1) - Equity Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning Balance</a></td>
<td class="nump">1,947<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Number of options, Cancelled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending Balance</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">1,947<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">1,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 326.20<span></span>
</td>
<td class="nump">$ 7,204.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">364.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">328.00<span></span>
</td>
<td class="nump">1,664.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">328.00<span></span>
</td>
<td class="nump">1,292.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">325.97<span></span>
</td>
<td class="nump">$ 326.20<span></span>
</td>
<td class="nump">$ 7,204.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 325.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years, Outstanding, Ending Balance</a></td>
<td class="text">6 years 11 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life in Years, Exercisable</a></td>
<td class="text">6 years 8 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant</a></td>
<td class="nump">2,961,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840916944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares | shares</a></td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 325.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life of Options Outstanding</a></td>
<td class="text">6 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable | shares | shares</a></td>
<td class="nump">1,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 325.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember', window );">280.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of Exercise Prices</a></td>
<td class="nump">$ 280.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares | shares</a></td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 280.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life of Options Outstanding</a></td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable | shares | shares</a></td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 280.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember', window );">328.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Range of Exercise Prices</a></td>
<td class="nump">$ 328.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares | shares</a></td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 328.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life of Options Outstanding</a></td>
<td class="text">6 years 10 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of Options Exercisable | shares | shares</a></td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 328.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=aytu_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829503184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 3) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Beginning balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">39,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(1,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod', window );">Cancelled | shares</a></td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, Ending balance | shares</a></td>
<td class="nump">37,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">39.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">40.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue', window );">Cancelled | $ / shares</a></td>
<td class="nump">40.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested | $ / shares</a></td>
<td class="nump">$ 39.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested, Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested in period weighted average cancelled date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageCancelledDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6669539408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 597,000<span></span>
</td>
<td class="nump">$ 3,227,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">349,000<span></span>
</td>
<td class="nump">2,502,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 248,000<span></span>
</td>
<td class="nump">$ 725,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830414480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 5) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">14,342<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement', window );">Issuance of settlement warrants to initial investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering', window );">Warrants issued to investors in connection with the registered offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering', window );">Warrants issued to placement agents for the registered offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering', window );">Warrants issued in connection with the August 2017 private offering</a></td>
<td class="nump">296,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter', window );">Warrants issued to underwriters in connection with the August 2017 private offering</a></td>
<td class="nump">19,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection', window );">Warrants issued in connection with the March 2018 public offering</a></td>
<td class="nump">1,533,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice', window );">Warrants issued to investor</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsExpired', window );">Warrants expired</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice', window );">Warrants exercised</a></td>
<td class="num">(80,750)<span></span>
</td>
<td class="num">(7,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstanding', window );">Number of Warrants Outstanding, Ending Balance</a></td>
<td class="nump">1,882,661<span></span>
</td>
<td class="nump">14,342<span></span>
</td>
<td class="nump">5,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 1,005.80<span></span>
</td>
<td class="nump">$ 2,480.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice', window );">Issuance of settlement warrants to initial investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice', window );">Warrants issued to investors in connection with the registered offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">744.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice', window );">Warrants issued to placement agents for the registered offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice', window );">Warrants issued in connection with the August 2017 private offering</a></td>
<td class="nump">72.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice', window );">Warrants issued to underwriters in connection with the August 2017 private offering</a></td>
<td class="nump">72.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice', window );">Warrants issued in connection with the March 2018 public offering</a></td>
<td class="nump">10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice', window );">Warrants issued to investor</a></td>
<td class="nump">10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares', window );">Warrants expired</a></td>
<td class="nump">21,744.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice', window );">Warrants exercised</a></td>
<td class="nump">8.20<span></span>
</td>
<td class="nump">300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="nump">$ 25.94<span></span>
</td>
<td class="nump">$ 1,005.80<span></span>
</td>
<td class="nump">$ 2,480.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne', window );">Weighted Average Remaining Contractual Life in Years, Outstanding, Beginning Balance</a></td>
<td class="text">4 years 7 months 10 days<span></span>
</td>
<td class="text">4 years 2 months 23 days<span></span>
</td>
<td class="text">4 years 8 months 16 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ClassOfWarrantOrRightsWeightedAverageRemainingContractualTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents share based compensation share warrants weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantWeightedAverageExercisePriceWarrantPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation share warrants issued to investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share based compensation share warrants expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation share warrants investor weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsInvestorWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued as part of a settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued as part of a settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation share warrants issued on connection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConnection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation share warrants issued on connection with private offering weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnConnectionWithPrivateOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon investor private offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnInvestorsInConnectionWithPrivateOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued to placement agents for the registered offering for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon the private offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnPrivateOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon placement agents for registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon the registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued upon underwritters.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwriter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants issued upon underwriter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsIssuedOnUnderwritersForPrivateOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation warrants exercised weighted average exercise price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationWarrantsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation warrants issued to investor weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_ShareBasedCompensationWarrantsIssuedToInvestorWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828815536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details 6) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionExpectedDividendRate', window );">Dividend yields</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionWeightedAverageExpectedDividend', window );">Expected volatility</a></td>
<td class="nump">173.40%<span></span>
</td>
<td class="nump">156.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">4 years 1 month 16 days<span></span>
</td>
<td class="text">3 years 5 months 16 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionWeightedAverageExpectedDividend', window );">Expected volatility</a></td>
<td class="nump">188.00%<span></span>
</td>
<td class="nump">169.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.69%<span></span>
</td>
<td class="nump">1.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_FairValueAssumptionExpectedTerm', window );">Contractual term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 8 months 2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_FairValueAssumptionWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_FairValueAssumptionWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6844256368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,515<span></span>
</td>
<td class="nump">$ 2,502,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Expense related to awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_NewWarrantsToPurchaseOfCommonStock', window );">New warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Restricted stock for accelerated vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_MayTwoZeroOneSixWarrantsMember', window );">May 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=aytu_OctoberTwoZeroOneSixWarrantsMember', window );">October 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Unrecognized expense, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_NovemberTwoThousandSixTeenPublicOfferingMember', window );">November 2016 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsExercisePriceTerm', window );">Warrants exercise price term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember', window );">November 2016 Public Offering One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsExercisePriceTerm', window );">Warrants exercise price term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember', window );">Aytu Bioscience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember', window );">Aytu Bioscience Inc [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Unrecognized expense, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized expense share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grant purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_VestingExpiryDate', window );">Vesting expiry date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">July 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member] | Aytu Bioscience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember', window );">2015 Stock Option and Incentive Plan [Member] | Executive Officer Director And Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_VestingExpiryDate', window );">Vesting expiry date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">November 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenPlanMember', window );">2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_VestingExpiryDate', window );">Vesting expiry date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenPlanMember', window );">2015 Plan [Member] | Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_VestingExpiryDate', window );">Vesting expiry date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="nump">$ 21,744.00<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.00<span></span>
</td>
<td class="nump">$ 300.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744.00<span></span>
</td>
<td class="nump">$ 2,400.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsExercisePriceTerm', window );">Warrants exercise price term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsGeneratedNoncashExpense', window );">Warrants generated non-cash expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_IncrementalFairValueOfWarrant', window );">Incremental fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EquityInstrumentsTextualAbstract', window );"><strong>Equity Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsToPurchaseOfCommonStockShares', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_WarrantsExercisePriceTerm', window );">Warrants exercise price term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EquityInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EquityInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_IncrementalFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incremental fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_IncrementalFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_NewWarrantsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New Warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_NewWarrantsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_VestingExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>vesting expiry date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_VestingExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsExercisePriceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsExercisePriceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsGeneratedNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants generated a non-cash expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsGeneratedNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_WarrantsToPurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants to purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_WarrantsToPurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of compensation cost was accelerated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_MayTwoZeroOneSixWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_MayTwoZeroOneSixWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=aytu_OctoberTwoZeroOneSixWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=aytu_OctoberTwoZeroOneSixWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_NovemberTwoThousandSixTeenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_NovemberTwoThousandSixTeenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aytu_NovemberTwoThousandSixTeenPublicOfferingOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_TwoThousandFifteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficerDirectorAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficerDirectorAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aytu_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aytu_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6852615856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AgreementAxis=aytu_SponsoredResearchAgreementMember', window );">Sponsored Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Agreement term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This agreement was terminated in March 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Amount agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_PrepaidExpensesAmortizationPeriod', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AgreementAxis=aytu_ServicesAgreementMember', window );">Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Monthly payment</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Agreement term, description</a></td>
<td class="text">This agreement was terminated in June 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficerOneMember', window );">Jarrett Disbrow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock purchases offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Share purchased of executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Joshua Disbrow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock purchases offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=aytu_GreenMember', window );">Mr. Green [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Share purchased of executive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_PrepaidExpensesAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses amortization period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_PrepaidExpensesAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AgreementAxis=aytu_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AgreementAxis=aytu_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AgreementAxis=aytu_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AgreementAxis=aytu_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=aytu_ExecutiveOfficerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=aytu_GreenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=aytu_GreenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822947904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Consolidated revenue</a></td>
<td class="nump">$ 3,660,120<span></span>
</td>
<td class="nump">$ 3,221,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Consolidated net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(10,187,863)<span></span>
</td>
<td class="num">(22,508,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Total assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,060,093<span></span>
</td>
<td class="nump">14,998,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember', window );">Aytu Women's Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Consolidated revenue</a></td>
<td class="nump">243,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Consolidated net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(2,405,000)<span></span>
</td>
<td class="num">(159,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Total assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">3,220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember', window );">Aytu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Consolidated revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Consolidated revenue</a></td>
<td class="nump">3,417,000<span></span>
</td>
<td class="nump">3,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Consolidated net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(7,783,000)<span></span>
</td>
<td class="num">(22,349,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Total assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 21,053,000<span></span>
</td>
<td class="nump">$ 11,779,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuWomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aytu_AytuBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816988496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>Segments / Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SegmentInformationTextualAbstract', window );"><strong>Segment Information (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SegmentInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SegmentInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831839696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_EmployeeBenefitPlanTextualAbstract', window );"><strong>Employee Benefit Plan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Description of contributed to plan by employees</a></td>
<td class="text">The Company matches 50% of the first 6% contributed
to the plan by employees.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employees contributed plan amount</a></td>
<td class="nump">$ 119,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_EmployeeBenefitPlanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_EmployeeBenefitPlanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans. Includes, but is not limited to, plan utilized, employee group covered, and employer matching contributions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830807344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of reverse stock split</a></td>
<td class="text">Aytu effected a reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the &#8220;Reverse Stock Splits&#8221;). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_AssetPurchase', window );">Asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aytu_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A reverse stock split in which
each common stockholder received one share of common stock for every 20 shares outstanding, which was effected on August 10, 2018.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_AssetPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_AssetPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aytu_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aytu_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aytu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^;L.N-W=M_;'P5;!OX=1?M%U!+ P04    "  (A"9-F5R<(Q &  "<)P
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M<"()YXJ=K8C^2Y#<?X0(G1"A]D=3B,#MCYS^2/OCJ=] W/:25$L:+<%/&./
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MYK8?'&HW_!:R;</HQ\JP1?;1SS-)UJ,$[B3\ILC"Y+<5@%IA#2@<'A?88(4
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M*-V^ZV]UN&_&/FY\Z/QYZE&S6Z.\^@]02P,$%     @ "(0F37W&\2BC!@
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M+)\D]BC9G<(PPU*16VNL=8[9EL*9L;E51K,:5N"@65;D.B=< 8(5(%"!DE5
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MAQ]+DK#W!?1EY(]K0%9R0G"PRT<;80%P[T"@=Y 3 O;H5I0 B#)GX\L5TYP
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M)S-^@;F>:TKFXK_!!22&!R68HS32Q964@_-&S2PH18G7:>]TW,?I)MW/L&T
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M0:KG#4:I^"]P!>'#@Q*?H];"QA75HW5:)A8O1;*G>><J[E.ZR1-L&T 3@"Z
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MXWL\VWG,9L.;8?E!;/W&Y6]02P,$%     @ "(0F330IQZFU 0  T@,  !D
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MC,>7C?UOC/& 4I(;'*$./]AJ*&A\.+[#LYW';#:\&98?Q-9O7/X&4$L#!!0
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MV[F?!A 4R@/< <AC>4\>.BEH ?DL((-[  $%7J2^#@(%FC;!;8" &B</:0!
M12C=<"<@H,R+!QT$"J4;;@8$5'KQD&X(%$@WBML!!95>^.D&08%TH[@=4%#I
MA=]V$*@,M!V*VP$%E5[Z;0>" GE <3N@H-)+/P\@R,^#Y&[V:;@\N:E/17MQ
M:=W(>;<[3I9KZF:G?_!^+/W.Y*EJ5;03VDQ@;DXZ"J&Y\25],K5\-I/PN*CY
M4=O/TGS+?ASL%UITPZB;C//VZB]02P,$%     @ "(0F3>=I$_<) @  3@8
M !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULC55AC]HP#/TK57_ I0T4
M"BJ5X*9IDS8)W;3M<V@-K2YINB30V[]?DI:NQQF)+R1VGY^?G<1DG52ON@(P
MP9O@C=Z$E3'MFA!=5""8?I(M-/;+42K!C#75B>A6 2M]D."$1M&""%8W89YY
MWU[EF3P;7C>P5X$^"\'4WQUPV6W".+PZ7NI399R#Y%G+3O #S,]VKZQ%1I:R
M%M#H6C:!@N,FW,;K74Q=@$?\JJ'3DWW@2CE(^>J,K^4FC)PBX% 81\'L<H%G
MX-PQ61U_!M)PS.D"I_LK^V=?O"WFP#0\2_Z[+DVU"=,P*.'(SMR\R.X+# 4E
M83!4_PTNP"W<*;$Y"LFU_PV*LS92#"Q6BF!O_5HW?NT&_FL8'D"' 'H30/I$
M7ODG9EB>*=D%JF]^R]P9QVMJ>U,XIV^%_V;%:^N]Y'299.3BB ;,KL?0"28>
M$<2RCRDHEF)'/X13/'R&*ISY\/D[A0N<8(X2S#W![!W!$B=(4(($49#>] C#
MK/ D"S3)XB-!&MTDP3!WCF*))EDB!'<.(T4)TL=[N4()5HB"V4V9&&:.)XDC
M_%9'"$5RA^+.PX@?+S5&+_XVI@]<' R4WMYO,GG. M3)#S(=%/+<^"DZ\8[#
M<NMG)?D/[R?M=Z9.=:.#@S1VJ/BG?Y32@-42/=E;7-GA/AH<CL9MEW:O^@G7
M&T:VP_0FXU](_@]02P,$%     @ "(0F3;/GC\KX 0  RP4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL=53MCILP$'P5Q .<B?,%$2!=[E2U4BM%
M5[7][< FH+,QM4VXOGUMPU%*]OY@[WIV9M;(F_92O>H*P 1O@C<Z"RMCV@,A
MNJA ,/T@6VCLR44JP8P-U97H5@$K?9'@A$;1C@A6-V&>^MQ)Y:GL#*\;.*E
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MQKCIWL[5_);GA9'#TJ9D_5>4GU!+ P04    "  (A"9-UO3 O<4!   W!
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QM5.V.G" 4?17" RS*C-WI
M1$UV=M.T29M,MFG[F]&KD@6Q@./V[0OH6CO+'^%>SCGW Z[YI/2+Z0 L>I6B
M-P7NK!V.A)BJ \G,G1J@=R>-TI)99^J6F$$#JP-)"D*3Y .1C/>XS(/OK,M<
MC5;P'LX:F5%*IO^<0*BIP"E^<SSSMK/>0<I\8"U\!_MC.&MGD56EYA)ZPU6/
M-#0%?DB/I\SC ^ GA\EL]LA7<E'JQ1M?Z@(G/B$04%FOP-QRA4<0P@NY-'XO
MFG@-Z8G;_9OZIU"[J^7"##PJ\8O7MBOP :,:&C8*^ZRFS[#4DV&T%/\5KB <
MW&?B8E1*F/!%U6BLDHN*2T6RUWGE?5BG^22C"RU.H N!KH1#B$/F0"'S)V99
MF6LU(3WW?F#^BM,C=;VIO#.T(IRYY(WS7LM=>LC)U0LMF-.,H1M,NB*(4U]#
MT%B($WU'IW'Z+IKA+M!W6WIZ'Q?81P7V06#_7XD?;TJ,8&@2#Y)%@V01@?0F
M2 QSVPJRN3@)N@U/UJ!*C7T8EXUWG8J'\%+(/_@\4M^8;GEOT$59]WS")3=*
M67"I)'<NE\Y-\6H(:*S?WKN]GM_R;%@U+&-*UG]%^1=02P,$%     @ "(0F
M30UXLS M @  0@<  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC57;
MCML@$/T5RQ^P&.Q<Y5A*MJI:J96BK=H^$V<26PO&!1)O_[Z O6[6.Y'VQ<!P
MYIP9##-YI_2SJ0!L]")%8S9Q96V[)L24%4AN'E0+C=LY*2VY=4M])J;5P(_!
M20K"DF1.)*^;N,B#;:^+7%VLJ!O8Z\A<I.3Z[PZ$ZC8QC5\-3_6YLMY BKSE
M9_@!]F>[UVY%1I9C+:$QM6HB#:=-O*7K'<V\0T#\JJ$S-_/(IW)0ZMDOOAXW
M<>(C @&E]13<#5=X!"$\DXOCST :CYK>\7;^ROXY).^2.7 #CTK\KH^VVL3+
M.#K"B5^$?5+=%Q@2FL71D/TWN()P<!^)TRB5,.$;E1=CE1Q87"B2O_1CW82Q
MZW<6J\$-=V"# QL=ED&']$(A\D_<\B+7JHMT?_@M]_^8KID[F](;PU&$/1>\
M<=9KD;(T)U=/-&!V/8;=8.B(((Y]E&"8Q(Z]<V>X>XI&F ;W]$V$&4Z0H019
M(,C>$,PF*6*8.2XR0T5F",%B(H)AEKC('!69(P2KB0B"21-<9(&*+!""._][
MB1(L/_[#5BC!"HF 3=+$,"DN0A/\YB<(13:]^AAH=D?GS@NC",6=NT71%[2E
M[.-'2O%71%,DBND%14%W;BC%'QM%7M+[4\5 JXD.N2EA$O0Y%&\3E>K2A,YQ
M8QT;Q):%$O@?WG>7[UR?Z\9$!V5=(0WE[J24!1=+\N!>9>4:VK@0<+)^NG!S
MW5?U?F%5.W0L,K;-XA]02P,$%     @ "(0F32(__I:V 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL;5/;;IPP$/T5RQ\0@Z'I:@5(V515
M*K72*E6;9R\,8,47:ILE_?O:AA"2\F)[QG/.G!F/BTF;9]L#./0BA;(E[IT;
MCH38N@?)[(T>0/F;5AO)G#=-1^Q@@#41) 6A27)+).,*5T7TG4U5Z-$)KN!L
MD!VE9.;O"82>2ISB5\<C[WH7'*0J!M;!3W"_AK/Q%EE9&BY!6:X5,M"6^"X]
MGO(0'P-^<YCLYHQ")1>MGX/QK2EQ$@2!@-H%!N:W*]R#$('(R_BS<.(U90!N
MSZ_L7V/MOI8+LW"OQ1-O7%_B T8-M&P4[E%/#[#4\PFCI?CO< 7APX,2GZ/6
MPL85U:-U6BXL7HID+_/.5=RG^2;+%]@^@"X N@(.,0^9$T7E7YAC56'TA,S<
M^X&%)TZ/U/>F#L[8BGCGQ5OOO599GA3D&HB6F-,<0S<QZ1I!//N:@NZE.-'_
MX'0?GNTJS"(\V\+I89\@WR7((T'^KL3T0XE[,1]5DDU/)9@N3I-%M1Y5G.2-
M=QW8.QK?Y"U\GO8?S'1<6731SK]L['^KM0,O);GQ(]3[#[8: EH7CI_]V<QC
M-AM.#\L/(NLWKOX!4$L#!!0    (  B$)DU\TUBU@P(  /0)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;(U68:^:,!3]*X0?\&@+"A@DF2[+EFR)
M><NVSU6KD@>4M57>_OW:@HS1*_&+M.7<<\[%WMMF+1=O\L*8\MZKLI9K_Z)4
MLPH">;BPBLH7WK!:OSEQ45&EI^(<R$8P>K1!51D0A)9!18O:SS.[MA-YQJ^J
M+&JV$YZ\5A45?S:LY.W:Q_Y]X;4X7Y19"/*LH6?VG:D?S4[H63"P'(N*U;+@
MM2?8:>U_P*LM3DR 1?PL6"M'8\^DLN?\S4R^'-<^,HY8R0[*4%#]N+$M*TO#
MI'W\[DG]0=,$CL=W]D\V>9W,GDJVY>6OXJ@N:S_QO2,[T6NI7GG[F?4)+7RO
MS_XKN[%2PXT3K7'@I;2_WN$J%:]Z%FVEHN_=LZCML^WY[V%P .D#R!" H]F
ML \()P%!Y\RF^I$JFF>"MY[H_JV&FDV!5Z'^F >S:+^=?:>SE7KUEH=1F 4W
M0]1C-AV&C##D?\36183_(($V,+@@H MBXZ-1/$;QQ$6'65I,W;F(%FD43:P
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MXEPQ38I>M/.+OH(-DY*=E!G&>BRZ>T@W4;SI[UC!<-'+_P)02P,$%     @
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MXZN:'0F=#^8=VC;-5G*\&:9GP^:W6[\#4$L#!!0    (  B$)DW#2#$5_ $
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M!5Z 4D.DT_@S<H:3I F<WZ_LGVWMNI8#D?#"Z>_VJ)HBW(3!$4[D3-4K'[[
M6$\:!F/QW^ "5,--)EJCXE3:WZ Z2\79R*)38>3=G6UGSV'DOX;Y _ 8@*<
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MFD&NN:C4H1U2O<NDO/@+4$L#!!0    (  B$)DU96VH+WP$  &@$   9
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;'U4V6Z<,!3]%8L/B-E"TA$@9::J
M6JF51JF:/GO@LBA>J&V&]._KA1!F!O4%V]?GG+OX7O))R%?5 6CTQBA71=!I
M/>PP5E4'C*@[,0 W-XV0C&ASE"U6@P12.Q*C. [###/2\Z#,G>THRUR,FO8<
MCA*ID3$B_^Z!BJD(HN#=\-RWG;8&7.8#:>$GZ%_#49H37E3JG@%7O>!(0E,$
M3]'ND%J\ [ST,*G5'ME,3D*\VL.WN@A"&Q!0J+15(&8YPP$HM4(FC#^S9K"X
MM,3U_EW]B\O=Y'(B"@Z"_NYKW17!8X!J:,A(];.8OL*<SWV YN2_PQFH@=M(
MC(]*4.6^J!J5%FQ6,:$P\N;7GKMU\C?9_4S;)L0S(5X(4?9?0C(3D@^"JR;V
MD;E4/Q--RER*"4G_6 .Q/1'M$E/,RAI=[=R=R589Z[E,LX<<GZW0C-E[3+S"
M1 L"&_7%1;SE8A_?T.-+!X=;1!)O>T@VDT@</UE["+-M@713('4"Z445'J^J
MX#&9PW#OY%,:AN%5+K>P*+F ^7#PZH$8R-;ULD*5&+FVI5A9EW%YBNT#7]GW
M9HQ\UW_(^!G\063;<X5.0IOV<8_<"*'!1!G>F<;NS-@O!PJ-MML'LY>^^?U!
MBV&>:[S\7,I_4$L#!!0    (  B$)DTQ%9,VYP$  /4$   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;(54VXZ;,!3\%>3WKKGG(D!J4E6MU$K15ML^
M.W (:&U,;2=L_[Z^L)0EM.4A]K%GYLR XVS@XEDV ,I[8;23.6J4ZO<8R[(!
M1N0#[Z'3.S47C"A=B@N6O0!261*C./3]%#/2=JC([-I)%!F_*MIV<!*>O#)&
MQ*\#4#[D*$"O"X_MI5%F 1=93R[P#=13?Q*ZPI-*U3+H9,L[3T"=H_?!_I@8
MO 5\;V&0L[EGDIPY?S;%YRI'OC$$%$IE%(@>;G $2HV0MO%SU$132T.<SU_5
M/]KL.LN92#AR^J.M5).C+?(JJ,F5JD<^?((Q3X*\,?P7N '5<.-$]R@YE?;7
M*Z]2<3:J:"N,O+BQ[>PXN)TT&6GKA' DA!,AB/])B$9"M"!@Y\Q&_4 4*3+!
M!T^XC]43<R:"?:1?9FD6[;NS>SJMU*NW(DYW&;X9H1%S<)APA@G?(H[WB.@/
M!&L#DXMPU45H^=&\@Y^N"T2K I$5B.<"2;*(X3"IQ73.Y-;7SR++?V%O[,2K
M=N([._%FT>?@,,FLS[L@BN_]K.'\W5\-):N&DA5#"S_)7>XP3G9QO+"S ML$
MX6:[<(-G!]!<"%^)N+2=],Y<Z;-L3US-N0(MZ3]HS4;?05-!H59FNM%SX?Z)
MKE"\'R\9/-UTQ6]02P,$%     @ "(0F30^;"4 % @  >04  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&ULC539;MLP$/P501\0RCH#0Q80.PA:H 6,
M%&V>:7EU(*2HDI25_GUY*+)L,VU>3'(Y,[NSIC8?&7\5#8#TWBCIQ,9OI.S7
M"(FR 8K%'>NA4S<5XQ1+=>0U$CT'?#0D2E 8!"FBN.W\(C>Q/2]R-DC2=K#G
MGA@HQ?S/%@@;-_[*?P\\MW4C=0 5>8]K^ 'R9[_GZH1FE6-+H1,MZSP.U<9_
M6*UWF<8;P*\61K'8>]K)@;%7??AZW/B!+@@(E%(K8+6<8 >$:"%5QN])TY]3
M:N)R_Z[^9+PK+P<L8,?(2WN4S<:_][TC5'@@\IF-7V#RD_C>9/X;G( HN*Y$
MY2@9$>;7*P<A&9U45"D4O]FU[<PZVILTF6AN0C@1PIFP2O])B"9"=";$QKRM
MS%A]Q!(7.6>CQ^V?U6/])E;K2#6SU$'3.W.GW H5/15QMLK120M-F*W%A O,
M&8&4^IPB=*78AC?T\#+![A81A>X,D=-$9/C1A8D/!&*G0&P$X@N!Z*H+%I,:
M3&>[D"11%B179ARX++C/L@]ZEC@+2AP%Q6Z!U"F0?KXEF5,@^T1+LANK81($
MP55#_H>RQ:#%BZ7 :_-Q"Z]D0R?UVUA$Y_GQ$.H7?Q7?JKEBQ\!9Q@ZE[YC7
M;2>\ Y/J>S*OOF),@BHRN%,=;]0<G \$*JFWF=IS.PWL0;)^&G1HGK;%7U!+
M P04    "  (A"9-UZ[A[3("   Z!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6R-5>UNFS 4?17$ ]38?"4105HR59NT25&G=;^=Q FH!E/;"=W;
MSS:4$7*I^@=_G7O.N<;7SEHA7U3!F/;>*EZKM5]HW:P04H>"550]B(;59N4D
M9$6U&<HS4HUD].B"*HY($"2HHF7MYYF;V\D\$Q?-RYKMI*<N547EWPWCHEW[
MV'^?>"K/A;83*,\:>F:_F/[=[*09H8'E6%:L5J6H/<E.:_\+7FTQL0$.\5RR
M5HWZGDUE+\2+'7P_KOW .F*<';2EH*:YLBWCW#(9'Z\]J3]HVL!Q_YW]T25O
MDME3Q;:"_RF/NEC["]\[LA.]</TDVF^L3RCVO3[['^S*N(%;)T;C(+AR7^]P
M45I4/8NQ4M&WKBUKU[;=2A+W87  Z0/($("C#P/"/B"<!*#.F4OU*]4TSZ1H
M/=G]K8;:0X%7H=G,@YUT>^?63+;*S%[S*(TS=+5$/6;38<@(0VX1VWM$^!^"
MC('!!0%=$!<?WKB8(0A!@M 11#<$R22-#I,X3-VE$<7+*)KD L!23-(%;"<"
M[41W=LARAB &">+/;T@"$B2.(!YG$>#E9$< 4!P$ :R3@CHIH$."B0X FM=9
M@#H+2 =/= #0O,X2U%E".I/CO@% \SHX@ LO@)3":>D!J ^D9FH<WQW'<'KL
M-SUHK(0)GI>""QF33Q1B#[JMQ.1>"HTN,?NJ_*3R7-;*VPMM[D-W:YV$T,QP
M!@_&>&$>LF' V4G;;FKZLKO-NX$63?]2H>&YS/\!4$L#!!0    (  B$)DWL
MLDDW# ,  .X,   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;)57VXZ;
M,!#]%<0'+-A<O4HB;5)5K=1*JZW:/GL3)T$+F-I.LOW[VH:EQ![V\@+8G#ES
M9F"&87'AXDD>&5/!<U.W<AD>E>INHTANCZRA\H9WK-5W]EPT5.FE.$2R$XSN
MK%%31SB.\ZBA51NN%G;O7JP6_*3JJF7W(I"GIJ'B[YK5_+(,4?BR\5 =CLIL
M1*M%1P_L!U,_NWNA5]'(LJL:ULJ*MX%@^V5XAVXW.#,&%O&K8A<YN0Y,*(^<
M/YG%U]TRC(TB5K.M,A14G\YLP^K:,&D=?P;2</1I#*?7+^R?;? ZF$<JV8;7
MOZN=.B[#,@QV;$]/M7K@ER]L""@+@R'Z;^S,:@TW2K2/+:^E/0;;DU2\&5BT
ME(8^]^>JM>=+?R='@QEL@ <#/!JDV:L&R6"0. 91K\R&^HDJNEH(?@E$_[0Z
M:EX*=)OH9&[-ILV=O:>CE7KWO$J+8A&=#=& 6?<8/,&@$1%I]M$%AERLL6>>
M%N6UBPV$(;"3!(PCL03)E*",88(4)$@M07I%@)Q$])C<8MH^$44<QTXL/BHK
MIZ@K,1DH)@/$8$=,C\DF;EPA/B)-9X7DH) <$)(X0@",HW63>TH2%,]**4 I
M!2 E=:04OI\R]I_0F[ K.24HIP3D9(Z<TGL3<%+Z<GQ8,?^<"*B& &IR1PWQ
MHD8$)X@01PZ *Y,\A^6@&&XK,2"HF*&8Z4SH_26-P,YSAS"@HG2[&P1R<_(&
MZ%H,W*%0XE.0N7C@'H72#Z0$[BP(:BU>2@ 0F>GY"&X<".@*Q&UA".@+,U[@
MGH" ID#F*. Z1N4'<@H7'X*JS\LI "*I^YI!H P6@^'*PT#E>8D?0'#BAR_R
M:Y!K(7#]8@0(F>DB&*Y?C-__;#!<=1BH.N^S,8#R=WX0,%R=&!@AB#M+@:!R
MQ@]<PABJ3N+Z\4&9%T\TF1(;)@YVH);!EI]:9::QR>XXM-]A,V4Z^VL]S/>C
M]W^:_D_@.Q6'JI7!(U=ZAK63YIYSQ;3&^$9K/.J?CW%1L[TREX6^%OT$WB\4
M[X:_BVC\Q5G] U!+ P04    "  (A"9-?K%8&$D"  "G!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6Q]55V/FS 0_"N(]SN,^8X(TI&J:J56BJYJ
M^^R034!G,+6=Y/KO:QN.X\!-'H*]GIW9L6&=WQA_$36 =%Y;VHFM6TO9;SQ/
M5#6T1#RR'CJU<F*\)5)-^=D3/0=R-$DM]3!"L=>2IG.+W,3VO,C91=*F@SUW
MQ*5M"?]; F6WK>N[;X'GYEQ+'?"*O"=G^ 'R9[_G:N9-+,>FA4XTK',XG+;N
MD[_991IO +\:N(G9V-%.#HR]Z,G7X]9%NB"@4$G-0-3C"CN@5!.I,OZ,G.XD
MJ1/GXS?VS\:[\G(@ G:,_FZ.LMZZJ>L<X40N5#ZSVQ<8_42N,YK_!E>@"JXK
M41H5H\+\.]5%2-:.+*J4EKP.SZ8SS]NP$@9CFCT!CPEX2O#CNPG!F!"\)X3&
M_%"9L?J)2%+DG-T</AQ63_0[X6\"M9F5#IJ],VO*K5#1:Q$A/_>NFFC$E ,&
MSS#O"$^Q3Q+8)E'B53K^*+!;(P)L5PBL)@*3'WPP\1^"T$H0&H)P[A"AQ2X,
MF-A@.H-Y\)&?)FD<+.Q8D!A'* U0:"\JLA85K8J*T$*J'##13,J/D?G9E6*K
M4FQ1"A=*\4HI\>\()5:A9"6TW+PR63L*HCM"J54H70LE"Z%T)?209#A*HFSY
M>J;K\XPS%&<)SNPU9=::,LLN1XNBLI54:#U.;_9]M\#/IA4*IV*73NHO:1:=
MNNT3UOUA$2]5%QZ:YCO-T,*_$WYN.N$<F%3=Q_2($V,25)GH46U;K6Z-:4+A
M)/4P46,^],YA(ED_7@O>=#<5_P!02P,$%     @ "(0F33P1ZVZ7 @  DPH
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M-.VEU,+DBY],;T=SCKX.*K'7]C8S]VHX3 X#+=OQH!Q=3^O+?U!+ P04
M"  (A"9-$L(12C\#  !D#@  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6R55V&3FC 0_2L,/^ @@01TU)E3SVMGVIF;Z[3]C!J5.2 4HE[_?4/(<1 6
MJE^$Q+>[;W?S$C*[\N*M/#$FK/<TR<JY?1(BGSI.N3NQ-"H?>,XR^<^!%VDD
MY+ X.F5>L&BOC-+$P:Y+G32*,WLQ4W,OQ6+&SR*),_926.4Y3:/B[Y(E_#JW
MD?TQ\1H?3Z*:<!:S/#JR'TS\S%\*.7(:+_LX95D9\\PJV&%N/Z+I,Z:5@4+\
MBMFU;+U;52I;SM^JP=?]W'8K1BQA.U&YB.3CPE8L22I/DL<?[=1N8E:&[?</
M[QN5O$QF&Y5LQ9/?\5Z<YG9H6WMVB,Z)>.77+TPG1&Q+9_^-75@BX143&6/'
MDU+]6KMS*7BJO4@J:?1>/^-,/:_U/Q1K,]@ :P/<&,C88P:>-O!N-?"U@?]I
MX(\:$&U &H/0'36@VH#>:A!H@\"@Y-355>U:1R):S I^M8IZQ>51M;#1-) +
M8E=-JOZK_V3'2CE[69!),',NE2.-6=88W,&$7<P*PDRZF*<^!C4(1[)LJ&*(
MZA+WS*GK&C3Z&(\:5-=]C&\0[2-P%[$!XAB09XCN0+X>V!I/.? Z#C#LP <=
M^,J!WW'@&:G6&*HP6=T3WR>A:U9V P")[Y$VL$.)@)0(0,FL?A]#J%E_"./!
M1"A(A )$B$&DC_%-'J.0#HT I!$ -*BQIH-^Y5UWL.XA&"<$X@2P@PGH8'+[
M8D0NO-.X_^_]$@#Y_D"F:&!'0T"<<, %N-,\(GQ'MK!XD7=+MA!H,A 'UC@"
M1(Z&"@9K$I$[LH75A  Y(61LB"!H* XL%P3IQ3/C] 7CDQ'%(%@R"- ,&MAC
M$"P:=(=J,*P:#*@&]<ZK&D1:&9.)UTU9GUMNOS;8&RD.AD6& 9$A8@:#0'0@
M#JQ$C $7 QL7AI6([SA',2PR#(FLUX3^"4E<N E]I(?#L2; PL7 :6HVX0D$
MA2:C<5"7#+P%X!M.U+4&M3.G%$K<:7V_IJPXJNM*:>WX.1-5+UNSS97H4=T2
MC/D5FJX1,/^$IIOZPO/IOKY_?8^*8YR5UI8+^=6MOHT/G LF^;L/LDXG>>5K
M!@D[B.HUD.]%?>^I!X+G^D[G-!?+Q3]02P,$%     @ "(0F3<IX5VV' P
M9A,  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULE9CO;ILP%,5?!?$
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M>Q)G)(FB/>&T%[C,O>VLRER.AO4"S@KID7.J_AZ!R:G ,7XQ//9M9YR!E/E
M6_@!YN=P5O9$%I6ZYR!T+P52T!3X(3Z<,H?W@%\]3'JU1RZ3BY1/[O"U+G#D
M @(&E7$*U"Y7. %C3LB&\6?6Q(M+1USO7]0_^]QM+A>JX239[[XV78$_8%1#
M0T=F'N7T!>9\=AC-R7^#*S +=Y%8'Y5DVG]1-6HC^:QB0^'T.:R]\.L4;G;)
M3-LF)#,A60CQ_K^$=":DKP1?31(B\ZE^HH:6N9(34N&Q!NIZ(CZDMIB5,_K:
M^3N;K;;6:[E/LIQ<G=",.09,LL+$"X)8]<5%LN7BF+RC)V\=G-XCTF3;0[J9
M1.KYZ=I#?+\MD&T*9%X@>U.%W4T5 F;O,2)4(;/3$MWDL@%+/ZYA(1RR>B .
MJO6]K%$E1V%<*5;695P>? O=V(]VC$+7O\J$&?Q.5=L+C2[2V/;QC]Q(:<!&
M&=W9QN[LV"\'!HUQVWN[5Z'YP\'(89YKLOQ<RG]02P,$%     @ "(0F35=V
MDO?. @  OPH  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULE5;K;ILP
M&'T5Q ,4;*Z)DDC-K9NT256K;;_=Q$E0 3/;2;JWGVU<PN5+E/X!;,XY/@>;
MSYZ<&7\7!TJE\U'DI9BZ!RFKL>>)S8$61#RPBI;JS8[Q@DC5Y'M/5)R2K2$5
MN8=]/_8*DI7N;&+ZGOELPHXRSTKZS!UQ+ K"_\UISLY3%[F?'2_9_B!UAS>;
M5&1/7ZG\53USU?(:E6U6T%)DK'0XW4W=1S1^0K$F&,3OC)Y%Z]G14=X8>]>-
M[]NIZVM'-*<;J26(NIWH@N:Y5E(^_EI1MQE3$]O/G^IK$UZ%>2."+EC^)]O*
MP]1-76=+=^28RQ=V_D9MH,AU;/H?]$1S!==.U!@;E@MS=39'(5EA5925@GS4
M]ZPT]W/])DHM#29@2\ -08U]BQ!80G A!#<)H26$%T)XDQ!90G0O(;:$^$*(
M;Q(22TAZ(WCUUS73M222S":<G1U>K[B*Z(6-QHE:$!O=:>;?O%,S)E3O:1;C
M>.*=M)#%S&L,;F&B4=K%K(<8U" \Y:"Q@2$;<SR@QSCI#K& ,#T;2P@SZF)6
M ";P>W&&&-Q%/ T101S!D0/PRP=&(.S8N/+-0E @- )!1P## A$H$ $.@M[<
MUYC88$J#&?E^[VLM[P&MAJ!@ %H/00BU0)U0,1@J!D*%/;_QT I*AXZ',(3P
MT#, "_ UTPEH.@%,1[V9@#"]/W5Y!V9U!V8-81(X4 H&2@&!%!88@0*C^Q<W
M\N'*Y@,>>K5@84&=R=-K]]KTH2M5% W&PNF5:H# "OB(\!<2PQ4% 24E[*W6
M)PMJ)\;1K<1P\4$A,-:5\H7@\H.B+R2&?W8$_.UAKU*O+2AJ)0ZC85ZOM646
ME._-"4DX&W8LI2[TK=[F%/:(]9;;ZY^C\:H^2UUDZJ/=3\+W62F<-R;5AFZV
MW1UCDBJ7_H/R=U"GR::1TYW4CXEZYO61JFY(5MGCHM><66?_ 5!+ P04
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MT/&@4L!9C0>,]4K S8;;*DI6BA]@ ,P.VDZ$1XX6=#RN8K$I0.V@4#NC@Q?
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M*K:*_41&7>]!$%$<XB0)2I(@) D@2>Q)J ] $$V <Z0H1XIP@&)7J?WZXQ3
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MX7 HV46U6Z+WHAN2NH/B33\ >L,4FOT%4$L#!!0    (  B$)DVM*MSR; (
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MGQ8U/4L]3=2<#\UO6$C6C8W=F_Y=Y'\ 4$L#!!0    (  B$)DU%*QN8,0(
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M*#L9S6H2"Y;-/N:!T3[<N/<I9@XAYF1F;H E\2*+S'3>AZ8M"O<7-!%&$Z4
MN([3 V'H$(!.%IK%(R/SCP8:68=W9,2-C(.[EJ62S7%H!UMOIRYUUY_\[T9O
M+><C]2V/,;[1K>C8./X),_:QG_/F6-2M]Z(ZW5 -;<]!J4[J',.%WDPGW3K?
M'DIYZ/K;5-\W8_\X/G3J//7&P:U!7_\/4$L#!!0    (  B$)DW_OZ(X=P(
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M P2I(V2*(<C!;"">.2P$A?!E#8'RN!,+NG/?T>,%@L#[O$+X@1(!0 2[UP4
MI6%X1PQ\]5'T0)D (()#5\P4E(9W&AV"VPB"^HA;*@ H)FZM * T='MB,&KR
M%1-'.P^EE_-SK4P['5F'F;O"9D@X]K69Q79X?-!T@_PG%<>BEMZ.*SV"[* X
M<*Z8UA@^Z69UTM\.PZ9D!V66B5Z+;H!V&\6;_N,@&+Y0LO]02P,$%     @
M"(0F34T-&SV?!P  /2X  !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&UL
ME5KM4N,X$'R55!Y@8WU+%%"UA&5A%P*U5W?WVPL&4IO$7&+@[NW/CIU@:Z:S
M]A^2F!Z-I%&W1B,?O^?K7YOG+"M&_RX7J\W)^+DH7HXFD\W]<[9,-Y_REVQ5
M_N<Q7R_3HORY?IIL7M99^K U6BXF,DGL9)G.5^/3X^VSN_7I<?Y:+.:K[&X]
MVKPNE^GZO[-LD;^?C,5X]^#'_.FYJ!Y,3H]?TJ?LCZSX\^5N7?Z:[%MYF"^S
MU6:>KT;K[/%D_%D<W05?&6P1?\VS]TWK^Z@:RL\\_U7]N'HX&2=5C[)%=E]4
M3:3EQULVS1:+JJ6R'_\TC8[W/BO#]O==ZQ?;P9>#^9ENLFF^^'O^4#R?C/UX
M]) ]IJ^+XD?^?IDU S+C43/ZZ^PM6Y3PJB>EC_M\L=G^'=V_;HI\V;12=F69
M_EM_SE?;S_>F_9T9;R ; [DW*'T?,E"-@?HPT <-=&.@^WHPC8'Y,+ '#6QC
M8#\,W$$#UQBXOF/PC8'O:Q :@]#70"2[R"6]3?;!_HBV4(=-=N$6O>,M=@$7
MO2,N=B$7'S&7O_&R"[HPO;WLPBYL9#*I2;)EW7E:I*?'Z_Q]M*Z%XR6M]$D<
ME59EX]73+8^W_RR9MRF?OIWZ1!U/WJJ6&LQ9C9$MC F^B[GF,*&+F5&,V",F
M93?W?95L7\\DL?>)[OJ84HRR45_/N79,%_.%P]@NYH+S%8WY*\58[;J82PX3
M]?F*PT2^OG']B>;G.]..C&/98PYO*";R-*,(V47<,GXBR!T7!L<O&L4O<+5M
M075:\'P+FF]!;UO0G1;BI5UC[!:SJI>V%4F2\(X,[\@01\)$$S*K,:;E2&EO
M1+1\;PWICS2)3(+D.V3Y#EDZ<I%$';+44] &#MWQGASC242>. P8C^>]>*:%
M2.QFGD92!3B<P#L*C*.8'X%$LEHPR%&U-;+ZG3"NHM5PU8#:@]*RZZQ1: H4
M#H]>H$U%,)VRL2]!)D!B3_R6\%E(XLG:R--E VJ/2D%'0$:$HHZ" FT (1&Z
MOQ8)H!&"B@0S8(;^&HX8D%]0]MN@8T^6!%$KI8$G0'Y!F6V# 6T :@L_8&X!
M:P6EK0TB'C'EK=,.[$D2L%92UM(H2DI&I\'42L!$29E(@R@I$X5)#$K. !4E
M0\5 QD2I*.4!V9. CI+2T0L4!$!'.8".$M!14CIZ$>5*LP;DV_H3/B%/@(Z2
MTI%F!Y+NQD+CR05\E-Q.&T ;@(]R !\EX*-DME$9;5E7DME'2PD"KA0@I&*V
M41DG( VH[<HX R97 48J9F^4((U1@&I*]I]<A?)B;D,C(U9<D@*6@@(\4TP"
M33BB: 8-Q4X!,BJ&C#+.[QB0-FCN !<5DQA+U%E ,N4&Q!"03-&$EHFA'Z+N
M"G!1<2DM"6+H'T0-F*@Y)L9!9$ PB!H047-$!%F'!D34 XBH 1%U#R).-26B
MPX<LC4ZR/9@XU0P3@3YI0$3-$=&"-@#'M!TPM8!CFMG(9%1]N6Y T3D$. )$
MU)2(9'.^UO1HJ1R.(2"B9I)4!SAF ,=,TG]N#:"/X>@3GR<-S2RUL"!/,X!D
MAB:67J+> I*9 64@ ]AC*'M(+CUK0)T"3<(<M>]Z +N]0D4CAFND/&7H@5"8
MH+ S0$K#;7S$&3T3RF!%8H"X&L!>TX.]YX:R5[5SLKJ:RZ!$#+K@0#1PUPS,
MQFW=,"!-2DULKU#F:H#T&*:HI0@/.1#(  P0'D.%AVC<C:$9@+)PF5F@3Y;)
M >+2\'D#$K(CW'$Q^V('4UU8M(YF.UC2A8%-RP)1M(PH*E ELD#N[("<P@*Y
ML\SQF&Q\EN84$DN"!:IHJ2K2K<]RV3UV!:3.,E*':DT6E;0'I!46")/M(4Q?
M+)-6:'A:M(#=EB.NC%W5(*'1$N^Z ORV3(:O@&0[0%PW(+%P@$..2RRBV9TZ
MFEA8-+<.$,TQ>44\M],&) Q2F:XKP$?'\%$!;7& :&Y N<H!!CDN,8^W5,?<
M,<&%ZP#/'),I$ EO0%C"NZ[0W1&EHX/73X!G;D"YR@$"N1[EXYFCY2J?P-GU
M@&>^SZV/9VY]]($,TP-">DI((\"FY@'7_(!-S0,2^1X'Y:^>;FI*&&?B"U(&
M)R7(B#Q@I.]QG#[S=.N3HET5J76F@;5KQ"+YY./1'3R;UR5V!J/B)/8;UU#<
MI^]<UW7<U"V#$A:N,2!,OD?I[HP!M:L^S13U -W^!M3M,E XSRF<BQW1@KP)
M."'V0.(\DW&HN'#3@-J^K,!%(H\NR;E;\OA X9EK<NG1# +!]%Q-D:@8/5'(
M R?7 !0S]+AQNPH#;MP"4,O W;@11X(Z4@>D.0!9#5P*$YW'+P.]<Q/.T\M_
M!G?@/!" 2@<FU=&H#2"L84"J$X"B!.:BG)15 TUURA.X4@;D9@%H0>#>E(GY
MV8"@Q'<] 24(W-E#Q9XH",I; #(0&!F(;\2F@;M;Z,Y??0#L :Q[-6F]N;C,
MUD_;]XTWH_O\=554O6D]W;_3_%E6;SY&S\_$T7?!/+\61S?<\YDXNJW?9/YP
M6[]8?9.NG^:KS>AG7A3Y<ONRY&.>%UDYKN13.:+G+'W8_UADCT7UM4JBU_4+
MS?6/(G\YJ5_6GNS?&#_]'U!+ P04    "  (A"9-Q':90-4"   V"P  &0
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M D06@C1=.2L,ORF +?<PX+T-P?LN;C%]MA&B:8K2=PV9UX3?%3"]+%@TT]B
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M?Y5(G(H]$E7&-+_6)3R<G/Y0[O-DT:(V1,L>RC4LH?Z?1#+:4P,BRR:$\NV
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M*7L@B V34US19/0M_DH?Q]^F! 7RO03TR$\.-%+YX3&7[\[@L@D^RVI75L1
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MU5;\6Z]91GRBL]#0H/ S2?MYB)8V0SE,+*)$00J+%C<L51.VWKAK3KJ04#@
M,\?.7WCRB<([*T3-CL4G?8MW@^@D5U)MFK$4EU%WO(HQ>0EFB>[SK6<0B8CC
M/CC;2]5Z/7CPGK%?L[+H?.@A6_"Y6HI<8F5@09SA%/!.152*G<^1(QVG;CXB
M$CN*?EWWD@QZ8,B+>@@^?A1*FE$%5W/':"P_L>[<IUP8]50-V[@8@F*)^L5
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ME&Y-1?,[OPB%#[S\T&Q;VK%8>X>.N-CDXJ(;3X[3X!Z@S^J(PPJ@Q\J97#]
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ME5%[=U]N[TOF6W0&N0\F,.<KNI<#70-DC">#;AQ,@#KG'4D)D='6.- M0O1
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M\W1RETD&X&?Q>G#X^.,NDRG<;Q2\E,ZX/='@ '/NDX/*;_9O5_,K?8,1#9G
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M5)!R1/>M*R;E$T5 3LT>\#Y^[)^2'IGJR05MKLI/%5KE'RN0UZK[!Q)$C##
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M][L[HX8LBN59?GF]N\/E_DG#QE2'>O 5_L+94(QQ]<OL^F:]!W2->(2N_4(
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M,[L\!*U .=DA]\(K]^SE7?@"=CX Y)S]H1CK'\SLNA^($<?^/++U+._O>&4
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M7#.7-3Y'U.FRW]G7C/9DHVF8?;/O+(=U_(U*O$1-531/F]VT/BK[9D(2@G(
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MG>/Y[NJ(",DF(([<U7S-?[:D(1^$3\3^XYR(18Q((V*+H,03[[I!]B,('_.
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M:R9PE^']G&^?<9WZZ?Z)TL.X)8?KZ\TO\>O4/Q%A6E&>?P-02P,$%     @
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MR*I19-4HLA8HLA8HLA8HLA8HLA8HLA9'E'4\YIUI^M^2/%F[_IS/QO^A+=X
M4$L! A0#%     @ "(0F31\CSP/     $P(   L              ( !
M %]R96QS+RYR96QS4$L! A0#%     @ "(0F36;S"V""    L0   !
M         ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  (A"9-
MY"G+8.X    K @  $0              @ &9 0  9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  (A"9-F5R<(Q &  "<)P  $P              @ &V
M @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  B$)DT]P84>IP(
M  4*   8              "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  (A"9-!=(=LK,$  !N%@  &               @ '4
M"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ "(0F3:6Q
M * \ @  M <  !@              ( !O1   'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    (  B$)DT)Y[48N0,  #0/   8
M  "  2\3  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  (
MA"9-?<;Q**,&  #L)P  &               @ $>%P  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ "(0F38%LVKDL @  : 8  !@
M         ( !]QT  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   (  B$)DW0Q-**_ 8  $LF   8              "  5D@  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  (A"9-3%H_:; !  #2 P
M&               @ &+)P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ "(0F3;I<KM"U 0  T@,  !@              ( !<2D  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  B$)DWK+J4ZM $
M -(#   9              "  5PK  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ "(0F34KL38*S 0  T@,  !D              ( !
M1RT  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  (A"9-
M-^,J [0!  #2 P  &0              @ $Q+P  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    (  B$)DTT*<>IM0$  -(#   9
M      "  1PQ  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ "(0F34"NS0JT 0  T@,  !D              ( !"#,  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  (A"9-$?:IY[,!  #2 P
M&0              @ 'S-   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    (  B$)DVWUVMNM0$  -(#   9              "  =TV  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ "(0F3>QWA2*U
M 0  T@,  !D              ( !R3@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  (A"9-0K83F[,!  #2 P  &0
M@ &U.@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  B$
M)DWC3*$WM0$  -(#   9              "  9\\  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ "(0F341'&1&V @  >PL  !D
M         ( !BSX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  (A"9-YVD3]PD"  !.!@  &0              @ %X00  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  B$)DVSYX_*^ $  ,L%
M   9              "  ;A#  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ "(0F3:#L+JW\ 0  "P8  !D              ( !YT4
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  (A"9-X];G
M(<,!   W!   &0              @ $:2   >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    (  B$)DW6],"]Q0$  #<$   9
M  "  11*  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M"(0F30UXLS M @  0@<  !D              ( !$$P  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  (A"9-(C_^EK8!  #2 P  &0
M            @ %T3@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    (  B$)DU\TUBU@P(  /0)   9              "  6%0  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ "(0F36TJ+)6M 0
MQP,  !D              ( !&U,  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  (A"9-PT@Q%?P!  !3!0  &0              @ '_
M5   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  B$)DT]
MD0 TH0<  "LP   9              "  3)7  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ "(0F34_0E%=N @  -0D  !D
M     ( !"E\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B$)DT/FPE !0(  'D%   9              "
M 9]K  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ "(0F
M3=>NX>TR @  .@<  !D              ( !VVT  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  (A"9-[+))-PP#  #N#   &0
M        @ %$<   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   (  B$)DU^L5@820(  *<&   9              "  8=S  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ "(0F33P1ZVZ7 @  DPH
M !D              ( !!W8  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  (A"9-.+OU[S "  !G!P  &0              @ '5>
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  B$)DUOR"^?
M00(  -P&   9              "  3Q[  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ "(0F37ZF(/1K @  R <  !D
M ( !M'T  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  (
MA"9-U:E;"P "  ")!0  &0              @ %6@   >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  B$)DU+%E45H@,  #,1   9
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M970U,"YX;6Q02P$"% ,4    "  (A"9-5W:2]\X"  "_"@  &0
M    @ &WD@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M  B$)DTX?ZU9N0@  ,\V   9              "  ;R5  !X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ "(0F34J_4ILS @  0@<  !D
M             ( !K)X  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    "  (A"9-7=9#]D4#  #F#0  &0              @ $6H0  >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (  B$)DTTM*S1IP(
M )$*   9              "  9*D  !X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ "(0F3:TJW/)L @  :0@  !D              ( !
M<*<  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  (A"9-
M12L;F#$"  "1!@  &0              @ $3J@  >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    (  B$)DU,IN[_B ,  *P/   9
M      "  7NL  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ "(0F3?^_HCAW @  K0@  !D              ( !.K   'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  (A"9-30T;/9\'   ]+@
M&0              @ 'HL@  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    (  B$)DW$=IE U0(  #8+   9              "  ;ZZ  !X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ "(0F3:0>\3KS
M @  I@L  !D              ( !RKT  'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    "  (A"9-^ZRL([T!  #2 P  &0
M@ 'TP   >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (  B$
M)DTVVN5 S0$  #P$   9              "  >C"  !X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ "(0F39:=7(G= 0  _@0  !D
M         ( ![,0  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
M    "  (A"9-0?_$0SFB  !"=P( %               @ $ QP  >&PO<VAA
M<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  (A"9-I^^JW:D"  ">$   #0
M            @ %K:0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  B$)DV?
MG4!]-@0  'TJ   /              "  3]L 0!X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    "  (A"9-VKGW5R\"   X)P  &@              @ &B< $
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  (A"9-,&^I
M3/4!  "/)@  $P              @ $)<P$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     2@!* #@4   O=0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>257</ContextCount>
  <ElementCount>460</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/ConsolidatedStatementOfStockholdersEquityParentheticalUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Fair Value Considerations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderations</Role>
      <ShortName>Fair Value Considerations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Equity Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstruments</Role>
      <ShortName>Equity Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMerger</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Fair Value Considerations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderationsTables</Role>
      <ShortName>Fair Value Considerations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/FairValueConsiderations</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Equity Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsTables</Role>
      <ShortName>Equity Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aytubio.com/role/SegmentInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails1</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetails2</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerDetailsTextual</Role>
      <ShortName>Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/BusinessBasisOfPresentationBusinessCombinationsDivestituresLicensesupplyAgreementAndMergerTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Summary of Significant Accounting Policies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails4</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Summary of Significant Accounting Policies (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails5</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Summary of Significant Accounting Policies (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetails6</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/GoingConcern</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Fair Value Considerations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderationsDetails</Role>
      <ShortName>Fair Value Considerations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Fair Value Considerations (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderationsDetails1</Role>
      <ShortName>Fair Value Considerations (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Fair Value Considerations (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderationsDetails2</Role>
      <ShortName>Fair Value Considerations (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Fair Value Considerations (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderationsDetails3</Role>
      <ShortName>Fair Value Considerations (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Fair Value Considerations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/FairValueConsiderationsDetailsTextual</Role>
      <ShortName>Fair Value Considerations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/FairValueConsiderationsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/IncomeTaxesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/CommonStock</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails</Role>
      <ShortName>Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Equity Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails1</Role>
      <ShortName>Equity Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Equity Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails2</Role>
      <ShortName>Equity Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Equity Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails3</Role>
      <ShortName>Equity Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Equity Instruments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails4</Role>
      <ShortName>Equity Instruments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Equity Instruments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails5</Role>
      <ShortName>Equity Instruments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Equity Instruments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetails6</Role>
      <ShortName>Equity Instruments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Equity Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EquityInstrumentsDetailsTextual</Role>
      <ShortName>Equity Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EquityInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SegmentInformationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SegmentInformationDetailsTextual</Role>
      <ShortName>Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SegmentInformationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="aytu-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aytubio.com/role/SubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aytu-20180630.xml</File>
    <File>aytu-20180630.xsd</File>
    <File>aytu-20180630_cal.xml</File>
    <File>aytu-20180630_def.xml</File>
    <File>aytu-20180630_lab.xml</File>
    <File>aytu-20180630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001213900-18-012209-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-18-012209-xbrl.zip
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M)NJS]*BYT2TO3GC!_NE*/@( 2H:[*:N4QM,(/FP_$%U>K24:,U72Y%*NS91
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M[UXW91P SR\. D.0!"+_-F4U,\"34QD4$D68_HC&VY.(<.!E&,.+OLWUL@'
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M-'R$JG,ZL>!)[.#I<^Y.Q8S:%_@?7,#IAL4].D2P%@+PG+6DVTM)MD!VW-J
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M6"$WC4CMV(E=EU#RP+'!,&$:@H3)/.><.B*85J6,CL&+.!8.+@5'"X$!,E,
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M@J][XP.Y^>+QXRB/M,1$I5KJJTEJ!!/)O/%C@@@W_(WP;+.[#')>G+G:&C1
M(*"C\]\_&1$14> E8F.Z]GVM"<+*M[ZU35 4]&[TK*Q)-@2/Z%U6A\KE$@8$
M:UC3)8LN1JNF2R9=])HNF70Q:KIDTJ5=TR7C0 *#F9E36*%2ZOP2>#L:#B,
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M,U\(8T-3SO0(F+7%N0V/3BI\[DD(I_ 5[LIP)1V; >A1\\,=7S0V/6\E.CP
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M<>"?CCI7KV34N-]0U2;E.#(]HULTZ+ )I2)&C;+XULA:>:PX'/8'O:XR&O
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M"I=3#\W\I;DBEH6/7^C-%H&QL&P;3W?M3SRV0-'"E\09XH3*23#X&>UL!V0
M8?(!(#!JS"D8&=K].'!Q>$U;YST[&K@&31\*EXB>"5_^;BW"!? ![,D,F42
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M" ?(!/#OBWZCTVHU"00ICPHH*!N[@2)8A6,AWP[L- 7.AL4 J&%#0&.M 4-
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M3C7=P$M:JN:E>I\/KBF("\B*K4T]=Z'=@NX#.5Z/DRBI&?P:2\T3H4=2^D>
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MB6F*(J]7&2Y)@/$1J9C:"#:[G Z 8_JFX/>[<8?FJ-.=L,G?6R \2/#-D\A
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M:@RZ"OD#3W?@AFNS##/.6RWOK"58;A(^Y\0="U\<K4:4/C_C<7#A3.T9+,B
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MZ"F-E>7?? 0,#P'5/7Z:-L063^[Z\KDKV@'L^8$IT"!) /+9%=7$P)ZX\L=
MA0E_1N*M2#1XY&5MGFAOO$WZU4# Z3O&-!5*PU&4T_"DS?D_V 1[JTVP*IOU
M8)H G^D6$Q,=A@'ZC(7F]47G]9^@@$/4QP01N/EBAD1GQ&Z U6"AF2>TK/C#
M=_&9VYB0"B^[F0)D(R<3A_GGS<VG3"!&!U12*QAIFX2JX7[[8U/$2@('QG4F
M$T'B"^7/+ AE"1X%M=!)S[7/03&[T<@+V.^&Q]:(*2SZ_YK'<E&*/R^"*42+
M)A': $0U%DG.-7Y$74ZX) (,TU1F@XX5T\B*DN%_8.<,1@#_!,NU$%\R?"(L
MJ0#1+\-4)A+3-@ >C+Y=LL>!YA% 1 _9((O"$-^I?V<O&M^I_V=K2TF3FX'7
M3$0"7ND@Y80"U(NR30R S$G*3+9F[V',8(*M&WI;QS%!OPCW.]I M@ZP9/%@
M&@%9$3L6<)1NK'P\_4^$0BM<8($8#%5I^BF5.G:!#%-/,S)(]TF+VO<^D).P
MOC@_Y&SB"DI9JGY"*W@HA*\83<>]D>SQ-I%U-KB.BN1)/L[<0"86LE])G7I0
M85,[(Q^MN*& +X7U!@A[BA9,I\4F#% B+?(O!QRG<(Z?]4&NL0_#9O HQ)ER
M" F_R0RO@QD._L.].T,9@Y<P('N55*,=D4RP+?J;3(NAN',IACUQT6HRMA*Q
MBA%,__2NAO4.8,>(=@$"E&CC-V1 BY%:* BB(NBS))9!8RU/48*9\7L- R]O
MJ!B,I+B1LKZB?('=  0#!X<,H^!)\#B&SQW+EW'W)I("&>4P5W<@#VB\#=%E
M2A=:G%!/H=\QP6)$%0 &V!4>(LL104XM^0?*Y;% 6=%'+.]A93A<,.O96X'U
M'NCZ W^3>7]&A2T# 8\XA1" /9H/F#P8(C+C\Z&('X3P-]3%2E6ZS &HA/)/
M(T2$H7<Q)S=6:AD^%:4Z*')@*]X+9B# 61&9(3;V4:?(59[[#7MD@27A4ZB'
M3(H(119I8.9 I&*E^W/.%IF#H, %A@BGXR&"LYLHW'V8!B^UAR#(J&'+)/7M
MZ#P=Z3F&;&3YVB11L7SA@SN'&VU(]KA^N?2_%9"Z:-LR;2&67-8SDEA(3GCR
M]E%] 2<JKS,E"WT#4D7L2T,*)9N3C.D2=&Y-!)HJW$F.I 2?80*<'M+!L6^K
MPB0H_IUQ0#:R<1%ZE[AL4^/!)O!'&#M\D 2#ADC>+4IYPZ$6/''*)LA>&P*A
M9A;2V[)EG/K'S)G#CR@R =282^: L0B^YR9RFI?3E93U:M[X20X8@F,P80X:
M.=Y(-;W@6RD/@S?P7GDPO W):O3R7O-G#4Q@,HN,VP,] Y?$'K]2M\J#7=&]
MLD3_/(O\H?!<\5VCC4-2/KH0&'R#0\Q'6/8(30TD#\=S1W,$WPQBI5)?\6HJ
M 3,"4.)) D7M_(+XWI2_QMW?&(WJ*''8]:';;M+#MZ^MJV[SLM5LF*K.<,(0
MB#_4[OC^V32Y+C&,@*%G\ )C;93C^NRE$99;S6M36UZD;WW.A+! K1:S#KP9
M?9>1C$4,A?K<5T<F53&A&<DSD%%\ZE9(:%%7/U&D2(S<F,PI*0EH:SKE#\B4
MET8VQQQE9"D;$(1_,7.MB R:Q,2*BXR0RU2(R&MUI7_!07(\Y18ZY#(%OE@4
M1<JW T60^G;2[-$*TC;]WB ;?$4Z!O-)&I2$,2!K(WRGC0%]-MJ;EH1&'W+Z
MQC(U54LC+'L?M^36OB*W]K7AUE8VX$/&>B:GAZZ3I&</BH&#$\,T#X$3*E+4
M9$+KQA4D<6X:S%Z.2[/]:=@C%#C'V$&6OS(7"N::].S"A8N%MR',-Y1*=WD[
MN@\P;A#,.*\A=$=T=Q:,A2?UOLX[,;=%C5PC-)K W)VGJ1!22*#@$>%W#&?H
M-Q(4 !2R'EOXY--,!(T$SC'<6 ?..91<B1N\98[Z#.<%..<P'S!751G)I%@W
M*N06[@\,(A>,#*G>%@A8L@<YTY;4>$SI8S+@P>0+B?PU27X7D1'ZHUP!!]07
M,=B3CB4![0EJ5HQ\_@8,/B^@&<&5E>:9#8^-#;,P*^I<36:S*<>7;:.E@4=/
MFK"DQ7SQ6Q!%SZU/P(? ^E/@[EM4GB<@KS*A"ZPG=Z2,V@N/4#3#M %&$=D7
M"\X@QL!<<&1-WQ(S;[*+I*E,4G*:*X*6!Y.5+!7\ZD%@JCR2.5[7@^WO)Q0+
MI1N&]%=@%R0Q9C)0^#1S%0JB5U(ZG2=B1.?L+Y5%/&"U#>W^C>M1Z!'!IP@<
M;IWW'(J)1T$:=IW1J4%?DTP)8$2.[M"+Z8J X)#88B;4:V(D& RWAL6X)FZ7
M[UUXYX/TLR-G2LM0>3H^S]?'-QZ8*<D=^3KX-/X_A1_2UB04P$$ W21D4*YE
M7[<[=NOZFM9I#>Q.OY^'3=A'MBI>O=8VI FF[V3[\;/B8W,-[W5\5&_2W0]3
M8T+J1\Q]XPNGZ*7131]#%DMQ=4EOTJ=E3[SPL(9BY&#F':^ISX.2@RAL#Z]T
M+VD!V 9+0Z21JJB299'R#DWX?RL;)<W.?^_#H23I)>8;6/*[0ZKB-Q7[J*K"
M_6)F_QB!Z_3"P$VQDTE)=Z)[?=U(*3X&EQ&#*$+'+^W<Z\KT0_#3Y"<Z0TAF
M@)I!9/XB$TI.YSXHN>N&IJ^67@ZYR!A!B+E+<6(&-!<J$M*L'!T,*;K2126@
MT^BU6T> X&4[;JTP#2H; R*!&@9#XWY7IN?(C+E4VLKE.$5P<0<1!_XQ"8HJ
MF4@"I[(9A:D&^*^$TFAERA3=;!_ZYO94(8$TA*EDK0H(<,Y:?HD .2$I^:,8
MQN@FGD.(^83*^<Y;0QVJ2B88IS)% Y-'?IGL"D[N79!.BBCU3ECGI;8(N_..
M!?^*T;U/LQ,H9M"P_C3RUAP3,A4$D4X;,+N8Z0B)JIE(\2'- ;7Y@JBPL3\M
M*E@&X'V1D<>W\#!F]B7#"*0*%=]P#)$@64RJ2WP54K?N'+I"D$:&OX#<L1C&
MICS3 >U<:<>1X,!$$)MSC(Y0HTNMHDZD$DRTB<F82\;RJ"21NE&4I!E\E"7.
M::YW*ATKG1F47H*$X@[L*D%)BDA<2&I$[O2BL1$KRR%V"F !J'?SI931=4B-
M7Y2V>,TA!"LE@L;"L532DKH9RR DG##\WIM;[_E8,SER@1_@[=,TG=!U3/\Q
MBY+#O_D])\^R6T#9J7C5),G]YO8/Z_>@0=]>-J_Y/L>XUC(C])<47<P&[2^^
M!#-PCZY:@^?6[2B8$6]],.L]C:I0O?,+?*U\Y?.&>=%E?,%Y)IX38OV;NHU5
M-^^233%LS54(:3XUFDAY(7:.UID9T[(^%.^89S.@E:D!-UN.*=4 !^JMLEJ,
M9'TKVEB<&X!\1Q445%@RE16A/F>F+60/<N8.S0NCG@YI+I%*F^8#(TDCG!#K
MC!1QSS!8'\>HG=ZSJ/@K<4)<A+.*>7R8S$D:9&L=U85X?.]2H#-E!5LG^,L$
M1D D(QW5F3M5-[?'"DN=@$^,M*T"7F':;.56*;,,-ZO5)7<,FKWGUFNB9%W-
M]H83&:6L<BRU2(8;.)\"#I4CC)H79-9+9@%=I,)JC0X.,ZQ '^(2,9D..1>N
M=,J""V1 $T;.B&$'5P23*+&,;Z0=!;Y1R92A7V#:E!O-@LCQHN=I2I&R011<
M[,P 1$OWO2[F,\5H@]X!!TD8X2\\H#LS<X.LPPCS4!D4,G_C.0L= WA9XB#S
M/-A&C:P[E3V=N2*7U4* FHEX6,0!WB'(,W.B_"+HQL(A980!\%<:A=$YA;-D
MZ %5Z.5(#.&Q$GI97JPC)229IAZODCO:/G"QY$E6D:BL90+C;5:@N)$I4VYT
M5G56K&1"3;;R"%,!8HT#P<5Y+$ZEC):2Q[;N@P>L'P.(S8Q&(;Z1.-<9S-A%
M Z%R=.%]MNS%E<$[KB*3-1DCP/R$(WMZ(3?*(=WB1@"$?'ZE7J.6=<UN1M:]
MU[6;C,!+2]=AH[;[2')$BKU.K_E\A3B+J)Y/RS/#OEW(<-)U-.013X/O2H9&
M M4^AQ!B,=-EP0_!)?W;R"3'6L=%5M5I&1E30!8"DB/-S$C5CXJWTCK4[.($
MQ5(AXT+DQC #$I#=K-SQ10L!+N#!3*F1+,!+1?)BQJC.NU-@I.DU"TM3P:X8
M1PLU#0A.)M\WA?QERKCDQZ#C:KQ? H5LSTMKURH.4.FD^8!I*X6T@CA@GLT"
M0MN7)Q+%^(M[&6.7\LHX)BFF/#=FOR>-6FEYNX3V3$F?JT4=OE Z3]FSI9IC
M@77.P#"+5&3HR1G7IU(6M"'Z^4PPW[EA\M6RW3AQHQ%@C//-'Y/\UVM+?EZ6
MH*"E&]8*\9\Q8%-]5$3VD3H(V:E#WI/S/3H#K@1-*S5KL]DGAG6K#-/4MO85
M5JA"SBC&\P,E^ ..>F5RVG/3R2OEZGX6(VX_\)B':X.#%ULW*A$V4K9]]N:H
M\F[P)N&B=U@RH88PM_I DR%>X1% F@^YMH,4YQIME*P+?')5^Z2LYNU?8A&M
M_D>K;?Y#LE+Z09.TK_YWDSD%>#^925;$H@_V0( $9BJ1/3;L9"I)X16Z& JP
M/G-)'!>0O,:V/<XH9MEBO4ZB.)B*D*E)*OQ^L_\\;<FD^R^@2@S%O? C%'2A
M8+D=J)*[3%;DC L8P94P:VI'\FUTST%0L 31XI-O--).(L;.E7XT,H?^E> (
M;EET:YDQ(Q(^B 24S2X9,Y/$0_<]3N4Y0D2NQPR["*B<(+E=>;N"E=X43:!6
M(^:/"7V.)6<3DLHR"[?Q:0?TTAC%(HI_"F^8LPS1\1NYL=F02.T =\QWZ94+
M[ZW+NG_*EC1DFP1)N&@02)1ARP^M9.B*FZNI)"[14M"1VX*#E!5&#L9AV1=9
M2 M.PRED_,F%C>R+ATP,"2TH(XV8LH=BR07D(0%MQ@'6[GJZ6M563E'Z 5.+
MF8L.',7&M.-QEI)"1#"4U0:4+LV<E=(GLUP##'RY$(7/'@2CRA?,FK1QLW!W
M+"XC<8?=%@@ Q>3(Q<"!P'@R=NY&TG!G#-1D*]U9QYO_5PUL S(C3R;2MFPF
MY)$],R1V=6I\-92EQQ?61>LYB4VD/"WU^32#6&7PXS+BATP6D?46N-@,W^3*
M< J1E=&?:935#AH,&U8.*:QCA6[$5)!&<!][%05V0X%B'4'&[8@0;T)"PJ+)
M3,O5Q[AX>I,?L18S +MH/\=^=$(]6[0%^@(O[4#^QEA:GVT5,_3<.V>Q_%VF
MQX#JF !VT>J*TQ2A&,B&TP@N.L^U,-KZ/(S&)LKQ2J]\86_86X9'4YB) 0WK
M8Q(:5K(1GPX#ZNA$<(#<<*BD(^*[?6!?L"L)L*?.L3<Z3(4)5K?),$8;B.#I
M=)N7W6:V*^7(F8%WZ:D!)[*SY))H9LWQ(#AQE)B$A/0*"2U_HKUPE"/L<LK2
M9TY =74/0E[EWN''Z2E^"1:^Z/+:!R'CI*K4BG.AT:$D2.F6/G7^S(YRW.I1
MF4)*%^*="S%&6@.FMV!VFC'PP(EY*8JX!$Y^L5#H)$%D9G.47D1F:V@BJ32Q
M+O05SFLMG;T0=["&'3$+6)=GM=K445%V5]Z!2T&5AM"+S%HV51?-;I-_@"HH
M=XJ@\"@N0PTU9.A7._$DK6=2B)%I3'5]W-O(BNZ%B)7DHM0/ZLBJ5(Y1A^]D
MC/ZL,<;T<K/P1*3].<,QR7-AF+%2(E>]G *98(5Z""M/(\Z;U-7DMA+'^&<0
MRM0:57F @+"62H,<1L*6632_1.DKJ"2/8/5/CT3'Y9/M&!['Z(CAXJORST4O
MO=7)Q,?S<S9U9+7UTGK-+0(PKUV8O8R9G/AN.EXN\]723K88\/CWRAC+SP^Z
M%YZV/5(-3WZR3K(SO I\1^AB?I2MDQN-BW7.[7(BX%G9=E$ !:I^9RA1R%@(
MJ'(;)<""0XU16]8N>>$Y9(A0&E]4FSP6(U )@7\I^\ZX/EE=W"=G&"2QK%QE
MO/!UCHD;RJXJ3)N2*9S!=.K&_"EZ]5@&JU%,V*/&!BGN9%0:<$J6>!:I*2(.
MF!M L=^5(=S40M_'NP;98"U6%:2=3\FW5GZR;EHG6Q(:/,(RF=L^KAFMM8:)
M>:,(>,>X4"RD*<%*WUD4LZ?)$C^.! .I]$X,0Z.Q3,&M7?^RV<Y(I=^PY4PF
M5#?HMI?OYC(1";,7N<-C$2Z#"3*C=?'YXQ_/97VGO+Y1-VF6A[Z"R)3GP]/R
M6I4(D54\-<%)LUYEC6I6D4]DGP]Z6(H&SOCQ E#H9/GZ5JL-H/CQ/6B^W]2#
M',L9>?!:MF><-)Y'M*93) WURWZ?_(W,7N).9KI.W '^"GTECS&UTM3\TEB1
MJ7>:E!O+R#7%@B'#-[C^&6QX_6/)JY^;@G 6F^JI=4=YZP[GD.C.H92IS#C&
M/Z5/L]@4AQ_0/JL34U"*NNURW7[ >V+Z33=JM&_#*R$7;][X.M4QJN+20*O.
M"\B1'NHT98L)Z2Q+'3=V60VH8B=*HR+KE!"KH<AAK<%EJYEAK<QL@_=35'!"
MZQ/-:[8DS266<\U?T'[0?]*7B[J-S= (=B]%$Y"Z#=;'FJ,HH(8[Z::*9,4
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MWSX;)!(T11US\=Z^J/^A;GV8W_G0N#+^QR])='GG.+,7[QPW_#>BYHT;C;P
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MY0CKW@%J:]O7_9;=[/74FQ0Z"8CL:^XHR)SWCBHP^*<D1"S&EL2\P:>X1[N
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MI9U60O=\,<]MP8V15O$[[<2DJIM5L'+%!JRDB>+'TG)D,1K'A#::74@XQ*_
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MPR=G3L&1+P#B*R\8??OU[W_#S?Q#+7<[NA?CQ(/%TA^9R]YBR.<C.]HWF/4
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MA?5.#Q>J6N/"I[=8X: K%)1WZL0+FNOQD/W>"S76OQDI'D-RT;8'S=5QB<?
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MVK.LYQ^8P!-A33'3BIA6("UA>#"ZIYAY5D(!F2ON6\]23H,#ZSO\>:$"L",
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M0F%<@0N)G_!GJQ6&@0,/_NT=M[ 3+M$IT&WQ'^ W"KOF;7LPZ$).XY"X'TB
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MG.;H*3<PP8G4Y?.*DH2E]=I,2VQCY5%_@]60,SH7Z.QLP7]>D!$"\B L%%^
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ML*2&)MT E ?R[7 6J9FEG".ZM!6)D_SZS3PVK2K-1FJ"37) 8AU.+,$LX^#
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M1<DSN9+"1N$N2IZYHJ0VWNY12=MGP"S7UNK"XHF^Q+:/R*>H.=&BAM?<VM=
M'JQ/A/F(685.8[->"7DP/FE2_--'[-4K(0^V)\*, J!$E[%5KX1N=#H1Y@T
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MG;X-V2[W>L.V'+:[>V=>%#0)69RF"#=(VE9_^@-(2J)$) !2( '(FH>>L@V
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M0N?^@>\9S\T]6E$BD#:8O6IWX\USN_$>E]<'%])"R<\$)P*+2M;SC>F!FCA
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M2.JMEW*++^7U+]1'Z!U4F71Q>S9T^ZE:X'./"#< *F,G[^<J%BOB=1]_&B#
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M#<R?GPE"XF?T*BU,O9"K88YL<@')5W>]U.$C_7#N+^;;@WEQ^O4V;AN!'(9
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MJ0N F"A+<:&B\PX' ^7&**#4J",GDU,XF\=10.+GC&"O^"L.DO)1C0@1I5-
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M:56I+SQI%3&  9>)EF-X5:2HHP6UBB-J;;/TMLS"7Y4N2T#G$D]2-?L8XHC
MX$:FV1@K%1UBA,!FN544Q33Z*4BN@SBZ3,^"75P&B1(T&AZ7 #)2OP\F)0,8
M8)EHR1WSMCR(,KV)4U2S 8/<#2Z#.,71AR!/R09#?0TM(W8),K7"?72)*<'
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MY/1.LWGHU![D\I 1>\>1J8;<-2NAHN$8\!(1?<I*;/(&3$#G$C]2-?NXX8C
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M=&LZ-8M+()HHWX>>BMZ[[[-0DKN(("R(\: >$[CEG<@RG0_4\/A&F]+3*1E
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M3VDAR8_3M#95[#^-Q8 !\73=5:C>07K&I#!LZAGH82*=!F?,8/P@9N, >6!
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MEQTB$ SLY[""6W 3JI-J,/26V^QQ==Z*8K_#&!FL%!Y-ZD46'=2Z\H4Y UE
MCXS:Z3L_M<J#*"DQ*;2-@UI-+E*B1_T/#&7E"PPPU84VBXM,-)M(C-<Q.<WI
M8V3 (*>/D@.,JS-24^3+V"5RUK"@H.6!@;B+(,[I]6L3*IWV@SD^XH &[T;K
M](8>J]#LDE5@1][\]30H8N5;YQGE.[TQF[M9!G=H<PD',SKFMH@+]";R$?L
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MM-#<?)C1C=KG>WR7W9#?VH$IFAF6^Y:S^7WIYFI7 $M]",8:86'K=*,K[_.
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M?588>.2-,4-BQW<\&.1TYM'W[BUT]-T]QODT\/4X86"/,\4,>BW;\2!OK+(
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M*,T]46-\*-N@W6!W" .R-&<*QL,CXCN<;]>;Y@Y"NG[0,[I=EID:,ERCZ;C
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M6KR:43_9=*X49,V-:O;V2 )=PTE0XJBU_/;5J_0 'H?]*[^<,3#=<JQ;7MH
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M(+R3<G0 YU2?Z+0_$CL?*9S_@G;[^R0.(:"YWI>H2F]-;3XCT: 0;]$85F/
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MKP+)F0Z(^V)5X722O#F_FC<0FZX9 +B8RO<BO-'MO:.#RYPWB49GG19&LR5
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MQ>$A8BJ4H&S6-H5]/^CN=B?G1V&)4QBF3,%I0NA2@?7FL@+"UC"W%<KM<&,
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MKTXV1DQJLFZ0G[C6$^<>==N<P6O&8OTCK>N<6IW'1^"Z/KGIGXA;R72/#(A
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M&.02(75%_$*R_N>9EP:Z!]@6/T$C_A B DU_E3T>4'G ;8&B&\!+;[N?(29
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M09A1:1?XE,2ILG"Y@X]!!8**1<4=PYT%3&XC:]>ZQI_,1!E;;[>,K613-1D
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M![<H/(JL(4GA_[I@Z30)BE6JQD#6!RWT:$\$U#P8^);;J78_)7'J(M^"ZF-
MZ;#O.<;8!O5<[WU5%)51"5P4B\-I61_P(A>^\Y+&\KC:<,(4+-')7,_Q@&)E
M/\QG'[':BW<#5TC%'[]P(C=TOW>@B3J_ K95D1(6!XRF+$*FP@"'=0 V2&(
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MDT4QH#(TXD,S-*+J/ZH-0"(FHIK7/5N*=18]ZV,AY#TH)'K7!3<TVA$Q0&I
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M+G?^D_\?4$L! A0#%     @ "(0F31=];7>_0@$ EHT/ !$
M ( !     &%Y='4M,C Q.# V,S N>&UL4$L! A0#%     @ "(0F3389FE1*
M&@  !$D! !$              ( ![D(! &%Y='4M,C Q.# V,S N>'-D4$L!
M A0#%     @ "(0F3::^;X]Y%   728! !4              ( !9UT! &%Y
M='4M,C Q.# V,S!?8V%L+GAM;%!+ 0(4 Q0    (  B$)DW5789$>4P  /AX
M!0 5              "  1-R 0!A>71U+3(P,3@P-C,P7V1E9BYX;6Q02P$"
M% ,4    "  (A"9-U;'XELND  !O@0D %0              @ &_O@$ 87ET
M=2TR,#$X,#8S,%]L86(N>&UL4$L! A0#%     @ "(0F32MX77K-:0  AHL'
M !4              ( !O6," &%Y='4M,C Q.# V,S!?<')E+GAM;%!+!08
1    !@ & (H!  "]S0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
